

FP

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/054974 A2

(51) International Patent Classification⁷: **C07D 211/00**

(21) International Application Number:
PCT/US2003/039644

(22) International Filing Date:
12 December 2003 (12.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/433,634 13 December 2002 (13.12.2002) US

(71) Applicant (*for all designated States except US*):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA PA
(US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KAZMIERSKI**,
Wieslaw, Mieczyslaw [US/US]; GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park, NC
27709 (US). **AQUINO**, Christopher, Joseph [US/US];
GlaxoSmithKline, Five Moore Drive, PO Box 13398,
Research Triangle Park, NC 27709 (US). **BIFULCO**, Neil
[US/US]; GlaxoSmithKline, Five Moore Drive, PO Box
13398, Research Triangle Park, NC 27709 (US). **BOROS**,
Eric, Eugene [US/US]; GlaxoSmithKline, Five Moore
Drive, PO Box 13398, Research Triangle Park, NC 27709
(US). **CHAUDER**, Brian, Andrew [CA/US]; Glaxo-
SmithKline, Five Moore Drive, PO Box 13398, Research
Triangle Park, NC 27709 (US). **CHONG**, Pek, Yoke
[MY/US]; GlaxoSmithKline, Five Moore Drive, PO Box
13398, Research Triangle Park, NC 27709 (US). **DUAN**,
Maosheng [CN/US]; GlaxoSmithKline, Five Moore
Drive, PO Box 13398, Research Triangle Park, NC 27709
(US). **DEANDA, JR.**, Felix [US/US]; GlaxoSmithKline,
Five Moore Drive, PO Box 13398, Research Triangle
Park, NC 27709 (US). **KOBLE**, Cecilia, Suarez [VE/US];
GlaxoSmithKline, Five Moore Drive, PO Box 13398,

Research Triangle Park, NC 27709 (US). **MCLEAN**, Ed,
Williams [US/US]; GlaxoSmithKline, Five Moore Drive,
PO Box 13398, Research Triangle Park, NC 27709 (US).
PECKHAM, Jennifer, Poole [US/US]; GlaxoSmithKline,
Five Moore Drive, PO Box 13398, Research Triangle Park,
NC 27709 (US). **PERKINS**, Angilique, C [US/US]; Glaxo-
SmithKline, Five Moore Drive, PO Box 13398, Research
Triangle Park, NC 27709 (US). **THOMPSON**, James,
Benjamin [US/US]; GlaxoSmithKline, Five Moore Drive,
PO Box 13398, Research Triangle Park, NC 27709 (US).
VANDERWALL, Dana [US/US]; GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park, NC
27709 (US).

(74) Agents: **LEVY**, David, J et al.; GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park, NC
27709 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 2004/054974 A2

(54) Title: CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

(57) Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

5

FIELD OF THE INVENTION

The present invention relates to a novel class of piperidine derivatives useful as antagonists of the chemokine receptor CCR5, compositions containing such compounds and methods of treating HIV infection and associated conditions. The invention also relates to methods of treatment or prophylaxis of other CCR5 mediated diseases and disorders.

BACKGROUND OF THE INVENTION

The human immunodeficiency virus ("HIV") is the causative agent for acquired immunodeficiency syndrome ("AIDS"), a disease characterized by the destruction of the immune system, particularly of CD4⁺ T-cells, with attendant susceptibility to opportunistic infections, and its precursor AIDS-related complex ("ARC"), a syndrome characterized by symptoms such as persistent generalized lymphadenopathy, fever and weight loss.

In addition to CD4, HIV requires a co-receptor for entry into target cells. The chemokine receptors function together with CD4 as co-receptors for HIV. The chemokine receptors CXCR4 and CCR5 have been identified as the main co-receptors for HIV-1. CCR5 acts as a major co-receptor for fusion and entry of macrophage-tropic HIV into host cells. These chemokine receptors are thought to play an essential role in the establishment and dissemination of an HIV infection. Therefore, CCR5 antagonists are useful as therapeutic agents active against HIV.

CCR5 receptors have also been reported to mediate cell transfer in inflammatory and immunoregulatory diseases and disorders such as multiple sclerosis, rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma, rheumatoid arthritis, Crohns Disease, inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease, autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis,

Sjogren's syndrome (dermatomyositis), systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or organs, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis, and immune mediated disorders.


5 There is a continued need to find new therapeutic agents to treat human diseases. CCR5 is an attractive target for the discovery of new therapeutics due to its important role in viral infections, particularly HIV infections, and other inflammatory and immune diseases and disorders.

10

SUMMARY OF THE INVENTION

The present invention features compounds that are CCR5 antagonists and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC. These compounds having the general formula I:

15



wherein R^1 , R^2 , R^3 , X , Y , m , n and Ring A are as defined herein. The compounds of this invention may also be either pharmaceutically acceptable salts or pharmaceutical composition ingredients.

20

The present invention also features pharmaceutical compositions, comprising the above-mentioned compounds that are suitable for the prevention or treatment of CCR5-related diseases and conditions.

25

The present invention also features methods of antagonizing CCR5 chemokine receptor activity in a biological sample comprising contacting the biological sample with an effective amount of compounds of formula I or pharmaceutically acceptable derivatives or compositions thereof. The present invention also features methods of antagonizing CCR5 chemokine receptor activity in a patient comprising administering to the patient a therapeutically effective amount of compounds of formula I or pharmaceutically acceptable derivatives or compositions thereof.


The present invention further features methods of treating AIDS, methods of preventing infection by HIV, and methods of treating infection by HIV as monotherapy or in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines.

5 The present invention further features methods of synthesizing compounds of formula I and preparing pharmaceutical compositions comprising these above-mentioned compounds.

10

DETAILED DESCRIPTION OF THE INVENTION

The present invention features a compound of formula (I):



15

(I)

or a pharmaceutically acceptable derivative thereof, wherein:

R^1 is alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl, wherein said alkyl is optionally substituted by one or more R^7 , said carbocyclyl or heterocyclyl is optionally substituted by one or more R^8 and said aryl or heteroaryl is optionally substituted by one or more R^6 ; or R^1 and X taken together form a saturated, partially saturated or aromatic 5-7 membered ring having 0-3 heteroatoms chosen from oxygen, sulfur, nitrogen and phosphorus that is fused to Ring A;

20 X is a C_{1-5} alkylene chain, wherein said C_{1-5} alkylene chain is optionally substituted by one or more groups chosen from =O, =S and halo, and wherein said C_{1-5} alkylene chain optionally contains 1-3 heteroatoms chosen from oxygen, sulfur, nitrogen and phosphorus;

- each R^2 is independently chosen from $-OR^0$, $-C(O)R^0$, $-C(O)N(R^0)_2$, $-N(R^0)(-V_m-R^+)$, $-S(O)_2-R^0$, $-S(O)_2-N(R^0)_2$, $-(CH_2)_a-N(R^0)(-V_b-R^+)$, $-(CH_2)_a-(-V_b-R^+)$, halo, alkyl, aryl, carbocyclyl, heteroaryl and heterocyclyl, wherein said alkyl is optionally substituted by one or more R^7 , said aryl or heteroaryl is optionally substituted by one or more R^6 , and said carbocyclyl or heterocyclyl is optionally substituted by one or more R^8 ; or two adjacent R^2 s on Ring A are optionally taken together to form a fused, saturated, partially saturated or aromatic 4-7 membered ring having 0-3 heteroatoms chosen from oxygen, sulfur, nitrogen and phosphorus; or two geminal R^2 s are optionally taken together to form a spiro, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms chosen from oxygen, sulfur and nitrogen, said fused or spiro ring being optionally substituted by one or more groups chosen from oxo, alkyl optionally substituted by one or more R^7 , and aryl optionally substituted by one or more R^6 ;
- each a is independently 0-3;
- each b is independently 0 or 1;
- V is alkyl, $-C(O)-$, $-S(O)_2-$, $-C(O)O-$, or $-C(O)-N(R^0)-$ (where V is attached to R^+ through the right hand side of the radical as shown hereinafter);
- R^+ is alkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, wherein said alkyl is optionally substituted by one or more R^7 and said aralkyl or aryl is optionally substituted by one or more R^6 ;
- m is 0 or 1;
- n is 0-5;
- R^3 is H, halo, $-N(R^0)_2$, $-N(R^0)C(O)R^0$, $-CN$, $-CF_3$, alkyl optionally substituted by one or more groups chosen from R^7 , and $-S$ -aryl optionally substituted by $-(CH_2)_{1-6}-N(R^0)SO_2(R^0)$, carbocyclyl, aryl, heteroaryl or heterocyclyl, wherein said carbocyclyl or heterocyclyl is optionally substituted by one or more R^8 , and said aryl or heteroaryl is optionally substituted by one or more R^6 ;
- Y is $-(CR^4R^5)_p-$, $-C(O)-$, $-C(O)C(O)-$, $-C(S)-$, $-O-(CH_2)_{0-4}-C(O)-$, $-N(R^0)-C(O)-$, $-C(O)-N(R^0)-$, $-N(R^0)-C(S)-$, $-S(O)-$, $-O-C(=N-CN)-$,

-O-C(=N-R⁰)-, -S-C(=N-CN)-, -N(R⁰)-C(=N-CN)-, -C(=N-CN)-,
 -N(R⁰)-C[=N-C(O)-R⁰]-, -N(R⁰)-C[=N-S(O)_t-R⁰]-, -N(R⁰)-C(=N-OR⁰)-,
 -N(R⁰)-C(=N-R⁰)-, -C(=N-R⁰)-, -(CH₂)₀₋₄-C(O)-O-, -C(=N-CN)-O-,
 -C(=N-R⁰)-O-, or -C(=N-CN)-S- (where Y is attached to R³ through the left
 5 hand side of the radical as shown hereinafter);

each R⁴ is independently H or alkyl optionally substituted by R⁷;

each R⁵ is independently chosen from H, -C(O)-OR⁰, aryl optionally
 substituted by R⁶, -C(O)-OR⁶, -C(O)-N(R⁰)₂, -S(O)₂-N(R⁰)₂, -S(O)₂-R⁰, and
 heteroaryl optionally substituted by R⁶;

10 p is 1-5;

t is 1 or 2;

each R⁶ is independently chosen from halo, -CF₃,

-OCF₃, -OR⁰, -SR⁰, -SCF₃, -R⁰, methylenedioxy, ethylenedioxy, -NO₂, -CN,
 -N(R⁰)₂, -NR⁰C(O)R⁰, -NR⁰C(O)N(R⁰)₂, -NR⁰C(S)N(R⁰)₂, -NR⁰CO₂R⁰,
 15 -NR⁰NR⁰C(O)R⁰, -NR⁰NR⁰C(O)N(R⁰)₂, -NR⁰NR⁰CO₂R⁰, -C(O)C(O)R⁰,
 -C(O)CH₂C(O)R⁰, -CO₂R⁰, -O-C(O)R⁰, -C(O)R⁰, -C(O)N(R⁰)₂, -OC(O)N(R⁰)₂,
 -S(O)_tR⁰, -S(O)_t-OR⁰, -SO₂N(R⁰)C(O)R⁰, -NR⁰SO₂N(R⁰)₂, -NR⁰SO₂R⁰,
 -C(=S)N(R⁰)₂, -C(=NH)-N(R⁰)₂, -C(=N-OR⁰)-N(R⁰)₂, -O-(CH₂)₀₋₆-SO₂N(R⁰)₂,
 -(CH₂)₁₋₆NHC(O)R⁰, -SO₂N(R⁰)₂, -(CH₂)₁₋₆-OR⁰, -(CH₂)₁₋₆-SR⁰, -(CH₂)₁₋₆-CN,
 20 -(CH₂)₁₋₆-N(R⁰)₂, -(CH₂)₁₋₆CO₂R⁰, -C(O)N(R⁰)N(R⁰)₂, -C(O)N(R⁰)OH,
 -C(O)N(R⁰)SO₂R⁰, -S(O)_tN(R⁰)OR, and -(CH₂)₁₋₆-C(O)R⁰, wherein the two R⁰s
 on the same nitrogen optionally taken together forming a 5-8 membered
 saturated, partially saturated or aromatic ring having additional 0-4 ring
 heteroatoms chosen from oxygen, nitrogen, sulfur and phosphorus;

25 each R⁷ is independently chosen from halogen, -CF₃, -R⁰, -OR⁰, -SR⁰,
 aryl optionally substituted by R⁶, -NO₂, -CN, -N(R⁰)₂, -NR⁰C(O)R⁰,
 -NR⁰C(O)N(R⁰)₂, -N(R⁰)C(S)N(R⁰)₂, -NR⁰CO₂R⁰, -NR⁰NR⁰C(O)R⁰,
 -NR⁰NR⁰C(O)N(R⁰)₂, -NR⁰NR⁰CO₂R⁰, -C(O)C(O)R⁰, -C(O)CH₂C(O)R⁰,
 -CO₂R⁰, -C(O)R⁰, -C(O)N(R⁰)-N(R⁰)₂, -C(O)N(R⁰)₂, -C(O)NR⁰SO₂R⁰,
 30 -OC(O)N(R⁰)₂, -S(O)_tR⁰, -NR⁰SO₂N(R⁰)₂, -NR⁰SO₂R⁰, -C(=S)N(R⁰)₂,
 -C(=NH)-N(R⁰)₂, -(CH₂)₁₋₆-C(O)R⁰, -SO₂N(R⁰)₂, -OCF₃, -SCF₃, -(CH₂)₁₋₆-SR⁰,
 methylenedioxy, ethylenedioxy, -(CH₂)₁₋₆-CN, -(CH₂)₁₋₆-N(R⁰)₂,

-S(O)_tN(R⁰)OR⁰, -(CH₂)₁₋₆-C(O)R⁰, -C(=N-OR⁰)-N(R⁰)₂, -O-(CH₂)₀₋₆-SO₂N(R⁰)₂, and -(CH₂)₁₋₆-NHC(O)R⁰, wherein the two R⁰s on the same nitrogen optionally taken together form a 5-8 membered saturated, partially saturated or aromatic ring having additional 0-4 ring heteroatoms chosen from oxygen, nitrogen, sulfur and phosphorous;

each R⁸ is independently chosen from R⁷, =O, =S, =N(R⁰), and =N(CN);

each R⁰ is independently chosen from R*, -C(O)-aralkyl, -S(O)_t-heteroaryl, carbocyclalkyl, aralkyl, heteroaralkyl, and heterocyclalkyl, wherein each member of R⁰ except H is optionally substituted by one or more groups chosen from R*, -OR*, N(R*)₂, =O, =S, halo, -CF₃, -NO₂, -CN, -C(O)R*, -CO₂R*, -C(O)-aryl, -C(O)-heteroaryl, -O-aryl, aralkyl, -S(O)_t-aryl, -NR*SO₂R*, -NR*C(O)R*, -NR*C(O)N(R*)₂, -N(R*)C(S)N(R*)₂, -NR*CO₂R*, -NR*NR*C(O)R*, -NR*NR*C(O)N(R*)₂, -NR*NR*CO₂R*, -C(O)C(O)R*, -C(O)CH₂C(O)R*, -C(O)N(R*)N(R*)₂, -C(O)N(R*)₂, -C(O)NR*SO₂R*, -OC(O)N(R*)₂, -S(O)_tR*, -NR*SO₂N(R*)₂, and -SO₂N(R*)₂ wherein the two R*s on the same nitrogen optionally taken together form a 5-8 membered saturated, partially saturated or aromatic ring having additional 0-4 ring heteroatoms chosen from oxygen, nitrogen, sulfur and phosphorus; and

each R* is independently H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclalkyl;

provided that when R¹ is m-methylphenyl, X is a C₂ unsubstituted saturated alkylene chain, and R² substituted Ring A is 4-benzyl or 4-phenyl-4'-hydroxy substituted N-piperinyl, R³-(Y)_m- is other than H, triphenylmethyl, benzoyl, 2,4-dimethoxybenzoyl, (3,5-dimethoxyphenyl)acetyl, or (3-chlorophenyl)acetyl.

As used herein, the following definitions shall apply unless otherwise indicated. The phrase "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted" or with the term "(un)substituted." Unless otherwise indicated, an optionally substituted group may have a

substituent at each substitutable position of the group, and each substitution is independent of the other.

The term "alkyl", alone or in combination with any other term, refers to a C₁₋₂₀ straight or branched acyclic hydrocarbon radical that is either
5 completely saturated or contains one or more units of unsaturation.

Preferably, an alkyl radical contains from one to twelve carbon atoms. More preferably, an alkyl radical contains from one to eight carbon atoms. A C₂₋₂₀

linear or branched alkyl radical having at least one carbon-carbon double bond is also referred to as "alkenyl". The double bond(s) of the unsaturated

10 hydrocarbon chain may be in either the cis or trans configuration and may occur in any stable point along the chain. A C₂₋₂₀ linear or branched alkyl having at least one carbon-carbon triple bond is also referred to as "alkynyl".

The triple bond(s) in an alkynyl radical may occur in any stable point along the chain. The terms "alkoxy", "hydroxyalkyl", "alkoxyalkyl", and "alkoxycarbonyl",

15 alone or in combination with any other term, include both straight and branched hydrocarbon chains.

Examples of alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, n-hexyl, ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, hexenyl,
20 hexadienyl, ethynyl, propynyl, butynyl, pentynyl and the like.

The term "alkoxy" refers to an alkyl ether radical (–O-alkyl). Examples of alkoxy radicals include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like.

The term "cycloalkyl", "carbocyclyl", "carbocyclic", "carbocycle", or
25 "carbocyclo", alone or in combination with any other term, refers to a monocyclic or polycyclic non-aromatic hydrocarbon ring radical having three to twenty carbon atoms, preferably from three to twelve carbon atoms, and more preferably from three to ten carbon atoms. If polycyclic, each ring in a carbocyclyl radical is non-aromatic unless otherwise indicated. A carbocyclyl
30 radical is either completely saturated or contains one or more units of unsaturation but is not aromatic. The unsaturation, if present, may occur in any point in the ring that may result in any chemically stable configuration.

The term "cycloalkyl", "carbocyclyl", "carbocyclic", "carbocycle", or "carbocyclo" also includes hydrocarbon rings that are fused to one or more aromatic rings, such as in tetrahydronaphthyl, where the radical or point of attachment is on the non-aromatic ring.

5 Unless otherwise indicated, the term "cycloalkyl", "carbocyclyl", "carbocyclic", "carbocycle", or "carbocyclo" also includes each possible positional isomer of a non-aromatic hydrocarbon radical, such as in 1-decahydronaphthyl, 2-decahydronaphthyl, 1-tetrahydronaphthyl and 2-tetrahydronaphthyl. Examples of suitable cycloalkyl groups include, but are
10 not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, decahydronaphthyl, tetrahydronaphthyl and the like.

The term "halogen" refers fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).

The term "aryl", alone or in combination with any other term, refers to
15 an aromatic monocyclic or polycyclic hydrocarbon ring radical containing five to twenty carbon atoms, preferably from six to fourteen carbon atoms, and more preferably from six to ten carbon atoms. Also included within the scope of the term "aryl", as it is used herein, is a group in which an aromatic hydrocarbon ring is fused to one or more non-aromatic carbocyclic or
20 heteroatom-containing rings, such as in an indanyl, phenanthridinyl or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic hydrocarbon ring.

Unless otherwise indicated, the term "aryl" also includes each possible positional isomer of an aromatic hydrocarbon radical, such as in 1-naphthyl,
25 2-naphthyl, 5-tetrahydronaphthyl, 6-tetrahydronaphthyl, 1-phenanthridinyl, 2-phenanthridinyl, 3-phenanthridinyl, 4-phenanthridinyl, 7-phenanthridinyl, 8-phenanthridinyl, 9-phenanthridinyl and 10-phenanthridinyl. Examples of aryl radicals include, but are not limited to, phenyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl, indanyl,
30 phenanthridinyl and the like. The term "aralkyl" refers to an alkyl group substituted by an aryl. Examples of aralkyl groups include, but are not limited to, benzyl and phenethyl.

The term "heterocycle", "heterocyclic", or "heterocyclyl", alone or in combination with any other term, refers to a non-aromatic monocyclic or polycyclic ring radical containing three to twenty carbon atoms, preferably three to seven carbon atoms if monocyclic and eight to eleven carbon atoms if bicyclic, and in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, and S. If polycyclic, each ring in a heterocyclyl radical is non-aromatic unless otherwise indicated. A heterocyclic ring may be fully saturated or may contain one or more units of unsaturation but is not aromatic. The unsaturation, if present, may occur in any point in the ring that may result in any chemically stable configuration. The heterocyclic ring may be attached at a carbon or heteroatom that results in the creation of a stable structure. Preferred heterocycles include 5-7 membered monocyclic heterocycles and 8-10 membered bicyclic heterocycles.

Also included within the scope of the term "heterocycle", "heterocyclic", or "heterocyclyl" is a group in which a non-aromatic heteroatom-containing ring is fused to one or more aromatic rings, such as in an indoliny, chromanyl, phenanthridinyl or tetrahydro-quinoliny, where the radical or point of attachment is on the non-aromatic heteroatom-containing ring. Unless otherwise indicated, the term "heterocycle", "heterocyclic", or "heterocyclyl" also includes each possible positional isomer of a heterocyclic radical, such as in 1-decahydroquinoline, 2-decahydroquinoline, 3-decahydroquinoline, 4-decahydroquinoline, 5-decahydroquinoline, 6-decahydroquinoline, 7-decahydroquinoline, 8-decahydroquinoline, 4a-decahydroquinoline, 8a-decahydroquinoline, 1-indoliny, 2-indoliny, 3-indoliny, 1-tetrahydroquinoline, 2-tetrahydro-quinoline, 3-tetrahydroquinoline and 4-tetrahydro-quinoline. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl.

Examples of heterocyclic groups include, but are not limited to, imidazoliny, 2,3-dihydro-1H-imidazolyl, imidazolidiny, indazolinoly, perhydropyridazyl, pyrroliny, pyrrolidiny, 4H-pyrazolyl, piperidiny, pyranly, pyrazolinyl, piperazinyl, morpholinyl, thiamorpholinyl, thiazolidiny,

thiamorpholinyl, oxopiperidinyl, oxopyrrolidinyl, azepinyl, tetrahydrofuranyl, oxoazepinyl, tetrahydropyranyl, thiazolyl, dioxolyl, dioxinyl, oxathiyl, benzodioxolyl, dithiyl, dithiolanyl, tetrahydrothiophenyl, sulfolanyl, dioxanyl, dioxolanyl, tetrahydrofurodihydrofuranyl, dihydropyranyl,
5 tetrahydropyranodihydrofuranyl, tetrahydrofurofuranyl, tetrahydropyranofuranyl, diazolonyl, phthalimidinyl, benzoxanyl, benzopyrrolidinyl, benzopiperidinyl, benzoxolanyl, benzothiolanyl and benzothianyl.

The term "heteroaryl", alone or in combination with any other term, refers to an aromatic monocyclic or polycyclic ring radical containing five to
10 twenty carbon atoms, preferably five to ten carbon atoms, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, S and P. Preferred heteroaryl groups include 5-6 membered monocyclic heteroaryls and 8-10 membered bicyclic heteroaryls.

Also included within the scope of the term "heteroaryl" is a group in
15 which a heteroaromatic ring is fused to one or more aromatic or non-aromatic rings where the radical or point of attachment is on the heteroaromatic ring. Examples include, but are not limited to, pyrido[3,4-d]pyrimidinyl, 7,8-dihydro-pyrido[3,4-d]pyrimidine and 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidine. Unless otherwise indicated, the term "heteroaryl" also includes each possible
20 positional isomer of a heteroaryl radical, such as in 2-pyrido[3,4-d]pyrimidinyl and 4-pyrido[3,4-d]pyrimidinyl. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl.

Examples of heteroaryl groups include, but are not limited to, imidazolyl, quinolyl, isoquinolyl, indolyl, indazolyl, pyridazyl, pyridyl, pyrrolyl,
25 pyrazolyl, pyrazinyl, quinoxalyl, pyrimidinyl, pyridazinyl, furyl, thienyl, triazolyl, thiazolyl, carbazolyl, carbolinyl, tetrazolyl, benzofuranyl, oxazolyl, benzoxazolyl, isoxazolyl, isothiazolyl, thiadiazolyl, furazanyl, oxadiazolyl, benzimidazolyl, benzothienyl, quinolinyl, benzotriazolyl, benzothiazolyl, isoquinolinyl, isoindolyl, acridinyl and benzoisoxazolyl.

30 The term "heteroatom" means nitrogen, oxygen, sulfur, or phosphorus and includes any oxidized form of nitrogen, such as N(O) [N⁺-O⁻], sulfur such as S(O) and S(O)₂, phosphorus such as PO₃ and PO₄ and the quaternized

form of any basic nitrogen. Suitable substituents on a substitutable ring nitrogen include alkyl, $-N(R')_2$, $-C(O)R'$, $-CO_2R'$, $-C(O)C(O)R'$, $-C(O)CH_2C(O)R'$, $-SO_2R'$, $-SO_2N(R')_2$, $-C(=S)N(R')_2$, $-C(=NH)-N(R')_2$, and $-NR'SO_2R'$; wherein R' is hydrogen, alkyl, phenyl (Ph), $-OPh$, $-CH_2Ph$, wherein
5 said alkyl or phenyl is optionally substituted by one or more groups independently chosen from alkyl, amino, alkylamino, dialkylamino, aminocarbonyl, halo, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxy carbonyl, alkyl carbonyl, hydroxy, haloalkoxy, and haloalkyl.

10 The term "alkylene chain" refers to a straight or branched hydrocarbon chain that may be fully saturated or have one or more units of unsaturation. The unsaturation may occur in any stable point along the chain. The double bond(s) in the unsaturated alkylidene chain may be in either the cis or trans configuration.

15 A combination of substituents or variables is permissible only if such a combination results in a stable or chemically feasible compound. A stable compound or chemically feasible compound is one in which the chemical structure is not substantially altered when kept at a temperature of 40 °C or less, in the absence of moisture or other chemically reactive conditions, for at
20 least a week.


Unless otherwise stated, structures depicted herein are also meant to include all endo or exo, cis or trans isomers as well as all stereochemical forms of the structure, i.e., the R and S configurations for each asymmetric center. Therefore, racemates and racemic mixtures, single enantiomers,
25 diastereomeric mixtures and individual diastereoisomers of the present compounds are expressly included within the scope of the invention. Although the specific compounds exemplified herein may be depicted in a particular stereochemical configuration, compounds having either the opposite stereochemistry at any given chiral center or mixtures thereof are also
30 envisioned.

Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more

isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a ^{13}C - or ^{14}C -enriched carbon are also within the scope of this invention.

5 It will be apparent to one skilled in the art that certain compounds of this invention may exist in alternative tautomeric forms. All such tautomeric forms of the present compounds are within the scope of the invention. Unless otherwise indicated, the representation of either tautomer is meant to include the other.

10 Certain preferred compounds of the present invention are those represented by formula II:



or a pharmaceutically acceptable derivative thereof, wherein R^2 , R^3 , R^6 , n , Y and Ring A are as defined for formula I.

15 Preferred compounds of formula II are those wherein Ring A is a heterocycle having one ring nitrogen and 0-1 additional ring oxygen or ring nitrogen. Other preferred compounds of formula II are those wherein Ring A is piperidinyl, piperaziny, pyrrolidinyl, azabicyclo[3.2.1] octanyl, aza-bicyclo[3.2.1]octenyl or oxa-aza-bicyclo [4.3.1]decanyl. In some embodiments
20 of the invention, Ring A is connected to the alkylene chain X through an endocyclic nitrogen.

Also preferred are compounds of formula II, wherein R^2 is aryl, aralkyl, heteroaryl, heterocyclyl, $-\text{N}(\text{H})(-\text{V}_m-\text{R}^+)$, or $-\text{N}(\text{alkyl})(-\text{V}_m-\text{R}^+)$, wherein V is $-\text{C}(\text{O})-$, $-\text{S}(\text{O})_2-$, $-\text{C}(\text{O})\text{O}-$ or $-\text{C}(\text{O})-\text{N}(\text{H})-$, m is 0 or 1, R^+ is phenyl or benzyl,
25 and said aryl, aralkyl, heteroaryl or heterocyclyl is optionally substituted. More preferably, R^2 of compounds of formula II is phenyl, naphthyl, benzyl, $-\text{NH}$ -phenyl, $-\text{NH}$ -benzyl, $-\text{NHC}(\text{O})$ -phenyl, $-\text{NHSO}_2$ -phenyl,

-NHC(O)NH-phenyl, benzoimidazolyl, dihydrobenzo-imidazolyl, oxodihydrobenzoimidazolyl, 3H-indolyl, quinolinyl, dihydro-1H-isoindolyl, dioxodihydro-1H-isoindolyl, tetrahydroquinoxalyl, dioxotetrahydro-quinoxalyl, 3H-imidazo[4,5-b]pyridinyl, dihydro-1H-imidazo [4,5-b]pyridinyl, 5 benzotriazolyl, oxadiazolyl or triazolyl, wherein each member of R² is optionally substituted. Preferred substituents of R² include alkyl, halo, -SO₂R⁰, -CF₃, alkoxy, -NR⁰, -N(R⁰)C(O)R⁰, -N(R⁰)C(O)OR⁰, -N(R⁰)C(S)N(R⁰)₂, =O, -(CH₂)₁₋₆-C(O)R⁰, optionally substituted alkyl, and optionally substituted aralkyl. More preferred substituents of R² include 10 methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, F, Cl, -SO₂CH₃, -CF₃, -OMe, -OEt, -NH₂, -NHMe, -N(H)C(O)Me, -N(H)C(O)OMe, -N(H)C(O)OEt, -N(H)C(S)N(H)(Me), =O, -(CH₂)₂SO₂Ph, =O, -CH₂-C(O)-cyclopropyl, and methoxy substituted benzyl. Preferably, n is 1-3, and more preferably, n is 1-2. In certain embodiments of the invention, R² is attached to Ring A through a 15 R² nitrogen.


Preferred Y of formula II includes -C(O)-, -O-C(O)-, -N(R⁰)-C(O)-, -S(O)₂-, -O-C(=N-CN)-, -S-C(=N-CN)-, -N(R⁰)-C(=N-CN)-, -C(=N-CN)-, -N(R⁰)-C(S)-, -N(R⁰)-C(=N-OR⁰)-, -N(R⁰)-C[=N-S(O)_t-R⁰], -O-C(=N-R⁰)-, -N(R⁰)-C[=N-C(O)-R⁰], -N(R⁰)-C(=N-R⁰)-, and -C(=N-R⁰)-. More preferably, 20 each R⁰ in Y is independently R* and m is 1.

Preferred R³ of formula II includes optionally substituted alkyl, aryl, heteroaryl, heterocyclyl and carbocyclyl. More preferred R³ of formula II includes optionally substituted fully saturated alkyl, 3-7 membered carbocyclyl, 5-7 membered aryl, 6-10 membered heteroaryl and 4-10 25 membered heterocyclyl. Even more preferred R³ of formula II includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclohexenyl, tetrahydrofuranyl, azetidiny, piperidinyl, hexahydrofuro[2,3-b]furanyl, oxopyrrolidinyl, dihydro-2H-[1,3]thiazinyl, tetrahydro-pyrimidinyl, dihydrobenzo[1,4]dioxinyl, dihydro-2H-benzo[1,2,4]thiadiazinyl, 30 dihydrobenzo[d]isothiazolyl, morpholinyl, dihydro-1H-imidazolyl, dihydrobenzooxazolyl, chromenyl, dihydroquinolinyl, pyrrolyl, benzotriazolyl, benzothiazolyl, benzofuranyl, furanyl, pyridyl, thienyl, thiadiazolyl, isoxazolyl,


triazolyl, thiazolyl, benzoyl, isothiazolyl, imidazolyl, indolyl, pyrazolo[3,4-b]pyridinyl, quinoxalynyl, and phenyl. Preferred substituents of R³ includes halo, methylenedioxy, -OR⁰, R⁰, -C(O)OR⁰, -SO₂R⁰, -SO₂(OR⁰), -SO₂N(R⁰)₂, -SO₂N(R⁰)OR⁰, and -SO₂N(R⁰)C(O)R⁰. More preferred substituents of R³ includes Cl, Br, F, CF₃, Me, tetrazolyl, methylenedioxy, -OMe, -C(O)OH, -SO₂R⁰, -SO₂(OH), -SO₂NH₂, -SO₂NHMe, -SO₂N(H)C(O)Me, and -SO₂N(H)OMe.


In certain embodiments of the invention, $-(Y)_m-R^3$ is selected from the following:


10




15 More preferably, $-(Y)_m-R^3$ is selected from the following:







18



5

In one embodiment m is 1, Y is $-\text{C}(\text{O})-$, and R³ is aryl, heteroaryl, alkyl, or cycloalkyl, each optionally substituted.

10 In one embodiment m is 1, Y is $-(\text{C}=\text{N}-\text{CN})-\text{O}-$, and R³ is optionally substituted aryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocycl.

In one embodiment m is 1, Y is $-(CH_2)-$, and R^3 is optionally substituted aryl.

5 In one embodiment m is 1, Y is $-C(O)O-$, and R^3 is optionally substituted alkyl or optionally substituted aryl.

In one embodiment m is 0 and R^3 is optionally substituted heteroaryl or optionally substituted heterocyclyl.


10

In one embodiment X is $-(CH_2)-$, $-(CH_2-CH_2)-$, or $-(CH_2-CH_2-CH_2)-$. Further X is optionally substituted by one or more halogen or oxo. Still further X is disubstituted with halogen. Still further X is disubstituted with fluoro. Specifically X may be $-(CF_2-CH_2)-$. Further X optionally has 1-3 heteroatoms selected from oxygen, phosphorus, sulfur, or nitrogen.


15





In one embodiment the A ring is selected from the following, where the asterisk (*) indicates the preferred, but not limiting, point(s) of substitution:

20








Suitably each R^2 , with the asterisk (*) indicating a preferred, but not limiting, point of substitution from Ring A, independently is selected from







5





23







Suitably the A ring is tropane or piperidine, either optionally substituted with one or more R². Preferably, A--R² is comprised of one of the following:








27






In one embodiment the A ring contains at least one additional nitrogen atom and said A ring optionally is N-substituted. Suitably the A ring is N-substituted with $-(CH_2)_a-(V_b-R^+)$.


Preferred R^6 of formula II includes alkyl, halo, SO_2R^0 and $SO_2N(R^0)_2$. More preferred R^6 of formula II includes Me, F, Cl, SO_2NH_2 , SO_2Me , and methylenedioxy.

Other preferred compounds of the present invention are those represented by formula III:



or a pharmaceutically acceptable derivative thereof, wherein R^2 , R^3 , R^5 , R^6 , n and Ring A are as defined for formula I. Preferred compounds of formula III are those wherein R^3 is optionally substituted aryl. More preferably, R^3 is phenyl optionally substituted by one or more alkyl (such as Me) or halo (such as F and Cl).

Other preferred compounds of the present invention are those represented by formulae IV-IX:



R^3 in formulae IV-VII is as defined for formula I.

Preferred compounds of formula I have one or more, and more preferably all, of the features selected from the group consisting of:

- (a) R^1 is alkyl, aryl, heteroaryl or heterocyclyl, wherein said alkyl is optionally substituted by one or more R^7 , said aryl or heteroaryl is optionally substituted by one or more R^6 , and said heterocyclyl is optionally substituted by one or more R^8 ;
- (b) X is a C_{1-5} alkylene chain optionally substituted by one or more groups chosen from =O and halo;
- (c) Ring A is an 8-10 membered bicyclic ring having 0-5 ring heteroatoms chosen from oxygen, sulfur and nitrogen;
- (d) R^2 is aryl, heteroaryl or heterocyclyl, wherein said aryl or heteroaryl is optionally substituted by one or more R^6 and said heterocyclyl is optionally substituted by one or more R^8 ;
- (e) Y is $-C(R^0)[C(O)OR^0]-$, $-C(O)-$, $-O-C(O)-$, $-N(R^0)-C(O)-$, $-S(O)_2-$, $-O-C(=N-CN)-$, $-S-C(=N-CN)-$, $-N(R^0)-C(=N-CN)-$,

-C(=N-CN)-, -N(R⁰)-C(S)-, -N(R⁰)-C(=N-OR⁰)-,
 -N(R⁰)-C[=N-S(O)_t-R⁰], -O-C(=N-R⁰)-, -N(R⁰)-C[=N-C(O)-R⁰],
 -N(R⁰)-C(=N-R⁰)-, or -C(=N-R⁰)-; wherein each R⁰ is independently R* and m
 is 1; and

- 5 (f) R³ is alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl,
 wherein said alkyl is optionally substituted by one or more R⁷, said aryl or
 heteroaryl is optionally substituted by one or more R⁶, and said heterocyclyl or
 carbocyclyl is optionally substituted by one or more R⁸.

More preferred compounds of the present invention have one or more,
 10 and more preferably all, of the features selected from the group consisting of:

(a) R¹ is aryl optionally substituted by one or more R⁶;

(b) X is a C₂ alkylene chain optionally substituted by one or more
 groups chosen from =O and halo;

(c) Ring A is an 8-9 membered bicyclic ring having one ring
 15 nitrogen and 0-4 additional ring heteroatoms chosen from oxygen, sulfur and
 nitrogen;

(d) R² is heteroaryl optionally substituted by one or more R⁶, or
 heterocyclyl optionally substituted by one or more R⁸;

(e) Y is -C(R⁰)[C(O)OR⁰]-, -CH(COOH)-, -C(O)-, -O-C(O)-,
 20 -N(R⁰)-C(O)-, -O-C(=N-CN)-, or -N(R⁰)-C(S)-; wherein each R⁰ is
 independently R* and m is 1; and

(f) R³ is alkyl optionally substituted by one or more R⁷, aryl or
 heteroaryl wherein said aryl or heteroaryl is optionally substituted by one or
 more R⁶.

25 Other more preferred compounds of the present invention have one or
 more, and more preferably all, of the features selected from the group
 consisting of:

(a) R¹ is phenyl optionally substituted by one or more groups
 chosen from alkyl, halo, -OR⁰, -CF₃, R⁰, -SO₂R⁰, methylenedioxy and -
 30 SO₂N(R⁰)₂; wherein each R⁰ is independently R*;

(b) X is a saturated C₂ alkylene chain optionally substituted by
 one or more groups chosen from =O and halo;

(c) Ring A is an 8-9 membered non-aromatic bicyclic ring having one ring nitrogen and 0-1 additional ring heteroatoms chosen from oxygen, sulfur and nitrogen;

(d) R² is a 9-10 membered bicyclic heteroaryl or heterocyclyl each having one to three ring nitrogens, wherein said heteroaryl is optionally substituted by one or more groups chosen from alkyl, halo, -SO₂R⁰, -CF₃, alkoxy, -NR⁰, -N(R⁰)C(O)R⁰, -N(R⁰)C(O)OR⁰, and -N(R⁰)C(S)N(R⁰)₂ and said heterocyclyl is optionally substituted by one or more groups chosen from alkyl, halo, -SO₂R⁰, -CF₃, alkoxy, -NR⁰,
10 -N(R⁰)C(O)R⁰, -N(R⁰)C(O)OR⁰, -N(R⁰)C(S)N(R⁰)₂ and =O;

(e) Y is -CH(COOH)-, -CH(COOMe)-, -C(O)-, -O-C(O)-, -N(R⁰)-C(O)-, -O-C(=N-CN)-, or -N(R⁰)-C(S)-; wherein each R⁰ is independently H and m is 1; and

(f) R³ is methyl, butyl, pentyl, cyclobutyl optionally substituted by one or more R⁸, phenyl, pyrazolyl, thiadiazolyl, benzotriazolyl, pyrrolyl, benzothiazolyl, benzofuranyl, furanyl, pyridyl, thienyl, isoxazolyl, triazolyl, thiazolyl, isothiazolyl, imidazolyl, indolyl, pyrazolo[3,4-b]pyridinyl, or quinoxalinyl, wherein each member of R³ except methyl, butyl, pentyl and cyclobutyl is optionally substituted by one or more R⁶ and said methyl, butyl
20 and pentyl are optionally substituted by one or more R⁷.

Even more preferred compounds of the present invention have one or more, and more preferably all, of the features selected from the group consisting of:

(a) R¹ is phenyl optionally substituted by one or more groups
25 chosen from halo, -CF₃, methyleneoxy, alkyl, alkoxy and sulfonamide;

(b) X is a saturated C₂ alkylene chain;

(c) Ring A is azabicyclo[3.2.1]octanyl or piperidinyl;


(d) R² is benzoimidazolyl, imidazo[4,5-b]pyridinyl, benzotriazolyl, or oxadiazolyl, wherein each member of R² is optionally substituted by one or
30 more groups chosen from alkyl, halo, R⁰, -SO₂R⁰, -CF₃, alkoxy, benzyl, -CH₂-pyridyl and -NR⁰;

(e) Y is -C(O)-, -C(S)-, -C(O)C(O)-, -O-C(O)-, -CH(COOH)-,

-CH(COOMe)-, -NH-C(O)-, -NH-C(S)-, -SO₂-, -CH₂-, or -O-C(=N-CN)- and m is 0 or 1; and

- (f) R³ is methyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptanyl, phenyl, naphthyl, thienyl, furanyl, benzofuranyl, thiazolyl, isothiazolyl, isoxazolyl, pyrazolyl, pyrrolyl, piperidinyl, pyrimidinyl, benzoxazole-2-thionyl, imidazolyl, oxiranyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, thioxodihydrotriazinonyl, dihydrotetrazolethionyl, benzotriazolyl, pyrrolidinonyl, pyrrolidine-2,5-dionyl, imidazolidin-2-onyl, indolyl, dihydrofuran-2-onyl, pyrimidine-2,4-dionyl, quinolinyl, pyran-2-onyl, benzothiazolyl, dihydrobenzo[1,4]dioxinyl, quinoxalinyl, chromen-4-onyl, tetrazolyl, pyridyl, thiadiazolyl or thiazinedionyl, wherein said R³ is optionally substituted by one or more groups chosen from -C(O)OR⁰, -C(O)N(R⁰)SO₂R⁰, -N(R⁰)C(O)R⁰, -N(R⁰)C(O)OR⁰, NO₂, CN, CF₃, halo, methylenedioxy, -OR⁰, -N(R⁰)₂, R⁰, tetrazolyl, -SO₂R⁰, -SO₂(OR⁰), -SO₂N(R⁰)₂, -SO₂N(R⁰)OR⁰, -SO₂N(CH₂CH₂OR⁰)₂, -O-SO₂N(R⁰)₂, -NR⁰SO₂R⁰, -N(R⁰)C(O)N(R⁰)₂, -SO₂N(R⁰)(CH₂CF₃), -SO₂NH(cyclopropyl), and -SO₂N(R⁰)-C(O)R⁰.

- 20 The compounds of this invention generally may be prepared from known or readily prepared starting materials, following methods known to those skilled in the art, such as those illustrated by general Scheme I below, wherein R corresponds to R₃-(Y)_m- in formula I, and by the examples described herein.

Scheme I

Other compounds of this invention may be prepared by one skilled in the art following the teachings of the specification coupled with knowledge in the art using reagents that are readily synthesized or commercially available.

Compounds of the present invention are useful as CCR5 antagonists. One aspect of the instant invention relates to methods of antagonizing CCR5 chemokine receptor activity in a biological sample comprising contacting the biological sample with compounds of formula I or pharmaceutically acceptable derivatives thereof. Another aspect of the instant invention relates to methods of antagonizing CCR5 chemokine receptor activity in a patient comprising administering to the patient with a therapeutically effective amount of compounds of formula I or pharmaceutically acceptable derivatives thereof. The antagonistic activity of the present compounds towards the chemokine

receptor CCR5 may be assayed by methods known in the art, for example, by using the methods as described in example 801.

According to one embodiment of the invention, compounds of formulae I-VII or salts thereof may be formulated into compositions. In a preferred
5 embodiment, the composition is a pharmaceutical composition, which comprises a compound of formula I and pharmaceutically acceptable carrier, adjuvant or vehicle. In one embodiment, the composition comprises an amount of a CCR5 antagonist of the present invention effective to antagonize CCR5 chemokine receptor activity in a biological sample or in a patient. In
10 another embodiment, compounds of this invention and pharmaceutical compositions thereof, which comprise an amount of a CCR5 antagonist of the present invention effective to antagonize CCR5 chemokine receptor activity to treat or prevent a CCR5-mediated disease or disorder and a pharmaceutically acceptable carrier, adjuvant or vehicle, may be formulated for administration
15 to a patient, for example, for oral administration.

The term "pharmaceutically effective amount" or "therapeutically effective amount" refers to an amount of a compound of this invention that is effective in treating a CCR5-related disease, for example a virus infection, for example an HIV infection, in a patient either as monotherapy or in
20 combination with other agents.

The term "antagonist of CCR5 chemokine receptor" refers to a compound that binds to the chemokine receptor CCR5 but fails to elicit a response thereby blocking agonist action. The term "antagonizing CCR5 chemokine receptor" refers to binding to the receptor but failing to elicit a
25 response thereby blocking agonist action, i.e, inhibiting a function of CCR5. For example, an antagonist of CCR5 chemokine receptor may inhibit the binding of one or more ligands (e.g., MIP-1 α , RANTES, MIP-1 β , and gp120) to CCR5 and/or inhibit signal transduction mediated through CCR5 (e.g., GDP/GTP exchange by CCR5-associated G proteins, intracellular calcium
30 flux). Accordingly, CCR5-mediated processes and cellular responses (e.g., proliferation, migration, chemotactic responses, secretion or degranulation) can be inhibited with an antagonist of CCR5.

The term "CCR5 mediated disease or disorder" or "CCR5 related disease or disorder" is used herein at all occurrences to mean any disease, disorder or other deleterious condition or state in which CCR5 is known to play a role.

5 The term "treatment" as used herein refers to the alleviation of symptoms of a particular disorder in a patient, or the improvement of an ascertainable measurement associated with a particular disorder, and may include the suppression of symptom recurrence in an asymptomatic patient such as a patient in whom a viral infection has become latent. The term
10 "prophylaxis" refers to preventing a disease or condition or preventing the occurrence of symptoms of such a disease or condition, in a patient. As used herein, the term "patient" refers to a mammal, including a human.

As used herein, the term "subject" refers to a patient or a biological sample. The term "biological sample", as used herein, includes, without
15 limitation, cell cultures or extracts thereof; preparations of an enzyme suitable for *in vitro* assay; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.

The term "pharmaceutically acceptable carrier, adjuvant or vehicle"
20 refers to a carrier, adjuvant or vehicle that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the therapeutic agent.

The term "pharmaceutically acceptable derivative" means any
25 pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favored derivatives are those that increase the bioavailability of the compounds of this
30 invention when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological

compartment (e.g., the brain or lymphatic system) relative to the parent species.

Throughout this specification, the word "comprise" or variations such as "comprises" or "comprising" will be understood to imply the inclusion of a
5 stated integer or groups of integers but not the exclusion of any other integer or group of integers.

Pharmaceutically acceptable salts of the compounds according to the invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include
10 hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be
15 employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g., magnesium), ammonium, NW_4^+ (wherein W is C_{1-4}
20 alkyl) and other amine salts. Physiologically acceptable salts of a hydrogen atom or an amino group include salts of organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids and inorganic acids such as hydrochloric, sulfuric,
25 phosphoric and sulfamic acids. Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as Na^+ , NH_4^+ , and NW_4^+ (wherein W is a C_{1-4} alkyl group).

Any reference to any of the above compounds also includes a
30 reference to a pharmaceutically acceptable salt thereof.

Salts of the compounds of the present invention may be made by methods known to a person skilled in the art. For example, treatment of a

compound of the present invention with an appropriate base or acid in an appropriate solvent will yield the corresponding salt.

Esters of the compounds of the present invention are independently selected from the following groups: (1) carboxylic acid esters obtained by
5 esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl
10 optionally substituted by, for example, halogen, C₁₋₄alkyl, or C₁₋₄alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C₁₋₂₀ alcohol or
15 reactive derivative thereof, or by a 2,3-di (C₆₋₂₄)acyl glycerol.

In such esters, unless otherwise specified, any alkyl moiety present advantageously contains from 1 to 18 carbon atoms, particularly from 1 to 6 carbon atoms, more particularly from 1 to 4 carbon atoms. Any cycloalkyl moiety present in such esters advantageously contains from 3 to 6 carbon
20 atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group.

The present invention features compounds according to the invention for use in medical therapy, for example for the treatment including prophylaxis of CCR5-related diseases and disorders, including but not limited to, viral
25 infections such as an HIV infection and associated conditions.

As discussed above, the compounds of the present invention are CCR5 antagonists. Accordingly, these compounds are capable of targeting and inhibiting the entry of a virus, e.g. HIV, into its target cell. The compounds according to the invention are especially useful for the treatment
30 of AIDS and related clinical conditions such as AIDS related complex (ARC), progressive generalized lymphadenopathy (PGL), Kaposi's sarcoma, thrombocytopenic purpura, AIDS-related neurological conditions such as

AIDS dementia complex, multiple sclerosis or tropical paraperesis, anti-HIV antibody-positive and HIV-positive conditions, including such conditions in asymptomatic patients.

According to another aspect, the present invention provides a method
5 for the treatment including prevention of the symptoms or effects of a viral infection in an infected patient, for example, a mammal including a human, which comprises treating said patient with a pharmaceutically effective amount of a compound according to the invention. According to one aspect of the invention, the viral infection is a retroviral infection, in particular an HIV
10 infection. A further aspect of the invention includes a method for the treatment including prevention of the symptoms or effects of an HBV infection.

The compounds according to the invention may also be used in adjuvant therapy in the treatment of HIV infections or HIV-associated symptoms or effects, for example Kaposi's sarcoma.

15 The compounds of the present invention may also be used in the treatment (including prevention) of other CCR5-related diseases and conditions, including multiple sclerosis, rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma and topic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, Crohns Disease,
20 inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease, autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis, Sjogren's syndrome (dermatomyositis), systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or
25 organs, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis, psoriasis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), sarcoidosis, immune-mediated disorders, and bacterial infections, including bubonic and pneumonic plague, particularly infections of Yersinia pestis.

30 The present invention further provides a method for the treatment of a clinical condition in a patient, for example, a mammal including a human which clinical condition includes those which have been discussed

hereinbefore, which comprises treating said patient with a pharmaceutically effective amount of a compound according to the invention. The present invention also includes a method for the treatment including prophylaxis of any of the aforementioned diseases or conditions.

5 In yet a further aspect, the present invention provides the use of a compound according to the invention in the manufacture of a medicament for the treatment including prophylaxis of any of the above mentioned CCR5-related diseases or conditions including viral infections (e.g., HIV infection) and associated conditions.

10 Reference herein to treatment extends to prophylaxis as well as the treatment of established conditions, disorders and infections, symptoms thereof, and associated clinical conditions.

 The above compounds according to the invention and their pharmaceutically acceptable derivatives may be employed in combination
15 with other therapeutic agents for the treatment of the above infections or conditions. Combination therapies according to the present invention comprise the administration of a compound of the present invention or a pharmaceutically acceptable derivative thereof and another pharmaceutically active agent. The active ingredient(s) and pharmaceutically active agents
20 may be administered simultaneously (i.e., concurrently) in either the same or different pharmaceutical compositions or sequentially in any order. The amounts of the active ingredient(s) and pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.

25 Examples of such therapeutic agents include, but are not limited to, agents that are effective for the treatment of viral infections or associated conditions. Among these agents are (1- α , 2- β , 3- α)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine [(-)BHCG, SQ-34514, lobucavir]; 9-[(2R,3R,4S)-3,4-bis(hydroxy methyl)2-oxetanosyl]adenine (oxetanocin-G);
30 acyclic nucleosides, for example acyclovir, valaciclovir, famciclovir, ganciclovir, and penciclovir; acyclic nucleoside phosphonates, for example (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl) cytosine (HPMPC), [[[2-(6-

amino-9H-purin-9-yl)ethoxy] methyl]phosphinylidene] bis(oxymethylene)-2,2-
 dimethyl propanoic acid (bis-POM PMEA, adefovir dipivoxil), [[[1R)-2-(6-
 amino-9H-purin-9-yl)-1-methylethoxy]methyl] phosphonic acid (tenofovir), and
 (R)-[[2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid bis-
 5 (isopropoxycarbonyloxymethyl)ester (bis-POC-PMPA); ribonucleotide
 reductase inhibitors, for example 2-acetylpyridine 5-[(2-
 chloroanilino)thiocarbonyl] thiocarbonohydrazone and hydroxyurea;
 nucleoside reverse transcriptase inhibitors, for example 3'-azido-3'-
 deoxythymidine (AZT, zidovudine), 2',3'-dideoxycytidine (ddC, zalcitabine),
 10 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine (ddI, didanosine), 2',3'-
 didehydrothymidine (d4T, stavudine), (-)-beta-D-2,6-diaminopurine dioxolane
 (DAPD), 3'-azido-2',3'-dideoxythymidine-5'-H-phosphophosphate
 (phosphonovir), 2'-deoxy-5-iodo-uridine (idoxuridine), (-)-cis-1-(2-
 hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine), cis-1-(2-
 15 (hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC), 3'-deoxy-3'-
 fluorothymidine, 5-chloro-2',3'-dideoxy-3'-fluorouridine, (-)-cis-4-[2-amino-6-
 (cyclo-propylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (abacavir), 9-
 [4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G), ABT-606 (2HM-H2G)
 and ribavirin; protease inhibitors, for example indinavir, ritonavir, nelfinavir,
 20 amprenavir, saquinavir, fosamprenavir, (R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-
 3-N-[(R)-2-N-(isoquinolin-5-yloxyacetyl)amino-3-methylthio-propanoyl]amino-
 4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide (KNI-272), 4R-
 (4alpha, 5alpha,6beta))-1,3-bis[(3-aminophenyl)methyl]hexahydro-5,6-
 dihydroxy-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one dimethanesulfonate
 25 (mozenavir), 3-[1-[3-[2-(5-trifluoromethylpyridinyl)-
 sulfonylamino]phenyl]propyl]-4- hydroxy-6alpha-phenethyl-6beta-propyl-5,6-
 dihydro-2-pyranone (tipranavir), N'-[2(S)-Hydroxy-3(S)-[N-(methoxycarbonyl)-
 l-tert-leucylamino]-4-phenylbutyl-N^{alpha}-(methoxycarbonyl)-N'-[4-(2-
 pyridyl)benzyl]-L- tert-leucylhydrazide (BMS-232632), 3-(2(S)-Hydroxy-3(S)-
 30 (3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethyl-N-(2-
 methylbenzyl)thiazolidine-4(R)-carboxamide (AG-1776), N-(2(R)-hydroxy-
 1(S)-indanyl)-2(R)-phenyl-methyl-4(S)-hydroxy-5-(1-(1-(4-

benzo[b]furanylmethyl)-2(S)-N'-(tert-butyl
 carboxamido)piperazinyl)pentanamide (MK-944A); interferons such as α -
 interferon; renal excretion inhibitors such as probenecid; nucleoside transport
 inhibitors such as dipyridamole, pentoxifylline, N-acetylcysteine (NAC),
 5 Procysteine, α -trichosanthin, phosphonoformic acid; as well as
 immunomodulators such as interleukin II or thymosin, granulocyte
 macrophage colony stimulating factors, erythropoietin, soluble CD₄ and
 genetically engineered derivatives thereof; non-nucleoside reverse
 transcriptase inhibitors (NNRTIs), for example nevirapine (BI-RG-587), alpha-
 10 ((2-acetyl-5-methylphenyl)amino)-2,6-dichloro-benzeneacetamide (loviride), 1-
 [3-(isopropyl amino)-2-pyridyl]-4-[5-(methanesulfonamido)-1H-indol-2-
 ylcarbonyl]piperazine monomethanesulfonate (delavirdine), (10R, 11S, 12S)-
 12-Hydroxy-6, 6, 10, 11-tetramethyl-4-propyl-11,12-dihydro-2H, 6H, 10H-
 benzo(1, 2-b:3, 4-b':5, 6-b'')tripyrane-2-one ((+) calanolide A), (4S)-6-Chloro-4-
 15 [1E)-cyclopropyl ethenyl)-3,4- dihydro-4-(trifluoromethyl)-2(1H)-quinazolinone
 (DPC-083), (S)-6-chloro-4-(cyclopropyl ethynyl)-1,4-dihydro-4-
 (trifluoromethyl)-2H-3,1-benzoxazin-2-one (efavirenz, DMP 266), 1-(ethoxy
 methyl)-5-(1-methylethyl)-6-(phenylmethyl)-2,4(1H,3H)-pyrimidinedione (MKC-
 442), and 5-(3,5-dichloro phenyl)thio-4-isopropyl-1-(4-pyridyl)methyl-1H-
 20 imidazol-2-ylmethyl carbamate (capravirine); glycoprotein 120 antagonists, for
 example PRO-2000, PRO-542 and 1,4-bis[3-[(2, 4- dichlorophenyl)carbonyl
 amino]-2-oxo-5,8-disodiumsulfanyl]naphthalyl-2, 5-dimethoxyphenyl-1, 4-
 dihydrazone (FP-21399); cytokine antagonists, for example reticulose
 (Product-R), 1,1'-azobis-formamide (ADA), 1,11-(1,4-phenylenebis
 25 (methylene))bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride (AMD-
 3100); integrase inhibitors; and fusion inhibitors, for example T-20 and T-
 1249.

The present invention further includes the use of a compound
 according to the invention in the manufacture of a medicament for
 30 simultaneous or sequential administration with at least another therapeutic
 agent, such as those defined hereinbefore.

Compounds of the present invention may be administered with an agent known to inhibit or reduce the metabolism of compounds, for example ritonavir. Accordingly, the present invention features a method for the treatment including prophylaxis of a disease as hereinbefore described by
5 administration of a compound of the present invention in combination with a metabolic inhibitor. Such combination may be administered simultaneously or sequentially.

In general a suitable dose for each of the above-mentioned conditions will be in the range of 0.01 to 250 mg per kilogram body weight of the
10 recipient (e.g. a human) per day, preferably in the range of 0.1 to 100 mg per kilogram body weight per day and most preferably in the range 0.5 to 30 mg per kilogram body weight per day and particularly in the range 1.0 to 20 mg per kilogram body weight per day. Unless otherwise indicated, all weights of active ingredient are calculated as the parent compound of formula (I); for
15 salts or esters thereof, the weights would be increased proportionally. The desired dose may be presented as one, two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. In some cases the desired dose may be given on alternative days. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1000
20 mg or 50 to 500 mg, preferably 20 to 500 mg, and most preferably 50 to 400 mg of active ingredient per unit dosage form.

While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition. The compositions of the present invention comprise at least one active ingredient, as defined
25 above, together with one or more acceptable carriers thereof and optionally other therapeutic agents. Each carrier must be acceptable in the sense of being compatible with the other ingredients of the composition and not injurious to the patient.

Pharmaceutical compositions include those suitable for oral, rectal,
30 nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, and intravitreal) administration. The compositions may conveniently be

presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods represent a further feature of the present invention and include the step of bringing into association the active ingredients with the carrier, which constitutes one or more accessory
5 ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.

The present invention further includes a pharmaceutical composition as hereinbefore defined wherein a compound of the present invention or a
10 pharmaceutically acceptable derivative thereof and another therapeutic agent are presented separately from one another as a kit of parts.

Compositions suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain
15 the active compound 1) in an optionally buffered, aqueous solution or 2) dissolved and/or dispersed in an adhesive or 3) dispersed in a polymer. A suitable concentration of the active compound is about 1% to 25%, preferably about 3% to 15%. As one particular possibility, the active compound may be delivered from the patch by electrotransport or iontophoresis as generally
20 described in Pharmaceutical Research 3(6), 318 (1986).

Pharmaceutical compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, caplets, cachets or tablets each containing a predetermined amount of the active
25 ingredients; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by
30 compressing in a suitable machine the active ingredients in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent,

preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent. Molded tablets may be made by molding a mixture of the powdered compound moistened with an inert liquid diluent in a suitable machine. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredients therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.

Pharmaceutical compositions suitable for topical administration in the mouth include lozenges comprising the active ingredients in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Pharmaceutical compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray Pharmaceutical compositions containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Pharmaceutical compositions for rectal administration may be presented as a suppository with a suitable carrier comprising, for example, cocoa butter or a salicylate or other materials commonly used in the art. The suppositories may be conveniently formed by admixture of the active combination with the softened or melted carrier(s) followed by chilling and shaping in molds.

Pharmaceutical compositions suitable for parenteral administration include aqueous and nonaqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the pharmaceutical composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents; and liposomes or other

microparticulate systems which are designed to target the compound to blood components or one or more organs. The pharmaceutical compositions may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

Unit dosage pharmaceutical compositions include those containing a daily dose or daily subdose of the active ingredients, as hereinbefore recited, or an appropriate fraction thereof.

It should be understood that in addition to the ingredients particularly mentioned above the pharmaceutical compositions of this invention may include other agents conventional in the art having regard to the type of pharmaceutical composition in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents.

In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.

EXAMPLES

General Procedures

Plate purification chromatographic conditions:

Prep. HPLC Conditions A

Approximately 100 milligrams of the impure compound was dissolved in 500 microliters of methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into a Phenomenex Luna C18 5 micron particle HPLC column (21.20 mm X 150 mm). Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 2.5 using formic acid as buffer. Void

volume was 2 minutes, and a linear gradient to 100% methanol in 10 minutes with a five minute wash at 100% methanol eluted the compound in approximately 10 minutes. A Micromass Platform LC mass spectrometer was used to monitor a split off the eluate for desired mass, and the purified fractions were collected using Micromass Fractionlynx software. About 35 mg of purified compound was isolated.

Prep. HPLC Conditions B

Approximately 100 milligrams of the impure compound was dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C18 5 micron particle HPLC column (19mmX150mm). Initial solvent flow was 20 ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer. Void volume was 2 minutes, and a linear gradient to 100% methanol in 10 minutes with a five minute wash at 100% methanol eluted the compound in approximately 10 minutes. A Micromass Platform LC mass spectrometer was used to monitor a split off the eluate for desired mass, and the purified fractions were collected using Micromass Fractionlynx software. About 35 mg of purified compound was isolated.

Analytical and Preparative C18 HPLC chromatography

Method W

Analytical High Pressure Liquid Chromatography data was acquired using a Waters LC-UV system. The system operated using a Waters Symmetry Shield RP18 3.9 x 150 mm, 5 µm column at 1.5 mL/minute. The mobile phase consisted of Water (0.1% DEA) and Acetonitrile (0.1% DEA). The gradient used started with a 10% ACN (0.1% DEA): 90% H2O (0.1% DEA) and moved to 90% ACN (0.1% DEA):10% H2O (0.1% DEA) over 7 minutes. There was a one minute wash of the column using 100% ACN (0.1% DEA) for one minute, until eight minutes and then original conditions returned at 8.1 minutes to 8.5 minutes.

Method Y

Preparative High Pressure Liquid Chromatography data was acquired using a Waters LC-UV system. The system operated using a Waters Symmetry Shield RP18 3.9 x 150 mm, 5 μ m column at 35 mL/minute. The mobile phase consisted of Water (0.1% DEA) and Acetonitrile (0.1% DEA). The gradient used started with a 10% ACN (0.1% DEA):90% H₂O (0.1% DEA) and moved to 90% ACN (0.1% DEA):10% H₂O (0.1% DEA) over 7 minutes. There was a one minute wash of the column using 100% ACN (0.1% DEA) for one minute, until eight minutes and then original conditions returned at 8.1 minutes to 8.5 minutes.

Low resolution, open-access LC-MS data were acquired in either ESI pos/neg or APCI pos/neg mode with scanning from 100-1100 amu @ 0.5 sec/scan.

LC conditions: flowrate 0.8 mL/min. 85% H₂O (0.1% formic acid) to 100% MeOH (0.075% formic acid) in 6 minutes. Phenomenex Max-RP column, 2.0x50 mm.


High Resolution Mass Spectra were acquired using Micromass LCT mass spectrometer (time-of-flight) with flow injection (FIA-MS) at 0.3 mL/min with 100% MeOH (0.1% formic acid), run time of 2 minutes, in ESI+ mode, scanning from 100-1100 amu @ 0.5 sec/scan.

Reserpine was used as the lock mass (m/z 609.2812) and to adjust mass scale.

Example 1

Compound IV of Scheme I was synthesized according to the procedure outlined in Scheme II below.

Scheme II



Tert-Butyl 4-cyano-4-phenylpiperidine-1-carboxylate (1a)

To a suspension of 4-cyano-4-phenylpiperidine hydrochloride (50.4 g, 0.266 mol) in tetrahydrofuran (440 ml) was added triethylamine (95 ml), followed by addition of a solution of di-tert-butyl dicarbonate (47.95 g, 0.22 mol) in tetrahydrofuran (150 ml) dropwise. The reaction mixture was stirred at room temperature for 2 hours. The solids were filtered and the filtrate was diluted with 200 ml of ethyl acetate, washed once with 200 ml of 1N citric acid, once with 200 ml of saturated aqueous sodium bicarbonate and once with 200 ml of brine. After drying over sodium sulfate, the solution was concentrated to a colorless thick oil (64.40 g, 99%). ¹H-NMR (300 MHz, CDCl₃): δ 7.51-7.34 (m, 5H), 4.33-4.18 (m, 2H), 3.27-3.19 (m, 2H), 2.14-1.92 (m, 4H), and 1.51 (s, 9H). ES-LCMS *m/z* 308 (M+H).

Tert-Butyl 4-formyl-4-phenylpiperidine-1-carboxylate (1b)

To a solution of tert-butyl 4-cyano-4-phenylpiperidine-1-carboxylate (33.32 g, 0.116 mol) in toluene (600 ml), cooled to -78 °C was added a 1M solution of diisobutylaluminum hydride in toluene (248 ml) over a period of 3 h. The reaction mixture was allowed to warm up to -35 °C over a period of 2 h and stirred at -35 °C for 1 hour. The reaction mixture was quenched by dropwise addition of 150 ml of methanol, followed by addition of 150 ml of saturated aqueous ammonium chloride and filtration through Celite. The organic layer was washed once with 200 ml of water, once with 200 ml of brine and after drying over sodium sulfate, the solution was concentrated to a

light yellow oil (29.71 g, 88%). $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 9.43 (s, 1H), 7.55-7.18 (m, 5H), 3.92-3.82 (m, 2H), 3.31-3.18 (m, 2H), 2.40-1.92 (m, 4H), and 1.38 (s, 9H). ES-LCMS m/z 290 (M+H).

5 Tert-Butyl 4-[(E/Z)-2-methoxyethenyl]-4-phenylpiperidine-1-carboxylate (1c)

To a slurry of (methoxymethyl)triphenyl-phosphonium chloride (7.39 g, 21.56 mmol) in tetrahydrofuran (90 ml) was added a 1M solution of potassium tert-butoxide in tetrahydrofuran (22 ml) dropwise. The reaction mixture was stirred at room temperature for 30 minutes and a solution of tert-butyl 4-
10 formyl-4-phenylpiperidine-1-carboxylate (6.24 g, 21.56 mmol) in tetrahydrofuran (18 ml) was added dropwise. The mixture was stirred at room temperature for 16 hours and then heated to reflux for 2 hours. The mixture was allowed to cool to room temperature, diluted with 100 ml of water and 100 ml of ethyl acetate. The aqueous layer was extracted twice with 100 ml
15 portions of ethyl acetate and washed once with 100 ml of brine. After drying over sodium sulfate, the solution was concentrated to a brown oil, which was further purified by column chromatography on silica gel. Elution with a gradient of 10-40% ethyl acetate in hexanes afforded a 1:1 mixture of E/Z isomers as a light yellow oil (4.64 g, 68%). $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ
20 7.51-7.19 (m, 5H), 6.07 and 4.84 (d, $J=13.0$ Hz, 1H), 5.95 and 4.23 (d, $J=7.1$ Hz, 1H), 3.95-3.78 (m, 2H), 3.54 and 3.51 (s, 3H), 3.30-3.06 (m, 2H), 2.20-2.09 (m, 2H), 1.98-1.76 (m, 2H), and 1.52 and 1.49 (s, 9H). ES-LCMS m/z 318 (M+H).


25 Tert-Butyl 4-(2-oxoethyl)-4-phenylpiperidine-1-carboxylate (Compound V)

To a solution of tert-butyl 4-[(E/Z)-2-methoxyethenyl]-4-phenylpiperidine-1-carboxylate (4.64 g, 14.61 mmol) in acetone (48 ml) was added dropwise a solution of p-toluenesulfonic acid monohydrate (1.95 g, 10.28 mmol) in water (24 ml). The
30 reaction mixture was stirred at room temperature for 48 hours. Acetone was evaporated without using any heat, and the reaction mixture was made basic

with solid sodium bicarbonate to pH 9, extracted with three 30 ml portions of dichloromethane and washed once with 30 ml of brine. After drying over sodium sulfate, the solution was concentrated to a colorless oil, which was further purified by column chromatography on silica gel. Elution with 25% ethyl acetate in hexanes afforded the product (2.23 g, 50%). ¹H-NMR (300 MHz, CDCl₃): δ 9.39 (s, 1H), 7.43-7.25 (m, 5H), 3.69-3.61 (m, 2H), 3.31-3.22 (m, 2H), 2.65 (s, 2H), 2.28-2.23 (m, 2H), 1.92-1.83 (m, 2H), and 1.46 (s, 9H). ES-LCMS *m/z* 304 (M+H).

10 (1-Benzoyl-4-phenylpiperidine-4-yl) acetaldehyde (2)

(1-Benzoyl-4-phenylpiperidine-4-yl) acetaldehyde (2) was synthesized according to the procedure outlined below.




To a solution of tert-butyl 4-[(E/Z)-2-methoxyethenyl]-4-phenylpiperidine-1-carboxylate (8.75 g, 27.57 mmol) obtained by following the procedure outlined in example 1c above in tetrahydrofuran (27 ml) was added a 4M solution of hydrochloric acid in dioxane (9 ml). The reaction mixture was stirred at room temperature for 1 hour and concentrated to an oil. The mixture was dissolved in dichloromethane (40 ml) and cooled to 0 °C. A solution of benzoyl chloride (4.65 g, 33.08 mmol) in dichloromethane (5 ml) was added dropwise, followed by the addition of triethylamine 8.37 g, 82.71 mmol) in dichloromethane (5 ml). The mixture was stirred at room temperature for 1 hour, quenched by addition of 5 ml water, and washed once with 150 ml of saturated aqueous sodium bicarbonate and once with 150 ml of brine. After drying over sodium sulfate, the solution was concentrated to an oil, which was further purified by column chromatography on silica gel. Elution with a gradient of 25-50% ethyl acetate in hexanes afforded a light yellow oil (3.47 g,

41%). $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 9.37 (s, 1H), 7.42-7.25 (m, 10H), 4.14-4.09 (m, 1H), 3.54-3.30 (m, 3H), 2.67 (s, 2H), 2.38-2.24 (m, 2H), and 1.97-1.85 (m, 2H). ES-LCMS m/z 308 (M+H).


5 The synthesis of endo 1-(8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (compound IV of Scheme I):

a) *endo tert*-Butyl 3-Anilino-8-azabicyclo[3.2.1]octane-8-carboxylate



Sodium triacetoxyborohydride (125 g, 0.59 mol) was added portionwise during 45 min to a mechanically stirred mixture of *tert*-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (88.3 g, 0.39 mol), pulverized 4A molecular sieves (88g) and benzylamine (44.1 g, 0.41 mol) in dichloromethane (1 L) at rt under Nitrogen. The mixture was stirred at rt for 2 days. Saturated sodium carbonate solution (1 L) was added. The mixture was stirred for 1 h at room temperature, filtered and the aqueous was further extracted with dichloromethane (3 x 500 mL). The combined organic layers were dried and concentrated to a white solid (123 g, 99%). $^1\text{H NMR}$ (400 MHz; CDCl_3) δ 7.24–7.33 (m, 5H), 4.19 (m, 1H), 4.10 (m, 1H), 3.76 (s, 2H), 3.00 (t, 1H), 2.15 (m, 3H), 1.91 (m, 2H), 1.60 (m, 1H), 1.57 (m, 1H), 1.49 (m, 1H), 1.48 (m, 1H), 1.45 (s, 9H). AP-LCMS m/z 317 (M+1).

b) *endo tert*-Butyl 3-Amino-8-azabicyclo[3.2.1]octane-8-carboxylate




A stirred mixture of *tert*-butyl 3-anilino-8-azabicyclo[3.2.1]octane-8-carboxylate (123 g, 0.39 mol), ammonium formate (175 g, 2.78 mol) and 20% palladium hydroxide on carbon (12.3 g) in absolute ethanol (1.5 L) was heated to 50°C under nitrogen for 7 h. The mixture was filtered and the filtrate was

concentrated. The residue in ethyl acetate was washed with water, dried and concentrated to give the product (65.4 g, 74%). ^1H NMR (400 MHz; CDCl_3) δ 4.19 (m, 1H), 4.10 (m, 1H), 3.30 (t, 1H), 3.03–2.19 (m, 4H), 1.94 (m, 2H), 1.58 (m, 2H), 1.44 (s, 9H). AP-LCMS m/z 127 (M-99).

5


c) *endo tert*-Butyl 3-[(2-Nitrophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate)



A mixture of *tert*-butyl 3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (65.4 g, 0.29 mol), *N,N*-diisopropylethylamine (56 mL, 0.32 mol) and 1-fluoro-2-nitrobenzene (40.9 g, 0.29 mol) in 1-methyl-2-pyrrolidinone (200 mL) was heated at 70°C under nitrogen for 16 h. The reaction mixture was diluted with water (500 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic layers were dried and concentrated to an orange oil. Purification was accomplished by chromatography on silica gel eluting with dichloromethane and ethyl acetate:hexane 1:1 in succession to give an orange solid (98.2 g, 98%). ^1H NMR (400 MHz; CDCl_3) δ 8.74 (m, 1H), 8.18 (m, 1H), 7.43 (m, 1H), 6.61 – 6.73 (m, 2H), 4.26 (m, 2H), 3.90 (t, 1H), 2.26 – 2.32 (m, 2H), 2.03 (m, 4H), 1.83 (m, 2H), 1.44 (s, 9H).

20

d) *endo tert*-Butyl 3-[(2-Aminophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate




A mixture of *tert*-butyl 3-[(2-nitrophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (98.2 g, 0.28 mol) and 10% palladium

25

on carbon (10 g) in ethanol:ethyl acetate 1:1 (1 L) was hydrogenated for 24 h at atmospheric pressure. Uptake of hydrogen was 17.4 L. The mixture was filtered through celite and concentrated to give the product (76.2 g, 86%). ¹H NMR (400 MHz; CDCl₃) δ 6.67–6.83 (m, 3H), 6.57 (m, 1H), 4.25 (m, 1H), 4.17 (m, 1H), 3.70 (m, 2H), 3.32 (br s, 2H), 2.28 (m, 2H), 1.98–2.07 (m, 4H), 1.76 (m, 2H), 1.47 (s, 9H). AP-LCMS *m/z* 318 (M+1).


e) endo 1-(8-Azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole Hydrochloride




10

A solution of tert-butyl 3-[(2-aminophenyl) amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (76.2 g, 0.24 mol) in triethylorthoacetate (250 mL) was refluxed under nitrogen for 2.5 h. The mixture was concentrated, redissolved in ethyl acetate (500 mL), washed with water (2 x 200 mL), washed with brine, dried and concentrated to a dark oil. The oil was dissolved in ethanol (250 mL), treated with 6 N hydrochloric acid (200 mL) and refluxed for 2 h. The reaction mixture was cooled to room temperature, concentrated to 300 mL and the resulting pale pink precipitate was collected by filtering, washed with ethanol (50 mL) and dried (61.5 g, 92%). ¹H NMR (400 MHz; DMSO-d₆) δ 10.16 (d, J=10 Hz, 1H), 9.47 (d, J=10 Hz, 1H), 7.95 (d of d, J=3,6 Hz, 1H), 7.79 (d of d, J=4,8 Hz, 1H), 7.54 (m, 2H), 5.63 (m, 1H), 4.13 (d, J=9 Hz, 2H), 2.88 (s, 3H), 2.71 (m, 2H), 2.17 (m, 6H). ES-LCMS *m/z* 242 (M+1).


25 The synthesis of exo-amine: exo-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole

8-Benzyl-8-azabicyclo[3.2.1]octan-3-one


- To cooled 192 ml of 0.025M HCl at 0°C was added 60 g (454 mmol) of 2,5-dimethoxytetrahydrofuran and the mixture was stirred at 0 °C for 17 hrs.
- 5 Then sequentially 78g(543.6mmol) of benzyl amine, 66 g (452.0 mmol) of 3-oxopentanedioic acid, and 20.4 g (248.4 mmol) of sodium acetate in 360 ml of water was added all at 0°C. The mixture was allowed to warm to room temperature and was stirred at room temperature for 1 hr. The mixture was clear, golden yellow in color. The mixture was heated to 50 °C for 2 hrs. The
- 10 mixture turned cloudy. The mixture was then cooled to ambient temperature and adjusted to pH~12 using 50% NaOH in water. The mixture was extracted with ethyl acetate (x3), dried over sodium sulfate and removed solvent to yield a brown oil. The mixture was further purified by distillation, desired product collected ~120 °C. 25 g crude product was recovered as a yellow oil to be
- 15 carried on to next step.

8-Benzyl-8-azabicyclo[3.2.1]octan-3-one oxime


- 20 4.85 g (22.56 mmol) of 8-benzyl-8-azabicyclo[3.2.1]octan-3-one was dissolved in 60 ml of ethanol. 3.13 g (45 mmol) hydroxylamine hydrochloride was then added followed by 1.8 g (45 mmol) of NaOH in 15 ml of water. The mixture was refluxed for 20 hrs and was cooled to ambient temperature. The solvent was removed in vacuo. The residue was diluted with ethyl acetate
- 25 and washed with water and the organic layer was dried over sodium sulfate. The solvent was removed to give 4.28 g of product as a light yellow solid.

8-Benzyl-8-azabicyclo[3.2.1]octan-3-amine

To 3.9 g (16.9mmol) 8-benzyl-8-azabicyclo[3.2.1]octan-3-one oxime was added 3.5 g of sodium in 200 ml of pentanol by portion over 1 hr. The mixture was refluxed for 3 hrs and cooled to ambient temperature. The reaction mixture was quenched with water and extracted with 6 N HCl. The aqueous layer was basified using NaOH pellets and extracted with EtOAc. The organic layer was dried over magnesium sulfate and the solvent was removed to afford 2.9 g (80%) of crude product as a brown oil.


8-Benzyl-N-(2-nitrophenyl)-8-azabicyclo[3.2.1]octan-3-amine

5.62g(27.82mmol) 8-benzyl-8-azabicyclo[3.2.1]octan-3-amine and 9.7ml(55.46mmol) of Hunig's base were dissolved in 200ml NMP. 4.32g(30.60mmol) 1-fluoro-2-nitrobenzene was then added and the mixture was stirred at RT for 3 hrs. The reaction mixture was diluted with EtOAc and washed with water and dried over sodium sulfate. The solvent was removed partially under reduced pressure and was left in refrigerator overnight. The solid was filtered off to afford 2.92 g of product as a yellow powder. The solvent was removed from filtration to give additional 5.7 g of product as an orange-yellow residue.

N-(8-Benzyl-8-azabicyclo[3.2.1]oct-3-yl)benzene-1,2-diamine


2.92 g (9.04 mmol) 8-benzyl-N-(2-nitrophenyl)-8-azabicyclo[3.2.1]octan-3-amine was dissolved in 150 ml EtOAc and 25 ml Methanol. 1g Pd/C was then added and the mixture was stirred at 1 atm H₂ for 3.5 hrs. Yellow color disappeared and the reaction mixture was filtered through celite. The solvent was removed to afford 2.2 g of desired solid.

1-(8-Benzyl-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



7.7 g (25.08 mmol) N-(8-benzyl-8-azabicyclo [3.2.1]oct-3-yl)benzene-1,2-diamine was refluxed in 200 ml of 1,1,1-triethoxyethane for 18 hrs. The mixture was cooled to ambient temperature and the solvent was then removed. The residue was dissolved in toluene and 1.8 g (9.47 mmol) of p-toluenesulfonic acid was added and the reaction mixture was heated to reflux while stirring for 18 hrs. The mixture was cooled to ambient temperature and filtered off solid and removed toluene under reduced pressure. The crude product was purified by flash column chromatography with 5% methanol and 0.5% ammonium hydroxide in dichloromethane on silica gel. 2.2g of the product was recovered as a yellow residue.

1-(8-Azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



2.2 g (6.65 mmol) 1-(8-benzyl-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole was dissolved in 150 ml ethanol and 2.09 g (33.23 mmol) ammonium formate and 0.4 g palladium hydroxide (20% on carbon) were added. The mixture was refluxed for 2.5 hrs. The mixture was cooled to ambient temperature and filtered through celite. The solvent was removed


under reduced pressure and the crude product was purified by column chromatography $\text{CH}_2\text{Cl}:\text{CH}_3\text{OH}:\text{NH}_4\text{OH}(95:5:0.5)$ to afford 1.06 g of the desired product as a solid.

5

Example 2

Endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (compound II in Scheme I) was prepared by following the procedure depicted in Scheme III below.

10

Scheme III

tert-butyl 4-{2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-endo-azabicyclo[3.2.1]oct-8-yl)ethyl]-4-phenylpiperidine-1-carboxylate (III)}

To a solution of 483 mg (2.0 mmol) of *endo* 1-(8-Azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (IV) and of 606 mg (2.0 mmol) tert-butyl 4-(2-oxoethyl)-4-phenylpiperidine-1-carboxylate (V) in 25 mL dichloroethylene was added 847 mg (4.0 mmol) of sodium triacetoxyborohydride at room temperature and stirred for 30 minutes. The reaction was quenched with 10% aqueous sodium bicarbonate, solvents were removed and the residue partitioned between ethyl acetate and water, resulting in 925 mg of *tert*-butyl 4-{2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-endo-azabicyclo[3.2.1]oct-8-yl)ethyl]-4-phenylpiperidine-1-carboxylate III (87.6% yield). ^1H NMR (400 MHz, CDCl_3): δ 7.21 (1H, d, $J=8.3$ Hz), 6.63-6.97 (8H, m), 4.15 (1H, m), 3.20 (2H, m), 2.78m (4H, m), 2.12 (3H, s), 1.92 (2H, m), 1.70 (2H, m), 1.45 (6H, m), 1.33 (4H, m), 1.18 (2H, m), and 1.02 (9H, s). ^{13}C NMR (400 MHz, CDCl_3): δ 155.2, 152.0, 144.9, 143.6, 133.8, 128.7, 126.8, 126.3, 121.6, 119.7, 111.0, 79.6, 57.4, 48.1, 46.3, 42.0, 41.0 (broad),

40.2 (broad), 39.4 (quat), 36.6, 35.8 (broad), 30.0, 28.7, and 14.9. MS ES+ (m/z) M+1 = 529.61.


5 endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (Compound II)

0.67g (1.27 mmol) of *tert*-butyl 4-{2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-*endo*-azabicyclo[3.2.1]oct-8-yl)ethyl]-4-phenylpiperidine-1-carboxylate III was dissolved in 5 mL dichloromethane and added 14 mL of 4N hydrochloric acid in dioxane. The mixture was stirred at room temperature
10 for 30 minutes, resulting in a gummy precipitate. Solvents were decanted and the gum dried in vacuo, resulting in 0.63 g (quantitative) of *endo* 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride II, which was subsequently used without additional work-up. MS ES+ (m/z) M+1 = 429.30.

15

Neutralization of Dihydrochloride II to Free base IIa: endo 2-Methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (Compound IIa)


2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride was partitioned between saturated
20 sodium bicarbonate solution (300 mL) and dichloromethane (600 mL). The organic layer was dried over anhydrous sodium sulfate. After evaporation of solvents, 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole IIa was obtained as foam, which
25 was used for the next step without further purification.

Example 31-(8-{2-[1-(2,2-Dimethylpropanoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (3)

- 5 To a solution of *endo* 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole dihydrochloride II (0.18 g, 0.42 mmol) in dichloromethane (5 ml) was added triethylamine (0.117 ml), followed by addition of trimethylacetyl chloride (0.056 g, 0.462 mmol). The mixture was stirred at room temperature for 1 h and 0.5 ml water and 1 ml saturated aqueous sodium bicarbonate were added. The mixture was extracted three times with 5 ml of ethyl acetate and washed once with 5 ml brine. After drying over sodium sulfate, the solution was concentrated to a tan oil, which was further purified by column chromatography on silica gel. Elution with a gradient of 2.5-5% methanol in dichloromethane afforded a colorless oil
- 10 (0.142 g, 66%). ¹H-NMR (300 MHz, DMSO-*d*₆) δ 7.49 (d, *J*=7.2 Hz, 1H), 7.40-7.35 (m, 5H), 7.23-7.20 (m, 1H), 7.14-7.08 (m, 2H), 4.54-4.50 (m, 1H), 3.80-3.76 (m, 2H), 3.34-3.23 (m, 4H), 2.49 (s, 3H), 2.38-2.32 (m, 2H), 2.09-2.05 (m, 2H), 1.87-1.74 (m, 10H), 1.59-1.57 (m, 2H), 1.18 (s, 6H), 1.11 (s, 3H). ES-LCMS *m/z* 513 (M+H). HRMS *m/z* (M+H)⁺ calcd 513.3593, (M+H)⁺ obsvd
- 15 513.3586.
- 20

Example 4

4-[(4-{2-[3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (4)




5 4-[(4-{2-[3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (25.8 mg, 83%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride II (25.3 mg, 0.05 mmol) and *p*-carboxybenzenesulfonamide (10 mg, 0.05 mmol) by
10 the similar procedure outlined for example 5. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.86 (d, *J*=8.2 Hz, 2 H), 7.57 (d, *J*=8.4 Hz, 2 H), 7.49-7.47 (m, 2 H), 7.39-7.34 (m, 4 H), 7.24-7.20 (m, 1 H), 7.14-7.06 (m, 2 H), 4.52-4.47 (m, 1 H), 3.89 (br, 1 H), 3.22-3.15 (m, 6 H), 2.44 (s, 3 H), 2.42-2.30 (m, 2 H), 2.14-2.08 (br, 2 H), 1.87-1.72 (m, 10 H), 1.58 (d, *J*=7.6 Hz, 2 H). HRMS *m/z* (*M*+H)⁺ calcd
15 612.3008; obsd 612.2993.

Example 5

2-chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl] benzenesulfonamide

20 example 5 via carbodiimide coupling



To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride II (102 mg, 0.2 mmol) in dichloromethane (15 mL) was added 3-chloro-4-sulfamoylbenzoic acid (48 mg, 0.2 mmol) and triethylamine (60 μL, 0.4 mmol). The resulting
25


mixture was then cooled down on an ice-water bath before the addition of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (38 mg, 0.2 mmol) and 4-dimethylaminopyridine (4.8 mg, 0.04 mmol). After being stirred overnight at ambient temperature, the reaction mixture was diluted with
5 dichloromethane (40 mL) and washed with saturated sodium bicarbonate solution. The organic phase was dried over anhydrous sodium sulfate. After evaporation of the solvent, the crude product was purified by flash chromatography on silica gel, eluting with a gradient of 0-10% methanol in ethyl acetate to afford 2-chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]
10 benzenesulfonamide as amorphous solid (69 mg, 53%). ¹H NMR (300 MHz, DMSO-d₆) δ 7.87-7.71 (m, 3 H), 7.57 (s, 1 H), 7.50-7.47 (m, 2 H), 7.38-7.33 (m, 4 H), 7.24 (s, 1 H), 7.14-7.06 (m, 2 H), 4.49 (m, 1 H), 3.98 (m, 1 H), 3.42-3.23 (m, 5 H), 3.06-3.00 (m, 1 H), 2.43 (s, 3 H), 2.39-2.22 (m, 2 H), 2.17-2.08
15 (m, 2 H), 1.92-1.76 (m, 10 H), 1.58-1.56 (br, 2 H). HRMS *m/z* (M+H)⁺ calcd 646.2619; obsd 646.2610.

example 5 via HATU coupling


To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (200 mg, 0.4
20 mmol) in DMF (8 mL) was added 3-chloro-4-sulfamoylbenzoic acid (94 mg, 0.4 mmol), triethylamine (166 μL, 1.2 mmol) and HATU (152 mg, 0.4 mmol). The resulting mixture was stirred at ambient temperature for 3 hours before being diluted with methylene chloride (50 mL). The reaction was then washed
25 with saturated sodium bicarbonate solution. The organic phase was dried over anhydrous sodium sulfate. After evaporation of the solvent, the crude product was purified by flash chromatography on silica gel, eluting with a gradient of 0-10% methanol in ethyl acetate to afford 2-chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl] benzenesulfonamide as amorphous solid (120
30 mg, 47%). ¹H NMR (300 MHz, DMSO-d₆) δ 7.87-7.71 (m, 3 H), 7.57 (s, 1 H), 7.50-7.47 (m, 2 H), 7.38-7.33 (m, 4 H), 7.24 (s, 1 H), 7.14-7.06 (m, 2 H), 4.49

(m, 1 H), 3.98 (m, 1 H), 3.42-3.23 (m, 5 H), 3.06-3.00 (m, 1 H), 2.43 (s, 3 H), 2.39-2.22 (m, 2 H), 2.17-2.08 (m, 2 H), 1.92-1.76 (m, 10 H), 1.58-1.56 (br, 2 H). HRMS m/z (M+H)⁺ calcd: 646.2619; obsd: 646.2610.

5

Example 6

Phenyl N-cyano-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (6)




To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride II (253 mg, 0.5 mmol) in dichloromethane (20 mL) was added triethyl-amine (140 μ L, 1 mmol) and diphenylcyanocarbonimide (143 mg, 0.6 mmol). The resulting mixture was stirred at ambient temperature for 4 hours before it was quenched with saturated sodium bicarbonate solution. The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate. After evaporation of the solvent, the residue was purified by flash chromatography on silical gel, eluting with a gradient of 0-10% methanol in ethyl acetate to afford phenyl N-cyano-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate as amorphous solid (270 mg, 94%). ¹H NMR (300 MHz, CDCl₃) δ 7.69-7.66 (m, 1 H), 7.41-7.36 (m, 4 H), 7.30-7.21 (m, 5 H), 7.19-7.12 (m, 2 H), 7.06-7.03 (m, 2 H), 4.65-4.58 (m, 1 H), 4.07 (br, 1 H), 3.37 (br, 2 H), 3.23 (br, 2 H), 2.56 (s,

3 H), 2.40-2.32 (m, 4 H), 1.93-1.82 (m, 11 H), 1.62 (d, $J = 7.9$, 2 H). HRMS m/z (M+H)⁺ calcd 573.3344; obsd 573.3348.


Example 7

5 Methyl N-cyano-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-
azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (7)




To a stirred solution of phenyl N-cyano-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1] oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate **6** (35 mg, 0.06 mmol) in THF (1 mL) was added sodium methoxide in methanol (100 μ L, ~ 0.8 M, freshly made from methanol and sodium). The resulting mixture was stirred at ambient temperature for 30 minutes before evaporation of the solvent. The crude product was then purified by flash chromatography on silical gel, eluting with a gradient of 0-15% methanol in ethyl acetate to afford methyl N-cyano-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate as amorphous solid (21.8 mg, 72 %). ¹H NMR (300 MHz, CDCl₃) δ 7.69-7.66 (m, 1H), 7.42-7.37 (m, 2H), 7.32-7.24 (m, 4H), 7.21-7.13 (m, 2H), 4.64 (br, 1H), 4.19-4.07 (br, 2H), 3.92 (s, 3H), 3.40-3.27 (m, 4H), 2.59 (s, 3H), 2.35-2.30 (m, 4H), 1.97-1.83 (m, 10H), 1.66-1.63 (m, 2H). HRMS m/z (M+H)⁺ calcd 511.3185; obsd 511.3211.

64

Example 8

5 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo-[3.2.1]oct-8-yl]ethyl}-
4-phenylpiperidin-1-yl)carbonyl]benzoic acid (8)




To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride II (25.3 mg, 0.05 mmol) in 1,2-dichloroethane (3 mL) was added triethyl amine (14 μL , 0.1 mmol) and phthalic anhydride (7.4 mg, 0.05 mmol). The resulting mixture was stirred at ambient temperature for 4 hours. After evaporation of the solvents, the residue was purified by flash chromatography on silical gel, eluting with a gradient of 10-30% methanol in ethyl acetate to afford 2-[(4-{2-[3-(2-methyl-

10

1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid as amorphous solid (29 mg, quant.). ¹H NMR (300 MHz, DMSO-d₆) δ 7.94 (d, J=6.6 Hz, 1H), 7.53-7.50 (m, 1H), 7.48-7.36 (m, 7H), 7.25-7.21 (m, 1H), 7.17-7.09 (m, 3H), 4.61-4.54 (m, 1H), 3.26 (br, 4H),
 5 3.95 (br, 1H), 3.09 (br, 1H), 2.46 (s, 3H), 2.42-2.32 (m, 3H), 2.24-2.06 (m, 1H), 2.00-1.86 (m, 5H), 1.86-1.76 (m, 5H), 1.61 (d, J=7.7Hz, 2H). HRMS m/z (M+H)⁺ calcd 577.3179; obsd 577.3176.

Example 9


10 methyl 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate (9)



To a stirred solution of 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid 8
 15 (40 mg, 0.07mmol) in methanol (2 mL) was added (trimethylsilyl)diazomethane (0.35 mL, 2.0 M in hexanes). The resulting mixture was further stirred for 30 minutes. After evaporation of solvents, the residue was purified by flash chromatography on silical gel, eluting with a gradient of 0-10% methanol in ethyl acetate to afford methyl 2-[(4-{2-[3-(2-
 20 methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate 9 as an oil (40 mg, quant.). ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, J=7.6Hz, 1H), 7.64 (d, J=7.7Hz, 1H), 7.54 (s, 1H), 7.45-7.41 (m, 1H), 7.37-7.34 (m, 2), 7.29-7.21 (m, 5H), 7.18-7.10 (m, 2H), 4.63-4.53 (m, 1H), 4.21-4.18 (m, 1H), 3.86 (br, 3H), 3.44 (br, 1H), 3.24
 25 (br, 3H), 3.08 (br, 1H), 2.53 (s, 3H), 2.36-2.34 (m, 3H), 1.91-1.71 (m, 11H), 1.59 (d, J=7.0Hz, 2H). HRMS m/z (M+H)⁺ calcd 591.3335; obsd 591.3353.

Example 10

methyl 3-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate (10)




5 To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole IIa (300 mg, 0.7 mmol) in dichloromethane (10 mL) was added isophthalic acid monomethyl ester (138.9 mg, 0.77 mmol) and triethyl amine (107 μ L, 0.77 mmol). The resulting mixture was then cooled down on an ice-water bath before the addition of 1-

10 [3-(dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (146.7 mg, 0.77 mmol) and 4-dimethylaminopyridine (8.5mg, 0.07mmole). After being stirred for 4 hours at ambient temperature, the reaction mixture was quenched with saturated sodium bicarbonate solution and extracted with dichloromethane (3 X 40 mL). The combined organic phase was dried over anhydrous sodium

15 sulfate. After evaporation of the solvent, the crude product was purified by flash chromatography on silica gel, eluting with a gradient of 0-10% methanol in ethyl acetate to afford methyl 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate 10 as amorphous solid (297 mg, 72%). ^1H NMR (300 MHz, CDCl_3) δ 8.13-8.08 (m, 2H), 7.70 (d, $J=8.3\text{Hz}$, 1H), 7.63 (d, $J=7.5\text{Hz}$, 1H), 7.53 (t, $J=7.7\text{ Hz}$, 1H), 7.45-7.40 (m, 2H), 7.35-7.30 (m, 4H), 7.20-7.15 (m, 2H), 4.68 (br, 1H), 4.2 (br, 1H), 3.96 (s, 3H), 3.57 (br, 1H), 3.43-4.31 (m, 4H), 2.60 (s, 3H), 2.42 (br, 3H), 2.19 (br, 1H), 1.99-1.92 (m, 10H), 1.69 (br, 2H). HRMS m/z ($M+H$) $^+$ calcd 591.33335; obsd 591.3325.

Example 11

3-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid (11)



5 To a precooled (0 °C) stirred solution of methyl 3-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate 10 (20 mg, 0.034mmol) in a 2 mL-mixed solvent of THF-H₂O (3:1) was added lithium hydroxide monohydrate (4.3 mg, 0.1 mmol). The resulting mixture was stirred for 2 hours at 0 °C before being buffered with


10 saturated sodium bicarbonate solution. The reaction mixture was then extracted with dichloromethane (3 x 20 mL). The combined extracts were washed with brine and dried over anhydrous sodium sulfate. After evaporation of the solvent, the crude product was purified by flash

15 chromatography on silical gel, eluting with a gradient of 10-30% methanol in ethyl acetate to afford 3-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid 11 as white powder solid (18 mg, 95%). ¹H NMR (300 MHz, DMSO-d₆) δ 7.98 (s, 1H), 7.91 (s, 1H), 7.51 (d, J=6.9Hz, 1H), 7.40-7.36 (m, 7H), 7.26-7.24 (m, 2H), 7.14-7.08 (m, 2H), 4.55-4.49 (m, 1H), 3.92 (br, 1H), 3.34 (br, 1H), 4.24


20 (br, 2H), 2.45 (s, 3H), 2.39-2.32 (m, 3H), 2.14 (br, 3H), 1.86-1.73 (m, 10H), 1.59 (d, J=7.3 Hz, 2H). HRMS m/z (M+H)⁺ calcd 577.3179; obsd 577.3192.

Example 12

ethyl 2-ethyl-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]butanoate (12)



5 2-(ethoxycarbonyl)-2-ethylbutanoic acid




A solution of diethyl-malonic acid diethyl ester (3.0g, 13.89mmol) and potassium hydroxide (0.778g, 13.89mmol) in ethanol (50ml) was stirred at room temperature for 18 hrs. The solvent was evaporated off and the residue was dissolved in water (20 ml) and extracted with dichloromethane (20ml). This organic layer was discarded. The aqueous layer was then acidified with concentrated HCl and extracted with dichloromethane (3 x 20 ml). The combined organic layers were dried over magnesium sulfate and concentrated to give a colorless oil **12a** (1.9 g, 72%). ¹H NMR (300MHz, Methanol-d₄) δ 4.17 (m, 2H), 1.89 (m, 4H), 1.25 (m, 3H), 0.83 (m, 6H). ES-LCMS m/z 188 (M+H)

A solution of 2-(ethoxycarbonyl)-2-ethylbutanoic acid **12a** (0.043g, 0.25mmol), 1-1'-Carbonyldiimidazole (0.048g, 0.25mmol) and 1-Hydroxybenzotriazole hydrate (0.034g, 0.25mmol) in dichloromethane (8ml) was stirred for 10 min at RT. Then 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole **Ila** (0.090g, 0.21mmol) and triethylamine (0.64g, 0.088ml, 0.63mmol) were added and stirred for 18 hrs at room temperature. The reaction was diluted with dichloromethane (10ml) and extracted 1M citric acid (3 x 10ml). The aqueous layer was neutralized with 1M sodium carbonate and extracted with dichloromethane (3

x 10ml). Organic layer was dried using magnesium sulfate and solvent evaporated to white oil. The desired product was further purified column chromatography on silica gel using an elution gradient of dichloromethane: methanol (100:0 to 90:10) to afford the product as a colorless oil (0.115g, 91%). ¹H NMR (300MHz, CDCl₃) δ 7.88 (d, 1H), 7.67 (t, 1H), 7.40-7.15 (m, 7H), 5.20-4.50 (m, 3H), 4.15 (m, 3H), 3.41 (m, 3H), 3.12 (m, 2H), 2.55 (s, 3H), 2.45 (m, 1H), 2.20-1.60 (m, 16H), 1.44 (s, 1H), 1.21 (m, 3H) 0.87 (m, 6H). HRMS C₃₇H₅₀N₄O₃ m/z (M+H)_{Cal.} 599.3961; (M+H)_{Obs.} 599.3981.

Example 13


2-ethyl-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperdin-1-yl)carbonyl]butonic acid



A solution of ethyl 2-ethyl-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperdin-1-yl)carbonyl]butonate 12 (0.100 g, 0.17 mmol), 5 N NaOH (10 ml) and ethanol (4 ml) was stirred at 90 °C for 3 hrs. The reaction was evaporated to dryness and residue was suspend in water (10 ml) and neutralized with 1 N HCl. The aqueous layer was extracted with ethyl acetate (3 x 10 ml). The organic layer was dried using magnesium sulfate and concentrated down to form a white oil **13** (0.060 g, 62%). ¹H NMR (300 MHz, CDCl₃) δ 7.80 (d, 1H), 7.38-7.23 (m, 8H), 4.73 (m, 1H), 4.12 (m, 1H), 3.20 (m, 3H), 2.66 (s, 3H), 2.24 (m, 2H), 2.05-1.70 (m, 9H), 1.60 (m, 2H), 1.35-1.05 (m, 15H). HRMS C₃₅H₄₆N₄O₃ m/z (M+H)_{Cal.} 571.3648; (M+H)_{Obs.} 571.3650.


Example 14

Ethyl 1-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-
azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-
yl)carbonyl]cyclobutanecarboxylate



5

1-(ethoxycarbonyl)cyclobutanecarboxylic acid



14a

A solution of diethyl ester (1.6 g, 8.20 mmol) and potassium hydroxide (0.459 g, 8.20 mmol) in ethanol (50 ml) was stirred at room temperature for 18
 10 hrs. The solvent was evaporated off and the residue was dissolved in water (20 ml) and extracted with dichloromethane (20 ml). This organic layer was discarded. The aqueous layer was then acidified with concentrated HCl and extracted with dichloromethane (3 x 20 ml). The combined organic layers were dried over magnesium sulfate and concentrated to give a colorless oil
 15 (0.900 g, 63%). ¹H NMR (300MHz, CDCl₃) δ 4.25 (m, 2H), 2.60 (m, 4H), 2.00 (m, 2H), 1.30 (m, 3H). ES-LCMS m/z 172 (M+H).


A solution of 1-(ethoxycarbonyl)cyclobutane carboxylic acid (0.043 g, 0.25 mmol), 1-1'-carbonyl-diimidazole (0.048 g, 0.25 mmol) and 1-Hydroxybenzo-triazole hydrate (0.034 g, 0.25 mmol) in dichloro-methane (8
 20 ml) was stirred for 10 min at RT. Then 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole IIa (0.090 g, 0.21 mmol) and triethylamine (0.64 g, 0.088 ml, 0.63 mmol) were added and stirred for 18 hrs at room temperature. The reaction was diluted with dichloromethane (10 ml) and extracted 1 M citric acid (3 x 10 ml). The
 25 aqueous layer was neutralized with 1M sodium carbonate and extracted with

dichloromethane (3 x 10 ml). The organic layer was dried using magnesium sulfate and the solvent evaporated to white oil. The desired product was further purified column chromatography on silica gel using an elution gradient of dichloromethane: methanol (100:0 to 90:10) to afford the product as a colorless oil 14 (0.085g, 70%). ¹H NMR (300 MHz, CDCl₃) δ 7.89 (m, 1H), 7.67 (m, 1H), 7.26 (m, 7H), 4.86 (m, 1H), 4.25-3.90 (m, 3H), 3.89 (s, 2H), 3.21 (m, 2H), 2.96 (m, 1H), 2.70-2.35 (m, 9H), 2.55-1.55 (m, 16H), 1.22 (m, 3H). HRMS C₃₆H₄₆N₄O₃ m/z 583.3648 (M+H)_{Cal.}; 583.3623 (M+H)_{Obs.}

10

Example 15

1-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]cyclobutanecarboxylic acid





A solution of ethyl 1-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]cyclobutanecarboxylate from example 14 (0.050 g, 0.086 mmol), 5 N NaOH (10 ml) and ethanol (4 ml) was stirred at 90°C for 3 hrs. The reaction was evaporated to dryness and residue was suspend in water (10 ml) and neutralized with 1N HCl. The aqueous layer was extracted with ethyl acetate (3 x 10 ml). The organic layer was dried using magnesium sulfate and concentrated down to form a white oil (0.032 g, 67%). ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, 1H), 7.27 (m, 8H), 4.63 (m, 1H), 3.84 (m, 1H), 3.41 (m, 1H), 3.25-2.95 (m, 4H), 2.87 (m, 1H), 2.58 (s, 3H), 2.45-2.20 (m, 4H), 2.05 (m, 2H), 1.89 (m, 8H), 1.63 (m, 5H), 1.61 (s, 2H). HRMS C₃₄H₄₂N₄O₃ m/z 555.3335 (M+H)_{Cal.}; 555.3320 (M+H)_{Obs.}

Example 16

Endo-1-(8-{2-[4-(3-chlorophenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo [3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (**16**) was synthesized according to the method outlined below.

5

*tert*-butyl 4-(1-cyano-2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate (**16a**)


10

A mixture of *tert*-butyl 4-oxo-1-piperidinecarboxylate (25.25 g, 127 mmol), ethyl cyanoacetate (13.8 ml, 130 mmol), ammonium acetate (2.73 g, 35.4 mmol), glacial acetic acid (6.3 ml) and benzene (250 ml) was heated for 4 hours at reflux under Dean Stark conditions. The reaction mixture was cooled to room temperature and washed successively with water, sodium bicarbonate solution and brine. Drying, filtration and evaporation of the organic phase provided *tert*-butyl 4-(1-cyano-2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate as an oil that crystallized on standing (37 g, 99%). ¹H NMR (400 MHz, CDCl₃): δ 4.28 (q, 2H, J = 7 Hz), 3.60 (br t,

15


2H, J = 6 Hz), 3.54 (br t, 2H, J = 6 Hz), 3.12 (t, 2H, J = 6 Hz), 2.76 (t, 2H, J = 6 Hz), 1.47 (s, 9H), and 1.35 (t, 3H, J = 7 Hz). ES-LCMS m/z 293 (M-1).

5 *tert*-butyl 4-(3-chlorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate (**16b**)




A solution of 1-chloro-3-iodobenzene (14.1 g, 59.28 mmol) in diethyl ether (12 ml) was added dropwise to a mixture of magnesium turnings (1.59 g, 65.4 mmol) in diethyl ether (50 ml) at room temperature. When the
10 Grignard reaction was complete, the resulting organomagnesium reagent was added dropwise to a stirred mixture of compound 16a (5.0 g, 17 mmol) and cuprous iodide (800 mg, 4.2 mmol) in tetrahydrofuran (30 mL) cooled to 0°C. The reaction mixture was stirred 1 hour at 0°C and then quenched with saturated ammonium chloride solution. Ethyl acetate (500 ml) was added and
15 the mixture was washed successively with saturated ammonium chloride, water and brine. The organic layer was dried and concentrated and the resulting crude material was purified by column chromatography on silica gel eluting with 4:1 hexane:ethyl acetate. This afforded *tert*-butyl 4-(3-chlorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate (**16b**)
20 as an oil (5.2 g, 75%). ¹H NMR (400 MHz, CDCl₃): δ 7.37-7.26 (m, 4H), 3.99 (br.q, 2H, J=6Hz), 3.91 (br m, 2H), 3.58 (s, 1H), 2.88 (br.m, 2H), 2.52 (ddd, 2H, J=6, 4, 3Hz), 2.04 (m, 2H), 1.43 (s, 9H), and 1.06 (t, 3H, J = 6 Hz). ES-LCMS m/z 429 (M+Na⁺).

[1-(*tert*-butoxycarbonyl)-4-(3-chlorophenyl)piperidin-4-yl](cyano)acetic acid (16c)




5 A solution of **16b** (5.2 g, 12.8 mmol) was dissolved in ethanol (30 ml) and 4 M aqueous sodium hydroxide (30 ml, 120 mmol) was added. The resulting solution was stirred at room temperature for 6.5 hours and then stored at 0°C overnight. Concentrated hydrochloric acid (10 ml) was added dropwise at 0°C and the mixture was then adjusted to pH~4 with 1 M
10 hydrochloric acid. The solution was extracted with ethyl acetate (500 ml) and the aqueous phase was acidified to pH~3 and re-extracted with ethyl acetate. Both ethyl acetate layers were combined and washed with water and brine and then dried and concentrated to afford [1-(*tert*-butoxycarbonyl)-4-(3-chlorophenyl) piperidin-4-yl](cyano)acetic acid (**16c**) as a rigid foam (3.75 g,
15 77%). This material was used without further purification.


tert-butyl 4-(3-chlorophenyl)-4-(cyanomethyl) piperidine-1-carboxylate (16d)



16d (3.75 g, 9.90 mmol) was dissolved in acetonitrile (30 ml) and
20 cupric oxide (355 mg, 0.025 mmol) was added. This mixture was heated at reflux with stirring for 30 minutes and then cooled to room temperature and filtered through celite. Evaporation of the filtrate gave *tert*-butyl 4-(3-chlorophenyl)-4-(cyanomethyl)piperidine-1-carboxylate **16d** as an oil that crystallized on standing (3.0 g, 91%). ¹H NMR (400 MHz, CDCl₃): δ 7.37-7.27
25 (m, 4H), 3.74 (br.m, 2H), 3.08 (br.t, 2H, J=11Hz), 2.55 (s, 2H), 2.27 (br.dd, 2H, J = 11, 3Hz), 1.86 (ddd, 2H, J=14, 11, 4Hz), and 1.44 (s, 9H).

tert-butyl 4-(3-chlorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate (16e)


A solution of **16d** (1.96 g, 5.85 mmol) in dichloromethane (25 mL) was cooled to -30°C and a 1M solution of diisobutyl aluminum hydride in dichloromethane (15.5 ml, 17.5 mmol) was added dropwise. During this addition the internal temperature was maintained at or below -35°C . When the addition was complete, the reaction mixture was stirred 30 min and then quenched at -35°C with methanol (0.7 ml) followed by saturated citric acid solution (50 ml). The mixture was allowed to warm to room temperature and then extracted with dichloromethane. Combined dichloromethane layers were dried, filtered and evaporated to provide *tert*-butyl 4-(3-chlorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate (**16e**) as an oil (1.3 g, 66%). ^1H NMR (400 MHz, CDCl_3): δ 9.40 (t, 1H, $J = 3$ Hz), 7.34-7.22 (m, 4H), 3.61 (m, 2H), 3.26 (ddd, 2H, $J=13, 9, 3\text{Hz}$), 2.66 (d, 2H, $J=3\text{Hz}$), 2.19 (m, 2H), 1.86 (ddd, 2H, $J=13, 9, 3\text{Hz}$), and 1.44 (s, 9H). ^{13}C NMR (100MHz, CDCl_3): δ 201.4 (CH), 154.97 (C), 145.8 (C), 135.2 (C), 130.4 (CH), 127.3 (CH), 127.0 (CH), 124.9 (CH), 79.9 (C), 54.6 (2CH₂), 53.3 (C), 39.2 (CH₂), 35.5 (2CH₂), and 28.6 (3CH₃).

tert-butyl endo-4-(3-chlorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate (16f)

Sodium triacetoxyborohydride (286 mg, 1.35 mmol) was added in one portion to a stirred mixture of 3-*endo*-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-


1*H*-benzimidazole dihydrochloride (compound IV, 250 mg, 0.90 mmol), **16e** (304 mg, 0.90 mmol), triethylamine (0.25 ml, 1.79 mmol) and powdered molecular sieves (250 mg) in dichloromethane (3 ml). After stirring 1 hour at room temperature, the reaction was quenched with saturated sodium bicarbonate solution and the dichloromethane layer was removed. The aqueous layer was extracted with dichloromethane and the combined organic layers were dried, filtered and concentrated to afford *tert*-butyl *endo*-4-(3-chlorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate as a rigid foam (500 mg, 99%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.47 (dd, 1H, *J* = 7, 2 Hz), 7.40 (br s, 1H), 7.39-7.35 (m, 3H), 7.27 (d, 1H, *J* = 7 Hz), 7.11 (dd, 1H, *J* = 7, 6 Hz), 7.08 (dd, 1H, *J* = 7, 6 Hz), 4.50 (m, 1H, *J* = 8 Hz), 3.48 (m, 2H); 3.24 (m, 2H), 3.11 (m, 2H), 2.48 (s, 3H), 2.35 (br dd, 2H, *J* = 15, 9 Hz), 1.98 (m, 2H), 1.90-1.70 (m, 10H), 1.59 (d, 2H, *J* = 8 Hz), and 1.36 (s, 9H). ES-LCMS *m/z* 585 (*M*+Na⁺).

endo-1-(8-{2-[4-(3-chlorophenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (**16g**)



To a stirring solution of the product from example 16f (500 mg, 0.888 mmol) in dichloromethane (6 ml) was added a 4 M solution of hydrogen chloride in 1,4-dioxane (7 ml, 28 mmol). After stirring 15 minutes at room temperature, the supernatant was decanted. The remaining precipitate was triturated with ethyl acetate and dried under high vacuum to afford *endo*-1-(8-{2-[4-(3-chlorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo [3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (**16g**) as a pink solid (548 mg, 100%). This material was used without further purification. ES-LCMS *m/z* 463 (*M*+H).


endo-1-(8-{2-[4-(3-chlorophenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (16)



To a solution of **16g** (165 mg, 0.308 mmol) and triethylamine (0.086 ml, 0.616 mmol) in dichloromethane (3 ml) was added pivaloyl chloride (0.040 ml, 0.325 mmol). After stirring 1 hour at room temperature the reaction mixture was quenched with saturated sodium bicarbonate solution. The organic layer was separated, dried and concentrated. Purification of the resulting material by chromatography on silica gel eluting with 24:1 dichloromethane:methanol gave *endo*-1-(8-{2-[4-(3-chlorophenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (**16**) as a rigid white foam (100 mg, 59%). ¹H NMR (400 MHz, DMSO-d₆): δ 7.48 (d, 1H, J = 7 Hz), 7.42 (s, 1H), 7.41-7.34 (m, 3H), 7.28 (d, 1H, J = 7 Hz), 7.11 (br.t, 1H, J = 7 Hz), 7.08 (br.t, 1H, J = 7), 4.50 (m, 1H, J = 8 Hz), 3.73 (m, 2H), 3.29 (s, 3H), 3.25 (m, 4H), 2.35 (br.dd, 2H, J~22, 9 Hz), 2.02 (m 2H), 1.84-1.73 (m, 10H), 1.59 (d, 2H, J = 8 Hz), and 1.16 (s, 9H). ES-LCMS *m/z* 547 (M+H). HRMS C₃₃H₄₃ClN₄O *m/z* 547.3186 (M+H)_{Cal.} 547.3204 (M+H)_{Obs.}

Example 17

1-((1R,5S)-8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




To a stirred solution of *endo* 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1] oct-3-yl}-1H-benzimidazole dihydrochloride II

(0.53 g, 1.06 mmol) in dichloromethane (10 mL) and triethylamine (0.32 g, 3.18 mmol) was added benzoyl chloride (0.156g, 1.11 mmol) at 0 °C. The ice bath was then removed and the mixture allowed to stir for 30 min. The solvents were then removed in vacuo and the resulting solid was partitioned
5 between ethyl acetate and water (3x). The organic layer was dried with magnesium sulfate and the solvent removed in vacuo, yielding crude **17**, which was then purified using the supercritical fluid chromatography, resulting in 525 mg of pure 1-((1R,5S)-8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole **17** (yield 93%). ¹H
10 NMR (400 MHz, CDCl₃) δ 7.20 (1H, m), 6.94 (7H, m), 6.82 (4H, m), 6.70 (2H, m), 4.15 (1H, m), 3.75 (1H, m), 3.11 (1H, m), 2.98 (4H, m), 2.93 (1H, m), 2.78 (3H, m), 2.05 (3H, s), 2.04 (2H, m), 1.88 (3H, m), 1.70 (1H, m), 1.59–1.24 (4H, m), 1.14 (2H, m). HRMS m/z (M+H)⁺ Calcd 533.3280; (M+H)⁺ Obs 533.3300.

15

Example 18

1-((1R,5S)-8-[2-[1-(cyclopentylcarbonyl)-4-phenylpiperidin-4-yl]ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




20 To a stirred solution of *endo* 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1] oct-3-yl}-1H-benzimidazole dihydrochloride II (0.38 g, 0.75 mmol) in dichloromethane (7 mL) and triethylamine (0.227g, 2.25 mmol) was added cyclopentane carbonyl chloride (0.104g, 0.79 mmol) at 0 °C. The ice bath was then removed and the mixture allowed to stir
25 for 20 min. The solvents were then removed in vacuo and the solid partitioned between dichloroethane and water (3x), and the organic layer evaporated in vacuo resulting in 0.270 g of crude product. Following SFC

purification, 156 mg of the desired product 1-((1R,5S)-8-{2-[1-(cyclopentylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (**18**). ^1H NMR (400 MHz, CD_3OD) δ 7.40 (1H, m), 7.25 (5H, m), 7.10 (3H, m), 4.52 (1H, m), 3.84 (1H, m), 3.63 (1H, m), 3.20-2.94 (4H, m), 2.86 (1H, m), 2.39 (3H, s), 2.10 (4H, m), 1.92-1.36 (20H, m).
 HRMS m/z ($\text{M}+\text{H}$) $^+$ $_{\text{Calc}}$ 525.3606; ($\text{M}+\text{H}$) $^+$ $_{\text{Obs}}$ 525.3593.

Example 19

1-((1R,5S)-8-{2-[1-(2-furoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




To a stirred solution of endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1] oct-3-yl}-1H-benzimidazole dihydrochloride II (0.35 g, 0.69 mmol) in dichloromethane (7 mL) and triethylamine (0.209 g, 2.07 mmol) was added 2-furoyl chloride (0.094g, 0.72 mmol) at 0 °C. The ice bath was then removed and the mixture allowed to stir for 30 min. The solvents were then removed in vacuo and the solid was added ethyl acetate and water. The insoluble precipitate was then filtered off and subsequently characterized as the desired product **19**. Additional 0.18 g of the desired product **19** was obtained by extracting the organic layer with water (3x), drying with magnesium sulfate and evaporating solvents in vacuo. Following the SFC purification, on a portion of crude **19**, 60 mg of the desired product 1-((1R,5S)-8-{2-[1-(2-furoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole **19** was obtained (calculated yield 86%). ^1H NMR (400 MHz, CD_3OD) δ 7.57 (1H, dist. d, $J=1.1\text{Hz}$), 7.47 (1H, d, $J=7.1\text{ Hz}$), 7.43-7.29 (5H, m), 7.26-7.09 (3H, m), 6.89 (1H, d, $J=3.6\text{Hz}$), 6.48 (1H, dd,

J=1.8, 3.6Hz), 4.08 (2H, m), 3.84 (2H, m), 2.60 (5H, m), 2.42 (3H, s), 2.30 (2H, m), 2.20 (2H, m), 2.05 (7H, m), 1.83 (2H, m). HRMS m/z (M+H)⁺ Calc 523.3062; (M+H)⁺ Obs 523.3073.

5

Example 20


2-methyl-1-(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-1-oxo-2-propanol




2-hydroxy-2-methylpropanoic acid (36 mg, 0.35 mmole) was dissolved in 0.92 ml of 1,2-dichloroethane. To this was added 1,1'-carbonyldiimidazole (37 mg, 0.23 mmole) and shaken for 30 min. 2-Methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (50 mg, 0.12 mmole) was added as a dry powder and shaking was resumed overnight. 1 ml of NaHCO₃ sat. was added to the reaction mixture and shaken, followed by filtration through a hydrophobic frit and concentrated to an oil. The oil was separated on silica using gradient flash chromatography (0-8% MeOH in CHCl₃) to afford 2-methyl-1-(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-1-oxo-2-propanol **20** 23.7 mg (38%) as a white glassy solid. ¹H NMR (300 MHz, CDCl₃) δ 7.7-7.6 (m, 1H), 7.1-7.4 (m, 8H), 4.7 (s, 1H), 4.0 (s, 2H), 3.2-3.4 (m, 4H), 2.6 (s, 3H), 2.2-2.5 (m, 5H), 2.1-1.7 (m, 11H), 1.7-1.5 (m, 2H).

Selected coupling methods used in the synthesis of compounds of formula I from II or IIa (Scheme I)


25

Method A (HATU)

To 117 μ moles of each acid was added 117 μ moles (1 eq.) of amine-scaffold dissolved in 1 mL DMF and 351 μ moles (3 eq.) of DIPEA in 1 mL
5 DMF at ambient temperature. After shaking 5 min to affect dissolution of materials, 117 μ moles (1 eq.) of HATU in 1 mL DMF was added and the reaction mixture and shaken at ambient temperature for 16 h. 351 μ moles of solid supported MP-Carbonate (Argonaut Technologies, Inc.) was added to the reaction mixture and shaken an additional 20h. The resin-bound
10 carbonate was filtered off and the reaction mixture concentrated to dryness. The approximately 100 milligrams of impure compound was dissolved in 300 microliters of DMSO and brought up to a final volume of 500 microliters using methanol. This 500 microliter solution was injected by a Waters 2767 autosampler into an XTerra C18 5 micron particle HPLC column
15 (19mmX150mm). Initial solvent flow was 20ml/min with 30% methanol and 70% water at a pH of 11 using ammonium hydroxide as buffer. Void volume was 2 minutes, and a linear gradient to 100% methanol in 10 minutes with a five minute wash at 100% methanol eluted the compound in approximately 10 minutes. A Micromass Platform LC mass spectrometer was used to monitor and split off the eluate for desired mass, and the purified fractions were
20 collected using Micromass Fractionlynx software. Isolated compounds were characterized by LC-MS and ^1H NMR. Yields and representative data were included in the accompanying tables.


Method B (anhydride)

To 117 μ moles of the anhydride in 1 mL DCM was added 117 μ moles (1 eq.) of amine-scaffold dissolved in 1 mL DCM and stirred at ambient temperature for 1 h. In some cases, product crystalized from the reaction mixture and was isolated by filtration. Otherwise, the reaction mixture was concentrated and purified either by normal phase flash chromatography (SiO_2 , $\text{CHCl}_3/\text{CH}_3\text{OH}$) or by reverse phase mass-directed HPLC as described in the Preparative HPLC Conditions A. Yields and representative data were included in the accompanying tables.

Method C – example of TFA-mediated Boc-deprotection -Example 21

Boc-derivative (248 μ moles) was dissolved in 3 mL DCM and treated with 3 mL TFA for 40 min at ambient temperature. The reaction mixture was concentrated and pumped dry to give the TFA salt (example 21, mass 224 mg, Exact Mass = 543.3573) as a clear oil. Yield and representative data were included in the accompanying tables.


Method D – sulfonamide via sulfonyl chloride or amide via acyl chloride -
Example 22 and Example 23



Product from example 21 (91 μ moles) was dissolved in 2 mL DCM and
5 cooled to 0°C was treated with TEA (273 μ moles, 3 eq.) followed by either
acetyl chloride or methanesulfonyl chloride (91 μ moles, 1 eq.). The reaction
mixture was stirred 5 min at 0°C and then allowed to warm to ambient
temperature and stirred an additional 30 min. The reaction mixture was
diluted with 10 mL DCM, washed successively with saturated NaHCO₃ and
10 brine, dried over MgSO₄, filtered, and concentrated to give the acetyl
derivative (example 22) or methylsulfonyl (example 23), respectively.
Products were purified by reverse phase mass-directed HPLC as described in
Preparative HPLC Conditions A. Yields and representative data were
included in the accompanying tables.

15


Method E – example of TFA-mediated Boc-deprotection




The Boc-protected amine (1.02 mmoles) was dissolved in 5 mL DCM
and treated with 5 mL TFA at ambient temperature for 1 h. The reaction
20 mixture was concentrated and treated with a biphasic mixture of EtOAc and
saturated aqueous NaHCO₃. The mixture was stirred vigorously, and the
solid filtered off and washed successively with water and EtOAc to give the

TFA salt of the amine. Yields and representative data were included in the accompanying tables.

Method F – HATU mediated formation of amides - Example 24




5 3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid (259 mg, 449 μ moles) was combined with 2,4-dimethoxybenzylamine (449 μ moles, 1 eq.) in 3 mL DMF with DIPEA (449 μ moles, 1 eq.) and treated with
10 HATU (449 μ moles, 1 eq.) at ambient temperature for 16 h. The reaction mixture was concentrated, dissolved in EtOAc, washed successively with saturated NaHCO_3 and brine, dried over MgSO_4 , filtered, and concentrated. Products were purified by reverse phase HPLC as described in Preparative HPLC Conditions A to give the desired product. Yields and representative
15 data were included in the accompanying tables.





















The product (73 mg, 101 μ moles) was dissolved in 3 mL DCM and treated with 3 mL TFA at ambient temperature for 24h. The reaction mixture was concentrated, dissolved in DCM, washed with saturated aqueous
20 NaHCO_3 , dried over MgSO_4 , filtered and concentrated. The crude product was purified by normal phase flash chromatography (SiO_2 , DCM/ CH_3OH) to give the desired product.










The accompanying tables list yields and representative data for compounds of the present invention.




















Example #	Acid # (for non-commercial compounds)	R	X	Y	% yield	LCMS result	Ion	Acylation/co upling Method
25			H	C	63	573	(M+H)	Acid chloride
26			H	C		522	(M+H)	CDI
27			H	C		529	(M+H)	A
28			H	C		527	(M+H)	A
29			H	C		513	(M+H)	A
30			H	C		648	(M+H)	A
31			H	C		499	(M+H)	A










33			H	C		568	(M+H)	A
34			H	C	13	658	(M+H)	A
35			H	C	17	658	(M+H)	A
36			H	C	34	626	(M+H)	A
37			H	C	8	542	(M+H)	A
37			H	C	8	570	(M+H)	A
38			H	C	41	597	(M+H)	A
39			H	C	17	557	(M+H)	A
40			H	C	39	584	(M+H)	A










41			H	C	39	601	(M+H)	A
42			H	C	12	591	(M+H)	A
43			H	C		620	(M+H)	A
43			H	C	44	608	(M+H)	A
44			H	C	26	606	(M+H)	A
45			H	C	41	582	(M+H)	A
46			H	C	32	591	(M+H)	A
47			H	C	6	604	(M+H)	A
48			H	C	36	598	(M+H)	A











49			H	C	15	571	(M+H)	A
50			H	C	19	589	(M+H)	A
51			H	C	27	602	(M+H)	A
52			H	C	40	604	(M+H)	A
53			H	C	33	541	(M+H)	A
54			H	C	46	550	(M+H)	A
55			H	C	43	579	(M+H)	A
56			H	C	48	579	(M+H)	A
57			H	C	49	708	(M+H)	A










58			H	C	49	550	(M+H)	A
59			H	C		647	(M+H)	A
60			H	C	66	568	(M+H)	A
61			H	C	25	561	(M+H)	A
62			H	C	33	577	(M+H)	A
63			H	C	69	565	(M+H)	A
64			H	C	60	549	(M+H)	A
65			H	C	69	569	(M+H)	A










66			H	C	48	601	(M+H)	A
67			H	C	65	601	(M+H)	A
68			H	C	34	561	(M+H)	A
69			H	C	46	581	(M+H)	A
70			H	C	10	581	(M+H)	A
71			H	C	61	575	(M+H)	A
72			H	C	60	601	(M+H)	A
73			H	C	59	567	(M+H)	A
74			H	C	56	575	(M+H)	A











75			H	C	100	589	(M+H)	A
76			H	C	97	583	(M+H)	A
77			H	C	77	567	(M+H)	A
78			H	C	59	499	(M+H)	A
79			H	C	87	551	(M+H)	A
80			H	C	60	543	(M+H)	A
81			H	C	68	572	(M+H)	A
82			H	C	54	553	(M+H)	A
83			H	C	66	586	(M+H)	A










84			H	C	48	568	(M+H)	A
85			H	C	79	578	(M+H)	A
86			H	C	48	569	(M+H)	A
87			H	C	87	567	(M+H)	A
88			H	C	73	578	(M+H)	A
89			H	C	49	547	(M+H)	A
90			H	C	100	583	(M+H)	A
91			H	C	69	601	(M+H)	A
92			H	C	69	577	(M+H)	A










93			H	C	19	601	(M+H)	A
94			H	C	72	591	(M+H)	A
95			H	C	73	560	(M+H)	A
96			H	C	77	547	(M+H)	A
97			H	C	81	577	(M+H)	A
98			H	C	44	548	(M+H)	A
99			H	C	64	577	(M+H)	A
100			H	C	54	561	(M+H)	A
101			H	C	67	601	(M+H)	A
102			H	C	50	561	(M+H)	A










103			H	C	84	585	(M+H)	A
104			H	C	71	602	(M+H)	A
105			H	C	84	539	(M+H)	A
106			H	C	63	579	(M+H)	A
107			H	C	50	602	(M+H)	A
108			H	C	16	540	(M+H)	A
109			H	C	38	511	(M+H)	A
110			H	C	50	593	(M+H)	A
111			H	C	78	601	(M+H)	A










112			H	C	65	550	(M+H)	A
113			H	C	67	601	(M+H)	A
114			H	C	60	548	(M+H)	A
115			H	C	12	580	(M+H)	A
116			H	C	87	514	(M+H)	A
117			H	C	48	559	(M+H)	A
118			H	C	56	586	(M+H)	A
119			H	C	58	581	(M+H)	A
120			H	C	59	607	(M+H)	A










121			H	C	68	561	(M+H)	A
122			H	C	15	589	(M+H)	A
123			H	C	52	603	(M+H)	A
124			H	C	17	581	(M+H)	A
125			H	C	61	591	(M+H)	A
126			H	C	58	569	(M+H)	A
127			H	C	52	569	(M+H)	A
128			H	C	59	609	(M+H)	A
129			H	C	59	553	(M+H)	A
130			H	C	58	573	(M+H)	A











131			H	C	69	599	(M+H)	A
132			H	C	48	601	(M+H)	A
133			H	C	58	575	(M+H)	A
134			H	C	53	554	(M+H)	A
135			H	C	31	589	(M+H)	A
136			H	C	47	591	(M+H)	A
137			H	C	60	599	(M+H)	A
138			H	C	49	591	(M+H)	A
139			H	C	36	539	(M+H)	A










140			H	C	53	582	(M+H)	A
141			H	C	48	600	(M+H)	A
142			H	C	47	605	(M+H)	A
143			H	C	48	571	(M+H)	A
144			H	C	11	555	(M+H)	A
145			H	C	27	485	(M+H)	A
146			H	C	31	585	(M+H)	A
147			H	C	47	584	(M+H)	A
148			H	C	41	497	(M+H)	A









149			H	C	18	550	(M+H)	A
150			H	C	94	579	(M+H)	A
151			H	C	89	557	(M+H)	A
152			H	C	81	591	(M+H)	A
153			H	C	44	587	(M+H)	A
154			H	C	71	583	(M+H)	A
155			H	C	81	591	(M+H)	A
156			H	C	29	572	(M+H)	A
157			H	C	64	565	(M+H)	A











158			H	C	73	601	(M+H)	A
159			H	C	43	513	(M+H)	A
160			H	C	64	572	(M+H)	A
161			H	C	61	593	(M+H)	A
162			H	C	64	583	(M+H)	A
163			H	C	75	511	(M+H)	A
164			H	C	66	591	(M+H)	A
165			H	C	81	591	(M+H)	A
166			H	C	47	605	(M+H)	A











167		H	C	60	569	(M+H)	A
168		H	C	44	549	(M+H)	A
169		H	C	62	594	(M+H)	A
170		H	C	37	553	(M+H)	A
171		H	C	55	591	(M+H)	A
172		H	C	8	578	(M+H)	A
173		H	C	58	581	(M+H)	A
174		H	C	12	569	(M+H)	A
175		H	C	62	597	(M+H)	A












176			H	C	48	547	(M+H)	A
177			H	C	53	575	(M+H)	A
178			H	C	57	575	(M+H)	A
179			H	C	36	573	(M+H)	A
180			H	C	68	542	(M+H)	A
181			H	C	15	607	(M+H)	A
182			H	C	43	568	(M+H)	A
183			H	C	49	601	(M+H)	A
184			H	C	40	599	(M+H)	A
185			H	C	47	541	(M+H)	A










186			H	C	43	551	(M+H)	A
187			H	C	51	604	(M+H)	A
188			H	C	17	581	(M+H)	A
189			H	C	90	585.31	(M-1)	A
190			H	C	20	751.18	(M+H)	A
191			H	C	29	590.14	(M+H)	A
192			H	C	7	668.18	(M+H)	A
193			H	C	71	575.17	(M+H)	A
194			H	C	25	677.78	(M+H)	A

195			H	C	53	675.81	(M+H)	A
196			H	C	59	574.92	(M+H)	A
197			H	C	74	810.85	(M+H)	A
198			H	C	44	582.92	(M+H)	A
199			H	C	9	590.15	(M+H)	A
200			H	C	84	589.97	(M+H)	A
201			H	C	31	604.03	(M+H)	A
202			H	C	11	561.19	(M+H)	A










203			H	C	11	613.09	(M+H)	A
204			H	C	21	685.72	(M+H)	A
205			H	C	25	643.83	(M+H)	A
206			H	C	18	725.84	(M+H)	A
207			H	C	26	562.89	(M+H)	A
208			H	C	23	721.94	(M+H)	A
209			H	C	16	612.04	(M+H)	A
210			H	C	13	628.03	(M+H)	A
211			H	C	50	839.75	(M+H)	A
212			H	C	40	825.76	(M+H)	A

213		H	C	38	639.75	(M+H)	A
214		H	C	44	625.79	(M+H)	A
215		H	C	42	610.79	(M+H)	A
216		H	C	35	596.81	(M+H)	A
217		H	C	30	716.05	(M+H)	A
218		H	C	40	641.85	(M+H)	A
219		H	C	33	740.89	(M+H)	A
220		H	C	24	574.89	(M+H)	A
221		H	C	26	701.75	(M+H)	A
222		H	C	32	767.25	(M+H)	A

223			H	C	26	627.08	(M+H)	A
224			H	C	28	718.13	(M+H)	A
225			H	C	16	880.29	(M+H)	A
226			H	C	24	702.17	(M+H)	A
227			H	C	20	751.18	(M+H)	A
228			H	C	4	685.14	(M+H)	A
229			H	C	17	699.16	(M+H)	A
230			H	C	27	640.17	(M+H)	A
231			H	C	20	640.17	(M+H)	A
232			H	C	16	713.17	(M+H)	A
233			H	C	64	654.17	(M+H)	A

234			H	C	44	642.12	(M+H)	A
235	Acid 3		H	C	47	660.01	(M+H)	A
236	Acid 4		H	C	64	688.05	(M+H)	A
237	Acid 5		H	C	66	704.08	(M+H)	A
238	Acid 6		H	C	22	654.16	(M+H)	A
239	Acid 7		H	C	20	670.17	(M+H)	A
240	Acid 8		H	C	19	654.16	(M+H)	A
241	Acid 9		H	C	14	670.19	(M+H)	A
242	Acid 10		H	C	15	658.12	(M+H)	A

243	Acid 11		H	C	19	656.12	(M+H)	A
244	Acid 12		H	C	53	659.84	(M+H)	A
245	Acid 13		H	C	30	703.96	(M+H)	A
246	Acid 14		H	C	35	762.11	(M+H)	A
247			H	C	8	623.02	(M+H)	A
248	Acid 15		H	C	44	673.86	(M+H)	A
249	Acid 16		H	C	46	848.02	(M+H)	A
250	Acid 2		H	C	38	844.14	(M+H)	A
251			H	C	72	584.13	(M+H)	A
252			H	C	60	529.14	(M+H)	A












253			H	C	65	577.15	(M+H)	A
254			H	C	51	569.17	(M+H)	A
255			H	C	41	569.17	(M+H)	A
256			H	C	47	555.19	(M+H)	A
257			H	C	72	515.16	(M+H)	A
258			H	C	24	543.18	(M+H)	A
259			H	C	70	700.05	(M+H)	A
260			H	C	68	577.15	(M+H)	A
261			H	C	63	577.15	(M+H)	A










262			H	C	52	702.03	(M+H)	A
263			H	C	68	577.15	(M+H)	A
264			H	C	33	684.08	(M+H)	A
265			H	C	72	700.05	(M+H)	A
266			H	C	62	702.02	(M+H)	A
267	Acid 17		H	C	48	694.05	(M+H)	A
268			H	C	33	708.14	(M+H)	A
269			H	C	54	593.15	(M+H)	A
270			H	C	54	608.22	(M+H)	A
271			H	C	48	594.25	(M+H)	A








272			H	C	8	691.08	(M+H)	A
273	Acid 18		H	C	40	674.06	(M+H)	A
274	Acid 19		H	C	48	688.04	(M+H)	A
275	Acid 20		H	C	40	686.06	(M+H)	A
276	Acid 21		H	C	39	711.97	(M+H)	A
277			H	C	41	679.93	(M+H)	A
278	Acid 22		H	C	82	630.01	(M+H)	A
279	Acid 23		H	C	53	644.00	(M+H)	A
280	Acid 24		H	C	59	658.02	(M+H)	A
281	Acid 25		H	C	50	672.00	(M+H)	A
282	Acid 28		H	C	53	670.01	(M+H)	A

283	Acid 27		H	C	44	672.03	(M+H)	A
284	Acid 28		H	C	49	711.98	(M+H)	A
285	Acid 29		H	C	46	727.95	(M+H)	A
286	Acid 30		H	C	45	727.95	(M+H)	A
287			F	C	33	665.04	(M+H)	A
288	Acid 3		F	C	51	678.05	(M+H)	A
289	Acid 18		F	C	37	692.03	(M+H)	A
290	Acid 19		F	C	47	708.08	(M+H)	A
291	Acid 20		F	C	39	704.06	(M+H)	A
292	Acid 4		F	C	37	705.94	(M+H)	A
293	Acid 12		F	C	38	678.05	(M+H)	A
294			F	C	45	681.88	(M+H)	A

295	Acid 22		F	C	57	647.99	(M+H)	A
296			F	C	22	683.99	(M+H)	A
297	Acid 28		F	C	54	729.95	(M+H)	A
298	Acid 29		F	C	54	745.92	(M+H)	A
299	Acid 30		F	C	52	745.89	(M+H)	A
300	Acid 21		F	C	51	729.98	(M+H)	A
301			F	C	45	697.90	(M+H)	A
302	Acid 23		F	C	50	681.97	(M+H)	A
303	Acid 24		F	C	48	676.04	(M+H)	A
304	Acid 25		F	C	52	690.00	(M+H)	A
305	Acid 26		F	C	53	687.97	(M+H)	A
306	Acid 27		F	C	41	690.00	(M+H)	A

307			CH ₃	C	28	661.06	(M+H)	A
308	Acid 3		CH ₃	C	35	674.06	(M+H)	A
309	Acid 18		CH ₃	C	46	688.04	(M+H)	A
310	Acid 19		CH ₃	C	44	702.05	(M+H)	A
311	Acid 20		CH ₃	C	42	700.07	(M+H)	A
312	Acid 4		CH ₃	C	35	702.10	(M+H)	A
313	Acid 12		CH ₃	C	45	674.06	(M+H)	A
314			CH ₃	C	54	693.92	(M+H)	A
315			CH ₃	C	47	659.97	(M+H)	A
316	Acid 1		H	N	44	567.92	(M+H)	A
317			H	N	37	513.93	(M+H)	A


318			H	N	35	523.89	(M+H)	A
319			H	C	47	525.23	(M+H)	B
320			H	C	68	527.42	(M-1)	B
321			H	C	90	579.46	(M-1)	B
322			H	C	78	581.48	(M-1)	B
323			H	C	92	541.42	(M-1)	B
324			H	C	99	569.43	(M-1)	B
325			H	C	94	555.46	(M-1)	B
326			H	C	24	577.29	(M-1)	B

21			H	C	100	544.21	(M+H)	C
328			H	C	88	588.12	(M+H)	D
329			H	C	46	622.13	(M+H)	D
330			H	C	70	429.25	(M+H)	E
331			H	N	100	430.28	(M+H)	E
332			H	C	31	728.12	(M+H)	F
333			H	C	35	576.05	(M+H)	G

Proton NMR data for selected compounds from the above table:

Example 186

1-((1*R*,5*S*)-8-{2-[1-(2-fluorobenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole




5 ^1H NMR (400 MHz, Methanol- d_4 , ppm) δ 1.3 (m, 1H), 1.7 (m, 2H), 1.9 (m, 6H), 2.0 (m, 2H), 2.2 (m, 1H), 2.4 (m, 3H), 2.5 (s, 3H), 3.2 (m, 1H), 3.3 (m, 4H), 3.5 (m, 1H), 4.2 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 2H), 7.4 (m, 6H), 7.5 (m, 3 H).

10

Example 147


2-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]quinoline



15 ^1H NMR (400 MHz, Methanol- d_4 , ppm) δ 1.9 (s, 1H), 2.3 (m, 2H), 2.6 (m, 9H), 2.9 (m, 1H), 3.1 (m, 3H), 3.2 (m, 2H), 3.9 (m, 5H), 4.2 (m, $J=3.6\text{Hz}$, 1H), 4.8 (m, 1H), 5.4 (m, 1H), 7.8 (m, 2H), 7.9 (m, 1H), 8.0 (m, 1H), 8.0 (m, $J=8.2\text{Hz}$, 1H), 8.1 (s, 5H), 8.1 (m, 3H), 8.1 (m; $J=4.3, 2.5\text{Hz}$, 1H), 8.2 (m, 1H).

Example 146

1-((1R,5S)-8-{2-[1-(2-chloro-6-fluorobenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, Methanol- d_4 , ppm) δ 1.2 (m, 1H), 1.6 (m, 2H), 1.8 (m, 8H), 1.9 (m, 2H), 2.3 (m, 4H), 2.4 (m, 3H), 3.1 (m, 1H), 3.3 (m, 3H), 4.1 (m, 1H), 4.6 (m, 1H), 7.1 (m, 2H), 7.2 (m, 2H), 7.3 (m, 6H), 7.4 (m, 1H), 7.4 (m, 1H).

10

Example 166


2,2-dimethyl-3-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-3-oxo-1-phenyl-1-propanol



15 ^1H NMR (400 MHz, Methanol- d_4 , ppm) δ 1.8 (m, 3H), 1.9 (s, 3H), 2.3 (m, 3H), 2.5 (m, 5H), 2.7 (m, 4H), 3.0 (m, 2H), 3.1 (m, 3H), 3.2 (m, 3H), 4.0 (m, 5H), 4.7 (m, 2H), 5.4 (m, 1H), 7.8 (m, 2H), 7.9 (m, 2H), 7.9 (m, 1H), 8.0 (m, 1H), 8.1 (m, 6H), 8.2 (m, 2H).

Example 105

1-((1R,5S)-8-{2-[1-(2,2-dimethyl-4-pentenoyl)-4-phenyl-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




- 5 ¹H NMR (400 MHz, Methanol-d₄, ppm) δ 0.6 (m, 1H), 0.9 (m, 1H), 1.5 (m, 1H), 1.7 (m, 3H), 1.9 (m, 9H), 2.3 (m, 2H), 2.4 (m, 4H), 2.5 (d, J=6.1Hz, 3H), 3.1 (m, 1H), 3.3 (m, 5H), 4.0 (m, 3H), 4.8 (m, 1H), 5.0 (m, 2H), 5.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

10

Example 101


1-((1R,5S)-8-{2-[1-(2,6-dichlorobenzoyl)-4-phenyl-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



- 15 ¹H NMR (400 MHz, Methanol-d₄, ppm) δ 1.2 (m, 1H), 1.6 (m, 2H), 1.8 (m, 6H), 1.9 (m, 2H), 2.2 (m, 1H), 2.3 (m, 3H), 2.4 (m, 3H), 3.1 (m, 1H), 3.3 (m, 5H), 4.1 (m, 1H), 4.7 (m, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (m, 5H), 7.4 (m, 2H), 7.4 (m, 1H), 7.4 (m, 1H).

Example 84

1-[(1R,5S)-8-(2-{1-[(2-chloro-3-pyridinyl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




- 5 ^1H NMR (400 MHz, Methanol- d_4 , ppm) δ 1.6 (d, $J=7.5\text{Hz}$, 2H), 1.9 (m, 9H), 2.2 (d, $J=15.7\text{Hz}$, 1H), 2.4 (m, 3H), 2.5 (m, 3H), 3.1 (m, 1H), 3.3 (m, 5H), 4.1 (dd, $J=9.3, 4.3\text{Hz}$, 1H), 4.7 (m, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (m, 5H), 7.4 (m, 2H), 7.8 (m, 1H), 8.4 (m, 1H).

10

Example 334


1-[(1R,5S)-8-{2-[1-(2-ethylbutanoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



- 15 ^1H NMR (400 MHz, Methanol- d_4 , ppm) δ 1.4 (t, $J=7.5\text{Hz}$, 3H), 1.6 (t, $J=7.5\text{Hz}$, 3H), 1.9 (m, 1H), 2.2 (m, 6H), 2.5 (m, 9H), 2.9 (m, 2H), 3.1 (m, 2H), 3.2 (d, $J=6.4\text{Hz}$, 3H), 3.4 (m, 1H), 3.9 (m, 1H), 4.0 (none, 2H), 4.0 (m, 1H), 4.5 (m, 1H), 4.7 (m, 1H), 5.4 (m, 1H), 7.8 (m, 2H), 7.9 (m, 1H), 8.1 (m, 5H), 8.2 (m, 1H).

Example 335

1-((1R,5S)-8-{2-[1-(2-ethylbutanoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




- 5 ¹H NMR (400 MHz, Methanol-d₄, ppm) δ 1.2 (s, 1H), 1.6 (m, 2H), 1.8 (m, 9H), 2.2 (m, 1H), 2.3 (m, 3H), 2.4 (m, 3H), 3.1 (m, 1H), 3.3 (m, 4H), 4.1 (m, 1H), 4.7 (m, 1H), 7.1 (m, 2H), 7.2 (m, 2H), 7.3 (m, 1H), 7.3 (m, 5H), 7.4 (dd, J=8.6, 6.1Hz, 1H), 7.4 (m, 1H).

10

Example 336


2-methyl-1-((1R,5S)-8-{2-[1-(2-methylbenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole



- 15 ¹H NMR (400 MHz, Methanol-d₄, ppm) δ 1.2 (m, 1H), 1.6 (m, 2H), 1.7 (m, 1H), 1.9 (m, 8H), 2.1 (m, 2H), 2.3 (m, 4H), 2.4 (m, 3H), 3.1 (m, 1H), 3.3 (m, 5H), 4.1 (m, 1H), 4.6 (m, 1H), 7.1 (m, 7H), 7.3 (m, 5H), 7.4 (m, 1H).

Example 337

3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-2-pyridinol




- 5 ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.5 (m, 2H), 1.8 (m, 9H), 2.0 (m, 2H), 2.3 (m, 3H), 2.4 (s, 3H), 3.2 (d, $J=6.4\text{Hz}$, 4H), 3.7 (s, 2H), 4.5 (m, 1H), 6.4 (m, 2H), 7.0 (d, $J=8.6\text{Hz}$, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (m, 5H), 7.4 (m, 1H), 9.8 (s, 1H).

10

Example 338


5-methoxy-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]phenol



- 15 ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.5 (m, 2H), 1.8 (m, 8H), 2.1 (m, 2H), 2.3 (m, 2H), 2.4 (m, 3H), 2.4 (m, 1H), 3.2 (d, $J=7.1\text{Hz}$, 3H), 3.3 (s, 3H), 3.6 (m, 2H), 3.7 (s, 2H), 4.5 (m, 1H), 6.4 (m, 2H), 7.0 (d, $J=8.2\text{Hz}$, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (m, 5H), 7.4 (m, 1H), 9.8 (s, 1H).

Example 339

4-methoxy-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]phenol




- 5 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.5 (m, 2H), 1.8 (m, 9H), 2.0 (m, 2H), 2.3 (m, 2H), 2.4 (m, 3H), 2.5 (m, 1H), 3.2 (m, 6H), 3.6 (s, 2H), 3.8 (m, 1H), 4.4 (m, 1H), 6.6 (d, J=2.9Hz, 1H), 6.7 (d, J=8.6Hz, 1H), 6.8 (m, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (m, 5H), 7.4 (dd, J=8.2, 6.4Hz, 1H), 9.2 (s, 1H).

10

Example 340


6-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-2-pyridinol



- 15 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.5 (m, 2H), 1.8 (m, 8H), 2.1 (m, 2H), 2.3 (m, 2H), 2.4 (m, 3H), 2.5 (m, 1H), 3.3 (m, 7H), 3.8 (s, 1H), 4.5 (m, 1H), 6.3 (d, J=6.4Hz, 1H), 6.4 (d, J=9.3Hz, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (m, 5H), 7.4 (m, 2H).

Example 341


1-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]cyclopentanol



- 5 ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.7 (m, 15H), 2.0 (m, 3H), 2.3 (m, 2H), 2.4 (m, 4H), 2.5 (m, 1H), 2.7 (m, 1H), 3.2 (m, 7H), 3.8 (d, $J=109.2\text{Hz}$, 1H), 4.5 (m, 1H), 7.1 (m, 2H), 7.1 (m, 1H), 7.3 (m, 5H), 7.4 (m, $J=7.1\text{Hz}$, 1H).

Example 51


- 10 5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2-furansulfonamide



- 15 ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.2 (s, 1H), 1.5 (m, 2H), 1.8 (m, 8H), 2.1 (m, 1H), 2.3 (m, 2H), 2.4 (s, 3H), 2.5 (m, 3H), 3.2 (m, 2H), 3.2 (m, 1H), 3.4 (m, 2H), 3.8 (m, 2H), 4.5 (m, 1H), 7.1 (m, 2H), 7.2 (t, $J=7.0\text{Hz}$, 1H), 7.3 (m, 5H), 7.4 (m, 1H).

Example 50

3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-1-benzofuran-6-ol




- 5 ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.5 (m, 2H), 1.7 (m, 9H), 2.1 (d, $J=5.7\text{Hz}$, 2H), 2.3 (m, 2H), 2.4 (s, 3H), 2.5 (m, 2H), 2.5 (m, 1H), 3.2 (m, 2H), 3.3 (m, 1H), 3.7 (m, 2H), 4.5 (m, 1H), 6.8 (dd, $J=8.6, 2.1\text{Hz}$, 1H), 6.9 (d, $J=1.8\text{Hz}$, 1H), 7.1 (m, 2H), 7.2 (t, $J=7.0\text{Hz}$, 1H), 7.3 (m, 6H), 7.4 (m, 1H), 8.0 (s, 1H).

10

Example 44


4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-1,3-benzoxazole-2(3H)-thione



- 15 ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.7 (s, 3H), 1.9 (m, 7H), 2.0 (m, 3H), 2.2 (m, 1H), 2.4 (m, 5H), 2.5 (m, 2H), 3.1 (m, 2H), 3.4 (m, 2H), 3.9 (m, 1H), 4.6 (m, 1H), 7.1 (m, 4H), 7.2 (m, 1H), 7.3 (m, 6H), 7.4 (m, 1H).

Example 43

N-[2,2-dimethyl-3-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)-3-oxopropanoyl]methane sulfonamide



5

3-Ethoxy-2,2-dimethyl-3-oxopropanoic acid (100 mg, 0.624 mmole) was added to a stirring suspension of 2.5 equivalents of PS-DCC from Argonaut and 3 equivalents of dimethylaminopyridine in DCM. To this was added methanesulfonamide (41.6 mg, 0.437 mmole). The solution was filtered of and concentrated to give 69.3 mg of ethyl 2,2-dimethyl-3-[(methylsulfonyl)amino]-3-oxopropanoate (67% yield crude). MS ES- 236 (M-H). ¹H NMR (300 MHz, Chloroform-d) δ ppm 1.4 (t, J=6.7Hz, 3H), 1.6 (s, 6H), 3.3 (m, 3H), 4.3 (m, 2H).

10

15

Ethyl 2,2-dimethyl-3-[(methylsulfonyl)amino]-3-oxopropanoate was hydrolyzed without purification in 2 ml of 1,4-dioxane and 2 ml of 1M LiOH at 45 °C. The solvent was removed under vacuum and the residue 2,2-dimethyl-N-(methylsulfonyl)-3-oxo-alanine was used in the next step without further purification. MS ES- 209 (M-H) ¹H NMR (400 MHz, methanol-d₄) δ ppm 1.4 (s, 6H) and 3.2 (s, 3H).

20

Example 43

N-[2,2-dimethyl-3-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-
azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)-3-oxopropanoyl]


methanesulfonamide was made using the HATU coupling method A. MS ES+

5 620 (M+H). ¹H NMR (300 MHz, methanol-d₄) δ ppm 1.4 (m, 4H), 1.9 (s, 2H),
 2.2 (m, 2H), 2.3 (s, 4H), 2.4 (m, 2H), 2.8 (m, 2H), 2.8 (s, 3H), 2.9 (m, 2H), 3.2
 (d, J=7.5Hz, 2H), 3.3 (m, 2H), 3.5 (s, 1H), 4.1 (d, J=8.5Hz, 2H), 4.9 (s, 6H),
 5.3 (s, 1H), 7.3 (m, 1H), 7.5 (d, J=4.2Hz, 4H), 7.6 (m, 2H), 7.8 (m, 2H).

10

Example 42


N-{4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-
8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-2-pyridinyl}acetamide



¹H NMR (400 MHz, methanol-d₄) δ ppm 1.6 (m, 2H), 1.8 (m, 9H), 2.2 (m, 2H),
 15 2.3 (m, 3H), 2.4 (m, 3H), 3.2 (m, 8H), 3.4 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H),
 7.0 (dd, J=5.0, 1.4Hz, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (m, 5H), 7.4 (m, 1H),
 8.0 (s, 1H), 8.3 (d, J=5.0Hz, 1H).

Example 39


4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-1,2,5-thiadiazol-3-ol



- 5 ¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.6 (d, J=7.5Hz, 2H), 1.8 (m, 7H), 2.1 (s, 2H), 2.3 (s, 2H), 2.5 (s, 3H), 2.5 (m, 2H), 3.1 (m, 1H), 3.4 (m, 6H), 3.8 (s, 1H), 4.5 (s, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 37


- 10 1,1-dimethyl-2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)-2-oxoethylformamide



- 15 ¹H NMR (400 MHz, methanol-d₄) δ ppm 1.5 (m, 6H), 1.7 (m, 2H), 1.9 (m, 8H), 2.2 (s, 2H), 2.4 (m, 2H), 2.5 (s, 3H), 3.3 (m, 4H), 3.3 (m, 2H), 3.6 (m, 1H), 4.0 (s, 2H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H), 8.0 (s, 1H).

Example 36


N-{4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]phenyl}methanesulfonamide formate salt



¹H NMR (400 MHz, methanol-d₄) δ ppm 1.8 (m, 11H), 2.2 (m, 3H), 2.3 (m, 1H), 2.4 (m, 5H), 2.9 (m, 3H), 3.2 (m, 3H), 3.4 (m, 2H), 3.6 (m, 1H), 4.0 (m, J=4.3Hz, 1H), 4.7 (m, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.2 (m, 2H), 7.3 (m, 6H), 7.4 (m, 1H).

Example 35


N,N,2,5-tetramethyl-4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-3-furansulfonamide formate salt



¹H NMR (400 MHz, chloroform-d) δ ppm 1.6 (m, 2H), 1.8 (m, 8H), 2.1 (m, 5H), 2.3 (m, 4H), 2.4 (m, 6H), 2.6 (m, 3H), 2.7 (m, 3H), 3.1 (m, 2H), 3.3 (m, 2H), 3.4 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H), 7.1 (m, 2H), 7.1 (m, 1H), 7.3 (m, 5H), 7.4 (m, 1H).

Example 33


2-methyl-1-[(1R,5S)-8-(2-{1-[2-methyl-2-(1H-1,2,4-triazol-1-yl)propanoyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



- 5 ^1H NMR (300 MHz, chloroform- d) δ ppm 1.5 (m, 5H), 1.7 (d, $J=15.1\text{Hz}$, 3H), 1.9 (m, 10H), 2.0 (s, 2H), 2.4 (m, 3H), 2.6 (s, 3H), 3.0 (m, 5H), 4.6 (m, 1H), 7.2 (m, 5H), 7.3 (m, 3H), 7.6 (m, 1H), 8.0 (s, 1H), 8.1 (s, 1H).

Example 31


- 10 1-[(1R,5S)-8-[2-(1-isobutyryl-4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



- 15 ^1H NMR (300 MHz, chloroform- d) δ ppm 1.1 (d, $J=6.7\text{Hz}$, 3H), 1.1 (d, $J=6.7\text{Hz}$, 3H), 1.2 (m, 2H), 1.6 (m, $J=7.3, 7.3\text{Hz}$, 2H), 1.8 (m, 8H), 2.2 (m, 2H), 2.4 (m, 2H), 2.5 (m, 3H), 2.8 (m, 1H), 3.2 (m, 4H), 3.7 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H), 7.2 (m, 3H), 7.3 (m, 5H), 7.7 (m, 1H).

Example 30

benzyl 1,1-dimethyl-2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-2-oxoethylcarbamate




- 5 ¹H NMR (400 MHz, chloroform-d) δ ppm 1.0 (m, *J*=7.1, 7.1Hz, 1H), 1.5 (m, 8H), 1.8 (d, *J*=6.1Hz, 4H), 1.9 (m, 7H), 2.1 (m, 3H), 2.3 (m, 2H), 2.5 (s, 3H), 3.3 (m, 4H), 4.6 (m, 1H), 5.0 (s, 2H), 7.1 (m, 3H), 7.3 (m, 8H), 7.4 (t, *J*=7.7Hz, 2H), 7.6 (m, 1H).

10

Example 29


1-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]cyclopropanol



- 15 ¹H NMR (400 MHz, chloroform-d) δ ppm 0.9 (m, *J*=20.3Hz, 2H), 1.0 (m, 2H), 1.3 (m, 4H), 1.6 (m, 3H), 1.8 (m, 6H), 2.2 (m, 2H), 2.4 (m, 2H), 2.6 (s, 3H), 3.2 (d, *J*=3.2Hz, 4H), 4.1 (m, 2H), 4.6 (m, 1H), 7.1 (m, 2H), 7.3 (m, 4H), 7.4 (t, *J*=7.7Hz, 2H), 7.6 (d, *J*=7.1Hz, 1H).

Example 28

1-((1R,5S)-8-{2-[1-(2,2-dimethylbutanoyl)-4-phenyl-4-piperidinylethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




- 5 ^1H NMR (400 MHz, chloroform- d) δ ppm 0.9 (t, $J=7.5\text{Hz}$, 3H), 1.2 (s, 6H), 1.6 (m, 4H), 1.8 (m, 8H), 2.2 (dd, $J=12.5$, 3.2Hz, 2H), 2.3 (m, 2H), 2.5 (m, 1H), 2.6 (s, 3H), 3.0 (m, 1H), 3.2 (m, 4H), 3.9 (m, 2H), 4.6 (m, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (m, 3H), 7.4 (m, 2H), 7.6 (m, 1H).

10

Example 27


2,2-dimethyl-3-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-3-oxo-1-propanol



- 15 ^1H NMR (400 MHz, chloroform- d) δ ppm 1.0 (d, $J=6.8\text{Hz}$, 2H), 1.2 (s, 6H), 1.6 (m, 2H), 1.8 (m, 4H), 1.9 (m, 4H), 2.2 (dd, $J=12.0$, 2.7Hz, 2H), 2.3 (m, 2H), 2.6 (s, 3H), 3.2 (m, $J=11.1$, 11.1Hz, 4H), 3.5 (s, 2H), 3.8 (m, 1H), 3.9 (d, $J=13.2\text{Hz}$, 2H), 4.6 (m, 1H), 7.1 (m, 2H), 7.3 (m, 4H), 7.4 (m, 2H), 7.6 (m, 1H).

Example 26


1-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]cyclopropanecarbonitrile



- 5 To a solution of 1-cyanocyclopropane-carboxylic acid (38.9 mg, 0.351 mmole) in 1 ml of DCE was added carbonyldiamidazole (38.0 mg, 0.234 mmole) and the mixture was stirred until gas evolution stopped. 2-Methyl-1-
 10 {[(1R,5S)-8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole (50.0 mg, 0.117 mmole) was added and the resulting mixture was stirred overnight. The solvent was evaporated and the reaction mixture was flashed on silica using a gradient of 1-8% MeOH in CHCl₃ to afford 1-[(4-
 15 {2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]cyclopropanecarbonitrile. MS ES+ 522 (M+H). ¹H NMR (300 MHz, chloroform-d) δ ppm 1.6 (m, J=43.1Hz, 6H), 1.9 (d, J=25.3Hz, 10H), 2.4 (m, J=10.0Hz, 4H), 2.6 (s, 3H), 3.3 (m, 3H), 3.5 (m, 1H), 4.1 (m, 2H), 4.7 (m, 1H), 7.3 (m, 8H), 7.7 (m, 1H).

Example 25

1-[(1R,5S)-8-(2-{1-[(3-chloro-2-thienyl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




5 ^1H NMR (300 MHz, methanol- d_4) δ ppm 0.9 (m, 1H), 1.1 (m, 3H), 1.6 (d, $J=12.2\text{Hz}$, 2H), 1.9 (m, 8H), 2.3 (m, 4H), 2.4 (s, 3H), 3.2 (m, 2H), 3.6 (m, 1H), 4.0 (m, $J=7.1\text{Hz}$, 1H), 4.7 (m, 1H), 6.9 (d, $J=5.2\text{Hz}$, 1H), 7.1 (m, 2H), 7.2 (d, $J=6.2\text{Hz}$, 1H), 7.3 (m, 5H), 7.4 (m, $J=1.5\text{Hz}$, 1H), 7.6 (d, $J=5.2\text{Hz}$, 1H).

10

Example 342


1-[(1R,5S)-8-(2-{1-[(3-chlorophenyl)sulfonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



15 ^1H NMR (300 MHz, chloroform- d) δ ppm 1.6 (m, 2H), 1.7 (m, 4H), 1.9 (m, 8H), 2.4 (m, 4H), 2.6 (s, 3H), 2.8 (m, 2H), 3.4 (m, 2H), 4.6 (m, 1H), 7.2 (m, 5H), 7.3 (m, 3H), 7.4 (t, $J=7.9\text{Hz}$, 1H), 7.5 (m, 1H), 7.6 (d, $J=7.8\text{Hz}$, 1H), 7.7 (m, 1H), 7.7 (m, $J=1.8, 1.8\text{Hz}$, 1H).

Example 343

2-methyl-1-[(1R,5S)-8-(2-{1-[(3-methylphenyl)sulfonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




5 ^1H NMR (300 MHz, chloroform- d) δ ppm 1.6 (m, 2H), 1.7 (dd, $J=9.3$, 5.6Hz, 2H), 1.9 (m, 8H), 2.3 (m, 4H), 2.4 (s, 3H), 2.5 (d, $J=13.9$ Hz, 3H), 2.8 (m, 2H), 3.2 (m, 2H), 3.4 (m, 2H), 4.5 (m, 1H), 7.1 (m, 5H), 7.3 (m, 5H), 7.5 (m, 2H), 7.6 (m, 1H).

10

Example 344


4-chlorophenyl 1,1-dimethyl-2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-2-oxoethyl ether



15 ^1H NMR (300 MHz, chloroform- d) δ ppm 1.3 (m, 1H), 1.6 (m, 11H), 1.9 (m, 7H), 2.2 (m, $J=10.7$ Hz, 1H), 2.4 (m, $J=23.3$ Hz, 2H), 2.6 (s, 3H), 3.1 (m, 1H), 3.2 (m, 2H), 3.4 (m, 1H), 4.2 (m, 2H), 4.6 (m, 1H), 6.8 (m, 2H), 7.2 (m, 8H), 7.3 (m, 2H), 7.7 (m, 1H).

Example 34

2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]phenyl dimethylsulfamate formate salt




5

^1H NMR (400 MHz, chloroform- d) δ ppm 1.9 (m, 10H), 2.3 (m, 9H), 2.7 (s, 3H), 2.9 (s, 3H), 3.1 (m, 2H), 3.4 (m, 3H), 4.1 (m, $J=13.6\text{Hz}$, 1H), 4.7 (m, 1H), 7.1 (m, 2H), 7.2 (m, 4H), 7.3 (m, 4H), 7.4 (m, 2H), 7.4 (m, 1H).

10

Example 37

5-methyl-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-4-isothiazolol




15

^1H NMR (300 MHz, DMSO- d_6) δ ppm 2.7 (m, 3H), 3.1 (m, 4H), 3.3 (m, 10H), 3.6 (m, 2H), 3.8 (s, 6H), 4.0 (m, 3H), 4.2 (m, 1H), 4.7 (m, 1H), 8.6 (m, $J=4.6, 4.6\text{Hz}$, 2H), 8.7 (d, $J=6.6\text{Hz}$, 1H), 8.8 (d, $J=14.8\text{Hz}$, 5H), 8.9 (m, 1H).

Example 38


N-{5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-1,3-thiazol-2-yl}acetamide



5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.6 (s, 1H), 2.0 (m, 12H), 2.5 (m, 5H), 3.1 (s, 2H), 3.2 (m, 2H), 3.5 (m, 4H), 3.7 (m, 2H), 4.0 (m, 2H), 7.1 (m, 4H), 7.3 (m, 5H), 7.5 (m, 1H).

Example 43


10 2-(isopropylamino)-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-4-pyrimidinol



15 ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.1 (dd, $J=20.0, 6.4\text{Hz}$, 5H), 1.6 (d, $J=7.8\text{Hz}$, 2H), 1.8 (m, 8H), 2.1 (m, 2H), 2.4 (m, 2H), 2.5 (d, $J=7.5\text{Hz}$, 3H), 2.5 (m, 1H), 3.3 (m, 8H), 3.8 (m, $J=21.0\text{Hz}$, 1H), 4.0 (m, 1H), 4.5 (m, 1H), 6.7 (s, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H), 7.8 (s, 1H).

Example 45

3,3,5-trimethyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2-pyrrolidinone




5

^1H NMR (400 MHz, DMSO- d_6) δ ppm 0.9 (m, 3H), 1.1 (s, 3H), 1.4 (m, 2H), 1.6 (m, 2H), 1.8 (m, 8H), 2.0 (m, 3H), 2.3 (m, 3H), 2.5 (m, 1H), 3.3 (m, 4H), 3.3 (d, $J=11.1\text{Hz}$, 5H), 3.7 (m, $J=1.4\text{Hz}$, 2H), 4.5 (m, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H), 7.8 (s, 1H).

10

Example 46

N-{2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-3-pyridinyl}acetamide




15

^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.6 (m, 2H), 1.8 (m, 8H), 2.0 (s, 3H), 2.2 (m, 2H), 2.4 (m, 2H), 2.4 (s, 3H), 2.5 (m, 2H), 3.1 (m, 1H), 3.3 (m, 3H), 3.4 (dd, $J=7.0, 3.0\text{Hz}$, 1H), 3.9 (m, 1H), 4.5 (m, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.4 (dd, $J=8.2, 4.6\text{Hz}$, 1H), 7.5 (m, 1H), 8.0 (m, 1H), 8.3 (m, 1H), 9.7 (s, 1H).

20

Example 52

N-[2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)-2-oxo-1-phenylethyl]acetamide




5 ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.6 (m, 3H), 1.8 (m, 9H), 2.0 (m, 2H), 2.4 (m, 2H), 2.5 (m, 3H), 3.2 (m, 4H), 3.4 (d, $J=11.4\text{Hz}$, 3H), 3.6 (m, 2H), 3.8 (m, 1H), 4.5 (m, 1H), 5.9 (dd, $J=24.6, 7.8\text{Hz}$, 1H), 7.1 (m, 2H), 7.3 (m, 10H), 7.5 (d, $J=7.1\text{Hz}$, 1H), 8.5 (dd, $J=7.8, 5.4\text{Hz}$, 1H).

10

Example 59


6-chloro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-3-pyridinesulfonamide



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.6 (m, 2H), 1.8 (m, 8H), 2.0 (d, $J=6.6\text{Hz}$, 2H), 2.2 (d, $J=7.7\text{Hz}$, 2H), 2.4 (m, 4H), 2.5 (s, 3H), 3.1 (m, 2H), 3.3 (m, 3H), 4.1 (m, 1H), 4.7 (s, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (m, 5H), 7.4 (m, 1H), 8.2 (m, $J=61.5, 2.4\text{Hz}$, 1H), 8.8 (dd, $J=2.4, 1.5\text{Hz}$, 1H).

Example 345

1-((1R,5S)-8-{2-[1-(3-cyclohexylpropanoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 0.8 (m, 2H), 1.2 (m, 4H), 1.4 (q, $J=7.4\text{Hz}$, 2H), 1.8 (m, 16H), 2.2 (m, 2H), 2.3 (m, 4H), 2.5 (s, 3H), 3.1 (m, 1H), 3.2 (m, 4H), 3.7 (dd, $J=9.5, 4.8\text{Hz}$, 1H), 3.9 (m, 1H), 4.7 (m, 1H), 7.1 (m, 3H), 7.3 (m, 5H), 7.4 (m, 1H).

10

Example 346


N-[2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-2-oxoethyl]benzamide



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.4 (m, 4H), 2.5 (m, $J=3.6\text{Hz}$, 3H), 3.2 (m, 1H), 3.3 (m, 4H), 3.8 (m, 1H), 4.0 (m, 1H), 4.3 (m, 2H), 4.7 (m, 1H), 7.2 (m, 3H), 7.4 (m, 7H), 7.5 (m, 2H), 7.9 (m, 1H).

Example 347

2-methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(3-pyridinyl carbonyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.6 (m, 2H), 1.9 (m, 10H), 2.2 (m, 1H), 2.3 (m, 4H), 2.4 (s, 3H), 3.2 (m, 3H), 3.5 (m, 1H), 4.1 (m, $J=13.2\text{Hz}$, 1H), 4.7 (m, 1H), 7.1 (m, 3H), 7.3 (m, 5H), 7.4 (m, 2H), 7.8 (m, 1H), 8.5 (d, $J=1.4\text{Hz}$, 1H), 8.6 (dd, $J=5.0, 1.8\text{Hz}$, 1H).

10

Example 348

3-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-3-oxo-2-phenyl-1-propanol




15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.6 (m, 2H), 1.8 (m, 10H), 2.1 (m, 1H), 2.4 (m, 2H), 2.5 (s, 3H), 2.5 (s, 2H), 3.1 (m, 3H), 3.3 (m, 2H), 3.7 (m, 2H), 4.1 (m, 2H), 4.7 (m, 1H), 7.3 (m, 13H), 7.5 (m, 1H).

143

Example 349

4-[2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)-2-oxoethyl]phenol




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.4 (m, 1H), 1.6 (m, 1H), 2.0 (m, 8H), 2.3 (m, 2H), 2.4 (s, 3H), 2.5 (m, 2H), 3.0 (m, 1H), 3.1 (m, 1H), 3.4 (s, 1H), 3.6 (m, 5H), 3.9 (m, 1H), 4.9 (m, 1H), 6.6 (m, 2H), 7.0 (m, 2H), 7.2 (m, 3H), 7.3 (m, 5H), 7.4 (m, 1H), 7.5 (m, 1H).

10

Example 350


2-methyl-1-[(1R,5S)-8-(2-[4-phenyl-1-[2-(trifluoromethyl)benzoyl]-4-piperidiny]ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.8 (m, 10H), 2.1 (m, 3H), 2.4 (m, 6H), 3.0 (m, 2H), 3.2 (m, 1H), 3.4 (m, 2H), 4.1 (m, 1H), 4.7 (m, 1H), 7.1 (m, 3H), 7.3 (m, 1H), 7.3 (m, 5H), 7.4 (m, 1H), 7.6 (m, 3H).

Example 351

1-((1R,5S)-8-{2-[1-(3-chloro-2-fluorobenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ¹H NMR (400 MHz, methanol-d₄) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.3 (m, 1H), 2.4 (m, 3H), 2.5 (s, 3H), 3.2 (m, 2H), 3.4 (m, 1H), 3.4 (m, 2H), 4.2 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.3 (m, 2H), 7.4 (m, 6H), 7.5 (m, 1H), 7.6 (m, 1H).

10

Example 352

1-[(1R,5S)-8-(2-{1-[6-chloro-2-pyridinyl]carbonyl}-4-phenyl-4-piperidinyl)ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




15 ¹H NMR (400 MHz, methanol-d₄) δ ppm 1.6 (m, 2H), 1.9 (m, 10H), 2.2 (m, 1H), 2.4 (m, 3H), 2.4 (s, 3H), 3.2 (m, 1H), 3.3 (m, 3H), 3.5 (m, 1H), 4.1 (m, 1H), 4.7 (m, 1H), 7.1 (m, 3H), 7.3 (m, 5H), 7.4 (m, 3H), 7.8 (t, J=7.7Hz, 1H).

145

Example 353


1-((1R,5S)-8-{2-[1-(2-chloroisonicotinoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.3 (m, 1H), 2.4 (m, 3H), 2.5 (s, 3H), 2.6 (m, 1H), 3.3 (m, 3H), 3.5 (m, 1H), 4.2 (m, 1H), 4.7 (m, 1H), 7.2 (m, 3H), 7.4 (m, 6H), 7.5 (m, 2H), 8.5 (d, $J=5.0\text{Hz}$, 1H).

Example 354


10 1-((1R,5S)-8-{2-[1-(4-chloro-2-fluorobenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.6 (m, 2H), 1.8 (m, 10H), 2.2 (m, 1H), 2.3 (m, 3H), 2.4 (s, 3H), 2.5 (m, 1H), 3.1 (m, 1H), 3.3 (m, 2H), 3.4 (m, 1H), 4.1 (m, 1H), 4.6 (m, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (m, 8H), 7.4 (m, 1H).

Example 355

1-((1R,5S)-8-{2-[1-(2,3-dimethylbenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ¹H NMR (400 MHz, methanol-d₄) δ ppm 1.8 (m, 10H), 2.0 (s, 3H), 2.1 (m, 1H), 2.2 (m, 3H), 2.3 (m, 4H), 2.4 (m, 3H), 2.5 (m, 1H), 3.0 (m, 1H), 3.3 (m, 4H), 4.1 (m, 1H), 4.6 (m, 1H), 6.8 (d, J=7.1Hz, 1H), 7.1 (m, 5H), 7.3 (m, 5H), 7.4 (m, 1H).

10

Example 356


1-((1R,5S)-8-{2-[1-(1H-indol-5-ylcarbonyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



15 ¹H NMR (400 MHz, methanol-d₄) δ ppm 1.6 (m, 2H), 1.9 (m, 10H), 2.2 (m, 3H), 2.4 (m, 4H), 3.3 (m, 2H), 3.7 (m, 1H), 4.1 (m, 1H), 4.5 (m, 2H), 4.7 (m, 1H), 6.4 (d, J=2.5Hz, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.2 (d, J=3.2Hz, 1H), 7.3 (m, 8H), 7.4 (m, 1H), 7.6 (s, 1H).

Example 357

1-((1R,5S)-8-{2-[1-(1H-indol-6-ylcarbonyl)-4-phenyl-4-piperidinylethyl]-8-azabicyclo[3.2.1]oct-3-yl}-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.2 (m, 2H), 1.6 (m, 2H), 1.8 (m, 8H), 2.2 (m, 5H), 2.4 (m, 3H), 2.5 (m, 1H), 3.3 (m, 2H), 3.6 (m, 1H), 4.0 (m, 1H), 4.6 (m, 1H), 6.4 (d, $J=2.1\text{Hz}$, 1H), 7.0 (dd, $J=7.8, 1.4\text{Hz}$, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (d, $J=3.2\text{Hz}$, 1H), 7.3 (m, 6H), 7.4 (s, 1H), 7.4 (m, 1H), 7.5 (m, 1H).

10

Example 358


2-chloro-6-[(4-{2-[1-(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]phenol



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.3 (m, 2H), 1.7 (m, 2H), 2.0 (m, 10H), 2.4 (m, 5H), 2.5 (m, 3H), 3.6 (m, 2H), 4.1 (m, 1H), 4.7 (m, 1H), 6.9 (t, $J=7.7\text{Hz}$, 1H), 7.1 (d, $J=7.5\text{Hz}$, 1H), 7.2 (m, 3H), 7.4 (m, 6H), 7.5 (m, 1H).

Example 359

2-methyl-1-[(1R,5S)-8-(2-{1-[3-(2-methylphenyl) propanoyl]-4-phenyl-4-piperidiny]ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.2 (m, 1H), 1.4 (m, 1H), 1.6 (m, 4H), 1.9 (m, 6H), 2.1 (m, 1H), 2.3 (m, 3H), 2.3 (m, 2H), 2.5 (m, 3H), 2.6 (m, 4H), 2.8 (m, 2 H), 3.0 (m, 2H), 3.2 (d, $J=5.7$ Hz, 1H), 3.5 (m, 1H), 3.9 (m, 1H), 4.6 (m, 1H), 7.0 (m, 2H), 7.0 (m, 2H), 7.1 (m, 2H), 7.1 (m, 1H), 7.3 (m, 5H), 7.4 (m, 1H).

10.

Example 360


2-methyl-1-[(1R,5S)-8-(2-{1-[4-methylcyclohexyl] carbonyl]-4-phenyl-4-piperidiny]ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 0.8 (m, 2H), 0.9 (m, 4H), 1.5 (m, 18H), 2.3 (m, 4H), 2.5 (m, 3H), 2.5 (m, 1H), 3.1 (m, 1H), 3.2 (m, 3H), 3.7 (m, 1H), 3.9 (m, 1H), 4.7 (m, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (m, 5H), 7.4 (m, 1H).

Example 361

2-methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(3-phenyl-butanoyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.2 (m, 4H), 1.4 (m, 1H), 1.6 (m, 3H), 1.9 (m, 8H), 2.3 (m, 2H), 2.5 (m, 1H), 2.7 (m, 2H), 3.0 (m, 2H), 3.0 (m, 1H), 3.2 (m, 4H), 3.5 (m, 1H), 3.7 (m, 1H), 3.9 (m, 1H), 4.7 (m, 1H), 7.1 (m, 5H), 7.3 (m, 8H), 7.4 (m, 1H).

10

Example 362


3-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-3-oxopropyl phenyl ether



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.3 (m, 4H), 1.8 (m, 10H), 2.4 (m, 4H), 2.5 (s, 3H), 2.6 (m, 1H), 2.9 (m, 2H), 3.2 (m, 1H), 3.4 (m, 2H), 3.8 (m, 1H), 4.0 (m, 1H), 4.8 (m, 1H), 6.9 (m, 3H), 7.2 (m, 5H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 363

1-((1R,5S)-8-{2-[1-(cyclohexylacetyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.0 (m, 2H), 1.2 (m, 3H), 1.7 (m, 9H), 1.9 (m, 11H), 2.3 (m, 4H), 2.4 (m, 2H), 2.5 (s, 3H), 3.2 (m, 1H), 3.3 (m, 1H), 3.8 (m, 1H), 4.0 (m, 1H), 4.8 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

10

Example 62


1-((1R,5S)-8-{2-[1-(1,3-benzodioxol-5-ylcarbonyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.3 (m, 2H), 1.7 (m, 2H), 1.9 (m, 11H), 2.3 (m, 5H), 2.5 (d, $J=6.4\text{Hz}$, 3H), 2.6 (m, 1H), 3.3 (m, 1H), 3.7 (m, 1H), 4.1 (m, 1H), 4.7 (m, 1H), 6.9 (m, 2H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 6H), 7.5 (m, 1H).

Example 63


1-[(1R,5S)-8-(2-{1-[fluoro(phenyl)acetyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.9 (m, 14H), 2.3 (m, 3H), 2.5 (m, 3H), 3.0 (m, 3H), 3.6 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H), 6.3 (dd, $J=48.3$, 20.9Hz, 1H), 7.3 (m, 14H).

Example 64


10 3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2-pyridinylamine



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.3 (m, 4H), 2.5 (s, 3H), 3.3 (m, 2H), 3.8 (m, 4H), 4.7 (m, 1H), 6.7 (dd, $J=7.3$, 5.2Hz, 1H), 7.2 (m, 3H), 7.4 (m, 5H), 7.5 (m, 1H), 8.0 (dd, $J=5.2$, 2.0Hz, 1H).

Example 66

2-[4-(2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-4-phenyl-1-piperidiny]carbonyl]-4H-chromen-4-one




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.3 (m, 3H), 1.7 (m, 2H), 2.0 (m, 8H), 2.4 (m, 4H), 2.5 (m, 3H), 2.9 (m, 1H), 3.1 (m, 1H), 3.3 (m, 2H), 3.6 (m, 1H), 4.1 (m, 1H), 4.8 (m, 1H), 7.2 (m, 2H), 7.3 (m, 1H), 7.4 (m, 5H), 7.5 (m, 2H), 7.6 (d, $J=7.8\text{Hz}$, 1H), 7.8 (m, 1H), 8.2 (dd, $J=8.0, 1.6\text{Hz}$, 1H).

10

Example 67


2-methyl-1-[(1R,5S)-8-(2-[4-phenyl-1-[3-(trifluoromethyl)benzoyl]-4-piperidiny]ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.3 (m, 1H), 1.7 (m, 2H), 1.9 (m, 10H), 2.3 (m, 1H), 2.4 (m, 4H), 2.5 (s, 3H), 3.3 (m, 2H), 3.5 (m, 1H), 4.2 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H), 7.7 (m, 2H), 7.7 (s, 1H), 7.8 (m, 1H).

Example 71

2-methyl-1-[(1R,5S)-8-(2-{1-[3-(4-methylphenyl) propanoyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.5 (m, 1H), 1.7 (m, 4H), 1.8 (m, 2H), 1.9 (m, 10H), 2.2 (m, 1H), 2.2 (s, 3H), 2.4 (m, 2H), 2.5 (m, 3H), 2.8 (m, 2H), 3.2 (m, 2H), 3.6 (m, 1H), 3.9 (m, 1H), 4.7 (m, 1H), 7.1 (m, 3H), 7.2 (m, 3H), 7.4 (m, 6H), 7.5 (m, 1H).

10

Example 72


1-[(1R,5S)-8-(2-[1-(3,4-dichlorobenzoyl)-4-phenyl-4-piperidinyl]ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 11H), 2.3 (m, 1H), 2.4 (m, 4H), 2.5 (m, 3H), 3.3 (m, 2H), 3.6 (m, 1H), 4.1 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.3 (dd, $J=8.2, 1.8\text{Hz}$, 1H), 7.4 (m, 5H), 7.5 (m, 1H), 7.6 (m, 2H).

Example 73

1-((1R,5S)-8-{2-[1-(3-chlorobenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.2 (m, 1H), 2.4 (m, 3H), 2.5 (s, 3H), 3.3 (m, 4H), 3.6 (m, 1H), 4.1 (m, $J=11.1$, 4.3Hz, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.3 (m, 1H), 7.4 (m, 5H), 7.4 (m, 2H), 7.5 (m, 1H).

10

Example 74


1-((1R,5S)-8-{2-[1-(mesitylcarbonyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.8 (m, 1H), 1.9 (m, 10H), 2.1 (s, 3H), 2.2 (m, 1H), 2.3 (m, 6H), 2.4 (m, 3H), 2.5 (m, 3H), 3.1 (m, 1H), 3.3 (m, 3H), 4.2 (m, 1H), 4.7 (m, 1H), 6.9 (s, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 78

1-((1R,5S)-8-[2-(1-butyl-4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.0 (t, $J=7.4\text{Hz}$, 3H), 1.6 (m, 4H), 1.9 (m, 10H), 2.4 (m, 7H), 2.5 (s, 3H), 3.2 (m, 1H), 3.3 (m, 2H), 3.7 (m, 1H), 4.0 (d, $J=3.7\text{ Hz}$, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

10

Example 79


1-((1R,5S)-8-[2-[1-(3-fluorobenzoyl)-4-phenyl-4-piperidinyl]ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 2.0 (m, 10H), 2.2 (m, 1H), 2.4 (m, 3H), 2.5 (m, 3H), 3.3 (m, 4H), 3.5 (m, $J=5.6, 1.6\text{Hz}$, 1H), 4.1 (m, $J=4.0\text{Hz}$, 1H), 4.7 (m, 1H), 7.2 (m, 6H), 7.4 (m, 5H), 7.5 (m, 1H), 7.5 (m, 1H).

Example 81

N-((1S,2R)-2-hydroxy-1-((4-(2-((1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)ethyl)-4-phenyl-1-piperidinyl)carbonyl)propyl)acetamide




5

¹H NMR (400 MHz, methanol-d₄) δ ppm 1.2 (m, 3H), 1.7 (m, 2H), 1.9 (m, 13H), 2.4 (m, 5H), 2.5 (s, 3H), 3.3 (m, 5H), 4.0 (m, 3H), 4.8 (m, 2H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

10

Example 82

2-methyl-1-((1R,5S)-8-(2-[4-phenyl-1-(4,4,4-trifluorobutanoyl)-4-piperidinyl]ethyl)-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




¹H NMR (400 MHz, methanol-d₄) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.3 (m, 2H), 2.5 (m, 4H), 2.5 (s, 3H), 2.7 (m, 2H), 3.2 (m, 1H), 3.3 (m, 3H), 3.7 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

15

Example 83

1-((1R,5S)-8-{2-[1-(1H-indol-3-ylacetyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.4 (m, 1H), 1.7 (m, 6H), 1.9 (m, 6H), 2.0 (m, 1H), 2.2 (m, 1H), 2.4 (m, 2H), 2.5 (s, 3H), 3.1 (m, 1H), 3.2 (m, 3H), 3.8 (m, 2H), 3.9 (m, 1H), 4.1 (m, 1H), 4.7 (m, 1H), 7.0 (t, $J=7.0\text{Hz}$, 1H), 7.1 (m, 2H), 7.2 (m, 3H), 7.4 (m, 6H), 7.5 (m, 1H), 7.6 (d, $J=7.8\text{Hz}$, 1H).

10

Example 85


2-methyl-1-((1R,5S)-8-{2-[1-(3-nitrobenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 2.0 (m, 12H), 2.3 (m, 1H), 2.4 (m, 3H), 2.5 (s, 3H), 3.3 (m, 2H), 3.6 (m, 1H), 4.2 (m, $J=13.6\text{Hz}$, 1H), 4.7 (m, 1H), 7.2 (m, 3H), 7.4 (m, 5H), 7.5 (m, 1H), 7.7 (t, $J=7.8\text{Hz}$, 1H), 7.8 (d, $J=7.8\text{Hz}$, 1H), 8.3 (s, 1H), 8.3 (d, $J=8.2\text{ Hz}$, 1H).

Example 86

5,5-dimethyl-4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]dihydro-2(3H)-furanone




5

¹H NMR (400 MHz, methanol-d₄) δ ppm 1.2 (m, 2H), 1.5 (m, 3H), 1.9 (m, 14H), 2.4 (m, 4H), 2.5 (s, 3H), 2.8 (m, 2H), 3.1 (m, 1H), 3.4 (m, 2H), 3.8 (m, 2H), 4.1 (m, 1H), 4.8 (m, 1H), 7.2 (m, 3H), 7.4 (m, 5H), 7.5 (m, 1H).

10

Example 88

2-methyl-1-((1R,5S)-8-{2-[1-(2-nitrobenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




¹H NMR (400 MHz, methanol-d₄) δ ppm 1.3 (m, 1H), 1.7 (m, 2H), 2.0 (m, 10H), 2.2 (m, 1H), 2.4 (m, 3H), 2.5 (m, J=1.4 Hz, 3H), 3.2 (m, 2H), 3.4 (m, 2H), 4.2 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.3 (m, 1H), 7.4 (m, 6H), 7.5 (m, 1H), 7.7 (m, 1H), 7.8 (m, 1H), 8.2 (m, 1H).

15

Example 90


2-methyl-1-((1R,5S)-8-{2-[1-(1-naphthoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole



5 ¹H NMR (400 MHz, methanol-d₄) δ ppm 0.6 (m, 2H), 1.8 (m, 12H), 2.4 (m, 4H), 2.5 (m, 3H), 3.3 (m, 2H), 3.5 (m, 1H), 4.3 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 6H), 7.5 (m, 5H), 7.9 (m, 2H).

Example 91


10 1-((1R,5S)-8-{2-[1-(2,3-dichlorobenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



15 ¹H NMR (400 MHz, methanol-d₄) δ ppm 1.8 (m, 2H), 1.9 (m, 8H), 2.1 (m, 2H), 2.3 (m, 1H), 2.5 (m, 3H), 2.5 (m, 3H), 3.2 (m, 1H), 3.4 (m, 4H), 4.2 (m, 1H), 4.8 (m, 1H), 7.2 (m, 2H), 7.3 (m, 1H), 7.4 (m, 7H), 7.5 (m, 1H), 7.6 (m, 1H).

Example 92

1-methyl-2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-2-oxoethyl phenyl ether




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.5 (dd, $J=19.8, 6.6\text{Hz}$, 3H), 1.9 (m, 13H), 2.3 (m, 2H), 2.4 (m, 2H), 2.5 (m, 3H), 3.1 (m, 1H), 3.3 (m, 2H), 3.9 (m, 2H), 4.7 (m, 1H), 5.1 (m, 1H), 6.9 (m, 3H), 7.2 (m, 5H), 7.4 (m, 5H), 7.5 (m, 1H).

10

Example 93


3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-4H-chromen-4-one



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 8H), 2.1 (m, 2H), 2.4 (m, 4H), 2.5 (m, $J=1.4\text{Hz}$, 3H), 3.3 (m, 4H), 3.5 (m, 1H), 4.2 (s, 1H), 4.8 (m, 1H), 7.0 (m, 1H), 7.2 (m, 2H), 7.3 (m, 1H), 7.4 (m, 5H), 7.5 (m, 2H), 7.7 (d, $J=7.8\text{Hz}$, 1H), 7.8 (m, 1H), 8.2 (dd, $J=8.2, 1.4\text{Hz}$, 1H).

Example 94

1-((1R,5S)-8-{2-[1-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H) 2.0 (m, 10H) 2.3 (m, 4H) 2.6 (m, 3H) 3.1 (m, 1H) 3.4 (m, 3H) 4.0 (m, 2H) 4.2 (m, 1H) 4.4 (m, 1H) 4.8 (m, 1H) 5.1 (m, 1H) 6.8 (m, 3H) 6.9 (m, 1H) 7.2 (m, 2H) 7.3 (t, $J=7.0\text{Hz}$, 1H) 7.4 (m, 5H) 7.5 (m, 1H).

10

Example 96


2-methyl-1-((1R,5S)-8-{2-[1-(4-methylbenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.2 (m, 2H), 2.4 (m, 7H), 2.5 (s, 3H), 3.3 (m, 2H), 3.6 (m, 1H), 4.1 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.3 (m, 5H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 97

1-(((1R,5S)-8-{2-[1-(4-ethoxybenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.3 (m, 1H), 1.4 (t, $J=7.1\text{Hz}$, 3H), 1.7 (m, 2H), 1.9 (m, 10H), 2.3 (m, 4H), 2.5 (m, 3H), 3.3 (m, 3H), 3.7 (m, 1H), 4.1 (m, 3H), 4.7 (m, 1H), 7.0 (m, 2H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 2H), 7.4 (m, 5H), 7.5 (m, 1H).

10

Example 99


1-(((1R,5S)-8-{2-[1-(2-ethoxybenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.2 (t, $J=7.1\text{Hz}$, 2H), 1.5 (t, $J=7.0\text{Hz}$, 2H), 1.9 (m, 12H), 2.3 (m, 5H), 2.5 (m, 3H), 3.2 (m, 1H), 3.4 (m, 3H), 4.0 (q, $J=7.1\text{Hz}$, 1H), 4.1 (m, 2H), 4.7 (m, 1H), 7.0 (m, 3H), 7.2 (m, 3H), 7.4 (m, 5H), 7.5 (d, $J=7.1\text{Hz}$, 1H).

Example 100


1-((1R,5S)-8-{2-[1-(2,4-dimethylbenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



- 5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.9 (m, 13H), 2.2 (m, 3H), 2.3 (m, 7H), 2.5 (s, 3H), 3.1 (m, 1H), 3.4 (m, 3H), 4.1 (m, $J=11.1, 4.6\text{Hz}$, 1H), 4.7 (m, 1H), 7.1 (m, 3H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 104


- 10 1-((1R,5S)-8-{2-[1-(2,4-dimethylbenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



- 15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.3 (m, 1H), 1.7 (m, 5H), 1.9 (m, 7H), 2.2 (m, 1H), 2.4 (m, 4H), 2.5 (s, 3H), 3.1 (m, 1H), 3.2 (m, 3H), 3.8 (m, 2H), 4.1 (t, $J=5.5\text{Hz}$, 1H), 4.7 (d, $J=8.6\text{Hz}$, 1H), 6.7 (dd, $J=8.6, 2.1\text{Hz}$, 1H), 7.0 (d, $J=2.5\text{Hz}$, 1H), 7.1 (s, 1H), 7.2 (m, 4H), 7.3 (m, 5H), 7.4 (dd, $J=5.9, 2.7\text{Hz}$, 1H), 7.5 (m, 1H).

Example 106


1-((1R,5S)-8-[2-(1-([2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropyl]carbonyl)-4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



¹H NMR (400 MHz, methanol-d₄) δ ppm 1.2 (m, 3H), 1.3 (m, 2H), 1.8 (m, 20H), 2.2 (m, 3H), 2.4 (m, 3H), 2.5 (s, 3H), 3.4 (m, 1H), 3.8 (m, 2H), 4.1 (m, 1H), 4.8 (m, 1H), 4.9 (m, 1H), 5.1 (dd, J=35.7, 8.9Hz, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 107


2-methyl-1-((1R,5S)-8-[2-(4-phenyl-1-[4-(trifluoro-methyl)-3-pyridinyl]carbonyl)-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole



¹H NMR (400 MHz, methanol-d₄) δ ppm 1.3 (m, 1H), 1.9 (m, 12H), 2.3 (m, 1H), 2.4 (m, 4H), 2.5 (m, 3H), 3.2 (m, 1H), 3.4 (m, 2H), 4.2 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.3 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H), 7.8 (dd, J=13.7, 5.2Hz, 1H), 8.7 (m, J=72.4Hz, 1H), 8.9 (t, J=5.7Hz, 1H).

Example 108


1-[(4-{2-[1-(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]cyclopropanecarboxamide



- 5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.3 (m, 7H), 1.7 (m, 2H), 2.0 (m, 10H), 2.4 (m, 4H), 2.5 (s, 2H), 3.3 (m, 4H), 3.8 (m, 1H), 4.1 (m, $J=11.4$, 6.1Hz, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 109


- 10 2-methyl-1-[(1R,5S)-8-(2-{1-[(2-methylcyclopropyl) carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



- 15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.1 (m, 5H), 1.9 (m, 14H), 2.3 (m, 4H), 2.6 (m, 3H), 3.2 (m, 1H), 3.3 (m, 2H), 3.5 (m, 1H), 4.0 (m, 2H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 111


2-methyl-1-[(1R,5S)-8-(2-{4-phenyl-1-[(1-phenylcyclopentyl)carbonyl]-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.2 (m, 1H), 1.7 (m, 10H), 2.0 (m, 7H), 2.3 (m, 6H), 2.5 (m, 3H), 2.9 (m, 1H), 3.2 (m, 3H), 3.4 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H), 7.2 (m, 7H), 7.3 (m, 5H), 7.4 (m, 1H), 7.5 (m, 1H).

Example 113


10 1-[(1R,5S)-8-{2-[1-(2,4-dichlorobenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 11H), 2.3 (m, 1H), 2.4 (m, 4H), 2.5 (m, $J=2.5\text{Hz}$, 3H), 3.2 (m, 1H), 3.3 (m, 2H), 4.2 (m, 1H), 4.7 (m, $J=10.9, 9.1\text{Hz}$, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 6H), 7.5 (m, 3H).

Example 117

2-methyl-1-((1R,5S)-8-(2-[4-phenyl-1-(4-vinylbenzoyl)-4-piperidinyl]ethyl)-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.2 (m, 1H), 2.4 (m, 4H), 2.5 (m, 3H), 3.3 (m, 4H), 3.6 (m, 1H), 4.1 (m, $J=11.1$, 4.3 Hz, 1H), 4.7 (m, 1H), 5.3 (d, $J=11.1$ Hz, 1H), 5.9 (d, $J=17.5$ Hz, 1H), 6.8 (dd, $J=17.7$, 10.9 Hz, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (d, 7H), 7.5 (m, 2H).

10

Example 120


1-[(1R,5S)-8-(2-{1-[(3,5-dimethoxyphenyl)acetyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 5H), 1.9 (m, 8H), 2.2 (m, 2H), 2.4 (m, 3H), 2.5 (m, 3H), 3.2 (m, 4H), 3.7 (m, 8H), 4.0 (m, 1H), 4.7 (t, 1H), 6.4 (t, $J=2.1$ Hz, 1H), 6.4 (d, $J=2.1$ Hz, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 123

methyl 4-{1-[4-{2-[1-(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl]carbonyl]cyclopropyl}phenyl ether




5

¹H NMR (400 MHz, methanol-d₄) δ ppm 1.3 (m, 6H), 1.7 (m, 2H), 2.0 (m, 8H), 2.2 (m, 1H), 2.4 (m, 3H), 2.5 (s, 3H), 3.2 (m, 5H), 3.7 (s, 3H), 3.8 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H), 6.9 (m, 2H), 7.1 (m, 2H), 7.2 (m, 3H), 7.3 (m, 4H), 7.5 (m, 1H).

10

Example 127

1-((1R,5S)-8-{2-[1-(2,4-difluorobenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




15

¹H NMR (400 MHz, methanol-d₄) δ ppm 1.7 (m, 2H), 1.9 (m, 8H), 2.3 (m, 1H), 2.4 (m, 3H), 2.5 (m, 3H), 3.2 (m, 1H), 3.3 (m, 5H), 3.5 (m, 1H), 4.2 (m, 1H), 4.7 (m, 1H), 7.1 (m, *J*=9.6, 9.6Hz, 2H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 6H), 7.5 (m, 1H).

Example 128


1-((1R,5S)-8-{2-[1-([1,1'-biphenyl]-2-ylcarbonyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.5 (m, 3H), 1.9 (m, 8H), 2.2 (m, 1H), 2.4 (m, 2H), 2.5 (m, 3H), 2.8 (m, 1H), 3.0 (m, 1H), 3.2 (m, 3H), 3.4 (m, 1H), 3.8 (m, 1H), 4.2 (m, 1H), 4.7 (m, 1H), 7.4 (m, 18H).

Example 130


10 2-methyl-1-[(1R,5S)-8-(2-{4-phenyl-1-[(1-phenylcyclopropyl)carbonyl]-4-piperidinyl]ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.3 (m, 5H), 1.6 (m, 2H), 1.7 (m, 3H), 1.9 (m, 8H), 2.2 (m, 1H), 2.4 (m, 2H), 2.5 (m, 3H), 3.2 (m, 3H), 3.8 (m, 1H), 4.0 (m, $J=12.1, 5.7\text{Hz}$, 1H), 4.7 (m, 1H), 7.2 (m, 6H), 7.3 (m, 6H), 7.4 (m, 1H), 7.5 (m, 1H).

Example 131


1-[(1R,5S)-8-(2-{1-[4-(1H-imidazol-1-yl)benzoyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



¹H NMR (400 MHz, methanol-d₄) δ ppm 1.7 (m, 2H), 2.0 (m, 10H), 2.3 (m, 1H), 2.4 (m, 4H), 2.5 (m, 3H), 3.4 (m, 3H), 3.6 (m, 1H), 4.2 (m, 1H), 4.7 (m, 1H), 7.2 (m, 3H), 7.2 (m, 1H), 7.4 (m, 6H), 7.5 (m, 1H), 7.6 (m, 2H), 7.6 (d, J=1.4 Hz, 1H), 7.7 (m, 2H).

Example 133


1-((1R,5S)-8-{2-[1-(4-isopropylbenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



¹H NMR (400 MHz, methanol-d₄) δ ppm 1.3 (m, 6H), 1.7 (m, 2H), 1.9 (m, 10H), 2.2 (m, 1H), 2.4 (m, 3H), 2.5 (s, 3H), 2.9 (m, 1H), 3.3 (m, 4H), 3.6 (m, 1H), 4.1 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.3 (m, 3H), 7.4 (m, 6H), 7.5 (m, 1H).

Example 134

methyl 3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2-pyridinyl
ether




5

^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, $J=7.5\text{Hz}$, 2H), 1.9 (m, 10H), 2.2 (m, 1H), 2.4 (m, 3H), 2.5 (m, 3H), 3.2 (m, 1H), 3.3 (m, 4H), 3.9 (d, $J=54.6\text{Hz}$, 3H), 4.2 (m, 1H), 4.7 (m, 1H), 7.1 (m, 1H), 7.2 (m, 2H), 7.2 (d, $J=4.6\text{Hz}$, 1H), 7.4 (m, 5H), 7.5 (m, 1H), 7.6 (dd, $J=53.7$, 7.3Hz, 1H), 8.2 (dd, $J=5.2$, 2.0Hz, 1H).

10

Example 136

2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]phenyl propyl ether



15


^1H NMR (400 MHz, methanol- d_4) δ ppm 1.0 (m, 3H), 1.6 (m, 1H), 1.7 (m, 2H), 1.9 (m, 11H), 2.2 (m, 1H), 2.4 (m, 4H), 2.5 (d, $J=7.1\text{Hz}$, 3H), 3.2 (m, 2H), 3.4 (m, 2H), 3.9 (t, $J=6.4\text{Hz}$, 1H), 4.1 (m, 2H), 4.7 (m, 1H), 7.1 (m, 4H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

20

172

Example 138

methyl 2-[3-(4-(2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-4-phenyl-1-piperidiny]-3-oxopropyl]phenyl ether




5

¹H NMR (400 MHz, methanol-d₄) δ ppm 1.5 (m, 1H), 1.7 (m, 3H), 1.8 (m, 2H), 1.9 (m, 6H), 2.1 (m, 1H), 2.2 (m, 1H), 2.4 (m, 2H), 2.5 (m, *J*=5.7Hz, 3H), 2.6 (m, 4H), 2.9 (m, 2H), 3.1 (m, 2H), 3.3 (m, 1H), 3.6 (m, 1H), 3.8 (s, 3H), 4.0 (m, 1H), 4.7 (m, 1H), 6.8 (t, *J*=7.0Hz, 1H), 6.9 (d, *J*=8.2Hz, 1H), 7.1 (dd, *J*=7.5, 1.8Hz, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

10

Example 139

1-((1R,5S)-8-{2-[1-(cyclopentylacetyl)-4-phenyl-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




15

¹H NMR (400 MHz, methanol-d₄) δ ppm 1.2 (m, 1H), 1.6 (m, 4H), 1.9 (m, 12H), 2.2 (m, 3H), 2.4 (m, 4H), 2.6 (m, 3H), 2.8 (t, *J*=5.7Hz, 1H), 2.9 (d, *J*=2.1Hz, 1H), 3.2 (m, 1H), 3.3 (m, 3H), 3.5 (m, 1H), 3.8 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

20

Example 141

2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny]carbonyl]-4(1H)-quinolinone




- 5 ¹H NMR (400 MHz, methanol-d₄) δ ppm 1.7 (m, 2H), 2.0 (m, 10H), 2.4 (m, 4H), 2.5 (m, 3H), 3.3 (m, 4H), 3.6 (m, 1H), 4.2 (m, 1H), 4.7 (m, 1H), 6.3 (s, 1H), 7.2 (m, 2H), 7.3 (m, 1H), 7.4 (m, 7H), 7.5 (m, 1H), 7.6 (d, J=8.2Hz, 1H), 7.7 (m, 1H), 8.3 (d, J=7.1Hz, 1H).

10

Example 142


1-[(1R,5S)-8-(2-{1-[3-(1,3-benzodioxol-5-yl)propanoyl]-4-phenyl-4-piperidiny]ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



- 15 ¹H NMR (400 MHz, methanol-d₄) δ ppm 1.5 (m, 1H), 1.7 (m, 3H), 1.8 (m, 2H), 2.0 (m, 7H), 2.2 (m, 1H), 2.4 (m, 2H), 2.5 (s, 3H), 2.6 (m, 3H), 2.8 (m, 2H), 3.2 (m, 2H), 3.3 (m, J=3.9Hz, 1H), 3.6 (m, 1H), 3.9 (m, 1H), 4.7 (m, 1H), 5.8 (d, J=1.4Hz, 1H), 5.9 (s, 1H), 6.7 (m, 3H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 144

2-methyl-1-[(1R,5S)-8-(2-{1-[(4-methyl-1,2,3-thiadiazol-5-yl)carbonyl]-4-phenyl-4-piperidiny] ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.4 (m, 2H), 1.7 (m, 2H), 1.9 (m, 10H), 2.4 (m, 5H), 2.6 (m, 3H), 2.8 (m, 1H), 3.0 (m, 1H), 3.3 (m, 1H), 3.4 (m, 1H), 3.6 (m, 1H), 4.2 (m, 1H), 4.8 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

10

Example 145


2-methyl-1-[(1R,5S)-8-[2-(4-phenyl-1-propionyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.1 (t, $J=7.5\text{Hz}$, 3H), 1.7 (m, 2H), 1.9 (m, 10H), 2.3 (s, 2H), 2.4 (m, 4H), 2.5 (d, $J=6.6\text{Hz}$, 3H), 3.2 (m, 2H), 3.3 (m, 2H), 3.6 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 149

2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-3-pyridinol




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 2.0 (m, 10H), 2.4 (m, 5H), 2.5 (m, 3H), 3.2 (m, 1H), 3.3 (m, 3H), 3.5 (m, 1H), 4.2 (m, $J=4.6\text{Hz}$, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.3 (m, 2H), 7.4 (m, 5H), 7.5 (m, 1H), 8.1 (dd, $J=3.9, 2.1\text{Hz}$, 1H).

10

Example 150


4,6-dimethyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2H-pyran-2-one



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.6 (m, 2H), 1.9 (m, 13H), 2.1 (m, 1H), 2.2 (m, $J=6.4\text{Hz}$, 1H), 2.3 (m, 3H), 2.4 (m, 4H), 2.5 (m, $J=1.4\text{Hz}$, 3H), 2.8 (m, 1H), 3.0 (m, 1H), 3.6 (m, 1H), 4.2 (m, 1H), 4.7 (m, 1H), 6.1 (d, $J=21.8\text{Hz}$, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 151

N-{1-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]propyl}urea




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 0.9 (m, 3H), 1.6 (m, 4H), 1.9 (m, 11H), 2.4 (m, 6), 2.5 (m, $J=1.8\text{Hz}$, 3H), 2.8 (m, 1H), 3.0 (m, 2H), 3.4 (m, 1H), 3.8 (m, 1H), 4.1 (m, 1H), 4.7 (m, 1H), 4.8 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

10

Example 154


1-[(1R,5S)-8-(2-{1-[(3,5-difluorophenyl)acetyl]-4-phenyl-4-piperidiny}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.8 (m, 12H), 2.3 (m, 2H), 2.4 (m, 4H), 2.5 (s, 3H), 3.2 (m, 1H), 3.3 (m, 2H), 3.8 (m, 2H), 4.0 (m, 1H), 4.7 (m, 1H), 6.8 (m, 2H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 6H), 7.5 (m, 1H).

Example 156

1-((1R,5S)-8-{2-[1-(1H-indol-3-ylcarbonyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.4 (m, 7H), 2.5 (s, 3H), 2.8 (m, 1H), 3.1 (m, 1H), 3.5 (m, $J=10.3$, 10.3Hz, 1H), 4.1 (dd, $J=11.6$, 6.2Hz, 1H), 4.7 (m, 1H), 7.2 (m, 4H), 7.2 (m, 1H), 7.4 (m, 7H), 7.5 (m, 1H), 7.6 (m, 1H).

10

Example 157


1-((1R,5S)-8-{2-[1-(2-fluoro-5-methylbenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.4 (m, 10H), 2.9 (m, 1H), 3.2 (m, 2H), 3.4 (m, 1H), 3.5 (m, 1H), 4.2 (m, 1H), 4.7 (m, 1H), 7.1 (m, 1H), 7.2 (m, 2H), 7.3 (m, 1H), 7.4 (m, 7H), 7.5 (m, 1H).

Example 158

3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny]carbonyl]-2H-chromen-2-one




5

¹H NMR (400 MHz, methanol-d₄) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.4 (m, 5H), 2.5 (m, 3H), 2.9 (m, 1H), 3.2 (m, 2H), 3.6 (m, 1H), 4.1 (m, 1H), 4.7 (m, 1H), 7.0 (m, 1H), 7.2 (m, 4H), 7.4 (m, 6H), 7.5 (m, *J*=6.8Hz, 1H), 7.7 (m, 1H), 8.1 (s, 1H).

10

Example 159

2-methyl-1-(((1R,5S)-8-{2-[1-(3-methylbutanoyl)-4-phenyl-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




15

¹H NMR (400 MHz, methanol-d₄) δ ppm 1.0 (m, 6H), 1.7 (m, 2H), 1.9 (m, 12H), 2.3 (m, 4H), 2.4 (m, 2H), 2.5 (m, *J*=6.4Hz, 3H), 3.2 (m, 1H), 3.3 (m, 2H), 3.8 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 160

1-((1R,5S)-8-{2-[1-(1H-indol-4-ylcarbonyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5

^1H NMR (400 MHz, methanol- d_4) δ ppm 1.6 (m, 2H), 1.9 (m, 13H), 2.2 (m, 1H), 2.4 (m, 5H), 3.3 (m, 2H), 3.5 (m, 2H), 4.2 (m, 1H), 4.7 (m, 1H), 6.4 (d, $J=2.9\text{Hz}$, 1H), 7.0 (d, $J=7.1\text{Hz}$, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.3 (m, $J=3.4$, 3.4Hz, 1H), 7.4 (m, 6H), 7.5 (d, $J=8.2\text{Hz}$, 1H), 7.5 (m, 1H).

10

Example 162

1-((1R,5S)-8-(2-{1-[1-(3-ethoxy-2-thienyl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




15

^1H NMR (400 MHz, methanol- d_4) δ ppm 1.4 (t, $J=7.1\text{Hz}$, 3H), 1.7 (m, 2H), 2.0 (m, 11H), 2.4 (m, 4H), 2.5 (m, 3H), 3.3 (m, 4H), 3.9 (m, 2H), 4.2 (m, 2H), 4.7 (m, 1H), 6.9 (d, $J=5.7\text{Hz}$, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

180

Example 163

2-methyl-1-[(1R,5S)-8-(2-{1-[(1-methylcyclopropyl) carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 0.6 (d, $J=1.4\text{Hz}$, 2H), 0.9 (m, 2H), 1.3 (d, $J=20.0\text{Hz}$, 3H), 1.7 (m, 2H), 1.9 (m, 10H), 2.3 (m, 4H), 2.5 (s, 3H), 2.8 (m, 1H), 3.0 (m, 1H), 3.3 (m, 2H), 4.0 (m, 2H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

10

Example 164

methyl 3-[3-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-3-oxopropyl]phenyl ether




15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.4 (m, 1H), 1.7 (m, 2H), 1.8 (m, 1H), 2.0 (m, 11H), 2.2 (m, 1H), 2.4 (m, 2H), 2.5 (m, 3H), 2.7 (m, 2H), 2.9 (m, 2H), 3.1 (m, 2H), 3.6 (m, 1H), 3.7 (s, 3H), 4.0 (m, 1H), 4.7 (m, 1H), 6.7 (dd, $J=7.8, 2.1\text{Hz}$, 1H), 6.8 (m, 2H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 6H), 7.5 (m, 1H).

20

Example 167

methyl 3-[3-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-3-oxopropyl]phenyl ether




5

¹H NMR (400 MHz, methanol-d₄) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.3 (m, 1H), 2.4 (m, 3H), 2.5 (s, 3H), 3.2 (m, 1H), 3.3 (m, 3H), 3.5 (m, 1H), 4.2 (m, J=8.9, 4.6Hz, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 4H), 7.4 (m, 5H), 7.5 (m, 1H).

10

Example 168

5-[4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl]carbonyl]-2-pyridinylamine




15

¹H NMR (400 MHz, methanol-d₄) δ ppm 1.7 (m, 2H), 2.0 (m, 10H), 2.3 (m, 5H), 2.5 (m, 3H), 2.9 (m, 2H), 3.3 (m, 3H), 3.9 (m, 2H), 4.7 (m, 1H), 6.6 (d, J=8.6Hz, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 2H), 8.0 (d, J=2.1Hz, 1H).

Example 169

1-[(1R,5S)-8-(2-{1-[(2,6-dimethoxy-3-pyridinyl) carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




5

^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.2 (m, 1H), 2.4 (m, 4H), 2.5 (m, 3H), 3.2 (m, 1H), 3.3 (m, 2H), 3.4 (m, 1H), 4.0 (m, 6H), 4.1 (m, 1H), 4.7 (m, 1H), 6.4 (d, $J=7.8\text{Hz}$, 1H), 7.2 (m, 2H), 7.2 (t, $J=6.4\text{Hz}$, 1H), 7.4 (m, 5H), 7.5 (m, 2H).

10

Example 171

methyl 4-[3-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-3-oxopropyl]phenyl ether




15

^1H NMR (400 MHz, methanol- d_4) δ ppm 1.4 (m, 1H), 1.7 (m, 3H), 1.9 (m, 8H), 2.1 (m, 1H), 2.4 (m, 3H), 2.5 (s, 3H), 2.8 (m, 3H), 3.1 (m, 2H), 3.3 (m, 2H), 3.6 (m, 2H), 3.7 (d, $J=12.8\text{Hz}$, 3H), 3.9 (m, 1H), 4.7 (m, 1H), 6.8 (m, 2H), 7.1 (m, 2H), 7.2 (m, 2H), 7.4 (m, 6H), 7.5 (m, 1H).

20

Example 172

2-methyl-1-((1R,5S)-8-{2-[1-(4-nitrobenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




5

¹H NMR (400 MHz, methanol-d₄) δ ppm 1.7 (d, *J*=7.8Hz, 2H), 2.0 (d, *J*=12.5Hz, 8H), 2.5 (d, *J*=7.1Hz, 3H), 2.7 (s, 3H), 2.8 (m, *J*=13.6Hz, 2H), 3.1 (s, 1H), 3.3 (m, 3H), 3.5 (s, 2H), 4.2 (m, 1H), 4.8 (d, *J*=31.8Hz, 1H), 7.2 (m, 3H), 7.4 (m, 8H), 7.7 (m, 1H), 8.3 (d, *J*=8.9Hz, 1H).

10

Example 173

1-((1R,5S)-8-{2-[1-(4-ethylbenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




15

¹H NMR (400 MHz, methanol-d₄) δ ppm 1.3 (m, 3H), 1.7 (m, 2H), 1.9 (m, 8H), 2.2 (m, 1H), 2.4 (m, 4H), 2.5 (s, 3H), 2.7 (m, 4H), 3.3 (m, 3H), 3.6 (m, 1H), 4.1 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.3 (m, 3H), 7.4 (m, 6H), 7.5 (m, 1H).

Example 175


1-((1R,5S)-8-{2-[1-(4-chloro-2-methoxybenzoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



¹H NMR (400 MHz, methanol-d₄) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.2 (m, 1H), 2.4 (m, 3H), 2.5 (m, 3H), 3.1 (m, 2H), 3.3 (m, 3H), 3.8 (m, J=57.4Hz, 3H), 4.1 (m, 1H), 4.7 (m, 1H), 7.0 (m, 1H), 7.1 (m, 2H), 7.2 (m, 2H), 7.3 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 178

2-methyl-1-((1R,5S)-8-{2-[1-(2-methyl-3-phenylpropanoyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




¹H NMR (400 MHz, methanol-d₄) δ ppm 1.1 (m, J=16.8, 6.8Hz, 3H), 1.4 (m, 1H), 1.6 (m, 4H), 1.9 (m, 8H), 2.1 (m, J=69.7, 13.7Hz, 2H), 2.4 (m, 3H), 2.8 (m, 3H), 3.1 (m, 1H), 3.2 (m, 2H), 3.4 (m, 1H), 3.7 (m, 2H), 4.1 (m, J=13.6Hz, 1H), 4.7 (m, 1H), 7.0 (m, 1H), 7.1 (m, 1H), 7.2 (m, 5H), 7.4 (m, 6H), 7.5 (m, 1H).

185

Example 179

2-methyl-1-[(1R,5S)-8-(2-{4-phenyl-1-[(3E)-4-phenyl-3-butenoyl]-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 11H), 2.4 (m, 5H), 2.5 (s, 3H), 3.2 (m, 1H), 3.4 (m, 3H), 3.8 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H), 6.3 (m, 1H), 6.5 (d, $J=16.1\text{Hz}$, 1H), 7.2 (m, 2H), 7.3 (m, 3H), 7.4 (m, 8H), 7.5 (m, 1H).

10

Example 181


1-[(1R,5S)-8-[2-(1-{[1-(4-chlorophenyl)cyclopropyl] carbonyl}-4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo [3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.4 (m, 4H), 1.7 (m, 4H), 1.9 (m, 8H), 2.1 (s, 1H), 2.3 (m, 1H), 2.4 (m, 3H), 2.5 (s, 3H), 3.2 (m, 3H), 3.8 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H), 7.2 (m, 4H), 7.4 (m, 8H), 7.5 (m, 1H).

Example 183

2-methyl-1-[(1R,5S)-8-(2-{4-phenyl-1-[4-(trifluoromethyl)benzoyl]-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 10H), 2.2 (m, 1H), 2.4 (m, 4H), 2.5 (m, 3H), 3.3 (m, 4H), 4.2 (m, $J=8.9$, 4.6Hz, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H), 7.6 (d, $J=7.8$ Hz, 2H), 7.8 (d, $J=7.8$ Hz, 2H).

10

Example 326A

4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2-imidazolidinone



15 ^1H NMR (400 MHz, methanol- d_4) δ ppm 1.7 (m, 2H), 1.9 (m, 12H), 2.3 (m, 3H), 2.4 (m, 2H), 2.5 (s, 3H), 3.2 (m, 4H), 3.5 (m, 1H), 3.6 (m, 1H), 3.8 (m, 1H), 4.0 (m, 1H), 4.7 (m, 1H), 7.2 (m, 2H), 7.2 (m, 1H), 7.4 (m, 5H), 7.5 (m, 1H).

Example 326B

20 ^1H NMR (300 MHz, CD_3OD) δ ppm 1.97-2.45 (m, 12H), 2.62 (s, 3H), 2.70-2.93 (m, 5H), 3.12 (m, 1H), 3.42 (m, 1H), 4.02-4.20 (m, 3H), 5.35 (m, 1H), 7.23 (m, 1H), 7.33-7.44 (m, 5H), 7.62 (m, 2H), 8.73 (m, 3H).

Example 249

¹H NMR (300 MHz, CD₃OD) δ 7.63-8.00 (m, 3H), 7.49-7.59 (m, 1H),
7.36-7.49 (m, 5H), 7.14-7.33 (m, 3H), 4.68-4.83 (m, 1H), 4.16-4.30 (m, 1H),
3.36-3.51 (m, 2H, under methanol), 3.11-3.28 (m, 1H), 2.56 (s, 3H), 2.34-2.51
5 (m, 3H), 2.23-2.34 (m, 1H), 1.85-2.01 (m, 10H), 1.59-1.77 (m, 2H), 1.18-1.38
(m, 4H).

Example 236

¹H NMR (300 MHz, CD₃OD) δ 7.64-7.98 (m, 3H), 7.48-7.59 (m, 1H),
10 7.35-7.47 (m, 5H), 7.16-7.31 (m, 3H), 4.67-4.82 (m, 1H), 4.13-4.30 (m, 1H),
3.35-3.50 (m, 4H, under methanol), 3.11-3.27 (m, 1H), 2.55 (s, 3H), 2.36-2.52
(m, 3H), 2.23-2.36 (m, 1H), 1.83-2.11 (m, 10H), 1.64-1.75 (m, 2H), 1.31 (s,
1H), 0.98-1.15 (m, 7H).

Example 21

¹H NMR (300 MHz, CD₃OD) δ 7.71-7.86 (m, 2H), 7.55-7.68 (m, 2H),
7.40-7.55 (m, 4H), 7.27-7.40 (m, 1H), 5.22-5.46 (m, 1H), 4.31-4.46 (d,
J=12.25 Hz, 1H), 4.03-4.28 (m, 2H), 3.99 (s, 2H), 3.77-3.97 (m, 2H), 3.42-3.61
(m, 1H), 3.35 (s, 3H), 2.87-3.02 (m, 2H), 2.83 (s, 3H), 2.66-2.79 (m, 2H), 2.33-
20 2.52 (m, 3H), 2.10-2.33 (m, 7H), 1.72-2.08 (m, 2H), 1.40 (s, 1H), 1.19-1.36
(m, 5H).

Example 252

¹H NMR (300 MHz, CD₃OD) δ 7.49-7.59 (m, 1H), 7.33-7.49 (m, 5H),
25 7.12-7.31 (m, 3H), 4.67-4.84 (m, 1H), 3.97-4.12 (m, 1H), 3.76-3.89 (m, 1H),
3.34-3.40 (m, 1H, under methanol), 3.12-3.26 (m, 1H), 2.65 (s, 3H), 2.51-2.61
(m, 5H), 2.36-2.51 (m, 2H), 2.22-2.36 (m, 2H), 1.74-2.12 (m, 10H), 1.61-1.74
(m, 2H), 1.21-1.32 (d, J=1.69 Hz, 6H).

Example 253

¹H NMR (300 MHz, CD₃OD) δ 7.48-7.61 (m, 1H), 7.14-7.48 (m, 13H),
5.03-5.15 (m, 1H), 4.66-4.82 (m, 1H), 3.91-4.09 (m, 1H), 3.57-3.77 (m, 1H),

3.00-3.29 (m, 2H), 2.71-2.95 (m, 2H), 2.62-2.71 (m, 6H), 2.57 (s, 3H), 2.32-2.51 (m, 2H), 2.08-2.30 (m, 1H), 1.60-2.08 (m, 10H).

Example 254

5 ¹H NMR (300 MHz, CD₃OD) δ 7.50-7.59 (m, 1H), 7.34-7.50 (m, 5H), 7.14-7.31 (m, 3H), 4.67-4.83 (m, 1H), 4.33-4.52 (bs, 1H), 3.92-4.15 (bs, 1H), 3.48-3.70 (bs, 1H), 3.08-3.27 (bs, 1H), 2.62-2.70 (m, 6H), 2.51-2.62 (m, 3H), 2.35 (s, 3H), 1.78-2.08 (m, 8H), 1.55-1.73 (m, 4H).

10 Example 255

¹H NMR (300 MHz, CD₃OD) δ 7.32-7.60 (m, 6H), 7.11-7.32 (m, 3H), 4.69-4.84 (m, 1H), 3.34-3.41 (m, 2H, under methanol), 2.66 (s, 1H), 2.56 (s, 3H), 2.36-2.52 (m, 2H), 2.21-2.35 (m, 2H), 1.49-2.21 (m, 18H).

15 Example 256

¹H NMR (300 MHz, CD₃OD) δ 7.33-7.59 (m, 6H), 7.12-7.31 (m, 3H), 4.71-4.85 (m, 1H), 3.84-4.15 (m, 1H), 3.34-3.50 (m, 2H, under methanol), 2.63-2.75 (m, 7H), 2.56 (s, 3H), 2.35-2.52 (m, 2H), 2.20-2.35 (m, 2H), 1.49-2.10 (m, 17H), 1.28 (s, 2H).

20

Example 257

¹H NMR (300 MHz, CD₃OD) δ 7.33-7.59 (m, 6H), 7.13-7.31 (m, 3H), 4.66-4.85 (m, 1H), 4.13-4.25 (m, 1H), 3.94-4.13 (m, 1H), 3.71-3.86 (m, 1H), 3.35-3.41 (m, 1H, under methanol), 3.09-3.27 (m, 1H), 2.64-2.71 (m, 5H),
25 2.53-2.64 (m, 4H), 2.20-2.53 (m, 5H), 1.74-2.12 (m, 8H), 1.63-1.74 (m, 2H), 1.18-1.27 (m, 3H).

Example 258

¹H NMR (300 MHz, CD₃OD) δ 7.35-7.59 (m, 6H), 7.13-7.32 (m, 3H),
30 4.67-4.85 (m, 1H), 3.98-4.32 (m, 1H), 3.35-3.63 (m, 1H, under methanol), 2.66 (s, 6H), 2.56 (s, 3H), 2.36-2.52 (m, 2H), 2.24-2.36 (m, 2H), 1.77-2.09 (m, 10H), 1.60-1.77 (m, 4H), 1.30 (s, 1H), 0.77-0.96 (t, J=7.26 Hz, 6H).

Example 260

¹H NMR (300 MHz, CD₃OD) δ 7.50-7.61 (m, 1H), 7.13-7.50 (m, 13H),
4.62-4.81 (m, 1H), 3.89-4.13 (m, 1H), 3.69-3.89 (m, 1H), 3.12-3.31 (m, 2H),
5 2.62-2.71 (m, 7H), 2.56 (s, 3H), 2.28-2.47 (m, 2H), 2.06-2.27 (m, 1H), 1.73-
2.03 (m, 5H), 1.51-1.73 (m, 7H).

Example 262

¹H NMR (300 MHz, CD₃OD) δ 7.50-7.61 (m, 1H), 7.15-7.50 (m, 17H),
10 4.71-4.84 (m, 1H), 4.48 (s, 2H), 4.06-4.24 (m, 1H), 3.58-3.75 (m, 1H), 3.35-
3.52 (m, 2H), 2.59-2.80 (m, 9H), 2.50 (s, 4H), 2.09-2.21 (m, 2H), 1.90-2.08
(m, 5H), 1.71-1.83 (m, 2H).

Example 263

¹H NMR (300 MHz, CD₃OD) δ 7.51-7.60 (m, 1H), 7.10-7.51 (m, 13H),
15 4.61-4.79 (m, 1H), 3.38-4.14 (m, 1H), 3.68-3.88 (m, 1H), 3.14-3.29 (m, 2H),
2.58-2.72 (m, 8H), 2.53 (s, 3H), 2.28-2.48 (m, 2H), 2.06-2.28 (m, 1H), 1.75-
2.03 (m, 5H), 1.55-1.73 (m, 6H).

Example 264

¹H NMR (300 MHz, CD₃OD) δ 7.73-7.96 (dd, 1H, J=43.02, 7.44), 7.49-
7.68 (m, 2H), 7.34-7.48 (m, 5H), 7.12-7.34 (m, 3H), 4.67-4.83 (m, 1H), 4.12-
4.31 (m, 1H), 3.34-3.44 (m, 3H, under methanol), 3.12-3.28 (m, 1H), 2.56 (s,
3H), 2.35-2.52 (m, 3H), 2.23-2.35 (m, 1H), 1.83-2.12 (m, 11H), 1.62-1.78 (m,
20 2H), 1.10-1.21 (d, J=6.23 Hz, 2H).

Example 265

¹H NMR (300 MHz, CD₃OD) δ 7.985-8.04 (m, 2H), 7.62-7.77 (m, 2H),
7.49-7.61 (m, 1H), 7.33-7.48 (m, 5H), 7.12-7.33 (m, 3H), 4.66-4.84 (m, 1H),
30 4.09-4.27 (m, 1H), 3.64-3.80 (t, J=5.8 Hz, 4H), 3.46-3.64 (m, 1H), 2.61-2.73
(m, 7H), 2.51-2.60 (m, 3H), 2.35-2.50 (m, 3H), 2.19-2.35 (m, 1H), 1.79-2.15
(m, 9H), 1.57-1.79 (m, 3H), 1.19-1.41 (m, 3H).

Example 235

¹H NMR (300 MHz, CD₃OD) δ 7.67-7.94 (m, 3H), 7.48-7.60 (m, 1H),
7.34-7.48 (m, 5H), 7.13-7.33 (m, 3H), 4.66-4.83 (m, 1H), 4.16-4.29 (m, 1H),
5 3.33-3.49 (m, 4H, under methanol), 3.12-3.28 (m, 1H), 2.57-2.61 (m, 1H),
2.51-2.57 (m, 4H), 2.36-2.51 (m, 3H), 2.23-2.36 (m, 1H), 1.83-2.09 (m, 12H),
1.61-1.76 (m, 2H).

Example 237

10 ¹H NMR (300 MHz, CD₃OD) δ 7.66-7.94 (m, 3H), 7.48-7.58 (m, 1H),
7.35-7.48 (m, 5H), 7.13-7.33 (m, 3H), 4.68-4.83 (m, 1H), 4.15-4.29 (m, 1H),
3.34-3.46 (m, 6H, under methanol), 3.16-3.28 (m, 4H), 3.02-3.14 (m, 2H),
2.55 (s, 3H), 2.35-2.50 (m, 3H), 2.24-2.35 (m, 1H), 1.83-2.13 (m, 11H), 1.63-
1.77 (m, 2H).

15

Example 288

¹H NMR (300 MHz, CD₃OD) δ 7.67-7.94 (m, 3H), 7.51-7.59 (m, 1H),
7.38-7.51 (m, 2H), 7.16-7.30 (m, 4H), 6.97-7.08 (m, 1H), 4.68-4.82 (m, 1H),
4.13-4.29 (m, 1H), 3.35-3.54 (m, 3H, under methanol), 2.40-2.81 (m, 12H),
20 1.86-2.16 (m, 9H), 1.67-1.80 (m, 2H), 1.23-1.33 (m, 2H).

Example 364

¹H NMR (300 MHz, CD₃OD) δ 7.65-7.97 (m, 3H), 7.51-7.62 (m, 1H),
7.38-7.51 (m, 2H), 7.13-7.32 (m, 4H), 6.94-7.12 (m, 1H), 4.68-4.82 (m, 1H),
25 4.08-4.30 (m, 1H), 3.34-3.65 (m, 4H, under methanol), 2.84-3.06 (m, 2H),
2.67 (s, 3H), 2.44-2.61 (m, 4H), 2.32-2.44 (m, 1H), 2.16-2.32 (m, 2H), 1.77-
2.16 (m, 9H), 1.27-1.39 (m, 2H), 1.00-1.17 (m, 3H).

Example 291

30 ¹H NMR (300 MHz, CD₃OD) δ 7.68-7.96 (m, 3H), 7.50-7.59 (m, 1H),
7.38-7.50 (m, 2H), 7.14-7.33 (m, 4H), 6.95-7.11 (m, 1H), 4.68-4.83 (m, 1H),
4.08-4.32 (m, 1H), 3.34-3.61 (m, 5H, under methanol), 2.61-2.71 (m, 4H),

2.57 (s, 3H), 2.08-2.31 (m, 2H), 1.84-2.08 (m, 7H), 1.69-1.84 (m, 1H), 1.30 (s, 4H), 0.39-0.67 (m, 4H).

Example 292

5 ¹H NMR (300 MHz, CD₃OD) δ 7.64-7.98 (m, 3H), 7.50-7.58 (m, 1H),
7.37-7.50 (m, 2H), 7.11-7.31 (m, 4H), 6.95-7.09 (m, 1H), 4.65-4.81 (m, 1H),
4.09-4.27 (m, 1H), 3.36-3.56 (m, 4H, under methanol), 3.08-3.26 (m, 1H),
2.57 (s, 3H), 2.31-2.51 (m, 4H), 2.16-2.31 (m, 1H), 1.78-2.13 (m, 11H), 1.64-
1.78 (m, 2H), 0.96-1.11 (m, 6H).

10

Example 308

¹H NMR (300 MHz, CD₃OD) δ 7.63-7.93 (m, 3H), 7.49-7.59 (m, 1H),
7.38-7.48 (m, 1H), 7.13-7.35 (m, 5H), 7.03-7.13 (m, 1H), 4.67-4.83 (m, 1H),
4.15-4.29 (m, 1H), 3.34-3.41 (m, 5H, under methanol), 3.12-3.29 (m, 1H),
15 2.52-2.61 (m, 6H), 2.40-2.52 (m, 3H), 2.34-2.40 (m, 4H), 2.19-2.34 (m, 1H),
1.83-2.11 (m, 9H), 1.63-1.75 (m, 2H).

Example 309

¹H NMR (300 MHz, CD₃OD) δ 7.71-7.93 (m, 3H), 7.53-7.59 (m, 1H),
20 7.40-7.49 (m, 2H), 7.17-7.29 (m, 4H), 6.97-7.08 (m, 1H), 4.11-4.28 (m, 1H),
3.48-3.61 (m, 1H), 3.34-3.48 (m, 3H, under methanol), 3.12-3.30 (m, 1H),
2.84-3.03 (m, 2H), 2.67 (s, 3H), 2.49-2.62 (m, 3H), 2.31-2.46 (m, 1H), 2.16-
2.31 (m, 2H), 1.80-2.15 (m, 9H), 1.27-1.41 (m, 3H), 1.01-1.13 (m, 3H).

25

Example 310

¹H NMR (300 MHz, CD₃OD) δ 7.67-7.93 (m, 3H), 7.51-7.57 (m, 1H),
7.40-7.45 (m, 1H), 7.17-7.33 (m, 5H), 7.05-7.12 (m, 1H), 4.69-4.84 (m, 1H),
4.11-4.31 (m, 1H), 3.35-3.48 (m, 2H, under methanol), 3.13-3.28 (m, 1H),
2.79-2.94 (m, 2H), 2.67 (s, 3H), 2.57 (s, 2H), 2.41-2.53 (m, 2H), 2.33-2.41 (m,
30 3H), 2.20-2.33 (m, 1H), 1.82-2.11 (m, 9H), 1.63-1.77 (m, 2H), 1.39-1.57 (m,
2H), 0.80-0.96 (m, 3H).

Example 311

¹H NMR (300 MHz, CD₃OD) δ 7.68-7.97 (m, 3H), 7.50-7.59 (m, 1H),
7.38-7.48 (m, 1H), 7.15-7.36 (m, 5H), 7.04-7.15 (m, 1H), 4.69-4.83 (m, 1H),
4.14-4.34 (m, 1H), 3.34-3.48 (m, 2H, under methanol), 3.13-3.26 (m, 1H),
5 2.67 (s, 2H), 2.57 (s, 3H), 2.42-2.51 (m, 2H), 2.33-2.42 (m, 3H), 2.13-2.33 (m,
2H), 1.81-2.13 (m, 9H), 1.66-1.79 (d, J= 7.76 Hz, 2H), 1.31 (s, 3H), 0.44-0.65
(m, 4H).

Example 312

10 ¹H NMR (300 MHz, CD₃OD) δ 7.66-7.94 (m, 3H), 7.51-7.56 (m, 1H),
7.39-7.45 (m, 1H), 7.16-7.33 (m, 5H), 7.05-7.13 (m, 1H), 4.72-4.83 (m, 1H),
4.13-4.31 (m, 1H), 3.35-3.49 (m, 3H, under methanol), 3.10-3.27 (m, 1H),
2.68 (s, 2H), 2.55 (s, 3H), 2.34-2.51 (m, 6H), 2.20-2.34 (m, 1H), 1.85-2.12 (m,
10H), 1.65-1.77 (m, 2H), 1.31 (s, 1H), 0.97-1.12 (m, 6H).

15

Example 293

¹H NMR (300 MHz, CD₃OD) δ 8.08 (s, 1H), 7.61-7.76 (m, 2H), 7.50-
7.58 (m, 1H), 7.36-7.49 (m, 2H), 7.13-7.31 (m, 4H), 6.94-7.07 (m, 1H), 4.68-
4.82 (m, 1H), 4.08-4.22 (m, 1H), 3.52-3.67 (m, 1H), 3.35-3.51 (m, 4H, under
20 methanol), 2.52-2.62 (m, 6H), 2.34-2.52 (m, 3H), 2.17-2.30 (m, 1H), 1.81-2.14
(m, 11H), 1.64-1.77 (m, 2H).

Example 273

¹H NMR (300 MHz, CD₃OD) δ 7.66-7.94 (m, 3H), 7.49-7.57 (m, 1H),
25 7.35-7.49 (m, 5H), 7.23-7.33 (m, 1H), 7.14-7.23 (m, 2H), 4.67-4.83 (m, 1H),
4.16-4.30 (m, 1H), 3.34-3.43 (m, 4H, under methanol), 3.11-3.26 (m, 1H),
2.86-3.03 (m, 2H), 2.55 (s, 3H), 2.36-2.52 (m, 3H), 2.22-2.36 (m, 1H), 1.86-
2.11 (m, 11H), 1.64-1.76 (m, 2H), 1.01-1.14 (dd, J=16.03, 7.5 Hz, 3H).

30

Example 274

¹H NMR (300 MHz, CD₃OD) δ 7.65-7.94 (m, 3H), 7.48-7.60 (m, 1H),
7.35-7.48 (m, 5H), 7.23-7.30 (m, 1H), 7.15-7.23 (m, 2H), 4.66-4.82 (m, 1H),

4.16-4.27 (m, 1H), 3.34-3.46 (m, 4H, under methanol), 3.10-3.27 (m, 1H),
2.77-2.92 (m, 2H), 2.55 (s, 3H), 2.35-2.51 (m, 3H), 2.21-2.35 (m, 1H), 1.84-
2.09 (m, 11H), 1.61-1.75 (m, 2H), 1.37-1.56 (m, 2H), 0.81-0.94 (dd, $J=16.10$,
7.48 Hz, 3H).

5

Example 275

^1H NMR (300 MHz, CD_3OD) δ 7.68-7.98 (m, 3H), 7.48-7.60 (m, 1H),
7.35-7.48 (m, 5H), 7.24-7.35 (m, 1H), 7.14-7.24 (m, 2H), 4.66-4.82 (m, 1H),
4.16-4.30 (m, 1H), 3.34-3.43 (m, 6H, under methanol), 2.55 (s, 3H), 2.35-2.51
10 (m, 2H), 2.13-2.35 (m, 2H), 1.83-2.12 (m, 9H), 1.65-1.76 (m, 2H), 1.30 (s, 2
H), 0.41-0.61 (m, 3H).

Example 210

^1H NMR (300 MHz, CD_3OD) δ 7.91-8.00 (m, 1H), 7.87 (s, 1H), 7.64-
15 7.74 (m, 2H), 7.50-7.58 (m, 1H), 7.36-7.49 (m, 5H), 7.22-7.32 (m, 1H), 7.14-
7.22 (m, 2H), 4.69-4.82 (m, 1H), 4.09-4.30 (m, 1H), 3.47-3.66 (m, 1H), 3.34-
3.39 (m, 3H, under methanol), 2.50-2.59 (m, 6H), 2.36-2.50 (m, 3H), 2.22-
2.35 (m, 1H), 1.83-2.11 (m, 10H), 1.65-1.76 (m, 2H), 1.30 (s, 2 H).

20

Example 294

^1H NMR (300 MHz, CD_3OD) δ 7.74-7.96 (dd, $J=38.00$, 7.77 Hz, 1H),
7.49-7.68 (m, 2H), 7.35-7.49 (m, 2H), 7.12-7.32 (m, 4H), 6.94-7.09 (m, 1H),
4.66-4.83 (m, 1H), 4.12-4.25 (m, 1H), 3.34-3.54 (m, 3H, under methanol),
3.13-3.28 (m, 1H), 2.56 (s, 3H), 2.30-2.52 (m, 3H), 2.16-2.30 (m, 1H), 1.79-
25 2.09 (m, 9H), 1.64-1.78 (m, 2H), 1.26-1.39 (m, 1H), 1.09-1.19 (d, $J=6.13$ Hz,
3H).

Example 295

^1H NMR (300 MHz, CD_3OD) δ 7.99-8.10 (m, 1H), 7.86-7.99 (m, 1H),
30 7.50-7.59 (m, 1H), 7.36-7.50 (m, 3H), 7.13-7.30 (m, 4H), 6.95-7.07 (m, 1H),
4.67-4.83 (m, 1H), 4.13-4.25 (m, 1H), 3.42-3.59 (m, 1H), 3.34-3.41 (m, 2H,
under methanol), 2.56 (s, 3H), 2.30-2.50 (m, 3H), 2.18-2.30 (m, 1H), 1.80-

2.12 (m, 10H), 1.65-1.80 (m, 2H), 1.22-1.42 (m, 1H), 1.09-1.19 (d, $J=6.23$ Hz, 3H).

Example 296

5 ^1H NMR (300 MHz, CD_3OD) δ 7.89-8.00 (m, 1H), 7.61-7.88 (m, 2H),
7.50-7.60 (m, 1H), 7.34-7.50 (m, 2H), 7.12-7.34 (m, 4H), 6.94-7.07 (m, 1H),
4.64-4.83 (m, 1H), 4.10-4.27 (m, 1H), 3.34-3.54 (m, 3H, under methanol),
3.12-3.27 (m, 1H), 2.56 (s, 3H), 2.30-2.51 (m, 3H), 2.16-2.30 (m, 1H), 1.79-
2.12 (m, 11H), 1.63-1.79 (m, 2H), 1.23-1.36 (m, 2H).

10

Example 297

^1H NMR (300 MHz, CD_3OD) δ 7.98-8.04 (m, 1H), 7.87-7.96 (m, 1H),
7.50-7.57 (m, 1H), 7.38-7.48 (m, 3H), 7.15-7.28 (m, 4H), 6.96-7.05 (m, 1H),
4.66-4.83 (m, 1H), 4.13-4.24 (m, 1H), 3.64-3.76 (m, 2H), 3.41-3.54 (m, 2H),
15 3.30-3.34 (m, 3H), 3.18-3.29 (m, 1H), 2.543 (s, 3H), 2.30-2.51 (m, 3H), 2.15-
2.29 (m, 1H), 1.84-2.09 (m, 9H), 1.66-1.76 (m, 2H), 1.27-1.32 (m, 1H).

Example 298

^1H NMR (300 MHz, CD_3OD) δ 7.67-7.95 (m, 3H), 7.50-7.58 (m, 1H),
20 7.39-7.46 (m, 2H), 7.15-7.27 (m, 4H), 6.96-7.06 (m, 1H), 4.65-4.83 (m, 1H),
4.11-4.26 (m, 1H), 3.63-3.80 (m, 2H), 3.37-3.54 (m, 2H), 3.29-3.34 (m, 3H),
3.11-3.27 (m, 1H), 2.54 (s, 3H), 2.31-2.51 (m, 3H), 2.17-2.29 (m, 1H), 1.86-
2.09 (m, 9H), 1.64-1.77 (m, 2H), 1.27-1.33 (m, 1H).

25

Example 315

^1H NMR (300 MHz, CD_3OD) δ 7.64-7.97 (m, 3H), 7.50-7.56 (m, 1H),
7.38-7.45 (m, 1H), 7.14-7.33 (m, 5H), 7.04-7.12 (m, 1H), 4.67-4.83 (m, 1H),
4.16-4.27 (m, 1H), 3.37-3.46 (m, 1H), 3.30-3.34 (m, 5H), 3.11-3.27 (m, 1H),
2.54 (s, 3H), 2.41-2.51 (m, 2H), 2.33-2.40 (m, 3H), 2.22-2.32 (m, 1H), 1.81-
30 2.10 (m, 10H), 1.64-1.74 (m, 2H), 1.27-1.35 (m, 1H).

Example 278

¹H NMR (300 MHz, CD₃OD) δ 8.00-8.08 (m, 1H), 7.85-7.98 (br.s, 1H),
7.50-7.58 (m, 1H), 7.36-7.46 (m, 1H), 7.36-7.46 (m, 6H), 7.23-7.32 (m, 1H),
7.14-7.22 (m, 2H), 4.67-4.83 (m, 1H), 4.15-4.28 (m, 1H), 3.18-3.58 (m, 7H),
5 2.51-2.57 (m, 3H), 2.34-2.50 (m, 3H), 1.81-2.09 (m, 10H), 1.62-1.75 (m, 2H),
1.26-1.33 (m, 1H).

Example 279

¹H NMR (300 MHz, CD₃OD) δ 7.94-8.01 (m, 1H), 7.79-7.92 (m, 1H),
10 7.51-7.57 (m, 1H), 7.37-7.47 (m, 6H), 7.23-7.31 (m, 1H), 7.16-7.22 (m, 2H),
4.68-4.81 (m, 1H), 4.16-4.29 (m, 1H), 3.42-3.59 (m, 2H), 3.20-3.41 (m, 7H),
2.52-2.60 (m, 4H), 2.25-2.49 (m, 3H), 1.85-2.09 (m, 8H), 1.66-1.75 (m, 1H),
1.28-1.34 (s, 2H).

Example 280

¹H NMR (300 MHz, CD₃OD) δ 7.95-8.02 (m, 1H), 7.82-7.93 (m, 1H),
7.51-7.56 (m, 1H) 7.37-7.47 (m, 6H), 7.23-7.30 (m, 1H), 7.15-7.23 (m, 2H),
4.66-4.83 (m, 1H), 4.15-4.29 (m, 1H), 3.17-3.58 (m, 8H), 2.86-2.99 (q, 2H),
2.52-2.56 (s, 3H), 2.35-2.50 (m, 3H), 1.81-2.10 (m, 8H), 1.63-1.74 (q, 2H),
20 1.27-1.34 (s, 1H), 1.01-1.13 (t, 3H).

Example 281

¹H NMR (300 MHz, CD₃OD) δ 7.95-8.02 (m, 1H), 7.83-7.94 (br s, 1H),
7.50-7.57 (m, 1H), 7.37-7.48 (m, 6H), 7.23-7.30 (m, 1H), 7.15-7.23 (m, 2H),
25 4.67-4.83 (m, 1H), 4.16-4.27 (m, 1H), 3.30-3.33(m, 4H), 2.80-2.89 (m, 2H),
2.54 (s, 3H), 2.35-2.51 (m, 3H), 2.24-2.34 (m, 1H), 1.84-2.11 (m, 8H), 1.65-
1.76 (m, 2H), 1.40-1.55 (m, 2H), 1.30 (s, 2H), 0.88 (t, J=7.4Hz, 3H).

Example 282

¹H NMR (300 MHz, CD₃OD) δ 7.98-8.05 (m, 1H), 7.85-7.96 (m, 1H),
30 7.50-7.57 (m, 1H), 7.37-7.50 (m, 6H), 7.22-7.32 (m, 1H), 7.15-7.22 (m, 2H),
4.67-4.83 (m, 1H), 4.16-4.29 (m, 1H), 3.37-3.59 (m, 2H), 3.29-3.34 (m, 4H),

2.54 (s, 3H), 2.36-2.51 (m, 3H), 2.17-2.35 (m, 2H), 1.82-2.10 (m, 8H), 1.64-1.75 (m, 2H), 1.31 (s, 2H), 0.44-0.62 (m, 4H).

Example 283

5 ¹H NMR (300 MHz, CD₃OD) δ 7.96-8.03 (m, 1H), 7.84-7.95 (m, 1H), 7.50-7.57 (m, 1H), 7.37-7.47 (m, 6H), 7.22-7.30 (m, 1H), 7.15-7.22 (m, 2H), 4.68-4.83 (m, 1H), 4.16-4.28 (m, 1H), 3.18-3.53 (m, 7H), 2.54 (s, 3H), 2.35-2.51 (m, 3H), 2.24-2.35 (m, 1H), 1.84-2.09 (m, 8H), 1.65-1.75 (m, 2H), 1.28-1.32 (m, 2H), 1.01-1.09 (d, J=6.4Hz, 6H).

10

Example 303

¹H NMR (300 MHz, CD₃OD) δ 7.95-8.02 (m, 1H), 7.84-7.94 (m, 1H), 7.50-7.57 (m, 1H), 7.37-7.48 (m, 3H), 7.25-7.28 (m, 1H), 7.14-7.25 (m, 4H), 6.96-7.05 (m, 1H), 4.66-4.82 (m, 1H), 4.12-4.24 (m, 1H), 3.18-3.56 (m, 6H),
15 2.88-2.98 (q, J=7.3Hz, 2H), 2.4 (s, 3H), 2.31-2.51 (m, 3H), 2.18-2.29 (m, 1H), 1.83-2.09 (m, 8H), 1.65-1.76 (m, 2H), 1.28-1.32 (m, 1H), 1.08 (t, J=7.3Hz, 3H).

Example 304

20 ¹H NMR (300 MHz, CD₃OD) δ 7.95-8.02 (m, 1H), 7.83-7.93 (m, 1H), 7.51-7.57 (m, 1H), 7.38-7.48 (m, 3H), 7.26-7.29 (m, 1H), 7.16-7.26 (m, 3H), 6.97-7.07 (m, 1H), 4.68-4.83 (m, 1H), 4.10-4.24 (m, 1H), 3.37-3.54 (m, 1H), 3.30-3.54 (m, 4H), 2.80-2.88 (t, J=7.0Hz, 2H), 2.54 (s, 3H), 2.31-2.50 (m, 3H), 2.17-2.30 (m, 1H), 1.83-2.11 (m, 8H), 1.68-1.77 (m, 2H), 1.41-1.55 (m, 2H),
25 1.30 (m, 3H), 0.88 (t, J=7.0Hz, 3H).

Example 305

¹H NMR (300 MHz, CD₃OD) δ 7.98-8.05 (m, 1H), 7.86-7.97 (m, 1H), 7.51-7.57 (m, 1H), 7.39-7.50 (m, 3H), 7.25-7.29 (m, 1H), 7.16-7.25 (m, 3H),
30 6.96-7.06 (m, 1H), 4.68-4.82 (m, 1H), 4.13-4.25 (m, 1H), 3.42-3.59 (m, 2H), 3.30-3.34 (m, 4H), 3.19-3.29 (m, 1H), 2.54 (s, 3H), 2.32-2.51 (m, 3H), 2.16-

2.28 (m, 2H), 1.83-2.10 (m, 8H), 1.66-1.77 (m, 2H), 1.30 (s, 1H), 0.45-0.62 (m, 4H).

Example 306

5 ¹H NMR (300 MHz, CD₃OD) δ 7.96-8.04 (m, 1H), 7.86-7.94 (m, 1H),
7.50-7.56 (m, 1H), 7.38-7.48 (m, 3H), 7.16-7.28 (m, 4H), 6.97-7.05 (m, 1H),
4.67-4.82 (m, 1H), 4.13-4.24 (m, 1H), 3.37-3.55 (m, 4H), 3.30-3.34 (m, 4H),
3.18-3.29 (m, 1H), 2.55 (s, 3H), 2.32-2.49 (m, 3H), 2.19-2.28 (m, 1H), 1.85-
2.10 (m, 8H), 1.67-1.76 (m, 2H), 1.28-1.32 (m, 1H), 1.02-1.10 (d, J=6.6Hz,
10 6H).

Example 284

¹H NMR (300 MHz, CD₃OD) δ 7.97-8.04 (m, 1H), 7.85-7.97 (m, 1H),
7.50-7.57 (m, 1H), 7.37-7.48 (m, 6H), 7.23-7.30 (m, 1H), 7.14-7.23 (m, 2H),
15 4.67-4.82 (m, 1H), 4.16-4.27 (m, 1H), 3.63-3.77 (m, 2H), 3.37-3.52 (m, 2H),
3.30-3.34 (m, 3H), 3.18-3.29 (m, 1H), 2.55 (s, 3H), 2.36-2.50 (m, 3H), 2.23-
2.34 (m, 1H), 1.83-2.09 (m, 9H), 1.64-1.73 (m, 2H), 1.30 (s, 1H).

Example 285

20 ¹H NMR (300 MHz, CD₃OD) δ 7.75-7.94 (m, 3H), 7.50-7.57 (m, 1H),
7.36-7.46 (m, 5H), 7.23-7.30 (m, 1H), 7.14-7.23 (m, 2H), 4.66-4.82 (m, 1H),
4.17-4.28 (m, 1H), 3.62-3.82 (m, 2H), 3.36-3.47 (m, 2H), 3.30-3.34 (m, 4H),
3.11-3.26 (m, 1H), 2.54 (s, 3H), 2.37-2.51 (m, 3H), 2.23-2.34 (m, 1H), 1.85-
2.10 (m, 8H), 1.64-1.74 (m, 2H), 1.30 (s, 1H).

25

Example 365

¹H NMR (300 MHz, CD₃OD) δ 7.81-8.10 (m, 2H), 7.47-7.60 (m, 1H),
7.35-7.47 (m, 5H), 7.14-7.31 (m, 3H), 4.69-4.84 (m, 1H), 4.14-4.31 (m, 1H),
3.35-3.49 (m, 2H, under methanol), 3.11-3.27 (m, 1H), 2.50-2.64 (m, 6H),
30 2.36-2.50 (m, 3H), 2.22-2.36 (m, 1H), 1.82-2.10 (m, 11H), 1.62-1.75 (m, 2H),
1.11-1.20 (d, J=6.14 Hz, 2H).

Example 366

¹H NMR (300 MHz, CD₃OD) δ 7.64-7.95 (m, 3H), 7.49-7.59 (m, 1H), 7.34-7.48 (m, 2H), 7.10-7.30 (m, 4H), 6.95-7.06 (m, 1H), 4.72-4.83 (m, 1H), 4.11-4.25 (m, 1H), 3.34-3.53 (m, 5H, under methanol), 3.07-3.29 (m, 1H),
5 2.76-2.93 (m, 2H), 2.67 (s, 1H), 2.42-2.60 (m, 4H), 2.29-2.42 (m, 1H), 1.74-2.29 (m, 12H), 1.26-1.56 (m, 3H), 0.80-0.96 (m, 3H).


Example 367

¹H NMR (300 MHz, CD₃OD) δ 7.65-7.92 (m, 2H), 7.47-7.65 (m, 2H),
10 7.37-7.47 (m, 1H), 7.12-7.36 (m, 5H), 7.04-7.12 (m, 1H), 4.69-4.83 (m, 1H), 4.08-4.31 (m, 1H), 3.34-3.47 (m, 3H, under methanol), 3.13-3.28 (m, 3H), 2.32-2.64 (m, 8H), 2.20-2.32 (m, 1H), 1.79-2.13 (m, 9H), 1.64-1.78 (m, 2H), 1.24-1.43 (m, 5H).


15

Synthesis of Acids


Acid 1: 2-methyl-2-(1H-tetrazol-5-yl)propanoic acid




20 Ethyl 2-methyl-2-(1H-tetrazol-5-yl)propanoate




The title compound was prepared from ethyl 2-cyano-2-methylpropanoate (3.67 g, 26 mmoles) via the literature procedure [J. Org. Chem., 58(15), 4139 (1993)] to give 3.83 g (80%) of pure product as an
25 amber solid. ¹³C NMR (300 MHz, CDCl₃) δ 174.04, 159.73, 62.74, 42.30, 25.74, 14.12.

2-methyl-2-(1H-tetrazol-5-yl)propanoic acid

Ethyl 2-methyl-2-(1H-tetrazol-5-yl) propanoate (1.50 g, 8.14 mmoles) was dissolved in 8 mL EtOH and treated with 6.7 mL 6N NaOH at ambient temperature for 18h. The reaction mixture was concentrated to dryness and the resultant solid was extracted with EtOH. Inorganics were filtered off and the filtrate were concentrated to give the title compound (1.24 g, 7.94 mmoles, 98%) as a tan solid. ¹³C NMR (300 MHz, D₂O) δ 176.88, 159.60, 41.69, 24.07.

Acid 2: N-(tert-butoxycarbonyl)-3-hydroxy-L-valine


3-Hydroxy-L-valine (500 mg, 3.75 mmoles) in 10 mL DMF with TEA (1 eq.) was treated with di(tert-butyl)dicarbonate (3.75 mmoles, 1 eq.) for 18h at ambient temperature. The reaction mixture was diluted with water, pH adjusted to 10 with 6 N NaOH, washed with EtOAc, and the aqueous phase was isolated. The aqueous phase was combined with fresh DCM, pH adjusted to 4 with 1N HCl. The organic phase was isolated, dried over MgSO₄, filtered and concentrated to give the title compound (68%) as a clear oil. ¹H NMR (300 MHz, CD₃OD) δ 4.09 (s, 1H), 1.46 (s, 9H), 1.30 (s, 3H), 1.26 (s, 3H).

Synthesis of Sulfonamide Benzoid Acids via Chlorosulfonylation/amination ProcedureMethod G – primary sulfonamide, lower sulfonamides*4-chloro-3-(chlorosulfonyl)benzoic acid*

At 5-10 °C, to stirred chlorosulfonic acid (200 mL) was added 4-chlorobenzoic acid (78 g, 0.5 mol). The reaction mixture was then brought up to 150~160 °C for 5 hours. After being cooled down to room temperature, the reaction mixture was slowly poured onto a large amount of ice and extracted with ether. The combined organic extracts were washed with ice water and dried over anhydrous magnesium sulfate. Evaporation of solvents afforded 4-chloro-3-(chlorosulfonyl)benzoic acid as a solid (76 g), which was directly used in the next steps.

4-Fluoro-3-(chlorosulfonyl)benzoic acid, 2,6-difluoro-3-(chlorosulfonyl)benzoic acid, 2,6-dichloro-3-(chlorosulfonyl)benzoic acid, 3,4-difluoro-5-(chloro-sulfonyl)benzoic acid, 2,6-methyl-3-(chlorosulfonyl) benzoic acid, 4-bromo-3-(chlorosulfonyl)benzoic acid, 2,6-difluoro-3-(chlorosulfonyl)benzoic acid, 4-methoxy-3-(chlorosulfonyl)benzoic acid, 5-chloro-3-(chloro-sulfonyl)-2-hydroxybenzoic acid, 2-chloro-5-(chloro-sulfonyl)benzoic acid, and 3-(chlorosulfonyl)-4-fluorobenzoic acid were prepared with the same procedure as above except for varying temperatures and heating time based on substrates. In some cases, the pure product was obtained as a precipitate from the ice quench in which case the product was filtered off and no extraction was necessary.


Synthesis of 3-(aminosulfonyl)-4-fluorobenzoic acid



To ~50 mL of liquid ammonia at -78 °C was added 7.0 grams of freshly prepared 4-fluoro-3-(chloro-sulfonyl)benzoic acid. The excess ammonia was then naturally evaporated to dryness overnight at room temperature. The crude solid was dissolved in water (50 mL) and acidified to pH~6 with HCl (conc.). After removal of the precipitate by filtration, the filtrate was further acidified to pH ~1. The desired product was precipitated and collected by filtration (5.0 g). ES LC-MS m/z (M-1)- 218.

Acids **16**, **22**, **31**, **37**, **43**, and **49** were prepared by this same method. Yields and representative data are included in the accompanying tables.

Method H – secondary and tertiary sulfonamides


























To the sulfonyl halide (8.00 mmoles) in 6 mL THF was added a 2N solution of the amine (24.0 mmoles, 3 eq.) in THF and the mixture was stirred overnight at ambient temperature. The reaction mixture was concentrated to dryness and partitioned between DCM and H₂O. The pH was adjusted to 10 with 6N NaOH and the aqueous phase was isolated. The aqueous phase was acidified to pH 2 with 6N HCl and the reaction mixture was stirred vigorously to give a white precipitate. The precipitate was filtered off, washed with water and air dried to give the desired product. In cases where precipitation did not occur, the aqueous phase was extracted with EtOAc, organic phases were combined, dried over MgSO₄, filtered, and concentrated to give the desired products. Yields and representative data are included in the accompanying tables.










Table of Carboxylic Acids









Acid #	Structure	Yield	ES-LCMS	Ion	Method
Acid 3		10	248.20	(M+H)	H
Acid 4		69	276.26	(M-1)	H

Acid 5		68	292.21	(M-1)	H
Acid 6		84	242.29	(M-1)	H
Acid 7		53	258.27	(M-1)	H
Acid 8		86	242.30	(M-1)	H
Acid 9		66	258.27	(M-1)	H
Acid 10		74	244.26	(M-1)	H
Acid 11		70	244.22	(M-1)	H
Acid 12		46	249.85, 251.83	(M+H)	H
Acid 13		10	294.10, 296.10	(M+H)	H
Acid 14		10	352.12, 354.12	(M+H)	H

Acid 15		20	264.14	(M+H)	H
Acid 16		70	233.88	(M-1)	G
Acid 17		62	282.19	(M-1)	H
Acid 18		69	263.87, 265.92	(M+H)	H
Acid 19		75	277.93, 279.88	(M+H)	H
Acid 20		79	275.96, 277.85	(M+H)	H
Acid 21		36	300.08	(M-1)	H
Acid 22		62	217.92	(M-1)	G
Acid 23		31	232.05	(M-1)	H
Acid 24		36	245.98	(M-1)	H
Acid 25		80	260.00	(M-1)	H
Acid 26		83	258.03	(M-1)	H


Acid 27		62	260.02	(M-1)	H
Acid 28		55	300.07	(M-1)	H
Acid 29		47	316.03	(M-1)	H
Acid 30		34	316.01	(M-1)	H
Acid 31		48	236	(M-1)	G
Acid 32		54	250	(M-1)	H
Acid 33		58	264	(M-1)	H
Acid 34		61	278	(M-1)	H
Acid 35		66	278	(M-1)	H
Acid 36		56	276	(M-1)	H
Acid 37		39	279	(M-1)	G

Acid 38		41	293	(M-1)	H
Acid 39		33	307	(M-1)	H
Acid 40		42	321	(M-1)	H
Acid 41		38	321	(M-1)	H
Acid 42		29	319	(M-1)	H
Acid 43		61	250	(M-1)	G
Acid 44		68	264	(M-1)	H
Acid 45		62	278	(M-1)	H
Acid 46		57	292	(M-1)	H


Acid 47		65	292	(M-1)	H
Acid 48		70	290	(M-1)	H
Acid 49		49	230	(M-1)	G
Acid 50		47	244	(M-1)	H
Acid 51		53	258	(M-1)	H
Acid 52		42	272	(M-1)	H
Acid 53		51	272	(M-1)	H
Acid 54		44	270	(M-1)	H

Example 368

1-benzoyl-4-(2-{4-[3-(4-methoxybenzyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}ethyl)-4-phenylpiperidine




5 *tert*-butyl 4-[3-(4-methoxybenzyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate



1-(*tert*-Butoxycarbonyl)piperidine-4-carboxylic acid (2.29 g, 10.0 mmoles) in 10 mL DMF was treated with 1,1'-carbonyldiimidazole (1.62 g, 10 mmoles, 1 eq.) at ambient temperature for 30 min until CO₂ evolution ceased.
 10 (1*Z*)-*N*'-hydroxy-2-(4-methoxyphenyl)ethanimidamide [*J. Med. Chem.*, 36(11), 1529 (1993)] (10.0 mmoles, 1 eq.) was dissolved in 5 mL DMF and added to the reaction mixture. The reaction mixture was heated at 70 °C for 6h then at 120°C for an additional 6h. The reaction mixture was diluted with EtOAc and washed successively with water, 1N citric acid, saturated aqueous NaHCO₃,
 15 and brine. The organic phase was isolated, dried over MgSO₄, filtered and concentrated to give the title compound as an amber oil. ¹H NMR (300 MHz, CDCl₃) δ 7.26 (d, 2H, J=8.5Hz), 6.88 (d, 2H, J=8.5Hz), 4.10 (m, 2H), 4.00 (s, 2H), 3.80 (s, 3H), 3.08 (m, 1H), 2.97-2.90 (m, 2H), 2.04 (m, 2H), 1.87-1.73 (m, 2H), 1.47 (s, 9H). ES-LCMS *m/z* 395.99 (M+Na).

20


4-[3-(4-methoxybenzyl)-1,2,4-oxadiazol-5-yl]piperidine





Tert-butyl 4-[3-(4-methoxybenzyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate was treated with 10 mL TFA/DCM (1:1) for 30 min at ambient

temperature. The reaction mixture was concentrated and the crude product was crystalized from EtOAc/Et₂O, filtered and dried to give the TFA salt of 4-[3-(4-methoxybenzyl)-1,2,4-oxadiazol-5-yl]piperidine as a tan solid (1.23g, 3.17mmol, 32%, 3 steps). ¹H NMR (300 MHz, DMSO-d₆) δ 7.22 (d, 2H, J=8.5Hz), 6.88 (d, 2H, J=8.5Hz), 4.00 (s, 2H), 3.72 (s, 3H), 3.43-3.29 (m, 2H), 3.02 (m, 2H), 2.17 (m, 2H), 1.92-1.80 (m, 2H). ES-LCMS *m/z* 274.30 (M+H).

1-benzoyl-4-(2-{4-[3-(4-methoxybenzyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}ethyl)-4-phenylpiperidine




The TFA salt of 4-[3-(4-methoxybenzyl)-1,2,4-oxadiazol-5-yl]piperidine (29 mg, 0.076 mmol) was combined with (1-benzoyl-4-phenylpiperidin-4-yl)acetaldehyde (21 mg, 0.069 mmol) in 2 mL DCM and treated with NaBH(OAc)₃ (43 mg, 0.203 mmol) at ambient temperature with agitation for 18h. 1 mL of saturated aqueous NaHCO₃ was added and agitated 1h. The organic phase was separated and concentrated. The crude product was purified by HPLC to give 1-benzoyl-4-(2-{4-[3-(4-methoxybenzyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}ethyl)-4-phenylpiperidine (16.1 mg, 0.026 mmol, 38%) as the formate salt. ¹H NMR (300 MHz, CD₃OD) δ 7.49-7.37 (m, 9H), 7.28 (m, 1H), 7.20 (d, 2H, J=8.8Hz), 6.86 (d, 2H, J=8.8Hz), 4.19 (m, 1H), 3.96 (s, 2H), 3.76 (s, 3H), 3.59 (m, 1H), 3.37-3.20 (m, 3H), 3.12-2.95 (m, 3H), 2.45-1.73 (m, 13H). ES-LCMS *m/z* 565.29 (M+H). HRMS C₃₅H₄₀N₄O₃ *m/z* 565.3179 (M+H)_{Cal.} 565.3183 (M+H)_{Obs.}

Example 3693-[(5-{1-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl] piperidin-4-yl}-1,2,4-oxadiazol-3-yl)methyl]pyridine5 (1Z)-N'-hydroxy-2-pyridin-3-ylethanimidamide

Hydroxylamine hydrochloride (0.87 g, 0.0125 mmol) was added to 0.5M NaOCH₃ (25 mL, 0.0125 mmol) and stirred at ambient temperature for 30 min. The reaction mixture was filtered and the filtrate was combined with
 10 pyridin-3-ylacetonitrile (1.18 g, 0.010 mmol). The resultant mixture was heated at reflux for 2h, stirred at ambient temperature overnight and concentrated to give crude (1Z)-N'-hydroxy-2-pyridin-3-ylethanimidamide which was used immediately without purification. ES-LCMS *m/z* 152.18 (M+H).


15

tert-butyl 4-[3-(pyridin-3-ylmethyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate

1-(*Tert*-butoxycarbonyl)piperidine-4-carboxylic acid (2.29 g, 0.010
 20 mmol) was treated with 1,1'-carbonyldiimidazole (1.62 g, 0.010 mmol) in DMF (5 mL) at ambient temperature for 30 min. Following this activation period, the crude (1Z)-N'-hydroxy-2-pyridin-3-ylethanimidamide (0.010 mmol) was added and the reaction mixture heated at 70 °C for 6h followed by 120°C for an additional 6h. The reaction mixture was cooled and partitioned between

EtOAc and water. The organic phase was separated, washed successively with saturated NaHCO₃ and brine, dried over MgSO₄, filtered and concentrated to give *tert*-butyl 4-[3-(pyridin-3-ylmethyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate. ¹H NMR (300 MHz, CDCl₃) δ 8.61 (s, 1H), 8.53 (m, 1H), 7.67 (d, 1H, J=7.7Hz), 7.28 (m, 1H), 4.20-4.05 (m, 2H), 4.08 (s, 2H), 3.08 (m, 1H), 2.94 (m, 2H), 2.04 (m, 2H), 1.87-1.73 (m, 2H), 1.47 (s, 9H). ES-LCMS *m/z* 367.36 (M+Na).


3-[(5-piperidin-4-yl-1,2,4-oxadiazol-3-yl)methyl]pyridine



tert-Butyl 4-[3-(pyridin-3-ylmethyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate was treated with 10 mL TFA/DCM (1:1) for 30 min at ambient temperature. The reaction mixture was concentrated to give the di-TFA salt of 3-[(5-piperidin-4-yl-1,2,4-oxadiazol-3-yl)methyl]pyridine as an amber oil (4.0 g, 8.47 mmol, 85%, 3 steps). ¹H NMR (300 MHz, DMSO-d₆) δ 8.78 (s, 1H), 8.70 (d, 1H, J=5.0Hz), 8.51 (br.s, 1H), 8.18 (d, 1H, J=7.9Hz), 7.75 (m, 1H), 4.30 (s, 2H), 3.44-3.30 (m, 3H), 3.09-3.00 (m, 2H), 2.20-2.16 (m, 2H), 1.93-1.80 (m, 2H).

Example 370


3-[(5-{1-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]piperidin-4-yl}-1,2,4-oxadiazol-3-yl)methyl]pyridine




The TFA salt of 3-[(5-piperidin-4-yl-1,2,4-oxadiazol-3-yl)methyl]pyridine (27 mg, 0.076 mmol) was combined with (1-benzoyl-4-phenylpiperidin-4-yl)acetaldehyde (21 mg, 0.069 mmol) in 2 mL DCM and treated with NaBH(OAc)₃ (43 mg, 0.203 mmol) at ambient temperature with agitation for

18h. 1mL of saturated aqueous NaHCO₃ was added and agitated 1h. The organic phase was separated and concentrated. The crude product was purified by HPLC (METHOD) to give 3-[(5-{1-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]piperidin-4-yl}-1,2,4-oxadiazol-3-yl)methyl]pyridine (14.2 mg, 0.024 mmol, 34%) as the formate salt. ¹H NMR (300 MHz, CD₃OD) δ 8.52-8.44 (m, 2H), 7.80 (d, 1H, J=7.9Hz), 7.48-7.38 (m, 10H), 7.26 (m, 1H), 4.19 (m, 1H), 4.13 (s, 2H), 3.59 (m, 1H), 3.36-3.29 (m, 3H), 3.12-3.02 (m, 3H), 2.47-1.45 (m, 13H). ES-LCMS *m/z* 536.25 (M+H). HRMS C₃₃H₃₇N₅O₂ *m/z* 536.3026 (M+H)_{Cal.} 536.3018 (M+H)_{Obs.}.


Reductive Amination Method I











The TFA or HCl salt of the amine (390 μmoles) was combined with (1-benzoyl-4-phenylpiperidin-4-yl)acetaldehyde (120 mg, 390 μmoles, 1 eq.) in 4mL DCE and/or 4mL DMF and treated with NaBH(OAc)₃ (585 μmoles, 1.5 eq.) with or without TEA (780 μmoles, 2 eq.) at ambient temperature with agitation for 18h. The reaction mixture was concentrated, dissolved in 5 mL DCM, and agitated 1h with 5 mL of saturated aqueous NaHCO₃. The organic phase was separated and concentrated. The crude product was purified either by normal phase flash chromatography (SiO₂, CHCl₃/CH₃OH) or by reverse phase mass-directed HPLC as described in Preparative HPLC Conditions A. Yields and representative data are included in the accompanying tables.

















The HCl salt of the amine (1.66 mmoles) was combined with *tert*-butyl 4-(2-oxoethyl)-4-phenyl piperidine-1-carboxylate (1.66 mmoles, 1 eq.) in 10 mL DCE and 10 mL DCM and treated with $\text{NaBH}(\text{OAc})_3$ (2.49 mmoles, 1.5 eq.) with TEA (3.33 moles, 2 eq.) at ambient temperature with agitation for 18h. The reaction mixture was washed with saturated aqueous NaHCO_3 , the organic phase separated, dried over MgSO_4 , filtered and concentrated. The crude product was purified by normal phase flash chromatography (SiO_2 , $\text{CHCl}_3/\text{CH}_3\text{OH}$) to give the desired product. Yields and representative data are included in the accompanying tables.









10

Example #	Amine #	R1	R2	% yield	LCMS result	Ion	Method
371	Amine 1			55	519.32	(M+H)	I
372	Amine 2			17	547.35	(M+H)	I
373	Amine 3			26	687.30	(M+H)	I
374	Amine 4			64	611.26	(M+H)	I

375	Amine 5			53	551.18	(M+H)	1
376	Amine 6			50	551.18	(M+H)	1
377	Amine 7			52	534.19	(M+H)	1
378	Amine 8			57	587.14	(M+H)	1
379	Amine 9			7	553.12	(M+H)	1
380	Amine 10			37	549.38	(M+H)	1
381	Amine 11			22	563.40	(M+H)	1

214

382	Amine 12			11	534.43	(M+H)	I
383	Amine 13			42	548.36	(M+H)	I
384	Amine 14			68	530.21	(M+H)	J

Additional analytical data of selected compounds from table above:

Example 371

5 Endo-1-[8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole

¹H NMR (300 MHz, CD₃OD) δ 8.46 (s, 1H), 7.70 (m, 1H), 7.51-7.28 (m, 13H), 4.80 (m, 1H), 4.23 (m, 1H), 3.71 (m, 2H), 3.62 (m, 1H), 3.35-3.22 (m, 2H), 2.74-1.67 (m, 16H). HRMS C₃₄H₃₈N₄O *m/z* 519.3124 (M+H)_{Cal.};

10 519.3110 (M+H)_{Obs.}

Example 372

Endo-1-[8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-2-ethyl-1H-benzimidazole

15 ¹H NMR (300 MHz, CD₃OD) δ ppm 1.35 (t, *J*=7.8 Hz, 3H), 1.76-2.53 (m, 16H), 2.89 (q, *J*=7.7Hz, 2H), 3.31-3.46 (m, 4H), 3.62 (m, 1H), 4.19 (m, 1H), 4.80 (m, 1H), 7.17-7.29 (m, 3H), 7.39-7.49 (m, 10H), 7.57 (m, 1H).

Example 380

Endo-1-{8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-2-methoxy-1H-benzimidazole

¹H NMR (300 MHz, CD₃OD) δ 7.49-7.39 (m, 10H), 7.32 (m, 1H), 7.24 (m, 1H), 7.16 (m, 2H), 4.81 (pent, 1H), 4.25 (m, 1H), 4.17 (s, 3H), 3.75 (m, 2H), 3.63 (m, 1H), 3.35-3.27 (m, 2H), 2.65-1.79 (m, 16H). ES-LCMS *m/z* 549.38 (M+H). HRMS C₃₅H₄₀N₄O₂ *m/z* 549.3230 (M+H)_{Cal.}; 549.3217 (M+H)_{Obs.}.

Example 381

Endo-1-{8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-2-ethoxy-1H-benzimidazole

¹H NMR (300 MHz, CD₃OD) δ 7.51-7.39 (m, 10H), 7.32 (m, 1H), 7.24 (m, 1H), 7.16 (m, 2H), 4.85 (pent, 1H), 4.57 (q, 2H, J = 7.0Hz), 4.23 (m, 1H), 3.73 (m, 2H), 3.63 (m, 1H), 3.35-3.27 (m, 2H), 2.65-1.79 (m, 16H). ES-LCMS *m/z* 563.40 (M+H). HRMS C₃₆H₄₂N₄O₂ *m/z* 563.3386 (M+H)_{Cal.}; 563.3368 (M+H)_{Obs.}.

Example 382

Endo-1-{8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazol-2-amine


¹H NMR (300 MHz, CD₃OD) δ 7.48-7.40 (m, 9H), 7.28 (m, 3H), 7.13 (m, 2H), 4.61 (pent, 1H), 4.19 (m, 1H), 3.59 (m, 1H), 3.39-3.27 (m, 4H), 2.48-1.65 (m, 16H). HRMS C₃₄H₃₉N₅O *m/z* 534.3233 (M+H)_{Cal.}; 534.3241 (M+H)_{Obs.}.

Preparation of Amines 1-14:

Amine 1: prepared by the literature procedure described in WO 00/38680.


Amine 2: *Endo-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-ethyl-1H-benzimidazole*

216



Endo-tert-butyl 3-[(2-aminophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (WO 00/38680) (2.5 g, 7.80 mmol) was treated with 20 mL 1,1,1-triethoxypropane at reflux for 3h. The reaction mixture was concentrated to dryness, redissolved in CH₃OH (10 mL), and treated with 6 N HCl at reflux for 1h. The reaction mixture was concentrated to dryness, chased with EtOH, and triturated with EtOH to give a solid that was filtered and dried to give the HCl salt of *endo-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-ethyl-1H-benzimidazole* (1.35 g, 4.11 mmol, 53%) as a grey solid. ¹H NMR (300 MHz, D₂O) δ 7.72-7.65 (m, 2H), 7.49-7.46 (m, 2H), 4.99 (m, 1H) 4.19 (m, 2H), 3.10 (q, 2H, J=7.6Hz), 2.76-2.70 (m, 2H), 2.40-2.18 (m, 6H), 1.35 (t, 3H, J=7.6Hz). ES-LCMS *m/z* 256.07 (M+H).

Amine 3: Endo-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-[2-(phenylsulfonyl)ethyl]-1H-benzimidazole




Endo-tert-butyl 3-[(2-aminophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (WO 00/38680) (1.8 g, 5.70 mmol) was treated with 20 mL [(3,3,3-triethoxypropyl)sulfonyl]benzene at 150 °C for 3h. The reaction mixture was concentrated to dryness, redissolved in CH₃OH (10 mL), and treated with 6 N HCl at reflux for 1h. The reaction mixture was concentrated to dryness, chased with EtOH, and triturated with EtOH to give a solid that was filtered and dried to give the di-HCl salt of *endo-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-[2-(phenylsulfonyl)ethyl]-1H-benzimidazole* (1.68 g, 3.59 mmol, 63%) as a grey solid. ¹H NMR (300 MHz, D₂O) δ 7.72-7.69 (m, 2H), 7.64 (m, 1H), 7.58 (m, 1H), 7.49-7.44 (m, 3H), 7.36 (m, 2H), 4.99 (m, 1H) 4.19 (m, 2H), 3.93


217

(t, 2H, $J=7.0\text{Hz}$), 3.63 (t, 2H, $J=7.0\text{Hz}$), 2.75-2.65 (m, 2H), 2.33-2.15 (m, 6H).
ES-LCMS m/z 396.14 (M+H).

Amine 4: *Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-5-*
5 *(methylsulfonyl)-1H-benzimidazole*




Endo-tert-butyl (1R,5S)-3-[[4-(methylsulfonyl)-2-nitrophenyl]amino]-8-
azabicyclo[3.2.1]octane-8-carboxylate



10 *Endo-tert-butyl (1R,5S)-3-amino-8-azabicyclo[3.2.1]octane-8-*
carboxylate (WO 00/38680) (1.5 g, 6.66 mmol) was treated with 1-fluoro-4-
(methylsulfonyl)-2-nitrobenzene (1.46 g, 1 eq.) in 10 mL NMP with DIPEA
(947 mg, 1.1 eq.) at 70°C for 3h. The reaction mixture was diluted with 5 mL
NMP, cooled to ambient temperature, and water added to incipient
15 cloudiness. The reaction mixture was stirred until a heavy precipitate formed.
The precipitate was filtered off, washed successively with NMP/water (1:1)
and water, and air dried to give *endo-tert-butyl (1R,5S)-3-[[4-(methylsulfonyl)-*
2-nitrophenyl]amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (2.21 g, 78%)
as a yellow solid. ^1H NMR (300 MHz, DMSO- d_6) δ 8.90 (d, 1H, $J=7.0\text{Hz}$), 8.53
20 (d, 1H, $J=2.0\text{Hz}$), 7.94 (dd, 1H, $J=9.2, 2.0\text{Hz}$), 7.17 (d, 1H, $J=9.3\text{Hz}$), 4.11 (m,
3H), 3.21 (s, 3H), 2.16 (m, 2H), 1.94 (m, 4H), 1.80 (m, 2H), 1.42 (s, 9H).


Endo-tert-butyl (1R,5S)-3-[[2-amino-4-(methylsulfonyl) phenyl]amino]-8-azabicyclo[3.2.1]octane-8-carboxylate



Endo-tert-butyl (1R,5S)-3-[[4-(methyl sulfonyl)-2-nitrophenyl]amino]-8-azabicyclo[3.2.1] octane-8-carboxylate (2.21 g, 5.19 mmoles) was subjected to catalytic hydrogenation with 10% Pd/C (260 mg) in EtOH/EtOAc (1:1, 100 mL) under 1atm H₂(g) for 16h. The catalyst was filtered off and the filtrate concentrated to a purple oil which was carried on to the next step without further characterization.

10


Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-5-(methylsulfonyl)-1H-benzimidazole




Endo-tert-butyl (1R,5S)-3-[[2-amino-4-(methylsulfonyl)phenyl]amino]-8-azabicyclo[3.2.1] octane-8-carboxylate was treated with 1,1,1-triethoxyethane at reflux for 2h. The reaction mixture was concentrated to dryness, redissolved in CH₃OH (10 mL), and treated with 6 N HCl at reflux for 1h. The reaction mixture was concentrated to dryness, chased with EtOH, and triturated with EtOH to give a solid that was filtered and dried to give the di-HCl salt of *endo-tert-butyl (1R,5S)-3-[[2-amino-4-(methylsulfonyl) phenyl]amino]-8-azabicyclo[3.2.1]octane-8-carboxylate* as a grey solid. ¹H

NMR (300 MHz, D₂O) δ 8.27 (m, 1H), 7.98-7.89 (m, 2H), 5.00 (m, 1H), 4.20 (m, 2H), 3.21 (s, 3H), 2.77 (s, 3H), 2.79-2.70 (m, 2H), 2.35-2.15 (6H).

Amine 5: *Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-5-fluoro-2-methyl-1H-benzimidazole*




Endo-tert-butyl (1R,5S)-3-[(4-fluoro-2-nitrophenyl) amino]-8-azabicyclo[3.2.1]octane-8-carboxylate



10 *Endo-tert-butyl (1R,5S)-3-amino-8-azabicyclo[3.2.1]octane-8-*
carboxylate (WO 00/38680) (2.0 g, 8.88 mmoles) was treated with 1,4-
 difluoro-2-nitrobenzene (1.41 g, 1 eq.) in 10 mL NMP with DIPEA (1.26 g, 1.1
 eq.) at 70 °C for 16h. The reaction mixture was cooled to ambient
 temperature, and water (4 mL) added to incipient cloudiness. The reaction
 15 mixture was stirred until a heavy precipitate formed. The precipitate was
 filtered off, washed successively with NMP/water (1:1) and water, and air
 dried to give *tert-butyl (1R,5S)-3-[(4-fluoro-2-nitrophenyl)amino]-8-*
azabicyclo[3.2.1]octane-8-carboxylate as an orange solid (2.74g , 7.50
 mmoles, 84%). ¹H NMR (300 MHz, CDCl₃) δ 8.66 (d, 1H, *J*=5.7Hz), 7.93 (m,
 20 1H), 7.27 (m, 1H), 6.72 (m, 1H), 4.29 (m, 3H), 3.91 (m, 1H), 2.40-2.29 (m,
 2H), 2.15-2.01 (m, 4H), 1.80 (m, 2H), 1.50 (s, 9H).


Endo-tert-butyl (1R,5S)-3-[(2-amino-4-fluorophenyl) amino]-8-azabicyclo[3.2.1]octane-8-carboxylate



5 *Endo-tert-butyl (1R,5S)-3-[(4-fluoro-2-nitrophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate* (2.74 g, 7.50 mmoles) was subjected to catalytic hydrogenation with 10% Pd/C (300 mg) in EtOH/EtOAc (1:1, 80 mL) under 1atm H₂(g) for 16h. The catalyst was filtered off and the filtrate concentrated to give the title compound (2.57 g, 100%) as a white foam. ES-LCMS *m/z* 336.26 (M+H).


10

Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-5-fluoro-2-methyl-1H-benzimidazole




15 *Endo-tert-butyl (1R,5S)-3-[(2-amino-4-fluorophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate* was treated with 1,1,1-triethoxyethane and a catalytic amount of camphor sulphonic acid at reflux for 3h. The reaction mixture was concentrated to dryness, redissolved in CH₃OH (10 mL), and treated with 6N HCl at reflux for 1h. The reaction mixture was concentrated to dryness, chased with EtOH, and triturated with EtOH to give a solid that was filtered and dried to give the di-HCl salt of *endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-5-fluoro-2-methyl-1H-benzimidazole* as a grey solid.
20 ES-LCMS *m/z* 260.27 (M+H).

Amine 6: *Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro-2-methyl-1H-benzimidazole*




Prepared according to the method of Amine 5 from 1,3-difluoro-2-nitrobenzene. ES-LCMS *m/z* 260.24 (M+H).

Amine 7: *Endo-3-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-3H-imidazo[4,5-b]pyridine*




Prepared according to the method of Amine 5 from 2-chloro-3-nitropyridine. ES-LCMS *m/z* 243.22 (M+H).

Amine 8: *Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-2-(trifluoromethyl)-1H-benzimidazole*




Endo-tert-butyl (1R,5S)-3-[2-(trifluoromethyl)-1H-benzimidazol-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate



To a solution of trifluoroacetic acid (496 mg, 4.35 mmoles) in 5 mL DMF was added CDI (4.35 mmoles, 1 eq.) and stirred 30 min at ambient temperature until CO₂ evolution ceased. The reaction mixture was then cooled in an ice bath and *Endo-tert*-butyl 3-[(2-aminophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (WO 00/38680) (1.38 g, 4.35 mmoles, 1 eq.) dissolved in 10mL DMF was added slowly. The reaction mixture was stirred 30 min at 0°C and then warmed to ambient temperature and stirred for 30 min. The reaction mixture was then heated at 80°C for 16h. The reaction mixture was concentrated, dissolved in DCM, washed successively with saturated aqueous NaHCO₃ and water (3x). The organic phase was separated, dried over MgSO₄ and concentrated. A major impurity was removed by precipitation with Et₂O, filtered off, and the filtrate concentrated to dryness. The crude product was purified by normal phase flash chromatography (SiO₂, 10→40% EtOAc/Hexanes) to give *Endo-tert*-butyl (1*R*,5*S*)-3-[2-(trifluoromethyl)-1*H*-benzimidazol-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate (0.36 g, 0.91 mmoles, 21%). ES-LCMS *m/z* 396.27 (M+H).


*Endo-1-[(1*R*,5*S*)-8-azabicyclo[3.2.1]oct-3-yl]-2-(trifluoromethyl)-1*H*-benzimidazole*




Endo-tert-butyl (1*R*,5*S*)-3-[2-(trifluoro-methyl)-1*H*-benzimidazol-1-yl]-8-azabicyclo [3.2.1]octane-8-carboxylate (330 mg, 0.84 mmoles) was dissolved in 6 mL DCM and treated with 4 mL 4N HCl in Dioxane at ambient temperature for 30 minutes. A solid precipitated from the reaction mixture and was filtered off to give the HCl salt of *Endo-1-[(1*R*,5*S*)-8-azabicyclo[3.2.1]oct-3-yl]-2-(trifluoromethyl)-1*H*-benzimidazole* (260 mg, 0.78 mmoles, 94%) as a pink solid. ES-LCMS *m/z* 295.67 (M+H).

223

Amine 9: *Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-2-chloro-1H-benzimidazole*




5 *Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-1,3-dihydro-2H-benzimidazol-2-one*



The title compound was obtained as a major by-product of the reaction of *Endo-tert-butyl* 3-[(2-aminophenyl)amino]-8-azabicyclo[3.2.1]octane-8-
 10 carboxylate (WO 00/38680) (1.7 g, 5.36 mmol) with 1-(triethoxymethoxy)ethane (5 mL) at 150 °C for 3h, followed by concentration, dissolution in CH₃OH (10 mL), and treatment with 6 N HCl at reflux for 1h. The reaction mixture was concentrated to dryness, chased with EtOH, and triturated with EtOH to give a solid that was filtered and dried to give the HCl
 15 salt of *Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-1,3-dihydro-2H-benzimidazol-2-one* (0.73 g, 3.00 mmoles, 56%). ES-LCMS *m/z* 244.00 (M+H).

Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-2-chloro-1H-benzimidazole




20

Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-1,3-dihydro-2H-benzimidazol-2-one (0.73 g, 3.00 mmoles) was treated with 5 mL POCl₃ with


a catalytic amount of DMAP at reflux for 12h. The reaction was cooled and quenched with slow addition of 6N NaOH until pH was basic. The reaction mixture was extracted with DCM, dried over MgSO₄, filtered and concentrated to give impure *Endo*-1-[(1*R*,5*S*)-8-azabicyclo[3.2.1]oct-3-yl]-2-chloro-1*H*-benzimidazole as a tan foam. The crude amine was used as is. ES-LCMS *m/z* 262.23 (M+H).

Amine 10: *Endo*-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-methoxy-1*H*-benzimidazole
Endo-*tert*-butyl 3-(2-methoxy-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate



Endo-*tert*-butyl 3-[(2-aminophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (WO 00/38680) (1.0 g, 3.15 mmol) was treated with 5 mL tetramethyl orthocarbonate at reflux for 40h. The reaction mixture was concentrated to dryness and purified by flash chromatography on silica gel eluted with 20% EtOAc in hexanes to give *Endo*-*tert*-butyl 3-(2-methoxy-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (0.50 g, 1.40 mmol, 44%) as an orange oil. ES-LCMS *m/z* 358.11 (M+H).

Endo-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-methoxy-1*H*-benzimidazole



Tert-butyl 3-(2-methoxy-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (0.50 g, 1.40 mmol) suspended in DCM (2 mL) was treated with TFA (1 mL) at ambient temperature for 5 min. The reaction mixture was concentrated to dryness and the product was crystallized from EtOAc/Et₂O to give the di-TFA salt of *Endo*-1-(8-azabicyclo[3.2.1]oct-3-


yl)-2-methoxy-1*H*-benzimidazole (340 mg, 0.722 mmol, 51%) as a tan solid.

¹H NMR (300 MHz, D₂O) δ 7.35 (m, 1H), 7.26 (m, 1H), 7.12 (m, 2H), 4.65 (m, 1H), 4.08-4.00 (m, 2H), 4.03 (s, 3H), 2.55-2.45 (m, 2H), 2.17-2.02 (m, 6H).

ES-LCMS *m/z* 258.02 (M+H).


5

Amine 11: *Endo*-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-ethoxy-1*H*-benzimidazole
Endo-*tert*-butyl 3-(2-ethoxy-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate



10 *Endo*-*tert*-butyl 3-[(2-aminophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (WO 00/38680) (1.7 g, 5.36 mmol) was treated with 10 mL tetraethyl orthocarbonate at reflux for 16h. The reaction mixture was concentrated to dryness and purified by flash chromatography on silica gel eluted with DCM followed by 20% EtOAc in Hexanes to give *Endo*-*tert*-butyl 3-(2-ethoxy-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate
 15 (1.15 g, 3.10 mmol, 58%) as an amber oil. ES-LCMS *m/z* 372.19 (M+H).

Endo-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-ethoxy-1*H*-benzimidazole




20 *Endo*-*tert*-butyl 3-(2-ethoxy-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (1.15 g, 3.10 mmol) suspended in DCM (4 mL) was treated with TFA (1 mL) at ambient temperature for 5 min. The reaction mixture was concentrated to dryness and the product crystallized from EtOAc/Et₂O to give the di-TFA salt of *Endo*-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-ethoxy-1*H*-benzimidazole (715 mg, 1.43 mmol, 46%) as a white powder.
 25 ¹H NMR (300 MHz, D₂O) δ 7.36 (m, 1H), 7.27 (m, 1H), 7.12 (m, 2H), 4.65 (m,

1H), 4.43 (q, 2H, J=7.1 Hz), 4.00 (m, 2H), 2.54-2.43 (m, 2H), 2.16-2.00 (m, 6H). ES-LCMS m/z 272.05 (M+H).

Amine 12: *Endo-1-(8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazol-2-amine*

5


Endo-tert-butyl 3-(2-amino-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate



Endo-tert-butyl 3-[(2-aminophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (WO 00/38680) (2.5 g, 7.88 mmol) was treated with BrCN (0.92 g, 8.66 mmol) in CH₃OH (30 mL) at reflux for 3h and concentrated to give *endo-tert-butyl 3-(2-amino-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate* (2.30 g, 6.73 mmol, 85%). ¹H NMR (300 MHz, DMSO-d₆) δ 7.15 (d, 2H, J = 7.6 Hz), 6.97-6.86 (m, 2H), 6.21 (s, 2H), 4.34 (m, 2H), 4.22 (pent, 1H), 2.42-2.32 (m, 2H), 1.98-1.85 (m, 6H), 1.44 (s, 9H). ES-LCMS m/z 343.12 (M+H).

15

Endo-1-(8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazol-2-amine




20

Endo-tert-butyl 3-(2-amino-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (0.244 g, 0.713 mmol) suspended in DCM (2 mL) was treated with TFA (2 mL) at ambient temperature for 30 min. The reaction mixture was concentrated to dryness and the product crystallized from EtOAc to give the di-TFA salt of *Endo-1-(8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazol-2-amine* (320 mg, 0.681 mmol, 95%) as a white solid. ¹H NMR


25

(300 MHz, D₂O) δ 7.40-7.20 (m, 4H), 4.66-4.49 (m, 1H), 4.16 (m, 2H), 2.71-2.60 (m, 2H), 2.29-2.11 (m, 6H). ES-LCMS m/z 243.04 (M+H).

Amine 13: *Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-N-methyl-1H-benzimidazol-2-amine*




Endo-tert-butyl (1R,5S)-3-[2-(methylamino)-1H-benzimidazol-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate



Endo-tert-butyl 3-[(2-aminophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (WO 00/38680) (900 mg, 2.83 mmol) in THF was treated with methyl isothiocyanate (230 mg, 3.15 mmoles, 1.1 eq.) at 0°C for 1h followed by 16h at ambient temperature. The reaction mixture was concentrated, redissolved in 7mL DMF and treated with 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (815 mg, 1.5 eq.) at ambient temperature for 16h. The reaction mixture was concentrated, dissolved in EtOAc, washed successively with saturated aqueous NaHCO₃, water (3x), and brine. The organic phase was separated, dried over MgSO₄ and concentrated to give the desired product, *endo-tert-butyl (1R,5S)-3-[2-(methylamino)-1H-benzimidazol-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate*. ES-LCMS m/z 357.15 (M+H).

Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-N-methyl-1H-benzimidazol-2-amine


228




Endo-tert-butyl (1R,5S)-3-[2-(methylamino)-1H-benzimidazol-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate was dissolved in 3 mL CH₃OH and treated with 3 mL 4N HCl in Dioxane at ambient temperature for 30 minutes.

5 The reaction mixture was concentrated and triturated with EtOH, filtered, and dried to give the di-HCl salt of *Endo-1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-N-methyl-1H-benzimidazol-2-amine* (201 mg, 0.61 mmol, 60%) as a pink solid. ES-LCMS *m/z* 257.04 (M+H).

- 10 Amine 14: *Endo-3-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-3H-imidazo[4,5-b]pyridine*



Endo-tert-butyl (1R,5S)-3-[(3-nitropyridin-2-yl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate




15

Endo-tert-butyl (1R,5S)-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (WO 00/38680) (8.64 g, 38.3 mmol) was treated with 2-chloro-3-nitropyridine (6.08 g, 1 eq.) in 50 mL NMP with DIPEA (10.9 g, 2.2 eq.) at 70°C for 16h. The reaction mixture was cooled to ambient temperature, and

20 water (60 mL) added to incipient cloudiness. The reaction mixture was stirred until a heavy precipitate formed. The precipitate was filtered off, washed successively with NMP/water (1:1) and water, and air dried to give *endo-tert-*


butyl (1*R*,5*S*)-3-[(3-nitropyridin-2-yl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate as a brown solid (11.5 g, 33.0 mmol, 86%).

Endo-tert-butyl (1*R*,5*S*)-3-[(3-aminopyridin-2-yl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate



Endo-tert-butyl (1*R*,5*S*)-3-[(3-nitropyridin-2-yl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (5.17 g, 14.8 mmol) was subjected to catalytic hydrogenation with 10% Pd/C (500 mg) in EtOH/EtOAc (1:1, 200 mL) under 1 atm H₂(g) for 16h. The catalyst was filtered off and the filtrate was concentrated to give *Endo-tert-butyl* (1*R*,5*S*)-3-[(3-aminopyridin-2-yl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate as a brown foam and was used in the next step without further characterization.


Endo-tert-butyl (1*R*,5*S*)-3-(2-ethoxy-2-methyl-1,2-dihydro-3*H*-imidazo[4,5-*b*]pyridin-3-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate



Endo-tert-butyl (1*R*,5*S*)-3-[(3-aminopyridin-2-yl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (2.85 g, 8.52 mmol) was treated with 1,1,1-triethoxyethane and a catalytic amount of camphor sulphonic acid at reflux for 3h. The reaction mixture was concentrated to dryness, dissolved in EtOAc, washed with saturated aqueous NaHCO₃, the organic phase separated, dried over MgSO₄, filtered and concentrated. The crude product was purified by normal phase flash chromatography (SiO₂, 10→40%


EtOAc/Hexanes) to give *endo-tert*-butyl (1*R*,5*S*)-3-(2-ethoxy-2-methyl-1,2-dihydro-3*H*-imidazo[4,5-*b*]pyridin-3-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (2.66 g, 6.84 mmoles, 80%). ES-LCMS *m/z* 411.08 (M+Na).

- 5 *Endo-tert*-butyl (1*R*,5*S*)-3-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-3-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate



- Endo-tert*-butyl (1*R*,5*S*)-3-(2-ethoxy-2-methyl-1,2-dihydro-3*H*-imidazo[4,5-*b*]pyridin-3-yl)-8-azabicyclo [3.2.1]octane-8-carboxylate (2.66 g, 6.84 mmoles) and a catalytic amount of camphor sulphonic acid were combined in NMP at 150 °C for 12h. The reaction mixture was cooled to ambient temperature, diluted with EtOAc, washed successively with saturated aqueous NaHCO₃ and brine (5x). The organic phase was separated, dried over MgSO₄, filtered and concentrated. The crude product was purified by normal phase flash chromatography (SiO₂, EtOAc) to give *Endo-tert*-butyl (1*R*,5*S*)-3-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-3-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (1.60 g, 4.67 mmoles, 68%). ES-LCMS *m/z* 343.24 (M+H).


- Endo*-3-[(1*R*,5*S*)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-3*H*-imidazo[4,5-*b*]pyridine



- Endo-tert*-butyl (1*R*,5*S*)-3-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-3-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (1.60 g, 4.67 mmoles) was dissolved in 15 mL DCM and treated with 4 N HCl in dioxane at ambient temperature for 30 min. A precipitate formed directly from the reaction mixture and was

filtered and dried to give the HCl salt of *Endo*-3-[(1*R*,5*S*)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-3*H*-imidazo[4,5-*b*]pyridine as a brown solid. ES-LCMS m/z 243.22 (M+H).

5 Synthesis of the 5-(aminosulfonyl)-2-chloronicotinic acid




2-Hydroxynicotinic acid (10.0 g, 71.8 mmol) was dissolved in 25 ml of chlorosulfonic acid and heated to 160°C overnight. After cooling the reaction was slowly poured into ice and stirred in an ice bath until a white precipitate
10 formed. The solid was filtered off and dried under vacuum to afford 7.55 g of 5-(chlorosulfonyl)-2-hydroxynicotinic acid (44% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 7.9 (dd, *J*=2.5, 0.7Hz, 1H) 8.4 (dd, *J*=2.6, 0.7Hz, 1H).

5-(Chlorosulfonyl)-2-hydroxynicotinic acid (500 mg, 2.10 mmol) was suspended in 5 ml of POCl₃ in a sealed tube and heated to 130 °C until all
15 solid had dissolved. The reaction was cooled to 0 °C and poured onto ice and stirred until a solid formed. The filtered white solid was dried to afford 2-chloro-5-(chlorosulfonyl)nicotinic acid. ¹H NMR (400 MHz, Acetone-*d*₆) δ ppm 8.9 (d, *J*=2.6Hz, 10H), 9.3 (d, *J*=2.6Hz, 10H).

2-Chloro-5-(chlorosulfonyl)nicotinic acid (400 mg, 1.56 mmol) was
20 stirred in a slurry of ice and excess ammonium hydroxide was added at 0°C and stirred until all of the ice had melted. The resulting solution was evaporated to afford a white solid 5-(aminosulfonyl)-2-chloronicotinic acid. MS ES+ 237 (M+H). ¹H NMR (400 MHz, DMSO-*D*₆) δ ppm 8.1 (dd, *J*=2.6, 0.9Hz, 1H), 8.6 (m, 1H).

232


2-[[[(dimethylamino)sulfonyl]oxy}benzoic acid



Methyl 2-[[[(dimethylamino)sulfonyl]oxy} benzoate (325.0 mg, 1.253 mmol) was dissolved in 2 ml of 1,4-dioxane and 2 ml of 1M LiOH was added.

- 5 The resulting solution was shaken overnight at 45°C. The reaction mixture was washed with DCE and separated using a hydrophobic frit. The aqueous layer was acidified to give a white solid which was filtered and dried to afford 244.4 mg (80% yield) of 2-[[[(dimethyl-amino)sulfonyl]oxy}benzoic acid.

Example	Acid source	R	X	Y	% yield	LCMS result	ion	Method
Example 385	Commercial		H	C	34	652	(M+H)	sulfonyl
Example 386	Commercial		H	C	21	603	(M+H)	sulfonyl
Example 343	Commercial		H	C	41	583	(M+H)	sulfonyl
Example 387	Commercial		H	C	74	637	(M+H)	sulfonyl

Example 3861-[(1*R*,5*S*)-8-(2-[1-[(3-chlorophenyl)sulfonyl]-4-phenyl-4-piperidinyl]ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole


5


3-Chlorobenzenesulfonyl chloride (31.6 mg, 0.122 mmol) was added to a solution of 2-methyl-1-[(1*R*,5*S*)-8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole (50.0 mg, 0.117 mmol) and diisopropylethylamine (44.9 mg, 0.348 mmol) in DCM. The reactions were quenched with sat. NaHCO₃ and separated with a hydrophobic frit. Flash chromatography on silica 0 to 10% MeOH in EtOAc afforded 1-[(1*R*,5*S*)-8-(2-[1-[(3-chlorophenyl)sulfonyl]-4-phenyl-4-piperidinyl]ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole 14.7 mg (20% yield). MS ES⁺ 603(M+H). ¹H NMR (300 MHz, chloroform-*d*) δ ppm 1.6 (m, 2H), 1.7 (m, 4H), 1.9 (m, 8H), 2.4 (m, 4H), 2.6 (s, 3H), 2.8 (m, 2H), 3.4 (m, 2H), 4.6 (m, 1H), 7.2 (m, 5H), 7.3 (m, 3H), 7.4 (t, *J*=7.9Hz, 1H), 7.5 (m, 1H), 7.6 (d, *J*=7.8Hz, 1H), 7.7 (m, 1H), 7.7 (m, *J*=1.8, 1.8Hz, 1H).

15

General Scheme Towards Pyrimidinyl and Tetrahydro-biimidazolyl Derivatives of 2-Methyl-1-{8-[2-(4-Phenylpiperidin-4-yl)ethyl]-8-Azabicyclo[3.2.1]oct-3-yl}-1*H*-Benzimidazole

20



Example 388Preparation of 2-methyl-1-{8-[2-(4-phenyl-1-pyrimidin-2-yl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole


5 To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) in *N, N*-dimethylformamide (2 mL) was added 2-chloropyrimidine (8.6 mg, 0.075 mmol) and triethylamine (21 μ L, 0.15 mmol). The resulting mixture was stirred at 80 °C for 2.5 hours. After evaporation of the solvent, the crude

10 product was directly purified by flash chromatography on silical gel, eluting with a gradient of 0-10% triethylamine in methanol to afford 2-methyl-1-{8-[2-(4-phenyl-1-pyrimidin-2-yl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole as amorphous solid (16.2 mg, 65%). ^1H NMR (300 MHz, CDCl_3) δ 8.30 (d, $J=6.0\text{Hz}$, 2H), 7.67 (dd, $J=2.6, 7.0\text{Hz}$, 1H), 7.39-7.37 (m, 4H), 7.35-7.22 (m, 3H), 7.21-7.14 (m, 2H), 6.45 (t, $J=4.7\text{Hz}$, 1H), 4.64 (m, 1H), 4.17-4.09 (m, 2H), 3.61-3.52 (m, 2H), 3.28-3.25 (m, 2H), 2.59 (s, 3H), 2.44-2.33 (m, 2H), 2.29-2.22 (m, 2H), 1.97-1.85 (m, 10H), 1.62 (d, $J=7.7\text{Hz}$, 2H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd: 507.3236; obsd: 507.3248.

15

Example 389

Preparation of 2-methyl-1-(8-{2-[4-phenyl-1-(4,4',5,5'-tetrahydro-1'H-1,2'-biimidazol-2-yl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole



5


2-Methyl-1-(8-{2-[4-phenyl-1-(4,4',5,5'-tetrahydro-1'H-1,2'-biimidazol-2-yl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole (16 mg, 58%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) and 2-methylthio-2-imidazoline hydroiodide (24.4 mg, 0.1 mmol) by the similar procedure outlined in example 388. ¹H NMR (300 MHz, CDCl₃) δ 7.68-7.65 (m, 1H), 7.40-7.35 (m, 2H), 7.31-7.25 (m, 4H), 7.21-7.12 (m, 2H), 5.87 (br, 1H), 4.65-4.58 (m, 1H), 4.06-3.97 (m, 2H), 3.17-3.65 (m, 6H), 3.32-3.26 (m, 4H), 3.12-3.06 (m, 2H), 2.58 (s, 3H), 2.42-2.32 (m, 2H), 2.25-2.19 (m, 2H), 1.97-1.86 (m, 10H), 1.62 (d, J=7.9Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 565.3767, obsd: 565.3755.

15

Preparation of Carboximidoate, Carboximidamide and Carbimido-thioate Derivatives of 2-Methyl-1-{8-[2-(4-Phenylpiperidin-4-yl)ethyl]-8-Azabicyclo-[3.2.1]oct-3-yl}-1H-Benzimidazole

20

236




5

Example 390

Preparation of 5-(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-1H-1,2,4-triazol-3-amine


237



To a stirred solution of phenyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (18 mg, 0.031 mmol) in isopropyl alcohol (1 mL) was added hydrazine (3.6 μ L, 0.11 mmol). The resulting mixture was then stirred at 80 °C for 4 hours. After evaporation of the solvents, the residue was purified by flash chromatography to afford 5-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-1*H*-1,2,4-triazol-3-amine as white solid (12.5 mg, 79%). ¹H NMR (300 MHz, CDCl₃) δ 7.67-7.64 (m, 2H), 7.39-7.29 (m, 5H), 7.25-7.13 (m, 3H), 4.66-4.55 (m, 2H), 4.28 (br, 2H), 3.56-3.49 (m, 3H), 3.27-3.21 (m, 4H), 2.57 (s, 3H), 2.42-2.22 (m, 4H), 1.96-1.82 (m, 9H), 1.64-1.62 (m, 2H). HRMS *m/z* (*M*+*H*)⁺ calcd: 511.3298, obsd: 511.3289.

Example 391

Preparation of isopropyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate



Isopropyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (13 mg, 92%) was obtained as amorphous solid from phenyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (15 mg, 0.026 mmol) and sodium isopropoxide by the similar procedure outlined in example 7. ¹H NMR (300 MHz, CDCl₃) δ 7.67 (d, *J*=7.0Hz, 1H), 7.42-7.35 (m, 2H), 7.29-7.21 (m, 4H),


238

7.19-7.13 (m, 2H), 5.30-5.22 (m, 1H), 4.69 (br, 1H), 4.14-4.02 (m, 2H), 3.38-3.20 (m, 4H), 2.59 (s, 3H), 2.41-2.14 (m, 4H), 1.94-1.68 (m, 12H), 1.32 (d, $J=6.2\text{Hz}$, 6H). HRMS m/z ($M+H$)⁺ calcd: 539.3498, obsd: 539.3503.

5

Example 392

Preparation of cyclopentyl N-cyano-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate




Cyclopentyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (15 mg, 81%) was obtained from phenyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (19 mg, 0.033 mmol) and sodium cyclopentoxide by the similar procedure outlined in example 7. ¹H NMR (CDCl₃, 300 MHz): δ 7.67 (d, $J=6.9\text{Hz}$, 1H), 7.42-7.31 (m, 2H), 7.29-7.24 (m, 4H), 7.19-7.12 (m, 2H), 5.51-5.47 (m, 1H), 4.68 (br, 1H), 3.99 (br, 2H), 3.35-3.28 (m, 4H), 2.59 (s, 3H), 2.42-2.28 (m, 4H), 1.97-1.81 (m, 14H), 1.75-1.62 (m, 6H). HRMS m/z ($M+H$)⁺ calcd: 565.3655, obsd: 565.3663.

20

Example 393A

Preparation of N'-cyano-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidamide




Phenyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (100 mg,

25

0.175 mmol) and a solution of ammonia in methanol (2 mL, 1.4 M) was stirred at ambient temperature for 20 hours. After evaporation of the excess ammonia and the solvent, the residue was subject to flash chromatography (Mega Bond Elut Si, MeOH/EtOAc, 10% to 40%) to afford *N'*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidamide as amorphous solid (79 mg, 91%). ¹H NMR (CDCl₃, 300 MHz): δ 7.68-7.65 (m, 1H), 7.42-7.34 (m, 2H), 7.30-7.24 (m, 4H), 7.20-7.18 (m, 2H), 6.11 (s, 2H), 4.65 (t, J=8.5Hz, 1H), 3.82-3.78 (m, 2H), 3.27-3.20 (m, 4H), 2.53 (s, 3H), 2.45-2.25 (m, 4H), 1.96-1.84 (m, 10H), 1.64 (d, J=7.5Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 496.3189, obsd: 496.3181.

Example 393B

Preparation of *N'*-cyano-*N*-methyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidamide




15

N'-cyano-*N*-methyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidamide (18 mg, quant.) was obtained from phenyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (20 mg, 0.035 mmol) and methylamine (0.7 mL, 2 M in EtOH) by the similar procedure outlined in example 393. ¹H NMR (CDCl₃, 300 MHz) δ 7.69 (d, J=7.3Hz, 1H), 7.44-7.39 (m, 2H), 7.32-7.25 (m, 4H), 7.22-7.16 (m, 2H), 5.37 (s, 1H), 4.83 (br, 1H), 3.80-3.76 (m, 2H), 3.35-3.24 (m, 4H), 3.03 (d, J=4.6Hz, 3H), 2.63 (s, 3H), 2.56-2.29 (m, 4H), 2.08-1.89 (m, 10H), 1.73-1.71 (m, 2H). HRMS *m/z* (M+H)⁺ calcd: 510.3345, obsd: 510.3348.

25

Example 394

Preparation of (4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)(morpholin-4-yl)methylidene-cyanamide




5

(4-{2-[3-(2-Methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)(morpholin-4-yl)methylidenecyanamide (5.1 mg, 26%) was obtained from phenyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (20 mg, 0.035 mmol) and morpholine (2 mL) by the similar procedure outlined in example 393. ¹H NMR (CDCl₃, 300 MHz) δ 7.67 (d, J=7.5Hz, 1H), 7.41-7.37 (m, 2H), 7.29-7.25 (m, 4H), 7.21-7.13 (m, 2H), 3.71-3.63 (m, 7H), 3.44-3.30 (m, 7H), 2.64 (s, 3H), 2.32-2.16 (m, 4H), 1.98 (br, 8H), 1.69 (br, 6H). HRMS *m/z* (M+H)⁺ calcd: 566.3607, obsd: 566.3610.

15

Example 395

Preparation of methyl *N*-cyano-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbimidothioate



20


To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) in dichloromethane (2 mL) was added triethylamine (14 μL, 1 mmol) and dimethylcyanodithioiminocarbonate (8.8 mg, 0.06 mmol). The resulting mixture was stirred at ambient temperature for 3 hours before it was quenched with saturated sodium bicarbonate solution. The layers were

25

separated and the aqueous layer was extracted with dichloromethane (2 x 10 mL). The combined organic extracts were dried over anhydrous sodium sulfate. After evaporation of the solvent, the crude product was purified by flash chromatography on silical gel, eluting with a gradient of 0-15% methanol in ethyl acetate to afford methyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbimidothioate as amorphous solid (18 mg, 68%). ¹H NMR (300 MHz, CDCl₃) δ 7.70(d, J=7.0Hz, 1H), 7.46-7.37 (m, 2H), 7.33-7.28 (m, 4H), 7.24-7.16 (m, 2H), 4.72 (br, 1H), 4.29-4.24 (m, 2H), 3.46 (t, J=11.1Hz, 2H), 3.31 (br, 2H), 2.78 (s, 3H), 2.62 (s, 3H), 2.54-2.35 (m, 4H), 2.08-1.86 (m, 10H), 1.69 (d, J=7.7Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 527.2957, obsd: 527.2933.

Example 396

Preparation of isopropyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbimidothioate




To a stirred solution of phenyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1] oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (20 mg, 0.035 mmol) in THF (1 mL) was added sodium 2-propanethiolate (6.8 mg, 0.07 mmol). The resulting mixture was stirred at ambient temperature for 30 minutes before evaporation of the solvent. The crude product was then purified by flash chromatography on silical gel, eluting with a gradient of 0-10% methanol in ethyl acetate to afford isopropyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo [3.2.1] oct-8-yl]ethyl}-4-phenylpiperidine-1-carbimidothioate as a white solid (14 mg, 72 %). ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=7.5Hz, 1H), 7.45-7.40 (m, 2H), 7.32-7.24 (m, 4H), 7.21-7.14 (m, 2H), 4.39-4.26 (m, 3H), 3.53 (br, 4H), 2.65 (s, 3H),

242

2.33-2.05 (m, 4H), 1.99-1.85 (m, 13H), 1.38 (d, $J=6.4\text{Hz}$, 6H). HRMS m/z (M+H)⁺ calcd: 555.3270, obsd: 555.3274.


Example 397

5 Preparation of cyclopentyl N-cyano-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbimidothioate




Cyclopentyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbimidothioate (20 mg, quant.) was obtained as amorphous solid from phenyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (20 mg, 0.035 mmol) and sodium cyclopentanethiolate by the similar procedure outlined in example 396. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, $J=7.2\text{Hz}$, 1H), 7.44-7.39 (m, 2H), 7.31-7.22 (m, 4H), 7.20-7.13 (m, 2H), 4.46-4.42 (m, 1H), 4.28-4.23 (m, 2H), 3.52-3.45 (m, 4H), 2.63 (s, 3H), 2.52 (br, 2H), 2.33-2.28 (m, 2H), 2.18-2.10 (m, 4H), 2.05-1.91 (m, 8H), 1.87-1.54 (m, 9H). HRMS m/z (M+H)⁺ calcd: 581.3426, obsd: 581.3438.

20 Preparation of Amide Derivatives Through HATU Promoted Amidation Method



Example 398

Preparation of 2-methyl-1-(8-{2-[4-phenyl-1-(1H-pyrazol-4-ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




5 2-Methyl-1-(8-{2-[4-phenyl-1-(1H-pyrazol-4-ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1] oct-3-yl)-1H-benzimidazole (27 mg, quant.) was obtained as amorphous solid from 2-methyl-1-(8-{2-(4-phenyl piperidin-4-yl)ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) and 4-pyrazolecarboxylic acid (6 mg, 0.05 mmol) by the
10 similar procedure outlined in example 5. ¹H NMR (300 MHz, DMSO-d₆ 100°C) δ 7.84 (s, 2H), 7.54-7.51 (m, 1H), 7.47-7.38 (m, 5H), 7.28-7.24 (m, 1H), 7.18-7.11 (m, 2H), 3.91-3.86 (m, 3H), 3.46-3.40 (m, 4H), 3.08 (br, 3H), 2.53 (s, 3H), 2.16 (m, 2H), 2.08-1.74 (m, 12H). HRMS *m/z* (M+H)⁺ calcd: 523.3185, obsd: 523.3195.

15

Example 399

Preparation of 2-methyl-1-[(1R,5S)-8-(2-{1-[(5-methyl-1H-pyrazol-3-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole



20

2-Methyl-1-[(1R, 5S)-8-(2-{1-[(5-methyl-1H-pyrazol-3-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole (34 mg, 53%) was obtained as amorphous solid from 2-methyl-1-(8-{2-(4-phenylpiperidin-4-yl)ethyl}-8-azabicyclo [3.2.1]oct-3-yl)-1H-benzimidazole (51
25 mg, 0.12 mmol), 5-methyl-1H-pyrazole-3-carboxylic acid (15 mg, 0.12 mmol)

244


and HATU (47 mg, 0.12 mmol) by the similar procedure outlined in example 5.

^1H NMR (300 MHz, DMSO- d_6) δ 12.78 (s, 1H), 7.49-7.47 (m, 1H), 7.38-7.33 (m, 4H), 7.23-7.21 (m, 1H), 7.11-7.05 (m, 3H), 6.24 (s, 1H), 4.50 (br, 1H), 4.12 (br, 1H), 3.86 (br, 1H), 3.60 (br, 1H), 3.23 (br, 3H), 2.45 (s, 3H), 2.39-2.32 (m, 2H), 2.23 (s, 3H), 2.09 (br, 2H), 1.97-1.71 (m, 10H), 1.58-1.55 (m, 2H).

HRMS m/z ($M+H$) $^+$ calcd: 537.3342, obsd: 537.3367.

Example 400

Preparation of 6-methyl-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyridin-2(1H)-one




6-Methyl-3-[(4-{2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyridin-2(1H)-one (30 mg, 53%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo [3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (51 mg, 0.10 mmol), 2-hydroxyl-6-methylpyridine-3-carboxylic acid (15 mg, 0.10 mmol) and HATU (38 mg, 0.10 mmol) by the similar procedure outlined in example 5. ^1H NMR (400 MHz, CDCl_3) δ 8.15 (d, $J=7.5\text{Hz}$, 1H), 7.65 (d, $J=7.3\text{Hz}$, 1H), 7.50-7.34 (m, 2H), 7.30-7.21 (m, 5H), 7.19-7.12 (m, 2H), 6.18 (d, $J=7.5\text{Hz}$, 1H), 4.66-4.56 (m, 1H), 4.14-4.07 (m, 1H), 3.88 (br, 2H), 3.25 (br, 3H), 2.56 (s, 3H), 2.40-2.08 (m, 8H), 1.93-1.84 (m, 10H), 1.61 (d, $J=6.5\text{Hz}$, 2H). HRMS m/z ($M+H$) $^+$ calcd: 564.3339, obsd: 564.3349.

25

245

Example 401

Preparation of 5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyridin-2(1H)-one



5


5-[(4-{2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyridin-2(1H)-one (28 mg, 51 %) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (51 mg, 0.10 mmol), 6-hydroxynicotinic acid (14 mg, 0.10 mmol) and HATU (38 mg, 0.10 mmol) by the similar procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.66-7.62 (m, 2H), 7.54 (d, J=7.4Hz, 1H), 7.40-7.36 (m, 2H), 7.35-7.23 (m, 4H), 7.19-7.12 (m, 2H), 6.57 (d, J=9.6Hz, 1H), 4.64-4.59 (m, 1H), 3.88 (br, 2H), 3.34-3.25 (m, 4H), 2.56 (s, 3H), 2.41-2.20 (m, 4H), 1.93-1.82 (m, 10H), 1.62 (d, J=6.2Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 550.3182, obsd: 550.3169.

10

15

Example 402

Preparation of 5-chloro-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyridin-2(1H)-one



20

25


5-Chloro-3-[(4-{2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyridin-2(1H)-one (20 mg, 34%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo [3.2.1]oct-3-yl}-1H-benzimidazole

246

dihydrochloride (51 mg, 0.10 mmol), 5-chloro-2-hydroxypyridine-3-carboxylic acid (18 mg, 0.10 mmol) and HATU (38 mg, 0.10 mmol) by the similar procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J=8.4Hz, 1H), 7.51-7.45 (m, 2H), 7.40-7.35 (m, 2H), 7.31-7.24 (m, 4H), 7.22-7.12 (m, 2H), 4.64-4.58 (m, 1H), 4.15-4.08 (m, 2H), 3.45-3.23 (m, 6H), 2.57 (s, 3H), 2.42-2.26 (m, 5H), 1.94-1.85 (m, 10H), 1.60 (d, J=6.8Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 584.2792, obsd: 584.2785.

Example 403

10 Preparation of 3-chloro-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyridin-2-(1*H*)-one




15 3-Chloro-5-[(4-{2-[(1*R*, 5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyridin-2-(1*H*)-one (25 mg, 42%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo [3.2.1]oct-3-yl}-1*H*-benzimidazole dihydrochloride (51 mg, 0.10 mmol), 5-chloro-6-hydroxynicotinic acid (18 mg, 0.10 mmol) and HATU (38 mg, 0.10 mmol) by the similar procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.76 (s, 1H), 7.66-7.63 (m, 2H), 7.41-7.38 (m, 2H), 7.35-7.24 (m, 4H), 7.19-7.12 (m, 2H), 4.64-4.59 (m, 1H), 3.89 (br, 2H), 3.35-3.26 (m, 4H), 2.57 (s, 3H), 2.41-2.28 (m, 4H), 1.94-1.83 (m, 11H), 1.62 (d, J=7.9 Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 584.2792, obsd: 584.2787.

25

Example 404

Preparation of (2S)-N¹,N¹-bis{4-[2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-1-[N-(methanesulfonyl)-L-seryl]-4-phenylpiperidin-2-yl]-N²-(methanesulfonyl)-L-serinamide




5

(2S)-N¹,N¹-Bis{4-[2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-1-[N-(methanesulfonyl)-L-seryl]-4-phenylpiperidin-2-yl]-N²-(methanesulfonyl)-L-serinamide (43 mg, 50 %) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (70 mg, 0.14 mmol), N-(methanesulfonyl)-L-serine (28 mg, 0.15 mmol, prepared from L-serine and methanesulfonyl chloride) and HATU (57 mg, 0.15 mmol) by the similar procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J=8.4Hz, 1H), 7.40-7.36 (m, 2H), 7.29-7.23 (m, 4H), 7.19-7.12 (m, 2H), 5.78 (dd, J=8.6, 16.5Hz, 1H), 4.63-4.58 (m, 1H), 4.56-4.45 (m, 1H), 4.09-4.04 (m, 1H), 3.85-3.65 (m, 3H), 3.40-3.09 (m, 4H), 3.02 (s, 3/2H), 2.90 (s, 3/2H), 2.57 (s, 3H), 2.41-2.20 (m, 5H), 1.99-1.74 (m, 10H), 1.64-1.59 (m, 2H). HRMS *m/z* (M+H)⁺ calcd: 594.3114, obsd: 594.3114.

15

Example 405


Preparation of (2S,3R)-N¹,N¹-bis{4-[2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-1-[N-(methylsulfonyl)-L-threonyl]-4-phenylpiperidin-2-yl]-N²-(methylsulfonyl)-L-threoninamide



5

(2S, 3R)-N¹,N¹-Bis{4-[2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-1-[N-(methylsulfonyl)-L-threonyl]-4-phenylpiperidin-2-yl]-N²-(methylsulfonyl)-L-threoninamide (54 mg, 63%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (70 mg, 0.14 mmol), N-(methylsulfonyl)-L-threonine (33 mg, 0.17 mmol, prepared from L-threonine and methanesulfonyl chloride) and HATU (57 mg, 0.15 mmol) by the similar procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J=8.6Hz, 1H), 7.38-7.35 (m, 2H), 7.28-7.22 (m, 4H), 7.18-7.11 (m, 2H), 6.00 (br, 1H), 4.64-4.54 (m, 1H), 4.29 (d, J=9.7Hz, 1H), 4.08-4.00 (m, 1H), 3.94-3.91 (m, 1H), 3.77-3.71 (m, 1H), 3.40-3.06 (m, 5H), 2.98 (s, 3/2H), 2.84 (s, 3/2H), 2.56 (s, 3H), 2.39-2.20 (m, 4H), 1.98-1.73 (m, 10H), 1.62-1.57 (m, 2H), 1.32 (d, J=6.2Hz, 3/2H), 1.25 (d, J=6.2Hz, 3/2H). HRMS m/z (M+H)⁺ calcd: 608.3271, obsd: 608.3283.

20


Example 406Preparation of 1-(8-{2-[1-(isoxazol-3-ylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole

- 5 To a pre-cooled (0 °C) solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo [3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) in dichloromethane (3 mL) was added isoxazole-5-carbonyl chloride (7.2 mg, 0.055 mmol) and triethylamine (15 µL, 0.11 mmol). The resulting mixture was stirred overnight at ambient temperature and was
- 10 then diluted with ethyl acetate (20 mL). After being washed with saturated sodium bicarbonate solution, the organic phase was dried over anhydrous sodium sulfate and evaporated. The crude product was purified by flash chromatography on silical gel, eluting with a gradient of 0-10% methanol in ethyl acetate to afford 1-(8-{2-[1-(isoxazol-3-ylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole as
- 15 amorphous solid (18.4 mg, 68%). ¹H NMR (300 MHz, CDCl₃) δ 8.32 (d, J=1.8Hz), 7.67 (dd, J=2.6, 7.0Hz, 1H), 7.43-7.38 (m, 2H), 7.34-7.24 (m, 4H), 7.21-7.13 (m, 2H), 6.74 (d, J=1.8Hz), 4.64 (br, 1H), 4.23-4.18 (m, 1H), 3.93-3.89 (m, 1H), 3.45-3.27 (m, 4H), 2.58 (s, 3H), 2.44-2.31 (m, 4H), 1.96-1.86
- 20 (m, 10H), 1.67-1.60 (m, 2H). HRMS *m/z* (M+H)⁺ calcd: 524.3026, obsd: 524.3024.


Preparation of the derivatives of 2-Methyl-1-{8-[2-(4-Phenylpiperidin-4-yl)ethyl]-8-Azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole with Heterocycle-

25 Methylene-Piperidine Linkages by Reductive Amination


250

**Example 407**

Preparation of 2-methyl-1-(8-{2-[4-phenyl-1-(1,3-thiazol-2-ylmethyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




To a stirred solution of 2-methyl-1-(8-{2-[4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) in 1,2-dichloroethane (1 mL) was added triethylamine (14 μ L, 0.1 mmol), 2-thiazole-carboxaldehyde (6.6 mg, 0.05 mmol) and sodium triacetoxylborohydride (10.6 mg, 0.05 mmol). The resulting mixture was stirred for 4 hours at ambient temperature before it was quenched with saturated sodium bicarbonate solution. The aqueous phase was extracted with ethyl acetate (2 x 10 mL). The combined extracts was washed with brine and dried over anhydrous sodium sulfate. After evaporation of the solvents, the residue was brought to a flash chromatography on silical gel, eluting with a gradient of 0-10% methanol in ethyl acetate to afford 2-methyl-1-(8-{2-[4-phenyl-1-(1,3-thiazol-2-ylmethyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole (23 mg, 87%). ^1H NMR (300 MHz, CDCl_3) δ 7.79-7.65 (m, 2H), 7.46-7.37 (m, 2H), 7.34-7.15 (m, 7H), 5.32 (br, 1H), 3.68 (s, 2H), 3.54 (br, 2H), 2.82-2.80 (m, 2H), 2.67 (s, 3H), 2.63-2.47 (m, 4H), 2.25 (br, 4H), 2.08-1.96 (m, 8H), 1.86 (br, 2H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd: 526.3004, obsd: 526.3008.

Example 408Preparation of 1-(8-{2-[1-(1H-imidazol-2-ylmethyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole

- 5 1-(8-{2-[1-(1H-imidazol-2-ylmethyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (9.9 mg, 39%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) and imidazol-2-carboxaldehyde (14.4 mg, 0.15 mmol)
- 10 following the procedure outlined in example 407. ¹H NMR (300 MHz, CDCl₃) δ 9.78 (s, 10H), 7.69 (d, J=7.1 Hz, 2H), 7.41-7.27 (m, 5H), 7.25-7.17 (m, 3H), 7.03 (s, 2H), 4.68-4.63 (m, 1H), 3.63 (s, 2H), 3.26 (br, 2H), 2.66-2.64 (m, 2H), 2.60 (s, 3H), 2.45-2.35 (m, 4H), 2.20-2.10 (m, 4H), 1.96-1.71 (m, 8H), 1.63 (d, J=7.7Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 509.3393, obsd: 509.3393.

15

Example 409Preparation of 1-(8-{2-[1-(2-furylmethyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole

- 20 1-(8-{2-[1-(2-Furylmethyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (18.4 mg, 72 %) was obtained as oil from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) and 2-furaldehyde (4.8 mg, 0.05 mmol) following the procedure
- 25 outlined in example 407. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=7.0Hz, 1H), 7.40-7.19 (m, 9H), 6.34 (s, 1H), 6.19 (s, 1H), 4.68-4.61 (m, 1H), 3.50 (s, 2H),


252

3.25 (br, 2H), 2.67 (br, 2H), 2.60 (s, 3H), 2.45-2.26 (m, 6H), 1.96-1.80 (m, 10H), 1.62 (d, $J=7.8\text{Hz}$, 2H). HRMS m/z ($M+H$)⁺ calcd: 509.3280, obsd: 509.3276.

5

Example 410

Preparation of (4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid




(4-{2-[3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid (5.2 mg, 21 %) was obtained as oil from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydro-chloride (25.3 mg, 0.05 mmol) and glyoxylic acid monohydrate (4.6 mg, 0.05 mmol) following the procedure outlined in example 407. ¹H NMR (300 MHz; CDCl₃) δ 7.69 (s, 1H), 7.44 (d, $J=7.3\text{ Hz}$, 2H), 7.33-7.28 (m, 4H), 7.21 (br, 2H), 4.63 (m, 1H), 3.93-3.85 (m, 3H), 3.32 (br, 2H), 3.10-3.06 (m, 2H), 2.63 (s, 3H), 2.54-2.33 (m, 4H), 2.01-1.90 (m, 11H), 1.68 (d, $J=7.7\text{Hz}$, 2H). HRMS m/z ($M+H$)⁺ calcd: 487.3073, obsd: 487.3089.

20

Example 411

Preparation of 2,3-dimethoxy-6-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)methyl]benzoic acid




2,3-Dimethoxy-6-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)methyl]benzoic acid

25

(14.4 mg, 46%) was obtained as oil from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) and 6-formyl-2,3-dimethoxybenzoic acid (10.5 mg, 0.05 mmol) following the procedure outlined in example 407. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J=7.4 Hz, 1H), 7.41-7.39 (m, 2H), 7.30-7.23 (m, 4H), 7.23-7.14 (m, 2H), 6.81-6.77 (m, 2H), 4.63-4.58 (m, 1H), 3.95 (s, 3H), 3.86 (s, 3H), 3.65 (s, 2H), 3.23 (br, 2H), 2.95 (br, 2H), 2.57 (s, 3H), 2.42-2.38 (m, 6H), 1.94-1.81 (m, 10H), 1.62 (d, J=7.7 Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 623.3597, obsd: 623.3585.


Preparation of Substituted Phenyl Acetic Acid Derivatives of 2-Methyl-1-{8-[2-(4-Phenylpiperidin-4-yl)ethyl]-8-Azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole by Petasis Coupling



15

Example 412


Preparation of (4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)(phenyl)acetic acid



To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) in THF (3 mL) was added triethyl amine (14 μ L), glyoxylic acid monohydrate (4.6 mg, 0.05 mmol) and phenyl boronic acid (6.1 mg, 0.05 mmol). The resulting mixture was then purged with nitrogen and sealed. After being heated to 60 °C for 3 hours, the solvent was evaporated and the residue was purified by flash chromatography on silical gel, eluting with a gradient of 10-80% methanol in ethyl acetate to afford (4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)(phenyl)acetic acid (22 mg, 76%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.41 (s, 1H), 7.53-7.48 (m, 3H), 7.36-7.34 (m, 8H), 7.24-7.23 (m, 1H), 7.17-7.09 (m, 2H), 4.58-4.45 (m, 1H), 4.20 (s, 1H), 3.24-3.21 (m, 2H), 3.08 (br, 1H), 2.82-2.65 (m, 2H), 2.82-2.65 (m, 2H), 2.44 (s, 3H), 2.39-2.05 (m, 7H), 1.83-1.68 (m, 8H), 1.59 (d, *J*=7.6Hz, 2H). HRMS *m/z* (*M*+*H*)⁺ calcd: 563.3386, obsd: 563.3390.

Example 413

Synthesis of methyl (4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)(phenyl)acetate



20


To a stirred solution of (4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)(phenyl)acetic acid (prepared above) (12 mg, 0.02 mmol) in methanol (2 mL) was added (trimethylsilyl)diazomethane (100 μ L, 2.0 M in hexans). The reaction mixture was stirred for 30 minutes at room temperature. After evaporation of the solvents, the residue was purified by flash chromatography, eluting with a gradient of 0-10% methanol in ethyl acetate, to afford an oil (10 mg, 81%) as

25

methyl (4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)(phenyl)acetate. ¹H NMR (300 MHz, CDCl₃) δ 7.67 (d, J=7.1Hz, 1H), 7.45-7.42 (m, 2H), 7.37-7.27 (m, 8H), 7.23-7.15 (m, 3H), 4.61 (m, 1H), 3.89 (s, 1H), 3.67 (s, 3H), 3.25-3.24 (m, 2H), 2.72-2.70 (m, 1H), 2.55 (s, 4H), 2.42-2.16 (m, 6H), 2.03-1.85 (m, 7H), 1.81-1.76 (m, 3H), 1.61-1.58 (m, 2H). HRMS *m/z* (M+H)⁺ calcd: 577.3543, obsd: 577.3557.

Example 414


Preparation of (5-chlorothiophen-2-yl)(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid



(5-Chlorothiophen-2-yl)(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid (29 mg, 96%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) and 5-chlorothiophene-2-boronic acid (8.1 mg, 0.05 mmol) following the procedure outlined in example 412. ¹H NMR (300 MHz, DMSO-*d*₆, 100°C) δ 7.50-7.45 (m, 1H), 7.38-7.32 (m, 5H), 7.17-7.12 (m, 3H), 6.99-6.86 (m, 2H), 4.61-4.57 (m, 1H), 4.30-4.24 (m, 1H), 3.23 (br, 3H), 2.82-2.80 (m, 3H), 2.57-2.37 (m, 7H), 2.14 (br, 2H), 1.93-1.77 (m, 8H), 1.64-1.61 (m, 2H). HRMS *m/z* (M+H)⁺ calcd: 603.2561, obsd: 603.2552.

Example 415


Preparation of (4-methoxyphenyl)(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid



5 (4-Methoxyphenyl)(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid (25.6 mg, 86%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) and 4-methoxyphenylboronic acid (7.6
10 mg, 0.05 mmol) following the procedure outlined in example 412. ¹H NMR (300 MHz, DMSO-*d*₆, 80°C) δ 9.44 (s, 1H), 7.52 (d, *J*=7.0Hz, 1H), 7.38-7.36 (m, 7H), 7.24-7.21 (m, 1H), 7.17-7.12 (m, 2H), 6.92 (d, *J*=8.2Hz, 2H), 4.60-4.51 (m, 1H), 4.04 (s, 1H), 3.78 (s, 3H), 3.26-3.22 (m, 3H), 2.97-2.90 (m, 2H), 2.75 (br, 1H), 2.47 (s, 3H), 2.40-1.81 (m, 9H), 1.63 (d, *J*=7.3Hz, 2H). HRMS
15 *m/z* (*M*+*H*)⁺ calcd: 593.3492, obsd: 593.3496.

Example 416

Preparation of (4-fluorophenyl)(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid




20

(4-Fluorophenyl)(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid (24.5 mg, 84%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-


257

phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) and 4-fluorophenylboronic acid (7 mg, 0.05 mmol) following the procedure outlined in example 412. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.52-7.48 (m, 3H), 7.37-7.35 (m, 4H), 7.24-7.05 (m, 6H), 4.54-4.48 (m, 1H), 4.07 (s, 1H), 3.23 (br, 2H), 2.98 (br, 1H), 2.69-2.63 (m, 2H), 2.45 (s, 3H), 2.42-2.31 (m, 3H), 2.18 (br, 2H), 2.00 (br, 2H), 1.87-1.74 (m, 8H), 1.59 (d, *J*=7.3Hz, 2H). HRMS *m/z* (*M*+*H*)⁺ calcd: 581.3293, obsd: 581.3287.

10

Example 417Synthesis of methyl (4-fluorophenyl)(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetate


Methyl (4-fluorophenyl)(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetate (12 mg, 96%) was obtained as a solid from (4-fluorophenyl)(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid (12 mg, 0.02 mmol) and (trimethylsilyl)diazomethane (100 μL 2.0 M in hexanes) following the procedure outlined for example 9. ¹H NMR (300 MHz, CDCl₃) δ 7.67 (d, *J*=7.1Hz, 1H), 7.47-7.45 (m, 1H), 7.41-7.38 (m, 2H), 7.32-7.29 (m, 5H), 7.17-7.11 (m, 3H), 7.09-7.06 (m, 2H), 4.60-4.40 (m, 1H), 4.00 (s, 1H), 3.54 (s, 3H), 3.17 (br, 2H), 2.60-2.43 (m, 1H), 2.43-2.41 (m, 4H), 2.33-2.25 (m, 2H), 2.24-2.20 (m, 1H), 2.19-2.00 (m, 3H), 1.78-1.69 (m, 10H), 1.54 (d, *J*=7.5Hz, 2H). HRMS *m/z* (*M*+*H*)⁺ calcd: 595.3448, obsd: 595.3467.

Example 418Preparation of 1,3-benzodioxol-5-yl(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid

5 1,3-Benzodioxol-5-yl(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid (25 mg, 81%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole dihydrochloride (25.3 mg, 0.05 mmol) and 3,4-dioxolmethylenepheryl boronic acid (9.3 mg, 0.05 mmol) following the procedure outlined in example 412. ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.40 (s, 1H), 7.52 (m, 1H), 7.38-7.37 (m, 5H), 7.24 (m, 1H), 7.17-7.08 (m, 3H), 6.96-6.87 (m, 2H), 6.03 (d, *J*=5.1Hz, 2H), 4.45-4.48 (m, 1H), 4.16 (s, 1H), 3.23-3.08 (m, 5H), 2.82 (br, 2H), 2.45 (s, 3H), 2.40-2.01 (m, 6H), 1.82-1.79 (m, 7H), 1.60 (d, *J*=7.4Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 607.3284, obsd: 607.3270.

10

15

Example 419Preparation of (2,6-dimethylphenyl)(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid

20


(2,6-Dimethylphenyl)(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid (26 mg, 90%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole

259


dihydrochloride (25.3 mg, 0.05 mmol) and 2,6-dimethylphenyl boronic acid (9 mg, 0.06 mmol) following the procedure outlined in example 412. ¹H NMR (300 MHz, DMSO-d₆) δ 9.31 (s, 1H), 7.48 (d, J=6.9Hz, 1H), 7.33-7.32 (m, 5H), 7.19-7.17 (m, 1H), 7.13-6.96 (m, 5H), 4.5-4.49 (m, 1H), 4.29 (s, 1H), 3.24 (br, 2H), 2.83 (br, 1H), 2.41 (s, 3H), 2.37 (m, 7H), 2.29-2.07 (m, 5H), 1.97-1.72 (m, 10H), 1.58 (d, J=7.2Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 591.3699, obsd: 591.3690.

Example 420


10 Preparation of (2,3-dimethylphenyl)(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid



(2,3-Dimethylphenyl)(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid (35 mg, 99%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (30 mg, 0.06 mmol) and 2,3-dimethylphenyl boronic acid (10.5 mg, 0.07 mmol) following the procedure outlined in example 412. ¹H NMR (300 MHz, DMSO-d₆) δ 9.37 (s, 1H), 7.49-7.47 (m, 1H), 7.39-7.32 (m, 6H), 7.22-7.18 (m, 1H), 7.13-7.03 (m, 4H), 4.5-4.44 (m, 2H), 3.23 (br, 2H), 3.04-2.88 (m, 2H), 2.71 (br, 1H), 2.56-2.51 (m, 1H), 2.39 (s, 3H), 2.36-2.29 (m, 2H), 2.25 (s, 3H), 2.22 (s, 3H), 2.15-1.93 (m, 5H), 1.81 (br, 7H), 1.58 (d, J=7.2Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 591.3699, obsd: 591.3706.

Example 421Synthesis of methyl (2,3-dimethylphenyl)(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetate

5 Methyl (2,3-dimethylphenyl)(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetate (40 mg, 66%) was obtained as a solid from (2,3-Dimethylphenyl)(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid (40 mg, 0.067 mmol) and (trimethylsilyl)diazomethane (300 μ L
10 2.0 M in hexanes) following the procedure outlined for example 9. ^1H NMR (300 MHz, CDCl_3) δ 7.67 (d, $J=7.8\text{Hz}$, 1H), 7.44-7.27 (m, 6H), 7.23-7.15 (m, 3H), 7.10-7.07 (m, 2H), 4.66-4.59 (m, 1H), 4.30 (s, 1H), 3.65 (s, 3H), 3.25 (br, 2H), 2.77 (br, 1H), 2.67 (br, 1H), 2.56 (s, 3H), 2.47-2.32 (m, 3H), 2.29 (s, 6H), 2.26-2.12 (m, 3H), 1.99-1.83 (m, 10H), 1.61-1.59 (m, 2H). HRMS m/z ($M+H$) $^+$
15 calcd: 605.3856, obsd: 605.3863.


Example 422Preparation of (3,5-dimethylphenyl)(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid

20

3,5-Dimethylphenyl)(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)acetic acid (28 mg, 94%) was obtained as amorphous solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole


dihydrochloride (25 mg, 0.05 mmol) and 3,5-dimethylphenyl boronic acid (9.0 mg, 0.06 mmol) following the procedure outlined in example 412. ^1H NMR (300 MHz, DMSO-d_6) δ 9.37 (s, 1H), 7.48-7.47 (m, 1H), 7.35-7.33 (m, 5H), 7.23-7.19 (m, 1H), 7.11-7.07 (m, 4H), 6.94 (s, 1H), 4.53-4.47 (m, 1H), 4.13 (s, 1H), 3.23-3.15 (m, 4H), 2.83 (br, 2H), 2.39 (s, 3H), 2.36-2.25 (m, 3H), 2.21 (s, 6H), 2.14 (m, 4H), 1.81-1.70 (m, 8H), 1.58 (d, $J=7.6\text{Hz}$, 2H). HRMS m/z (M+H) $^+$ calcd: 591.3699, obsd: 591.3707.

Preparation of ortho-, meta- and para-Carboxyl Benzamide Derivatives of 2-Methyl-1-{8-[2-(4-Phenylpiperidin-4-yl)ethyl]-8-Azabicyclo[3.2.1]oct-3-yl}-1H-Benzimidazole



Example 423

Preparation of ethyl 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate




5 To a stirred solution of 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid (58 mg, 0.1 mmol) in dichloromethane (5 mL) was added ethanol (8.6 μ L, 0.1 mmol) and triethyl amine (13 μ L, 0.1 mmol). The resulting mixture was then cooled down on an ice-water bath before the addition of 1-[3-

10 (dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (19 mg, 0.1 mmol) and 4-dimethylamino-pyridine (catalytic amount). After being stirred overnight at ambient temperature, the reaction mixture was diluted with dichloromethane (40 mL) and washed with saturated sodium bicarbonate solution. The organic phase was dried over anhydrous sodium sulfate. After

15 evaporation of the solvent, the crude product was purified by flash chromatography on silical gel, eluting with a gradient of 0-10% methanol in ethyl acetate to afford methyl 4-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate as amorphous solid (29 mg, 50%). ^1H NMR (300 MHz, CDCl_3) δ 8.01 (d, J=7.9Hz, 1H), 7.64 (d, J=7.6Hz, 1H), 7.53 (br, 1H), 7.42 (t, J=7.6Hz, 1H), 7.37-7.33 (m, 2H), 7.28-7.20 (m, 4H), 7.17-7.10 (m, 3H), 4.61-4.53 (m, 1H), 4.25 (br, 3H), 3.26-3.19 (m, 4H), 3.08 (br, 1H), 2.52 (s, 3H), 2.39-2.30 (m, 3H), 1.98-1.76 (m, 11H), 1.59 (d, J=7.8Hz, 2H), 1.37-1.18 (br, 3H). HRMS m/z (M+H) $^+$ calcd: 605.3491, obsd: 605.3496.

Example 424


Preparation of isopropyl 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate



Isopropyl 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate (12 mg, 19%) was obtained as an oil from 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid (58 mg, 0.1 mmol), isopropyl alcohol (10 μ L, 0.15 mmol) and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (19 mg, 0.1 mmol) followed the procedure outlined in example 423. ^1H NMR (400 MHz, CDCl_3) δ 8.00 (d, $J=7.7\text{Hz}$, 1H), 7.64 (d, $J=7.7\text{Hz}$, 1H), 7.52 (br, 1H), 7.42 (t, $J=7.6\text{Hz}$, 1H), 7.37-7.33 (m, 2H), 7.28-7.20 (m, 4H), 7.18-7.10 (m, 3H), 5.22-5.08 (m, 1H), 4.63-4.53 (m, 1H), 4.34-3.67 (m, 2H), 3.26-3.00 (m, 4H), 2.53 (s, 3H), 2.48-2.30 (m, 2H), 2.17-2.07 (br, 2H), 1.96-1.62 (m, 10H), 1.59 (d, $J=7.3\text{Hz}$, 2H), 1.35-1.09 (m, 6H). HRMS m/z ($M+H$) $^+$ calcd: 619.3648, obsd: 619.3637.

Example 425

Preparation of 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzamide



To a stirred solution of 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid (69 mg, 0.12 mmol) in methylene chloride (4 mL) was added ammonia (1 mL, 0.5 M in dioxane), triethylamine (18 μ L, 0.12 mmol) and HATU (46 mg, 0.12

mmol). The reaction mixture was stirred for 3 hours at ambient temperature before being diluted with methylene chloride and quenched with saturated sodium bicarbonate solution. The organic phase was dried over anhydrous sodium sulfate. After evaporation of the solvent, the crude product was


5 purified by flash chromatography on silical gel, eluting with a gradient of 0-20% methanol in ethyl acetate to afford 2-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzamide (57 mg, 83%) ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J=8.6Hz, 1H), 7.56 (d, J=7.3Hz, 1H), 7.46-7.42 (m, 2H), 7.38-7.34 (m, 2H),

10 7.30-7.21 (m, 4H), 7.18-7.08 (m, 3H), 6.91 (br, 1H), 5.74 (br, 1H), 4.63-4.54 (m, 1H), 4.26 (br, 1H), 3.47-3.08 (m, 5H), 2.54 (s, 3H), 2.40-2.30 (m, 3H), 2.11-2.06 (m, 1H), 1.97-1.80 (m, 10H), 1.59 (d, J=7.9Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 576.3338, obsd: 576.3337.

15

Example 426

Preparation of 2-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-*N*-propylbenzamide



20

2-[(4-{2-[3-(2-Methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-*N*-propylbenzamide (74 mg, quant.) was obtained as an oil from 2-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo-[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid (69 mg, 0.12 mmol), propylamine (14 mg, 0.24 mmol) and HATU (46 mg, 0.12


25 mmol) following the procedure outlined in example 425. ¹H NMR (400 MHz, CDCl₃) δ 7.76-7.74 (m, 1H), 7.65 (d, J=7.3Hz, 1H), 7.43 (br, 2H), 7.37-7.34 (m, 2H), 7.30-7.23 (m, 4H), 7.18-7.11 (m, 3H), 6.88-6.73 (br, 1H), 4.63-4.54 (m, 1H), 4.19 (br, 1H), 3.36-3.06 (m, 7H), 2.54 (s, 3H), 2.40-2.29 (m, 3H),

265

2.11-2.08 (m, 1H), 1.97-1.79 (m, 9H), 1.72-1.53 (m, 5H), 1.25-0.83 (m, 3H).
HRMS m/z (M+H)⁺ calcd: 618.3808, obsd: 618.3811.

Example 427

5 Preparation of N-cyclopropyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzamide




N-Cyclopropyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzamide (61
10 mg, 83%) was obtained as an oil from 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid (69 mg, 0.12 mmol), cyclopropylamine (14 mg, 0.24 mmol) and HATU (46 mg, 0.12 mmol) following the procedure outlined in
example 425. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J=7.9Hz, 1H), 7.65 (d, J=7.3Hz), 7.41-7.33 (m, 4H), 7.29-7.23 (m, 4H), 7.21-7.09 (m, 3H), 7.03-6.84 (m, 1H), 4.63-4.54 (m, 1H), 4.20-4.17 (m, 1H), 3.37-3.22 (m, 4H), 3.10-3.05 (m, 1H), 2.92-2.70 (m, 1H), 2.54 (s, 3H), 2.36-2.29 (m, 3H), 2.11 (br, 1H), 1.98-1.61 (m, 10H), 1.59 (d, J=7.9Hz, 2H), 0.86-0.47 (m, 4H). HRMS m/z (M+H)⁺ calcd: 616.3651, obsd: 616.3649.

20

Example 428

Preparation of 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]nicotinamide




25

To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (51 mg, 0.12 mmol) in dichloro-

methane (4 mL) was added 2,3-pyridinedicarboxylic anhydride (18 mg, 0.12 mmol) and triethylamine (17 μ L, 0.12 mmol). The resulting mixture was stirred for 2 hours at ambient temperature before addition of ammonia (1 mL, 0.5 M in doxane) and 47 mg of HATU. The reaction mixture was then stirred
 5 for another 2 hours. After being diluted with methylene chloride and washed with saturated sodium bicarbonate solution, the organic phase was dried over anhydrous sodium sulfate. Evaporation of the solvent and purification by flash chromatography afforded 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]nicotinamide
 10 as a foam (51 mg, 69%). ^1H NMR (300 MHz, CDCl_3) δ 8.63-8.61 (m, 1H), 8.17 (d, $J=6.8\text{Hz}$, 1H), 7.66-7.64 (m, 2H), 7.38-7.33 (m, 3H), 7.30-7.22 (m, 4H), 7.20-7.10 (m, 2H), 5.79 (s, 1H), 4.61-4.55 (m, 1H), 4.27-4.22 (m, 1H), 3.40-3.08 (m, 5H), 2.54 (s, 3H), 2.47-2.33 (m, 3H), 2.19-2.15 (m, 1H), 1.97-1.80 (m, 10H), 1.63-1.61 (m, 2H). HRMS m/z ($M+H$) $^+$ calcd: 577.3291, obsd:
 15 577.3286.

Example 429

Preparation of 2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-N-propylnicotinamide
 20




2-[(4-{2-[3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-N-propylnicotinamide (68 mg, 99%) was obtained as a foam from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (51 mg, 0.12 mmol), 2,3-pyridinedicarboxylic anhydride (18 mg, 0.12 mmol), propylamine (14 mg, 0.24 mmol) and HATU (47 mg, 0.12 mmol), following the procedure outlined in example 428. ^1H NMR (400 MHz, CDCl_3) δ 8.62-8.60 (m, 1H), 8.16 (d, $J=7.9\text{Hz}$, 1H), 7.65 (d, $J=8.6\text{Hz}$, 1H), 7.57 (t, $J=5.7\text{Hz}$, 1H), 7.39-7.33 (m, 3H),
 25

7.30-7.21 (m, 4H), 7.18-7.11 (m, 2H), 4.61-4.56 (m, 1H), 4.27-4.22 (dt, $J=13.2, 4.3\text{Hz}$, 1H), 3.38-3.31 (m, 3H), 3.22-3.06 (m, 4H), 2.54 (s, 3H), 2.40-2.31 (m, 3H), 2.17-2.14 (m, 1H), 1.92-1.80 (m, 10H), 1.62-1.52 (m, 4H), 0.93 (t, $J=7.3\text{Hz}$, 3H). HRMS m/z (M+H)⁺ calcd: 619.3761, obsd: 619.3785.


5

Example 430

Preparation of N-cyclopropyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]nicotinamide




10 N-Cyclopropyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]nicotinamide (58 mg, 78%) was obtained as a foam from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (51 mg, 0.12 mmol), 2,3-pyridinedicarboxylic anhydride (18 mg, 0.12 mmol),
 15 cyclopropylamine (14 mg, 0.24 mmol) and HATU (47 mg, 0.12 mmol) following the procedure outlined in example 428. ¹H NMR (400 MHz, CDCl₃) δ 8.56-8.54 (m, 1H), 8.03 (d, $J=7.8\text{Hz}$, 1H), 7.80 (s, 1H), 7.65 (d, $J=7.0\text{Hz}$, 1H), 7.37-7.22 (m, 5H), 7.20-7.12 (m, 2H), 4.62-4.55 (m, 1H), 4.23-4.19 (m, 1H), 3.35 (t, $J=10.6\text{Hz}$, 1H), 3.22-3.06 (m, 4H), 2.89-2.87 (m, 1H), 2.54 (s, 3H),
 20 3H), 2.47-2.33 (m, 3H), 2.18-2.09 (m, 1H), 1.88-1.83 (m, 10H), 1.61-1.58 (m, 2H), 0.84-0.62 (m, 2H), 0.59-0.56 (m, 2H). HRMS m/z (M+H)⁺ calcd: 617.3604, obsd: 617.3627.

Example 431Preparation of methyl 4-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate

5 To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (50.5 mg, 0.1 mmol) in dichloromethane (5 mL) was added terephthalic acid monomethyl ester (18 mg, 0.1 mmol) and triethyl amine (30 μ L, 0.2 mmol). The resulting mixture was then cooled down on an ice-water bath before the addition of 1-

10 [3-(dimethylamino)propyl]-3-ethylcarbo-diimide hydrochloride (19 mg, 0.1 mmol) and 4-dimethylaminopyridine (catalytic amount). After being stirred overnight at ambient temperature, the reaction mixture was diluted with dichloromethane (40 mL) and washed with saturated sodium bicarbonate solution. The organic phase was dried over anhydrous sodium sulfate. After


15 evaporation of the solvent, the crude product was purified by flash chromatography on silical gel, eluting with a gradient of 0-10% methanol in ethyl acetate to afford methyl 4-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate as amorphous solid (65 mg, quant.). ^1H NMR (300 MHz, CDCl_3) δ 8.11 (d, J=8.2Hz, 2H), 7.69 (d, J=7.2Hz, 1H), 7.47 (d, J=8.2Hz, 2H), 7.41 (d, J=7.3Hz, 2H), 7.34-7.24 (m, 4H), 7.21-7.15 (m, 2H), 4.66 (br, 1H), 4.26-4.21 (m, 1H), 3.97 (s, 3H), 3.52-3.30 (m, 5H), 2.60 (s, 3H), 2.40 (br, 3H), 2.21-2.17 (br, 1H), 1.99-1.79 (m, 10H), 1.68-1.66 (m, 2H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd: 591.3335, obsd: 591.3320.

Example 432Preparation of isopropyl 3-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate

5 Isopropyl 3-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate (10 mg, 16%) was obtained as an oil from 3-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid (70 mg, 0.12 mmol), isopropyl alcohol (10 μ L, 0.12 mmol) and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (23 mg, 0.12 mmol) following the procedure outlined in example 423. ^1H NMR (400 MHz, CDCl_3) δ 8.06 (d, $J=7.9\text{Hz}$, 1H), 8.04 (s, 1H), 7.64 (d, $J=7.2\text{Hz}$, 1H), 7.54 (d, $J=7.7\text{Hz}$, 1H), 7.46 (t, $J=7.7\text{Hz}$, 1H), 7.39-7.35 (m, 1H), 7.29-7.26 (m, 4H), 7.18-7.11 (m, 3H), 5.25-5.22 (m, 1H), 4.59 (br, 1H), 4.20 (br, 1H), 3.52 (br, 1H), 3.35 (br, 1H), 3.24 (br, 3H), 2.54 (s, 3H), 2.37-2.32 (m, 3H), 2.16 (br, 1H), 1.92-1.75 (m, 10H), 1.60 (d, $J=7.7\text{Hz}$, 2H), 1.35 (d, $J=6.2\text{Hz}$, 6H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd: 619.3648, obsd: 619.3649.

Example 433

20 Preparation of 4-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid





25 4-[(4-{2-[3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoic acid (15 mg, 43 %) was obtained as white powder from methyl 4-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-

yl)carbonyl]benzoate following the procedure outlined in the previous example. HRMS m/z (M+H)⁺ calcd: 577.3179, obsd: 577.3189.

Preparation of Carboxamides and Carboxthioamides of 2-Methyl-1-[8-[2-(4-Phenylpiperidin-4-yl)ethyl]-8-Azabicyclo[3.2.1]oct-3-yl]-1H-Benzimidazole


5



Example 434Preparation of N-cyano-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide

5 To a precooled (0 °C) solution of phenyl *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboximidoate (27 mg, 0.047mmol) in a mixed solvent of THF-H₂O (2 mL, 3:1) was added lithium hydroxide monohydrate (7.7 mg, 0.18 mmol). After stirring for 3 hours on an ice-water bath, the reaction mixture was diluted with
10 dichloromethane (20 mL) and buffered with saturated sodium bicarbonate solution (10 mL). The aqueous phase was extracted with dichloromethane (3x 10 mL). The combined extracts were washed with brine and dried over anhydrous sodium sulfate. After evaporation of solvents, the residue was purified by flash chromatography on silical gel, eluting with a gradient of 10-
15 30% methanol in ethyl acetate to afford *N*-cyano-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide as a white solid (20 mg, 83%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.46 (d, *J*=7.1Hz, 1H), 7.33-7.29 (m, 5H), 7.17-7.14 (m, 1H), 7.11-7.04 (m, 2H), 4.53-4.48 (m, 1H), 4.09 (br, 1H), 3.55-3.51 (m, 2H), 3.21 (br, 2H), 3.06-
20 3.03 (m, 2H), 2.45 (s, 3H), 2.37-2.29 (m, 2H), 1.87-1.64 (m, 10H), 1.59-1.55 (m, 4H). ¹³C NMR (125 MHz, DMSO-*d*₆) δ 165.0, 152.3, 146.7, 143.7, 134.0, 128.9, 127.3, 126.2, 125.0, 121.8, 121.4, 119.4, 111.6, 57.2, 55.6, 49.3, 48.0, 46.3, 36.3, 35.9, 30.0, 21.8, 14.9. HRMS *m/z* (*M*+*H*)⁺ calcd: 497.3029, obsd: 497.3026.


25

Example 435Preparation of N-isopropyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide

5 To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (20 mg, 0.047 mmol) in THF (2 mL) was added isopropyl isocyanate (4.3 mg, 0.047 mmol). The resulting mixture was stirred at ambient temperature overnight. After evaporation of the solvent, the residue was purified on silical gel, eluting with a gradient of

10 10-30% methanol in ethyl acetate to afford *N*-isopropyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide as white solid (15 mg, 63%). ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, J=7.2Hz, 1H), 7.43-7.38 (m, 2H), 7.34-7.24 (m, 4H), 7.22-7.15 (m, 2H), 4.67 (br, 1H), 4.24 (d, J=7.3Hz, 1H), 3.99 (m, 1H), 3.62-3.58 (m, 2H), 3.30 (br,

15 2H), 3.23-3.16 (m, 2H), 2.62 (s, 3H), 2.42 (br, 2H), 2.25-2.20 (m, 2H), 1.98-1.83 (m, 9H), 1.68 (br, 2H), 1.17 (d, J=6.4Hz, 6H). HRMS *m/z* (M+H)⁺ calcd: 514.3546, obsd: 514.3530.

Example 436Preparation of N-(tert-butyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide

N-(*tert*-Butyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo-[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide (39 mg, quant.) was


25 obtained as syrup from 2-methyl-1-{8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (30 mg, 0.07 mmol) and *t*-butyl isocyanate (6.9 mg, 0.07 mmol) following the procedure outlined in example

273

435. ^1H NMR (300 MHz, CDCl_3) δ 7.68 (d, $J=7.5\text{Hz}$, 1H), 7.41-7.36 (m, 2H), 7.32-7.22 (m, 4H), 7.20-7.13 (m, 2H), 4.75 (br, 1H), 4.31 (s, 1H), 3.57-3.53 (m, 2H), 3.35 (br, 2H), 3.18-3.12 (m, 2H), 2.62 (s, 3H), 2.47 (br, 2H), 2.22-2.17 (m, 2H), 1.97-1.81 (m, 10H), 1.71 (br, 2H), 1.34 (s, 9H). HRMS m/z (M+H) $^+$ calcd: 528.3702, obsd: 528.3722.

Example 437

Preparation of ethyl N-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]glycinate



10


- Ethyl N-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl piperidin-1-yl)carbonyl]glycinate (25 mg, 64%) was obtained as an oil from 2-methyl-1-{8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (30 mg, 0.07 mmol) and ethyl isocyanatoacetate (9 mg, 0.07 mmol) following the procedure outlined in example 435. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.46 (d, $J=7.2\text{Hz}$, 1H), 7.37-7.32 (m, 5H), 7.20-7.17 (m, 1H), 7.11-7.04 (m, 2H), 6.88 (t, $J=5.6\text{Hz}$, 1H), 4.51-4.47 (m, 1H), 4.02 (q, $J=7.1\text{Hz}$, 2H), 3.66 (d, $J=5.7\text{Hz}$, 2H), 3.51-3.47 (m, 2H), 3.20 (br, 2H), 3.05 (t, $J=9.7\text{Hz}$, 2H), 2.46 (s, 3H), 2.36-2.29 (m, 2H), 1.99 (br, 2H), 1.84-1.70 (m, 10H), 1.55 (d, $J=7.5\text{Hz}$, 2H), 1.13 (t, $J=7.2\text{Hz}$, 3H). HRMS m/z (M+H) $^+$ calcd: 558.3444, obsd: 558.3445.

20

Example 438

Preparation of N-cyclohexyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide


25



N-Cyclohexyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide (34 mg, 88%) was obtained as an oil from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (30 mg, 0.07 mmol) and cyclohexyl isocyanate (8.8 mg, 0.07 mmol) following the procedure outlined in example 435. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.46 (d, *J*=7.1Hz, 1H), 7.34-7.30 (m, 5H), 7.19-7.16 (m, 1H), 7.11-7.04 (m, 2H), 6.03 (d, *J*=7.7Hz, 1H), 4.51-4.46 (m, 1H), 3.47-3.43 (m, 2H), 3.35-3.34 (m, 1H), 3.19 (br, 2H), 3.04-2.99 (m, 2H), 2.45 (s, 3H), 2.36-2.28 (m, 2H), 2.00-1.95 (m, 2H), 1.81-1.67 (m, 14H), 1.61-1.51 (m, 3H), 1.19-1.00 (m, 5H). HRMS *m/z* (M+H)⁺ calcd: 554.3859, obsd: 554.3863.


Example 439

Preparation of 4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-*N*-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide




4-{2-[3-(2-Methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-*N*-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide (27 mg, 88%) was obtained as an oil from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (22 mg, 0.05mmol) and *p*-trifluoromethylphenyl isocyanate (9 mg, 0.05mmol) following the procedure outlined in example 435. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.83 (s, 1H), 7.65 (d, *J*=8.2Hz, 2H), 7.53 (d, *J*=8.2Hz, 2H), 7.45 (d, *J*=6.9Hz, 1H), 7.39-7.32 (m, 5H), 7.20 (t, *J*=7.0Hz, 1H), 7.10-7.06 (m, 2H), 4.50 (m, 1H), 3.70-3.66 (m, 2H), 3.21 (br, 4H), 2.46 (s, 3H), 2.34-2.29 (m, 2H), 2.11-2.07 (m, 2H), 1.84-1.71 (m, 10H), 1.55 (d, *J*=7.5Hz, 2H). HRMS *m/z* (M+H)⁺ calcd: 616.3263, obsd: 616.3258.

275

Example 440Preparation of N-isopropyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide

5 *N*-Isopropyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide (28 mg, quant.) was obtained as an oil from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (22 mg, 0.05 mmol) and isopropyl isothiocyanate (5.5 mg, 0.05 mmol) following the procedure
 10 outlined in example 435. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.46 (d, *J*=7.1 Hz, 1 H), 7.37-7.32 (m, 5 H), 7.20-7.15 (m, 2 H), 7.11-7.05 (m, 2 H), 4.53-4.45 (m, 1 H), 4.00-3.97 (m, 2 H), 3.48-3.43 (m, 2 H), 3.20 (br, 2 H), 2.46 (s, 3 H), 2.36-2.28 (m, 2 H), 2.06-2.01 (m, 2 H), 1.82-1.70 (m, 10 H), 1.55 (d, *J*=7.5 Hz, 2 H), 1.09 (d, *J*=6.6 Hz, 6 H). HRMS *m/z* (*M*+*H*)⁺ calcd: 530.3317, obsd:
 15 530.3310.

Example 441Preparation of N-methyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide

20 *N*-Methyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl piperidine-1-carbothioamide (23 mg, 92%) was obtained as an oil from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (22 mg, 0.05 mmol)
 25 and methyl isothiocyanate (4 mg, 0.055 mmol) following the procedure outlined in example 435. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.57 (d, *J*=4.1 Hz,


276

1H), 7.46 (d, J=7.1Hz, 1H), 7.38-7.27 (m, 5H), 7.19 (t, J=6.8Hz, 1H), 7.11-7.05 (m, 2H), 4.54-4.44 (m, 1H), 4.02-3.97 (m, 2H), 3.46-3.41 (m, 2H), 3.20 (br, 2H), 2.86 (d, J=3.9Hz, 3H), 2.46 (s, 3H), 2.41-2.28 (m, 2H), 2.07-2.03 (m, 2H), 1.91-1.70 (m, 10H), 1.55 (d, J=7.5Hz, 2H). HRMS m/z (M+H)⁺ calcd:

5 502.3004, obsd: 502.2994.

Example 442

Preparation of N-cyclohexyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide



10


N-Cyclohexyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide (26.9mg, 94%) was obtained as an oil from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (22mg, 0.05mmol)

15


and cyclohexyl isothiocyanate (7.7mg, 0.05mmol) following the procedure outlined in example 435. ¹H NMR (400 MHz, DMSO-d₆) δ 7.46 (d, J=7.2 Hz, 1 H), 7.37-7.32 (m, 5 H), 7.20-7.17 (m, 1 H), 7.13-7.05 (m, 3 H), 4.51-4.47 (m, 1 H), 4.14 (br, 1 H), 4.00-3.97 (m, 2 H), 3.45 (t, J=9.7 Hz, 2 H), 3.20 (br, 2 H), 2.46 (s, 3 H), 2.36-2.28 (m, 2 H), 2.05-2.01 (m, 2 H), 1.82-1.67 (m, 15 H), 1.55

20

(d, J=7.8 Hz, 2 H). 1.23-1.15 (m, 4 H). HRMS m/z (M+H)⁺ calcd: 570.3630, obsd: 570.3629.

Example 443Preparation of N-(4-fluorobenzyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide

5 N-(4-Fluorobenzyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide (27.6mg, 93%) was obtained as an oil from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (22mg, 0.05mmol) and 4-fluorobenzyl isothiocyanate (9.0mg, 0.054mmol) following the
 10 procedure outlined in example 435. ¹H NMR (400 MHz, DMSO-d₆) δ 8.13 (t, J=5.4 Hz, 1 H), 7.46 (d, J=7.5 Hz, 1 H), 7.39-7.30 (m, 5 H), 7.29-7.26 (m, 2 H), 7.20 (t, J=6.8 Hz, 1 H), 7.11-7.05 (m, 4 H), 4.73 (d, J=5.5 Hz, 2 H), 4.51-4.47 (m, 1 H), 4.07 (br, 2 H), 3.51 (t, J=9.9 Hz, 2 H), 3.21 (br, 2 H), 2.46 (s, 3 H), 2.41-2.29 (m, 2 H), 2.09-2.05 (m, 2 H), 1.83-1.71 (m, 10 H), 1.56 (d, J=7.7
 15 Hz, 2 H). HRMS *m/z* (M+H)⁺ calcd: 596.3223, obsd: 596.3232.

Example 444Preparation of N,N-dimethyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide


20

At 0 °C, to a stirred solution of phosgen (0.25 mL, 2.0 in toluene) was added a solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (71 mg, 0.17mmol) in methylene chloride and triethylamine (excess). The mixture was stirred for 30 minutes at
 25 0 °C and further one hour at room temperature. Nitrogen gas was then introduced to remove the excess phosgen. To this mixture was added


excess dimethylamine and the resulting mixture was stirred overnight at ambient temperature. After being diluted with methylene chloride, the organic phase was washed with brine, dried over anhydrous sodium sulfate and purified by flash chromatography. *N,N*-dimethyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl] ethyl}-4-phenylpiperidine-1-carboxamid was obtained as foam (52 mg, 63%). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J=7.3 Hz, 1 H), 7.37-7.34 (m, 2 H), 7.31-7.29 (m, 3 H), 7.23-7.12 (m, 3 H), 4.61 (br, 1 H), 3.44-3.38 (m, 2 H), 3.25 (br, 2 H), 3.12-3.06 (m, 2 H), 2.80 (s, 6 H), 2.58 (s, 3 H), 2.38-2.36 (m, 2 H), 2.19-2.15 (m, 2 H), 1.93-1.81 (m, 10 H), 1.61 (d, J=7.3 Hz, 2 H). HRMS *m/z* (M+H)⁺ calcd: 500.3389, obsd: 500.3386.

Example 445

Preparation of *N,N*-diethyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide




N,N-Diethyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide (50 mg, 57%) was obtained as an oil from 2-methyl-1-{8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]-oct-3-yl}-1*H*-benzimidazole (71 mg, 0.17mmol), phosgen and diethylamine following the procedure outlined in example 444. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J=7.3 Hz, 1 H), 7.37-7.29 (m, 5H), 7.23-7.12 (m, 3 H), 4.64-4.58 (m, 1 H), 3.41-3.35 (m, 2 H), 3.24-3.23 (m, 2 H), 3.17 (q, J=7.2 Hz, 4 H), 3.10-3.04 (m, 2 H), 2.57 (s, 3 H), 2.40-2.32 (m, 2 H), 2.19-2.15 (m, 2 H), 1.94-1.80 (m, 10 H), 1.60 (d, J=7.7 Hz, 2 H), 1.10 (t, J=7.0 Hz, 6 H). HRMS *m/z* (M+H)⁺ calcd: 528.3702, obsd: 528.3712.

Example 446Preparation of N, N-diallyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide

5 *N, N*-Diallyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide (42 mg, 46%) was obtained as an oil from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (71 mg, 0.17 mmol), phosgen and diallylamine following the procedure outlined in example 444.

10 ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J=7.1 Hz, 1 H), 7.37-7.33 (m, 2 H), 7.30-7.29 (m, 3 H), 7.23-7.12 (m, 3 H), 5.86-5.76 (m, 2 H), 5.18-5.13 (m, 4 H), 4.61 (br, 1 H), 3.72 (d, J=5.5Hz, 4 H), 3.47-3.41 (m, 2 H), 3.24 (br, 2 H), 3.12-3.06 (m, 2 H), 2.57 (s, 3 H), 2.40-2.32 (m, 2 H), 2.20-2.15 (m, 2 H), 1.99-1.80 (m, 10 H), 1.60 (d, J=7.7 Hz, 2 H). HRMS *m/z* (M+H)⁺ calcd: 552.3702, obsd:

15 552.3701.

Example 447Preparation of N-ethyl-N-methyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide

20 *N*-Ethyl-*N*-methyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide (53 mg, 62%) was obtained as an oil from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (71 mg, 0.17mmol),


25 phosgen and *N*-ethyl-*N*-methylamine following the procedure outlined in example 444. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J=7.1 Hz, 1 H), 7.37-7.33

(m, 2 H), 7.31-7.29 (m, 3 H), 7.23-7.12 (m, 3 H), 4.63-4.59 (m, 1 H), 3.41-3.36 (m, 2 H), 3.24 (br, 2 H), 3.18 (q, J=7.1 Hz, 2 H), 3.11-3.04 (m, 2 H), 2.77 (s, 3 H), 2.57 (s, 3 H), 2.40-2.32 (m, 2 H), 2.19-2.15 (m, 2 H), 1.99-1.80 (m, 10 H), 1.60 (d, J=7.9 Hz, 2 H), 1.12 (t, J=7.1 Hz, 3 H). HRMS m/z (M+H)⁺ calcd:

5 514.3546, obsd: 514.3526.

Example 448

Preparation of N,N-diisopropyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxamide



10

To a flask containing phosgen (2 mL, 2 M in toluene) in methylene chloride (10 mL) was added triethylamine (75 μ L, 0.5 mmol) and diisopropylamine (76 μ L, 0.5 mmol). The mixture was stirred at room temperature for 4 hours before nitrogen gas was introduced to remove excess phosgen. To this freshly prepared chlorodiisopropyl carbamate was added 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (85 mg, 0.2 mmol) and triethylamin (60 μ L, 0.4 mmol). The resulting mixture was stirred overnight at ambient temperature. The excess chlorocarbamate was quenched with 1 mL of methanol. After evaporation of solvent, the residue was directly purified by flash chromatography, eluting with a gradient of 0-5% methanol in ethyl acetate, to afford an oil (81 mg, 73%).


20

¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J=7.4 Hz, 1 H), 7.37-7.33 (m, 2 H), 7.31-7.30 (m, 3 H), 7.22-7.12 (m, 3 H), 4.63-4.59 (m, 1 H), 3.62-3.55 (m, 2 H), 3.29-3.23 (m, 4 H), 3.03-2.97 (m, 2 H), 2.57 (s, 3 H), 2.40-2.32 (m, 2 H), 2.18-2.14 (m, 2 H), 1.95-1.80 (m, 10 H), 1.60 (d, J=7.9 Hz, 2 H), 1.26 (d, J=6.6 Hz, 6 H). HRMS m/z (M+H)⁺ calcd: 556.4015, obsd: 556.4008.

25

Example 449

Preparation of N, N-dimethyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide




5 *N, N*-Dimethyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide (58 mg, 75%) was obtained as a foam from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]-oct-3-yl}-1*H*-benzimidazole dihydrochloride (75 mg, 0.15mmol), thiophosgen and dimethylamine following the procedure
10 outlined in example 444. ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J=7.1 Hz, 1 H), 7.45-7.35 (m, 2 H), 7.32-7.29 (m, 3 H), 7.25-7.19 (m, 1 H), 7.17-7.12 (m, 2 H), 4.63-4.58 (m, 1 H), 3.75-3.70 (m, 2 H), 3.32-3.24 (m, 4 H), 3.10 (s, 6 H), 2.58 (s, 3 H), 2.40-2.33 (m, 2 H), 2.26-2.22 (m, 2 H), 1.97-1.82 (m, 10 H), 1.61 (d, J=7.9 Hz, 2 H). HRMS *m/z* (M+H)⁺ calcd: 516.3161, obsd: 516.3158.

15

Example 450

Preparation of N-ethyl-N-methyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide




20 *N*-Ethyl-*N*-methyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide (62 mg, 78%) was obtained as a foam from 2-methyl-1-{8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]-oct-3-yl}-1*H*-benzimidazole dihydrochloride (75 mg, 0.15mmol), thiophosgen and *N*-ethyl-*N*-methylamine following the
25 procedure outlined in example 444. ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J=7.2 Hz, 1 H), 7.38-7.34 (m, 2 H), 7.31-7.29 (m, 3 H), 7.24-7.21 (m, 1 H),

7.18-7.12 (m, 2 H), 4.63-4.58 (m, 1 H), 3.72-3.66 (m, 2 H), 3.61 (q, J=7.0 Hz, 2 H), 3.31-3.24 (m, 4 H), 3.03 (s, 3 H), 2.57 (s, 3 H), 2.40-2.32 (m, 2 H), 2.26-2.21 (m, 2 H), 1.97-1.82 (m, 10 H), 1.60 (d, J=7.8 Hz, 2 H), 1.21 (t, J=7.1 Hz, 3 H). HRMS m/z (M+H)⁺ calcd: 530.3317, obsd: 530.3301.

5

Example 451


Preparation of N, N-diethyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide



10 *N,N*-Diethyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide (51 mg, 62%) was obtained as a foam from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole dihydrochloride (75 mg, 0.15mmol), thiophosgen and diethylamine following the procedure
15 outlined in example 444. ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J=7.4 Hz, 1 H), 7.38-7.34 (m, 2 H), 7.32-7.29 (m, 3 H), 7.25-7.21 (m, 1 H), 7.19-7.12 (m, 2 H), 4.63-4.59 (m, 1 H), 3.72-3.68 (m, 2 H), 3.57 (q, J=7.1 Hz, 4 H), 3.30-3.25 (m, 4 H), 2.58 (s, 3 H), 2.40-2.33 (m, 2 H), 2.25-2.21 (m, 2 H), 1.97-1.82 (m, 10 H), 1.61 (d, J=7.7 Hz, 2 H), 1.18 (t, J=7.1 Hz, 6 H). HRMS m/z (M+H)⁺
20 calcd: 544.3474, obsd: 544.3482.

Example 452

Preparation of N, N-diallyl-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide




25

N, N-Diallyl-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carbothioamide (55 mg,

65%) was obtained as a foam from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (75 mg, 0.15 mmol), thiophosgen and diallylamine following the procedure outlined in example 444. ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J=7.1 Hz, 1 H), 7.38-7.35 (m, 2 H), 7.31-7.29 (m, 3 H), 7.25-7.21 (m, 1 H), 7.19-7.12 (m, 2 H), 5.91-5.81 (m, 2 H), 5.23-5.17 (m, 4 H), 4.63-4.58 (m, 1 H), 4.10 (d, J=5.6 Hz, 4 H), 3.82-3.79 (m, 2 H), 3.35-3.25 (m, 4 H), 2.59 (s, 3 H), 2.40-2.32 (m, 2 H), 2.27-2.23 (m, 2 H), 1.97-1.80 (m, 10 H), 1.61 (d, J=7.9 Hz, 2 H). HRMS *m/z* (M+H)⁺ calcd: 568.3474, obsd: 568.3470.

Example 453


Preparation of 1-((1R,5S)-8-{2-[1-(1H-imidazol-1-ylcarbonothioyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (214 mg, 0.5 mmol) in methylene chloride was added 1-(1H-imidazol-1-ylcarbonothioyl)-1H-imidazole (89 mg, 0.5 mmol). The resulting mixture was stirred overnight. After evaporation of the solvents, the crude product was purified by flash chromatography, eluting with a gradient of 0-5% methanol in ethyl acetate, to afford 1-((1R, 5S)-8-{2-[1-(1H-imidazol-1-ylcarbonothioyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole as a foam (200 mg, 74%). ¹H NMR (400 MHz, CDCl₃) δ 7.83 (s, 1 H), 7.65 (d, J=7.1 Hz, 1 H), 7.42-7.39 (m, 2 H), 7.31-7.28 (m, 4 H), 7.19-7.10 (m, 3 H), 7.07 (s, 1 H), 4.62-4.56 (m, 1 H), 3.53 (br, 1 H), 3.24-3.22 (m, 2 H), 2.56 (s, 3 H), 2.40-2.32 (m, 4 H), 1.99-1.81 (m, 10 H), 1.62 (d, J=7.9 Hz, 2 H). HRMS *m/z* (M+H)⁺ calcd: 539.2957, obsd: 539.2958.

Preparation of N-acyl and N-sulfonyl guanidine Derivatives of 2-Methyl-1-{8-[2-(4-Phenylpiperidin-4-yl)ethyl]-8-Azabicyclo[3.2.1]-oct-3-yl}-1H-benzimidazole


Synthesis of Acyl and Sulfonyl Derivatives



5

Example 454

Preparation of N-[(1E)-[(4-chlorophenyl)amino](4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)methylidene]-2,2-dimethylpropanamide



10

To a solution of trimethylacetamide (10 mg, 0.1 mmol) in DMF (0.5 mL) was added sodium hydride (60%, 5.2 mg, 0.13 mmol). After stirring for 5 minutes, 4-chlorophenylisothiocyanate (17 mg, 0.1 mmol) was added. The reaction mixture was stirred at 60 °C for one hour before being cooled down to room temperature. To this reaction mixture was then added 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]-oct-3-yl}-1H-benzimidazole (35 mg, 0.08mmol), EDCI (19 mg, 0.1 mmol) and a catalytic amount of DMAP. After stirring at ambient temperature overnight, the reaction was quenched with water and extracted with dichloromethane (4x10 mL). The organic phase was washed with brine and dried over sodium sulfate. The solvent was removed and the residue was purified by flash chromatography on silical gel,


20

285

eluting with a gradient of 0-15% methanol in ethyl acetate to afford *N*-[(1*E*)-[(4-chlorophenyl)amino](4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)methylidene]-2,2-dimethylpropanamide as amorphous solid (20 mg, 38%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.9 (s, 1 H), 7.46 (d, *J*=8.8 Hz, 1 H), 7.39-7.33 (m, 6 H), 7.22-7.19 (m, 1 H), 7.13-7.05 (m, 3 H), 6.61 (d, *J*=8.6 Hz, 2 H), 4.51-4.47 (m, 1 H), 3.80-3.40 (m, 2 H), 3.26-3.13 (m, 4 H), 2.46 (s, 3 H), 2.37-2.30 (m, 2 H), 2.14 (br, 2 H), 1.85-1.71 (m, 10 H), 1.56 (d, *J*=7.4 Hz, 2 H), 0.88 (s, 9 H). HRMS *m/z* (*M*+*H*)⁺ calcd: 665.3735, obsd: 665.3741.



Example 455

Preparation of *N*-[(1*E*)-[(4-chlorophenyl)amino](4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)methylidene]methane-sulfonamide




N-[(1*E*)-[(4-Chlorophenyl)amino](4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)methylidene]methanesulfonamide (38 mg, 73%) was obtained as amorphous solid from methanesulfonamide (9.5 mg, 0.1 mmol), 4-chlorophenyl isothiocyanate (17 mg, 0.1 mmol) and 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (35 mg, 0.08mmol) following the procedure outlined in example 454. ¹H NMR (400 MHz, CDCl₃) δ 8.39 (s, 1H), 7.64 (d, *J*=7.1 Hz, 1H), 7.37-7.33 (m, 2H), 7.30-7.21 (m, 6H), 7.19-7.10 (m, 2H), 6.89 (d, *J*=8.6 Hz, 2H), 4.59-4.53 (m, 1H), 3.61 (d, *J*=13.5 Hz, 2H), 3.19 (br, 2H), 3.04 (t, *J*=11 Hz, 2H), 2.96 (s, 3H), 2.53 (s, 3H), 2.37-2.29 (m, 2 H), 2.20-2.16 (m, 2 H), 1.90-1.84 (m, 6H), 1.82-1.71 (m, 4H), 1.58 (d, *J*=7.4 Hz, 2H). HRMS *m/z* (*M*+*H*)⁺ calcd: 659.2935, obsd: 659.2935.

286

**Example 456**

- 5 To a stirred solution of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (505 mg, 1.0 mmol) in dichloromethane (20 mL) was added Boc- α -methyl alanine (203 mg, 1.0 mmol), triethylamine (470 μ L, 3.0 mmol) and HATU (380 mg, 1.0 mmol). The resulting mixture was stirred at ambient temperature overnight before
- 10 being quenched with saturated sodium bicarbonate. The layers were separated and the aqueous was extracted with dichloromethane. The combined organic phase was dried over anhydrous sodium sulfate. After evaporation of the solvent, the crude product was purified by flash chromatography on silical gel, eluting with a gradient of 0-8% methanol in
- 15 ethyl acetate to afford compound 456 as amorphous solid (579 mg, 94%). ^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, $J=7.1$ Hz, 1 H), 7.38-7.34 (m, 1 H), 7.30-7.20 (m, 3 H), 7.19-7.13 (m, 3 H), 5.04 (s, 1 H), 4.65-4.61 (m, 1 H), 4.09-4.02 (m, 2H), 3.29-3.20 (m, 5 H), 2.58 (s, 3 H), 2.44-2.36 (m, 2 H), 2.22-2.20 (m, 2 H), 1.95-1.89 (m, 5 H), 1.84-1.78 (m, 4 H), 1.64 (d, $J=7.8$ Hz, 2 H), 1.49 (s, 5
- 20 H), 1.39-1.35 (m, 10 H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd: 614.4070, obsd: 614.4086.

Example 457Preparation of 2-methyl-1-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-1-oxopropan-2-amine

5


To a stirred solution of the product from example 456 (307 mg, 0.50 mmol) in methylene chloride was added HCl (2 mL, 4 M in dioxane). The reaction mixture was stirred for one hour at ambient temperature.

Evaporation of solvents directly afforded 240 mg (99%) of white solid, which was then partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic phase was dried over anhydrous sodium sulfate. After removal of the solvent, the desired product was obtained as foam. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J=7.1 Hz, 1 H), 7.39-7.35 (m, 2 H), 7.31-7.22 (m, 4 H), 7.19-7.12 (m, 2 H), 4.64 (m, 1 H), 4.13-4.11 (m, 2 H), 3.40 (br, 2 H), 3.27 (br, 2 H), 2.57 (s, 3 H), 2.52-2.24 (m, 4 H), 1.94-1.91 (m, 4 H), 1.88-1.68 (m, 8 H), 1.63 (d, J=7.9 Hz, 2 H), 1.41 (s, 6 H). HRMS *m/z* (M+H)⁺ calcd: 514.3546, obsd: 514.3561.

15

Example 458

20 Preparation of (2S)-N,N-bis(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-D-prolylpiperidin-2-yl)-D-prolinamide




25 The Boc protected precursor was prepared from L-Boc-proline (47 mg, 0.15 mmol), 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-

azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole (64 mg, 0.15 mmol) and HATU (57 mg, 0.15 mmol), following the procedure outlined in example 456. After removal of Boc protecting group with a solution of 4*N* HCl in dioxane, (2*S*)-*N*, *N*- bis(4-{2-[(1*R*, 5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-*D*-prolyl-piperidin-2-yl)-*D*-prolinamide was obtained as an oil (80 mg, quant.). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, *J*=7.4 Hz, 1 H), 7.40-7.36 (m, 2 H), 7.30-7.28 (m, 3 H), 7.25-7.23 (m, 1 H), 7.21-7.12 (m, 2 H), 4.65-4.55 (m, 1 H), 4.11-4.02 (m, 1 H), 3.93-3.84 (m, 1 H), 3.68-3.63 (m, 1 H), 3.32-3.14 (m, 5 H), 2.85-2.73 (m, 1 H), 2.57 (s, 3 H), 2.40-2.24 (m, 6 H), 2.15-1.50 (m, 5 H). HRMS *m/z* (M+H)⁺ calcd: 526.3546, obsd: 526.3565.

Example 459

Preparation of N²-acetyl-N¹, N¹-bis(1-(N-acetyl-2-methylalanyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-2-yl)-2-methylalaninamide




At 0 °C, to a stirred solution of 2-methyl-1-(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-1-oxopropan-2-amine dihydrochloride (40 mg, 0.068mmol, obtained from compound 456 by removal of Boc protecting group with 4 M HCl in ether) in dichloromethane was added acetyl bromide (8.6 mg, 0.068 mmol), *N,N*-diethyl-isopropylamine (42 μL, 0.24 mmol) and DMAP (1 mg). The resulting mixture was stirred for 3 hours before being quenched with saturated sodium bicarbonate. The layers were separated and the aqueous layer was extracted with dichloromethane. The combined organic phase was dried over anhydrous sodium sulfate. After evaporation of the solvent, the crude product was purified by flash chromatography on silical gel, eluting with a


gradient of 0-10% methanol in ethyl acetate to afford N^2 -acetyl- N^1 , N^1 -bis(1-(N -acetyl-2-methylalanyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-2-yl)-2-methylalaninamide as amorphous solid (34 mg, 90%). ^1H NMR (400 MHz, CDCl_3), δ 7.67 (d, $J=6.5$ Hz, 1 H), 7.40-7.37 (m, 2 H), 7.30-7.26 (m, 3 H), 7.24-7.13 (m, 3 H), 7.07 (s, 1 H), 4.03-4.00 (m, 1 H), 3.67-3.61 (m, 2 H), 3.34 (t, $J=7.8$ Hz, 1 H), 3.08 (q, $J=7.3$ Hz, 1 H), 2.79-2.61 (m, 4 H), 2.43-2.08 (m, 6 H), 2.06-1.92 (m, 4 H), 1.85-1.80 (m, 2 H), 1.58 (s, 3 H), 1.54 (s, 3 H), 1.52-1.51 (m, 4 H), 1.43 (d, $J=6.6$ Hz, 4H). HRMS m/z ($M+H$) $^+$ calcd: 556.3651, obsd: 556.3647.

Example 460

Preparation of N^2 -(2,2-dimethylpropanoyl)- N^1 , N^1 -bis(1-[N -(2,2-dimethylpropanoyl)-2-methylalanyl]-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-2-yl)-2-methylalaninamide




N^2 -(2,2-dimethylpropanoyl)- N^1 , N^1 -bis(1-[N -(2,2-dimethylpropanoyl)-2-methylalanyl]-4-{2-[(1*R*, 5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1] oct-8-yl]ethyl}-4-phenylpiperidin-2-yl)-2-methyl alaninamide (17 mg, 42%) was obtained as an oil from 2-methyl-1-(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl piperidin-1-yl)-1-oxopropan-2-amine dihydrochloride (40 mg, 0.068 mmol) and pivaloyl chloride (8.4 μL , 0.068 mmol) following the procedure outlined in the example 459. ^1H NMR (400 MHz, CDCl_3), δ 7.66 (d, $J=7.1$ Hz, 1 H), 7.40-7.36 (m, 2 H), 7.30-7.23 (m, 4 H), 7.19-7.12 (m, 2 H), 4.61 (br, 1 H), 3.99 (br, 2 H), 3.32-3.26 (m, 4 H), 2.57 (s, 3 H), 2.41-2.23 (m, 4 H), 1.93-1.76 (m, 9 H), 1.65 (s, 6 H), 1.63-1.61 (m, 2 H), 1.19 (s, 9 H). HRMS m/z ($M+H$) $^+$ calcd: 598.4121, obsd: 598.4116.

Example 461

The product in example 461 (9 mg, 29 %) was obtained from 2-methyl-1-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-1-oxopropan-2-amine dihydrochloride (26 mg, 0.05mmol), 5-oxo-D-proline (6.5 mg, 0.05mmol) and HATU (19 mg, 0.05mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.79(s, 1 H), 7.65 (d, J=7.2 Hz, 1 H), 7.40-7.36 (m, 2 H), 7.30-7.23 (m, 4 H), 7.19-7.12 (m, 2 H), 6.72 (s, 1 H), 4.63-4.58 (m, 1 H), 4.14-4.09 (m, 1 H), 3.97 (br, 2 H), 3.31-3.25 (m, 4 H), 2.57 (s, 3 H), 2.54-2.10 (m, 9 H), 1.93-1.75 (m, 10 H), 1.67-1.60 (m, 8 H). HRMS *m/z* (M+H)⁺ calcd: 625.3866, obsd: 625.3863.

Example 462

Preparation of 2-Methyl-1-(8-{2-[4-phenyl-1-(1H-pyrrol-2-ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole



2-Methyl-1-(8-{2-[4-phenyl-1-(1H-pyrrol-2-ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1] oct-3-yl)-1H-benzimidazole (58.5 mg, 75%) was obtained as a white solid from 2-methyl-1-{8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (64 mg, 0.15 mmol), 1H-pyrrole-2-carboxylic acid (16.6 mg, 0.15 mmol) and HATU (57 mg, 0.15 mmol), following the procedure outlined in example 5. ¹H NMR (300 MHz, DMSO-d₆) δ 12.5 (br, 1 H), 7.68 (s, 1 H), 7.53-7.46 (m, 2 H), 7.41-7.32 (m, 5 H), 7.22-7.18 (m, 1 H), 7.13-7.04 (m, 3 H), 4.53-4.47 (m, 1 H), 4.11 (br, 1 H),


291

3.85 (br, 1 H), 3.27-3.09 (m, 4 H), 2.46 (s, 3 H), 2.39-2.29 (m, 2 H), 2.0 (br, 2 H), 1.97-1.70 (m, 10 H), 1.57-1.55 (m, 2 H). HRMS m/z (M+H)⁺ calcd: 522.3233, obsd: 522.3226.

5

Example 463


Preparation of (5R)-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyrrolidin-2-one



10 (5R)-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl piperidin-1-yl)carbonyl]pyrrolidin-2-one (59 mg, 85%) was obtained as white solid from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (64 mg, 0.15 mmol), 5-oxo-D-proline (19 mg, 0.15 mmol) and HATU (57 mg, 0.15 mmol), following the
 15 procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J=8.8 Hz, 1 H), 7.40-7.36 (m, 2 H), 7.30-7.23 (m, 4 H), 7.18-7.11 (m, 2 H), 6.20 (s, ½ H), 6.09 (s, ½ H), 4.62-4.56 (m, 1 H), 4.50-4.42 (m, 1 H), 4.07-4.02 (m, 1 H), 3.58-3.55 (m, 1 H), 3.25-3.16 (m, 4 H), 2.56 (s, 3 H), 2.46-2.14 (m, 47 H), 2.03-1.73 (m, 11 H), 1.63-1.58 (m, 2 H). HRMS m/z (M+H)⁺ calcd: 540.3339,
 20 obsd: 540.3361.

Example 464


Preparation of 1-(8-{2-[1-(1H-imidazol-5-ylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



5 1-(8-{2-[1-(1H-imidazol-5-ylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (18 mg, 23 %) was obtained from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (64 mg, 0.15 mmol), 1H-imidazole-5-carboxylic acid (17 mg, 0.15 mmol) and HATU (57 mg, 0.15
10 mmol), following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 9.68 (s, 1 H), 7.66 (d, J=8.6 Hz, 1 H), 7.41-7.23 (m, 6 H), 7.19-7.12 (m, 2 H), 6.90 (s, 1 H), 6.51 (s, 1 H), 6.24 (s, 1 H), 4.64-4.58 (m, 1 H), 4.20-4.14 (m, 2 H), 3.48 (br, 1 H), 3.25 (br, 2 H), 2.56 (s, 3 H), 2.41-2.28 (m, 4 H), 2.01-1.81 (m, 10 H), 1.64-1.58 (m, 2 H). HRMS *m/z* (M+H)⁺ calcd: 523.3185,
15 obsd: 523.3204.

Example 465

Preparation of 3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenol




20 3-[(4-{2-[(1R, 5S)-3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenol (70 mg, 84 %) was obtained from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (64 mg, 0.15 mmol), 3-hydroxybenzoic acid (21 mg, 0.15 mmol) and HATU (57 mg, 0.15 mmol),
25 following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ

7.66 (d, $J=6.9$ Hz, 1 H), 7.39-7.35 (m, 2 H), 7.31-7.24 (m, 4 H), 7.21-7.13 (m, 3 H), 6.94 (s, 1 H), 6.88-6.85 (m, 1 H), 6.81 (d, $J=7.5$ Hz, 1 H), 4.64-4.55 (m, 1 H), 4.13 (br, 1 H), 3.59-3.56 (m, 1 H), 3.40-3.37 (m, 1 H), 3.27-3.24 (m, 3 H), 2.49 (s, 3 H), 2.44-2.34 (m, 2 H), 2.26 (br, 1 H), 2.18-2.15 (m, 1 H), 1.99-1.79 (m, 10 H), 1.63-1.61 (m, 2 H). HRMS m/z ($M+H$)⁺ calcd: 549.3230, obsd: 549.3240.

Example 466


Preparation of 4-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl acetate



4-[(4-{2-[(1*R*, 5*S*)-3-(2-Methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl acetate (68 mg, 77 %) was obtained as a foam from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (64 mg, 0.15 mmol), 4-(acetyloxy) benzoic acid (27 mg, 0.15 mmol) and HATU (57 mg, 0.15 mmol), following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, $J=8.4$ Hz, 1 H), 7.41-7.33 (m, 4 H), 7.30-7.22 (m, 4 H), 7.21-7.08 (m, 4 H), 4.64-4.54 (m, 1 H), 4.10 (br, 1 H), 3.58 (br, 1 H), 3.36-3.24 (m, 4 H), 2.54 (s, 3 H), 2.39-2.34 (m, 3 H), 2.30 (s, 3 H), 2.14 (br, 21 H), 1.98-1.82 (m, 10 H), 1.60 (d, $J=7.8$ Hz, 2 H). HRMS m/z ($M+H$)⁺ calcd: 591.3335, obsd: 591.3348.

Example 467

Preparation of 4-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenol




5 4-[(4-{2-[(1*R*, 5*S*)-3-(2-Methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenol (27 mg, 33%) was obtained as a foam from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (64 mg, 0.15 mmol), 4-hydroxybenzoic acid (21 mg, 0.15 mmol) and HATU (57 mg, 0.15 mmol),
 10 following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.67-7.64 (m, 1 H), 7.39-7.23 (m, 8 H), 7.23-7.13 (m, 2 H), 6.84 (d, J=8.4 Hz, 2 H), 4.67-4.54 (m, 1 H), 4.13 (br, 1 H), 3.71 (br, 1 H), 3.40-3.26 (m, 4 H), 2.51 (s, 3 H), 2.40-2.11 (m, 4 H), 1.95-1.82 (m, 10 H), 1.62 (d, J=8.0 Hz, 2 H). HRMS *m/z* (M+H)⁺ calcd: 549.3230, obsd: 548.3233.

15

Example 468

Preparation of 2-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenol



20 2-[(4-{2-[(1*R*, 5*S*)-3-(2-Methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenol (70 mg, 85%) was obtained as a syrupy from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (64 mg, 0.15 mmol), 2-hydroxybenzoic acid (21 mg, 0.15 mmol) and HATU (57 mg, 0.15 mmol),
 25 following the procedure outlined in example 5. ¹H NMR (300 MHz, CDCl₃) δ 9.81 (s, 1 H), 7.65 (d, J=7.8 Hz, 1 H), 7.42-7.31 (m, 2 H), 7.30-7.11 (m, 8 H),


295

7.00 (d, $J=8.1$ Hz, 1 H), 6.83 (t, $J=7.4$ Hz, 1 H), 4.67-4.53 (m, 1 H), 4.07-4.02 (m, 4 H), 3.40 (t, $J=10.7$ Hz, 1 H), 3.25 (br, 2 H), 2.55 (s, 3 H), 2.42-2.29 (m, 4 H), 1.94-1.80 (m, 10 H), 1.63-1.58 (m, 2 H). HRMS m/z ($M+H$)⁺ calcd: 549.3230, obsd: 548.3223.

5

Example 469

Preparation of 2-[(4-{2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl acetate




10 2-[(4-{2-[(1R, 5S)-3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl acetate (60 mg, 68%) was obtained as syrup from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (64 mg, 0.15 mmol), 2-(acetyloxy)benzoic acid (27 mg, 0.15 mmol) and HATU (57 mg, 0.15 mmol),
15 following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, $J=8.4$ Hz, 1 H), 7.43-7.32 (m, 3 H), 7.30-7.23 (m, 6 H), 7.21-7.12 (m, 3 H), 4.62-4.56 (m, 1 H), 4.16-4.11 (m, 1 H), 3.46-3.34 (m, 2 H), 3.23-3.20 (m, 3 H), 2.53 (s, 3 H), 2.41-2.27 (m, 4 H), 2.16-2.13 (m, 2 H), 1.92-1.79 (m, 11 H), 1.62-1.57 (m, 2 H). HRMS m/z ($M+H$)⁺ calcd: 591.3335, obsd: 591.3341.

20

Example 470

Preparation of 4-fluoro-2-[(4-{2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenol




25 4-Fluoro-2-[(4-{2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenol (58 mg,


85%) was obtained as a foam from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (51 mg, 0.12 mmol), 5-fluoro-2-hydroxybenzoic acid (19 mg, 0.12 mmol) and HATU (47mg, 0.12 mmol), following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 9.67 (br, 1 H), 7.65 (d, J=7.0 Hz, 1 H), 7.41-7.37 (m, 2 H), 7.32-7.24(m, 4 H), 7.21-7.12 (m, 2 H), 7.05-7.01 (m, 1 H), 7.00-6.86 (m, 2 H), 4.61 (br, 1 H), 4.04-4.00 (m, 2 H), 3.38 (t, J=10.8 Hz, 2 H), 3.25 (br, 2 H), 2.55 (s, 3 H), 2.40-2.20 (m, 4 H), 1.94-1.83 (m, 10 H), 1.63-1.61 (m, 2 H). HRMS *m/z* (M+H)⁺ calcd: 567.3135, obsd: 567.3130.

Example 471


Preparation of 3-fluoro-2-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenol




3-Fluoro-2-[(4-{2-[(1*R*, 5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenol (53 mg, 78%) was obtained as a foam from 2-methyl-1-{8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (51 mg, 0.12 mmol), 6-fluoro-2-hydroxy-benzoic acid (19 mg, 0.12 mmol) and HATU (47mg, 0.12 mmol), following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J=8.6 Hz, 1 H), 7.44-7.36 (m, 2 H), 7.31-7.24(m, 3 H), 7.22-7.12 (m, 4 H), 6.97 (d, J=8.4 Hz, 1 H), 6.58 (t, J=9.0 Hz, 1 H), 4.64-4.55 (m, 1 H), 4.20 (br, 1 H), 3.59 (br, 1 H), 3.33 (br, 2 H), 2.54 (s, 3 H), 2.39-2.20 (m, 4 H), 1.99-1.81 (m, 10 H), 1.60 (d, J=7.1 Hz, 2 H). HRMS *m/z* (M+H)⁺ calcd: 567.3135, obsd: 567.3117.

Example 472Preparation of 5-chloro-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenol


5 5-Chloro-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenol (46 mg, 66%) was obtained as a foam from 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (51 mg, 0.12 mmol), 4-chloro-2-hydroxybenzoic acid (21 mg, 0.12 mmol) and HATU (47mg, 0.12 mmol), following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J=7.3 Hz, 1 H), 7.41-7.37 (m, 2 H), 7.32-7.24 (m, 4 H), 7.21-7.12 (m, 3 H), 7.02 (s, 1 H), 6.82 (d, J=6.4 Hz, 1 H), 4.60 (br, 1 H), 4.02-3.99 (m, 2 H), 3.41-3.35 (m, 2 H), 3.25 (br, 2 H), 2.56 (s, 3 H), 2.36-2.29 (m, 4 H), 1.94-1.84 (m, 10 H), 1.63-1.62 (m, 2 H). HRMS *m/z* (M+H)⁺ calcd: 583.2840, 15 obsd: 583.2839.

Preparation of meta- and para- N-substituted sulfonamides

298




4-Chloro-3-(chlorosulfonyl)benzoic acid has been synthesized as described elsewhere in this application (Method G).




5

3-(Aminosulfonyl)-4-fluorobenzoic acid has been synthesized according to as Method G detailed elsewhere in this application.




2,6-Difluoro-3-(aminosulfonyl)benzoic acid, 2,6-dichloro-3-(aminosulfonyl)benzoic acid, 3,4-difluoro-5-(aminosulfonyl)benzoic acid and 2,6-methyl-3-(aminosulfonyl)benzoic acid were prepared with the similar procedure as above.

10


Preparation of 3-fluoro-4-methylbenzenesulfonamide

To ~20 mL of liquid ammonia at -78°C was added 2.1g (10 mmol) of 3-fluoro-4-methyl benzenesulfonyl chloride. The excess ammonia was then naturally evaporated to dryness overnight at room temperature. The crude sulfonamide was partitioned methylene chloride (100mL) and water (100 mL). The aqueous phase was further extracted with methylene chloride. The combined organic extracts were dried over anhydrous sodium sulfate. Evaporation of the solvents afforded 1.9 g of 3-fluoro-4-methylbenzenesulfonamide as a solid.

Preparation of 4-(aminosulfonyl)-2-fluorobenzoic acid

To a stirred solution of 3-fluoro-4-methyl-benzenesulfonamide (prepared above) in 50 mL of water was added sodium carbonate (0.53g, 5 mmol) and potassium permanganate (3.16g, 20 mmol) portionwise over three hours at 50~60 °C. The resulting mixture was stirred for further 8 hours at this temperature before 0.2 mL of formic acid was added to quench the excess of potassium permanganate. The mixture was then filtered through celite while it was still hot and further washed with the hot water. The filtrate was concentrated to ~30 mL and adjusted to pH 9~10. The filtration was applied again to remove non-oxidized starting material. The final filtrate was acidified with HCl (conc.) to ~ pH 1 and 4-(aminosulfonyl)-2-fluorobenzoic acid was precipitated and collected by filtration as white solid (1.10g, 50%).

The corresponding 4-(aminosulfonyl)-2-chlorobenzoic acid was prepared by the similar procedures.

Example 473Preparation of 2-chloro-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-*N*-propylbenzenesulfonamide


5

To a stirred solution of 4-chloro-3-(chlorosulfonyl)benzoic acid (25.4 mg, 0.1 mmol) in dichloromethane (3 mL) was added propylamine (9 μ L, 0.11 mmol), *N,N*-diisopropylethylamine (39mg, 0.3 mmol) and 4-*N,N*-dimethylaminopyridine (2 mg, 0.016 mmol). After the resultant mixture was stirred overnight, a solution of 2-methyl-1-[(1*R*,5*S*)-8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole dihydrochloride (50 mg, 0.1 mmol) in *N,N*-dimethylformamide (3 mL) was added and followed by addition of *N,N*-diisopropylethylamine (39mg, 0.3 mmol) and HATU (38 mg, 0.1 mmol). The reaction mixture was stirred for further 4 hours before it was quenched with saturated sodium bicarbonate solution and extracted with dichloromethane. The combined organic extracts were dried over anhydrous sodium sulfate. After evaporation of solvents, the residue was purified by flash chromatography, eluting with a gradient of 0~8% methanol in ethyl acetate to afford 2-chloro-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-*N*-propylbenzenesulfonamide as solid (30 mg, 43%). ^1H NMR (400 MHz, CDCl_3) δ 8.09 (s, 1 H), 7.65 (d, $J=8.4$ Hz, 1 H), 7.65 (s, 2 H), 7.38 (t, $J=7.5$ Hz, 2 H), 7.30-7.23 (m, 4 H), 7.19-7.12 (m, 2 H), 5.10 (t, $J=6.0$ Hz, 1 H), 4.64-4.59 (m, 1 H), 4.19 (br, 1 H), 3.48 (br, 1 H), 3.34-3.35 (m, 4 H), 2.90 (q, $J=6.3$ Hz, 2 H), 2.57 (s, 3 H), 2.42-2.34 (m, 3 H), 2.20 (br, 1 H), 1.94-1.78 (m, 10 H), 1.62 (d, $J=6.4$ Hz, 2 H), 1.54-1.45 (m, 2 H), 0.88 (t, $J=7.5$ Hz, 3 H). HRMS m/z ($M+H$) $^+$ calcd: 688.3088, obsd: 688.3063.

25

Example 474

Preparation of 2-chloro-N-isopropyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide



5


2-Chloro-N-isopropyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide (10 mg, 15%) was obtained as solid from 4-chloro-3-(chlorosulfonyl)benzoic acid (25.4 mg, 0.1 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (50 mg, 0.1 mmol) and isopropylamine (9.4 μ L, 0.11 mmol) following the procedure outlined in example 473. ^1H NMR (300 MHz, CDCl_3) δ 8.11 (s, 1 H), 7.67 (d, $J=7.0$ Hz, 1 H), 7.57 (s, 2 H), 7.42-7.37 (m, 2 H), 7.30-7.20 (m, 4 H), 7.18-7.12 (m, 2 H), 4.89 (d, $J=7.5$ Hz, 1 H), 4.64-4.59 (m, 1 H), 4.18 (br, 1 H), 3.49-3.29 (m, 6 H), 2.58 (s, 3 H), 2.38-2.16 (m, 4 H), 1.95-1.88 (m, 10 H), 1.65-1.63 (m, 2 H), 1.10 (d, $J=6.5$ Hz, 6 H). HRMS m/z ($M+H$) $^+$ calcd: 688.3088, obsd: 688.3093.

10

15

Example 475

Preparation of 2-chloro-N-cyclopropyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




2-Chloro-N-cyclopropyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide (15 mg, 22%) was obtained as solid from 4-

25

chloro-3-(chlorosulfonyl)benzoic acid (25.4 mg, 0.1 mmol), 2-methyl-1-
 {(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-
 benzimidazole dihydrochloride (50 mg, 0.1 mmole), cyclopropylamine (7.6 μ L,
 0.11 mmol) and HATU (38 mg, 0.1 mmol) following the procedure outlined in
 5 example 473. ^1H NMR (400 MHz, CDCl_3) δ 8.14 (s, 1 H), 7.66 (d, $J=7.0$ Hz, 1
 H), 7.59 (s, 2 H), 7.41-7.37 (m, 2 H), 7.30-7.20 (m, 4 H), 7.18-7.13 (m, 2 H),
 5.46 (s, 1 H), 4.65-4.60 (m, 1 H), 4.19 (br, 1 H), 3.50 (br, 1 H), 3.35-3.26 (m, 4
 H), 2.57 (s, 3 H), 2.43-2.35 (m, 3 H), 2.19 (br, 2 H), 1.94-1.78 (m, 10 H), 1.63
 (d, $J=7.9$ Hz, 2 H), 0.68-0.58 (m, 4 H). HRMS m/z ($M+H$) $^+$ calcd: 686.2932,
 10 obsd: 686.2935.

Example 476

Preparation of N-acetyl-4-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-
 15 azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene-
 sulfonamide




To a precooled (0 $^{\circ}\text{C}$) solution of 4-[(4-{2-[3-(2-methyl-1*H*-
 benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-
 yl)carbonyl]benzene-sulfonamide (20 mg, 0.033 mmol) in dichloromethane (2
 20 mL) was added acetyl bromide (4.2 mg, 0.034 mmol) and *N,N*-diisopropylethyl
 amine (12 μ L, 0.66 mmol). The resulting mixture was stirred overnight at
 ambient temperature. After evaporation of the solvent, the crude product was
 purified by flash chromatography on silical gel, eluting with a gradient of 15-
 30% methanol in ethyl acetate to afford *N*-acetyl-4-[(4-{2-[3-(2-methyl-1*H*-
 25 benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-
 yl)carbonyl]benzene-sulfonamide as amorphous solid (14 mg, 66%). ^1H NMR
 (300 MHz, $\text{DMSO}-d_6$) δ 7.83 (d, $J=8.1$ Hz, 2 H), 7.48-7.46 (m, 3 H), 7.37-7.33
 (m, 5 H), 7.21 (br, 1 H), 7.13-7.05 (m, 2 H), 4.51 (t, $J=8.1$, 1 H), 3.88 (br, 1
 H), 3.67-3.15 (m, 6 H), 2.42 (s, 3 H), 2.37-2.30 (m, 2 H), 2.11-2.07 (br, 2 H),

1.96-1.72 (m, 13 H), 1.59 (d, $J=7.4$, 2 H). HRMS m/z ($M+H$)⁺ calcd: 654.3114, obsd: 654.3095.

Example 477


5 Preparation of 4-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-N-propionylbenzenesulfonamide



4-[(4-{2-[3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-N-propionylbenzenesulfonamide (13 mg, 59%) was obtained from 4-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-benzenesulfonamide (20 mg, 0.033 mmol) and propionyl chloride as amorphous solid by the similar procedure outlined in example 476. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.87 (d, $J=8.0$ Hz, 2 H), 7.53-7.42 (m, 3 H), 7.39-7.35 (m, 5 H), 7.25-7.21 (m, 1 H), 7.15-7.07 (m, 2 H), 4.66 (br, 1 H), 3.90 (br, 1 H), 3.19-3.16 (m, 5 H), 2.45 (s, 3 H), 2.42-2.35 (m, 2 H), 2.22-2.09 (m, 5 H), 1.98-1.78 (m, 10 H), 1.66 (d, $J=7.3$ Hz, 2 H), 1.17 (t, $J=7.2$ Hz, 3 H). HRMS m/z ($M+H$)⁺ calcd: 668.3271, obsd: 668.3256.

Example 478

20 Preparation of N-butyryl-4-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




25 N-butyryl-4-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (15

mg, 68%) was obtained from 4-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-benzenesulfonamide (20 mg, 0.033 mmol) and butyryl chloride by the similar procedure outlined in example 476. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.87 (d, J=8.1 Hz, 2 H), 7.52-7.4 (m, 3 H), 7.39-7.35 (m, 5 H), 7.25-7.21 (m, 1 H), 7.15-7.07 (m, 2 H), 4.69 (br, 1 H), 3.89 (br, 1 H), 3.16 (m, 5 H), 2.45 (s, 3 H), 2.42-2.35 (m, 2 H), 2.23-2.05 (m, 5 H), 1.98-1.78 (m, 10 H), 1.68-1.66 (m, 2 H), 1.40 (q, J=7.3 Hz, 2 H), 1.17 (t, J=7.3 Hz, 3 H). HRMS *m/z* (M+H)⁺ calcd: 682.3427, obsd: 682.3426.

Example 479


Preparation of N-isobutyryl-4-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



N-isobutyryl-4-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (14 mg, 64%) was obtained from 4-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-benzenesulfonamide (20 mg, 0.033 mmol) and isobutyryl chloride by the similar procedure outlined in example 476. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.84 (d, J=8.2 Hz, 2 H), 7.50-7.47 (m, 3 H), 7.41-7.35 (m, 5 H), 7.25-7.21 (m, 1 H), 7.15-7.07 (m, 2 H), 4.60 (br, 1 H), 3.90 (br, 1H), 3.75-3.16 (m, 5 H), 2.45 (s, 3 H), 2.42-2.23 (m, 3 H), 2.13-2.08 (m, 2 H), 1.98-1.78 (m, 11 H), 1.65-1.62 (m, 2 H), 0.92 (d, J=6.8 Hz, 6 H). HRMS *m/z* (M+H)⁺ calcd: 682.3427, obsd: 682.3408.

Example 480

Preparation of N-acetyl-2-chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene-sulfonamide



5


N-acetyl-2-chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl] benzene-sulfonamide (21.8 mg, quant.) was obtained as amorphous solid from 2-chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl] benzenesulfonamide and acetyl bromide following the procedure outlined in example 476. ¹H NMR (300 MHz, DMSO-d₆) δ 7.85-7.50 (m, 3 H), 7.49 (d, J=8.5 Hz, 1 H), 7.41-7.35 (m, 5 H), 7.25-7.21 (m, 1 H), 7.15-7.09 (m, 2 H), 4.54 (br, 1 H), 3.96 (br, 1 H), 3.42-3.29 (m, 5 H), 3.06-3.03 (m, 1 H), 2.45-2.36 (m, 5 H), 2.17-2.07 (m, 2 H), 1.98-1.75 (m, 10 H), 1.71-1.70 (m, 3 H), 1.63-1.61 (m, 2 H). HRMS *m/z* (M+H)⁺ calcd: 688.2724, obsd: 688.2745.

15

Example 481

Preparation of 2-chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-N-propionyl benzenesulfonamide

20




2-Chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-N-propionylbenzenesulfonamide (16 mg, 73%) was obtained as amorphous solid from 2-chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl piperidin-1-yl)carbonyl] benzenesulfonamide and propionyl chloride

25

following the procedure outlined in example 476. ^1H NMR (300 MHz, DMSO- d_6) δ 7.81-7.56 (m, 3 H), 7.49 (d, $J=8.4$ Hz, 1 H), 7.39-7.26 (m, 5 H), 7.24-7.08 (m, 3 H), 4.80 (br, 1 H), 3.99-3.93 (m, 1 H), 3.58-3.38 (m, 5 H), 3.11-2.99 (m, 1 H), 2.47 (m, 4 H), 2.22-1.72 (m, 17 H), 0.89-0.81 (m, 3 H). HRMS m/z (M+H) $^+$ calcd: 702.2881, obsd: 702.2885.

Example 482


Preparation of 2-chloro-N-isobutyryl-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl] benzenesulfonamide



2-Chloro-N-isobutyryl-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl] benzene-sulfonamide (19 mg, 80%) was obtained as amorphous solid from 2-chloro-5-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide and isobutyryl chloride following the procedure outlined in example 476. ^1H NMR (300 MHz, DMSO- d_6 , 100 $^\circ\text{C}$) δ 7.85-7.76 (m, 2 H), 7.60-7.50 (m, 2 H), 7.42-7.28 (m, 5 H), 7.26 (m, 1 H), 7.18-7.12 (m, 2 H), 4.76 (br, 1 H), 3.36-3.08 (m, 7 H), 2.53-2.27 (m, 7 H), 2.04-1.82 (m, 10 H), 1.69 (d, $J=7.6$ Hz, 2 H), 0.95 (d, $J=6.6$ Hz, 6 H). HRMS m/z (M+H) $^+$ calcd: 716.3037, obsd: 716.3013.

Example 483

Preparation of 2-fluoro-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene-sulfonamide



5


2-Fluoro-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (20 mg, 32%) was obtained as solid from 3-(aminosulfonyl)-4-fluorobenzoic acid (22 mg, 0.1 mmol), 2-methyl-1-[(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole dihydrochloride (50 mg, 0.1 mmol) and HATU (38 mg, 0.1 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.93-7.91(m, 1 H), 7.64-7.58 (m, 2 H), 7.40-7.36 (m, 2 H), 7.30-7.21 (m, 5 H), 7.19-7.12 (m, 2 H), 5.61 (br, 1 H), 4.66-4.56 (m, 1 H), 4.20 (br, 1 H), 3.56 (br, 1 H), 3.26 (m, 4 H), 2.57 (s, 3 H), 2.42-2.34 (m, 4 H), 2.20 (br, 2 H), 1.99-1.83 (m, 9 H), 1.62 (m, 2 H). HRMS *m/z* (M+H)⁺ calcd: 630.2914, obsd: 630.2925.

10

15

Example 484

Preparation of 2-fluoro-N-methyl-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene-sulfonamide



2-Fluoro-N-methyl-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene


20

25

sulfonamide (53.8mg, 56%) was obtained as solid from 4-fluoro-3-(chlorosulfonyl)benzoic acid (48 mg, 0.2 mmol), 2-methyl-1-((1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole dihydrochloride (76 mg, 0.15 mmol) and methylamine (0.10 mL, 2.0 M in THF) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.92-7.90(m, 1 H), 7.65-7.61 (m, 2 H), 7.40-7.36 (m, 2 H), 7.30-7.22 (m, 5 H), 7.18-7.12 (m, 2 H), 5.29 (d, J=4.9 Hz, 1 H), 4.63-4.58 (m, 1 H), 4.18 (br, 1 H), 3.50 (br, 1 H), 3.32-3.25 (m, 4 H), 2.71 (d, J=4.1 Hz, 3 H), 2.56 (s, 3 H), 2.41-2.33 (m, 3 H), 2.16 (br, 2 H), 1.92-1.81 (m, 10 H), 1.64-1.58 (m, 2 H). HRMS *m/z* (M+H)⁺ calcd: 644.3071, obsd: 644.3061.

Example 485


Preparation of N-ethyl-2-fluoro-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene-sulfonamide



N-Ethyl-2-fluoro-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide (30.5 mg, 30%) was obtained as solid from 4-fluoro-3-(chlorosulfonyl)benzoic acid (48 mg, 0.2 mmol), 2-methyl-1-((1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole dihydrochloride (76 mg, 0.15 mmol) and ethylamine (0.10 mL, 2.0 M in THF) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.93-7.90(m, 1 H), 7.66-7.61 (m, 2 H), 7.40-7.36 (m, 2 H), 7.30-7.22 (m, 5 H), 7.19-7.12 (m, 2 H), 4.94 (t, J=6.1 Hz, 1 H), 4.65-4.57 (m, 1 H), 4.17 (br, 1 H), 3.50 (br, 1 H), 3.26 (br, 4 H), 3.11-3.04 (m, 2 H), 2.56 (s, 3 H), 2.42-2.34 (m, 3 H), 2.20-2.17 (m, 1 H), 1.94-1.82 (m, 10 H), 1.64 (d, J=6.4 Hz, 2 H), 1.13 (t, J=7.1 Hz, 3 H). HRMS *m/z* (M+H)⁺ calcd: 658.3227, obsd: 658.3237.

Example 486

Preparation of 2-fluoro-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-
azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-*N*-
 5 propylbenzenesulfonamide



2-Fluoro-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-

azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-*N*-

propylbenzene sulfonamide (41.8 mg, 41%) was obtained as solid from 4-

10 fluoro-3-(chlorosulfonyl)benzoic acid (48 mg, 0.2 mmol), 2-methyl-1-[(1*R*,5*S*)-

8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-

benzimidazole dihydrochloride (76 mg, 0.15 mmol) and propylamine (16.5 μ L,

0.2mmol) following the procedure outlined in example 473. ^1H NMR (400

MHz, CDCl_3) δ 7.92-7.90(m, 1 H), 7.66-7.61 (m, 2 H), 7.40-7.36 (m, 2 H),

15 7.30-7.22 (m, 5 H), 7.19-7.12 (m, 2 H), 5.03 (t, $J=6.0$ Hz, 1 H), 4.64-4.56 (m, 1

H), 4.18 (br, 1 H), 3.50 (br, 1 H), 3.33-3.25 (m, 4 H), 2.97 (q, $J=6.8$ Hz, 2 H),


2.56 (s, 3 H), 2.42-2.34 (m, 3 H), 2.19 (br, 1 H), 2.10 (s, 1 H), 1.93-1.82 (m, 10

H), 1.62 (d, $J=6.4$ Hz, 2 H), 1.55-1.46 (m, 2 H), 0.88(t, $J=7.5$ Hz, 3 H). HRMS

m/z (M+H) $^+$ calcd: 672.3384, obsd: 672.3380.

Example 487

Preparation of 2-fluoro-N-isopropyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide



5


2-Fluoro-N-isopropyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide (35.6mg, 35%) was obtained as solid from 4-fluoro-3-(chlorosulfonyl)benzoic acid (48 mg, 0.2 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (76 mg, 0.15 mmol) and isopropylamine (17 μ L, 0.2mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3) δ 7.94-7.91 (m, 1 H), 7.67-7.61 (m, 2 H), 7.40-7.37 (m, 2 H), 7.30-7.22 (m, 5 H), 7.19-7.12 (m, 2 H), 4.75 (d, $J=7.5$ Hz, 1 H), 4.65-4.60 (m, 1 H), 4.19 (br, 1 H), 3.56-3.48 (m, 2 H), 3.33-3.26 (br, 4 H), 2.57 (s, 3 H), 2.41-2.34 (m, 3 H), 2.19-2.17 (br, 1 H), 1.94-1.82 (m, 11 H), 1.62 (d, $J=7.9$ Hz, 2 H), 1.11 (d, $J=6.4$ Hz, 6 H). HRMS m/z ($M+H$) $^+$ calcd: 672.3384, obsd: 672.3398.

10

15

Example 488

Preparation of N-cyclopropyl-2-fluoro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




25

N-Cyclopropyl-2-fluoro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-

yl)carbonyl]benzene sulfonamide (43.0 mg, 43%) was obtained as solid from 4-fluoro-3-(chlorosulfonyl)benzoic acid (48 mg, 0.2 mmol), cyclopropyl amine (14 μ L, 0.2mmol) and 2-methyl-1-((1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole dihydrochloride (76 mg, 0.15 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.97-7.95 (m, 1 H), 7.69-7.64 (m, 2 H), 7.40-7.36 (m, 2 H), 7.30-7.23 (m, 5 H), 7.19-7.12 (m, 2 H), 5.47 (s, 1 H), 4.64-4.56 (m, 1 H), 4.19 (br, 1 H), 3.51 (br, 1 H), 3.33-3.26 (m, 4 H), 2.56 (s, 3 H), 2.41-2.28 (m, 3 H), 2.27-2.17 (m, 2 H), 1.99-1.82 (m, 12 H), 1.62 (d, *J*=7.9 Hz, 2 H), 0.68-0.60 (m, 4 H).
 HRMS *m/z* (*M*+*H*)⁺ calcd: 670.3227, obsd: 670.3213.

Example 489

Preparation of 2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide




2-Fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide (35 mg, 54%) was obtained as solid from 3-(aminosulfonyl)-4-fluorobenzoic acid (22 mg, 0.1 mmol), 1-((1*R*,5*S*)-8-[2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (52 mg, 0.1 mmol) and HATU (38mg, 0.10mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.96 (dd, *J*=6.8 Hz, 2.1 Hz, 1 H), 7.63-7.61 (m, 1 H), 7.59-7.55 (m, 1 H), 7.37-7.32 (m, 1 H), 7.29-7.20 (m, 2 H), 7.18-7.10 (m, 2 H), 7.06 (d, *J*=8.0 Hz, 1 H), 6.99-6.90 (m, 2 H), 6.04 (br, 2 H), 4.66 (t, *J*=8.8 Hz, 1 H), 4.14-4.08 (m, 1 H), 3.50 (br, 1 H), 3.9 (br, 4 H), 2.52 (s, 3 H), 2.44-2.36 (m, 2

H), 2.24 (br, 1 H), 2.09 (br, 1 H), 1.96-1.84 (m, 10 H), 1.65 (d, J=7.8 Hz, 2 H).
HRMS m/z (M+H)⁺ calcd: 648.2820, obsd: 648.2822.

Example 490

- 5 Preparation of N-cyclopropyl-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide



- 10 N-Cyclopropyl-2-fluoro-5-[(4-(3-fluoro phenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide (22 mg, 32%) was obtained as solid from 4-fluoro-3-(chlorosulfonyl) benzoic acid (48 mg, 0.2 mmol), cyclopropyl amine (14 μ L, 0.2mmol) and 1-((1R,5S)-8-{2-[4-(3-fluorophenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (52
15 mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃), δ 7.96 (dd, J=6.7 Hz, 2.2 Hz, 1 H), 7.69-7.65 (m, 2 H), 7.39-7.33 (m, 1 H), 7.30-7.25 (m, 2 H), 7.19-7.12 (m, 2 H), 7.07 (d, J=8.0 Hz, 1 H), 7.01-6.94 (m, 2 H), 5.39 (s, 1 H), 4.66 (br, 1 H), 4.16 (br, 1 H), 3.54 (br, 1 H), 3.48-3.28 (m, 4 H), 2.58 (s, 3 H), 2.44-2.37 (m, 2 H), 2.29-2.20 (m, 2 H), 2.13 (br, 1
20 H), 1.97-1.81 (m, 10 H), 1.66 (d, J=7.9 Hz, 2 H), 0.68-0.61 (m, 4 H). HRMS m/z (M+H)⁺ calcd: 688.3133, obsd: 688.3146.


Example 491

2,4-difluoro-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide

5 Preparation of 3-(chlorosulfonyl)-2,6-difluorobenzoic acid



3-(Chlorosulfonyl)-2,6-difluorobenzoic acid (8.6 g, 67%) was obtained as solid from 2,6-difluorobenzoic acid (8 g, 50 mmol), following the procedure outlined in the preparation of 4-chloro-3-(chlorosulfonyl)benzoic acid.



10


2,4-Difluoro-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (22mg, 34%) was obtained as solid from 3-(aminosulfonyl)-2,6-difluorobenzoic acid (24 mg, 0.1 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (50 mg, 0.10 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 8.00-7.89 (m, 1 H), 7.64 (d, J=7.7 Hz, 1 H), 7.40-7.34 (m, 2 H), 7.30-7.24 (m, 4 H), 7.19-7.12 (m, 2 H), 7.07-6.97 (m, 1 H), 5.6 (br, 2 H), 4.66-4.55 (m, 1 H), 4.29-4.24 (m, 1 H), 3.58-3.31 (m, 2 H), 3.25-3.05 (m, 3 H), 2.54 (s, 3 H), 2.49-2.20 (m, 4 H), 1.99-1.76 (m, 10 H), 1.62 (d, J=7.7 Hz, 2 H). HRMS *m/z* (M+H)⁺ calcd: 648.2820, obsd: 648.2834.

15

20

Example 492

Preparation of 2,4-difluoro-N-methyl-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl] benzenesulfonamide




5

2,4-Difluoro-N-methyl-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide (90 mg, 40%) was obtained as solid from 3-(chlorosulfonyl)-2,6-difluorobenzoic acid (105 mg, 0.4 mmol), 2-methyl-1-[(1*R*,5*S*)-8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole dihydrochloride (177 mg, 0.35 mmol) and methylamine (230 μ L, 2.0 M in THF) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3) δ 7.98-7.92 (m, 1 H), 7.67-7.65 (d, 1 H), 7.41-7.37 (m, 2 H), 7.30-7.28 (m, 4 H), 7.21-7.03 (m, 3 H), 4.84(m, $\frac{1}{2}$ H, rotamer), 4.75-4.71 (m, $\frac{1}{2}$ H, rotamer), 4.66-4.58 (m, 1 H), 3.41- 3.20 (m, 5 H), 2.74 (d, $J=5.1$ Hz, 3/2 H, rotamer), 2.69 (d, $J=5.1$ Hz, 3/2 H, rotamer), 2.57 (s, 3/2 H, rotamer), 2.56 (s, 3/2 H, rotamer), 2.41-2.37 (m, 3 H), 2.26-2.23 (m, 2 H), 1.99-1.77 (m, 9 H), 1.69-1.62 (m, 4 H). HRMS m/z ($M+H$) $^+$ calcd: 662.2976, obsd: 662.2982.

15

Example 493

Preparation of N-ethyl-2, 4-difluoro-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




5

N-Ethyl-2, 4-difluoro-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (92 mg, 45%) was obtained as solid from 3-(chlorosulfonyl)-2,6-difluorobenzoic acid (105 mg, 0.4 mmol), 2-methyl-1-[(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole dihydrochloride (150 mg, 0.30 mmol) and ethylamine (230 μ L, 2.0 M in THF) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3) δ 8.01-7.92 (m, 1 H), 7.70 (m, $\frac{1}{2}$ H, rotamer), 7.66 (d, $J=7.1$ Hz, 1 H), 7.54-7.52 (m, $\frac{1}{2}$ H, rotamer), 7.41-7.32 (m, 2 H), 7.30-7.25 (m, 4 H), 7.20-7.13 (m, 2 H), 7.11-7.02 (m, 1 H), 4.90-4.59 (m, 2 H), 4.35-4.27 (m, 2 H), 3.42-3.20 (m, 5 H), 3.18-2.96 (m, 2 H), 2.57 (s, $\frac{3}{2}$ H, rotamer), 2.56 (s, $\frac{3}{2}$ H, rotamer), 2.42-2.35 (m, 3 H), 2.26-2.23 (m, 1 H), 1.99-1.76 (m, 9 H), 1.68-1.62 (m, 2 H), 0.89-0.82 (m, 3 H). HRMS m/z ($M+H$) $^+$ calcd: 676.3133, obsd: 676.3154.

15

Example 494

Preparation of 2,4-difluoro-N-isopropyl-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




5

2,4-Difluoro-N-isopropyl-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide (100 mg, 41%) was obtained as solid from 3-(chlorosulfonyl)-2,6-difluorobenzoic acid (105 mg, 0.4 mmol), 2-methyl-1-
 10 {[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (177 mg, 0.35 mmol) and isopropylamine (40 μ L, 0.45 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3) δ 8.01-7.93 (m, 1 H), 7.66 (d, $J=7.5$ Hz, 1 H), 7.41-7.37 (m, 2 H), 7.30-7.25 (m, 5 H), 7.20-7.14 (m, 2 H), 7.12-7.01 (m, 1 H), 4.80-4.65 (m, 2 H), 4.29-4.23 (m, 1 H), 3.55-3.49 (m, 1H), 3.40- 3.18 (m, 5 H), 2.58 (s, 3/2 H, rotamer), 2.57 (s, 3/2 H, rotamer), 2.40 (br, 3 H), 2.24-2.23 (m, 1 H), 1.96-1.73 (m, 10 H), 1.67-1.65 (m, 2 H), 1.21-1.16 (m, 3 H), 1.10-1.04 (m, 3 H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd: 690.3289, obsd: 690.3276.

15

Example 495

Preparation of N-cyclopropyl-2,4-difluoro-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




5

N-Cyclopropyl-2,4-difluoro-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide (110 mg, 48%) was obtained as solid from 3-(chlorosulfonyl)-2,6-difluorobenzoic acid (105 mg, 0.4 mmol), 2-methyl-1-
 10 {[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (150 mg, 0.30 mmol) and cyclopropylamine (32 μ L, 0.45 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3) δ 8.02-7.97 (m, 1 H), 7.65 (d, $J=7.2$ Hz, 1 H), 7.41-7.37 (m, 2 H), 7.30-7.24 (m, 4 H), 7.20-7.04 (m, 2 H), 5.43 (s, $\frac{1}{2}$ H, rotamer), 5.31 (s, $\frac{1}{2}$ H, rotamer), 4.65-4.59 (m, 1 H), 4.30-4.27 (m, 1 H), 3.39-3.20 (m, 5H), 2.57
 15 (s, $\frac{3}{2}$ H, rotamer), 2.56 (s, $\frac{3}{2}$ H, rotamer), 2.42-2.24 (m, 4H), 1.99-1.77 (m, 11 H), 1.65-1.60 (m, 2 H), 0.80-0.76 (m, 1 H), 0.75-0.55 (m, 3 H). HRMS m/z ($M+H$) $^+$ calcd: 688.3133, obsd: 688.3135.

Example 496

Preparation of 2,4-difluoro-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-*N*-propylbenzenesulfonamide




5

2,4-Difluoro-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-*N*-propylbenzenesulfonamide (34.6mg, 34%) was obtained as solid from 3-(chlorosulfonyl)-2,6-difluorobenzoic acid (52 mg, 0.2 mmol), 2-methyl-1-
 10 {[(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole dihydrochloride (76 mg, 0.15 mmol) and propylamine (16.5 μ L, 0.2 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3), δ 8.01-7.91 (m, 1 H), 7.65 (d, $J=7.1$ Hz, 1 H), 7.41-7.37 (m, 2 H), 7.30-7.28 (m, 4 H), 7.19-7.01 (m, 3 H), 4.96 (t, $J=5.8$ Hz, $\frac{1}{2}$ H, rotamer),
 15 4.87 (t, $J=6.2$ Hz, $\frac{1}{2}$ H, rotamer), 4.65-4.58 (m, 1 H), 4.31-4.25 (m, 1 H), 3.40-3.23 (m, 5 H), 2.57 (s, $\frac{3}{2}$ H, rotamer), 2.56 (s, $\frac{3}{2}$ H, rotamer), 2.39-2.37 (m, 3 H), 2.25-2.22 (m, 1 H), 1.97-1.76 (m, 10 H), 1.65-1.63 (m, 2 H), 1.56-1.47 (m, 2 H), 0.92-0.85 (m, 3 H). HRMS m/z ($M+H$) $^+$ calcd: 690.3289, obsd: 690.3301.

20

Example 497

Preparation of 2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide



5


2,4-Difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide (10 mg, 15%) was obtained as solid from 3-(aminosulfonyl)-2,6-difluorobenzoic acid (24 mg, 0.1 mmol), 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (52mg, 0.10 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 8.01-7.92 (m, 1 H), 7.65 (d, J=7.7 Hz, 1 H), 7.39-7.34 (m, 1 H), 7.30-7.26 (m, 1 H), 7.21-7.13 (m, 2 H), 7.08-6.95 (m, 4 H), 5.35 (br, 2 H), 4.64-4.60 (m, 1 H), 4.26-4.23 (m, 1 H), 3.48-3.20 (m, 5 H), 2.56 (s, 3 H), 2.46-2.17 (m, 4 H), 1.99-1.64 (m, 12 H). HRMS *m/z* (M+H)⁺ calcd: 666.2725, obsd: 666.2746.

15

Example 498

Preparation of 2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-methylbenzenesulfonamide

20




2,4-Difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-methylbenzenesulfonamide (14 mg, 21%) was obtained as solid from 2,6-

25

difluoro-3-(chlorosulfonyl)benzoic acid (52 mg, 0.2 mmol), methylamine (120 μ L, 2.0 M in THF) and 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (52 mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃), δ 7.94 (q, J=8.0 Hz, 1 H), 7.65 (d, J=7.3 Hz, 1 H), 7.35 (q, J=8.0 Hz, 1 H), 7.29 (d, J=8.0 Hz, 1 H), 7.19-7.12 (m, 2 H), 7.09-7.02 (m, 2 H), 6.98-6.94 (m, 2 H), 4.99-4.86 (two sets of multiplets, 1 H, rotamers), 4.63-4.61 (m, 1 H), 4.27-4.23 (m, 1 H), 3.41-3.34 (m, 2 H), 3.25-3.18 (m, 3 H), 2.73 (d, J=5.0 Hz, 3/2 H, rotamer), 2.70 (d, J=4.9 Hz, 3/2 H, rotamer), 2.57 (s, 3/2 H, rotamer), 2.56 (s, 3/2 H, rotamer), 2.43-2.28 (m, 3 H), 2.22-2.17 (m, 1 H), 1.94-1.77 (m, 10 H), 1.66-1.63 (m, 2 H). HRMS *m/z* (M+H)⁺ calcd: 680.2882, obsd: 680.2881.

Example 499

15 Preparation of N-ethyl-2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide



N-Ethyl-2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide (16 mg, 23%) was obtained as solid from 2,6-difluoro-3-(chlorosulfonyl) benzoic acid (52 mg, 0.2 mmol), ethylamine (120 μ L, 2.0 M in THF) and 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (52 mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.95 (q, J=8.0 Hz, 1 H), 7.66 (d, J=8.0 Hz, 1 H), 7.36 (q, J=8.0 Hz, 1 H), 7.30-7.28 (m, 1 H), 7.19-7.12 (m, 2 H), 7.09-7.04 (m, 2 H), 7.01-6.95 (m, 2 H), 4.93-4.84 (two sets of multiplets, 1


321

H, rotamers), 4.64 (br, 1 H), 4.27-4.24 (m, 1 H), 3.41-3.37 (m, 2 H), 3.26-3.25 (m, 3 H), 3.22-2.95 (m, 2 H), 2.58 (s, 3/2 H, rotamer), 2.56 (s, 3/2 H, rotamer), 2.43-2.30 (m, 3 H), 2.20-2.10 (m, 1 H), 1.95-1.78 (m, 10 H), 1.66-1.64 (m, 2 H), 1.16-1.10 (m, 3 H). HRMS m/z (M+H)⁺ calcd: 694.3039, obsd: 694.3051.

5

Example 500

Preparation of 2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-propylbenzenesulfonamide




10

2,4-Difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-propylbenzenesulfonamide (42mg, 59%) was obtained as solid from 2,6-difluoro-3-(chlorosulfonyl) benzoic acid (52 mg, 0.2 mmol), propylamine (18 μ L, 0.22mmol) and 1-((1R,5S)-8-{2-[4-(3-fluorophenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (52 mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.95-7.91 (m, 1 H), 7.65 (d, J=8.0 Hz, 1 H), 7.39-7.35 (m, 1 H), 7.30-7.29 (m, 1 H), 7.16-7.14 (m, 2 H), 7.12-7.04 (m, 2 H), 6.96-6.95 (m, 2 H), 5.05-4.97 (two sets of multiplets, 1 H, rotamers), 4.63-4.57 (m, 1 H), 4.26-4.23 (m, 1 H), 3.41-3.35 (m, 2 H), 3.25-3.21 (m, 4 H), 3.04-2.90 (m, 2 H), 2.57 (s, 3/2 H, rotamer), 2.56 (s, 3/2 H, rotamer), 2.39-2.34 (m, 3 H), 2.20-2.10 (m, 1 H), 1.97-1.80 (m, 10 H), 1.65-1.63 (m, 2 H), 1.54-1.49 (m, 2 H), 0.90-0.85 (m, 3 H). HRMS m/z (M+H)⁺ calcd: 708.3195, obsd: 708.3189.

25

Example 501

Preparation of 2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-isopropylbenzenesulfonamide




5

2,4-Difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-isopropylbenzenesulfonamide (40 mg, 56%) was obtained as solid from 2,6-difluoro-3-(chloro sulfonyl)benzoic acid (52 mg, 0.2 mmol), isopropylamine (19 μ L, 0.22 mmol) and 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo [3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (52 mg, 0.1 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3) δ 7.95 (q, $J=7.3$ Hz, 1 H), 7.65 (d, $J=7.1$ Hz, 1 H), 7.36 (q, $J=7.7$ Hz, 1 H), 7.29 (d, $J=7.7$ Hz, 1 H), 7.19-7.12 (m, 2 H), 7.10-7.04 (m, 2 H), 7.00-6.94 (m, 2 H), 4.91 (d, $J=7.7$ Hz, $\frac{1}{2}$ H, rotamer), 4.86 (d, $J=7.7$ Hz, $\frac{1}{2}$ H, rotamers), 4.62-4.59 (m, 1 H), 4.26-4.22 (m, 1 H), 3.55-3.50 (m, 1 H), 3.41-3.37 (m, 2 H), 3.24-3.19 (m, 3 H), 2.57 (s, $\frac{3}{2}$ H, rotamer), 2.56 (s, $\frac{3}{2}$ H, rotamer), 2.42-2.29 (m, 3 H), 2.17-2.14 (m, 1 H), 1.96-1.77 (m, 10 H), 1.66-1.65 (m, 2 H), 1.18 (dd, $J=15, 6.6$ Hz, 3 H, rotamer), 1.06 (dd, $J=15, 6.6$ Hz, 3 H, rotamer). HRMS m/z ($M+H$) $^+$ calcd: 708.3195, obsd: 708.3201.

20

Example 502

Preparation of N-cyclopropyl-2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide




5

N-Cyclopropyl-2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide (40 mg, 53%) was obtained as solid from 2,6-difluoro-3-(chlorosulfonyl)benzoic acid (52 mg, 0.2 mmol), cyclopropyl amine (14 μ L, 0.2mmol) and 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (52 mg, 0.1 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3), δ 7.98-7.96 (m, 1 H), 7.65 (d, $J=8.8$ Hz, 1 H), 7.38-7.33 (m, 1 H), 7.31-7.26 (m, 1 H), 7.19-7.12 (m, 2 H), 7.10-7.06 (m, 2 H), 7.04-6.94 (m, 2 H), 5.55 (s, $\frac{1}{2}$ H, rotamer), 5.49 (s, $\frac{1}{2}$ H, rotamer), 4.64-4.58 (m, 1 H), 4.27-4.22 (m, 1 H), 3.42-3.35 (m, 2 H), 3.25-3.19 (m, 3 H), 2.57 (s, $\frac{3}{2}$ H, rotamer), 2.56 (s, $\frac{3}{2}$ H, rotamer), 2.41-2.14 (m, 5 H), 2.03-1.77 (m, 10 H), 1.64 ($J=7.9$ Hz, 2 H), 0.78-0.73 (m, 1 H), 0.66-0.54 (m, 3 H). HRMS m/z ($M+H$) $^+$ calcd: 706.3038, obsd: 706.3044.

20

Example 503

Preparation of 3-fluoro-4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



5


3-Fluoro-4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (41 mg, 77%) was obtained as solid from 4-(aminosulfonyl)-2-fluorobenzoic acid (22 mg, 0.1 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, J=7.9 Hz, 1 H), 7.63-7.60 (m, 2 H), 7.40-7.36 (m, 2 H), 7.29-7.23 (m, 5 H), 7.18-7.12 (m, 2 H), 6.18 (br, 2 H), 4.61 (t, J=9 Hz, H), 4.21-4.18 (m, 1 H), 3.36-3.18 (m, 5 H), 2.49 (s, 3 H), 2.39-2.19 (m, 4 H), 1.96-1.81 (m, 10 H), 1.62 (d, J=7.9 Hz, 2 H). HRMS *m/z* (M+H)⁺ calcd: 630.2914, obsd: 630.2907.

10

15

Example 504

Preparation of 3-chloro-4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



3-Chloro-4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-

20


25

325

yl)carbonyl]benzenesulfonamide (27mg, 42%) was obtained as solid from 4-(amino sulfonyl)-2-chlorobenzoic acid (24 mg, 0.1 mmol), 2-methyl-1-
 {(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-
 benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1
 5 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃), δ 7.95 (s, ½ H, rotamer), 7.91 (s, ½ H, rotamer), 7.81-7.76 (m, 1 H), 7.64-7.62 (m, 1 H), 7.41-7.36 (m, 2 H), 7.30-7.23 (m, 5 H), 7.19-7.09 (m, 2 H), 6.05 (br, 2 H), 4.62 (br, 1 H), 4.26-4.17 (m, 1 H), 3.48- 3.07 (m, 5 H), 2.50 (s, 3/2 H, rotamer), 2.49 (s, 3/2 H, rotamer), 2.37-2.08 (m, 4 H), 1.94-1.71 (m,
 10 10 H), 1.62 (d, 2 H). HRMS *m/z* (M+H)⁺ calcd: 646.2619, obsd: 646.2626.

Example 505


Preparation of 3,4-difluoro-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene
 15 sulfonamide



3,4-Difluoro-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene
 sulfonamide (26mg, 40%) was obtained from 5-(aminosulfonyl)-2,3-
 20 difluorobenzoic acid (0.15mmol), 2-methyl-1-[(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.70-7.65 (m, 2 H), 7.47-7.37 (m, 3 H), 7.29-7.25 (m 4 H), 7.20-7.13 (m, 2 H), 4.84 (br, 1 H), 4.14-4.11 (m, 1
 25 H), 3.65-3.20 (m, 6 H), 2.57 (s, 3 H), 2.53-2.48 (m, 2 H), 2.30-2.11 (m, 3 H), 1.97-1.71 (m, 11 H). HRMS *m/z* (M+H)⁺ calcd: 648.2820, obsd: 648.2828.

Example 506

Preparation of 3,4-difluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide




5

3,4-Difluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide (20mg, 30%) was obtained from 5-(aminosulfonyl)-2,3-difluorobenzoic acid (0.15mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazolidihydrochloride (52 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.69-7.62 (m, 2 H), 7.46-7.42 (m, 1 H), 7.39-7.33 (m, 1 H), 7.30-7.26 (m, 1 H), 7.21-7.13 (m, 2 H), 7.06 (d, J=7.9 Hz), 7.00-6.95 (m, 2 H), 5.86 (br, 2 H), 4.66-4.61 (m, 1 H), 4.14-4.09 (m, 1 H), 3.51 (br, 1 H), 3.29 (br, 4 H), 2.54 (s, 3 H), 2.49-2.13 (m, 5 H), 1.95-1.83 (m, 9 H), 1.67-1.65 (m, 2 H). HRMS *m/z* (M+H)⁺ calcd: 666.2726, obsd: 666.2719.

10
15Example 507

Preparation of 2,3-Difluoro-N-methyl-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide




2,3-Difluoro-N-methyl-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene

20
25

sulfonamide (31 mg, 47%) was obtained as solid from 3-(chlorosulfonyl)-4,5-difluorobenzoic acid (52 mg, 0.2 mmol), methylamine (110 μ L, 2.0 M in THF), 2-methyl-1-((1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole dihydro chloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.68-7.64 (m, 2 H), 7.50-7.45 (m, 1 H), 7.41-7.37 (m, 2 H), 7.30-7.24 (m 4 H), 7.19-7.12 (m, 2 H), 5.26 (br, 1 H), 4.66-4.6 (m, 1 H), 4.17 (br, 1 H), 3.51 (br, 1 H), 3.27 (br, 4 H), 2.75 (d, J=2.3 Hz, 3 H), 2.57 (s, 3 H), 2.42-2.34 (m, 3 H), 2.20 (br, 1 H), 2.01-1.75 (m, 10 H), 1.63 (d, J=7.90 Hz, 2 H). HRMS *m/z* (M+H)⁺ calcd: 662.2976, obsd: 672.2985.

Example 508

Preparation of 2,3-difluoro-N-isopropyl-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




2,3-Difluoro-N-isopropyl-5-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene-sulfonamide (25 mg, 36%) was obtained as solid from 3-(chlorosulfonyl)-4,5-difluorobenzoic acid (52 mg, 0.2 mmol), isopropylamine (19 μ L, 0.2 mmol), 2-methyl-1-((1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.69-7.65 (m, 2 H), 7.50-7.45 (m, 1 H), 7.41-7.37 (m, 2 H), 7.30-7.24 (m 4 H), 7.19-7.12 (m, 2 H), 4.90 (d, J=7.7 Hz, 1 H), 4.65 (m, 1 H), 4.18 (br, 1 H), 3.61-3.51 (m, 2 H), 3.26 (br, 4 H), 2.57 (s, 3 H), 2.43-2.35 (m, 3 H), 2.201-2.19 (m, 1 H), 1.94-1.85 (m, 10 H), 1.63 (d,

J=7.90 Hz, 2 H), 1.14 (d, J=6.6 Hz, 6 H). HRMS m/z (M+H)⁺ calcd: 690.3289, obsd: 690.3309.

Example 509


- 5 Preparation of N-cyclopropyl-2,3-difluoro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



- 10 *N*-Cyclopropyl-2, 3-difluoro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (29 mg, 42%) was obtained as solid from 3-(chlorosulfonyl)-4,5-difluorobenzoic acid (52 mg, 0.2 mmol), isopropylamine (15 μ L, 0.2 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.72-7.71 (m, 1H), 7.66-7.64 (m, 1 H), 7.53-7.48 (m, 1 H), 7.41-7.37 (m, 2 H), 7.30-7.24 (m 4 H), 7.19-7.12 (m, 2 H), 5.61 (s, 1 H), 4.67-4.57 (m, 1 H), 4.18 (br, 1 H), 3.51 (br, 1 H), 3.27 (br, 4 H), 2.57 (s, 3 H), 2.42 -2.28 (m, 4H), 2.221-2.20 (m, 1 H), 1.94-1.76 (m, 10 H), 1.65-1.60 (m, 2 H), 0.71-0.61 (m, 4 H). HRMS m/z (M+H)⁺ calcd: 688.3133, obsd: 688.3123.
- 20

Example 510

Preparation of N-cyclopentyl-2,3-difluoro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




5

N-Cyclopentyl-2,3-difluoro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1] oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl] benzenesulfonamide (29 mg, 40%) was obtained as solid from 3-(chlorosulfonyl)-4,5-difluorobenzoic acid (52 mg, 0.2 mmol), isopentylamine (22 μ L, 0.2 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3) δ 7.69-7.65 (m, 2 H), 7.50-7.46 (m, 1 H), 7.41-7.37 (m, 2 H), 7.30-7.24 (m 4 H), 7.19-7.12 (m, 2 H), 5.01 (d, $J=7.3$ Hz, 1 H), 4.68-4.64 (m, 1 H), 4.18 (br, 1 H), 3.69-3.64 (m, 1 H), 3.51 (br, 1 H), 3.29 (br, 4 H), 2.57 (s, 3 H), 2.44-2.36 (m, 3 H), 2.20-2.18 (m, 1 H), 1.97-1.70 (m, 12 H), 1.69-1.60 (m, 4 H), 1.57-1.47 (m, 2 H), 1.45-1.24 (m, 2 H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd: 716.3446, obsd: 716.3456.

15

Example 511


Preparation of 4-fluoro-N-methyl-2-(methylamino)-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



5

4-Fluoro-N-methyl-2-(methylamino)-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (20mg, 30%) was obtained as solid from 6-fluoro-2-(methylamino)-3-[(methyl amino)sulfonyl]benzoic acid (205 mg, 0.8 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydro- chloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.79-7.74 (m, 1 H), 7.66-7.64 (m, 1 H), 7.41-7.34 (m, 2 H), 7.30-7.21 (m 4 H), 7.19-7.04 (m, 3 H), 6.95-6.40 (m, 1 H), 6.29-6.18 (m, 1 H), 5.07-4.93 (m, 1 H), 4.64 (br, 1 H), 4.37-4.08 (m, 1 H), 3.57-3.34 (m, 1 H), 3.39-3.12 (m, 4 H), 3.00 (d, J=5.4 Hz, 3/2 H, rotamer), 2.75 (d, J=5.2 Hz, 3/2 H, rotamer), 2.58-2.56 (m, 3 H), 2.41-2.07 (m, 4 H), 1.93-1.68 (m, 12 H), 1.63-1.61(m, 2 H). HRMS *m/z* (M+H)⁺ calcd: 673.3336, obsd: 673.3345.

20

Example 512Preparation of 2,4-dichloro-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide

5


2,4-Dichloro-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (36mg, 53%) was obtained as solid from 3-(aminosulfonyl)-2,6-dichlorobenzoic acid (51 mg, 0.15 mmol), 2-methyl-1-[(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473.

¹H NMR (400 MHz, CDCl₃) δ 7.99-7.94 (d, *J*=8.4 Hz, 1 H), 7.63-7.61 (d, *J*=7.2 Hz, 1 H), 7.43-7.36 (m, 3 H), 7.29-7.26 (m, 4 H), 7.18-7.08 (m, 2 H), 5.96 (br, 2 H), 4.63 (br, 1 H), 4.29-4.24 (m, 1 H), 3.40-3.12 (m, 5 H), 2.53 (s, 3 H), 2.48-2.36 (m, 3 H), 2.24-2.21 (m, 1 H), 1.99-1.84 (m, 9 H), 1.64-1.61(m, 2 H). HRMS *m/z* (M+H)⁺ calcd: 680.2229, obsd: 680.2228.

15

Example 513

20 Preparation of 2,4-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide



25 2,4-Dichloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide (30mg, 43%) was obtained as solid from 3-


332

(aminosulfonyl)-2,6-dichlorobenzoic acid (51 mg, 0.15 mmol), 2-methyl-1-
 {(1*R*,5*S*)-8-[2-(4-(3-fluorophenyl) piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-
 yl)-1*H*-benzimidazole dihydrochloride (52 mg, 0.1 mmol) and HATU (38mg,
 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400
 5 MHz, CDCl₃) δ 8.01-7.99 (m, 1 H), 7.64-7.62 (m, 1 H), 7.45-7.35 (m, 2 H),
 7.34-7.28 (m, 1 H), 7.22-7.12 (m, 2 H), 7.08-7.06 (m, 1 H), 6.99-6.95 (m, 2 H),
 5.79 (br, 2 H), 4.65-4.55 (m, 1 H), 4.27-4.23 (m, 1 H), 3.43-3.12 (m, 5 H), 2.54
 (s, 3 H), 2.41-2.37 (m, 4 H), 2.19-2.16 (m, 1 H), 1.94-1.83 (m, 9 H), 1.66-1.65
 (m, 2 H). HRMS *m/z* (M+H)⁺ calcd: 698.2135, obsd: 698.2141.

10

Example 514

Preparation of 2,4-dichloro-N-methyl-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-
 benzimidazol-1-yl)-8-azabicyclo[3.2.1] oct-8-yl]ethyl}-4-phenylpiperidin-1-
 yl)carbonyl]benzene sulfonamide




15

2,4-Dichloro-*N*-methyl-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-
 1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-
 yl)carbonyl]benzene sulfonamide (33mg, 48%) was obtained as solid from
 2,6-dichloro-3-(chlorosulfonyl)benzoic acid (58 mg, 0.20 mmol), methylamine
 20 (120 μL, 2.0 M in THF), 2-methyl-1-[(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-
 yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole dihydrochloride (51
 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined
 in example 473. ¹H NMR (400 MHz, CDCl₃) δ 8.06-8.03 (m, 1 H), 7.66-7.64
 (m, 1 H), 7.52-7.44 (m, 1 H), 7.41-7.37 (m, 2 H), 7.30-7.24 (m, 4 H), 7.19-7.12
 25 (m, 2 H), 5.31-5.13 (m, 1 H), 4.64 (br, 1 H), 4.34-4.25 (m, 1 H), 3.43-3.12 (m,
 5 H), 2.68-2.63 (m, 3 H), 2.57-2.55 (m, 3 H), 2.39-2.34 (m, 3 H), 2.26-2.20 (m,
 1 H), 1.99-1.82 (m, 10 H), 1.63-1.62(m, 2 H). HRMS *m/z* (M+H)⁺ calcd:
 694.2385, obsd: 694.2391.

Example 515

Preparation of 2,4-dichloro-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-*N*-propylbenzenesulfonamide



2,4-Dichloro-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-*N*-

propylbenzenesulfonamide (19mg, 26%) was obtained as solid from 2,6-

dichloro-3-(chlorosulfonyl)benzoic acid (58 mg, 0.20 mmol), propylamine (20

μ L, 0.24 mmol), 2-methyl-1-[(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-

azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole dihydrochloride (51 mg, 0.1

mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in

example 473. ^1H NMR (400 MHz, CDCl_3) δ 8.06-8.04 (m, 1 H), 7.65 (d, 1 H),

7.52-7.41 (m, 1 H), 7.39-7.32 (m, 2 H), 7.29-7.21 (m, 4 H), 7.19-7.12 (m, 2 H),

5.29-4.98 (m, 1 H), 4.63 (br, 1 H), 4.33-4.27 (m, 1 H), 3.42-3.12 (m, 5 H),


3.04-2.88 (m, 2 H), 2.86-2.77 (m, 1 H), 2.58-2.56 (m, 3 H), 2.40-2.37 (m, 3 H),

2.26-2.19 (m, 1 H), 1.93-1.63 (m, 14 H), 1.57-1.51 (m, 2 H), 0.92-0.85 (m, 3

H). HRMS m/z ($M+H$) $^+$ calcd: 722.2698, obsd: 722.2686.

Example 516

Preparation of 2,4-dichloro-N-isopropyl-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



5


2,4-Dichloro-N-isopropyl-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide (20 mg, 28%) was obtained as solid from 2,6-dichloro-3-(chlorosulfonyl)benzoic acid (58 mg, 0.20 mmol),

10 isopropylamine (20.5 μ L, 0.24 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3) δ 8.08-8.05 (m, 1 H), 7.66-7.65 (m, 1 H), 7.51-7.44 (m, 1 H), 7.41-7.37 (m, 2 H), 7.30-7.25 (m, 4 H), 7.20-7.12 (m, 2 H), 4.95-4.83 (m, 1 H), 4.64-4.62 (m, 1 H), 4.32-4.27 (m, 1 H), 3.49-3.34 (m, 2 H), 3.27-3.24 (m, 3 H), 3.19-3.14 (m, 1 H), 2.57-2.56 (m, 3 H), 2.40-2.37 (m, 3 H), 2.26-2.18 (m, 1 H), 1.96-1.82 (m, 10 H), 1.64-1.62 (m, 2 H), 1.21-1.02 (m, 6 H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd: 722.2698, obsd: 722.2702.

20

Example 517

Preparation of 2,4-dichloro-N-cyclopropyl-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



5


2,4-Dichloro-N-cyclopropyl-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide (35 mg, 49%) was obtained as solid from 2,6-dichloro-3-(chlorosulfonyl)benzoic acid (58 mg, 0.20 mmol),

10 cyclopropylamine (17 μ L, 0.24 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3) δ 8.12-8.09 (m, 1 H), 7.66-7.65 (m, 1 H), 7.54-7.46 (m, 1 H), 7.41-7.37 (m, 2 H), 7.30-7.25 (m, 4 H), 7.19-7.12 (m, 2 H), 5.67-5.54 (m, 1 H), 4.64 (br, 1 H), 4.33-4.27 (m, 1 H), 3.43-3.12 (m, 5 H), 2.58-2.56 (m, 3 H), 2.40-2.37 (m, 3 H), 2.26-2.19 (m, 2 H), 2.04-1.82 (m, 10 H), 1.64-1.63 (m, 2 H), 0.85-0.76 (m, 1 H), 0.67-0.54 (m, 3 H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd: 720.2542, obsd: 720.2558.

15

Example 518

Preparation of 2,4-dichloro-N-cyclopentyl-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




5

2,4-Dichloro-N-cyclopentyl-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1] oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl] benzenesulfonamide (28mg, 37%) was obtained as solid from 2,6-dichloro-3-(chlorosulfonyl)benzoic acid (58 mg, 0.20 mmol), cyclopentylamine (20 μ L, 0.24 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3) δ 8.08-8.06 (m, 1 H), 7.67-7.65 (m, 1 H), 7.52-7.44 (m, 1 H), 7.41-7.34 (m, 2 H), 7.29-7.25 (m, 4 H), 7.19-7.12 (m, 2 H), 5.09-4.96 (m, 1 H), 4.62 (br, 1 H), 4.31-4.28 (m, 1 H), 3.60-3.50 (m, 1 H), 3.42-3.11 (m, 5 H), 2.58-2.53 (m, 3 H), 2.40-2.37 (m, 4 H), 2.25-2.18 (m, 1 H), 1.99-1.75 (m, 11 H), 1.73-1.49 (m, 8 H). HRMS m/z (M+H) $^+$ calcd: 748.2855, obsd: 748.2863.

15

Example 519

Preparation of 2-chloro-N-methoxy-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide




5

2-Chloro-N-methoxy-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide (17 mg, 25%) was obtained as solid from 4-chloro-3-(chlorosulfonyl)benzoic acid (50 mg, 0.2 mmol), methoxyamine hydrochloride (21 mg, 0.20 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, J= 2.0 Hz, 1 H), 8.09 (br, 1, H), 7.67-7.57 (m, 3 H), 7.41-7.37 (m, 2 H), 7.30-7.24 (m, 4 H), 7.19-7.09 (m, 2 H), 4.67 (br, 1 H), 4.21-4.19 (m, 1 H), 3.77 (s, 3 H), 3.53-3.50 (m, 1 H), 3.35-3.28 (m, 4 H), 2.57 (s, 3 H), 2.39 (br, 3 H), 2.20-2.17 (m, 1 H), 1.95-1.77 (m, 10 H), 1.66-1.64 (m, 2 H). HRMS *m/z* (M+H)⁺ calcd: 676.2724, obsd: 676.2727.

15

Example 520

Preparation of 2-chloro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-methoxybenzenesulfonamide




5

2-Chloro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-methoxybenzenesulfonamide (10 mg, 14%) was obtained as solid from 4-chloro-3-(chloro sulfonyl)benzoic acid (50 mg, 0.2 mmol), methoxyamine hydrochloride (21mg, 0.20 mmol), 1-[(1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo [3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (52 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, J= 1.6 Hz, 1 H), 7.92 (br, 1, H), 7.71-7.59 (m, 3 H), 7.38 (q, J=7.7 Hz, 1 H), 7.30-7.26 (m, 1 H), 7.20--7.13 (m, 2 H), 7.08 (d, J=8.1 Hz, 1 H), 7.01-6.96 (m, 2 H), 4.67 (br, 1 H), 4.14-4.11 (m, 1 H), 3.78 (s, 3 H), 3.59 (br, 1 H), 3.54-3.31 (br, 4 H), 2.59 (s, 3 H), 2.44 (br, 2 H), 2.28 (br, 2 H), 2.11 (br, 2 H), 1.97-1.65 (m, 10 H). HRMS *m/z* (M+H)⁺ calcd: 694.2630, obsd: 694.2630.

20

Example 521

Preparation of 2-chloro-N-ethoxy-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide




5

2-Chloro-N-ethoxy-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene-sulfonamide (6 mg, 8%) was obtained as solid from 4-chloro-3-(chlorosulfonyl)benzoic acid (50 mg, 0.2 mmol), ethoxyamine hydrochloride (29 mg, 0.20 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 8.12 (s, 1 H), 7.80 (s, 1 H), 7.67-7.59 (m, 3 H), 7.41-7.38 (m, 2 H), 7.30-7.26 (m, 3 H), 7.20-7.12 (m, 2 H), 4.69 (br, 1 H), 4.21 (br, 1 H), 4.03 (q, J=7.0 Hz, 2 H), 3.51 (br, 1 H), 3.29 (br, 4 H), 2.58 (s, 3 H), 2.42-2.39 (m, 3 H), 2.16 (br, 1 H), 1.94 (br, 7 H), 1.69 (br, 5 H), 1.16 (t, J=7.0 Hz, 3 H). HRMS *m/z* (M+H)⁺ calcd: 690.2881, obsd: 690.2878.

15

Example 522

Preparation of 2-chloro-N-ethoxy-5-[(4-(3-fluoro phenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide




2-Chloro-N-ethoxy-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)

25

carbonyl]benzenesulfonamide (12mg, 17%) was obtained as solid from 4-chloro-3-(chlorosulfonyl)benzoic acid (50 mg, 0.2 mmol), ethoxyamine hydrochloride (29 mg, 0.20 mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (52 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, J= 1.8 Hz, 1 H), 7.82 (br, 1, H), 7.67-7.59 (m, 3 H), 7.37 (q, J=7.8 Hz, 1 H), 7.29 (d, J=7.7 Hz, 1 H), 7.20--7.13 (m, 2 H), 7.08 (d, J=8.1 Hz, 1 H), 7.01-6.96 (m, 2 H), 4.81 (br, 1 H), 4.17 (br, 1 H), 4.04 (q, J=7.1 Hz, 2 H), 3.53 (br, 1 H), 3.39-3.31 (br, 4 H), 2.59 (s, 3 H), 2.43 (br, 2 H), 2.29 (br, 1 H), 2.10 (br, 2 H), 1.97-1.93 (m, 8 H), 1.71 (br, 4 H), 1.16 (t, J=7.0 Hz, 3 H). HRMS *m/z* (M+H)⁺ calcd: 708.2787, obsd: 708.2797.

Example 523

Preparation of 4-chloro-N-methoxy-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene-sulfonamide




4-Chloro-N-methoxy-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide (2mg) was obtained as solid from 2-chloro-5-(chlorosulfonyl)benzoic acid (50 mg, 0.2 mmol), methoxyamine hydrochloride (21 mg, 0.20 mmol), 2-methyl-1-[(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.90-7.85 (m, 2 H), 7.66 (d, J=7.5 Hz, 1 H), 7.57 (m, 1 H), 7.42-7.33 (m, 2 H), 7.30-7.26 (m, 4 H), 7.20-7.12 (m, 3 H), 4.70 (br, 1 H), 4.30-4.22 (m, 1 H), 3.80 (d, J=7.1 Hz, 3 H), 3.42-3.09 (m,

341

7 H), 2.56 (s, 3 H), 2.43–2.08 (m, 4 H), 1.95–1.90 (m, 8 H), 1.89–1.75 (m, 3 H). HRMS m/z (M+H)⁺ calcd: 676.2724, obsd: 676.2722.

Example 524


- 5 Preparation of 4-chloro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-methoxybenzenesulfonamide



- 10 4-Chloro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-methoxy benzenesulfonamide (3.9 mg) was obtained as solid from 2-chloro-5-(chlorosulfonyl)benzoic acid (50 mg, 0.2 mmol), ethoxyamine hydrochloride (29 mg, 0.20 mmol), 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (52 mg, 0.1 mmol) and HATU (38 mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.89–7.85 (m, 2 H), 7.66 (d, J=7.7 Hz, 1 H), 7.61–7.55 (m, 1 H), 7.38–7.36 (m, 1 H), 7.31–7.29 (m, 1 H), 7.21–7.14 (m, 3 H), 7.10–7.05 (m, 1 H), 6.99–6.97 (m, 2 H), 4.68–4.63 (m, 1 H), 4.27–4.23 (m, 1 H), 3.80 (d, J=4 Hz, 3 H), 3.43–3.20 (m, 5 H), 3.18–3.09 (m, 1 H), 2.56 (s, 3 H), 2.43–2.30 (m, 4 H), 2.16–2.13 (m, 1 H), 1.96–1.89 (m, 10 H). HRMS m/z (M+H)⁺ calcd: 694.2630, obsd: 694.2625.
- 15
- 20

Example 525

Preparation of 4-chloro-N-ethoxy-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene-sulfonamide




5 4-Chloro-N-ethoxy-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene-sulfonamide (3.1 mg) was obtained as solid from 2-chloro-5-(chlorosulfonyl)benzoic acid (50 mg, 0.2 mmol), ethoxyamine hydrochloride (29 mg, 0.20 mmol), 2-methyl-1-[(1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (51 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.90-7.84 (m, 1 H), 7.65 (d, J=7.5 Hz, 1 H), 7.60-7.53 (m, 1 H), 7.41-7.32 (m, 2 H), 7.30-7.26 (m, 5 H), 7.19-7.14 (m, 3 H), 4.65 (br, 1 H), 4.30-4.22 (m, 1 H), 4.06-4.02 (m, 2 H), 3.33-3.25 (m, 5 H), 2.55 (s, 3 H), 2.38 (br, 3 H), 2.11-2.08 (m, 1 H), 1.99-1.89 (m, 9 H), 1.87-1.64 (m, 2 H), 1.22- 1.15 (m, 3 H). HRMS *m/z* (M+H)⁺ calcd: 690.2881, obsd: 690.2880.

20

Example 526

Preparation of 3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-2,4-dimethylbenzene sulfonamide




25

3-[(4-(3-Fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-2,4-

dimethylbenzene sulfonamide (25 mg, 38%) was obtained as solid from 3-(aminosulfonyl)-2,6-dimethylbenzoic acid (23 mg, 0.1 mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (52 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.89 (d, J=8.2 Hz, 1 H), 7.64 (d, J=7.2 Hz, 1 H), 7.36 (q, J=7.9 HZ, 1 H), 7.29 (d, J=7.4 Hz, 1 H), 7.19-7.10 (m, 3 H), 7.05 (d, J=7.9 HZ, 1 H), 6.99-6.95 (m, 2 H), 5.20 (br, 2 H), 4.61-4.56 (m, 1 H), 4.27-4.23 (m, 1 H), 3.46-3.41 (m, 1 H), 3.23 (br, 3 H), 3.10-3.05 (m, 1 H), 2.60 (s, 3/2 H, rotamer), 2.53 (s, 3 H), 2.41 (s, 3/2 H, rotamer), 2.37 (s, 3/2 H, rotamer), 2.33-2.29 (m, 2 H), 2.19 (s, 3/2 H, rotamer), 2.11-2.08 (m, 1 H), 1.94-1.82 (m, 10 H), 1.74-1.62 (m, 3 H). HRMS *m/z* (M+H)⁺ calcd: 658.3227, obsd: 658.3223.

Example 527

15 Preparation of 3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*,2,4-trimethyl benzenesulfonamide




20 3-[(4-(3-Fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*,2,4-trimethyl benzenesulfonamide (10 mg, 15%) was obtained as solid from 3-(chlorosulfonyl)-2,6-dimethylbenzoic acid (50 mg, 0.2 mmol), methylamine (120 μL, 2.0 M in THF), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (52 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.91-7.88 (m, 1 H), 7.66 (d, J=7.7 Hz, 1 H), 7.36 (q, J=7.7 HZ, 1 H), 7.29 (d, J=7.5 Hz, 1 H), 7.22-7.14 (m, 3 H), 7.05 (d, J=7.9 HZ, 1 H), 6.99-6.95 (m, 2 H), 4.63-4.52

(m, 2 H), 4.33-4.29 (m, 1 H), 3.43-3.34 (m, 1 H), 3.25 (br, 3 H), 3.05 (q, J=10.6 Hz, 1 H), 2.64-2.55 (m, 8 H), 2.42-4.21 (m, 7 H), 2.08 (br, 1 H), 1.95-1.88 (m, 6 H), 1.84-1.63 (m, 6 H). HRMS m/z (M+H)⁺ calcd: 672.3384, obsd: 672.3400.

5

Example 528


Preparation of N-ethyl-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-2,4-dimethylbenzenesulfonamide



10

N-Ethyl-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1] oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-2,4-dimethyl benzenesulfonamide (9.2mg, 14%) was obtained as solid from 3-(chlorosulfonyl)-2,6-dimethylbenzoic acid (50 mg, 0.2 mmol), ethylamine (120 μL, 2.0 M in THF), 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (52 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.89 (d, J=8.0 Hz, 1 H), 7.66 (d, J=7.3 Hz, 1 H), 7.36 (q, J=7.7 Hz, 1 H), 7.30 (d, J=8.1 Hz, 1 H), 7.21-7.13 (m, 3 H), 7.06 (d, J=7.9 HZ, 1 H), 6.99-6.95 (m, 2 H), 4.63-4.59 (m, 1 H), 4.51-4.49 (m, 1 H), 4.33-4.29 (m, 1 H), 3.40-3.34 (m, 1 H), 3.25-3.21 (m, 3 H), 3.11-3.05 (m, 1 H), 2.94-2.87 (m, 1 H), 2.62 (s, 3 H), 2.57 (s, 3 H), 2.55-2.30 (m, 3 H), 2.20 (s, 3 H), 2.09-2.06 (m, 1 H), 1.95-1.88 (m, 6 H), 1.84-1.63 (m, 6 H), 1.12 (t, J=7.2 Hz, 3 H). HRMS m/z (M+H)⁺ calcd: 686.3540, obsd: 686.3522.

25

Example 529Preparation of 3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-2,4-dimethyl-*N*-propylbenzenesulfonamide


5

3-[(4-(3-Fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-2,4-dimethyl-*N*-propylbenzenesulfonamide (8 mg, 12%) was obtained as solid from 3-(chlorosulfonyl)-2,6-dimethylbenzoic acid (50 mg, 0.2 mmol), propylamine (18 μ L, 0.22 mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (52 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3) δ 7.91-7.88 (m, 1 H), 7.66 (d, $J=7.7$ Hz, 1 H); 7.36 (q, $J=7.6$ HZ, 1 H), 7.33-7.31 (m, 1 H), 7.21-7.13 (m, 3 H), 7.06 (d, $J=7.3$ HZ, 1 H), 6.99-6.95 (m, 2 H), 4.63-4.59 (m, 1 H), 4.53-4.42 (m, 1 H), 4.33-4.24 (m, 1 H), 3.43-3.34 (m, 1 H), 3.25-3.21 (m, 3 H), 3.09-2.88 (m, 2 H), 2.84-2.76 (m, 1 H), 2.62-2.56 (m, 6 H), 2.42-2.20 (m, 6 H), 2.08-2.06 (m, 1 H), 1.95-1.88 (m, 6 H), 1.84-1.63 (m, 6 H), 1.53-1.46 (m, 2 H), 0.90-0.84 (m, 3 H). HRMS m/z ($M+H$) $^+$ calcd: 700.3697, obsd: 700.3696.

20

Example 530

Preparation of 3-[(4-(3-fluorophenyl)-4-{2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-isopropyl-2,4-dimethylbenzenesulfonamide




5

3-[(4-(3-Fluorophenyl)-4-{2-[(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-isopropyl-2,4-dimethylbenzenesulfonamide (8 mg, 12%) was obtained as solid from 3-(chlorosulfonyl)-2,6-dimethylbenzoic acid (50 mg, 0.2 mmol), isopropylamine (19 μ L, 0.22 mmol), 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (52 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CDCl_3) δ 7.94-7.92 (m, 1 H), 7.66 (d, $J=7.1$ Hz, 1 H), 7.36 (q, $J=7.7$ HZ, 1 H), 7.30-7.29 (m, 1 H), 7.21-7.14 (m, 3 H), 7.06 (d, $J=7.9$ HZ, 1 H), 6.99-6.95 (m, 2 H), 4.64-4.60 (m, 1 H), 4.34-4.24 (m, 2 H), 3.46-3.35 (m, 2 H), 3.25-3.20 (m, 3 H), 3.06-2.95 (m, 1 H), 2.61 (s, 3 H), 2.58 (s, 3 H), 2.44-2.30 (m, 3 H), 2.20 (s, 3 H), 2.08-2.06 (m, 1 H), 1.95-1.86 (m, 6 H), 1.85-1.64 (m, 6 H), 1.19-1.15 (m, 3H), 1.05-1.01 (m, 3 H). HRMS m/z (M+H) $^+$ calcd: 700.3697, obsd: 700.3711.

20

Example 531

Preparation of N-cyclopropyl-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-2,4-dimethylbenzenesulfonamide




5 *N*-Cyclopropyl-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-2,4-dimethylbenzenesulfonamide (12 mg, 17%) was obtained as solid from 3-(chlorosulfonyl)-2,6-dimethylbenzoic acid (50 mg, 0.2 mmol),
 10 cyclopropylamine (15 μ L, 0.22 mmol), 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (52 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, J=8.0 Hz, 1 H), 7.66 (d, J=8.0 Hz, 1 H), 7.38-7.34 (m, 1 H),
 15 7.31-7.29 (m, 1 H), 7.21-7.13 (m, 3 H), 7.06 (d, J=8.0 Hz, 1 H), 6.99-6.95 (m, 2 H), 5.29-5.14 (m, 1 H), 4.61(br, 1 H), 4.32-4.29 (m, 1 H), 3.60-3.37 (m, 2 H), 3.24-3.20 (m, 3 H), 3.06-3.01 (m, 2 H), 2.60-2.57 (m, 6 H), 2.40-2.30 (m, 3 H), 2.21 (s, 3 H), 2.08-2.06 (m, 1 H), 1.94-1.81 (m, 9 H), 1.69-1.63 (m, 3 H), 0.60-0.53 (m, 4 H). HRMS *m/z* (M+H)⁺ calcd: 698.3540, obsd: 698.3567.

20

Example 532


Preparation of N-cyclopentyl-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-2,4-dimethylbenzenesulfonamide



5

N-Cyclopentyl-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-2,4-dimethylbenzenesulfonamide (24 mg, 33%) was obtained as solid from 3-[(cyclopentyl amino)sulfonyl]-2,6-dimethyl benzoic acid (30 mg, 0.1 mmol), 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1] oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (52 mg, 0.1 mmol) and HATU (38mg, 0.1 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃) δ 7.93-7.91 (m, 1 H), 7.67-7.64 (m, 1 H), 7.36 (q, J=8.0 Hz, 1 H), 7.30-7.28 (m, 1 H), 7.21-7.12 (m, 3H), 7.07-7.05 (m, 1 H), 6.99-6.95 (m, 2 H), 4.63-4.53 (m, 2 H), 4.31-4.28 (m, 1 H), 3.59-3.50 (m, 1 H), 3.44-3.34 (m, 1 H), 3.24 (br, 3 H), 3.08 -3.00 (m, 1 H), 2.61 (s, 3/2H, rotamer), 2.57 (s, 3/2 H, rotamer), 2.56 (s, 3/2 H, rotamer), 2.41 (s, 3/2 H, rotamer), 2.39 (s, 3/2 H, rotamer), 2.36-2.34 (m, 3 H), 2.20 (s, 3/2 H, rotamer), 2.08 (br, 1 H), 1.95-1.76 (m, 10 H), 1.69-1.56 (m, 5 H), 1.52-1.45 (m, 3 H), 1.32-1.27 (m, 1 H). HRMS *m/z* (M+H)⁺ calcd: 726.3853, obsd: 726.3824.

20


Example 533Preparation of 4-hydroxy-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide

5

4-Hydroxy-3-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (20 mg) was obtained as solid from 5-(aminosulfonyl)-2-hydroxybenzoic acid (43 mg, 0.2 mmol), 2-methyl-1-
 10 {[(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-aza bicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole (100mg, 0.2 mmol) and HATU (76mg, 0.2 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.66 (s, 1 H), 7.74 (s, 1 H), 7.65 (dd, *J*=2.4, 8.2 Hz, 1 H), 7.54 (d, *J*=2.2 Hz, 1 H), 7.49-7.47 (m, 1 H), 7.38 (br, 5 H), 7.22-7.10 (m, 5 H), 6.96 (d, 8.6 Hz, 1 H), 4.48
 15 (br, 1 H), 3.90 (br, 1 H), 3.24 (br, 1 H), 3.09-3.03 (m, 4 H), 2.47-2.45 (m, 6 H), 2.09 (br, 5 H), 1.81 (br, 6 H), 1.57 (br, 1 H). HRMS *m/z* (*M*+*H*)⁺ calcd: 628.2958, obsd: 628.2958.

Example 534


20 Preparation of 6-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1,2-benzisothiazol-3(2*H*)-one 1,1-dioxide




25 6-[(4-{2-[(1*R*, 5*S*)-3-(2-Methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1,2-

benzothiazol-3(2*H*)-one 1,1-dioxide (78mg, 61%) was obtained as solid from 3-oxo-2,3-dihydro-1,2-benzisothiazole-6-carboxylic acid 1,1-dioxide (46 mg, 0.2 mmol), 2-methyl-1-((1*R*, 5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo [3.2.1]oct-3-yl)-1*H*-benzimidazole (100mg, 0.2 mmol) and HATU (76mg, 0.2 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.63-7.61 (m, 2 H), 7.57-7.54 (m, 1 H), 7.50-7.47 (m, 1 H), 7.44-7.33 (m, 5 H), 7.25-7.20 (m, 1 H), 7.15-7.07 (m, 3, H), 4.69-4.63 (m, 1 H), 3.93(br, 1 H), 3.47 (br, 3 H), 3.39-3.30 (m, 1 H), 2.48 (s, 3 H), 2.43-2.38 (m, 4 H), 2.27-2.20 (m, 4 H), 1.97-1.78 (m, 7 H), 1.78-1.66 (m, 2 H).
HRMS *m/z* (M+H)⁺ calcd: 638.2801, obsd: 638.2796.

Synthesis of amides via EDCI coupling - Method P





Synthesis of amides via HATU-mediated coupling - Method A




15

Synthesis of amides via anhydride - Method B










Synthesis of amides via Isatoic Anhydride opening - Method U

The following table includes compounds of the present invention that
 5 were prepared by the methods depicted above.



















Example	R	ES- LCMS	Ion	Method	Notes
535		637	M+H	P	1
536		635	M+H	A	
537		666	M+H	A	
538		694	M+H	A	

352









539		582	M+H	A	2
540		628	M+H	A	
541		628	M+H	A	3
542		746	M+H	A	3
543		668	M+H	A	3
544		615	M+H	U	
545		685	M+H	A	4

353


546		633	M+H	A	5
547		705	M+H	A	5
548		627	M+H	A	5
549		643	M+H	A	5
550		642	M+H	A	6
551		659	M+H	A	5
552		552	M+H	A	7

553		689	M+H	A	8
554		512	M+H	A	
555		536	M+H	A	
556		537	M+H	A	9
557		599	M+H	A	9
558		628	M+H	A	6
559		628	M+H	A	10
560		628	M+H	A	5
561		553	M+H	A	11

355

562		661	M+H	A	8
563		675	M+H	A	8
564		689	M+H	A	8
565		703	M+H	A	8
566		703	M+H	A	8
567		701	M+H	A	8
568		641	M+H	A	8
569		683	M+H	A	8


356

570		866	M+H	A	8
-----	---	-----	-----	---	---


Notes:

1. Compound was synthesized according to WO 00/66558, Schering Corporation, 2000.
- 5 2. Compound was synthesized according to procedure outlined for example 572.
3. Compound was synthesized according to the literature procedure described by M. H. Chen et al., *Org. Prep. Proced. Int.*, 2000, v32, pp. 381-384.
- 10 4. Compound was synthesized according to the literature procedure described in *J. Heterocycl. Chem.* 26(5), 1461-8 (1989).
5. Compound was synthesized according to the literature procedure described in *J. Chem. Res. Synop.* 12, 400-1 (1984).
6. Compound was synthesized according to the literature procedure
- 15 described in *Chem. Ber.*, 109(1), 268-73 (1976).
7. Compound was synthesized according to the procedure described in EP 0016565A1, 1980.
8. Compound was synthesized according to procedure outlined for example 572.
- 20 9. Compound was synthesized according to the literature procedure described in *J. Org. Chem.*, 41(6), 1041-51 (1976).
10. Compound was synthesized according to the literature procedure described in *J. Med. Chem.*, 33(2), 781-9 (1990).
11. Compound was synthesized according to the literature procedure
- 25 described in *Bioorganic & Medicinal Chemistry Letters*, 9(18), 2679-2684 (1999).

357


Example 571

Ethyl 1-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-
 azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl)piperidin-1-
 5 yl]carbonylcyclohexanecarboxylate was synthesized via EDCI-HOBt
 acylation method P. ^1H NMR (300MHz, CDCl_3) δ 7.66(d, 1H), 7.43-7.12(m,
 8H), 4.61(m, 1H), 4.22-4.09(m, 2H), 3.65(m, 1H), 3.33-3.05(m, 4H), 2.88(m,
 1H), 2.58(s, 3H), 2.46-2.11(m, 4H), 2.05(s, 1H), 2.00-1.83(m, 12H), 1.63-
 1.52(m, 6H), 1.50-1.37(m, 2H), 1.07-1.32 (m, 4H). HRMS $\text{C}_{38}\text{H}_{50}\text{N}_4\text{O}_3$ m/z
 10 611.3961 (M+H) $_{\text{Cal.}}$, 611.3973 (M+H) $_{\text{Obs.}}$

Example 572

2,2-Dimethyl-3-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-
 15 azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl)piperidin-1-yl)-3-oxopropanoic acid
 was prepared by treating title compound from example 628 with NaOH. ^1H
 NMR (300 MHz, CDCl_3) δ 7.75 (d, 1H), 7.43-7.12 (m, 8H), 4.68 (m, 1H), 4.07
 (m, 1H), 3.69 (m, 1H), 3.30-3.14 (m, 2H), 2.70-2.58 (m, 3H), 2.20 (m, 2H),
 2.05-1.73 (m, 7H), 1.50-1.07 (m, 12H), 1.02-0.74 (m, 3H). HRMS $\text{C}_{33}\text{H}_{42}\text{N}_4\text{O}_3$
 20 m/z 543.3335 (M+H) $_{\text{Cal.}}$, 543.3337 (M+H) $_{\text{Obs.}}$

358

Example 573


1-[(4-{2-[(1R,5S)-3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-

5 yl)carbonyl]cyclopropanecarboxylic acid was prepared by treating title compound from example 573 with NaOH. ¹H NMR (300 MHz, CDCl₃) δ 7.66 (d, 1H), 7.40-7.10 (m, 8H), 4.62 (m, 1H), 4.14 (m, 1H), 3.25 (m, 2H), 3.08 (m, 2H), 2.58 (s, 3H), 2.43-2.19(m, 3H), 2.05-1.78(m, 8H), 1.27(s, 6H) 0.92-0.78(m, 2H). HRMS C₃₃H₄₀N₄O₃ m/z 541.3179 (M+H)_{Cal.}, 541.3163 (M+H)_{Obs.}

10

Example 574

2-Methyl-1-[(1R,5S)-8-(2-{1-[(5-methylpyrazin-2-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




15 Method A (HATU). ¹H NMR (300 MHz, CDCl₃) δ 8.78(s, 1H), 8.41(s, 1H), 7.67(d, 1H), 7.45-7.09(m, 8H), 4.61(m, 1H), 4.25(m, 1H), 3.75(m, 1H), 3.42-3.19(m, 4H), 2.62(s, 3H), 2.57(s, 3H), 2.40-2.19(m, 4H), 2.00-1.79(m, 10H), 1.63(m, 2H). ES-LCMS m/z 548(M+H).

359

Example 575

2-Methyl-1-[(1R,5S)-8-(2-{1-[(1-oxidopyridin-3-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 8.23 (d, 1H), 7.68 (d, 1H), 7.45-7.10 (m, 11H), 4.61 (m, 1H), 4.24 (m, 1H), 3.53 (m, 1H), 3.30-3.18 (m, 4H), 2.58 (s, 3H), 2.40-2.29 (m, 3H), 2.01-1.80 (m, 9H), 1.65 (m, 4H). ES-LCMS m/z 549(M+H).

10

Example 576


1-[(1R,5S)-8-(2-{1-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



15 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.68 (d, 1H), 7.45-7.10 (m, 8H), 6.36 (s, 1H), 4.63 (m, 1H), 4.30-4.10 (m, 2H), 3.79 (s, 3H), 3.62 (m, 1H), 3.40-3.21 (m, 3H), 2.57 (s, 3H), 2.45-2.20 (m, 7H), 2.02-1.78 (m, 10H), 1.64-1.57 (m, 2H). ES-LCMS m/z 550(M+H).

Example 577

1-[(1R,5S)-8-(2-{1-[(5-chlorothiophen-2-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.68 (d, 1H), 7.45-7.01 (m, 9H), 6.86 (d, 1H), 4.61 (m, 1H), 4.15-3.97 (m, 2H), 3.41 (m, 2H), 3.25 (m, 2H), 2.57 (s, 3H), 2.45-2.25 (m, 4H), 2.00-1.77 (m, 10H), 1.61-1.58 (m, 2H). ES-LCMS m/z 572(M+H).

10

Example 578


5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1H-1,2,3-benzotriazole



15 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.94 (s, 1H), 7.84 (d, 1H), 7.69 (d, 1H), 7.48-7.14(m,10H), 4.64 (m, 1H), 4.27 (m, 1H), 3.61 (m, 1H), 3.49-3.22 (m, 4H), 2.54 (s, 3H), 2.45-2.30 (m, 3H), 2.22 (m, 1H), 2.05-1.73 (m, 10H), 1.68-1.57 (m, 2H). ES-LCMS m/z 573(M+H).

Example 579

1-[(1R,5S)-8-(2-{1-[(2-chloro-6-methylpyridin-3-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.70-7.55 (m, 1H), 7.47-7.08 (m, 10H), 4.61 (m, 1H), 4.23 (m, 1H), 3.49-3.17 (m, 5H), 2.57 (s, 6H), 2.45-2.29 (m, 3H), 2.13 (m, 1H), 2.02-1.78 (m, 10H), 1.68-1.56 (m, 2H). ES-LCMS m/z 581(M+H)

10

Example 580

6-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1,3-benzothiazole




15 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 9.08 (s, 1H), 8.20 (d, 1H), 8.03 (s, 1H), 7.69 (d, 1H), 7.55 (d, 1H), 7.41-7.09 (m, 8H), 4.61 (m, 1H), 4.23 (m, 1H), 3.62 (m, 1H), 3.48-3.17 (m, 4H), 2.55 (s, 3H), 2.45-2.28 (m, 3H), 2.25-2.09 (m, 2H), 2.01-1.78 (m, 9H), 1.63 (d, 2H). ES-LCMS m/z 589(M+H).

362

Example 581

methyl 6-[4-(2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-4-phenylpiperidin-1-yl]carbonyl]nicotinate




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 9.19 (s, 1H), 8.38 (d, 1H), 7.65 (d, 1H), 7.45-7.09 (m, 8H), 4.61 (m, 1H), 4.21 (m, 1H), 3.98 (s, 3H), 3.64 (m, 1H), 3.48-3.21 (m, 4H), 2.57 (s, 3H), 2.48-2.29 (m, 3H), 2.25-2.15 (m, 1H), 2.02-1.79 (m, 10H), 1.62-1.55 (m, 2H). ES-LCMS m/z 591(M+H).

10

Example 582

1-[(1R,5S)-8-(2-{1-[(4,5-dichloroisothiazol-3-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




15 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.68 (d, 1H), 7.43-7.09 (m, 8H), 4.65 (m, 1H), 4.30-4.13 (m, 1H), 3.60-3.17 (m, 5H), 2.58 (s, 3H), 2.46-2.19 (m, 4H), 2.05-1.81 (m, 10H), 1.69-1.59 (m, 2H). ES-LCMS m/z 607(M+H).

363

Example 583

1-[(1R,5S)-8-(2-{1-[(2,4-dimethyl-1,3-thiazol-5-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.65 (d, 1H), 7.46-7.18 (m, 8H), 4.61 (m, 1H), 3.98 (m, 1H), 3.42-3.19 (m, 4H), 2.67 (s, 3H), 2.56 (s, 3H), 2.41-2.19 (m, 7H), 2.05-1.75 (m, 10H), 1.70-1.55 (m, 2H). ES-LCMS m/z 567(M+H).

10

Example 584


1-((1R,5S)-8-{2-[1-(2,5-dimethyl-3-furoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



15 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.68 (d, 1H), 7.42-7.11 (m, 8H), 5.91 (s, 1H), 4.61 (m, 1H), 4.06 (m, 1H), 3.76 (m, 1H), 3.40-3.18 (m, 4H), 2.57 (s, 3H), 2.44-2.33 (m, 4H), 2.31 (s, 3H), 2.24 (s, 3H), 2.00-1.72 (m, 10H), 1.62-1.53 (m, 2H). ES-LCMS m/z 550(M+H).

Example 585

2-methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(thien-2-ylacetyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.71 (d, 1H), 7.43-7.09 (m, 9H), 7.01-6.83 (m, 2H), 4.75 (m, 1H), 4.10-3.97 (m, 1H), 3.90 (s, 2H), 3.84 (s, 1H), 3.75-3.59 (m, 4H), 2.54 (s, 3H), 2.52-2.36 (m, 1H), 2.25-1.57 (m, 14H). ES-LCMS m/z 552(M+H).

10

Example 586

2-methyl-1-((1R,5S)-8-{2-[1-(3-methyl-2-furoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




15 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.66 (d, 1H), 7.43-7.09 (m, 9H), 6.32 (s, 1H), 4.63(m, 1H), 3.98 (m, 1H), 3.48-3.20 (m, 4H), 2.58 (s, 3H), 2.48-2.20 (m, 7H), 2.02-1.78 (m, 10H), 1.70-1.55 (m, 2H). ES-LCMS m/z 536(M+H).

365

Example 587

1-((1R,5S)-8-{2-[1-(4,5-dimethyl-2-furoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.68 (d, 1H), 7.44-7.13 (m, 8H), 6.73 (s, 1H), 4.64(m,1H), 4.20-4.07 (m, 2H), 3.55-3.21 (m, 4H), 2.58 (s, 3H), 2.48-2.21 (m, 7H), 2.03-1.80 (m, 13H), 1.70-1.59 (m, 2H). ES-LCMS m/z 550(M+H).

10

Example 588

1-[(1R,5S)-8-(2-{1-[(1-tert-butyl-3-methyl-1H-pyrazol-5-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




15

Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.66 (d, 1H), 7.46-7.13 (m, 8H), 5.95 (s, 1H), 4.63 (m, 1H), 4.20-4.13 (m, 1H), 3.62-3.48 (m, 1H), 3.41-3.13 (m, 4H), 2.58 (s, 3H), 2.48-2.28 (m, 3H), 2.26 (s, 1H), 2.24-2.10 (m, 1H), 2.00-1.65 (m, 12H), 1.59 (s, 10H). ES-LCMS m/z 592(M+H).

366

Example 589

2-methyl-1-((1R,5S)-8-(2-[1-(1-oxidoisonicotinoyl)-4-phenylpiperidin-4-yl]ethyl)-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 8.25 (d, 2H), 8.18 (d, 1H), 7.42-7.12 (m, 10H), 4.63 (m, 1H), 3.39-3.20 (m, 4H), 2.58 (s, 3H), 2.41-2.30 (m, 3H), 1.97-1.77 (m, 10H), 1.68-1.49 (m, 5H). ES-LCMS m/z 549(M+H).

10

Example 590

2-methyl-1-[(1R,5S)-8-(2-{1-[(5-methylthien-2-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




15 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.68 (d, 1H), 7.45-7.06 (m, 9H), 6.69 (m, 1H), 4.64 (m, 1H), 4.19-4.00 (m, 2H), 3.44 (m, 2H), 3.30 (m, 2H), 2.58 (s, 3H), 2.51 (s, 3H), 2.48-2.23 (m, 4H), 2.04-1.81 (m, 10H), 1.70-1.60 (m, 2H). ES-LCMS m/z 552(M+H).

367

Example 591

1-((1R,5S)-8-{2-[1-(5-bromo-2-furoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.69 (d, 1H), 7.47-7.13 (m, 8H), 6.96 (d, 1H), 6.43 (d, 1H), 4.66 (m, 1H), 4.20-4.07 (m, 2H), 3.52-3.22 (m, 4H), 2.59 (s, 3H), 2.49-2.24 (m, 4H), 2.04-1.81 (m, 10H), 1.70-1.60 (m, 2H). ES-LCMS m/z 600(M+H).

10

Example 592

1-[(1R,5S)-8-(2-{1-[(5-bromothiophen-2-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




15 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.66 (d, 1H), 7.48-7.13 (m, 9H), 7.07-6.95 (m, 1H), 4.64 (m, 1H), 4.10-3.94 (m, 2H), 3.53-3.21 (m, 4H), 2.58 (s, 3H), 2.46-2.25 (m, 4H), 2.04-1.79 (m, 10H), 1.71-1.57 (m, 2H). ES-LCMS m/z 616(M+H).

368

Example 593

2-methyl-1-[(1R,5S)-8-[2-(4-phenyl-1-[4-
[(trifluoromethyl)thio]benzoyl]piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-
1H-benzimidazole




5

Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.80-7.62 (m, 3H), 7.50-7.11 (m, 11H), 4.63 (m, 1H), 4.25-4.13 (m, 1H), 3.60-3.17 (m, 4H), 2.57 (s, 1H), 2.44-2.29 (m, 3H), 2.20-2.08 (m, 1H), 2.02-1.70 (m, 10H), 1.62-1.57 (m, 2H). ES-LCMS m/z 632(M+H).

10

Example 594

2-methyl-1-[(1R,5S)-8-(2-[1-[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]-4-phenyl]piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




15

Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.74-7.65 (m, 2H), 7.51-7.14 (m, 12H), 4.59 (m, 1H), 4.18 (m, 1H), 3.38-3.17 (m, 4H), 2.57 (s, 3H), 2.48 (s, 3H), 2.44-2.17 (m, 4H), 2.01-1.54 (m, 12H). ES-LCMS m/z 613(M+H).

369

Example 595

1-[(1R,5S)-8-(2-{1-[(2,6-dichloropyridin-3-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.74-7.60 (m, 2H), 7.54-7.05 (m, 9H), 4.61 (m, 1H), 4.23 (m, 1H), 3.45-3.02 (m, 5H), 2.56 (s, 3H), 2.47-2.09 (m, 4H), 2.00-1.75 (m, 8H), 1.70-1.53 (m, 2H), 1.28-1.20 (m, 2H). ES-LCMS m/z 601(M+H).

10

Example 596

N-{4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}thiourea




15 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 8.95 (s, 1H), 7.67 (d, 1H), 7.45-7.06 (m, 10H), 6.35 (s, 1H), 4.61 (m, 1H), 4.20-4.09 (m, 1H), 3.71-3.51 (m, 1H), 3.48-3.16 (m, 4H), 2.56 (s, 3H), 2.46-2.13 (m, 4H), 2.04-1.55 (m, 13H), 1.27 (s, 2H). ES-LCMS m/z 606(M+H).

370

Example 597

methyl 3-fluoro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.85-7.63 (m, 2H), 7.42-7.09 (m, 10H), 4.62 (m, 1H), 4.30-4.15 (m, 1H), 3.94 (s, 3H), 3.62-3.19 (m, 5H), 2.57 (s, 3H), 2.46-2.12 (m, 4H), 2.00-1.75 (m, 10H), 1.73-1.55 (m, 2H). ES-LCMS m/z 608(M+H).

10

Example 598

1-[(1R,5S)-8-(2-{1-[(2,4-dimethylpyridin-3-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




15 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 8.36 (d, 1H), 7.65 (d, 1H), 7.44-7.23 (m, 8H), 7.05-6.93 (m, 1H), 4.61 (m, 1H), 4.36-4.25 (m, 1H), 3.50-3.03 (m, 7H), 2.56 (m, 4H), 2.37 (m, 4H), 2.15 (s, 3H), 1.97-1.54 (m, 12H). ES-LCMS m/z 561(M+H).

371

Example 599

methyl 2,5-dimethyl-4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzoate




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.83-7.60 (m, 2H), 7.50-7.08 (m, 9H), 4.62 (m, 1H), 4.30-4.11 (m, 1H), 3.91 (s, 2H), 3.42-3.08 (m, 6H), 2.94 (s, 3H), 2.81 (s, 3H), 2.57 (s, 3H), 2.40-2.14 (m, 4H), 2.05-1.75 (m, 10H), 2.20-1.57 (m, 2H). ES-LCMS m/z 618(M+H).

10

Example 600

1-((1R,5S)-8-{2-[1-(3,5-dichloro-1-oxidoisonicotinoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




15 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 8.23-8.10 (m, 1H), 7.70-7.61 (m, 1H), 7.45-7.08 (m, 9H), 4.61 (m, 1H), 4.35-4.24 (m, 1H), 2.58 (s, 3H), 2.48-2.22 (m, 4H), 2.04-1.77 (m, 10H), 1.70-1.57 (m, 2H). ES-LCMS m/z 617(M+H).

372

Example 601

N-{2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}methanesulfonamide




5 Method A (HATU). ¹H NMR (300 MHz, methanol-d₄) δ 7.90-7.75 (m, 2H), 7.71-7.41 (m, 10H), 7.36-7.24 (m, 1H), 5.31 (m, 1H), 4.25-4.04 (m, 3H), 3.62-3.53 (m, 1H), 3.51-3.26 (m, 8H), 3.04-2.90 (m, 1H), 2.84 (s, 3H), 2.78-2.69 (m, 1H), 2.52-2.13 (m, 10H), 2.10-1.82 (m, 2H). ES-LCMS m/z 625(M+H).

10

Example 602

4-chloro-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]aniline




15 Method B (Anhydride). ¹H NMR (300 MHz, methanol-d₄) δ 7.81-7.73 (m, 2H), 7.63-7.57 (m, 2H), 7.46 (s, 1H), 7.31 (m, 1H), 7.20-7.03 (m, 2H), 6.79(d,1H), 5.27 (m, 1H), 4.11-4.03 (m, 2H), 3.30 (m, 6H), 2.97-2.86 (m, 2H), 2.82 (s, 3H), 2.77-2.70 (m, 2H), 2.45-2.11 (m, 10H), 1.95-1.83 (m, 2H). ES-LCMS m/z 581(M+H).

20

373

Example 603

4-bromo-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]aniline




5 Method B (Anhydride). ^1H NMR (300 MHz, methanol- d_4) δ 8.08-7.93 (m, 2H), 7.85-7.72 (m, 2H), 7.64-7.55 (m, 2H), 7.50-7.42 (m, 4H), 7.34-7.27 (m, 1H), 6.80 (d, 1H), 5.31 (m, 1H), 4.14-4.00 (m, 1H), 3.38-3.27 (m, 6H), 2.98-2.87 (m, 2H), 2.86 (s, 3H), 2.83-2.71 (m, 2H), 2.44-2.14 (m, 10H), 2.00-1.85 (m, 2H). ES-LCMS m/z 625(M+H).

10

Example 604

1-[(1R,5S)-8-(2-{1-[(5-ethyl-1-phenyl-1H-1,2,3-triazol-4-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



15


Method A (HATU). Acid precursor synthesized according to procedure outlined in *J. Chem. Res. Synop.*, 12, 400-1 (1984). ^1H NMR (300 MHz, CDCl_3) δ 7.70-7.54 (m, 4H), 7.50-7.13 (m, 10H), 4.64 (m, 1H), 4.40-4.35 (m, 1H), 4.28-4.15 (m, 1H), 3.82-3.65 (m, 1H), 3.48-3.22 (m, 4H), 3.00-2.85 (m, 2H), 2.46-2.30 (m, 4H), 2.04-1.78 (m, 13H), 1.68-1.57 (m, 2H), 1.18-1.05 (m, 3H). ES-LCMS m/z 627(M+H).

20

374

Example 605

4-({5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1H-1,2,3-triazol-4-yl}oxy)phenol




5

Method A (HATU). Acid precursor synthesized according to procedure outlined in *J. Chem. Res. Synop.*, 12, 400-1 (1984). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, 1H), 7.58-7.11 (m, 10H), 6.92-6.88 (m, 1H), 6.75-6.69 (m, 1H), 4.76 (m, 1H), 4.20-3.95 (m, 2H), 3.52-3.21 (m, 4H), 2.52-2.29 (m, 6H), 2.19-1.55 (m, 12H), 1.25 (s, 2H). ES-LCMS m/z 631 (M+H).

10

Example 606

2-methyl-1-[(1R,5S)-8-(2-{1-[(1-methyl-1H-1,2,3-triazol-5-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



15


Method A (HATU). Acid precursor synthesized according to procedure outlined in *J. Org. Chem.* 41(6), 1041-51 (1976). ¹H NMR (300 MHz, CDCl₃) δ 7.75-7.62 (m, 2H), 7.46-7.11 (m, 8H), 4.67-4.53 (m, 1H), 4.16 (s, 3H), 3.85-3.71 (m, 1H), 3.46-3.18 (m, H), 2.45-2.22 (m, 4H), 1.98-1.58 (m, 16H). ES-LCMS m/z 537(M+H).

20

375

Example 607

(1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-phenylpiperidin-4-yl]ethyl}-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane




5 Method A (HATU). Amine portion synthesized according to the procedure described in WO01109106A2, Pfizer Corp. ¹H NMR (300 MHz, CDCl₃) δ 7.44-7.20 (m, 5H), 4.53 (m, 1H), 3.96-3.88 (m, 2H), 3.35-2.89 (m, 8H), 2.44 (s, 3H), 2.22-2.15 (m, 2H), 2.01-1.71 (m, 8H), 1.59-1.49 (m, 4H), 1.36 (d, 5H), 1.29 (s, 9H). ES-LCMS m/z 505(M+H).

10

Example 608

2-bromo-N-ethyl-5-[(4-{2-[1-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



15


Method A (HATU). ¹H NMR (300 MHz, CDCl₃) δ 8.14 (s, 1H), 7.80 (d, 1H), 7.68 (d, 1H), 7.48-7.15 (m, 9H), 5.19 (m, 1H), 4.63 (m, 1H), 4.24 (m, 1H), 3.57-3.49 (m, 1H), 3.38-3.19 (m, 4H), 3.04-2.95 (m, 2H), 2.58 (s, 3H), 2.44-2.33 (m, 3H), 2.22-2.17 (m, 1H), 1.95-1.75 (m, 10H), 1.61 (m, 2H), 1.12 (m, 3H). ES-LCMS m/z 717(M+H).

20

376

Example 609

2-bromo-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl piperidin-1-yl)carbonyl]-N-propylbenzenesulfonamide



5


Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 8.14 (s, 1H), 7.80 (d, 1H), 7.68 (d, 1H), 7.48-7.15 (m, 9H), 5.22 (m, 1H), 4.62 (m, 1H), 4.26 (m, 1H), 3.49 (m, 2H), 3.35-3.25 (m, 4H), 2.92-2.85 (m, 2H), 2.58 (s, 3H), 2.44-2.33 (m, 3H), 2.21-2.17 (m, 1H), 1.95-1.75 (m, 10H), 1.61 (m, 2H), 1.52 (m, 2H), 0.89 (m, 3H). ES-LCMS m/z 731(M+H).

10

Example 610

2-bromo-N-cyclopropyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide

15




Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 8.19 (s, 1H), 7.79 (d, 1H), 7.68 (d, 1H), 7.51-7.16 (m, 9H), 5.68 (m, 1H), 4.66 (m, 1H), 4.20 (m, 1H), 4.26 (m, 1H), 3.54-3.27 (m, 5H), 2.58 (s, 3H), 2.41-2.36 (m, 3H), 2.17 (m, 2H), 1.95-1.75 (m, 10H), 1.64 (m, 2H), 0.68 (m, 4H). ES-LCMS m/z 729(M+H).

20

377

Example 611

2-methyl-1-[(1R,5S)-8-(2-[4-phenyl-1-[(1-phenyl-1H-1,2,3-triazol-5-yl)carbonyl]piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




5 Method A (HATU). ¹H NMR (300 MHz, CDCl₃) δ 7.84 (s, 1H), 7.70-7.48 (m, 5H), 7.43-7.11 (m, 8H), 4.58 (m, 1H), 4.20-4.10 (m, 1H), 3.22 (m, 4H), 3.01 (m, 1H), 2.40-2.23 (m, 3H), 1.96-1.60 (m, 15H), 1.26 (m, 2H). ES-LCMS m/z 599(M+H).

10

Example 612

2-methyl-1-[(1R,5S)-8-{2-[4-phenyl-1-(1H-1,2,3-triazol-5-yl)carbonyl]piperidin-4-yl}ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




15 Method A (HATU). ¹H NMR (300 MHz, CDCl₃) δ 8.13 (s, 1H), 7.70 (d, 1H), 7.40-7.15 (m, 8H), 4.67 (m, 1H), 4.40 (m, 1H), 4.19 (m, 1H), 3.72 (m, 1H), 3.44-3.26 (m, 1H), 2.49-2.21 (m, 8H), 2.01-1.85 (m, 10H), 1.66 (m, 2H), 1.26 (s, 1H). ES-LCMS m/z 523(M+H).

378

Example 613

2-methyl-1-[(1R,5S)-8-(2-{4-phenyl-1-[(3-phenyloxiran-2-yl)carbonyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




5 Method A (HATU). ^1H NMR (300 MHz, CDCl_3) δ 7.66 (m, 1H), 7.38-7.16 (m, 13H), 4.59 (m, 1H), 4.08 (m, 1H), 3.62 (m, 1H), 3.24 (m, 2H), 2.59 (s, 3H), 2.55 (m, 1H), 2.34 (m, 2H), 1.93-1.82 (m, 5H), 1.70-1.52 (m, 10H), 1.25 (s, 2H). ES-LCMS m/z 574(M+H).

10

Example 614

N-ethyl-2,4-difluoro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




15 Method A (HATU). ^1H NMR (300 MHz, methanol- d_4) δ 7.60-7.37 (m, 7H), 7.22 (m, 3H), 6.59 (d, 1H), 4.79 (m, 1H), 3.63 (m, 1H), 3.44 (m, 2H), 3.24 (m, 2H), 2.96 (m, 2H), 2.55 (s, 3H), 2.50-2.33 (m, 2H), 2.12-1.90 (m, 10H), 1.79 (m, 2H), 1.20 (m, 3H), 1.07 (m, 3H). ES-LCMS m/z 675(M+H).

379

Example 615

2-methoxy-N-methyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




5

Method A (HATU). ^1H NMR (300 MHz, methanol- d_4) δ 7.90 (d, 1H), 7.69 (d, 1H), 7.56 (d, 1H), 7.48-7.37 (m, 5H), 7.32-7.19 (m, 4H), 4.78 (m, 1H), 4.03 (s, 3H), 3.39-3.31 (m, 4H), 2.55 (d, 6H), 2.45 (m, 2H), 2.29 (m, 2H), 2.11-1.82 (m, 10H), 1.73 (m, 2H), 1.30 (s, 3H). ES-LCMS m/z 655(M+H).

10

Example 616

N-ethyl-2-methoxy-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




15

Method A (HATU). ^1H NMR (300 MHz, methanol- d_4) δ 7.91 (s, 1H), 7.68 (m, 1H), 7.52 (m, 1H), 7.48-7.36 (m, 5H), 7.32-7.19 (m, 4H), 4.76 (m, 1H), 4.03 (s, 3H), 3.39-3.31 (m, 4H), 2.94 (m, 2H), 2.55 (s, 3H), 2.48-2.39 (m, 4H), 2.09-1.88 (m, 10H), 1.71 (m, 2H), 1.30 (s, 3H), 1.05 (m, 3H). ES-LCMS m/z 669(M+H).

20

Example 617

N-isopropyl-2-methoxy-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



5


Method A (HATU). ^1H NMR (300 MHz, methanol- d_4) δ 7.92 (d, 1H), 7.70 (m, 1H), 7.52 (m, 1H), 7.43-7.36 (m, 5H), 7.32-7.13 (m, 4H), 4.75 (m, 1H), 4.12 (m, 1H), 4.03 (s, 3H), 3.66 (m, 1H), 3.40-3.31 (m, 6H), 2.54 (s, 3H), 2.48-2.36 (m, 4H), 2.04-1.90 (m, 10H), 1.70 (m, 2H), 1.06 (d, 6H). ES-LCMS m/z 683(M+H).

10

Example 618

N-cyclopropyl-2-methoxy-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl] ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide

15




Method A (HATU). ^1H NMR (300 MHz, methanol- d_4) δ 7.95 (m, 1H), 7.73 (m, 1H), 7.52 (m, 1H), 7.48-7.39 (m, 5H), 7.30-7.15 (m, 4H), 4.76 (m, 1H), 4.17 (m, 1H), 4.03 (s, 3H), 3.69 (m, 1H), 3.40-3.31 (m, 6H), 2.54 (s, 3H), 2.48-2.36 (m, 4H), 2.21-1.90 (m, 10H), 1.71 (m, 2H), 0.55 (m, 4H). ES-LCMS m/z 681(M+H).

20

Example 619

2-chloro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]aniline




5 Method A (HATU). ¹H NMR (300 MHz, methanol-d₄) δ 7.53 (m, 1H), 7.41 (m, 5H), 7.27-7.17 (m, 4H), 6.82 (s, 1H), 6.62 (d, 1H), 4.74 (m, 1H), 4.70 (m, 1H), 3.66 (m, 1H), 3.36-3.24 (m, 6H), 2.52 (s, 3H), 2.45-2.40 (m, 2H), 2.22 (m, 1H), 2.02-1.83 (m, 10H), 1.70 (m, 2H). ES-LCMS m/z 581(M+H).

10

Example 620

N-[2-chloro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl]methane sulfonamide




15

Method A (HATU). Intermediate 4-chloro-3-[(methylsulfonyl)amino]benzoic acid was synthesized in same fashion as described in example 639 from precursor example 619. ¹H NMR (300 MHz, methanol-d₄) δ 7.72-7.68 (m, 2H), 7.53 (m, 2H), 7.41 (m, 5H), 7.27-7.17 (m, 3H), 4.73 (m, 1H), 4.14 (m, 1H), 3.53 (m, 7H), 3.30 (m, 2H), 2.51 (s, 3H),
20 2.45-2.29 (m, 4H), 2.01-1.89 (m, 10H), 1.69 (m, 2H). ES-LCMS m/z 659(M+H).

Example 621


1-((1R,5S)-8-{2-[1-(2,6-dimethoxybenzoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



5 Acylation via EDCI-HOBt Method P using 2,6-dimethoxybenzoic acid (Aldrich) on 0.21 mmol scale yielded 50 mg (40%) product. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, 1H), 7.42-7.15 (m, 9H), 6.68-6.47 (m, 2H), 4.67 (m, 1H), 4.23 (m, 1H), 3.85 (s, 3H), 3.72 (s, 3H), 3.47-3.35 (m, 4H), 3.15-3.04 (m, 1H), 2.55 (s, 3H), 2.48-2.25 (m, 3H), 2.20-2.07 (m, 1H), 2.03-1.72 (m, 10H),
10 1.65 (m, 2H). HRMS C₃₇H₄₄N₄O₃ m/z 593.3492 (M+H)_{Cal.}, 593.3478 (M+H)_{Obs.}

Example 622

15 1-((1R,5S)-8-{2-[1-(2,6-dimethylbenzoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




 Acylation via EDCI-HOBt Method P using 2,6-dimethylbenzoic acid (Aldrich) on 0.14 mmol scale yielded 53 mg (67%) product. ¹H NMR (300 MHz, CDCl₃) δ 7.87 (m, 1H), 7.51-6.97 (m, 11H), 5.51 (m, 2H), 4.22 (m, 1H),
20 4.05-3.88 (m, 2H), 3.50 (m, 1H), 3.28 (m, 1H), 3.09 (m, 3H), 2.82 (s, 3H), 2.62

383

(m, 1H), 2.30 (s, 6H), 2.20-2.02 (m, 10H), 1.88 (m, 1H), 1.71 (m, 1H). HRMS $C_{37}H_{44}N_4O$ m/z 561.3593 (M+H)_{Cal.}, 561.3585 (M+H)_{Obs.}

Example 623

- 5 3-chloro-2-[4-(2-[1-(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-4-phenylpiperidin-1-yl]carbonyl]aniline




- 10 Acylation via EDCI-HOBt Method P using 2-amino-6-chlorobenzoic acid (Aldrich) on 0.14 mmol scale yielded 41 mg (50%) product. 1H NMR (300 MHz, $CDCl_3$) δ 7.92 (m, 1H), 7.58-7.25 (m, 8H), 7.07 (m, 1H), 6.80-6.55 (m, 2H), 5.50 (m, 1H), 4.26 (m, 5H), 3.99 (m, 3H), 3.50-3.29 (m, 2H), 3.25-3.09 (m, 1H), 2.99 (m, 2H), 2.83 (s, 3H), 2.20-2.58 (m, 2H), 2.42-2.02 (m, 9H). HRMS $C_{35}H_{40}ClN_5O$ m/z 582.3000 (M+H)_{Cal.}, 582.3002 (M+H)_{Obs.}

15


Example 624

- 1-[1-(1R,5S)-8-(2-[1-(4,6-dimethylpyrimidin-5-yl)carbonyl]-4-phenylpiperidin-4-yl]ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



384

4,6-Dimethylpyrimidine-5-carboxylic acid was synthesized according to the procedure outlined in WO 00/66558, Schering Corporation, 2000, pages 67-69. Overall yield was 12% (3 steps).




5 Acylation via EDCI-HOBt Method P using 4,6-dimethylpyrimidine-5-carboxylic acid on 0.16 mmol scale yielded 46 mg (51%) of the product. ¹H NMR (300 MHz, CDCl₃) δ 8.92 (s, 1H), 7.55 (m, 1H), 7.43 (m, 5H), 7.20 (m, 3H), 4.88 (s, 1H), 4.74 (m, 1H), 4.27 (m, 1H), 3.51-3.07 (m, 5H), 2.54 (s, 6H), 2.50-2.20 (m, 7H), 2.05-1.84 (m, 9H), 1.69 (m, 2H). HRMS C₃₅H₄₂N₆O m/z

10 563.3498 (M+H)_{Cal.}, 563.3483 (M+H)_{Obs.}

Example 625

N-((1R,5S)-8-{2-[1-(3,5-dichloroisonicotinoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-N-[(2Z,4Z)-hexa-2,4-dienyl]ethanimidamide



15


 Acylation via EDCI-HOBt Method P using 4,6-dichloroisonicotinic acid (TCI America) on 0.16 mmol scale yielded 53 mg (55%) of the product. ¹H NMR (300 MHz, CDCl₃) δ 8.66 (s, 1H), 8.61 (s, 1H), 7.54 (d, 1H), 7.42 (m, 5H), 7.30-7.1 (m, 3H), 4.75 (m, 1H), 4.26 (m, 1H), 3.48-3.30 (m, 5H), 3.19 (m, 1H), 2.54 (s, 3H), 2.45-2.26 (m, 4H), 2.10-1.84 (m, 10H), 1.71 (m, 2H). HRMS C₃₄H₃₇Cl₂N₅O m/z 602.2453 (M+H)_{Cal.}, 602.2476 (M+H)_{Obs.}

20

385

Example 626


3-methyl-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]aniline



- 5 Acylation via EDCI-HOBt Method P using 2-amino-6-methylbrnzoic acid (Aldrich) on 0.1 6mmol scale yielded 39 mg (43%) of the product. ¹H NMR (300 MHz, CDCl₃) δ 7.55 (m, 1H), 7.42 (m, 5H), 7.20 (m, 3H), 7.03 (m, 1H), 6.70-6.53 (m, 2H), 4.88 (s, 3H), 4.74 (m, 1H), 4.20 (m, 1H), 3.55-3.26 (m, 3H), 2.27 (m, 2H), 2.10-1.84 (m, 10H), 1.71 (m, 2H), 1.30 (s, 1H). HRMS
- 10 C₃₆H₄₃N₅O m/z 562.3546 (M+H)_{Cal}, 562.3544 (M+H)_{Obs}.


Example 627

ethyl 2-ethyl-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperdin-1-yl)carbonyl]butonate



15

Preparation of 2-(ethoxycarbonyl)-2-ethylbutanoic acid



A solution of diethyl-malonic acid diethyl ester (3.0 g, 13.89 mmol) and potassium hydroxide (0.778 g, 13.89 mmol) in ethanol (50 ml) was stirred at

room temperature for 18 hrs. The solvent was evaporated off and the residue was dissolved in water (20 ml) and extracted with dichloromethane (20 ml). This organic layer was discarded. The aqueous layer was then acidified with concentrated HCl and extracted with dichloromethane (3 x 20 ml). The combined organic layers were dried over magnesium sulfate and concentrated to give a colorless oil (1.9 g, 72%). ¹H NMR (300 MHz, methanol-d₄) δ 4.17 (m, 2H), 1.89 (m, 4H), 1.25 (m, 3H), 0.83 (m, 6H). ES-LCMS m/z 188 (M+H).


- 10 *Preparation of ethyl 2-ethyl-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]butanoate (example 627)*

Acylation via EDCI-HOBt Method P using 2-(ethoxycarbonyl)-2-ethylbutanoic acid on 0.21mmol scale yielded 115 mg (91%) of colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 7.88 (d, 1H), 7.67 (m, 2H), 7.40-7.18 (m, 6H), 4.87 (m, 1H), 4.75-4.40 (m, 2H), 4.22 (m, 3H), 3.41 (m, 2H), 3.12 (m, 2H), 2.55 (s, 3H), 2.45 (m, 1H), 2.20-1.61 (m, 16H), 1.44 (s, 1H), 1.21 (m, 3H), 0.92-0.70 (m, 6H). HRMS C₃₇H₅₀N₄O₃ m/z 599.3961 (M+H)_{Cal}, 599.3981 (M+H)_{Obs}.

20

Example 628


ethyl 2,2-dimethyl-3-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-3-oxopropanoate



- 25 3-Ethoxy-2,2-dimethyl-3-oxopropanoic acid was prepared as in the case of diethyl dimethylmalonate on 15.96 mmol scale to give product as a

387


colorless oil (1.8 g, 70%). ^1H NMR (300 MHz, methanol- d_4) δ 4.17 (m, 2H), 1.43 (s, 6H), 1.25 (m, 3H). ES-LCMS m/z 160 ($\text{M}+\text{H}$).




The compound in example 628 was prepared via acylation (EDCI-HOBt Method P) using 3-ethoxy-2,2-dimethyl-3-oxopropanoic acid on 0.21 mmol scale, yielding 98 mg (82%) of the product as a colorless oil. ^1H NMR (300 MHz, CDCl_3) δ 7.69 (d, 1H), 7.38 (m, 2H), 7.28 (m, 4H), 7.17 (m, 2H), 4.69 (m, 1H), 4.17 (m, 2H), 3.30 (m, 2H), 3.08 (m, 1H), 2.58 (s, 3H), 2.39 (m, 2H), 2.20 (m, 2H), 1.97-1.60 (m, 12H), 1.50-1.37 (m, 4H), 1.30-1.18 (m, 5H), 0.87 (m, 2H). HRMS $\text{C}_{35}\text{H}_{46}\text{N}_4\text{O}_3$ m/z 571.3648 ($\text{M}+\text{H}$) $_{\text{Cal}}$, 571.3646 ($\text{M}+\text{H}$) $_{\text{Obs}}$.

Example 629

ethyl 1-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]cyclopropanecarboxylate




1-(Ethoxycarbonyl)cyclopropanecarboxylic acid was prepared as described in in case of diethyl 1,1-cyclopropanedicarboxylate on 16.13 mmol scale to give product as a colorless oil (2.1 g, 82%). ^1H NMR (300 MHz, methanol- d_4) δ 3.95 (m, 2H), 1.43 (s, 4H), 0.98 (m, 3H). ES-LCMS m/z 158 ($\text{M}+\text{H}$).



The compound in example 629 was prepared by acylation via EDCI-HOBt Method P using 1-(ethoxy carbonyl)cyclopropanecarboxylic acid on 0.21 mmol scale, yielding 82 mg (68%) product as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 7.67 (m, 1H), 7.45-7.10 (m, 8H), 4.62 (m, 1H), 4.15 (m, 2H), 3.69 (m, 1H), 3.26 (m, 4H), 2.58 (s, 3H), 2.44-2.15 (m, 5H), 1.97-1.76 (m, 10H), 1.63 (m, 2H), 1.45 (m, 3H), 1.35-1.16 (m, 5H). HRMS C₃₅H₄₄N₄O₃ m/z 569.3492 (M+H)_{Cal}, 569.3503 (M+H)_{Obs}.

Example 630


10 2-methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(pyrazin-2-ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole



The title compound was obtained by method A (HATU) using 2-pyrazinecarboxylic acid on 0.16 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 8.89 (s, 1H), 8.59 (dd, 2H), 7.67 (m, 1H), 7.45-7.10 (m, 8H), 4.61 (m, 1H), 4.32-4.05 (m, 1H), 3.71 (m, 1H), 3.44-3.21 (m, 4H), 2.56 (s, 3H), 2.42-2.22 (m, 4H), 2.00-1.79 (m, 10H), 1.63 (m, 2H). ES-LCMS m/z 534(M+H).

Example 631


2-methyl-1-[(1R,5S)-8-(2-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



5 The title compound in example 631 was synthesized using method A (HATU) with 1-methyl-1H-pyrrole-2-carboxylic acid on 0.16 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 7.65 (d, 1H), 7.45-7.12 (m, 8H), 6.68 (s, 1H), 6.30 (d, 1H), 6.08 (m, 1H), 4.62 (m, 1H), 4.04 (m, 2H), 3.76 (s, 3H), 3.44 (m, 2H), 3.26 (m, 2H), 2.57 (s, 3H), 2.44-2.18 (m, 4H), 2.03-1.78 (m, 10H), 1.63 (m, 2H). ES-LCMS m/z 535(M+H).

Example 632


2-methyl-1-[(1R,5S)-8-(2-[4-phenyl-1-(1,2,3-thiadiazol-4-ylcarbonyl)piperidin-4-yl]ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



15 The title compound in example 632 was synthesized using method A (HATU) utilizing 1,2,3-thiadiazole-4-carboxylic acid on 0.16 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 8.97 (m, 1H), 7.72-7.51 (m, 1H), 7.45-7.00 (m, 8H), 5.25 (m, 2H), 4.55 (m, 1H), 4.21 (m, 2H), 3.68-3.09 (m, 4H), 2.60-2.20 (m, 5H), 2.02-1.72 (m, 10H), 1.53 (m, 2H). ES-LCMS m/z 540(M+H).

Example 633

2-methyl-1-[(1R,5S)-8-(2-{1-[(2-methylpyridin-3-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



5


The title compound in example 633 was synthesized using method A (HATU) utilizing 2-methylnicotinic acid on 0.16 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 8.54 (d, 1H), 7.65 (m, 1H), 7.45-7.08 (m, 10H), 4.61 (m, 1H), 4.28 (m, 1H), 3.45-3.07 (m, 5H), 2.65-2.48 (m, 4H), 2.43-2.30 (m, 5H), 2.22-2.03 (m, 2H), 1.97-1.77 (m, 8H), 1.63 (m, 2H). ES-LCMS m/z 547(M+H).

10

Example 634

2-methyl-1-[(1R,5S)-8-(2-{1-[(6-methylpyridin-2-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole

15




The title compound in example 634 was synthesized using method A (HATU) utilizing 6-methylpyridine-2-carboxylic acid on 0.16 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 7.66 (m, 2H), 7.45-7.09 (m, 10H), 4.62 (m, 1H), 4.22 (m, 1H), 3.65 (m, 1H), 3.50-3.20 (m, 4H), 2.56 (m, 6H), 2.36 (m, 3H), 2.17 (m, 1H), 2.0-1.80 (m, 10H), 1.63 (m, 2H). ES-LCMS m/z 547(M+H).

20

391

Example 635

1-[(1R,5S)-8-(2-{1-[(2-fluoropyridin-3-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



5


The title compound in example 635 was synthesized using method A (HATU) utilizing 2-fluoronicotinic acid on 0.16 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 8.28 (d, 1H), 7.84 (m, 1H), 7.68 (m, 1H), 7.45-7.20 (m, 9H), 4.61 (m, 1H), 4.27 (m, 1H), 3.45-3.15 (m, 5H), 2.56 (s, 3H), 2.35 (m, 3H), 2.20 (m, 1H), 1.98-1.73 (m, 10H), 1.67-1.55 (m, 2H). ES-LCMS m/z 551(M+H).

10

Example 636

1-[(1R,5S)-8-(2-{1-[(4-bromo-1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole

15



The title compound in example 636 was synthesized using method A (HATU) utilizing 4-bromo-1-ethyl-3-methyl-1H-pyrazole-5-carboxylic acid on 0.16 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 7.66 (d, 1H), 7.50-7.05 (m, 8H), 4.64 (m, 1H), 4.30-2.86 (m, 2H), 3.55 (m, 1H), 3.40-3.28 (m, 4H), 2.58 (s,


20

392

3H), 2.37 (m, 3H), 2.25 (m, 3H), 2.12-1.78 (m, 10H), 1.65 (m, 2H), 1.46 (m, 2H), 1.33 (m, 3H). ES-LCMS m/z 642(M+H).

Example 637


- 5 2-methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(thien-3-ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole



- The title compound in example 637 was synthesized using method A (HATU) utilizing thiophene-3-carboxylic acid on 0.16 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 7.66 (d, 1H), 7.54-7.20 (m, 11H), 4.62 (m, 1H), 4.15 (m, 1H), 3.74 (m, 1H), 3.42-3.20 (m, 4H), 2.57 (s, 3H), 2.45-2.12 (m, 4H), 2.05-1.25 (m, 10H), 1.64 (m, 2H). ES-LCMS m/z 538(M+H).

Example 638

- 15 1-[(1R,5S)-8-(2-{1-[(3-bromothiien-2-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




- The title compound in example 638 was synthesized using method A (HATU) utilizing 3-bromothiophene-2-carboxylic acid on 0.16 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, 1H), 7.45-7.10 (m, 9H), 6.97 (d, 1H), 4.63

393

(m, 1H), 4.15 (m, 1H), 3.63 (m, 1H), 3.37-3.28 (m, 4H), 2.57 (s, 3H), 2.48-2.22 (m, 4H), 2.05-1.80 (m, 10H), 1.65 (m, 2H). ES-LCMS m/z 616(M+H).


Example 639

5




N-{3-[(4-{2-[(1R,5S)-3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}methane sulfonamide was synthesized as in the following scheme.

10




tert-butyl 3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenylcarbamate was prepared by Method A (HATU) using 3-[(tert-butoxycarbonyl)amino]benzoic acid on 1.64 mmol scale. Purification by reverse phase chromatography on C18 using Acetonitrile:water 10:90 to 90:10 and removal of solvent gave 635 mg of product (60%). ES-LCMS m/z 647(M+H).

15



3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenylamine was obtained by dissolving of Boc-derivative coupling product in 20 ml dichloromethane and treatment with 2 ml of trifluoroacetic acid at room temperature for 2 hrs.

- 5 Removal of solvent gave product in quantative yield. ES-LCMS m/z 547(M+H).




N-{3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-

- 10 yl)carbonyl]phenyl}methane sulfonamide was synthesized by dissolving the amine precursor (60 mg, 0.11 mmol) in 3 ml dichloromethane cooled to 0°C, followed by addition of 2 eq of Hunig base and methane sulfonyl chloride (12 mg, 0.11 mmol) and stirring overnight at room temperature. The solution was then diluted with DCM and washed with Na₂CO₃, dried organic layer with
15 MgSO₄ and rotovapped to dryness. Purified by reverse phase chromatography on C18 using Acetonitrile:water 10:90 to 90:10. Removal of solvent gave 38 mg (56%) of the product. ¹H NMR (300 MHz, methanol-d₄) δ 7.83 (m, 2H), 7.68-7.43 (m, 9H), 7.33 (m, 1H), 5.34 (m, 1H), 4.21-4.11 (m, 3H), 3.63 (m, 1H), 3.46 (s, 3H), 3.38-3.27 (m, 4H), 2.97 (m, 2H), 2.85 (s, 3H),
20 2.79 (m, 2H), 2.46 (m, 3H), 2.29-2.19(m, 7H), 1.99-1.87 (m, 2H). ES-LCMS m/z 625(M+H).


Example 640

- N-{4-[(4-{2-[(1R,5S)-3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}methane sulfonamide was synthesized similarly to the title compound in example 639.


395



Tert-butyl 4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenylcarbamate was prepared as described in example 639
 5 using 4-[(tert-butoxycarbonyl)amino]benzoic acid to give 545 mg (53%) of product. ES-LCMS m/z 647(M+H).




4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenylamine was prepared as in
 10 example 639. ES-LCMS m/z 547(M+H).



The title compound in example 640 (N-{4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}methanesulfonamide) was prepared as described for
 15 example 639 to give 28 mg (40%) of the title product of example 640. ¹H NMR (300 MHz, methanol-d₄) δ 7.85 (m, 2H), 7.66-7.41 (m, 10H), 7.33 (m, 1H), 5.39 (m, 1H), 4.21-4.09 (m, 3H), 3.63 (m, 1H), 3.46 (s, 6H), 2.97-2.92 (m,

396


2H), 2.85 (s, 3H), 2.73 (m, 2H), 2.46-2.37 (m, 3H), 2.24 (m, 7H), 1.97-1.90 (m, 2H). ES-LCMS m/z 625(M+H).

Example 641

5

2-[(4-{2-[(1R,5S)-3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-6-nitrophenylamine was synthesized by method B (Anhydride) using 4-nitroisatoic anhydride on 0.16 mmol scale. ¹H NMR (300 MHz, methanol-d₄) δ 7.80 (m, 1H), 7.60 (m, 3H), 7.46 (m, 5H), 7.31-7.25 (m, 2H), 5.31 (m, 1H), 4.20-4.10 (m, 2H), 3.52 (m, 1H), 3.35-3.22 (m, 3H), 2.94 (m, 2H), 2.82 (s, 3H), 2.75 (m, 2H), 2.40 (m, 3H), 2.20 (m, 7H), 1.93-1.86 (m, 2H). ES-LCMS m/z 592(M+H).

15

Example 642


2-[(4-{2-[(1R,5S)-3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-5-nitrophenylamine was synthesized by method B (Anhydride) using 5-nitroisatoic anhydride on 0.16 mmol scale. ¹H NMR (300 MHz, methanol-d₄) δ 8.00 (d, 2H), 7.78 (m, 2H), 7.60 (m, 2H), 7.45 (m, 4H), 7.31 (m, 1H) 6.79 (d,

20

397


1H), 5.30 (m, 1H), 4.10 (m, 2H), 3.40-3.22 (m, 4H), 2.94 (m, 2H), 2.81 (m, 3H), 2.75 (m, 2H), 2.45-2.14 (m, 10H), 1.92-1.90 (m, 2H). ES-LCMS m/z 592(M+H).

5

Example 643

2-Methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(1H-1,2,4-triazol-3-yl)carbonyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole was synthesized by method A (HATU) using 1H-1,2,4-triazole-3-carboxylic acid on 0.16 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 8.09 (s, 1H), 7.68 (m, 1H), 7.45-7.11 (m, 8H), 4.93 (m, 1H), 4.64 (m, 1H), 4.21 (m, 1H), 3.83 (m, 1H), 3.37-3.25 (m, 2H), 2.37 (m, 3H), 2.05-1.81 (m, 7H), 1.78-1.55 (m, 11H). ES-LCMS m/z 523(M+H).

15


Example 644

2-Methyl-1-[(1R,5S)-8-(2-{4-phenyl-1-[(1-phenyl-1H-1,2,4-triazol-3-yl)carbonyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole was synthesized by method A (HATU) using 1-phenyl-1H-1,2,4-triazole-3-carboxylic acid on 0.16 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 7.75-7.61 (m, 2H), 7.57-7.10 (m, 12H), 4.63 (m, 1H), 4.31 (m, 1H), 4.06 (m, 1H), 3.55-

20

398


3.38 (m, 2H), 3.25 (m, 2H), 2.37 (m, 4H), 2.04-1.61 (m, 14H), 1.26 (m, 2H).
ES-LCMS m/z 599(M+H).

Example 645

5

2-Bromo-N-methyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-
8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene
sulfonamide was obtained by method A (HATU) using acid 38 on 0.09 mmol
scale. ¹H NMR (300 MHz, CDCl₃) δ 8.14 (s, 1H), 7.79 (d, 1H), 7.66 (d, 1H),
7.52-7.08 (m, 9H), 5.47 (m, 1H), 4.62 (m, 1H), 4.25 (m, 1H), 3.50 (m, 1H),
3.26 (m, 4H), 2.57 (s, 3H), 2.39 (m, 3H), 2.18 (m, 1H), 2.04-1.58 (m, 12H),
1.27 (s, 3H). ES-LCMS m/z 703(M+H).

10


Example 646

15

2-Bromo-N-isopropyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-
yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene
sulfonamide was obtained by method A (HATU) using Acid 41 on 0.09 mmol
scale. ¹H NMR (300 MHz, CDCl₃) δ 8.16 (s, 1H), 7.80 (d, 1H), 7.65 (d, 1H),
7.50-7.08 (m, 9H), 5.09 (m, 1H), 4.63 (m, 1H), 4.23 (m, 1H), 3.46 (m, 1H),
3.26 (m, 4H), 2.58 (s, 3H), 2.36 (m, 3H), 2.18 (m, 1H), 2.00-1.75 (m, 10H),
1.65-1.58 (m, 2H), 1.12 (m, 6H). ES-LCMS m/z 731(M+H).


20

399

Example 647


2,4-Difluoro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene
 5 sulfonamide was obtained by method A (HATU) using Acid 31 on 0.14 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 7.40 (m, 2H), 7.30-7.10 (m, 9H), 4.84 (m, 1H), 4.24 (m, 1H), 3.40 (m, 2H), 2.98 (s, 3H), 2.30 (m, 5H), 2.15-1.72 (m, 12H). ES-LCMS m/z 647(M+H).

10

Example 648


2,4-Difluoro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-N-propylbenzenesulfonamide was obtained by method A (HATU) using Acid 34
 15 on 0.14 mmol scale. ¹H NMR (300 MHz, CDCl₃) δ 7.56 (m, 1H), 7.45-7.15 (m, 10H), 4.74 (m, 1H), 4.23 (m, 1H), 3.50-3.16 (m, 6H), 2.94 (m, 2H), 2.55 (s, 3H), 2.43 (m, 4H), 2.12-1.86 (m, 10H), 1.74 (m, 2H), 1.51 (m, 2H), 0.89 (m, 3H). ES-LCMS m/z 689(M+H).

400

Example 649

2,4-Difluoro-N-isopropyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl] benzenesulfonamide was obtained by method A (HATU) using
 5 Acid 35 on 0.14 mmol scale. ^1H NMR (300 MHz, CDCl_3) δ 7.68 (m, 1H), 7.45-7.15 (m, 9H), 7.00 (m, 1H), 4.83 (m, 1H), 4.62 (m, 1H), 4.28 (m, 1H), 3.60-3.18 (m, 6H), 2.58 (s, 3H), 2.44-2.15 (m, 4H), 2.00-1.76 (m, 10H), 1.62 (m, 2H), 1.13 (m, 6H). ES-LCMS m/z 689(M+H).


10

Example 650


N-Cyclopropyl-2,4-difluoro-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1] oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide was obtained by Method A (HATU) using
 15 Acid 36 on 0.14 mmol scale. ^1H NMR (300 MHz, CDCl_3) δ 7.67 (m, 1H), 7.45-7.22 (m, 8H), 7.10 (m, 2H), 4.61 (m, 1H), 4.24 (m, 1H), 3.36-3.24 (m, 5H), 2.57 (s, 3H), 2.29 (m, 5H), 1.95-1.60 (m, 10H), 1.62 (m, 2H), 1.25 (s, 4H). ES-LCMS m/z 687(M+H).

20

401


Example 651

Ethyl 3-(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-
 1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-
 5 oxopropanoate was obtained by Method A (HATU) using 3-ethoxy-2,2-
 dimethyl-3-oxopropanoic acid on 0.21 mmol scale. ¹H NMR (300 MHz,
 methanol-d₄) δ 7.55 (m, 1H), 7.43 (m, 2H), 7.19 (m, 4H), 7.00 (m, 1H), 4.72
 (m, 1H), 4.19 (m, 2H), 3.32 (m, 4H), 2.56 (s, 3H), 2.41 (m, 2H), 2.20 (m, 2H),
 2.08-1.79 (m, 10H), 1.69 (m, 2H), 1.40 (s, 5H), 1.25 (m, 6H). ES-LCMS m/z
 10 588(M+H).


Example 652

Ethyl 1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-
 1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]cyclopropane
 15 carboxylate was obtained by Method A (HATU) using 1-
 (ethoxycarbonyl)cyclopropanecarboxylic acid on 0.21 mmol scale. ¹H NMR
 (300 MHz, methanol-d₄) δ 7.55 (m, 1H), 7.44 (m, 2H), 7.19 (m, 4H), 7.00 (m,
 1H), 4.75 (m, 1H), 4.16 (m, 2H), 4.00 (m, 1H), 3.83 (m, 1H), 3.32 (m, 3H),
 2.56 (s, 3H), 2.46 (m, 2H), 2.29 (m, 2H), 2.10-1.83 (m, 10H), 1.69 (m, 2H),
 20 1.47 (s, 2H), 1.27 (m, 6H). ES-LCMS m/z 586(M+H).

402

Example 653

Ethyl 1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]cyclobutane
 5 carboxylate was obtained by Method A (HATU) using 1-(ethoxycarbonyl)cyclobutanecarboxylic acid on 0.21 mmol scale. ^1H NMR (300 MHz, methanol- d_4) δ 7.55 (m, 1H), 7.40 (m, 2H), 7.20 (m, 4H), 7.00 (m, 1H), 4.74 (m, 1H), 4.19 (m, 2H), 3.95 (m, 1H), 3.32 (m, 5H), 3.04 (m, 1H), 2.56 (s, 3H), 2.44 (m, 4H), 2.05-1.78 (m, 10H), 1.70 (m, 2H), 1.27 (m, 6H).
 10 ES-LCMS m/z 600(M+H).


Example 653B

Ethyl 2-ethyl-2-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]butanoate was obtained by Method A (HATU) using 2-(ethoxycarbonyl)-2-ethylbutanoic acid on 0.21 mmol scale. ^1H NMR (300 MHz, CDCl_3) δ 7.70 (d, 1H), 7.33 (m, 3H), 7.07 (m, 4H), 4.64 (m, 1H), 4.18 (m, 2H), 3.50 (m, 1H), 3.24 (m, 4H), 2.57 (s, 3H), 2.38 (m, 2H), 2.14 (m, 2H),
 15 1.94-1.69 (m, 10H), 1.62 (m, 2H), 1.24 (m, 7H), 0.77 (m, 5H). ES-LCMS m/z 616(M+H).
 20

403

Example 654

2-Chloro-5-[(4-(3-chlorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide




5

A mixture of 1-((1R,5S)-8-{2-[4-(3-chlorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (0.15 g, 0.32 mmol), 4-chloro-3-sulfamoylbenzoic acid (0.076 g, 0.32 mmol) and triethylamine (0.14 mL, 1 mmol) in dimethylformamide (1 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.133 g, 0.35 mmol) and the resulting mixture was stirred for 1 h at rt. The mixture was diluted with water and the resulting precipitate was collected, washed with saturated sodium bicarbonate and water, dried and purified by chromatography on silica gel eluting with a 120:15:1 to 60:15:1 gradient of chloroform:methanol:ammonium hydroxide to give 2-chloro-5-[(4-(3-chlorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide as a white solid (0.052 g, 24%). ¹H NMR (400 MHz, CD₃OD₃) δ 8.09 (s, 1H), 7.90 (s, 1H), 7.69 (m, 1H), 7.62 (m, 1H), 7.53 (m, 1H), 7.38–7.46 (m, 3H), 7.27–7.38 (m, 1H), 7.17–7.20 (m, 2H), 4.74 (m, 1H), 4.11 (m, 1H), 3.58 (m, 2H), 3.40 (m, 2H), 3.16–3.22 (m, 1H), 2.54 (s, 3H), 2.41–2.49 (m, 2H), 2.33–2.38 (m, 1H), 2.20–2.26 (m, 1H), 1.94–2.12 (m, 10H), 1.68–1.74 (m, 2H). HRMS C₃₅H₃₉Cl₂N₅O₃S *m/z* 680.2229 (M+H)_{Cal.}, 680.2239 (M+H)_{Obs.}

25

Example 655

1-((1R,5S)-8-{2-[1-(2,2-Dimethylpropanoyl)-4-(2-methylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



5 *Tert*-butyl 4-(1-cyano-2-ethoxy-2-oxoethyl)-4-(2-methylphenyl)piperidine-1-carboxylate. Using the same procedure as in Example 16b 1-bromo-2-methylbenzene (5.1 g, 30 mmol) was used in place of 1-chloro-3-iodobenzene to give *tert*-butyl 4-(1-cyano-2-ethoxy-2-oxoethyl)-4-(2-methylphenyl)piperidine-1-carboxylate as an oil that was used without further purification.

10 [1-(*tert*-Butoxycarbonyl)-4-(2-methylphenyl)piperidin-4-yl](cyano)acetic Acid. *tert*-Butyl 4-(1-cyano-2-ethoxy-2-oxoethyl)-4-(2-methylphenyl)piperidine-1-carboxylate was hydrolysed using the same procedure as in Example 16c to give [1-(*tert*-butoxycarbonyl)-4-(2-methylphenyl)piperidin-4-yl](cyano)acetic acid as an amber foam that was used without further purification.

15 *tert*-Butyl 4-(Cyanomethyl)-4-(2-methylphenyl) piperidine-1-carboxylate. [1-(*tert*-Butoxycarbonyl)-4-(2-methylphenyl)piperidin-4-yl](cyano)acetic acid was subjected to the same decarboxylation conditions used in Example 16d and purified by chromatography on silica gel eluting with a 1:9 to 1:1 ethyl acetate:hexane gradient to give *tert*-butyl 4-(cyanomethyl)-4-(2-methylphenyl)piperidine-1-carboxylate as a solid (2.4 g, 76% overall yield). ¹H NMR (400 MHz, CDCl₃) δ 7.33 (m, 1H), 7.19 (m, 3H), 3.72 (m, 2H), 3.15 (m, 2H), 2.76 (s, 2H), 2.50–2.55 (m, 2H), 2.48 (s, 3H), 1.93 (m, 2H), 1.44 (s, 9H). ES-LCMS *m/z* 337 (M+23).

25 *tert*-Butyl 4-(2-methylphenyl)-4-(2-oxoethyl)piperidine-1-carboxylate. Using the same procedure as in Example 16e using *tert*-butyl 4-

(cyanomethyl)-4-(2-methylphenyl) piperidine-1-carboxylate (2.4 g, 7.5 mmol) gave *tert*-butyl 4-(2-methylphenyl)-4-(2-oxoethyl)piperidine-1-carboxylate as a foam (1.6 g, 69%). ¹H NMR (400 MHz, CDCl₃) δ 9.32 (t, 1H), 7.31 (m, 1H), 7.18 (m, 3H), 3.51–3.58 (m, 2H), 3.37–3.44 (m, 2H), 2.83 (s, 2H), 2.53 (s, 3H), 2.33 (m, 2H), 1.96 (m, 2H), 1.44 (s, 9H). ES-LCMS *m/z* 340 (M+23).

tert-Butyl 4-{2-[3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(2-methylphenyl)piperidine-1-carboxylate.

Using the same procedure as in Example 16f using *tert*-butyl 4-(2-

methylphenyl)-4-(2-oxoethyl)piperidine-1-carboxylate (1.6 g, 5 mmol) gave

tert-butyl 4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(2-methylphenyl)piperidine-1-carboxylate as a solid (2.5 g, 94%).

¹H NMR (400 MHz, CDCl₃) δ 7.67 (m, 1H), 7.13–7.32 (m, 7H), 4.63 (m, 1H), 3.61 (m, 2H), 3.28 (m, 4H), 2.88 (m, 2H), 2.59 (s, 3H), 2.54 (s, 3H), 2.34–2.40 (m, 4H), 1.82–1.96 (m, 8H), 1.63 (m, 2H), 1.44 (s, 9H). ES-LCMS *m/z* 543 (M+1).

2-Methyl-1-(8-{2-[4-(2-methylphenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole Dihydrochloride. Using the same procedure as in Example 16g using *tert*-butyl 4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(2-

methylphenyl)piperidine-1-carboxylate (2.5 g, 4.6 mmol) gave 2-methyl-1-(8-

{2-[4-(2-methylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1] oct-3-yl)-1H-benzimidazole dihydrochloride as a solid (2.2 g, 100%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.28 (s, 1H), 9.02 (m, 2H), 7.89 (m, 1H), 7.80 (m, 1H), 7.55 (m, 2H), 7.20 (m, 4H), 6.05 (m, 1H), 4.11 (m, 2H), 3.26 (m, 2H), 3.05 (m, 1H), 2.88 (s, 4H), 2.81 (m, 3H), 2.53 (s, 3H), 2.33 (m, 2H), 2.13–2.23 (m, 8H), 2.08 (m, 2H). ES-LCMS *m/z* 443 (M+1).


1-((1*R*,5*S*)-8-{2-[1-(2,2-Dimethylpropanoyl)-4-(2-methylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo [3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (example 655). A mixture of 2-methyl-1-(8-{2-[4-(2-

methylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1] oct-3-yl)-1H-benzimidazole dihydrochloride (0.15 g, 0.31 mmol), triethylamine (0.087 mL, 0.62 mmol) and trimethylacetyl chloride (0.043 mL, 0.34 mmol) in

dichloromethane (3 mL) was stirred at rt for 1h. The reaction mixture was diluted with dichloromethane, washed with saturated sodium bicarbonate solution, dried, concentrated and purified by chromatography on silica gel eluting with 33:1 dichloromethane:methanol to give 1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(2-methylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole as a white solid (0.073 g, 45%).
¹H NMR (400 MHz, CDCl₃) δ 7.67 (m, 1H), 7.13–7.31 (m, 7H), 4.62 (m, 1H), 3.86 (m, 2H), 3.48 (m, 2H), 3.24 (m, 2H), 2.56 (m, 6H), 2.34 (m, 4H), 1.93 (m, 8H), 1.60 (m, 4H), 1.27 (s, 9H). HRMS C₃₄H₄₆N₄O *m/z* 527.3750 (M+H)_{Cal.}, 527.3749 (M+H)_{Obs.}.

Example 656

2-Chloro-5-[[4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(2-methylphenyl)piperidin-1-yl]carbonyl}benzenesulfonamide




A mixture of 2-methyl-1-(8-{2-[4-(2-methylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole dihydrochloride (0.30 g, 0.63 mmol), 4-chloro-3-sulfamoylbenzoic acid (0.15 g, 0.63 mmol) and triethylamine (0.3 mL, 2 mmol) in dimethylformamide (2 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.26 g, 0.69 mmol) and the resulting mixture was stirred for 1 h at rt. The mixture was diluted with water and the resulting precipitate was collected, washed with saturated sodium bicarbonate solution and water, dried and purified by chromatography on silica gel eluting with a gradient of 310:15:1 to 200:15:1 of chloroform:methanol:ammonium hydroxide to give 2-chloro-5-[[4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-

yl]ethyl}-4-(2-methylphenyl)piperidin-1-yl]carbonyl}benzenesulfonamide as a white solid (0.089 g, 21%). ^1H NMR (400 MHz, CD_3OD) δ 8.08 (s, 1H), 7.68 (m, 1H), 7.60 (m, 1H), 7.52 (m, 1H), 7.41 (m, 1H), 7.33 (m, 1H), 7.13–7.21 (m, 5H), 4.75 (m, 1H), 4.08 (m, 1H), 3.49 – 3.58 (m, 2H), 3.31 (m, 5H), 2.55 (m, 7H), 2.46 (m, 3H), 1.90–2.09 (m, 10H), 1.65 (m, 2H). HRMS $\text{C}_{36}\text{H}_{42}\text{ClN}_5\text{O}_3\text{S}$ m/z 660.2775 ($\text{M}+\text{H}$)_{Cal.}, 660.2764 ($\text{M}+\text{H}$)_{Obs.}.

Example 657


Methyl 3-{[4-{2-[(1R,5S)-3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(2-methylphenyl)piperidin-1-yl]carbonyl}benzoate



A mixture of 2-methyl-1-(8-{2-[4-(2-methyl phenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole dihydrochloride (0.40 g, 0.84 mmol), monomethyl isophthalate (0.15 g, 0.84 mmol) and triethylamine (0.4 mL, 2.9 mmol) in dimethylformamide (3 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.35 g, 0.92 mmol) and stirred at rt for 1 h. The mixture was diluted with water and the resultant precipitate was collected, washed with water, dried and purified by chromatography on silica gel eluting with 1:33 methanol:dichloromethane to give methyl 3-{[4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(2-methylphenyl) piperidin-1-yl]carbonyl}benzoate as a glass (0.240 g, 47%). ^1H NMR (400 MHz, CDCl_3) δ 8.08 (m, 2H), 7.67 (m, 2H), 7.59 (m, 1H), 7.49 (t, 1H), 7.13–7.29 (m, 6H), 4.62 (m, 1H), 4.11 (m, 1H), 3.93 (s, 3H), 3.56 (m, 2H), 3.26 (m, 2H), 2.54 (m, 5H), 2.36 (m, 4H), 1.95 (m, 10H), 1.64 (m, 4H). HRMS $\text{C}_{38}\text{H}_{44}\text{N}_4\text{O}_3$ m/z 605.3492 ($\text{M}+\text{H}$)_{Cal.} 605.3497 ($\text{M}+\text{H}$)_{Obs.}.

Example 658

3-[[4-{2-[(1R,5S)-3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(2-methylphenyl)piperidin-1-yl]carbonyl]benzoic Acid




5

A solution of methyl 3-[[4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(2-methylphenyl)piperidin-1-yl]carbonyl]benzoate (0.15 g, 0.29 mmol) in methanol (1 mL) was treated with 2N sodium hydroxide solution (1.5 mL) and let stir at rt for 4 h. The mixture was concentrated to remove methanol and acidified by adding 1N hydrochloric acid. The resulting precipitate was collected, washed with water and dried to give 3-[[4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(2-methylphenyl) piperidin-1-yl]carbonyl]benzoic acid as a pale pink solid (0.04 g, 31%). ¹H NMR (400 MHz, CD₃OD) δ 8.11 (m, 1H), 8.02 (s, 1H), 7.54 (m, 3H), 7.48 (m, 1H), 7.34 (m, 1H), 7.17–7.28 (m, 5H), 5.08 (m, 1H), 4.07 (m, 1H), 3.87 (m, 2H), 3.54 (m, 2H), 3.30 (m, 1H), 2.71 (m, 2H), 2.39–2.55 (m, 10H), 2.22–2.30 (m, 6H), 2.09 (m, 3H), 1.92 (m, 1H). HRMS C₃₇H₄₂N₄O₃ *m/z* 591.3335 (M+H)_{Cal.}, 591.3350 (M+H)_{Obs.}

20

Example 659

1-((1R,5S)-8-{2-[4-(1,3-Benzodioxol-5-yl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



5 *tert*-Butyl 4-(1,3-benzodioxol-5-yl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate. Using the same procedure as in Example 16b 4-bromo-1,2-(methylenedioxy)benzene (10.2 g, 51 mmol) was used in place of 1-chloro-3-iodobenzene and purified by chromatography on silica gel eluting with a 1:9 to 1:2 ethyl acetate:hexane gradient to give *tert*-butyl 4-(1,3-benzodioxol-5-yl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate as a foam (4.6 g, 65%). ¹H NMR (400 MHz, CDCl₃) δ 6.80 (m, 3H), 5.96 (s, 2H), 4.01 (m, 2H), 3.90 (m, 2H), 3.53 (s, 1H), 2.88 (m, 2H), 2.41–2.51 (m, 2H), 1.94–2.02 (m, 2H), 1.43 (s, 9H), 1.08 (t, 3H). ES-LCMS *m/z* 415 (M-1).

15 [4-(1,3-Benzodioxol-5-yl)-1-(*tert*-butoxycarbonyl)piperidin-4-yl](cyano)acetic Acid. *tert*-Butyl 4-(1,3-benzodioxol-5-yl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate (4.6 g, 11 mmol) was hydrolysed using the same procedure as in Example 16c to give [4-(1,3-benzodioxol-5-yl)-1-(*tert*-butoxycarbonyl)piperidin-4-yl](cyano)acetic acid as an amber foam (4.2 g, 100%). ¹H NMR (400 MHz, CDCl₃) δ 6.82 (m, 3H), 5.97 (s, 2H), 3.88 (m, 2H), 3.55 (s, 1H), 2.88 (m, 2H), 2.48 (m, 2H), 1.89–2.03 (m, 2H), 1.41 (s, 9H). ES-LCMS *m/z* 387 (M-1).

25 *tert*-Butyl 4-(1,3-benzodioxol-5-yl)-4-(cyano methyl)piperidine-1-carboxylate. [4-(1,3-Benzodioxol-5-yl)-1-(*tert*-butoxycarbonyl)piperidin-4-yl](cyano)acetic acid (4.2 g, 11 mmol) was subjected to the same decarboxylation conditions used in Example 16d and purified by chromatography on silica gel eluting with a 1:9 to 1:2 ethyl acetate:hexane gradient to give *tert*-butyl 4-(1,3-benzodioxol-5-yl)-4-(cyanomethyl) piperidine-

1-carboxylate as a foam (2.9 g, 80%). ¹H NMR (400 MHz, CDCl₃) δ 6.82 (m, 3H), 5.97 (s, 2H), 3.74 (m, 2H), 3.07 (m, 2H), 2.50 (s, 2H), 2.21 (m, 2H), 1.76–1.83 (m, 2H), 1.43 (s, 9H). ES-LCMS *m/z* 245 (M-99).

tert-Butyl 4-(1,3-benzodioxol-5-yl)-4-(2-oxoethyl)piperidine-1-carboxylate. Using the same procedure as in Example 16e *tert*-butyl 4-(1,3-benzodioxol-5-yl)-4-(cyanomethyl)piperidine-1-carboxylate (2.9 g, 8.6 mmol) gave *tert*-butyl 4-(1,3-benzodioxol-5-yl)-4-(2-oxoethyl)piperidine-1-carboxylate (2.0 g, 69%). ¹H NMR (400 MHz, CDCl₃) δ 9.39 (t, 1H), 6.79–6.84 (m, 3H), 5.96 (s, 2H), 3.57–3.63 (m, 2H), 3.21–3.27 (m, 2H), 2.58 (s, 2H), 2.10–2.16 (m, 2H), 1.77–1.84 (m, 2H), 1.43 (s, 9H).

tert-Butyl 4-(1,3-benzodioxol-5-yl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate. Using the same procedure as in Example 16f *tert*-butyl 4-(1,3-benzodioxol-5-yl)-4-(2-oxoethyl)piperidine-1-carboxylate (2.0 g, 5.8 mmol) gave *tert*-butyl 4-(1,3-benzodioxol-5-yl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate after chromatography on silica gel eluting with a dichloromethane to 1:9 methanol:dichloromethane gradient as a foam (2.4 g, 73%). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (m, 1H), 7.28 (m, 1H), 7.12–7.20 (m, 2H), 6.79 (m, 2H), 6.72 (m, 1H), 5.96 (s, 2H), 4.64 (m, 2H), 3.63 (m, 2H), 3.30 (m, 2H), 3.19 (m, 4H), 2.60 (s, 3H), 2.43 (m, 2H), 1.71–2.08 (m, 11H), 1.44 (s, 9H). ES-LCMS *m/z* 573 (M+1).


1-(8-{2-[4-(1,3-Benzodioxol-5-yl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride. Using the same procedure as in Example 16g *tert*-butyl 4-(1,3-benzodioxol-5-yl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate (2.4 g, 4.2 mmol) gave 1-(8-{2-[4-(1,3-benzodioxol-5-yl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride as a solid (2.1 g, 100%). ¹H NMR (400 MHz, DMSO-d₆) δ 11.22 (s, 1H), 9.06–9.13 (m, 2H), 7.88 (m, 1H), 7.80 (m, 1H), 7.56 (m, 2H), 7.02 (s, 1H), 6.91 (m, 1H), 6.82 (m, 1H), 6.02 (s, 2H), 4.07

(m, 2H), 3.19 (m, 2H), 2.88 (s, 3H), 2.78–2.83 (m, 4H), 2.52 (m, 2H), 1.95–2.26 (m, 11H). ES-LCMS m/z 473 (M+1).

Title compound in example 659. A mixture of 1-(8-{2-[4-(1,3-benzodioxol-5-yl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (0.2 g, 0.39 mmol), triethylamine (0.11 mL, 0.78 mmol) and trimethylacetyl chloride (0.053 mL, 0.43 mmol) in dichloromethane (4 mL) was stirred at rt for 1 h before the reaction mixture was quenched with saturated sodium bicarbonate solution. The organic layer was separated, dried and concentrated to give 1-((1R,5S)-8-{2-[4-(1,3-benzodioxol-5-yl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole as a foam (0.18 g, 82%). ^1H NMR (400 MHz, CDCl_3) δ 7.81 (m, 1H), 7.29 (m, 3H), 6.83 (m, 2H), 6.75 (m, 1H), 6.21 (m, 1H), 6.00 (s, 2H), 3.95 (m, 2H), 3.84 (m, 2H), 3.38 (m, 2H), 2.98 (m, 2H), 2.86 (s, 3H), 2.56 (m, 2H), 2.31 (m, 4H), 2.07–2.21 (m, 4H), 1.82 (m, 4H), 1.26 (s, 9H). HRMS $\text{C}_{34}\text{H}_{44}\text{N}_4\text{O}_3$ m/z 557.3492 (M+H) $_{\text{Cal.}}$, 557.3495 (M+H) $_{\text{Obs.}}$.

Example 660

5-[(4-(1,3-Benzodioxol-5-yl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-2-chlorobenzene sulfonamide




A mixture of 1-(8-{2-[4-(1,3-benzodioxol-5-yl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (0.40 g, 0.78 mmol), triethylamine (0.35 mL, 2.5 mmol) and 4-chloro-3-sulfamoylbenzoic acid (184 mg, 0.78 mmol) in dimethylformamide (2.5 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (327 mg, 0.86 mmol) and the resulting mixture was

stirred for 1 h at rt. The mixture was diluted with water and the resulting precipitate was collected, washed with saturated sodium bicarbonate solution and water, dried and purified by chromatography on silica gel eluting with a chloroform:methanol:ammonium hydroxide 400:15:1 to 200:15:1 gradient to
 5 give 5-[(4-(1,3-benzodioxol-5-yl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl) carbonyl]-2-chlorobenzenesulfonamide as a solid (0.09 g, 17%). ¹H NMR (400 MHz, CD₃OD) δ 8.08 (s, 1H), 7.67 (m, 1H), 7.59 (m, 1H), 7.51 (m, 1H), 7.41 (m, 1H), 7.17 (m, 2H), 6.94 (s, 1H), 6.81–6.86 (m, 2H), 5.93 (s, 2H), 4.74 (m, 1H),
 10 4.11 (m, 1H), 3.52 (m, 1H), 3.30 (m, 4H), 2.52 (s, 3H), 2.44 (m, 2H), 2.39 (m, 1H), 2.18 (m, 1H), 1.80–2.04 (m, 12H), 1.70 (m, 2H). HRMS C₃₆H₄₀ClN₅O₅ *m/z* 690.2517 (M+H)_{Cal.}, 690.2538 (M+H)_{Obs.}.

Example 661

15 1-[(1R,5S)-8-(2-{1-Benzyl-4-[3-(trifluoromethyl)phenyl] piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



The following compounds were prepared according to the procedures in Example 16.

20 *Ethyl (1-Benzylpiperidin-4-ylidene)(cyano)acetate*. Using the same procedure as in Example 16a 1-benzylpiperidin-4-one (47.3 g, 0.25 mol) was used in place of *tert*-butyl 4-oxo-1-piperidine carboxylate to give ethyl (1-benzylpiperidin-4-ylidene)(cyano)acetate as a solid (72.2 g, 100%). ¹H NMR (400 MHz, CDCl₃) δ 7.25–7.35 (m, 5H), 4.26 (q, 2H), 3.54 (s, 2H), 3.14 (m,
 25 2H), 2.78 (m, 2H), 2.64 (m, 2H), 2.59 (m, 2H), 1.33 (t, 3H). ES-LCMS *m/z* 283 (M-1).

Ethyl {1-Benzyl-4-[3-(trifluoromethyl)phenyl] piperidin-4-yl}(cyano)acetate. Using the same procedure as in Example 16b 3-

bromobenzotrifluoride (20.2 g, 0.09 mol) was used in place of 1-chloro-3-iodobenzene to give ethyl {1-benzyl-4-[3-(trifluoro methyl)phenyl]piperidin-4-yl}(cyano)acetate as a solid (5.6 g, 37%). ¹H NMR (400 MHz, CDCl₃) δ 7.51–7.63 (m, 4H), 7.22–7.35 (m, 5H), 3.92 (m, 2H), 3.69 (s, 1H), 3.40 (s, 2H), 2.67 (m, 2H), 2.51 (m, 2H), 2.18–2.29 (m, 4H), 0.99 (t, 3H). ES-LCMS *m/z* 431 (M+1).

{1-Benzyl-4-[3-(trifluoromethyl)phenyl] piperidin-4-yl}(cyano)acetic Acid. Ethyl {1-benzyl-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}(cyano) acetate (5.6 g, 0.013 mol) was hydrolysed using the same procedure as in Example 16c to give an amber foam (5.2 g, 100%) that was used without further purification.

{1-Benzyl-4-[3-(trifluoromethyl)phenyl] piperidin-4-yl}acetonitrile. {1-Benzyl-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}(cyano)acetic acid (5.2 g, 0.013 mol) was subjected to the same decarboxylation conditions used in Example 16d and purified by column chromatography on silica gel eluting with 1:1 hexane:ethyl acetate to give {1-benzyl-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}acetonitrile as a solid (2.9 g, 63%). ¹H NMR (400 MHz, CDCl₃) δ 7.51–7.58 (m, 4H), 7.25–7.36 (m, 5H), 3.49 (s, 2H), 2.60 (m, 4H), 2.35 (m, 4H), 2.10 (s, 2H). ES-LCMS *m/z* 359 (M+1).


{1-Benzyl-4-[3-(trifluoromethyl)phenyl] piperidin-4-yl}acetaldehyde. Using the same procedure as in Example 16e {1-benzyl-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}acetonitrile (2.4 g, 6.7 mmol) gave {1-benzyl-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}acetaldehyde as a tan foam (2.0 g, 83%). ¹H NMR (400 MHz, CDCl₃) δ 9.38 (t, 1H), 7.48–7.60 (m, 4H), 7.25–7.32 (m, 5H), 3.45 (s, 2H), 2.70 (s, 2H), 2.56 (m, 2H), 2.38 (m, 2H), 2.25 (m, 2H), 2.01 (m, 2H). ES-LCMS *m/z* 360 (M-1).

Title compound in example 661: 1-[(1R,5S)-8-(2-{1-Benzyl-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole. Using the same procedure as in Example 16f {1-benzyl-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}acetaldehyde (0.23 g, 0.64 mmol) was used in place of *tert*-butyl 4-(3-chlorophenyl)-4-(2-oxoethyl) piperidine-1-carboxylate to give 1-[(1R,5S)-8-(2-{1-benzyl-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-

methyl-1H-benzimidazole as a glass (0.10 g, 27%). ¹H NMR (400 MHz, CDCl₃) δ 7.67 (m, 1H), 7.55 (s, 1H), 7.49 (s, 3H), 7.26–7.33 (m, 6H), 7.12–7.20 (m, 2H), 4.63 (m, 1H), 3.53 (m, 2H), 3.25 (m, 2H), 2.72 (m, 2H), 2.56 (s, 3H), 2.38 (m, 4H), 2.24 (m, 2H), 1.84–1.94 (m, 10H), 1.63 (m, 2H). HRMS C₃₆H₄₁F₃N₄ *m/z* 587.3362 (M+H)_{Cal.}, 587.3375 (M+H)_{Obs.}.

Example 662

1-[(1R,5S)-8-(2-{1-(2,2-Dimethylpropanoyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




2-Methyl-1-[8-(2-{4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride. A mixture of 1-[(1R,5S)-8-(2-{1-benzyl-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole (0.2 g, 0.34 mmol), 1N hydrochloric acid (0.34 mL) and 10% Palladium on carbon (50 mg) in methanol (10 mL) was hydrogenated overnight at rt and atmospheric pressure. The mixture was filtered through celite and concentrated to give 2-methyl-1-[8-(2-{4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride as a solid (0.15 g, 89%) that was used without further purification.

Title compound in example 662: 1-[(1R,5S)-8-(2-{1-(2,2-Dimethylpropanoyl)-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole. A mixture of 2-methyl-1-[8-(2-{4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (0.05 g, 0.1 mmol), triethylamine (0.028 mL, 0.2 mmol) and trimethylacetyl chloride (0.014

mL, 0.11 mmol) in dichloromethane (1 mL) was stirred 1 h at rt before the reaction mixture was quenched with saturated sodium bicarbonate solution. The organic layer was separated, dried, concentrated and purified by chromatography on silica gel eluting with 1:33 methanol:dichloromethane to give 1-[(1R,5S)-8-(2-{1-(2,2-dimethylpropanoyl)-4-[3-(trifluoro methyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole as a glass (0.025 g, 43%). ¹H NMR (400 MHz, CDCl₃) δ 7.68 (m, 1H), 7.54 (m, 4H), 7.13–7.21 (m, 3H), 4.62 (m, 1H), 3.95 (m, 2H), 3.25 – 3.37 (m, 3H), 2.61 (s, 3H), 2.40 (m, 2H), 2.18 (m, 3H), 1.88 (m, 10H), 1.64 (m, 2H), 1.27 (s, 9H). HRMS C₃₄H₄₃F₃ON₄ *m/z* 581.3467 (M+H)_{Cal.}, 581.3476 (M+H)_{Obs.}.

Example 663

2-Chloro-5-({4-[2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-4-[3-(tri-fluoromethyl)phenyl]piperidin-1-yl]carbonyl)benzene-sulfonamide




A mixture of 2-methyl-1-[8-(2-{4-[3-(trifluoromethyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (0.1 g, 0.2 mmol), triethylamine (0.056 mL, 0.4 mmol) and 3-(aminosulfonyl)-4-chlorobenzoyl chloride (0.056 g, 0.22 mmol) in dichloromethane (2 mL) was stirred at rt for 1.5 h. The reaction mixture was diluted with dichloromethane, washed with saturated sodium bicarbonate solution, dried, concentrated and purified by three successive chromatographies on silica gel eluting with mixtures of methanol in dichloromethane to give 2-chloro-5-({4-[2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]carbonyl)benzenesulfonamide as a wax (0.002 g, 2%). ¹H NMR (400 MHz, CD₃OD₃) δ 7.79–7.94 (m, 2H), 7.57–7.71

(m, 5H), 7.40–7.54 (m, 2H), 7.15–7.21 (m, 2H), 4.73 (m, 1H), 4.15 (m, 1H), 3.39–3.55 (m, 4H), 3.16–3.22 (m, 1H), 2.52 (s, 3H), 2.34–2.50 (m, 3H), 2.22–2.32 (m, 1H), 1.94–2.12 (m, 10H), 1.68–1.74 (m, 2H). HRMS $C_{36}H_{39}ClF_3N_5O_3S$ m/z 714.2492 (M+H)_{Cal.}, 714.2496 (M+H)_{Obs.}.

5

Example 664

1-((1R,5S)-8-{2-[4-(3-Chloro-5-fluorophenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



10

tert-Butyl 4-(3-chloro-5-fluorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate. Using the same procedure as in Example 16b 1-bromo-3-chloro-5-fluorobenzene (10.7 g, 51 mmol) was used in place of 1-chloro-3-iodobenzene to give *tert*-butyl 4-(3-chloro-5-fluorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate as an amber foam that was used without further purification.

15

[1-(*tert*-Butoxycarbonyl)-4-(3-chloro-5-fluorophenyl)piperidin-4-yl](cyano)acetic Acid. *tert*-Butyl 4-(3-chloro-5-fluorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate was hydrolysed using the same procedure as in Example 16c to give [1-(*tert*-butoxycarbonyl)-4-(3-chloro-5-fluorophenyl) piperidin-4-yl](cyano)acetic acid as an amber foam that was used without further purification.

20

tert-Butyl 4-(3-chloro-5-fluorophenyl)-4-(cyanomethyl)piperidine-1-carboxylate. [1-(*tert*-Butoxycarbonyl)-4-(3-chloro-5-fluorophenyl)piperidin-4-yl](cyano)acetic acid was subjected to the same decarboxylation conditions used in Example 16d and purified by chromatography on silica gel eluting with 1:4 ethyl acetate:hexane to give *tert*-butyl 4-(3-chloro-5-fluorophenyl)-4-

25

(cyanomethyl)piperidine-1-carboxylate as a solid (2.3 g, 38% overall). ¹H NMR (400 MHz, CDCl₃) δ 7.13 (s, 1H), 7.05 (m, 1H), 6.98 (m, 1H), 3.71 (m, 2H), 3.11 (m, 2H), 2.55 (s, 2H), 2.20 (m, 2H), 1.86 (m, 2H), 1.43 (s, 9H). ES-LCMS *m/z* 253 (M-99).

5 *tert*-Butyl 4-(3-chloro-5-fluorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate. Using the same procedure as in Example 16e *tert*-butyl 4-(3-chloro-5-fluorophenyl)-4-(cyanomethyl)piperidine-1-carboxylate (2.3 g, 6.5 mmol) gave *tert*-butyl 4-(3-chloro-5-fluorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate as an amber foam (1.5 g, 65%). ¹H NMR (400 MHz, CDCl₃) δ
10 9.43 (t, 1H), 7.12 (s, 1H), 6.95–7.01 (m, 2H), 3.55–3.62 (m, 2H), 3.24–3.30 (m, 2H), 2.63 (s, 2H), 2.04–2.17 (m, 2H), 1.80–1.91 (m, 2H), 1.42 (s, 9H). ES-LCMS *m/z* 354 (M-1).

tert-Butyl 4-(3-chloro-5-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate.
15 Using the same procedure as in Example 16f *tert*-butyl 4-(3-chloro-5-fluorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate (1.5 g, 4.2 mmol) gave *tert*-butyl 4-(3-chloro-5-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate as a solid (1.7 g, 71%). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (m, 1H), 7.29 (m, 1H), 7.17 (m, 2H),
20 7.08 (s, 1H), 6.98 (m, 1H), 6.91 (m, 1H), 4.66 (m, 2H), 3.83 (m, 2H), 3.62 (m, 2H), 3.25 (4H), 3.01 (m, 1H), 2.60 (s, 3H), 2.44 (m, 2H), 2.02 (m, 4H), 1.71–1.86 (m, 6H), 1.43 (s, 9H). ES-LCMS *m/z* 581 (M+1).

 1-((1*R*,5*S*)-8-{2-[4-(3-Chloro-5-fluorophenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride. Using
25 the same procedure as in Example 16g *tert*-butyl 4-(3-chloro-5-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate (1.7g, 2.9 mmol) gave 1-((1*R*,5*S*)-8-{2-[4-(3-chloro-5-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride as a solid (1.5 g, 100%). ¹H NMR (400 MHz,
30 DMSO-*d*₆) δ 11.26 (s, 1H), 9.14 (s, 2H), 7.89 (m, 1H), 7.80 (m, 1H), 7.55 (m, 2H), 7.37 (m, 1H), 7.30 (m, 2H), 6.03 (m, 1H), 4.11 (m, 2H), 3.22 (m, 2H),


3.11 (m, 1H), 2.88 (s, 3H), 2.75–2.90 (m, 4H), 2.30 (m, 2H), 2.10–2.25 (m, 8H), 2.08 (m, 2H). ES-LCMS m/z 481 (M+1).

1-((1*R*,5*S*)-8-{2-[4-(3-Chloro-5-fluorophenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (example 664). A mixture of 1-((1*R*,5*S*)-8-{2-[4-(3-chloro-5-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (0.2 g, 0.39 mmol), triethylamine (0.11 mL, 0.78 mmol) and trimethylacetyl chloride (0.053 mL, 0.43 mmol) in dichloromethane (4 mL) was stirred at rt for 1 h before the reaction mixture was quenched with saturated sodium bicarbonate solution. The organic layer was separated, dried, concentrated and purified by two successive chromatographies on silica gel using a dichloromethane to methanol:dichloromethane 1:20 gradient to give 1-((1*R*,5*S*)-8-{2-[4-(3-chloro-5-fluorophenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole as a glass (0.06 g, 27%). ^1H NMR (400 MHz, CDCl_3) δ 7.67 (m, 1H), 7.29 (m, 1H), 7.17 (m, 2H), 7.09 (m, 1H), 7.00 (m, 1H), 6.93 (m, 1H), 4.72 (m, 1H), 3.90 (m, 2H), 3.37 (m, 4H), 2.61 (s, 3H), 2.47 (m, 2H), 1.89–2.11 (m, 8H), 1.78 (m, 6H), 1.27 (s, 9H). HRMS $\text{C}_{33}\text{H}_{42}\text{ClFN}_4\text{O}$ m/z 565.3109 (M+H)_{Cal.}, 565.3095 (M+H)_{Obs.}

Example 665

2-Chloro-5-[(4-(3-chloro-5-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzene sulfonamide

5




A mixture of 1-((1R,5S)-8-{2-[4-(3-chloro-5-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1] oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (0.40 g, 0.78 mmol), triethylamine (0.35 mL, 2.5 mmol) and 4-chloro-3-sulfamoylbenzoic acid (184 mg, 0.78 mmol) in dimethylformamide (2.5 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (327 mg, 0.86 mmol) and the resulting mixture was stirred for 1 h at rt. The mixture was diluted with water and the resulting precipitate was collected, washed with saturated sodium bicarbonate solution and water, dried and purified by chromatography on silica gel eluting with a gradient of chloroform:methanol:ammonium hydroxide 400:15:1 to 200:15:1 to give 2-chloro-5-[(4-(3-chloro-5-fluoro phenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide as a solid (0.20 g, 36%).

¹H NMR (400 MHz, CD₃OD) δ 8.09 (s, 1H), 7.67 (m, 1H), 7.60 (m, 1H), 7.51 (m, 1H), 7.42 (m, 1H) 7.30 (s, 1H), 7.10–7.21 (m, 4H), 4.72 (m, 1H), 4.06 (m, 1H), 3.57 (m, 1H), 3.47 (m, 1H), 3.30 (m, 3H), 2.52 (s, 3H), 2.40–2.48 (m, 4H), 2.27 (m, 1H), 2.14 (m, 1H), 1.83–2.04 (m, 10H), 1.70 (m, 2H). HRMS C₃₅H₃₈Cl₂FN₅O₃S *m/z* 698.2134 (M+H)_{Cal.}, 698.2161 (M+H)_{Obs.}

25

Example 666

1-((1R,5S)-8-{2-[1-(2,2-Dimethylpropanoyl)-4-(3-ethoxyphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



5 *tert*-Butyl 4-(1-cyano-2-ethoxy-2-oxoethyl)-4-(3-ethoxyphenyl)piperidine-1-carboxylate. Using the same procedure as in Example 16b 3-bromophenetole (10.2 g, 51 mmol) was used in place of 1-chloro-3-iodobenzene and purified by chromatography on silica gel eluting with a 1:9 to 1:2 ethyl acetate:hexane gradient to give *tert*-butyl 4-(1-cyano-2-ethoxy-2-oxoethyl)-4-(3-ethoxyphenyl)piperidine-1-carboxylate as an oil (5.4 g, 77%). ¹H NMR (400 MHz, CDCl₃) δ 7.29 (m, 1H), 6.81–6.91 (m, 3H), 3.90–4.04 (m, 4H), 3.55 (s, 1H), 2.86 (m, 2H), 2.54 (m, 2H), 1.95–2.05 (m, 4H), 1.43 (s, 9H), 1.40 (t, 3H), 1.04 (t, 3H). ES-LCMS *m/z* 317 (M-99).

15 [1-(*tert*-Butoxycarbonyl)-4-(3-ethoxyphenyl)piperidin-4-yl](cyano)acetic Acid. *tert*-Butyl 4-(1-cyano-2-ethoxy-2-oxoethyl)-4-(3-ethoxyphenyl)piperidine-1-carboxylate was hydrolysed using the same procedure as in Example 16c to give [1-(*tert*-butoxycarbonyl)-4-(3-ethoxyphenyl)piperidin-4-yl](cyano)acetic acid as a pale yellow foam that was used without further purification.

20 *tert*-Butyl 4-(cyanomethyl)-4-(3-ethoxyphenyl) piperidine-1-carboxylate. [1-(*tert*-Butoxycarbonyl)-4-(3-ethoxyphenyl)piperidin-4-yl](cyano)acetic acid was subjected to the same decarboxylation conditions used in Example 16d and purified by chromatography on silica gel eluting with a 1:9 to 1:2 ethyl acetate:hexane gradient to give *tert*-butyl 4-(cyanomethyl)-4-(3-ethoxyphenyl)piperidine-1-carboxylate as a solid (3.1 g, 72%). ¹H NMR (400 MHz, CDCl₃) δ 7.31 (m, 1H), 6.80–6.94 (m, 3H), 4.04 (m, 2H), 3.74–3.80 (m,

2H), 3.06 (m, 2H), 2.53 (s, 2H), 2.30 (m, 2H), 1.83 (m, 2H), 1.43 (s, 9H), 1.40 (t, 3H). ES-LCMS m/z 245 (M-99).

tert-Butyl 4-(3-ethoxyphenyl)-4-(2-oxoethyl) piperidine-1-carboxylate.

Using the same procedure as in Example 16e *tert*-butyl 4-(cyanomethyl)-4-(3-ethoxyphenyl)piperidine-1-carboxylate (3.1 g, 9 mmol) gave *tert*-butyl 4-(3-ethoxyphenyl)-4-(2-oxoethyl) piperidine-1-carboxylate as a solid (2.1 g, 68%).

^1H NMR (400 MHz, CDCl_3) δ 9.37 (t, 1H), 7.30 (m, 1H), 6.89–6.92 (m, 2H), 6.76 (m, 1H), 4.02 (m, 2H), 3.59–3.65 (m, 2H), 3.19–3.26 (m, 2H), 2.60 (s, 2H), 2.17–2.22 (m, 2H), 1.85 (m, 2H), 1.43 (s, 9H), 1.40 (m, 3H).


tert-Butyl 4-(3-ethoxyphenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate. Using the same procedure as in Example 16f *tert*-butyl 4-(3-ethoxy phenyl)-4-(2-oxoethyl)piperidine-1-carboxylate (2.1 g, 6 mmol) gave *tert*-butyl 4-(3-ethoxyphenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate after chromatography on silica gel eluting with a dichloromethane to 1:9 methanol:dichloromethane gradient as a solid (3.0 g, 88%). ^1H NMR (400 MHz, CDCl_3) δ 7.66 (m, 1H), 7.26 (m, 2H), 7.13–7.19 (m, 2H), 6.85 (m, 2H), 6.75 (m, 1H), 4.66 (m, 2H), 4.03 (m, 2H), 3.65 (m, 2H), 3.30 (m, 2H), 3.17 (m, 4H), 2.60 (s, 3H), 2.40 (m, 2H), 1.65–2.16 (m, 11H), 1.43 (s, 9H), 1.40 (m, 3H). ES-LCMS m/z 573 (M+1).

1-(8-{2-[4-(3-Ethoxyphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride. Using the same procedure as in Example 16g *tert*-butyl 4-(3-ethoxy phenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate (3.0 g, 5.2 mmol) gave 1-(8-{2-[4-(3-ethoxyphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1] oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride as a solid (2.6 g, 100%). ^1H NMR (400 MHz, DMSO-d_6) δ 11.21 (s, 1H), 9.04 (s, 2H), 7.88 (m, 1H), 7.80 (m, 1H), 7.55 (m, 2H), 7.31 (m, 1H), 6.83–6.94 (m, 3H), 6.02 (m, 1H), 4.07 (m, 2H), 3.21 (m, 2H), 2.88 (s, 3H), 2.75–2.83 (m, 4H), 2.52 (m, 2H), 2.18–2.34 (m, 8H), 2.08 (m, 4H), 1.33 (t, 3H). ES-LCMS m/z 473 (M+1).

1-((1R,5S)-8-{2-[1-(2,2-Dimethylpropanoyl)-4-(3-ethoxyphenyl)piperidin-4-yl]ethyl}-8-azabicyclo [3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (example 666). A mixture of 1-(8-{2-[4-(3-ethoxyphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (0.2 g, 0.39 mmol), triethylamine (0.11 mL, 0.78 mmol) and trimethylacetyl chloride (0.053 mL, 0.43 mmol) in dichloromethane (4 mL) was stirred at rt for 1 h before the reaction mixture was quenched with saturated sodium bicarbonate solution. The organic layer was separated, dried, concentrated and purified by chromatography on silica gel eluting with a dichloromethane to 1:9 methanol:dichloromethane gradient to give 1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(3-ethoxyphenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole as a foam (0.14 g, 65%). ¹H NMR (400 MHz, CDCl₃) δ 7.65 (m, 1H), 7.28 (m, 2H), 7.16 (m, 2H), 6.86 (m, 2H), 6.76 (m, 1H), 4.63 (m, 1H), 4.04 (m, 2H), 3.94 (m, 2H), 3.29 (m, 4H), 2.59 (s, 3H), 2.40 (m, 2H), 2.19 (m, 2H), 1.66–1.95 (m, 12H), 1.43 (t, 3H), 1.26 (s, 9H). HRMS C₃₅H₄₈N₄O₂ *m/z* 557.3856 (M+H)_{Cal.}, 557.3840 (M+H)_{Obs.}

Example 667

20 2-Chloro-5-[(4-(3-ethoxyphenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide




A mixture of 1-(8-{2-[4-(3-ethoxyphenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (0.40 g, 0.78 mmol), triethylamine (0.35 mL, 2.5 mmol) and 4-chloro-3-sulfamoylbenzoic acid (184 mg, 0.78 mmol) in dimethylformamide (2.5 mL)

was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (327 mg, 0.86 mmol) and the resulting mixture was stirred for 1 h at rt. The mixture was diluted with water and the resulting precipitate was collected, washed with saturated sodium bicarbonate solution and water, dried and purified by chromatography on silica gel eluting with a chloroform:methanol:ammonium hydroxide 400:15:1 to 200:15:1 gradient to give 2-chloro-5-[(4-(3-ethoxy phenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide as a solid (0.34 g, 62%). ¹H NMR (400 MHz, CD₃OD) δ 8.08 (s, 1H), 7.67 (m, 1H), 7.59 (m, 1H), 7.51 (m, 1H), 7.41 (m, 1H), 7.29 (m, 1H), 7.17 (m, 2H), 6.93–6.98 (m, 2H), 6.81 (m, 1H), 4.74 (m, 1H), 4.17 (m, 1H), 4.04 (m, 2H), 3.54 (m, 1H), 3.30 (m, 4H), 2.52 (s, 3H), 2.40–2.48 (m, 4H), 2.27 (m, 1H), 2.14 (m, 1H), 1.83–2.04 (m, 10H), 1.70 (m, 2H), 1.40 (t, 3H). HRMS C₃₇H₄₄ClN₅O₄S *m/z* 690.2881 (M+H)_{Cal.}, 690.2901 (M+H)_{Obs.}.

Example 668

3-(1-(2,2-Dimethylpropanoyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-4-yl)phenol



20

tert-Butyl 4-(cyanomethyl)-4-(3-methoxyphenyl)piperidine-1-carboxylate was prepared using the same procedures used in Example 16a-d using 1-bromo-3-methoxybenzene in the place of 1-chloro-3-iodobenzene in Example 16b.

25

tert-Butyl 4-(3-methoxyphenyl)-4-(2-oxoethyl)piperidine-1-carboxylate. Using the same procedure as in Example 16e tert-butyl 4-(cyanomethyl)-4-(3-methoxyphenyl)piperidine-1-carboxylate (1.2 g, 3.8 mmol) gave tert-butyl 4-(3-

methoxyphenyl)-4-(2-oxoethyl)piperidine-1-carboxylate as a foam (0.9 g, 69%). ¹H NMR (400 MHz, CDCl₃) δ 9.38 (t, 1H), 7.30 (m, 1H), 6.88–6.95 (m, 2H), 6.78 (m, 1H), 3.80 (s, 3H), 3.60 (m, 2H), 3.21–3.27 (m, 2H), 2.61 (s, 2H), 2.21 (m, 2H), 1.83 (m, 2H), 1.43 (s, 9H).

5 *tert*-Butyl 4-(3-methoxyphenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate. Using the same procedure as in Example 16f *tert*-butyl 4-(3-methoxy phenyl)-4-(2-oxoethyl)piperidine-1-carboxylate (0.9 g, 2.5 mmol) gave *tert*-butyl 4-(3-methoxyphenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate as a foam (1.2 g, 85%). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (m, 1H), 7.28 (m, 2H), 7.16 (m, 2H), 6.88 (m, 2H), 6.76 (m, 1H), 4.62 (m, 1H), 3.82 (s, 3H), 3.65 (m, 2H), 3.16–3.26 (m, 4H), 3.08 (m, 1H), 2.58 (s, 3H), 2.37 (m, 2H), 2.13 (m, 2H), 1.83–1.97 (m, 6H), 1.78 (m, 3H), 1.61 (m, 2H), 1.43 (s, 9H).

15 3-(4-{2-[3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-4-yl)phenol Hydrobromide. A mixture of *tert*-butyl 4-(3-methoxy phenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate (235 mg, 0.42 mmol) and 48% hydrobromic acid was heated at 100°C for 6 h. The mixture was concentrated and used without further purification.

20 3-(1-(2,2-Dimethylpropanoyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-4-yl)phenol (example 668). A mixture of 3-(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-4-yl)phenol hydrobromide (0.22 g, 0.42 mmol), triethylamine (0.117 mL, 0.84 mmol) and trimethylacetyl chloride (0.057 mL, 0.462 mmol) in dichloromethane (2 mL) was stirred at rt for 3h. The reaction mixture was diluted with dichloromethane, washed with saturated sodium bicarbonate solution, dried, concentrated and purified by chromatography on silica gel eluting with 33:1 dichloromethane:methanol to give 3-(1-(2,2-dimethyl propanoyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-4-yl)phenol as a white solid (0.070 g, 32%). ¹H NMR (400 MHz, DMSO-d₆) δ 9.25 (s, 1H), 7.47


425

(m, 1H), 7.34 (m, 1H), 7.05–7.15 (m, 3H), 6.77 (m, 1H), 6.73 (s, 1H), 6.59 (m, 1H), 4.51 (m, 1H), 3.74 (m, 2H), 3.24 (m, 4H), 2.47 (s, 3H), 2.36 (m, 2H), 1.97 (m, 2H), 1.86 (m, 4H), 1.75 (m, 6H), 1.58 (m, 2H), 1.15 (s, 9H). HRMS $C_{33}H_{44}N_4O_2$ m/z 529.3543 (M+H)_{Cal.}, 529.3542 (M+H)_{Obs.}

5

Example 669

2-Chloro-5-[(4-(3-hydroxyphenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide




10

A mixture of 3-(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl} piperidin-4-yl)phenol hydrobromide (0.25 g, 0.48 mmol), triethylamine (0.212 mL, 1.5 mmol) and 4-chloro-3-sulfamoylbenzoic acid (0.113 g, 0.48 mmol) in dimethylformamide (1.5 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.2 g, 0.53 mmol) and the resulting mixture was stirred for 1 h at rt. The mixture was diluted with water and the resulting precipitate was collected, washed with saturated sodium bicarbonate solution and water, dried and purified by column chromatography on silica gel eluting with 200:15:1 chloroform:methanol:ammonium hydroxide to give 2-chloro-5-[(4-(3-hydroxyphenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide as a pink solid (0.022 g, 7%). 1H NMR (400 MHz, CD_3OD) δ 8.08 (s, 1H), 7.67 (m, 1H), 7.60 (m, 1H), 7.51 (m, 1H), 7.41 (m, 1H), 7.18 (m, 3H), 6.84 (m, 2H), 6.67 (m, 1H), 4.74 (m, 1H), 4.15 (m, 1H), 3.54 (m, 1H), 3.32 (m, 7H), 2.52 (s, 3H), 2.34–2.50 (m, 3H), 2.20–2.30 (m, 1H), 1.78–2.10 (m, 10H), 1.65–1.72 (m, 2H). HRMS $C_{35}H_{40}ClN_5O_4S$ m/z 662.2568 (M+H)_{Cal.}, 662.2571 (M+H)_{Obs.}

25

Example 670

1-((1R,5S)-8-(2-[4-(4-Chloro-3-fluorophenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl)-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



5

tert-Butyl 4-(4-chloro-3-fluorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate. Using the same procedure as in Example 16b 1-bromo-4-chloro-5-fluorobenzene (10.7 g, 51 mmol) was used in place of 1-chloro-3-iodobenzene to give *tert*-butyl 4-(4-chloro-3-fluorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate as an amber foam that was used without further purification.

10

[1-(*tert*-Butoxycarbonyl)-4-(4-chloro-3-fluorophenyl)piperidin-4-yl](cyano)acetic Acid. *tert*-Butyl 4-(4-chloro-3-fluorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate was hydrolysed using the same procedure as in Example 16c to give [1-(*tert*-butoxycarbonyl)-4-(4-chloro-3-fluorophenyl) piperidin-4-yl](cyano)acetic acid as an amber solid that was used without further purification.

15

tert-Butyl 4-(4-chloro-3-fluorophenyl)-4-(cyanomethyl)piperidine-1-carboxylate. [1-(*tert*-Butoxycarbonyl)-4-(4-chloro-3-fluorophenyl)piperidin-4-yl](cyano)acetic acid was subjected to the same decarboxylation conditions used in Example 16d and chromatographed on silica gel eluting with a gradient of ethyl acetate:hexane 1:20 to 1:1 to give *tert*-butyl 4-(4-chloro-3-fluorophenyl)-4-(cyanomethyl)piperidine-1-carboxylate as a solid (2.3 g, 38% overall). ¹H NMR (400 MHz, CDCl₃) δ 7.44 (m, 1H), 7.09–7.16 (m, 2H), 3.69–3.75 (m, 2H), 3.09 (m, 2H), 2.54 (s, 2H), 2.20–2.25 (m, 2H), 1.85 (m, 2H), 1.43 (s, 9H). ES-LCMS *m/z* 253 (M-99).

25

tert-Butyl 4-(4-chloro-3-fluorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate. Using the same procedure as in Example 16e *tert*-butyl 4-(4-chloro-3-fluorophenyl)-4-(cyanomethyl)piperidine-1-carboxylate (2.3 g, 6.5 mmol) gave *tert*-butyl 4-(4-chloro-3-fluorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate as an amber foam (1.5 g, 65%). ¹H NMR (400 MHz, CDCl₃) δ 9.43 (t, 1H), 7.40 (m, 1H), 7.07–7.16 (m, 2H), 3.57–3.63 (m, 2H), 3.22–3.29 (m, 2H), 2.66 (s, 2H), 2.11–2.17 (m, 2H), 1.86 (m, 2H), 1.43 (s, 9H). ES-LCMS *m/z* 354 (M-1).

tert-Butyl 4-(4-chloro-3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate. Using the same procedure as in Example 16f *tert*-butyl 4-(4-chloro-3-fluorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate (1.5 g, 4.2 mmol) gave *tert*-butyl 4-(4-chloro-3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl} piperidine-1-carboxylate as a solid (1.4 g, 59%). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (m, 1H), 7.38 (m, 1H), 7.28 (m, 1H), 7.17 (m, 2H), 7.02–7.09 (m, 2H), 4.66 (m, 2H), 3.83 (m, 2H), 3.62 (m, 2H), 3.23 (m, 4H), 3.01 (m, 1H), 2.60 (s, 3H), 2.43 (m, 2H), 1.65–2.01 (m, 10H), 1.43 (s, 9H). ES-LCMS *m/z* 581 (M+1).


1-(8-{2-[4-(4-Chloro-3-fluorophenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride. Using the same procedure as in Example 16g *tert*-butyl 4-(4-chloro-3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl} piperidine-1-carboxylate (1.4 g, 2.4 mmol) gave 1-(8-{2-[4-(4-chloro-3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride as a solid (1.4 g, 93%). ¹H NMR (400 MHz, DMSO-d₆) δ 11.22 (s, 1H), 9.03 (s, 2H), 7.88 (m, 1H), 7.80 (m, 1H), 7.46–7.62 (m, 4H), 7.26 (m, 1H), 6.03 (m, 1H), 4.08 (m, 2H), 3.23 (m, 2H), 3.11 (m, 1H), 2.87 (s, 3H), 2.75–2.90 (m, 4H), 2.30 (m, 2H), 2.10–2.25 (m, 8H), 2.08 (m, 2H). ES-LCMS *m/z* 481 (M+1).

1-((1*R*,5*S*)-8-{2-[4-(4-Chloro-3-fluorophenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (example 670). A mixture of 1-(8-{2-[4-(4-chloro-3-

fluorophenyl)piperidin-4-yl]ethyl)-8-azabicyclo [3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (0.20 g, 0.39 mmol), triethylamine (0.11 mL, 0.78 mmol) and trimethylacetyl chloride (0.053 mL, 0.43 mmol) in dichloromethane (4 mL) was stirred at rt for 1 h before the reaction mixture was quenched with saturated sodium bicarbonate solution. The organic layer was separated, dried, concentrated and purified by chromatography on silica gel eluting with a dichloromethane to 1:9 methanol:dichloromethane gradient to give 1-((1R,5S)-8-{2-[4-(4-chloro-3-fluorophenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole as a white foam (0.11 g, 51%). ¹H NMR (400 MHz, CDCl₃) δ 7.67 (m, 1H), 7.40 (m, 1H), 7.29 (m, 1H), 7.03–7.19 (m, 4H), 4.72 (m, 1H), 3.90 (m, 2H), 3.33 (m, 4H), 2.59 (s, 3H), 2.42 (m, 2H), 1.78–2.13 (m, 14H), 1.27 (s, 9H). HRMS C₃₃H₄₂ClFN₄O *m/z* 565.3109 (M+H)_{Cal.}, 565.3134 (M+H)_{Obs.}.

Example 671

2-Chloro-5-[(4-(4-chloro-3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzene sulfonamide




A mixture of 1-(8-{2-[4-(4-chloro-3-fluoro phenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (0.40 g, 0.78 mmol), triethylamine (0.35 mL, 2.5 mmol) and 4-chloro-3-sulfamoylbenzoic acid (184 mg, 0.78 mmol) in dimethylformamide (2.5 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (327 mg, 0.86 mmol) and the resulting mixture was stirred for 1 h at rt. The mixture was diluted with water and the resulting

precipitate was collected, washed with saturated sodium bicarbonate solution, with water, dried and purified by chromatography on silica gel eluting with a 400:15:1 to 200:15:1 gradient of chloroform:methanol:ammonium hydroxide to give 2-chloro-5-[(4-(4-chloro-3-fluoro phenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide as a solid (0.24 g, 43%). ¹H NMR (400 MHz, CD₃OD) δ 8.09 (s, 1H), 7.68 (m, 1H), 7.61 (m, 1H), 7.34–7.54 (m, 4H), 7.17–7.26 (m, 3H), 4.73 (m, 1H), 4.09 (m, 1H), 3.59 (m, 1H), 3.43 (m, 1H), 3.30 (m, 3H), 2.53 (s, 3H), 2.40–2.48 (m, 4H), 2.28 (m, 1H), 2.16 (m, 1H), 1.83–2.04 (m, 10H), 1.70 (m, 2H). HRMS C₃₅H₃₈Cl₂FN₅O₃S *m/z* 698.2135 (M+H)_{Cal.}, 698.2142 (M+H)_{Obs.}

Example 672

2-Methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




A mixture of 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (75 mg, 0.16 mmol), tetrahydro-2-furoic acid (18 mg, 0.16 mmol) and triethylamine (48 mg, 0.48 mmol) in dimethylformamide (0.5 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (68 mg, 0.18 mmol) and the resulting mixture was stirred at rt for 1 h. The reaction mixture was diluted with water and the resulting precipitate was collected, washed with water and dried. The precipitate was triturated with a mixture of dichloromethane, methanol and hexane to give 2-methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole as an off-white solid (0.017 g, 20%). ¹H NMR (400 MHz, DMSO-d₆) δ 7.61–7.66 (m, 2H), 7.41 (m, 5H),

7.27–7.35 (m, 2H), 4.94 (m, 1H), 4.64 (m, 1H), 4.03 (m, 2H), 3.68–3.77 (m, 5H), 2.98–3.25 (m, 2H), 2.62–2.70 (m, 7H), 2.09–2.24 (m, 7H), 1.88–2.06 (m, 4H), 1.68–1.84 (m, 4H). HRMS $C_{33}H_{42}N_4O_2$ m/z 527.3386 (M+H)_{Cal.}, 527.3380 (M+H)_{Obs.}

5


Example 673

2-Methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole



10 A mixture of 2-methyl-1-{8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (75 mg, 0.16 mmol), tetrahydro-3-furoic acid (18 mg, 0.16 mmol) and triethylamine (48 mg, 0.48 mmol) in dimethylformamide (0.5 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (68
15 mg, 0.18 mmol) and the resulting mixture was stirred at rt for 1h. The reaction mixture was diluted with water and extracted with dichloromethane. The residue from the dichloromethane layer was purified by chromatography on silica gel eluting with 1:20 methanol:dichloromethane to give 2-methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole as a clear oil (0.019 g, 23%). ¹H
20 NMR (400 MHz, DMSO-*d*₆) δ 7.46 (m, 1H), 7.36 (m, 5H), 7.21 (m, 1H), 7.09 (m, 2H), 4.49 (m, 1H), 3.58–3.87 (m, 7H), 3.12–3.35 (m, 6H), 2.28–2.39 (m, 2H), 1.89–2.12 (m, 5H), 1.58–1.86 (m, 10H), 1.53–1.60 (m, 2H). HRMS $C_{33}H_{42}N_4O_2$ m/z 527.3386 (M+H)_{Cal.}, 527.3397 (M+H)_{Obs.}

25

Example 6741-((1R,5S)-8-{2-[1-(1-Benzofuran-2-ylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole


5 A mixture of 2-methyl-1-{8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (100 mg, 0.22 mmol), 2-benzofurancarboxylic acid (36 mg, 0.22 mmol) and triethylamine (66 mg, 0.66 mmol) in dimethylformamide (0.75 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (92

10 mg, 0.24 mmol) and the resulting mixture was stirred at rt for 1h. The reaction mixture was diluted with water and the resulting precipitate was collected, washed with water and dried. The precipitate was purified by chromatography on silica gel eluting with 1:20 methanol:dichloromethane to give 1-((1R,5S)-8-{2-[1-(1-benzofuran-2-ylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-

15 azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole as a clear oil (0.075 g, 60%). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (m, 2H), 7.52 (m, 1H), 7.26–7.44 (m, 9H), 7.16 (m, 2H), 4.61 (m, 1H), 4.16 (m, 2H), 3.40–3.57 (m, 2H), 3.26 (m, 1H), 2.57 (m, 3H), 2.34 (m, 4H), 1.94 (m, 9H), 1.62 (m, 4H). HRMS C₃₇H₄₀N₄O₂ *m/z* 573.3229 (M+H)_{Cal.}, 573.3238 (M+H)_{Obs.}

Example 675

(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl 4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxylate



5


A mixture of 2-methyl-1-{8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (100 mg, 0.22 mmol), (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl 4-nitrophenyl carbonate (78 mg, 0.26 mmol) and N,N-diisopropylethylamine (0.15 mL, 0.88 mmol) in acetonitrile (3 mL) was stirred at rt for 16 h. The reaction mixture was concentrated and the residue in dichloromethane was washed with saturated sodium carbonate solution, dried, concentrated and chromatographed on silica gel eluting with 1:40 methanol:dichloromethane to give (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl 4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxylate as a clear glass (0.064 g, 50%). ¹H NMR (400 MHz, CDCl₃) δ 7.38 (m, 2H), 7.29 (m, 5H), 7.16 (m, 2H), 5.71 (m, 1H), 5.18 (m, 1H), 4.59 (m, 1H), 3.75–4.04 (m, 7H), 3.22 (m, 3H), 3.05 (m, 1H), 2.58 (m, 3H), 2.19–2.36 (m, 4H), 1.80–1.92 (m, 9H), 1.61 (m, 5H). HRMS C₃₅H₄₄N₄O₄ *m/z* 585.3441 (M+H)_{Cal.}, 585.3440 (M+H)_{Obs.}.

20


433

Example 676

2-[(4-{2-[3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



5 Example 676 was prepared as outlined below.



10 *Methyl 2-[(tert-butoxycarbonyl)amino] sulfonylbenzoate 1a.* A mixture of methyl 2-(aminosulfonyl)benzoate (500 mg, 2.3 mmol, 1 eq.), triethylamine (320 μ L, 2.3 mmol, 1 eq.), 4-(dimethylamino)pyridine (281 mg, 2.3 mmol, 1 eq.) and di(*tert*-butyl) dicarbonate (1.0 g, 4.6 mmol, 2 eq.) in dichloromethane (20 mL) was stirred at RT for 2 h. The reaction was concentrated and the residue partitioned between dichloromethane and saturated ammonia chloride. The organic layer was dried and concentrated, and the residue

 15 purified by column chromatography on silica gel eluting with 1:1 hexane:ethyl acetate to afford methyl 2-[(tert-butoxycarbonyl)amino]sulfonylbenzoate (1a) as a white solid (326 mg, 45% yield). ^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.00 (m, 1H), 7.75 (m, 2H), 7.67 (m, 1H), 3.83 (s, 3H), 1.27 (s, 9H). ES-LCMS m/z 314.16 (M-H).

2-[[[(*tert*-butoxycarbonyl)amino]sulfonyl] benzoic acid 1b. A mixture of methyl 2-[[[(*tert*-butoxycarbonyl)amino]sulfonyl]benzoate 1a (400 mg, 1.3 mmol, 1 equiv) and lithium hydroxide (1.6 g, 39 mmol, 30 equiv) in tetrahydrofuran (10 mL) and water (2.5 mL) was stirred at RT for 18 h. The reaction was partially concentrated, acidified with 1N HCl and the product extracted into ethyl acetate. The organic layer was dried and concentrated to afford 2-[[[(*tert*-butoxy carbonyl)amino]sulfonyl]benzoic acid (1b) as a white solid (200 mg, 51% yield). ¹H NMR (300 MHz, DMSO) δ 7.94 (m, 1H), 7.71 (m, 3H), 1.26 (s, 9H). ES-LCMS *m/z* 300.08 (M-H).

tert-Butyl {2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}sulfonyl carbamate, 1c. To a solution of *endo* 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride II (238 mg, 0.47 mmol, 1 eq.) in dimethylformamide (14 mL) was added 2-[[[(*tert*-butoxycarbonyl)amino]sulfonyl]benzoic acid 1b (140 mg, 0.47 mmol, 1 eq.) and *N,N*-diisopropylethyl amine (0.3 mL, 1.41 mmol, 3 eq.). After stirring at RT for several minutes, *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluroniumhexafluorophosphate (179 mg, 1.41 mmol, 1 eq.) was added and the reaction was stirred for 2 h. The mixture was partitioned between dichloromethane and water. The organic layer was dried and concentrated to provide crude *tert*-butyl {2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1] oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl} sulfonylcarbamate 1c. The crude product was used without further purification.


2-[(4-{2-[3-(2-Methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide (example 676). A mixture of crude *tert*-butyl {2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}sulfonyl carbamate 1c and 4N HCl in dioxane (3 mL) was stirred at RT for 2 h. The reaction mixture was partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The organic layer was dried and concentrated and the residue was purified by prep. HPLC (Method Y) to provide 2-[(4-{2-[3-

435



(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide 1 as a white solid (45 mg, 16% yield). ^1H NMR (300 MHz, DMSO) δ 8.05 (m, 1H), 7.63 (m, 3H), 7.39–7.15 (m, 9H), 5.61 (m, 2H), 4.60 (m, 1H), 4.38 (m, 1H), 3.43–3.04 (m, 5H), 2.54 (s, 3H), 2.35–2.17 (m, 4H), 2.13–1.40 (m, 12H). ES-LCMS m/z 612.25 (M+H). Analytical HPLC (Method W) Rt 7.59 (95.89%).

Example 677


4-Chloro-N-methyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



Example 677 was prepared as outlined below.




A mixture of 3-chloro-4-(chlorosulfonyl) benzoic acid and 5-chloro-2-(chlorosulfonyl)benzoic acid, 2a.



3-Chlorobenzoic acid (7.0 g, 44.7 mmol, 1 equiv) was added at 0 °C to
5 chlorosulfonic acid (40 mL). The reaction mixture was heated to 120 °C for 72
h, cooled to RT and poured slowly over ice. The product was extracted into
diethyl ether, dried and concentrated to provide a 4:1 mixture of regioisomers,
5-chloro-4-(chlorosulfonyl)benzoic acid and 3-chloro-2-(chlorosulfonyl)benzoic
acid 2a as a brown solid (5.26 g, 46% yield). ¹H NMR (300 MHz, DMSO) δ
10 8.07 (m, 1H), 7.96 (m, 1H), 7.79 (m, 3 H), 7.59 (m, 1H). ES-LCMS m/z
234.85 (M-2H) for C₇H₅ClO₅S.

A mixture of 5-chloro-2-[(methylamino) sulfonyl]benzoic acid and 3-
chloro-4-[(methylamino) sulfonyl]benzoic acid, 2b.



15 To a solution of 3-chloro-4-(chlorosulfonyl)benzoic acid and 5-chloro-2-
(chlorosulfonyl)benzoic acid 2a (0.5 g, 1.96 mmol, 1 eq.) in dichloromethane
(10 mL) was added 4-(dimethylamino)pyridine (24 mg, 0.196 mmol, 0.1 eq.)
and 2M methyl amine in THF (2.94 mL, 5.88 mmol, 3 eq.). The reaction
20 mixture was stirred at RT for 18 h then concentrated to dryness. The residue
was acidified with 1N HCl and the product was extracted into
dichloromethane. The organic layer was concentrated, the residue taken up
in water and acidified with 1N HCl. The product was extracted into
dichloromethane, dried and concentrated to provide a crude mixture of 5-
25 chloro-2-[(methylamino)sulfonyl] benzoic acid and 3-chloro-4-


[(methylamino)sulfonyl] benzoic acid 2b. The residue was carried on without further purification. ES-LCMS m/z 248.01 (M-H).

4-Chloro-N-methyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-


5 *yl)carbonyl]benzenesulfonamide* (example 677). The title compound was prepared from a mixture of 5-chloro-2-[(methylamino)sulfonyl]benzoic acid and 3-chloro-4-[(methylamino)sulfonyl]benzoic acid 2b and endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride II following the general procedure for tert-butyl
10 {2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl piperidin-1-yl)carbonyl]phenyl}sulfonylcarbamate 1c. The desired regioisomer was purified by column chromatography on silica gel eluting with 10% methanol in ethyl acetate to afford 4-chloro-N-methyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1] oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide 2 as a white solid (15 mg,
15 8% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, 1H, J=7.9 Hz), 7.65 (m, 1H), 7.53 (m, 1H), 7.39 (m, 3H), 7.27 (m, 4H), 7.19–7.12 (m, 2 H), 5.12 (q, 1H, J=5.2 Hz), 4.60 (m, 1H), 4.20 (m, 1H), 3.48–3.20 (m, 5H), 2.64 (d, 3H, J=5.3 Hz), 2.56 (s, 3H), 2.40–2.33 (m, 3H), 2.18 (m, 1H), 1.93–1.62 (m, 12H). ES-LCMS m/z 662.30 (M+2H). Analytical HPLC (Method Y) Rt 4.16 (90.0%).
20

Example 678

4-Chloro-N-cyclopropyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-
25 yl)carbonyl]benzenesulfonamide



A mixture of 5-chloro-2-[(cyclopropylamino) sulfonyl]benzoic acid and 3-chloro-4-[(cyclopropyl amino)sulfonyl]benzoic acid, 2c.




The mixture was prepared from a mixture of 3-chloro-4-
 5 (chlorosulfonyl)benzoic acid and 5-chloro-2-(chloro sulfonyl)benzoic acid 2a
 and cyclopropyl amine following the general procedure for 5-chloro-2-[(methyl
 amino)sulfonyl]benzoic acid and 3-chloro-4-[(methyl amino)sulfonyl]benzoic
 acid 2b. The crude reaction mixture was carried on without further
 purification.
 10 ES-LCMS m/z 274 (M-H).

4-Chloro-N-cyclopropyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-
 azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene
 sulfonamide (example 678). The title compound was prepared from a mixture
 of 5-chloro-2-[(cyclopropyl amino)sulfonyl]benzoic acid and 3-chloro-4-[(cyclo
 15 propylamino)sulfonyl]benzoic acid 2c and endo 2-methyl-1-{8-[2-(4-
 phenylpiperidin-4-yl)ethyl]-8-azabicyclo [3.2.1]oct-3-yl}-1H-benzimidazole
 dihydrochloride II following the general procedure for tert-butyl {2-[(4-{2-[3-(2-
 methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}-4-phenyl
 piperidin-1-yl)carbonyl]phenyl}sulfonylcarbamate 1c. The desired regioisomer
 20 was purified by column chromatography on silica gel eluting with 10%
 methanol in ethyl acetate to afford 4-chloro-N-cyclopropyl-2-[(4-{2-[3-(2-
 methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}-4-
 phenylpiperidin-1-yl)carbonyl] benzene sulfonamide 3 as a white solid (15 mg,
 11% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, 1H, J=8.1 Hz), 7.65 (m,
 25 1H), 7.54 (m, 1H), 7.41–7.12 (m, 9H), 5.48 (s, 1H), 4.60 (m, 1H), 4.20 (m,
 1H), 3.45–3.23 (m, 6H), 2.56 (s, 3H), 2.40–2.33 (m, 3H), 2.20–2.17 (m, 1H),
 1.97–1.58 (m, 10H), 0.70–0.56 (m, 4H). ES-LCMS m/z 688.35 (M+2H).
 Analytical HPLC (Method Y) Rt 3.34 (89.34%).


Example 679

4-Chloro-N-isopropyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



5

A mixture of 5-chloro-2-[(isopropylamino) sulfonyl]benzoic acid and 3-chloro-4-[(isopropyl amino)sulfonyl]benzoic acid, 2d.



The mixture was prepared from a mixture of 3-chloro-4-


10 (chlorosulfonyl)benzoic acid and 5-chloro-2-(chloro sulfonyl)benzoic acid 2a and isopropyl amine following the general procedure for 5-chloro-2-[(methylamino) sulfonyl]benzoic acid and 3-chloro-4-[(methylamino) sulfonyl]benzoic acid 2b. The crude reaction mixture was carried on without further purification. ES-LCMS m/z 276 (M-H).

15 4-Chloro-N-isopropyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide (example 679). The title compound was prepared from a mixture of 5-chloro-2-[(isopropylamino) sulfonyl]benzoic acid and 3-chloro-4-[(isopropyl amino)sulfonyl]benzoic acid 2d and endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1] oct-3-yl}-1H-benzimidazole dihydrochloride II following the general procedure for tert-butyl {2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl} sulfonylcarbamate 1c. The desired regioisomer was purified by column chromatography on silica gel eluting with 25 10% methanol in ethyl acetate to afford 4-chloro-N-isopropyl-2-[(4-{2-[3-(2-


methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl)-4-phenyl piperidin-1-yl)carbonyl] benzenesulfonamide 4 as a white solid (30 mg, 22% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, 1H, J=8.0Hz), 7.65 (d, 1H, J=7.3Hz), 7.52 (m, 1H), 7.40–7.11 (m, 9H), 4.99 (d, 1H, J=7.32 Hz), 4.60 (m, 1H), 4.20 (m, 1H), 3.49–3.22 (m, 6H), 2.56 (s, 3H), 2.40–2.32 (m, 3H), 2.18 (m, 1H), 1.98–1.66 (m, 1H), 1.62 (m, 2H), 1.10 (d, 6 H, J=6.59Hz). ES-LCMS m/z 690.45 (M+2H). Analytical HPLC (Method Y) Rt 5.03 (88.43%).

Example 680

10 4-Chloro-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-N-propylbenzenesulfonamide



A mixture of 5-chloro-2-[(propylamino) sulfonyl]benzoic acid and 3-chloro-4-[(propylamino) sulfonyl]benzoic acid, 2e.



15


The mixture was prepared from a mixture of 3-chloro-4-(chlorosulfonyl)benzoic acid and 5-chloro-2-(chloro sulfonyl)benzoic acid 2a and propyl amine following the general procedure for 5-chloro-2-[(methylamino) sulfonyl]benzoic acid and 3-chloro-4-[(methylamino) sulfonyl]benzoic acid 2b. The crude reaction mixture was carried on without further purification. ES-LCMS m/z 276 (M-H).

20 4-Chloro-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-N-propylbenzene sulfonamide (example 680). The title compound was prepared
25 from a mixture of 5-chloro-2-[(propylamino) sulfonyl]benzoic acid and 3-

chloro-4-[(propylamino) sulfonyl]benzoic acid 2e and endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride II following the general procedure for tert-butyl {2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl} sulfonylcarbamate 1c. The desired regioisomer was purified by column chromatography on silica gel eluting with 10% methanol in ethyl acetate to afford 4-chloro-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-aza bicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-N-propylbenzenesulfonamide 5 as a white solid (15 mg, 11% yield). ¹H NMR (400 MHz, CDCl₃) δ (8.12, 1H, J=8.0Hz), 7.65 (m, 1H), 7.52 (m, 1H), 7.41–7.12 (m, 9H), 5.10 (t, 1H, J=6.0Hz), 4.59 (m, 1H), 4.20 (m, 1H), 3.48–3.19 (m, 6H), 2.89 (q, 1H, J=6.6Hz), 2.56 (s, 3H), 2.55–2.32 (m, 3H), 2.17 (m, 1H), 1.93–1.64 (m, 10H), 1.61 (m, 1H), 1.50 (m, 2H), 0.882 (t, 3H, J=7.3Hz). ES-LCMS m/z 690.33 (M+2H). Analytical HPLC (Method Y) Rt 5.39 (93.34%).


Example 681

4-Fluoro-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide




Example 681 was prepared as outlined below.

442



A mixture of 2-(chlorosulfonyl)-5-fluorobenzoic acid and 4-(chlorosulfonyl)-3-fluorobenzoic acid, 6a.

6a




- 5 3-Fluorobenzoic acid (7.0 g, 50 mmol, 1 equiv) was added at 0 °C to chlorosulfonic acid (40 mL). The reaction mixture was heated to 130 °C for 6 h, cooled to RT and poured slowly over ice. The product was extracted into diethyl ether, dried and concentrated to provide a 4:1 mixture of regioisomers, 2-(chloro sulfonyl)-5-fluorobenzoic acid and 4-(chlorosulfonyl)-3-fluorobenzoic acid 6b, as a brown solid (5.26 g, 46% yield). ¹H NMR (400 MHz, CDCl₃)
- 10 δ.8.14 (ddd, 1H, J=8.0Hz, 2.4Hz, 1.3Hz), 8.05–8.01 (m, 2H), 7.98 (ddd, 1H, J=6.8Hz, 2.4Hz, 1.6Hz), 7.79 (dd, 1H, J=6.8, 2.4Hz), 7.71 (td, 1H, J=8.1, 2.4Hz). ES-LCMS m/z 237.13 (M-H) for C₇H₅FO₅S.

- A mixture of 2-(aminosulfonyl)-5-fluoro benzoic acid and 4-(aminosulfonyl)-3-fluorobenzoic acid, 6b.
- 15

443

6b



Liquid ammonia was condensed at -78°C into a reaction vessel containing a mixture of 2-(chlorosulfonyl)-5-fluorobenzoic acid and 4-(chlorosulfonyl)-3-fluoro benzoic acid 6a (100 mg, 0.419 mmol, 1 eq.). The reaction mixture was
 5 allowed to evaporate slowly upon warming to RT over 18 h. The crude residue contained a mixture of 2-(aminosulfonyl)-5-fluorobenzoic acid and 4-(aminosulfonyl)-3-fluorobenzoic acid and was used without further purification. ES-LCMS m/z 218 (M-H).

4-Fluoro-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-

10 azabicyclo[3.2.1]oct-8-yl]ethyl]-4-phenylpiperidin-1-

yl)carbonyl]benzenesulfonamide (example 681). The title compound was

prepared from a mixture of 2-(aminosulfonyl)-5-fluorobenzoic acid and 4-

(aminosulfonyl)-3-fluorobenzoic acid 6b and endo 2-methyl-1-{8-[2-(4-

15 phenylpiperidin-4-yl)ethyl]-8-aza bicyclo[3.2.1]oct-3-yl]-1H-benzimidazole

dihydro-chloride II following the general procedure for tert-butyl {2-[(4-{2-[3-(2-

methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-4-

phenylpiperidin-1-yl)carbonyl]phenyl)sulfonylcarbamate 1c. The desired

regioisomer was purified by column chromatography on silica gel eluting with

20 20% methanol in ethyl acetate to afford 4-fluoro-2-[(4-{2-[3-(2-methyl-1H-

benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-4-phenylpiperidin-1-

yl)carbonyl]benzenesulfonamide 6 as a white solid (9.8 mg, 20% yield). ^1H

NMR (400 MHz, CDCl_3) δ 7.90 (t, 1H, $J=7.7\text{Hz}$), 7.64 (m, 1H), 7.39 (m, 2H),

7.30–7.12 (m, 8H), 5.69 (broad s, 2H), 4.59 (m, 1H), 4.20 (m, 1H), 3.48–3.19

(m, 5H), 2.52 (s, 3H), 2.40–2.32 (m, 3H), 2.18 (m, 1H), 2.04–1.70 (m, 10H),


25 1.62 (m, 2H). ES-LCMS m/z 630.19 (M+H). Analytical HPLC (Method Y) Rt

4.16 (90.0%).

Example 682


N-Cyclopropyl-4-fluoro-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzene sulfonamide was synthesized analogously to example 861.

5



A mixture of 2-[(cyclopropylamino)sulfonyl]-5-fluorobenzoic acid and 4-[(cyclopropylamino)sulfonyl]-3-fluorobenzoic acid, 6c.

6c



10 The mixture was prepared from a mixture of 2-(chloro sulfonyl)-5-fluorobenzoic acid and 4-(chlorosulfonyl)-3-fluorobenzoic acid 6a and cyclopropyl amine following the general procedure for 5-chloro-2-[(methylamino)sulfonyl]benzoic acid and 3-chloro-4-[(methylamino)sulfonyl]benzoic acid 2b. The crude reaction mixture was carried on without
15 further purification. ES-LCMS m/z 258 (M-H).


The title compound in example 682 was prepared from a mixture of 2-[(cyclopropylamino)sulfonyl]-5-fluorobenzoic acid and 4-[(cyclopropylamino)sulfonyl]-3-fluorobenzoic acid 6c and endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride II following the general procedure for tert-butyl {2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}sulfonylcarbamate 1c. The desired regioisomer was purified by column chromatography on silica gel eluting with 10% methanol in ethyl acetate to afford N-cyclopropyl-4-fluoro-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-
20
25

445

phenylpiperidin-1-yl)carbonyl]benzenesulfonamide 7 as a white solid (40 mg, 20% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.97 (t, 1H, J=7.4Hz), 7.65 (m, 1H), 7.38 (m, 2H, 7.29–7.12 (m, 8H), 5.87 (s, 1H), 4.59 (m, 1H), 4.19 (m, 2H), 3.50–3.10 (m, 5H), 2.55 (s, 3H), 2.39–2.16 (m, 5H), 1.92–1.73 (m, 10 H), 1.60 (m, 2H), 0.70–0.50 (m, 4H). ES-LCMS m/z 670.18 (M+H). Analytical HPLC (Method Y) Rt 4.35 (94.82%).


Example 683

4-Fluoro-N-isopropyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide



Example 683 was prepared analogously to example 681.

A mixture of 5-fluoro-2-[(isopropylamino)sulfonyl]benzoic acid and 4-fluoro-3-[(isopropylamino)sulfonyl]benzoic acid, 6d.




The mixture was prepared from a mixture of 2-(chloro sulfonyl)-5-fluorobenzoic acid and 4-(chlorosulfonyl)-3-fluorobenzoic acid 6a and isopropyl amine following the general procedure for 5-chloro-2-[(methylamino)sulfonyl]benzoic acid and 3-chloro-4-[(methylamino)sulfonyl]benzoic acid 2b. The crude reaction mixture was carried on without further purification. ES-LCMS m/z 260 (M-H).

Title compound in example 683 was prepared from a mixture of 5-fluoro-2-[(isopropylamino)sulfonyl] benzoic acid and 4-fluoro-3-[(isopropylamino)sulfonyl] benzoic acid 6d and endo 2-methyl-1-{8-[2-(4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole

dihydrochloride II following the general procedure for tert-butyl {2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl)sulfonyl carbamate 1c. The desired regioisomer was purified by column chromatography on silica gel eluting with
 5 10% methanol in ethyl acetate to afford 4-fluoro-N-isopropyl-2-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzenesulfonamide 8 as a white solid (45 mg, 25% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.92 (t, 1 H, J=7.5Hz), 7.65 (m, 1H), 7.38 (m, 2H), 7.29–7.11 (m, 8H), 5.14 (d, 1H, J=7.5Hz), 4.59 (m, 1H), 4.18 (m,
 10 1H), 3.54–3.18 (m, 6H), 2.55 (s, 3H), 2.39–2.18 (m, 4H), 1.91–1.81 (m, 10H), 1.61 (m, 2H), 1.15 (m, 6 H). ES-LCMS m/z 672.22 (M+H). Analytical HPLC (Method Y) Rt 4.30 (100.0%).

Example 684

15 1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(3-methoxyphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




This compound was prepared from 3-methoxyphenylmagnesium
 20 bromide and 16a employing methods similar to those described in example 16. ¹H NMR (400 MHz, DMSO-d₆) δ 7.47 (d, 1H, J=7 Hz), 7.34 (d, 1H, J=8 Hz), 7.27 (t, 1H, J=8 Hz), 7.11 (t, 1H, J=7 Hz), 7.08 (t, 1H, J=7 Hz), 6.94 (d, 1H, J=8 Hz), 6.88 (s, 1H), 6.79 (d, 1H, J=8 Hz), 4.51 (m, 1H), 3.75 (m, 2H), 3.74 (s, 3H), 3.23 (m, 4H), 2.50 (s, 3H, obscured by solvent peak), 2.34 (br
 25 dd, 2H, J=22, 9 Hz), 2.02 (m, 2H), 1.85 (m, 4H), 1.75 (m, 6H), 1.58 (d, 2H, J=8 Hz), 1.16 (s, 9H). HRMS C₃₄H₄₆N₄O₂ m/z 547.3186 (M+H)_{Cal.}, 543.3699 (M+H)_{Obs.} 543.3708.

447

Example 685


1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(4-
trifluoromethylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-
 5 methyl-1H-benzimidazole



This compound was prepared from 4-trifluoro methylphenylmagnesium bromide and 16a employing methods similar to those described in example 16. ¹H NMR (400 MHz, DMSO-d₆) δ 7.70 (d, 2H, J=8 Hz), 7.62 (d, 2H, J=8 Hz), 7.47 (d, 1H, J=7 Hz), 7.34 (d, 1H, J=7 Hz), 7.10 (t, 1H, J=7 Hz), 7.07 (t, 1H, J=7 Hz), 4.49 (m, 1H), 3.76 (m, 2H), 3.23 (m, 4H), 2.50 (s, 3H, obscured by solvent peak), 2.34 (br. dd, 2H, J=22, 9 Hz), 2.07 (m, 2H), 1.90-1.70 (m, 10H), 1.57 (d, 2H, J=7 Hz), 1.16 (s, 9H). HRMS C₃₄H₄₃F₃N₄O *m/z* 581.3467 (M+H)_{Cal.}, 581.3474 (M+H)_{Obs.}

Example 686

2-Chloro-5-((4-{2-[1-(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-
azabicyclo[3.2.1]oct-8-yl]ethyl}-4-[4-(trifluoromethyl)phenyl]piperidin-1-
yl]carbonyl)benzene sulfonamide




This compound was prepared from 4-trifluoro-methylphenylmagnesium bromide and 16a employing methods similar to those described in example 16. ¹H NMR (400 MHz, CD₃OD) δ 7.95-7.78 (m, 2H), 7.71 (d, 2H, J=8Hz), 7.67 (m, 1H), 7.64 (d, 2H, J=8Hz), 7.52 (br.d, 1H, J=7 Hz), 7.42 (br. d, 1H,

J=7 Hz), 7.20 (t, 1H, J=7 Hz), 7.17 (t, 1H, J=7 Hz), 4.74 (m, 1H), 4.19 (m, 1H), 3.40 (m, 4H), 3.18 (m, 1H), 2.52 (s, 3H), 2.43 (m, 3H), 2.25 (m, 1H), 1.99 (m, 10H), 1.71 (d, 2H, J=7 Hz). HRMS $C_{36}H_{39}ClF_3N_5O_3S$ m/z 714.2492 (M+H)_{Cal.}, 714.2492 (M+H)_{Obs.}

5

Example 687

2-Chloro-5-({4-[2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-4-[4-(methyl sulfonyl)phenyl]piperidin-1-yl}carbonyl)benzene sulfonamide




10

This compound was prepared from 4-(methyl thio)phenylmagnesium bromide and 16a employing methods similar to those described in example 16. The 4-(methylthio)phenyl intermediate corresponding to 16d was oxidized to the methylsulfonyl derivative with MCPBA and converted to compound 687 by methods similar to those outlined in example 16. 1H NMR (400 MHz, CD_3OD) δ 8.02 (d, 2H, J=6 Hz), 7.93 (m, 1H), 7.92 (m, 1H), 7.75 (d, 2H, J=6 Hz), 7.70 (m, 1H), 7.58 (d, 1H, J=7 Hz), 7.50 (d, 1H, J=7 Hz), 7.28 (m, 2H), 4.24 (m, 1H), 3.79 (m, 2H), 3.40 (m, 4H), 3.18 (m, 1H), 3.15 (s, 3H), 2.59 (s, 3H), 2.47 (m, 2H), 2.35 (m, 1H), 2.25-2.00 (m, 12H). HRMS $C_{36}H_{42}ClN_5O_5S_2$ m/z 724.2394 (M+H)_{Cal.}, 724.2372 (M+H)_{Obs.}

20

Example 688

1-[(1R,5S)-8-(2-{1-(2,2-Dimethylpropanoyl)-4-[4-(methylsulfonyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



5


This compound was prepared from 4-(methyl thio)phenylmagnesium bromide and 16a employing methods similar to those described in example 16. The 4-(methylthio)phenyl intermediate corresponding to 16d was oxidized to the methylsulfonyl derivative with MCPBA and converted by methods similar to those outlined in example 16. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.90 (d, 2H, J=8 Hz), 7.68 (d, 2H, J=8 Hz), 7.48 (d, 1H, J=6 Hz), 7.35 (d, 1H, J=7 Hz), 7.10 (m, 2H), 4.50 (m, 1H), 3.75 (m, 2H), 3.27 (m, 4H), 3.20 (s, 3H), 2.50 (s, 3H, obscured by solvent peak), 2.35 (dd, 1H, J=19, 10 Hz), 2.08 (m, 2H), 1.85 (m, 9H), 1.76 (m, 2H), 1.59 (m, 2H), 1.17 (s, 9H). HRMS C₃₄H₄₆N₄O₃S *m/z* 591.3369 (M+H)_{Cal.}, 591.3397 (M+H)_{Obs.}.

15

Example 689

2-Chloro-5-[(4-(3-isopropylphenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide

20




This compound was prepared from 3-isopropyl phenylmagnesium bromide and 16a employing methods similar to those described in example 16. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.93 (s, 1H), 7.68 (d, 1H, J=8 Hz), 7.63

450

(br, 2H), 7.61 (d, 1H, J=8Hz), 7.48 (d, 1H, J=7 Hz), 7.34 (d, 1H, J=7 Hz), 7.27 (t, 1H, J=8 Hz), 7.23 (s, 1H), 7.18 (d, 1H, J=7 Hz), 7.09 (m, 3H), 4.49 (m, 1H), 3.89 (m, 1H), 3.50-3.30 (m, 2H), 3.20 (m, 4H), 2.89 (m, 1H, J=7 Hz), 2.43 (s, 3H), 2.35 (br.dd, 2H, J=22, 10 Hz), 2.17 (m, 1H), 2.07 (m, 1H), 1.90-1.70 (m, 9H), 1.56 (br.d, 2H, J=8Hz), 1.20 (d, 6H, J=7 Hz). HRMS $C_{38}H_{46}ClN_5O_3S$ m/z 688.3088 (M+H)_{Cal.}, 688.3075 (M+H)_{Obs.}.

Example 690

Methyl 3-[(4-(3-isopropylphenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzoate




This compound was prepared from 3-isopropyl phenylmagnesium bromide and 16a employing methods similar to those described in example 16. 1H NMR (400 MHz, DMSO- d_6) δ 8.01 (d, 1H, J=7 Hz), 7.91 (s, 1H), 7.67 (d, 1H, J=8 Hz), 7.58 (t, 1H, J=8 Hz), 7.48 (d, 1H, J=7 Hz), 7.34 (d, 1H, J=7 Hz), 7.27 (t, 1H, J=8 Hz), 7.23 (s, 1H), 7.23 (d, 1H, J=8 Hz), 7.09 (m, 3H), 4.49 (m, 1H), 3.89 (m, 1H), 3.84 (s, 3H), 3.43 (m, 1H), 3.37 (m, 1H), 3.21 (m, 3H), 2.89 (m, 1H, J=7 Hz), 2.41 (s, 3H), 2.35 (m, 2H), 2.16 (m, 1H), 2.07 (m, 1H), 1.90-1.70 (m, 10H), 1.59 (br. d, 2H, J=8 Hz), 1.22 (d, 6H, J=8 Hz). HRMS $C_{40}H_{48}N_4O_3$ m/z 633.3805 (M+H)_{Cal.}, 633.3787 (M+H)_{Obs.}.

451

Example 691


3-[4-(3-Isopropylphenyl)-4-{2-[1(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl]carbonyl]benzoic acid



5 This compound was prepared by hydrolysis of the title compound in example 690 with lithium hydroxide employing methods familiar to those skilled in the art. ¹H NMR (400 MHz, DMSO-d₆) δ 13.1 (br, 1H), 7.99 (d, 1H, J=8 Hz), 7.89 (s, 1H), 7.63 (d, 1H, J=8Hz), 7.56 (t, 1H, J=7 Hz), 7.49 (d, 1H, J=7 Hz), 7.38 (br, 1H), 7.25 (m, 2H), 7.19 (d, 1H, J=8Hz), 7.11 (m, 3H), 4.51
10 (br, 1H), 3.91 (br, 1H), 3.45 (m, 1H), 3.40-3.20 (m, 4H), 2.89 (m, 1H, J=7 Hz), 2.45 (s, 3H), 2.40-1.60 (m, 16H), 1.20 (d, 6H, J=7 Hz). HRMS C₃₉H₄₆N₄O₃ m/z 619.3684 (M+H)_{Cal.}, 619.3643 (M+H)_{Obs.}

Example 692

15 (3S)-Tetrahydrofuran-3-yl 4-{2-[1(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxylate




A solution of 1-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}oxy)pyrrolidine-2,5-dione (US patent 6,344,465) (55 mg, 0.24 mmol), amine dihydrochloride II
20 (100 mg, 0.199 mmol) and *N,N*-diisopropylethylamine (0.14 mL, 0.80 mmol) in acetonitrile (3 mL) was stirred overnight at rt. The solvent was removed at reduced pressure and the remaining material was dissolved in dichloromethane, washed with saturated sodium bicarbonate solution and

dried over magnesium sulfate. Filtration and evaporation of the dichloromethane solution provided the crude product which was purified by chromatography on silica gel eluting with 5% methanol/dichloromethane. Title compound in example 692 was obtained as a white hygroscopic powder (70 mg, 65%). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, 1H, J=8 Hz), 7.37 (m, 2H), 7.30-7.20 (m, 4H), 7.16 (m, 2H), 5.25 (m, 1H), 4.61 (m, 1H), 3.85 (m, 4H), 3.73 (m, 2H), 3.22 (m, 4H), 2.58 (br s, 3H), 2.36 (m, 2H), 2.17 (m, 3H), 2.05-1.70 (m, 13H). HRMS C₃₃H₄₂N₄O₃ *m/z* 543.3335 (M+H)_{Cal.}, 543.3331 (M+H)_{Obs.}.


Example 693

1-{8-[2-(4-(3-fluorophenyl)-1-[[3-(trifluoromethyl) pyridin-2-yl]carbonyl]piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole



3-(Trifluoromethyl)-1H-pyrazole-4-carboxylic acid, 1a. A mixture of ethyl 3-(trifluoromethyl)-1H-pyrazole-4-carboxylate (100 mg, 0.48 mmol, 1 eq.), ethanol (5 mL) and 5N NaOH (5 mL) was heated to reflux for 72 h. The reaction was cooled to RT, acidified to pH 2 with 5 N HCl and the product extracted into ethyl acetate. The organic layers were dried over sodium sulfate, filtered and concentrated to provide 3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid (1a) as a white solid (80 mg, 93% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 13.95 (broad s, 1H), 8.49 (s, 1H), 3.50 (broad s, 1H). ES-LCMS *m/z* 181.16 (M+H).


453



1- $\{8-[2-(4-(3\text{-fluorophenyl})-1-[[3-(\text{trifluoro methyl})\text{pyridin-2-yl}]carbonyl]piperidin-4-yl)ethyl]-8\text{-azabicyclo}[3.2.1]\text{oct-3-yl}-2\text{-methyl-1H-benzimidazole}$ (example 693). To a solution of 1-(8-{2-[4-(3-fluoro
 5 phenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride II (130 mg, 0.25 mmol, 1 eq.) in dimethylformamide (4 mL) was added 3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid, 1a, (50 mg, 0.27 mmol, 1 eq.) and *N,N*-diisopropylethyl amine (180 μL , 1.0 mmol, 4 eq.). After stirring at RT for several min, O-(7-
 10 azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyl-uroniumhexafluorophosphate (95 mg, 0.25 mmol, 1 eq.) was added and the reaction was stirred for 2 h. The mixture was partitioned between dichloromethane and satd. aq. NaHCO_3 . The organic layer was dried and concentrated and the residue was purified by prep. HPLC (Method Y) to provide 1-(8-{2-[4-(3-fluorophenyl)-1-[[3-
 15 (trifluoromethyl)pyridin-2-yl]carbonyl]piperidin-4-yl)ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole 1 as a white solid (30 mg, 20% yield).
 ^1H NMR (300 MHz, DMSO-d_6) δ 7.65 (m, 2H), 7.32 (m, 2H), 7.16 (m, 2H), 7.07 (m, 1H), 6.97 (m, 2H), 4.62 (m, 1H), 4.18 (m, 1H), 3.50 (m, 1H), 3.27 (m, 4H), 2.52 (m, 3H), 2.45 – 2.09 (m, 4H), 2.04–1.47 (m, 12H). ES-LCMS m/z 609.39 (M+H). Analytical HPLC (Method W) R_t 2.79 (95.89%).
 20

Example 694

1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(4-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




example 694

5 The title compound was prepared according to procedures analogous to those described for example 16. ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, 1H, J=2.3 Hz), 7.66 (d, 1H, J=2.2 Hz), 7.32-7.25 (m, 2H), 7.18-7.15 (m, 2H), 7.09-7.04 (m, 2H), 4.68-4.55 (m, 1H), 3.95-3.90 (m, 2H), 3.41-3.20 (m, 4H), 2.57 (s, 3H), 2.43-2.33 (m, 2H), 2.19-2.14 (m, 2H), 1.95-1.62 (m, 12H), 1.26 (s, 9H). LRMS (ES, +ve ion) m/z 531.2 (M+H).

10

Example 695

1-((1R,5S)-8-{2-[4-(3,4-dichlorophenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



Example 695


15 The title compound was prepared according to procedures analogous to those described for example 16. ¹H NMR (300 MHz, CDCl₃) δ 7.66 (d, 1H, J=6.9 Hz), 7.45 (d, 1H, J=8.3 Hz), 7.39 (br. s, 1H), 7.32-7.27 (m, 1H), 7.20-7.14 (br. m, 3H), 4.62 (app quint, 1H, J=9.2 Hz), 3.97-3.87 (m, 2H), 3.41-3.25 (m, 4H), 2.58 (s, 3H), 2.44-2.34 (m, 2H), 2.16-2.10 (m, 2H), 1.97-1.65 (m, 12H), 1.27 (s, 9H). LRMS (ES, +ve ion) m/z 581.0 (M+), 583.3 (M+2, ³⁷Cl).

20

455

Example 696


1-((1R,5S)-8-{2-[1-benzoyl-4-(3,4-dichlorophenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



5 The title compound was prepared according to procedures analogous to those described for example 16. ^1H NMR (300 MHz, CDCl_3) δ 7.66 (d, 1H, $J=7.2$ Hz), 7.44 (app t) overlapping 7.39 (br s, 8H total), 7.32-7.25 (m) overlapping 7.26 (s, CHCl_3 , 2H total), 7.18-7.14 (m, 2H), 4.60 (app quint, 1H, $J=8.8$ Hz), 4.13 (br s, 1H), 3.57, 3.40, 3.27 (three overlapping br s, 6H total),
10 2.55 (s, 3H), 2.44-2.34 (m, 2H), 2.21-1.66 (m, 17H). FAB HRMS (calcd for MH^+ , $\text{C}_{35}\text{H}_{38}\text{Cl}_2\text{N}_4\text{O}$) 601.2501; Found 601.2501.

Example 697

15 1-((1R,5S)-8-{2-[1-benzoyl-4-(3-chlorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




20 The title compound was prepared according to procedures analogous to those described for example 16. ^1H NMR (300 MHz, CDCl_3) δ 7.66 (d, 1H, $J=6.9$ Hz), 7.42-7.14 (m, 12H), 4.60 (app quint, 1H, $J=9.1$ Hz), 4.13 (br s, 1H), 3.56, 3.42 and 3.27 (three overlapping br s, 6H total), 2.55 (s, 3H), 2.44-1.63 (m, 17H). FAB HRMS (calcd for MH^+ , $\text{C}_{35}\text{H}_{39}\text{ClN}_4\text{O}$) 567.2891; Found 567.2885.

456

Example 698


1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



- 5 The title compound was prepared according to procedures analogous to those described for example 16. ¹H NMR (300 MHz, CDCl₃) δ 7.66 (d, 1H, J=7.2 Hz), 7.38-7.29 (m, 2H), 7.20-6.92 (m, 5H), 4.61 (app quint, 1H, J=8.7 Hz), 3.96 and 3.91 (two overlapping br s, 2H total), 3.42-3.25 (m, 4H), 2.58 (s, 3H), 2.43-2.33 (m, 2H), 2.19-2.12 (m, 2H), 1.96-1.62 (m, 12H), 1.28 (s, 9H).
- 10 LRMS (ES, +ve ion) m/z 531.3 (M+H).

Example 699


1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-thien-2-yl]piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



- 15 The title compound was prepared according to procedures analogous to those described for example 16. ¹H NMR (300 MHz, CDCl₃) δ 7.66 (d, 1H, J=6.6 Hz), 7.33-7.15 (m, 4H), 6.99 (app t, 1H, J=4.3 Hz), 6.83 (d, 1H, J=3.3 Hz), 4.64 (app quint, 1H, J=9.0 Hz), 4.09 and 4.04 (two overlapping br s, 2H total), 3.33-3.20 (m, 4H), 2.58 (s, 3H), 2.45-2.34 (m, 2H), 2.20-1.64 (m, 14H), 1.28 (s, 9H). LRMS (ES, +ve ion) m/z 518.4 (M+).
- 20

Example 700

2-chloro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide



5


The title compound was prepared according to procedures analogous to those described for example 16. ¹H NMR (300 MHz, CD₃OD) δ 7.93 (app d, 2H, J=9.6 Hz), 7.78-7.64 (m, 1H), 7.53-7.39 (m, 3H), 7.24-7.15 (m, 4H), 6.99 (app t, 1H, J=8.0 Hz), 4.73 (app quint, 1H, J=9.6 Hz), 4.20-4.15 (br m, 1H), 3.48-3.29 (m) overlapping 3.30 (s, MeOH, 6H total), 3.22-3.14 (m, 1H), 2.52 (s, 3H), 2.48-2.34 (m, 3H), 2.10-1.88 (m, 11H), NH₂ (not observed).

10

Example 701

1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(3-ethylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole

15




The title compound was prepared according to procedures analogous to those described for example 16. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, 1H, J=7.2 Hz), 7.33-7.08 (m, 7H), 4.68 (app quint, 1H, J=8.8 Hz), 3.98-3.93 (br m, 2H), 3.63 (br m, 2H), 3.36-3.29 (m, 4H), 2.68 (q, 2H, J=7.5 Hz), 2.59 (s, 3H), 2.47-2.37 (m, 2H), 2.26-2.20 (m, 2H), 2.01-1.66 (m, 10H), 1.29 (s) overlapping 1.26 (t, J=7.7 Hz, 12 H total). LRMS (ES, +ve ion) m/z 541.4 (M+H).

20

Example 702


1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(4-ethylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



- 5 The title compound was prepared according to procedures analogous to those described for example 16. ¹H NMR (300 MHz, CDCl₃) δ 7.70-7.67 (m, 1H), 7.33-7.28 (m, 1H), 7.22-7.13 (m, 6H), 4.65 (app quint, 1H, J=8.9 Hz), 4.00-3.93 (m, 2H), 3.34-3.26 (m, 4H), 2.66 (q, 2H, J=7.5 Hz), 2.59 (s, 3H), 2.45-2.34 (m, 2H), 2.25-2.19 (m, 2H), 1.96-1.62 (m, 12H), 1.28 (s) overlapping
10 1.26 (t, J=7.7 Hz, 12 H total). LRMS (ES, +ve ion) m/z 541.4 (M+H).


Example 703

- Endo 1-((1R,5S)-8-{2-[4-(3-chloro-4-fluorophenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-
15 1H-benzimidazole was synthesized according to the procedures described in example 16 with a 3-chloro-4-fluoro instead of a 3-chloro substitution in the phenyl ring.




- Tert-butyl 4-(3-chloro-4-fluorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate was prepared and used without further
20 purification as described in example 16b from 1-fluoro-2-chloro-4-bromobenzene (10 g, 47.74 mmol) using tetrahydrofuran instead of diethyl ether as a solvent to afford an oil (6.76 g, 100%). ES-LCMS m/z 423 (M-H)⁺.

459




[1-(Tert-butoxycarbonyl)-4-(3-chloro-4-fluorophenyl)piperidin-4-yl](cyano) acetic acid was prepared and used without further purification as described in example 16c (6.76 g, 15.9 mmol) to afford an oil (6.31 g, 100%).



5

Tert-butyl endo 4-(3-chloro-4-fluorophenyl)-4-(cyanomethyl)piperidine-1-carboxylate was prepared as described in example 16d (6.31 g, 15.9 mmol), purified by column chromatography on silica gel, eluting with a gradient of 5-40% ethyl acetate in hexane to afford a beige solid (2.86 g, 51%). ¹H NMR (300 MHz, CDCl₃) δ 7.41 (dd, 1H, J=2.3, 2.5 Hz) 7.30-7.21 (m, 2H), 3.76-3.72 (m, 2H), 3.13 (br t, 2H, J=10.4 Hz), 2.57 (s, 2H), 2.29-2.24 (br m, 2H), 1.93-1.84 (m, 2H), 1.46 (s, 9H). ES-LCMS *m/z* 253 (M-BOC+H)⁺.


10



Tert-butyl 4-(3-chloro-4-fluorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate was prepared as described in example 16e from the product obtained in previous step (2.86 g, 8.106 mmol) to afford *tert*-butyl 4-(3-chloro-4-fluorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate as an oil (2.20 g, 76.2%). ¹H-NMR (300 MHz, CDCl₃) δ 9.45 (t, 1H, J=2.6 Hz), 7.40(dd, 1H, J=2.4 Hz), 7.28-7.20 (m, 2H), 3.66-3.60 (m, 2H), 3.33-3.25 (m, 2H), 2.68 (s, 2H), 2.24-2.17 (br m, 2H), 1.95-1.82 (m, 2H), 1.45 (s, 9H).


20

460



Tert-butyl 4-(3-chloro-4-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate was prepared as described in example 16f from the product obtained in previous step (2.20 g, 6.183 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 2-7% methanol in dichloromethane to afford a rigid foam (1.35 g, 61.2%). ¹H-NMR (300 MHz, CDCl₃) δ 7.70 (dd, 1H, J=2, 2.7 Hz), 7.35-7.31 (m, 2H), 7.23-7.11 (m, 4H), 4.72-4.63 (m, 1H), 3.90-3.81 (m, 2H), 3.68-3.63 (br m, 2H), 3.38-3.19 (m, 4H), 3.15-3.00 (m, 1H), 2.61 (s, 3H), 2.55-2.40 (m, 2H), 2.10-1.65 (m, 11H), 1.45 (s, 9H). ES-LCMS *m/z* 581 (M+H)⁺.

Endo 1-((1R,5S)-8-{2-[4-(3-chloro-4-fluoro phenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride was prepared and used without additional purification as described in example 16g from the product obtained in previous step (1.35 g, 2.26 mmol) to afford a rigid foam (1.28 g, 100%). ES-LCMS *m/z* 481 (M+H)⁺.



Endo 1-((1R,5S)-8-{2-[4-(3-chloro-4-fluoro phenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (example 703). Title compound in example 703 was prepared as described in example 16 from endo 1-((1R,5S)-8-{2-[4-(3-chloro-4-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (100 mg, 0.18 mmol), using 3 equivalents of triethylamine and then purified by column chromatography on silica gel,


eluting with a gradient of 2-5% methanol in dichloromethane to afford endo 1-((1R,5S)-8-{2-[4-(3-chloro-4-fluorophenyl)-1-(2,2-dimethylpropanoyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole as a rigid foam (40 mg, 39.2 %). ¹H-NMR (300 MHz, CDCl₃) δ 7.69 (d, 1H, J=6.9 Hz), 7.37-7.31 (m, 2H), 7.18-7.14 (m, 4H), 4.75-4.59 (m, 1H), 3.96-3.90 (m, 2H), 3.40-3.32 (m, 4H), 2.60 (s, 3H), 2.47-2.37 (m, 2H), 2.19-2.16 (m, 2H), 2.12-1.79 (m, 8H), 1.70-1.65 (m, 4H), 1.30 (s, 9H). HRMS m/z (M+H) 565.3109 Cal., 565.3104 Obs.

10

Example 704

Endo 2-chloro-5-[(4-(3-chloro-4-fluoro phenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide was prepared from endo 1-((1R,5S)-8-{2-[4-(3-chloro-4-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (200 mg, 0.36 mmol) as described in Example 719, purified by column chromatography on silica gel, eluting with a gradient of 0-5% methanol in dichloromethane to afford the title compound as an off white solid (37 mg, 14.6%). ¹H-NMR (300 MHz, CDCl₃) δ 8.14 (s, 1H), 7.69-7.54 (m, 3H), 7.35-7.29 (m, 2H), 7.20-7.15 (m, 4H), 5.41 (br s, 2H), 4.66-4.60 (m, 1H), 4.18-4.10 (m, 1H), 3.51-3.29 (m, 4H), 2.58 (s, 3H), 2.48-2.37 (m, 2H), 2.03-1.67 (m, 15H). HRMS m/z (M+H)⁺ 698.2135 Cal., 698.2132 Obs.

20




25


Example 705

Endo 1-[(1R,5S)-8-(2-{1-(2,2-dimethyl propanoyl)-4-[4-(methylthio)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-

1H-benzimidazole was synthesized according to the methods outlined in example 16 with a 4-methylthio instead of a 3-chloro substitution in the phenyl ring.




- 5 Tert-butyl endo 4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-[4-(methylthio)phenyl]piperidine-1-carboxylate was prepared as described in example 16f (1.15 g, 3.29 mmol scale) and purified by column chromatography on silica gel, eluting with a gradient of 2.5-5% methanol in dichloromethane to afford an oil (1.39 g, 73.5%). ¹H NMR (300 MHz, CDCl₃) δ 7.70 (d, 1H, J=7 Hz), 7.33-7.15 (m, 7H), 4.78-4.65 (m, 1H), 3.75-3.62 (br m, 2H), 3.38-3.31 (br m, 2H), 3.23-3.15 (m, 2H), 2.60 (s, 3H), 2.51 (s, 3H), 2.48-2.39 (m, 4H), 2.21-2.15 (m, 2H), 1.99-1.66 (m, 10H), 1.46 (s, 9H). ES-LCMS m/z 575 (M+H)⁺.
- 10




- 15 Endo 2-methyl-1-[(1R,5S)-8-(2-{4-[4-(methyl thio)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1] oct-3-yl]-1H-benzimidazole dihydrochloride was prepared and used without further purification as described in example 16g from product from previous step (1.39 g, 2.418 mmol) to afford off white solid (1.03 g, 78%). ES-LCMS m/z 475 (M+H)⁺.


463

**Example 705**


The title compound in example 705 endo 1-[(1R,5S)-8-(2-{1-(2,2-
 5 dimethylpropanoyl)-4-[4-(methyl thio)phenyl]piperidin-4-yl}ethyl)-8-
 azabicyclo[3.2.1] oct-3-yl]-2-methyl-1H-benzimidazole was prepared as
 described in example 16 from the product obtained in previous step (100 mg,
 0.183 mmol), using 3 equivalents of triethylamine and purified by column
 chromatography on silica gel, eluting with a gradient of 1-10% methanol in
 10 dichloromethane to afford beige solid (100.8 mg, 98.8 %). ¹H-NMR (300 MHz,
 CDCl₃) δ 7.69 (d, 1H, J=7.1 Hz), 7.34-7.18 (m, 7H), 4.71-4.57 (m, 1H), 3.99-
 3.94 (m, 2H), 3.32-3.25 (m, 4H), 2.59 (s, 3H), 2.52 (s, 3H), 2.45-2.35 (m, 2H),
 2.28-2.12 (m, 2H), 1.97-1.89 (m, 5H), 1.83-1.75 (m, 4H), 1.68-1.60 (m, 2H);
 1.35 (s, 9H). HRMS m/z (M+H) 559.3471 Cal., 559.3480 Obs.



464

Example 706

Endo 2-chloro-5-({4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-[4-(methylthio)phenyl]piperidin-1-yl}carbonyl)benzenesulfonamide was prepared from endo 2-methyl-1-[(1R,5S)-8-(2-{4-[4-(methylthio)phenyl] piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride (200 mg, 0.365 mmol) as described in Example 719 and purified by Plate Purification Method A to afford thick oil (61.4 mg, 24.3%). ¹H-NMR (300 MHz, CDCl₃) δ 8.41 (s, 1H), 7.70 (d, 1H, J=7.1 Hz), 7.61-7.53 (m, 2H), 7.31-7.17 (m, 7H), 4.93-4.86 (m, 1H), 4.19-4.15 (m, 1H), 3.57-3.44 (m, 4H), 3.37-3.27 (m, 2H), 2.59 (s, 3H), 2.52 (s, 3H), 2.46-2.00 (m, 8H), 1.96-1.78 (m, 7H). HRMS m/z (M+H)⁺ 692.2496 Cal., 692.2498 Obs.

Example 707

15


Endo 1-[(1R,5S)-8-(2-{1-(2,2-dimethyl-propanoyl)-4-[3-(methylthio)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole was synthesized according to the methods described in example 16 with a 3-methylthio instead of a 3-chloro substitution in the phenyl ring.

20

Tert-butyl 4-[3-(methylthio)phenyl]-4-(2-oxoethyl)piperidine-1-carboxylate was prepared and used without further purification as described in example 16e from respective intermediate described in example 720 (2.11 g,


465

6.09 mmol) to afford *tert*-butyl 4-[3-(methylthio)phenyl]-4-(2-oxoethyl)piperidine-1-carboxylate as an oil (1.14 g, 53.5%). ¹H-NMR (300 MHz, CDCl₃) δ 9.41(t, 1H, J=3 Hz), 7.36-7.26 (m, 1H), 7.17-7.04 (m, 3H), 3.66-3.61 (br m, 2H), 3.32-3.24 (m, 2H), 2.66 (s, 2H), 2.51 (s, 3H), 2.27-2.21 (br m, 2H), 1.91-1.82 (m, 2H), 1.46 (s, 9H).




Tert-butyl endo 4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-[3-(methylthio)phenyl]piperidine-1-carboxylate

was prepared as described in example 16f from the product obtained in previous step (1.14 g, 3.26 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 0-5% methanol in dichloromethane to afford a rigid foam (0.70 g, 37.3%). ¹H-NMR (300 MHz, CDCl₃) δ 7.70 (d, 1H, J=7 Hz), 7.34-7.08 (m, 7H), 4.70-4.65 (m, 1H), 3.75-3.65 (br m, 2H), 3.35-3.21 (m, 4H), 2.61 (s, 3H), 2.52 (s, 3H), 2.49-2.41 (m, 2H), 2.24-2.18 (m, 2H), 1.99-1.66 (m, 12H), 1.47 (s, 9H). ES-LCMS m/z 575 (M+H)⁺.




Endo 2-methyl-1-[(1R,5S)-8-(2-{4-[3-(methylthio)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole dihydrochloride was prepared and used without purification as described in example 16g from the product obtained in previous step (0.70 g, 1.217 mmol) to afford off white solid (0.353 g, 100%).

466




Endo 1-[(1R,5S)-8-(2-{1-(2,2-dimethyl propanoyl)-4-[3-(methylthio)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole was prepared as described in example 16 from the product
 5 obtained in previous step (100 mg, 0.1826 mmol), using 3 equivalents of triethylamine and purified by column chromatography on silica gel, eluting with a gradient of 0-5% methanol in dichloromethane to afford colorless oil (64 mg, 63 %). ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, 1H, J=6.9 Hz), 7.36-7.09 (m, 7H), 4.68-4.60 (m, 1H), 3.98-3.93 (br m, 2H), 3.36-3.29 (m, 4H), 2.60 (s, 3H), 2.53
 10 (s, 3H), 2.46-2.35 (m, 2H), 2.33-2.18 (m, 2H), 1.97-1.60 (m, 12H), 1.29 (s, 9H). HRMS m/z (M+H) 559.3471 Cal., 559.3464 Obs.



Example 708

endo 2-chloro-5-({4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-[3-(methylthio)phenyl]piperidin-1-yl}carbonyl)benzene sulfonamide




5

The title compound was prepared as described in Example 719 from dihydrochloride intermediate described in example 707 (200 mg, 0.365 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 3.75-7.50% methanol in dichloromethane with 0.25% ammonium hydroxide to afford white solid (110 mg, 44%). ¹H-NMR (300 MHz, CDCl₃) δ 8.13 (s, 1H), 7.67 (d, 1H, J=6.9Hz), 7.62-7.52 (m, 2H), 7.37-7.32 (m, 2H), 7.28-7.15 (m, 4H), 7.08 (d, 1H, J=7.6 Hz), 5.44 (br s, 2H), 4.71-4.60 (m, 1H), 4.25-4.18 (br m, 1H), 3.58-3.50 (br m, 1H), 3.40-3.27 (br m, 4H), 2.57 (s, 3H), 2.52 (s, 3H), 2.46-2.36 (m, 3H), 2.25-2.16 (br m, 1H), 2.06-1.62 (m, 12H). HRMS m/z (M+H)⁺ 692.2496 Cal., 692.2520 Obs.

15

Example 709


endo 1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(4-methylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



20


The title compound was synthesized according to the methods described in example 16 with a 4-methyl instead of a 3-chloro substitution in the phenyl ring.

Tert-butyl 4-(1-cyano-2-ethoxy-2-oxoethyl)-4-(4-methylphenyl)piperidine-1-carboxylate.




This intermediate was prepared as described in example 16b from 4-bromotoluene (11.97 g, 70 mmol) and using tetrahydrofuran instead of ether as a solvent and purified by column chromatography on silica gel, eluting with 9:1-6:1 hexane-ethyl acetate to afford oily product (5.32 g, 81%). ¹H-NMR (300 MHz, CDCl₃) δ 7.28-7.20 (m, 4H), 4.03-3.92 (m, 4H), 3.57 (s, 1H), 2.93-2.84 (m, 2H), 2.63-2.51 (br m, 2H), 2.36 (s, 3H), 1.45 (s, 9H), 1.05 (t, 3H, J=7.1 Hz). ES-LCMS *m/z* 287 (M-BOC+H)⁺.

[1-(tert-butoxycarbonyl)-4-(4-methylphenyl)piperidin-4-yl](cyano)acetic acid.



This intermediate was prepared and used without purification as described in example 16c from the product obtained in previous step (5.32 g, 13.76 mmol) to afford rigid foam (4.93 g, 100%). ES-LCMS *m/z* 259 (M-BOC+H).


Tert-butyl 4-(cyanomethyl)-4-(4-methylphenyl)piperidine-1-carboxylate.



469


This intermediate was prepared as described in example 16d from the product obtained in previous step (4.93 g, 13.76 mmol) to afford a thick oil (3.51 g, 81%). ¹H-NMR (300 MHz, CDCl₃) δ 7.28-7.21 (m, 4H), 3.80-3.72 (m, 2H), 3.10-3.03 (m, 2H), 2.54 (s, 2H), 2.37 (s, 3H) 2.35-2.31 (m, 2H), 1.89-1.80 (m, 2H), 1.46 (s, 9H). ES-LCMS *m/z* 215 (M-BOC+H)⁺.

Tert-butyl 4-(4-methylphenyl)-4-(2-oxoethyl)piperidine-1-carboxylate.



This intermediate was prepared as described in example 16e from the product obtained in previous step (1.55 g, 4.93 mmol) to afford an oil (1.28g, 82%). ¹H NMR (300 MHz, CDCl₃) δ 9.40 (t, 1H, J=2.9 Hz), 7.28-7.11 (m, 4H), 3.72-3.62 (m, 2H), 3.29-3.20 (m, 2H), 2.63 (s, 2H), 2.54 (s, 3H), 2.36-2.21 (m, 2H), 1.89-1.80 (m, 2H), 1.46 (s, 9H). ES-LCMS *m/z* 218 (M-BOC+H)⁺.


Tert-butyl endo 4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(4-methylphenyl)piperidine-1-carboxylate.




This intermediate was prepared as described in example 16f from the product obtained in previous step (0.60 g, 1.89 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 2-5% methanol in dichloromethane to afford a rigid foam (0.61 g, 59%). ¹H-NMR (300 MHz, CDCl₃) δ 7.70 (d, 1H, J=7.1 Hz), 7.33-7.12 (m, 7H), 4.71-4.65 (m, 1H), 3.75-3.62 (m, 2H), 3.40-3.19 (m, 4H), 2.60 (s, 3H), 2.48-2.25 (m, 2H), 2.36 (s, 3H), 2.22-2.09 (m, 2H), 2.05-1.60 (m, 12H), 1.45 (s, 9H). ES-LCMS *m/z* 543 (M+H)⁺.

470

Endo 2-methyl-1-((1R,5S)-8-{2-[4-(4-methyl phenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole dihydrochloride.



This intermediate was prepared and used without purification, as described in example 16g from the product obtained in previous step (0.61 g, 1.124 mmol) to afford a white solid (0.579 g, 100%).




The 1:1 formic acid salt of the title compound from example 709 endo 1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(4-methylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole was prepared as described in example 16 from the product obtained in previous step (100 mg, 0.194 mmol), using 3.2 equivalents of triethylamine and purified by Plate Purification Method A to afford a rigid foam (26.65 mg, 26 %). ¹H-NMR (300 MHz, CDCl₃) δ 8.44 (s, 1H), 7.71 (d, J=7.2 Hz, 1H), 7.30-7.16 (m, 7H), 6.20-5.80 (br s, 1H), 4.94-4.88 (m, 1H), 3.98-3.93 (m, 2H), 3.51-3.43 (m, 2H), 3.33-3.20 (m, 2H), 2.64-2.53 (m, 5H), 2.37 (s, 3H), 2.27-1.72 (m, 14H), 1.28 (s, 9H). HRMS m/z (M+H) 527.3750 Cal., 527.3745 Obs.

471

Example 710

formic acid salt (1:1) of endo methyl 3-{[4-{2-[{(1R, 5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}-4-(4-methylphenyl)piperidin-1-yl]carbonyl}benzoate

5 To a solution of the dihydrochloride intermediate obtained in Example



709 (250 mg, 0.485 mmol) in N,N-dimethylformamide (1 ml) was added methylhydrogen isophthalate (87.4 mg, 0.485 mmol), N,N-diisopropylethylamine (0.27 ml, 1.55 mmol) and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (184.3 mg, 0.485 mmol).

10 The reaction mixture was stirred at room temperature for 4h. Quenched by addition of a saturated solution of sodium bicarbonate and extracted with ethyl acetate (3x5 ml). The organic layer was washed with brine and concentrated. The product was purified by column chromatography on silica gel, eluting with a gradient of 2.5-5% methanol in dichloromethane. Further purification was

15 accomplished by Plate Purification Method A to afford a solid product (72.2 mg, 23%).


¹H NMR (300 MHz, CDCl₃) δ 8.43 (br s, 1H), 8.12-8.05 (m, 2H), 7.71 (d, 1H, J=7.3 Hz), 7.61-7.59 (m, 1H), 7.50 (t, 1H, J=7.6 Hz), 7.30-7.23 (m, 7H), 4.96-4.83 (m, 1H), 4.30-4.17 (m, 1H), 3.94 (s, 3H), 3.89-3.80 (m, 4H), 3.43-3.27 (m, 3H), 2.64-2.52 (m, 2H), 2.59 (s, 3H), 2.38(s, 3H), 2.35-1.92 (m, 12H).

20 HRMS m/z (M+H)⁺ 605.3492 Cal., 605.3479 Obs.

472

Example 711

endo 3-{[4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(4-methylphenyl)piperidin-1-yl]carbonyl}benzoic acid



5


The title compound was prepared as described in example 718 from the product obtained in example 710 (43 mg, 0.0673 mmol) to afford a white solid (35.5 mg, 89.3%). ¹H-NMR (300 MHz, MeOD) δ 8.15-8.11 (m, 1H), 8.05 (s, 1H), 7.60-7.50 (m, 4H), 7.38-7.19 (m, 6H), 5.23-5.13 (m, 1H), 4.23-4.10 (br m, 2H), 3.61-3.57 (br m, 1H), 3.40-3.28 (m, 4H), 2.80-2.60 (m, 4H), 2.59 (s, 3H), 2.42-2.15 (m, 9H), 2.38 (s, 3H), 2.05-1.75 (m, 2H). HRMS m/z (M+H)⁺ 591.3335 Cal., 591.3363 Obs.

10

Example 712

endo 1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(4-isopropylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole

15




20

The title compound was synthesized according to the methods outlined in example 16 with a 4-isopropyl instead of a 3-chloro substitution in the phenyl ring.


473

Tert-butyl 4-(1-cyano-2-ethoxy-2-oxoethyl)-4-(4-isopropylphenyl)piperidine-1-carboxylate.




This intermediate was prepared and used without further purification as described in example 16b from 1-bromo-4-isopropylbenzene (10.25 g, 51.48 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 9:1-6:1 hexane-ethyl acetate to afford 3.98g of oil product (56% yield). ES-LCMS m/z 413 ($M+Na$)⁺.

[1-(Tert-butoxycarbonyl)-4-(4-isopropylphenyl)piperidin-4-yl](cyano)acetic acid.




This intermediate was prepared and used without further purification as described in example 16c from the product obtained in previous step (3.98 g, 9.60 mmol) using isopropanol instead of ethanol to afford 3.71 g of oil (100%). ES-LCMS m/z 409 ($M+Na$)⁺.

Tert-butyl 4-(cyanomethyl)-4-(4-isopropyl phenyl)piperidine-1-carboxylate.



This intermediate was prepared as described in example 16d from the product from previous step (3.71 g, 9.60 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 10-20% ethyl acetate in hexane to afford an oil which solidified upon standing (2.62 g, 78%). ¹H-NMR (300 MHz, CDCl₃) δ 7.26-7.29 (m, 4H), 3.80-3.72 (m, 2H), 3.17-3.05 (m, 2H), 2.94-2.90 (m, 1H), 2.54 (s, 2H), 2.46-2.32 (m, 2H), 1.91-1.81 (m, 2H), 1.46 (s, 9H), 1.28 (s, 3H), 1.26 (s, 3H).

Tert-butyl 4-(4-isopropylphenyl)-4-(2-oxoethyl)piperidine-1-carboxylate.




This intermediate was prepared as described in example 16e from the product obtained in previous step (2.62 g, 7.65 mmol) to afford 1.53 g of an oil (58%). ¹H-NMR (300 MHz, CDCl₃) δ 9.40 (t, 1H, J=2.9 Hz), 7.30-7.20 (m, 4H) 3.66-3.61 (br m, 2H), 3.35-3.22 (m, 2H), 2.96-2.87 (m, 1H), 2.64 (d, 2H, J=2.9 Hz), 2.26-2.21 (br m, 2H), 1.90-1.81 (m, 2H), 1.46 (s, 9H) 1.27 (s, 3H), 1.25 (s, 3H). ES-LCMS *m/z* 368 (M+Na)⁺.

tert-butyl endo 4-(4-isopropylphenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate.

This intermediate was prepared as described in example 16f from the product obtained in previous step (0.30 g, 0.868 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 2-4% methanol in dichloromethane to afford a rigid foam (0.23 g, 60%). ¹H-NMR (300 MHz, CDCl₃) δ 7.69 (d, 1H, J=7 Hz), 7.33-7.19 (m, 7H), 4.75-4.65 (m, 1H), 3.84-3.65 (m, 2H), 3.39-3.22 (m, 4H), 2.96-2.85 (m, 1H), 2.60 (s, 3H), 2.47-2.37 (m, 2H), 2.16-2.09 (m, 2H), 2.05-1.87 (m, 10H), 1.85-1.80 (m, 2H), 1.45 (s, 9H), 1.29 (s, 3H), 1.27 (s, 3H). ES-LCMS *m/z* 571 (M+H)⁺.

Endo 1-[(1R,5S)-8-{2-[4-(4-isopropylphenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride.

475




This intermediate was prepared and used without further purification as described in example 16g from the product obtained in previous step (0.23 g, 0.403 mmol) to afford 0.219 g of a white solid (100%). ES-LCMS m/z 443 (M+H)⁺.

Endo 1-((1R,5S)-8-{2-[1-(2,2-dimethyl propanoyl)-4-(4-isopropylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (example 712). The title compound was prepared as described in example 16 from the dihydrochloride intermediate from example 711 (70 mg, 0.1287 mmol), using 3.2 equivalents of triethylamine and purified by column chromatography on silica gel, eluting with a gradient of 2-4% methanol in dichloromethane with 0.1% ammonium hydroxide to afford 49.7 mg of colorless oil. (70%). ¹H-NMR (300 MHz, CDCl₃) δ 7.68 (d, 1H, J=7.0 Hz), 7.33-7.16 (m, 7H), 4.78-4.60 (m, 1H), 3.98-3.93 (m, 2H), 3.36-3.20 (m, 4H), 2.97-2.88 (m, 1H), 2.59 (s, 3H), 2.45-2.35 (m, 2H), 2.24-2.19 (m, 2H), 1.96-1.73 (m, 10H), 1.66-1.64 (m, 2H), 1.29 (s, 9H), 1.28 (s, 3H), 1.26 (s, 3H). HRMS m/z (M+H) 555.4063 Cal., 555.4072 Obs.

Example 713

endo methyl 3-[(4-(4-isopropylphenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzoate




476

The title compound was prepared as described in example 719 from the dihydrochloride described in example 711 (70 mg, 0.1287 mmol) and methylhydrogen isophthalate (23.2 mg, 0.1287 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 2.5-5% methanol in dichloromethane to afford a beige solid (46 mg, 56.4%). ¹H-NMR (300 MHz, CDCl₃) δ 8.11-8.03 (m, 2H), 7.70 (d, 1H, J=7 Hz), 7.62-7.57 (m, 1H), 7.53-7.48 (m, 1H), 7.33-7.15 (m, 7H), 4.71-4.60 (m, 1H), 4.30-4.20 (br s, 1H), 3.94 (s, 3H), 3.45-3.20 (m, 4H), 2.98-2.89 (m, 1H), 2.57 (s, 3H), 2.45-2.19 (m, 4H), 1.97-1.59 (m, 13H), 1.30 (s, 3H), 1.28 (s, 3H). HRMS m/z (M+H)⁺ 633.3804 Cal., 633.3801 Obs.

Example 714

endo 3-[(4-(4-isopropylphenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzoic acid



15


The title compound was prepared as described in example 718 from title compound in example 713 (31 mg, 0.049 mmol) and purified by Plate Purification Method A to afford white solid (10.4 mg, 34.3%). ¹H-NMR (300 MHz, MeOH-d₄) δ 8.31 (s, 1H), 8.14 (t, 1H, J=3.3 Hz), 8.05 (s, 1H), 7.59-7.56 (m, 3H), 7.49 (d, 1H, J=6.7 Hz), 7.37-7.22 (m, 5H), 5.19-5.12 (m, 1H), 4.19-4.15 (br m, 2H), 3.89-3.82 (br m, 2H), 3.59-3.54 (m, 1H), 3.39-3.27 (m, 4H), 2.99-2.88 (m, 1H), 2.77-2.67 (br m, 2H), 2.59-2.45 (m, 2H), 2.56 (s, 3H), 2.37-1.80 (m, 10H), 1.27 (s, 3H), 1.25 (s, 3H). HRMS m/z (M+H)⁺ 619.3648 Cal., 619.3647 Obs.

25

Example 715

endo 2-chloro-5-[(4-(4-isopropylphenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1] oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzene sulfonamide

5




The title compound was prepared as described in Example 719 from dihydrochloride intermediate described in example 711 (100 mg, 0.184 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 2-4% methanol in dichloromethane with 1% ammonium hydroxide to afford an off white solid (43.2 mg, 34%). ¹H-NMR (300 MHz, CDCl₃) δ 8.13 (s, 1H), 7.67 (d, 1H, J=7Hz), 7.61-7.52 (m, 3H), 7.33-7.13 (m, 6H), 5.42 (br s, 2H), 4.67-4.61 (m, 1H), 4.24-4.18 (br m, 1H), 3.55-3.42 (br m, 1H), 3.38-3.20 (br m, 4H), 3.00-2.91 (m, 1H), 2.57 (s, 3H), 2.45-2.35 (m, 4H), 2.27-2.21 (br m, 1H), 1.98-1.70 (m, 11H), 1.28 (s, 3H), 1.26 (s, 3H). HRMS m/z (M+H)⁺ 688.3088 Cal., 688.3079 Obs.

478


Example 716

endo 1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(3-methylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole



- 5 The title compound was synthesized according to the methods outlined in example 16 with a 3-methyl instead of a 3-chloro substitution in the phenyl ring.


Tert-butyl 4-(1-cyano-2-ethoxy-2-oxoethyl)-4-(3-methylphenyl)piperidine-1-carboxylate.



10

This intermediate was prepared and used without further purification as described in example 16b from 3-bromotoluene (11.97 g, 70 mmol) to afford 6.13g of an oil (93.4%). ES-LCMS m/z 287 (M-BOC+H)⁺.

- 15 *[1-(Tert-butoxycarbonyl)-4-(3-methylphenyl)piperidin-4-yl](cyano)acetic acid.*




20

This intermediate was prepared as described in example 16c from the product obtained in previous step (6.13 g, 15.86 mmol) and was used without further purification to afford 5.68 g of an oil (100%). ES-LCMS m/z 259 (M-BOC+H)⁺.


Tert-butyl 4-(cyanomethyl)-4-(3-methylphenyl) piperidine-1-carboxylate.

479




This intermediate was prepared as described in example 16d from the product obtained in previous step (5.68 g, 15.86 mmol) to afford 2.66 g of an oil (2.66 g, 53.3%). ¹H NMR (300 MHz, CDCl₃) δ 7.34-7.28 (m, 1H), 7.18-7.12 (m, 3H) 3.82-3.72 (m, 2H), 3.13-3.04 (m, 2H), 2.55 (s, 2H), 2.39 (s, 3H) 2.37-2.31 (m, 2H), 1.91-1.82 (m, 2H), 1.46 (s, 9H). ES-LCMS *m/z* 215 (M-BOC+H)⁺.

Tert-butyl 4-(3-methylphenyl)-4-(2-oxoethyl)piperidine-1-carboxylate.



This intermediate was prepared as described in example 16e from the product described in previous step (2.66 g, 8.46 mmol) to afford 2.24g of an oil (83%). ¹H-NMR (300 MHz, CDCl₃) δ 9.39 (t, 1H, J=2.9 Hz), 7.31-7.28 (m, 1H), 7.20-7.07 (m, 3H), 3.68-3.60 (m, 2H), 3.31-3.22 (m, 2H), 2.64 (s, 2H), 2.38 (s, 3H), 2.27-2.21 (m, 2H), 1.90-1.81 (m, 2H), 1.46 (s, 9H).

Tert-butyl endo-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(3-methylphenyl)piperidine-1-carboxylate.




This intermediate was prepared as described in example 16f from the product obtained in previous step (0.60 g, 1.89 mmol) and purified by column chromatography on silica gel, eluting with 5% methanol in dichloromethane to afford 0.58 g of a rigid foam (0.58 g, 57%). ¹H-NMR (300 MHz, CDCl₃) δ 7.70-7.68 (d, 1H, J=7 Hz), 7.34-7.04 (m, 7H), 4.73-4.63 (m, 1H), 3.70-3.66 (m,

480

2H), 3.30-3.21 (m, 4H), 2.60 (s, 3H), 2.46-2.32 (m, 2H), 2.39 (s, 3H), 2.18-2.09 (m, 2H), 2.00-1.90 (m, 6H), 1.85-1.75 (m, 4H), 1.73-1.60 (m, 2H), 1.44 (s, 9H). ES-LCMS m/z 543 (M+H)⁺.


5 *Endo 2-methyl-1-((1R,5S)-8-{2-[4-(3-methyl phenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole dihydrochloride.*



This intermediate was prepared and used without further purification as described in example 16g from the product obtained in previous step (0.58 g, 1.068 mmol) to afford 0.55g of a white solid (100%). ES-LCMS m/z 443 (M+H)⁺.

Example 716


endo 1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(3-methylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1] oct-3-yl)-2-methyl-1H-benzimidazole



15 The title compound was prepared as described in example 16 from the product obtained in previous step (100 mg, 0.194 mmol), using 3.2 equivalents of triethylamine to afford 33 mg of a colorless oil (32%). ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, 1H, J=7.1 Hz), 7.33-7.06 (m, 7H), 4.70-4.50 (m, 1H), 3.99-3.94 (m, 2H), 3.36-3.20 (m, 4H), 2.60 (s, 3H), 2.50-2.35 (m, 2H), 2.40 (s, 3H), 2.24-2.20 (m, 2H), 1.96-1.60 (m, 12H), 1.30 (s, 9H). HRMS m/z (M+H)⁺ 527.3750 Cal., 527.3769 Obs.

Example 717

endo methyl 3-[[4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(3-methylphenyl)piperidin-1-yl]carbonyl]benzoate hydrochloride



5

To a solution of methyl hydrogen isophthalate (70 mg, 0.3879 mmol) in dichloromethane (4 ml) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (74.36 mg, 0.3879 mmol), 1-hydroxybenzotriazole (52.42 mg, 0.3879 mmol), endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo [3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride II (200 mg, 0.3879 mmol) and N,N-diisopropylethylamine (0.225 ml, 1.29 mmol). After stirring at room temperature overnight, 10% citric acid (5 ml) was added to the mixture and extracted with dichloromethane (2 x 10 ml). The combined organic phase was washed with water (10 ml) and dried over anhydrous sodium sulfate.


15

After evaporation of the solvent the product was purified by column chromatography on silica gel, eluting with 2% methanol in dichloromethane and then treated with 4M HCl-dioxane solution (1.2 ml) to afford endo methyl 3-[[4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(3-methylphenyl)piperidin-1-yl]carbonyl]benzoate hydrochloride as a rigid white foam (94 mg, 38%). ¹H NMR (300 MHz, CDCl₃) δ 12.19 (br s, 1H), 8.11-8.03 (m, 2H), 7.70-7.48 (m, 3H), 7.31-7.11 (m, 7H), 4.69-4.60 (m, 1H), 4.21-4.19 (m, 1H), 3.94 (s, 3H), 3.61-3.29 (m, 3H), 2.58 (s, 3H), 2.43-2.25 (m, 4H), 2.39 (s, 3H), 2.18-2.15 (m, 2H), 1.96-1.76 (m, 10H), 1.67-1.60 (m, 2H). HRMS m/z (M+H)⁺ 605.3524 Cal., 605.3484 Obs.

25

Example 719

endo 2-chloro-5-([4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(3-methylphenyl)piperidin-1-yl]carbonyl)benzene sulfonamide




5

To a solution of endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (200 mg, 0.3879 mmol) in N,N-dimethylformamide (1.5 ml) was added 4-chloro-3-sulfamoylbenzoic acid (91.4 mg, 0.3879 mmol), triethylamine (0.163 ml, 1.1637 mmol) and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (162.2 mg, 0.4267). The reaction mixture was stirred at room temperature for 2h. Water was added until a precipitate formed, after filtration the resulting solid was washed with saturated sodium bicarbonate solution (10 ml) and water (10 ml). The product was purified by column chromatography on silica gel, eluting with 5% methanol in dichloromethane with 0.5% ammonium hydroxide to afford endo 2-chloro-5-([4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(3-methylphenyl) piperidin-1-yl]carbonyl)benzenesulfonamide as a white solid (115 mg, 45%). ¹H-NMR (300 MHz, CDCl₃) δ 7.92-7.83 (m, 1H), 7.74-7.66 (m, 1H), 7.57-7.49 (m, 1H), 7.33-7.07 (m, 8H), 5.44 (br s, 2H), 4.69-4.62 (m, 1H), 4.35-4.23 (m, 1H), 3.42-3.16 (m, 6H), 2.55 (s, 3H), 2.45-2.30 (m, 2H), 2.35 (s, 3H), 2.28-2.18 (m, 1H), 2.05-1.60 (m, 12H). HRMS m/z (M+H)⁺ 660.2775 Cal., 660.2772 Obs.

20

Example 720

endo 1-[(1R,5S)-8-(2-{1-(2,2-dimethylpropanoyl)-4-[3-(methylsulfonyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




5

Title compound in example 720 was synthesized according to the methods outlined in example 16 with a 3-methylsulfonyl instead of a 3-chloro substitution in the phenyl ring.

Tert-butyl 4-(1-cyano-2-ethoxy-2-oxoethyl)-4-[3-(methylthio)phenyl]piperidine-1-carboxylate.

10




This intermediate was prepared as described in example 16b from 3-bromothioanisole (4.56 g, 22.45 mmol) and using tetrahydrofuran instead of diethyl ether as a solvent and purified by column chromatography on silica gel, eluting with a gradient of 9:1-6:1 hexane-ethyl acetate to afford *tert*-butyl 4-(1-cyano-2-ethoxy-2-oxoethyl)-4-[3-(methylthio)phenyl]piperidine-1-carboxylate as an oil (1.61 g, 71%). ¹H NMR (300 MHz, CDCl₃) δ 7.37-7.14 (m, 4H), 4.01-3.82 (m, 4H), 3.59 (s, 1H), 2.95-2.87 (m, 2H), 2.62-2.50 (m, 2H), 2.51 (s, 3H) 2.17-1.97 (m, 2H), 1.46 (m, 9H). ES-LCMS *m/z* 417 (M-H)⁻.

20


{1-(tert-butoxycarbonyl)-4-[3-(methylthio)phenyl]piperidin-4-yl}(cyano)acetic acid.

485




This intermediate was prepared and used without further purification as described in example 16c from the product obtained in previous step (1.61 g, 3.846 mmol) to afford 1.50g of an oil (100%).

5 *Tert-butyl 4-(cyanomethyl)-4-[3-(methylthio)phenyl]piperidine-1-carboxylate.*



This intermediate was prepared as described in example 16d from the product from previous step (1.50 g, 3.846 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 10-20% ethyl acetate in hexane to afford 1.13 g of an oil (yield 85%). ¹H-NMR (300 MHz, CDCl₃) δ 7.39-7.15 (m, 4H), 3.80-3.70 (br m, 2H), 3.14-3.06 (m, 2H), 2.56 (s, 2H), 2.52 (s, 3H), 2.35-2.30 (m, 2H), 1.92-1.83 (m, 2H), 1.46 (s, 9H).

15 *Tert-butyl 4-(cyanomethyl)-4-[3-(methylsulfonyl)phenyl]piperidine-1-carboxylate.*




To a solution of product from previous step (1.13 g, 3.26 mmol) in dichloromethane (5 ml) cooled in an ice bath to 0°C, was added a solution of m-chloroperbenzoic acid (1.46 g, 8.48 mmol) in dichloromethane (15 ml) dropwise. The mixture was stirred at 0°C for 1h and a 5% solution of sodium thiosulfate in saturated sodium bicarbonate (50 ml) was then added. The

20


resulting mixture was allowed to stir at room temperature for 30 minutes and extracted with dichloromethane (50 ml). The combined organic phase was washed with 1N NaOH (2x30 ml), water (2x20 ml), dried over anhydrous sodium sulfate and concentrated the solvent to afford *tert*-butyl 4-(cyanomethyl)-4-[3-(methylsulfonyl)phenyl] piperidine-1-carboxylate as a rigid foam (1.05 g, 85%). AP-LCMS m/z 279 (M-BOC+H)⁺. This material was used without further purification.

Tert-butyl 4-[3-(methylsulfonyl)phenyl]-4-(2-oxoethyl)piperidine-1-carboxylate.



This intermediate was prepared as described in example 16e from the product obtained in previous step (1.05 g, 2.774 mmol) to afford 0.69g of a rigid foam (yield 65%), which was used further without additional purification. AP-LCMS m/z 282 (M-BOC+H)⁺.

Tert-butyl endo 4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-[3-(methylsulfonyl)phenyl]piperidine-1-carboxylate.




This intermediate was prepared as described in example 16f from the product obtained in previous step (0.69 g, 1.808 mmol) and purified by column chromatography on silica gel, eluting with 5% methanol in dichloromethane to afford 0.37 g of an oil (yield 34%). ¹H-NMR (300 MHz, CDCl₃) δ 7.94 (s, 1H), 7.90-7.83 (m, 1H), 7.70-7.61 (m, 3H), 7.34-7.28 (m, 1H), 7.19-7.14 (m, 2H), 4.68-4.61 (m, 1H), 3.70-3.64 (m, 2H), 3.32-3.21 (m, 4H), 3.10 (s, 3H), 2.61 (s,

487


3H), 2.50-2.38 (m, 2H), 2.25-2.17 (m, 2H), 2.05-1.78 (m, 8H), 1.70-1.57 (m, 4H), 1.45 (s, 9H). ES-LCMS m/z 607 (M+H)⁺.

Tert-butyl endo 4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-[3-(methylsulfonyl)phenyl]piperidine-1-carboxylate dihydrochloride.




This intermediate was prepared as described in example 16g from the product from previous step (0.37 g, 0.6097 mmol) to afford the dihydrochloride as white solid (0.353 g, 100%). ES-LCMS m/z 507 (M+H)⁺. This material was used without further purification.

Endo 1-[(1R,5S)-8-(2-{1-(2,2-dimethyl propanoyl)-4-[3-(methylsulfonyl)phenyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole.




The title compound in example 720 was prepared as described in example 16 from the product obtained in previous step (100 mg, 0.1725 mmol), using 3.2 equivalents of triethylamine to afford 65.4 mg of a colorless oil (yield 64 %). ¹H-NMR (300 MHz, CDCl₃) δ 7.94 (s, 1H), 7.88-7.83 (m, 1H), 7.70-7.60 (m, 3H), 7.33-7.28 (m, 1H), 7.20-7.14 (m, 2H), 4.71-4.58 (m, 1H), 3.94-3.88 (m, 2H), 3.51-3.40 (m, 2H), 3.28-3.20 (m, 1H), 3.11 (s, 3H), 2.61 (s, 3H), 2.47-2.37 (m, 2H), 2.30-2.18 (m, 2H), 2.05-1.90 (m, 10H), 1.75-1.58 (m, 3H), 1.41 (s, 9H). HRMS m/z (M+H) 591.3369 Cal., 591.3369 Obs.

488

Example 721

Formic acid salt of endo-1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(3-isopropoxyphenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (1:1) was synthesized according to the methods outlined in example 16 with a 3-isopropoxy instead of a 3-chloro substitution in the phenyl ring.

Tert-butyl 4-(1-cyano-2-ethoxy-2-oxoethyl)-4-(3-isopropoxyphenyl)piperidine-1-carboxylate.




10

This intermediate was prepared as described in example 16b from 1-bromo-3-isopropoxybenzene (10 g, 46.5 mmol) using tetrahydrofuran instead of diethyl ether as a solvent and purified by column chromatography on silica gel, eluting with a gradient of 9:1-6:1 ethyl acetate in hexane to afford 4.68 g of an oil (yield 70%). ES-LCMS m/z 453 ($M+Na$)⁺. This material was used without further purification.


15

[1-(Tert-butoxycarbonyl)-4-(3-isopropoxyphenyl)piperidin-4-yl](cyano)acetic acid.




This intermediate was prepared and used without further purification as described in example 16c from the product obtained in previous step (4.68 g, 10.87 mmol) to afford 4.37g of an oil (yield 100%). ES-LCMS m/z 303 (M-BOC+H)⁺.

- 5 *Tert-butyl 4-(cyanomethyl)-4-(3-isopropoxyphenyl)piperidine-1-carboxylate.*



- This intermediate was prepared as described in example 16d from the product obtained in previous step (4.37 g, 10.87 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 10-20% ethyl acetate in hexane to afford 2.45 g of an oil (yield 62.5%). ¹H-NMR (300 MHz, CDCl₃) δ 7.32 (t, 1H, J=8 Hz), 6.93 (d, 1H, J=7.9 Hz), 6.89 (s, 1H), 6.83 (d, 1H, J=5.9 Hz), 4.61-4.53 (m, 1H), 3.81-3.72 (br m, 2H), 3.12-3.04 (m, 2H), 2.54 (s, 2H), 2.34-2.29 (m, 2H), 1.89-1.80 (m, 2H), 1.46 (s, 9H), 1.37 (s, 3H), 1.35 (s, 3H). ES-LCMS m/z 259 (M-BOC+H)⁺.
- 10
- 15


Tert-butyl 4-(3-isopropoxyphenyl)-4-(2-oxoethyl)piperidine-1-carboxylate.



- This intermediate was prepared and used without further purification as described in example 16e from the product obtained in previous step (2.45 g, 6.834 mmol) to afford 1.96 g of an oil (yield 79.3%).
- 20


Tert-butyl endo 4-(3-isopropoxyphenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}piperidine-1-carboxylate.

490



This intermediate was prepared as described in example 16f from the product obtained in previous step (1.96 g, 5.422 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 0-10% methanol in dichloromethane to afford 1.42g of a rigid foam (yield 46.4%). ¹H-NMR (300 MHz, CDCl₃) δ 7.70 (d, 1H, J=7.2 Hz), 7.30-7.15 (m, 3H), 6.93-6.70 (m, 4H), 4.74-4.61 (br m, 1H), 4.59-4.53 (m, 1H), 3.68-3.64 (br m, 2H), 3.35-3.00 (m, 4H), 2.61 (s, 3H), 2.57-2.41 (m, 2H), 2.20-2.15 (m, 2H), 2.05-1.60 (m, 12H), 1.46 (s, 9H), 1.37 (s, 3H), 1.35 (s, 9H).

Endo 1-((1R,5S)-8-{2-[4-(3-isopropoxyphenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride.



This intermediate was prepared and used without purification as described in example 16g from the product obtained in previous step (1.42 g, 2.42 mmol) to afford 1.32 g of a rigid foam (yield 97.5%). ES-LCMS *m/z* 487 (M + H)⁺.


Formic acid salt of *endo 1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-(3-isopropoxyphenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole*. The title compound in example 721 was prepared as described in example 16 from the product obtained in previous step (100 mg, 0.179 mmol), using 3 equivalents of triethylamine and purified by Plate Purification Method A to afford 21.2 mg of a colorless oil (yield 21 %). ¹H-NMR (300 MHz, CDCl₃) δ 8.46 (s, 1H), 7.70 (d, 1H, J=7.2 Hz), 7.32-7.15 (m, 4H), 6.93-6.78 (m, 3H), 4.85-4.76 (m, 1H), 4.62-4.54 (m, 1H), 3.98-3.93 (br m, 2H), 3.46-3.40 (br m, 2H), 3.36-3.28 (m, 2H), 2.60 (s, 3H), 2.57-2.46 (m, 2H),

491

2.21-1.73 (m, 14H), 1.39 (s, 3H), 1.37 (s, 3H), 1.30 (s, 9H). HRMS m/z (M+H)
571.4012 Cal., 571.4014 Obs.

Example 722


5 formic acid salt (1:1) of endo 2-chloro-5-[(4-(3-isopropoxyphenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide



The title compound in example 722 was prepared as described in
10 Example 719 from dihydrochloride described in example 721 (200 mg, 0.357
mmol) and purified by Plate Purification Method A to afford a 1:1 salt of a
formic acid and endo 2-chloro-5-[(4-(3-isopropoxyphenyl)-4-{2-[(1R,5S)-3-(2-
methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-
yl)carbonyl]benzenesulfonamide as an off-white solid (34 mg, 13%). ¹H-NMR
15 (300 MHz, CDCl₃) δ 8.41 (br s, 1H), 8.13 (s, 1H), 7.70 (d, 1H, J=7.2 Hz), 7.62-
7.53 (m, 1H), 7.59 (s, 1H), 7.34-7.24 (m, 2H), 7.20-7.15 (m, 2H), 6.87-6.80
(m, 3H), 4.83-4.77 (m, 1H), 4.65-4.52 (m, 1H), 4.22-4.19 (br m, 1H), 3.50-3.27
(m, 4H), 2.59 (s, 3H), 2.56-2.46 (m, 2H), 2.20-1.83 (m, 15H), 1.80-1.75 (m,
2H), 1.37 (s, 3H), 1.35 (s, 3H). HRMS m/z (M+H)⁺ 704.3037 Cal., 704.3055
20 Obs.

Example 723

endo 3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzonitrile




5 To a solution of 1,1'-carbonyldiimidazole (68.1 mg, 0.42 mmol) and 3-cyanobenzoic acid (51.5 mg, 0.35 mmol) in dichloromethane (6 ml) was added endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole II and converted to the free base (0.15 g, 0.35 mmol). The mixture was stirred at room temperature for 4h and

10 water (5 ml) was then added. The resultant mixture was extracted with dichloromethane (3x5 ml) and washed with saturated sodium bicarbonate (1x5 ml) and brine (1x5 ml). After drying over sodium sulfate, the solution was concentrated and purified by column chromatography on silica gel, eluting with 5% methanol in dichloro-methane to afford 70 mg of a colorless oil (yield

15 36%). ¹H NMR (300 MHz, CDCl₃) δ 7.74-7.22 (m, 11H), 7.20-7.13 (m, 2H), 4.69-4.55 (m, 1H), 4.30-4.20 (br m, 1H), 3.40-3.19 (m, 4H), 2.58 (s, 3H), 2.44-2.37 (m, 3H), 2.34-2.06 (br m, 1H), 1.96-1.84 (m, 11H), 1.65-1.60 (m, 2H). HRMS *m/z* (M+H) 558.3166 Cal., 558.3252 Obs.

Example 724


endo 2-methyl-1-[(1R,5S)-8-(2-{4-phenyl-1-[3-(2H-tetraazol-5-yl)benzoyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole



5 To a solution of title compound from example 723 (40 mg, 0.0717 mmol) in toluene (4 ml)) was added trimethylsilylazide (24.77 mg, 0.215 mmol) and dibutyltin oxide (16.18 mg, 0.065 mmol), the mixture was heated to reflux for 15 h, diluted with dichloromethane (20 ml), dried over sodium sulfate and concentrated. The crude product was purified by column
10 chromatography on silica gel, eluting with a gradient of 5-20% methanol in dichloromethane to afford endo 2-methyl-1-[(1R,5S)-8-(2-{4-phenyl-1-[3-(2H-tetraazol-5-yl)benzoyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1] oct-3-yl]-1H-benzimidazole as a solid (36 mg, 84%). ¹H-NMR (300 MHz, MeOD) δ 8.18 (d, 1H, J=7.8 Hz), 8.11 (s, 1H), 7.61-7.55 (m, 2H), 7.50-7.42 (m, 6H), 7.33-7.22 (m, 3H), 5.01-4.82 (m, 1H), 4.35-4.20 (br m, 1H), 3.85-3.80 (br m, 2H), 3.70-3.65 (br m, 1H), 3.32-3.27 (m, 2H), 2.73-2.63 (m, 2H), 2.57 (s, 3H), 2.53-2.50 (m, 1H), 2.48-2.37 (m, 1H), 2.31-1.86 (m, 12H). HRMS *m/z* (M+H) 601.3211 Cal., 601.387 Obs.

Example 725

endo N'-hydroxy-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-yl)carbonyl]benzenecarboximidamide




5

To a suspension of hydroxylamine hydrochloride (1.706 g, 24.55 mmol) in a 9:1 mixture of methanol-water (8 ml) was added triethylamine (3.42 ml, 24.55 mmol), followed by the title compound from example 723 (2.74 g, 4.91 mmol). After heating to reflux for 1h, a solid which precipitated was collected by filtration to afford endo N'-hydroxy-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-yl)carbonyl]benzenecarboximidamide (1.49 g, 51.3%). ¹H NMR (300 MHz, DMSO-d₆) δ 9.71 (s, 1H), 7.75 (d, 1H, J= 7.6 Hz), 7.66 (s, 1H), 7.51-7.35 (m, 8H), 7.26-7.21 (m, 1H), 7.15-7.07 (m, 2H), 5.88 (s, 2H), 4.57-4.51 (br m, 1H), 3.91-3.83 (br m, 1H), 3.50-3.40 (m, 2H), 3.26-3.16 (br m, 3H), 2.44 (s, 3H), 2.38-2.32 (m, 2H), 2.13-2.09 (br m, 2H), 1.85-1.73 (m, 10H), 1.61-1.58 (br m, 2H). HRMS *m/z* (M+H) 591.3448 Cal., 591.3458 Obs.

15

Example 726

endo 2-methyl-1-[(1R,5S)-8-(2-{1-[3-(2-oxido-3H-1,2,3, 5-oxathiadiazol-4-yl)benzoyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




5

The title compound was prepared (based on procedure from Yasuhisa Kohara, Keiji Kubo, Eiko Imamiya, Takeo Wada, Yoshiyuki Inada and Takehiko Naka, "Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres." *J. Med. Chem.*, 39, 5228-5235 (1996)) from the product
10 obtained in example 725 (200 mg, 0.339 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 2.5-15% methanol in dichloromethane to afford endo 2-methyl-1-[(1R,5S)-8-(2-{1-[3-(2-oxido-3H-1,2,3,5-oxathiadiazol-4-yl)benzoyl]-4-phenylpiperidin-4-yl}ethyl)-8-
15 azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole as a white solid (41 mg, 19 %).
¹H-NMR (300 MHz, MeOH-d₄) δ 8.02 (d, 1H, J=7.3 Hz), 7.96 (s, 1H), 7.60-7.43 (m, 8H), 7.34-7.23 (m, 3H), 4.98-4.89 (m, 1H), 4.30-4.24 (br m, 1H), 3.87-3.84 (br m, 2H), 3.71-3.63 (br m, 1H), 3.36-3.25 (m, 3H), 2.73-2.40 (m, 5H), 2.61 (s, 3H), 2.31-1.92 (m, 9H). HRMS *m/z* (M+H) 637.2961 Cal.,
20 637.2974 Obs.

Example 727

endo 3-{3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-
azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}-1,2,4-
thiadiazol-5(4H)-one

5



The title compound in example 727 was prepared (based on procedure from Yasuhisa Kohara, Keiji Kubo, Eiko Imamiya, Takeo Wada, Yoshiyuki Inada and Takehiko Naka, "Synthesis and Angiotensin II Receptor

10 Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres." *J. Med. Chem.*, 39, 5228-5235 (1996)) from the product obtained in example 725 (300 mg, 0.5078 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 5-10% methanol in dichloromethane to afford endo 3-{3-[(4-{2-[(1R,5S)-3-(2-

15 methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}-1,2,4-thiadiazol-5(4H)-one as a thick oil (57 mg, 17.7%). ¹H-NMR (300 MHz, MeOH-d₄) δ 8.06 (d, 1H, J=7.6 Hz), 8.00 (s, 1H), 7.82 (br s, 2H), 7.61-7.54 (m, 3H), 7.51-7.46 (m, 3H), 7.30-7.21 (m, 3H), 4.89-4.80 (m, 1H), 4.30-4.18 (br m, 1H), 3.75-3.52 (br m, 3H), 3.36-3.32


20 (m, 3H), 2.58-2.45 (m, 1H), 2.55 (s, 3H), 2.40-1.81 (m, 14H). HRMS *m/z* (M+H)⁺ 633.3011 Cal., 633.3013 Obs.

Example 728

endo 3-{3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-
azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}-1,2,4-
oxadiazole-5(4H)-thione

25


497



The title compound was prepared (based on procedure from Yasuhisa Kohara, Keiji Kubo, Eiko Imamiya, Takeo Wada, Yoshiyuki Inada and Takehiko Naka, "Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres." *J. Med. Chem.*, 39, 5228-5235 (1996)) from the product
 5 obtained in example 725 (300 mg, 0.5078 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 5-10% methanol in dichloromethane to afford endo 3-{3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-4-phenylpiperidin-1-yl)carbonyl]phenyl}-1,2,4-oxadiazole-5(4H)-thione as a white solid (32 mg,
 10 10%). ¹H-NMR (300 MHz, MeOH-d₄) δ 8.03 (d, 1H, J=7.6 Hz), 7.96 (s, 1H), 7.59-7.42 (m, 8H), 7.39-7.20 (m, 3H), 4.97-4.88 (m, 1H), 4.25-4.18 (br m, 1H), 3.73-3.25 (br m, 6H), 2.68-2.60 (m, 1H), 2.57 (s, 3H), 2.57-1.83 (m, 914H).
 15 HRMS *m/z* (M+H)⁺ 633.3011 Cal., 633.2999 Obs.

Example 729

20 exo 1-{(1R,5S)-8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-5-fluoro-2-methyl-1H-benzimidazole




The title compound was prepared from *exo* 5-fluoro-2-methyl-1-
{(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-
benzimidazole (200 mg, 0.448 mmol), which was obtained using analogous
chemistry to that described in the synthesis of *exo*1-(8-azabicyclo[3.2.1]oct-3-
yl)-2-methyl-1*H*-benzimidazole as described elsewhere in this application, and
5 benzoyl chloride (75.6 mg, 0.54 mmol). Products were purified by Plate
Purification Method A to afford *exo* 1-{(1*R*,5*S*)-8-[2-(1-benzoyl-4-
phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-5-fluoro-2-methyl-1*H*-
benzimidazole as an oil (1 mg, 0.4%). ES-LC/MS (CLND) *m/z* 551 (*M*+*H*)⁺.

10

Example 730

exo 1-{(1*R*,5*S*)-8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-
azabicyclo[3.2.1]oct-3-yl}-5-fluoro-1*H*-benzimidazole



The title compound was prepared as described in example 729 from
exo 5-fluoro-1-{(1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-
azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (100 mg, 0.231 mmol), which
was obtained using analogous chemistry to that described in the synthesis of
*exo*1-(8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole as described
elsewhere in this application, and benzoyl chloride (35.7 mg, 0.254 mmol)
and purified by Plate Purification Method A to afford *exo* 1-{(1*R*,5*S*)-8-[2-(1-
benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-5-fluoro-1*H*-
benzimidazole as an oil (1 mg, 0.8%). ES-LCMS (CLND) *m/z* 537 (*M*+*H*)⁺.


15

20

499

Example 731


exo 1-((1R,5S)-8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-5-(methylsulfonyl)-1H-benzimidazole



The title compound was prepared from exo 2-methyl-5-(methylsulfonyl)-1-((1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole (100 mg, 0.197 mmol), which was obtained using analogous chemistry to that described in the synthesis of exo-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole as described elsewhere in this application, and benzoyl chloride (41.5 mg, 0.296 mmol), purified by Plate Purification Method A to afford exo 1-((1R,5S)-8-[2-(1-benzoyl-4-phenyl piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-5-(methylsulfonyl)-1H-benzimidazole as an oil (1 mg, 0.8%). ES-LCMS (CLND) m/z 611 (M+H)⁺.

Example 732

exo 1-((1R,5S)-8-[2-[1-(cyclopentylcarbonyl)-4-phenylpiperidin-4-yl]ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-5-(methylsulfonyl)-1H-benzimidazole



The title compound was prepared from exo 2-methyl-5-(methylsulfonyl)-1-((1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-


500

azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole (100 mg, 0.197 mmol), which was obtained using analogous chemistry to that described in the synthesis of exo-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole as described elsewhere in this application, and cyclopentane carbonyl chloride (39.2 mg, 0.296 mmol) and purified by Plate Purification Method A to afford exo 1-
5 ((1R,5S)-8-{2-[1-(cyclopentyl carbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-5-(methylsulfonyl)-1H-benzimidazole as an oil (0.9 mg, 0.75%). ES-LCMS (CLND) m/z 603 (M+H)⁺.

10

Example 733

exo 1-((1R,5S)-8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-5-(trifluoromethyl)-1H-benzimidazole




The title compound was prepared from exo 1-((1R,5S)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-5-(trifluoromethyl)-1H-benzimidazole (110 mg, 0.228 mmol), which was obtained using analogous chemistry to that described in the synthesis of exo 1-(8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole as described elsewhere in this application, and benzoyl chloride (48.1 mg, 0.342 mmol). The crude was purified by Plate
15 Purification Method A to afford exo 1-((1R,5S)-8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-5-(trifluoromethyl)-1H-benzimidazole as an oil (3.4 mg, 2.5%). ES-LCMS (CLND) m/z 587 (M+H)⁺.

501

Example 734


exo 1-((1*R*,5*S*)-8-{2-[1-(cyclopentylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-5-(trifluoromethyl)-1*H*-benzimidazole



5 The title compound was prepared from exo 1-((1*R*,5*S*)-8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-5-(trifluoromethyl)-1*H*-benzimidazole (110 mg, 0.228 mmol), which was obtained using analogous chemistry to that described in the synthesis of exo 1-(8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole as described elsewhere in this application, and
 10 cyclopentane carbonyl chloride (48.1 mg, 0.342 mmol). The crude was purified by Plate Purification Method A to afford exo 1-((1*R*,5*S*)-8-[2-[1-(cyclopentylcarbonyl)-4-phenylpiperidin-4-yl]ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-5-(trifluoromethyl)-1*H*-benzimidazole as an oil (4.8 mg, 3.6%). ES-LCMS (CLND) m/z 579 ($M+H$)⁺.

15


Examples 735-737 were synthesized by deprotecting the Boc-protected intermediate depicted below and acylation via CDI method, described in example 723.



20

Example 735

endo 1-((1R,5S)-8-{2-[1-(cyclopropylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 The title compound was prepared as described in example 723 from cyclopropane carboxylic acid (9.3 mg, 0.108 mmol) and purified by column chromatography on silica gel, eluting with a gradient of 2-10% methanol in dichloromethene to afford endo 1-((1R,5S)-8-{2-[1-(cyclopropylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-
10 benzimidazole as a colorless oil (41 mg, 77%). ¹H-NMR (300 MHz, DMSO-d₆) δ 7.50 (dd, 1H, J=2.8, 2.1 Hz), 7.43-7.35 (m, 4H), 7.25-7.02 (m, 4H), 4.57-4.49 (m, 1H), 3.86-3.76 (m, 2H), 3.38-3.17 (m, 6H), 2.49 (s, 3H), 2.42-2.31 (m, 2H), 2.31-1.77 (m, 10H), 1.65-1.58 (m, 2H), 0.80-0.62 (m, 5H). HRMS *m/z* (M+H) 497.3280 Cal., 497.3274 Obs.

15

Example 736

endo 1-((1R,5S)-8-{2-[1-(1H-imidazol-1-ylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




20 The title compound was prepared as described in example 723 from 2-thiophene carboxylic acid (13.84 mg, 0.108 mmol). The reaction mixture was stirred at room temperature overnight. The crude product was purified by column chromatography on silica gel, eluting with a gradient of 2-10%

methanol in dichloromethane to afford endo 1-((1R,5S)-8-{2-[1-(1H-imidazol-1-ylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole as a colorless oil (28.6 mg, 49.4%). ¹H-NMR (300 MHz, CDCl₃) δ 7.86 (s, 1H), 7.71-7.67 (m, 1H), 7.45-7.39 (m, 2H), 7.33-7.24 (m, 4H), 7.22-7.11 (m, 4H), 4.67-4.62 (m, 1H), 3.91-3.80 (m, 2H), 3.40-3.22 (m, 4H), 2.60 (s, 3H), 2.50-2.34 (m, 4H), 2.10-1.96 (m, 10H), 1.69-1.63 (m, 2H). HRMS *m/z* (M+H) 523.3185 Cal., 523.3190 Obs.

Example 737

10 endo 4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzonitrile




The title compound was prepared as described in example 723 from 4-cyanobenzoic acid (47.53 mg, 0.322 mmol). The reaction mixture was stirred at room temperature overnight. The crude was purified by column chromatography on silica gel, eluting with 3% methanol in dichloromethane to afford endo 4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzonitrile as a colorless oil (58 mg, 32%). ¹H-NMR (300 MHz, CDCl₃) δ 7.74-7.67 (m, 3H), 7.51-7.26 (m, 8H), 7.22-7.13 (m, 2H), 4.65-4.59 (m, 1H), 4.25-4.20 (br m, 1H), 3.55-3.25 (m, 4H), 2.58 (s, 3H), 2.45-2.33 (br m, 3H), 2.21-2.17 (br m, 1H), 1.96-1.80 (m, 11H), 1.76-1.62 (m, 2H). HRMS *m/z* (M+H) 558.3318 Cal., 558.3237 Obs.

504

Example 738

endo 2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzonitrile




5 The title compound was prepared as described in example 710 by coupling 2-carboxybenzonitrile (36.5 mg, 0.247 mmol) *via* HATU (method M) and purified by column chromatography on silica gel, eluting with 5% methanol in dichloromethane to afford endo 2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzonitrile as a rigid foam (66 mg, 48%). ¹H NMR (300 MHz, CDCl₃) δ 7.75-7.65 (m, 3H), 7.56-7.15 (m, 10H), 4.69-4.63 (m, 1H), 4.32-4.27 (br m, 1H), 3.45-3.35 (m, 4H), 2.58 (s, 3H), 2.46-2.38 (m, 3H), 2.20-2.19 (br m, 2H), 2.17-1.82 (m, 10H), 1.75-1.62 (m, 2H). HRMS *m/z* (M+H) 558.3233 Cal., 558.3226 Obs.

15

Example 739

endo 2-methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(thien-2-ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




20 The title compound was prepared from 2-thiophene carboxylic acid (24 mg, 0.186 mmol) using EDCI-HOBT (method P) and purified by column chromatography on silica gel, eluting with 5% methanol in dichloromethane to afford endo 2-methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(thien-2-


ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole
as a colorless oil (14 mg, 14%). ¹H-NMR (300 MHz, CDCl₃) δ 7.68-7.67 (d,
1H, J=6.9 Hz), 7.46-7.15 (m, 10H), 7.13-7.04 (m, 1H), 4.66-4.60 (m, 1H),
4.16-4.00 (br m, 2H), 3.50-3.40 (m, 2H), 3.30-3.25 (br m, 2H), 2.58 (s, 3H),
5 2.42-2.28 (m, 4H), 2.11-1.98 (m, 10H), 1.72-1.63 (m, 2H). HRMS *m/z* (M+H)
539.2845 Cal., 539.2859 Obs.

Example 740

10 endo 1-cyclopropyl-2-[1-(8-{2-[1-(cyclopropylcarbonyl)-4-phenylpiperidine-4-
yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazol-2-yl]ethanone



The title compound was prepared as described in Example 3, from
cyclopropane carbonyl chloride (12.36 mg, 0.118 mmol), *via* acid chloride
Method Q, to afford endo 1-cyclopropyl-2-[1-(8-{2-[1-(cyclopropylcarbonyl)-4-
15 phenylpiperidine-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazol-2-
yl]ethanone as an off-white foam (26 mg, 43%). ¹H-NMR (300 MHz, CDCl₃) δ
7.76-7.72 (m, 1H), 7.40-7.34 (m, 5H), 7.33-7.18 (m, 3H), 4.56-4.54 (m, 1H),
4.23-4.19 (m, 2H), 4.15-3.94 (m, 2H), 3.48-3.40 (m, 1H), 3.38-3.26 (m, 3H),
2.42-2.13 (m, 5H), 1.94-1.74 (m, 11H), 1.70-1.62 (m, 2H), 1.13-1.03 (m, 2H),
20 1.02-0.95 (m, 4H), 0.88-0.75 (m, 2H). HRMS *m/z* (M+H) 565.3543 Cal.,
565.3541 Obs.

Synthesis of carbamates, examples 741-743Synthesis of 3 of the above scheme:

- 5 To a solution of **1** (0.3 g, 1 mmol) in dichloroethane (15 mL), amine **2** (0.032g, 0.148 mmol) was added $\text{NaBH}(\text{OAc})_3$ (0.424 g, 2 mmol). The mixture was stirred at r.t. overnight, and then quenched with saturated sodium bicarbonate solution, extracted with methylene chloride, dried over sodium sulfate, filtered and concentrated. Purification by chromatotron with
- 10 5% MeOH and 0.5% ammonium hydroxide in methylene chloride gave 0.267 g as white solid. ^1H NMR (400 MHz, CDCl_3 , ppm) δ 7.62-7.59 (1H, m), 7.36-7.28 (5H, m), 7.20-7.18 (1H, m), 7.14-7.10 (2H, m), 4.43-4.34 (1H, m), 3.68-3.60 (2H, broad), 3.24 (2H, broad s), 3.18 (2H, td, $J=9.3$ Hz, 2.5 Hz), 2.48 (3H, s), 2.39 (2H, broad t, $J=11.9$ Hz), 2.20-2.18 (4H, broad), 1.88-1.74 (6H, broad m), 2.10-1.97 (3H, m), 1.79-1.65 (6H, m), 1.55 (2H, d, $J=8.1$ Hz), 1.47 (2H, dd, $J=5.2$ Hz, 3.5 Hz), 1.40 (9H, s). ^{13}C NMR (400 MHz, CDCl_3 , ppm) δ 155.20, 151.20, 144.83, 143.19, 133.75, 128.82, 126.82, 126.37, 121.96, 121.69, 119.42, 111.49, 79.53, 58.71, 48.38, 46.41, 41.38, 40.66, 39.43, 35.75, 34.42, 28.69, 26.88, 14.96. LRMS: calcd. for $\text{C}_{34}\text{H}_{45}\text{Cl}_2\text{N}_4\text{O}_2$ ($\text{M}+\text{H}$) $^+$
- 15 611.3.
- 20

Synthesis of 4a-4c of the above scheme:

Deprotection of Boc with 25% TFA in dichloromethane at r.t. was followed by quenching with saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was dried, filtered and

507

concentrated. 1 eq. of chloroformates or phenyl isocyanate and 3 eq. triethyl amine were used at r.t. until the reactions were complete by LC-MS. The final products were purified by PHPLC.


5 Example 741: 1.7 mg. HRMS: calcd. for $C_{31}H_{41}N_4O_2$ ($M+H$)⁺ 501.3230, found: 501.3205.

Example 742: 1.3 mg. HRMS: calcd. for $C_{36}H_{43}N_4O_2$ ($M+H$)⁺ 548.3389, found: 548.3405.

Example 743: 1.0 mg. HRMS: calcd. for $C_{35}H_{42}N_5O$ ($M+H$)⁺ 563.3386, found: 563.3379.

10

The synthesis of analogues with C3-linker dichloro analogues



Synthesis of 2 of the above scheme:

15

To a suspension of bis(2-chloroethyl)amine hydrochloride (22.48 g, 125.9 mmol) in dichloroethane (300 mL), benzaldehyde (14.1 mL, 138.5

mmol), triethyl amine (43.8 mL, 314.9 mmol) and $\text{NaBH}(\text{OAc})_3$ were added sequentially. The cloudy content was stirred at r.t. overnight. It was then quenched with saturated sodium bicarbonate solution, extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated to give 35.7 g product as oil. ^1H NMR (400 MHz, CDCl_3) δ [ppm]: 7.33-7.31 (5H, m), 3.73 (2H, s), 3.49 (4H, t, $J=7.1$ Hz), 2.92 (4H, t, $J=7.2$ Hz). ^{13}C NMR (400 MHz, CDCl_3) δ [ppm]: 139.06, 128.83, 128.69, 127.87, 127.62, 127.24, 59.43, 56.59, 42.43.

Synthesis of 3 of the above scheme:

To a solution of **1** (1.18 g, 6.32 mmol) in toluene (50 mL), NaNH_2 (1.48 g, 50% in toluene, 18.96 mmol) was added at r.t. (the content turned red upon the addition of sodium amide). The mixture was then heated to reflux for 1 hour. The reaction was quenched with HCl (0.1N, 50 mL). The content pH was adjusted to ~11 with NaOH (50% aqous solution). The organic layer was separated. The aqueous layer was extracted twice with ethyl acetate. The combined organic layer was dried (Na_2SO_4), filtered and concentrated. The residue was purified by flash column chromatography with hexane/ethyl acetate (8/1 to 4/1) afforded 0.38 g product as red oil (17%). ^1H NMR (400 MHz, CDCl_3) δ [ppm]: 7.58 (1H, d, $J=2$ Hz), 7.49 (1H, d, $J=14.1$ Hz), 7.45-7.28 (6H, m), 3.59 (2H, s), 2.99 (2H, d, $J=11.8$ Hz), 2.51-2.48 (2H, broad m), 2.07-2.05 (4H, broad). ^{13}C NMR (400 MHz, CDCl_3) δ [ppm]: 140.75, 138.18, 133.49, 131.16, 129.29, 128.62, 128.47, 128.15, 127.54, 125.40, 121.47, 63.07, 50.75, 42.62, 36.78. LRMS: calcd. for $\text{C}_{19}\text{H}_{18}\text{Cl}_2\text{N}_2$ (M^+) 344.1, found 344.3.

Synthesis of 4 of the above scheme:

To a solution of **3** (3.28 g, 9.53 mmol) in dichloroethane (200 mL), 1-chloroethyl chloroformate (1.54 mL, 14.30 mmol) was added at 0°C and stirred for 15 mins. It was then heated to reflux for 1 hr. After cooling to the r.t., the dichloroethane was removed under reduced pressure. The residue was dissolved in methanol and heated to reflux for 20 mins (reaction was complete by GC-MS). The methanol was removed under reduced pressure. After redissolving the residue in THF (150 mL), $(\text{Boc})_2\text{O}$ (3.12 g, 14.3 mmol)

and triethyl amine (4.0 mL, 28.60 mmol) were added. The content was stirred at r.t. overnight. Ethyl acetate was added. The organic layer was washed with saturated sodium bicarbonate solution, dried (Na_2SO_4), filtered and concentrated. Flash column chromatography with hexane/EtOAc (8/1 to 6/1) afforded 0.677 g product as yellow solid (20% yield) and another impure fraction (0.894 g, ~85% purity). ^1H NMR (400 MHz, CDCl_3) δ [ppm]: 7.50 (1H, d, $J=2.2$ Hz), 7.43 (1H, d, $J=8.7$ Hz), 7.27 (1H, dd, $J=8.6$ Hz, 2.2 Hz), 4.24 (2H, broad s), 3.12 (2H, broad s), 2.03-1.98 (2H, m), 1.88-1.80 (2H, m), 1.43 (9H, s). ^{13}C NMR (400 MHz, CDCl_3) δ [ppm]: 154.45, 140.09, 133.57, 132.87, 131.28, 128.01, 125.31, 120.68, 80.51, 42.72, 41.31, 36.30, 28.59. LRMS: calcd. for $\text{C}_{17}\text{H}_{20}\text{Cl}_2\text{N}_2\text{O}_2$ (M^+) 354.1 found 354.2.

To a solution of the product from the last step (0.677 g, 1.91 mmol) in toluene (30 mL), DIBAL-H (5.7 mL, 1M in toluene) was added at -78°C . The content was warmed to -35°C over 3.5 hrs period. The reaction was completed (monitored by GC-MS) and then quenched with saturated ammonium chloride solution (30 mL). The content was extracted with ethyl acetate (GC-MS indicated that incomplete quenching might lead to the cleavage of Boc protecting group. MeOH might be a better choice of quenching reagent). So the content was retreated with $(\text{Boc})_2\text{O}$ (2 eq.) and triethyl amine (2 eq.) for 2 hrs. The organic layer was washed with NaOH (0.1N), separated, dried (Na_2SO_4), filtered and concentrated. Flash column chromatography with hexane/ethyl acetate (8/1) afforded 0.14 g (21% yield). ^1H NMR (400 MHz, CDCl_3) δ [ppm]: 9.38 (1H, s), 7.40 (1H, d, $J=17.4$ Hz), 7.36 (1H, d, $J=2.2$ Hz), 7.10 (1H, $J=2.1$ Hz), 3.86 (2H, broad s), 3.08 (2H, broad), 2.34 (2H, d, $J=13.7$ Hz), 1.92 (2H, broad), 1.44 (9H, s). LRMS calcd. for $\text{C}_{12}\text{H}_{13}\text{Cl}_2\text{NO}$ (M-Boc+H^+) 257.0, found 257.1.

Synthesis of 5 of the above scheme:

To a suspension of NaH (0.025 g, 60% in mineral oil, 0.627 mmol) in toluene, trimethyl phosphonoacetate (0.1 mL, 0.627 mmol) was added. The content was stirred at r.t. for 1 hr before 4 (0.14 g, 0.392 mmol) in toluene (2 mL) was added (in case of a large scale reaction, an ice bath is necessary to

control the reaction). The content was stirred at r.t. overnight during which it turned cloudy. The reaction was quenched with water. The content was extracted with ethyl acetate. The combined organic layer was dried (Na_2SO_4), filtered and concentrated. ^1H NMR (400 MHz, CDCl_3) δ [ppm]: (crude) 7.40 (1H, d, $J=8.6$ Hz), 7.33 (1H, $J=2$ Hz), 7.10 (1H, dd, $J=8.4$ Hz, 2.0 Hz), 6.90 (1H, $J=16.1$ Hz), 5.67 (1H, $J=16.1$ Hz), 3.71 (3H, s), 3.52-3.36 (4H, m), 2.08-1.96 (4H, m), 1.44 (9H, s).

Synthesis of 6 of the above scheme:

To a solution of the residue in EtOH (15 mL), PtO_2 was added. The content was stirred under 1 atm H_2 for 3 hrs (the reaction was complete by GC-MS). The content was filtered through celite and concentrated. Flash column chromatography with hexane/ethyl acetate (4/1) afforded 0.123 g (76% yield) product as oil. ^1H NMR (400 MHz, CDCl_3) δ [ppm]: 7.42 (1H, d, $J=8.4$ Hz), 7.32 (1H, $J=2.1$ Hz), 7.10 (1H, dd, $J=8.6$ Hz, 2.2 Hz), 3.64 (2H, broad), 3.57 (3H, s), 3.11 (2H, t, $J=10$ Hz), 2.07-1.89 (6H, m), 1.72-1.67 (2H, m), 1.43 (9H, s).

Synthesis of 7 of the above scheme:


DIBAL-H (0.593 mL, 1M in toluene, 0.593 mmol) was cooled to -78°C and added into a solution of 6 (0.123 g, 0.296 mmol) in toluene (15 mL) (also cooled to -78°C with a dry ice-acetone bath, necessary to prevent overreduction) dropwise (to keep the internal temperature as low as possible). The content was stirred at -78°C for 2.5 hrs and the reaction was quenched with a cooled MeOH (-78°C) dropwise (the addition needs to be slow to keep the internal temperature low and prevent overreduction). After the addition completed, the content was warmed to r.t. and filtered through celite. The filtrate was washed with brine. The aqueous layer was extracted with ethyl acetate. The combined organic layer was dried with Na_2SO_4 , filtered and concentrated. ^1H NMR (400 MHz, CDCl_3) δ [ppm]: 9.59 (1H, s), 7.41 (1H, d, $J=8.4$ Hz), 7.37 (1H, d, $J=3.8$ Hz), 7.31 (1H, dd, $J=8.3$ Hz, 2.2 Hz), 3.66-3.63 (2H, m), 3.12-3.06 (2H, m), 2.13-2.02 (4H, m), 1.89-1.85 (2H, m), 1.77-1.64 (2H, m), 1.44 (9H, s).

Synthesis of 10 of the above scheme:

To a solution of 7 (1/2 the residue from the last step, ~0.148 mmol) in THF (15 mL), amine 8 (0.032g, 0.148 mmol) was added. The content was stirred at r.t. for 10 mins before NaBH(OAc)₃ (0.094 g, 0.444 mmol) was added. It was stirred at r.t. overnight, and then quenched with saturated sodium bicarbonate solution, extracted with methylene chloride, dried over sodium sulfate, filtered and concentrated. Prep. TLC purification with 5% MeOH and 0.5% ammonium hydroxide in methylene chloride gave 9 mg product. ¹H NMR (400 MHz, CDCl₃) δ[ppm]: 9.13 (1H, s), 7.40 (1H, d, J=8.5 Hz), 7.34 (1H, d, J=1.9 Hz), 7.07 (1H, dd, J=8.4 Hz, 1.9 Hz), 4.32 (1H, broad s), 3.63 (2H, m), 3.12 (2H, broad t, J=10.2 Hz), 2.92 (2H, broad s), 2.42 (1H, broad s), 2.22 (2H, broad s), 2.10-1.97 (3H, m), 1.79-1.65 (6H, m), 1.58 (2H, broad s), 1.43 (9H, s), 1.12-1.08 (2H, broad). HRMS: calcd. for C₃₁H₄₁Cl₂N₄O₃ (M+H)⁺ 587.2556, found 587.2565.

Synthesis of 11 of the above scheme:

Following the route described towards 10, 43 mg of product 11 was synthesized. ¹H NMR (400 MHz, CDCl₃) δ[ppm]: 7.66-7.63 (1H, m), 7.56 (1H, broad s), 7.40-7.36 (2H, m), 7.20-7.13 (3H, m), 4.52-4.43 (1H, m), 3.63 (2H, m), 3.26 (2H, broad s), 3.18 (2H, td, J=9.2 Hz, 2.8 Hz), 2.58-2.48 (5H, broad), 2.33-2.28 (2H, m), 2.07-2.00 (4H, m), 1.76-1.60 (8H, m), 1.44 (9H, s), 1.19 (2H, broad s). LRMS: calcd. for C₃₄H₄₅Cl₂N₄O₂ (M+H)⁺ 611.3, found 611.0.

The synthesis of analogues with C3-linker- unsubstituted scaffoldSynthesis of 2 of the above scheme:

To a suspension of **1** (22 g, 98.8 mmol) in THF (300 mL), TEA (45 mL, 326 mmol) and (Boc)₂O (24 g, 110 mmol) were added and the content was stirred at r.t. overnight, followed by addition of HCl (250 mL, 0.1 N) and the mixture was extracted with ethyl acetate. The organic layer was combined, dried over Na₂SO₄, filtered and concentrated to give 26.2 g product as white crystalline solid (93% yield). ¹H NMR (400 MHz, CDCl₃) δ[ppm]: 7.46-7.25 (5H, m), 4.26 (2H, brs), 3.18 (2H, brs), 2.07 (2H, d, J=13.5Hz), 1.93 (3H, t, J=9.4Hz), 1.47 (9H, s). ¹³CNMR (400 MHz, CDCl₃) δ[ppm]: 154.67, 139.88, 129.54, 129.38, 128.57, 125.77, 121.60, 80.39, 43.20, 41.52, 36.48, 28.65. LRMS: m/z calcd. for C₁₇H₂₂N₂O₂ (M⁺) 286.17, found 286.2.

Synthesis of 3 of the above scheme:

DIBAL-H (60 mL, 1M in hexane, 60 mmol) was added to a solution of **2** (8.0 g, 28.0 mmol) in toluene (200 mL) at -78°C with a dry-ice acetone bath. The content was warmed to -35°C over about 2 hrs and stirred at -35°C for another hour. The reaction was quenched with saturated ammonium chloride (100 mL), filtered through celite. The organic layer was separated, dried (Na₂SO₄), filtered and concentrated to afford 6.95 g product as light yellow oil (86% yield). ¹H NMR (400 MHz, CDCl₃) δ[ppm]: 9.40 (1H, s), 7.45-7.25 (5H, m), 3.85 (2H, brs), 3.10 (2H, br), 2.36 (2H, d, J=13.6 Hz), 1.98 (2H, br), 1.44

(9H, s). ^{13}C NMR (400 MHz, CDCl_3) δ [ppm]: 201.18, 154.96, 138.34, 129.40, 128.02, 127.16, 79.93, 53.26, 40.88, 30.77, 28.64. LRMS: m/z calcd. for $\text{C}_{17}\text{H}_{23}\text{NO}_3$ 289.2, found 289.2 (M^+).


Synthesis of 4 of the above scheme:

5 To a suspension of NaH (1.15 g, 60% in mineral oil, 28.86 mmol) in toluene (100 mL) at 0°C, trimethyl phosphonoacetate (4.28 mL, 26.45 mmol) was added dropwise and the content was warmed up to r.t. and stirred for 50 mins. A solution of 3 (6.95 g, 24.05 mmol) in toluene (50 mL) was next added and the mixture stirred at r.t. overnight. Following addition of water, the
10 organic layer was separated, dried (Na_2SO_4), filtered and concentrated to give 8.26 g product as colorless oil (>90% purity by GC-MS analysis). LRMS: m/z calcd. for $\text{C}_{20}\text{H}_{27}\text{NO}_4$ 345.19, found 345.3 (M^+). The oil from the last step was dissolved in MeOH (200 mL). Pd/C (1g, 5%) was added. The content was stirred under 1 atm H_2 for 2.5 hrs and then filtered through celite. The solvent
15 was removed under reduced pressure. The residue was purified by flash column chromatography with hexane/ethyl acetate (2/1) to give 6.5 g product as colorless oil (78% yield over two steps). ^1H NMR (400 MHz, CDCl_3) δ [ppm]: 7.47-7.18 (5H, m), 3.70-3.64 (2H, m), 3.54 (3H, s), 3.12 (2H, m), 2.16-2.12 (2H, m), 1.98-1.87 (4H, m), 1.71-1.64 (2H, m), 1.43 (9H, s). LRMS: m/z
20 calcd. for $\text{C}_{20}\text{H}_{29}\text{NO}_4$ 347.2, found 347.3 (M^+).

Synthesis of 5 of the above scheme:

DIBAL-H (38 mL, 1M in toluene, 38 mmol) was cooled to -78°C and added into a solution of 4 (6.5 g, 18.73 mmol) in toluene (80 mL) (also cooled to -78°C with a dry ice-acetone bath to prevent overreduction) dropwise (to
25 keep the internal temperature as low as possible). The content was stirred at -78°C for 2.5 hrs and the reaction was quenched with a cooled MeOH (-78°C) dropwise (the addition needs to be slow to keep the internal temperature low and prevent overreduction). After the addition completed, the content was warmed to r.t. and filtered through celite. The filtrate was washed with brine.
30 The aqueous layer was extracted with ethyl acetate. The combined organic layer was dried with Na_2SO_4 , filtered and concentrated to give 5.72 g product

as light green oil (92% purity by GC-MS analysis). ^1H NMR (400 MHz, CDCl_3) δ [ppm]: 9.53 (1H, s), 7.46-7.25 (5H, m), 3.73-3.67 (2H, m), 3.10-3.05 (2H, m), 2.17-2.09 (4H, m), 1.90-1.86 (2H, t, $J=8.0$ Hz), 1.71-1.64 (2H, m), 1.43 (9H, s). LRMS: m/z calcd. for $\text{C}_{19}\text{H}_{27}\text{NO}_3$ 317.2, found 317.3 (M^+).




5


FlexChem Robins Block (24 glass tubes setting) was used for this parallel synthesis. To each glass tube, N_2 was flushed to remove air. Then amines (0.92 eq.), $\text{NaBH}(\text{OAc})_3$ (2 eq.), DCE (1 mL), and aldehyde (1 eq) in THF (1 mL) were added sequentially. The block was sealed and rotated at r.t. overnight. The content was drained through a 24 wells filter plate overnight and the filtrate was collect in the same 24 tubes setting. TFA (1 mL) was added to each tube. The block was sealed and shaken for 80 min. The reaction was complete as evident by LC-MS. The gasket was removed and the solvent and TFA were removed under reduced pressure. Saturated sodium bicarbonate was added to each tube followed by DCM. The organic layer was pipeted out to another 24 tubes block. Acid chlorides or chloroformates (2.7 eq) and PS-DIEA (2.7 eq) were added. The block was sealed and rotated overnight. It was cooled in a freezer for 20 mins before the gasket was removed. PS-Trisamine (2.7 eq) was added and the block was sealed and rotated at r.t. for 4 hrs. The content was filtered, concentrated and the residue was purified with Preparative HPLC. All the compounds were obtained as formic acid salt.

20


515



Example 744: 2.7 mg product. ^1H NMR (400 MHz, CDCl_3) δ [ppm]:
 11.00 (1H, s), 7.82 (1H, s), 7.41-7.34 (5H, m), 7.24-7.20 (2H, m), 6.98-6.93
 (3H, m), 6.61-6.59 (1H, m), 4.10-4.02 (1H, m), 3.93-3.88 (2H, m), 2.79 (2H,
 5 broad d, $J=15.4$ Hz), 2.26-2.16 (9H, m), 1.92 (2H, broad t, $J=11.5$ Hz), 1.76
 (2H, broad t, $J=10.1$ Hz), 10.64-10.55 (4H, m), 1.08-1.02 (2H, broad). HRMS:
 $\text{C}_{29}\text{H}_{37}\text{ClN}_4\text{O}_3$ calcd. for $(\text{M}+\text{H})^+$ 547.2476, found 547.2480.



Example 745: 6.7 mg product. ^1H NMR (400 MHz, CDCl_3) δ [ppm]:
 10.67 (1H, s), 7.79 (1H, s), 7.39-7.33 (5H, m), 7.21-7.18 (1H, t, $J=6.7$ Hz),
 6.97-6.92 (2H, m), 6.78 (2H, dd, $J=29.1$ Hz, 7.9 Hz), 6.59-6.58 (1H, m), 4.06-
 4.00 (1H, m), 3.90-3.87 (2H, m), 2.79 (2H, broad d, $J=10.5$ Hz), 2.28 (3H, s),
 2.25-2.15 (6H, m), 1.90 (2H, broad t, $J=11$ Hz), 1.68-1.63 (2H, m), 1.57-1.48
 15 (4H, m), 1.02 (2H, broad s). HRMS: $\text{C}_{32}\text{H}_{38}\text{N}_4\text{O}_3$ calcd. for $(\text{M}+\text{H})^+$ 527.3022,
 found 527.3013.




Example 746: 9.6 mg product. ^1H NMR (400 MHz, CDCl_3) δ [ppm]:
 10.67 (1H, s), 7.34-7.32 (5H, m), 7.19-7.17 (1H, m), 6.96 (1H, s), 6.77 (2H,
 20 dd, $J=28.8$ Hz, 7.7 Hz), 4.02-3.96 (3H, m), 3.06 (2H, m), 2.77 (2H, broad d,
 $J=10.7$ Hz), 2.28 (3H, s), 2.24-2.04 (6H, m), 1.88 (2H, broad d, $J=11.2$ Hz),


516

1.68-1.63 (2H, m), 1.57-1.51 (4H, m), 1.14 (3H, t, $J=7.1$ Hz), 1.04 (2H, m).


HRMS: $C_{30}H_{40}N_4O_3$ calcd. for $(M+H)^+$ 505.3179, found 505.3152.



5 Example 747: 5.3 mg product. 1H NMR (400 MHz, $CDCl_3$) δ [ppm]:
 10.68 (1H, s), 7.39-7.30 (10H, m), 7.23-7.19 (1H, m), 6.98 (1H, s), 6.79 (2H,
 dd, $J=22.4$ Hz, 8.9 Hz), 5.06 (2H, s), 4.09-4.01 (1H, m), 3.61 (2H, m), 3.12
 (2H, broad s), 2.79 (2H, broad d, $J=11.8$ Hz), 2.31 (3H, s), 2.28-2.09 (6H, m),
 1.91 (2H, t, $J=11.3$ Hz), 1.70 (2H, t, $J=9.9$ Hz), 1.60-1.50 (4H, m), 1.07-1.02
 10 (2H, m). HRMS: $C_{35}H_{42}N_4O_3$ calcd. for $(M+H)^+$ 567.3335, found 567.3334.



15 Example 748: 6.9 mg product. 1H NMR (400 MHz, $CDCl_3$) δ [ppm]:
 10.67 (1H, s), 7.36-7.31 (5H, m), 6.97 (1H, s), 6.78 (2H, dd, $J=28.2$ Hz, 7.7
 Hz), 4.03-4.00 (1H, broad s), 3.78-3.74 (1H, broad), 3.57-3.53 (1H, broad),
 3.15-3.10 (1H, m), 3.04-2.99 (1H, m), 2.76 (1H, m), 2.29 (3H, s), 2.27-2.04
 (9H, m), 1.85 (1H, broad s), 1.72-1.54 (6H, m), 1.08 (2H, broad s), 0.94 (3H, t,
 $J=7.5$ Hz). HRMS: $C_{30}H_{40}N_4O_3$ calcd. for $(M+H)^+$ 489.3229, found 489.3212.

Synthesis of C2-scaffold, BBN methodSynthesis of 1 of the BBN method:

^1H NMR (400 MHz, CDCl_3) δ [ppm]: 7.37-7.34 (2H, m), 7.28-7.25 (3H, m), 3.77-3.73 (2H, m), 3.19-3.13 (2H, m), 2.37-2.33 (2H, m), 1.99-1.93 (2H, m), 1.90 (3H, s), 1.43 (9H, s).

Synthesis of 2 of the BBN method:

To a solution of **1** (2.926 g, 9.66 mmol) in toluene (40 mL) at -78°C , KHMDS (0.5 M in toluene, 21.2 mL) was added dropwise. The content was stirred at -78°C for 10 mins and the dry ice-acetone bath was removed. The stirring was continued for another 15 mins and the content was cooled back to -78°C . $(\text{CF}_3\text{SO}_2)_2\text{NPh}$ (4.14 g, 11.6 mmol) in toluene (30 mL) was added. The resulting light brown content was stirred overnight during which it was warmed to r.t. After work-up with water and ethyl acetate, the residue was purified by flash column chromatography with hexane/EtOAc (20/1 to 10/1) to give 3.20 g product (yield 76%). ^1H NMR (400 MHz, CDCl_3) δ [ppm]: 7.46-7.44 (2H, m), 7.40-7.36 (2H, m), 7.30-7.26 (1H, m), 5.41 (1H, d, $J=5.0$ Hz), 5.32 (1H, d, $J=4.8$ Hz), 3.62-3.56 (2H, m), 3.34 (2H, broad s), 2.30-2.24 (2H, m), 2.14-2.08 (2H, m), 1.43 (9H, s). ^{13}C NMR (400 MHz, d_6 -acetone) δ [ppm]: 205.32, 160.71, 154.36, 140.30, 128.95, 127.60, 127.41, 103.26, 46.17, 40.65, 39.69, 33.04, 27.94.

Synthesis of 3 of the BBN method:

A suspension of K_2CO_3 (0.105 g, 0.76 mmol) and $(\text{CH}_3)_2\text{NH}\cdot\text{BH}_3$ (0.04 g, 0.76 mmol) in CH_3CN (1 mL) in a pressure tube was stirred at r.t. for 10

min. A solution of **2** (0.33 g, 0.76 mmol) in CH₃CN (4 mL) was added under nitrogen atmosphere, followed with Pd(PPh₃)₄. The tube was sealed. The content was stirred at 65 °C overnight. After cooling to r.t., the content was filtered and concentrated. The residue was purified by flash column


5 chromatography with hexane/EtOAc (20/1) to give 0.14 g product (64% yield).
¹H NMR (400 MHz, d₆-acetone) δ[ppm]: 7.36-7.29 (4H, m), 7.20-7.16 (1H, m), 5.85 (1H, dd, J=10.8 Hz, 17.7 Hz), 5.11 (1H, d, J=10.9 Hz), 4.95 (1H, d, J=17.6 Hz), 3.50-3.44 (2H, m), 3.41-3.33 (2H, m), 2.07-2.01 (2H, m), 1.96-1.91 (2H, m), 1.43 (9H, s). ¹³CNMR (400 MHz, d₆-acetone) δ[ppm]: 205.39,
10 154.55, 145.93, 145.84, 128.67, 126.88, 114.46, 113.49, 78.67, 43.48, 40.70, 34.98, 28.05. Elemental Analysis: calcd. for C₁₈H₁₅NO₂ C: 75.22%, H: 8.77%, N: 4.87%, found C 75.16%, H 8.81%, N 4.87%. IR is also available.

Synthesis of 4 of the BBN method:

To a solution of **3** (0.267 g, 0.93 mmol) in THF (20 mL) at r.t., 9-BBN
15 (2.8 mL, 0.5 M in THF) was added. The content was heated to reflux overnight. The content was cooled to rt. Sodium hydroxide (0.5 mL, 6.0 M in H₂O) was added, followed with hydrogen peroxide (30% in H₂O, 1 mL). The mixture was stirred at r.t. for 4 hrs, diluted with EtOAc, washed with brine. The organic layer was separated, dried over Na₂SO₄, filtered and
20 concentrated. The residue was purified with chromatotron (1/1 hexane/EtOAc) to give 0.28 g (99% yield) alcohol. ¹H NMR (400 MHz, d₆-acetone) δ[ppm]: 7.29-7.21 (4H, m), 7.16-7.13 (1H, m), 3.61-3.55 (2H, m), 3.26 (2H, t, J=7.3 Hz), 3.08-3.02 (2H, m), 2.10-2.07 (3H, m), 1.78 (2H, t, J=7.4 Hz), 1.71-1.64 (2H, m), 1.37 (9H, s).


25 To a suspension of Dess-Martin periodinane in dichloromethane (15 mL) at r.t., t-BuOH was added and the content was stirred for 10 mins. A solution of the alcohol in dichloromethane was added dropwise at r.t. and stirred for 15 mins. The content was diluted with Et₂O, washed with 1.3 N NaOH, dried over Na₂SO₄, filtered, and concentrated. The residue was
30 purified by flash column chromatography with hexane/EtOAc (3/1) to give 0.2 g product as oil (72% yield).

519



Example 749: HRMS calc. for $C_{38}H_{41}N_4O_2$ ($M+H$)⁺ 585.3230, found 585.3201.


5



Example 750: HRMS calc. for $C_{32}H_{37}N_4O_2$ ($M+H$)⁺ 509.2917, found 509.2948. ¹H NMR (400 MHz, $CDCl_3$) δ [ppm]: 7.92 (1H, s), 7.85 (1H, broad s), 7.71-7.23 (6 H, m), 4.57-4.42 (1H, m), 3.71-3.63 (4H, m), 3.23-3.17 (2H, m), 2.85-2.76 (2H, m), 2.59 (3H, s), 2.46-2.45 (2H, m), 2.07-1.98 (4H, m), 1.90-1.87 (2H, m), 1.80-1.70 (6H, m), 1.42 (9H, s). MS calcd for $C_{33}H_{45}N_4O_2$ ($M+H$)⁺ 529, found 529.

10

Example 707




15

¹H NMR (400 MHz, $CDCl_3$) δ [ppm]: 7.90 (1H, s), 7.51 (1H, s), 7.46-7.35 (7H, m), 6.99-6.94 (1H, m), 6.46 (1H, s), 4.49-4.43 (1H, m), 4.14-4.11 (2H, m), 3.48 (2H, s), 3.28 (2H, s), 2.56 (3H, s), 2.40-2.34 (4H, m), 2.19 (2H,

broad s), 1.93-1.85 (5H, m), 1.63-1.57 (5H, m). MS calcd. for $C_{33}H_{39}N_4O_2$ (M+H)⁺ 523, found 523.

O-linked piperidines were synthesized according to the scheme depicted below.



Synthesis of 3 in the scheme for O-linked piperidines:

$t\text{-BuLi}$ (31.2 mL, 1.7 M in pentane, 53.1 mmol) was added to Et_2O at –
 10 78°C, followed by 1-bromo-3,4-dichlorobenzene (3.4 mL, 26.6 mmol)
 dropwise. The content was stirred at -78°C for another 5 mins before 2 (4.92
 mL, 26.6 mmol) was added. It was stirred and gradually warmed up to r.t.
 overnight. Water was added. The mixture was extracted with ethyl acetate.
 The combined organic layer was dried over sodium sulfate, filtered and
 15 concentrated to afford 9 g product as light brown oil (100% yield). ^1H NMR

(400 MHz, CDCl_3) δ [ppm]: 7.62 (1H, d, $J=2.2$ Hz), 7.39 (1H, d, $J=8.4$ Hz), 7.36-7.30 (5H, m), 7.28-7.24 (1H, m), 3.58 (2H, s), 2.79 (2H, d, $J=11.4$ Hz), 2.44 (2H, t, $J=6.8$ Hz), 2.11 (2H, td, $J=13.4$ Hz, 3.5 Hz), 1.76 (1H, s), 1.68 (2H, dd, $J=13.9$ Hz, 2.2 Hz).

5 Synthesis of 4 in the scheme for O-linked piperidines:

To a solution of **3** (9.0 g, 26.87 mmol) in DMF, NaH (2.15 g, 60% in mineral oil, 53.73 mmol) and allyl bromide (2.8 mL, 32.24 mmol) were added. The content was stirred at r.t. overnight. The reaction was quenched with water, extracted with ethyl acetate, dried over sodium sulfate, filtered and
10 concentrated. The residue was purified by flash column chromatography with hexane/ethyl acetate (3/1) to give 7.47 g (74%) product as yellow oil. ^1H NMR (400 MHz, CDCl_3) δ [ppm]: 7.49 (1H, d, $J=2.0$ Hz), 7.40 (1H, d, $J=8.4$ Hz), 7.35-7.27 (5H, m), 7.27-7.23 (1H, m), 5.91-5.82 (1H, m), 5.28 (1H, dd, $J=17.2$ Hz, 1.6 Hz), 3.58-3.55 (4H, m), 2.74 (2H, d, $J=11.0$ Hz), 2.50-2.43 (2H, m),
15 1.98 (4H, d, $J=3.3$). LRMS: calcd. for $\text{C}_{21}\text{H}_{24}\text{Cl}_2\text{NO}$ ($\text{M}+\text{H}$) $^+$ 376, found 376.

Synthesis of 5 in the scheme for O-linked piperidines:

A solution of **4** (7.47 g, 199.92 mmol) in dichloroethane (120 mL) was cooled to 0 °C, 1-chloroethyl chloroformate (4.22 mL, 39.16 mmol) was added dropwise. The content was stirred at 0 °C for 15 mins and then heated to
20 reflux for 1 hr. The solvent was removed under reduced pressure. The residue was redissolved in MeOH and the content was refluxed for 1 hr. After cooling to r.t., water and ethyl acetate were added (saw precipitate). The content was filtered to give crystalline pale-white solid. To a suspension of the solid in THF (150 mL), triethyl amine (8.35 mL, 60 mmol) and $(\text{Boc})_2\text{O}$
25 were added. The content was stirred at r.t overnight. Water (100 mL) and brine (100 mL) were added. The mixture was extracted with ethyl acetate. The combined organic layer was washed with 0.1 N NaOH (2x), dried over sodium sulfate, filtered and concentrated. Flash column chromatography with hexane/ethyl acetate (9/1) gave 3.19 g product as colorless oil (42% yield).
30 ^1H NMR (400 MHz, CDCl_3) δ [ppm]: 7.45 (1H, d, $J=2.0$ Hz), 7.42 (1H, d, $J=8.4$ Hz), 7.22 (1H, dd, $J=8.4$ Hz, 2.2 Hz), 5.90-5.80 (1H, m), 5.27 (1H, dd, $J=17.2$

Hz, 1.6 Hz), 5.14 (1H, dd, J=10.5 Hz, 1.3 Hz), 3.99 (2H, d, J=13.0 Hz), 3.58 (2H, d, J=5.1 Hz), 3.18 (2H, d, J=9.2 Hz), 1.98 (2H, d, J=12.7 Hz), 1.80 (2H, td, J=13.2 Hz, 5.6 Hz), 1.46 (9H, s). LRMS: calcd. for $C_{19}H_{26}Cl_2NO_3$ (M+H)⁺ 386, found 386.

5 Synthesis of 6 in the scheme for O-linked piperidines:

To a solution of 5 (3.19 g, 8.29 mmol) in acetone (80 mL), *t*-BuOH (20 mL) and water (20 mL) were added, followed by OsO₄ (2.5% in *t*-BuOH, 5.2 mL, 0.42 mmol). The content was stirred at r.t for 5 mins and then NMO (1.94 g, 16.6 mmol) was added. It was stirred for another 2 hrs at r.t. The reaction
10 was quenched with saturated NaHSO₃ (100 mL), extracted with ethyl acetate, dried over sodium sulfate, filtered and concentrated to give 3.5 g colorless oil. To a solution of the oil in THF (100 mL), water (25 mL) was added, followed by NaIO₄ (4.44 g, 20.73 mmol). The content was stirred at r.t for 4 hrs. Water (100 mL) was added. The mixture was extracted with ethyl acetate. The
15 organic layer was washed with 1:1 water:brine, dried over sodium sulfate, filtered and concentrated to give 2.66 g product (83% yield). ¹H NMR (400 MHz, CDCl₃) δ[ppm]: 9.66 (1H, s), 7.46-7.43 (2H, m), 7.24-7.22 (2H, m), 4.00 (2H, broad d, J=10.6 Hz), 3.69 (2H, s), 3.22 (2H, broad d, J=11.7 Hz), 2.03-2.00 (2H, m), 1.90-1.83 (2H, m), 1.46 (9H, s).

20 Synthesis of 8a in the scheme for O-linked piperidines:

To a solution of 6 (0.885g, 2.29 mmol) in THF (10 mL), amine 7a (0.792 g, 3.44 mmol) was added. The content was stirred at r.t. for 5 mins and then NaBH(OAc)₃ (1.214 g, 5.73 mmol) was added. The content was stirred at r.t. overnight. The reaction was quenched with saturated sodium
25 bicarbonate solution, extracted with ethyl acetate, dried over sodium sulfate, filtered and concentrated. Chromatograph purification with 5%MeOH+0.5%ammonium hydroxide in methylene chloride gave 0.62 g product as white solid. ¹H NMR (400 MHz, CDCl₃) δ[ppm]: 7.89 (1H, s), 7.45-7.39 (2H, m), 7.26 (3H, broad s), 6.90-6.84 (3H, m), 4.72 (2H, s), 4.09-3.95
30 (2H, broad), 3.19 (4H, broad s), 2.87-2.63 (8H, m), 2.00-1.96 (2H, m), 1.77-1.67 (4H, m), 1.45 (9H, s). LRMS: calcd. for $C_{31}H_{41}Cl_2N_4O_4$ 603, found 603.

Synthesis of 8b in the scheme for O-linked piperidines:

0.48 g product as white solid. ¹H NMR (400 MHz, CDCl₃) δ[ppm]: 7.45-7.41 (2H, m), 7.29 (1H, d, J=7.5 Hz), 7.19-7.17 (1H, broad), 6.59-6.57 (1H, broad), 6.43-6.38 (2H, m), 6.25 (1H, s), 4.70 (2H, s), 4.02-3.93 (2H, broad), 3.78 (3H, s), 3.18 (4H, broad s), 2.85-2.62 (8H, m), 2.04-1.97 (2H, broad), 1.78-1.66 (4H, m), 1.46 (9H, s). LRMS: calcd. for C₃₂H₄₃Cl₂N₄O₅ 633, found 633.


Synthesis of 8c in the scheme for O-linked piperidines:

0.56 g product as white solid. ¹H NMR (400 MHz, CDCl₃) δ[ppm]: 7.44 (1H, d, J=1.6 Hz), 7.36 (1H, d, J=8.5 Hz), 7.32-7.28 (4H, m), 7.22-7.17 (2H, m), 4.37 (2H, s), 3.96 (2H, broad s), 3.28 (2H, s), 3.10 (4H, broad), 2.76 (2H, d, J=11.2 Hz), 2.47 (2H, t, J=5.7 Hz), 2.04-1.91 (4H, m), 1.88-1.74 (4H, m), 1.45 (9H, s). LRMS: calcd. for C₃₂H₄₃Cl₂N₄O₄ 617, found 617.


Parallel Synthesis using Robins Block

8a-8c were deprotected with TFA (1 mL) in dichloromethane (4 mL) at r.t for 20 min. Saturated sodium bicarbonate solution was added. The mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated. The residue was dissolved in dichloromethane (4 mL) and added to Robins block (1 mL/each tube). To each tube were added PS-DIEA (3 eq) and acid chloride (1.5 eq.). The block was sealed and rotated overnight. It was cooled in a freezer for 15 mins and opened. PS-Trisamine (3 eq.) was added. The block was sealed and rotated for 4 hrs. The content in each tube was poured into a 24-wells filtering block and drained overnight. The solvent was removed under reduced pressure and the residue was purified by preparative HPLC to give the desired product.

524


Example 752

^1H NMR (400 MHz, CD_3OD) δ [ppm]: 8.47 (1H, s), 7.67 (2H, d, $J=2.2$ Hz), 7.45 (1H, dd, $J=8.4$ Hz, 2.0 Hz), 7.26 (2H, t, $J=8.2$ Hz), 7.02-6.99 (3H, m), 6.89 (1H, t, $J=7.4$ Hz), 6.57 (1H, dd, $J=3.5$ Hz, 1.8 Hz), 4.72 (2H, s), 4.39 (2H, broad s), 3.75 (2H, td, $J=12.6$ Hz, 2.8 Hz), 3.44-3.29 (6H, m), 3.22 (2H, t, $J=5.0$ Hz), 2.79 (2H, td, $J=14.5$ Hz, 4.8 Hz), 2.24 (2H, d, $J=13.5$ Hz), 2.01-1.94 (4H, m). HRMS calcd. for $\text{C}_{31}\text{H}_{35}\text{Cl}_2\text{N}_4\text{O}_4$ ($\text{M}+\text{H}$) $^+$ 597.2035, found 597.2045.

Example 753

^1H NMR (400 MHz, CD_3OD) δ [ppm]: 8.55 (1H, s), 7.69 (1H, d, $J=1.8$ Hz), 7.58 (1H, dd, $J=5.7$ Hz, 1.8 Hz), 7.47 (1H, d, $J=8.4$ Hz), 7.30 (2H, t, $J=8.0$ Hz), 7.04 (2H, d, $J=8.2$ Hz), 6.92 (1H, t, $J=8.2$ Hz), 4.74 (2H, s), 4.45 (1H, broad d, $J=12.2$), 3.98 (1H, t, $J=13.5$ Hz), 3.72 (2H, t, $J=12.1$ Hz), 3.58 (1H, t, $J=8.2$ Hz), 3.43-3.32 (6H, m), 3.21 (2H, broad s), 3.16-3.08 (1H, m), 2.81 (2H, broad t, $J=10.6$ Hz), 2.32-2.15 (3H, m), 2.03-1.30 (10H, m). HRMS calcd. for $\text{C}_{32}\text{H}_{41}\text{Cl}_2\text{N}_4\text{O}_3$ ($\text{M}+\text{H}$) $^+$ 599.2555, found 599.2520.


525

Example 754

HRMS calcd. for $C_{28}H_{35}Cl_2N_4O_3$ (M+H)⁺ 545.2084, found 545.2062.


Elemental Analysis: calcd. for $C_{29}H_{37}Cl_2N_4O_5$ (formic acid salt) C 58.88%, H

5 6.13%, N 9.47%; found C 58.19%, H 6.13%, N 9.27%.


Example 755

¹HNMR (400 MHz, CD₃OD) δ[ppm]: 8.48 (1H, broad s), 7.86-7.79 (2H, m), 7.62-7.51 (5H, m), 7.41-7.32 (3H, m), 7.06-6.95 (3H, m), 4.76 (2H, s), 3.76 (2H, d, J=19.6 Hz), 3.51-2.99 (8H, m), 2.71 (2H, t, J=11.2 Hz), 2.58 (2H, td, J=14.5 Hz, 0.6 Hz), 2.20 (2H, t, J=13.5 Hz), 2.02 (2H, td, J=12.6 Hz, 4.1 Hz), 1.75 (2H, d, J=14.6 Hz). HRMS calcd for $C_{32}H_{37}Cl_2N_4O_4S$ (M+H)⁺ 643.1912, found 643.1926. Elemental Analysis for $C_{33}H_{38}Cl_2N_4O_4S$ (formic acid salt) calcd. C 57.47%, H 5.55%, N 8.12%; found C 56.94%, H 5.68%, N 8.04%.

526


Example 756

¹HNMR (400 MHz, CD₃OD) δ[ppm]: 8.51 (1H, broad s), 7.70 (1H, s), 7.59 (1H, d, J=8.5 Hz), 7.84 (1H, dd, J=6.5 Hz, 1.8 Hz), 7.21 (1H, t, J=8.1 Hz), 1.05 (1H, d, J=3.5 Hz), 6.68 (2H, dd, 8.3 Hz, 1.4 Hz), 6.61 (1H, dd, J=3.3 Hz, 1.7 Hz), 6.54-6.49 (3H, m), 4.72 (2H, s), 4.43 (2H, broad d, J=11.8 Hz), 3.85-3.75 (5H, m), 3.46-3.27 (8H, m), 2.85 (2H, td, J=14.5 Hz, 3.5 Hz), 2.28 (2H, d, J=13.5 Hz), 2.06-1.95 (4H, m). HRMS calcd. for C₃₂H₃₇Cl₂N₄O₅ (M+H)⁺, 627.2141 found 627.2128. Elemental Analysis for C₃₃H₃₈Cl₂N₄O₇ (formic acid salt) calcd. C 58.84%, H 5.69%, N 8.32%; found C 58.21% H 5.76%, N 8.26%.


Example 757

¹HNMR (400 MHz, CD₃OD) δ[ppm]: 8.51 (1H, broad s), 7.69 (1H, d, J=1.8 Hz), 7.58 (1H, d, J=8.4 Hz), 7.47 (1H, dd, J=8.4 Hz, 1.8 Hz), 7.22 (1H, t, J=8.1 Hz), 6.67 (1H, broad d, J=8.1 Hz), 6.55-6.50 (4H, m), 4.73 (2H, s), 4.45 (1H, d, J=12.8 Hz), 4.00 (1H, d, J=14.4 Hz), 3.79-3.62 (5H, m), 3.55 (1H, t, J=7.1 Hz), 3.45-3.32 (6H, m), 3.22-3.11 (4H, m), 2.80 (2H, td, J=14.3 Hz, 3.5 Hz), 2.22 (2H, broad d, J=11.6 Hz), 1.99-1.62 (10H, m). HRMS calcd. for C₃₃H₄₃Cl₂N₄O₄ (M+H)⁺ 629.2661, found 629.2664.

527


Example 758

¹HNMR (400 MHz, CD₃OD) δ[ppm]: 8.50 (1H, broad s), 7.69 (1H, d, J=1.8 Hz), 7.58 (1H, d, J=8.5 Hz), 7.47 (1H, dd, J=8.4 Hz, 1.8 Hz), 7.22 (1H, t, J=8.1 Hz), 6.68 (1H, dd, J=8.3 Hz, 1.6 Hz), 6.55-6.50 (4H, m), 4.73 (2H, s), 4.43 (1H, d, J=13.1 Hz), 3.86-3.74 (6H, m), 3.59 (1H, t, J=10.9 Hz), 3.44-3.32 (4H, m), 3.23 (2H, s), 3.12 (1H, t, J=9.4 Hz), 2.85-2.77 (2H, m), 2.25-2.25-2.17 (5H, m), 2.04-1.75 (4H, m). HRMS calcd. for C₂₉H₃₇Cl₂N₄O₄ (M+H)⁺ 575.2192, found 575.2190. Elemental Analysis calcd. for C₃₀H₃₉Cl₂N₄O₆ (formic acid salt) C 57.97%, H 6.16%, N 9.01%; found C 57.83%, H 6.31%, N 8.94%.


Example 759

¹HNMR (400 MHz, CD₃OD) δ[ppm]: 8.47 (1H, broad s), 7.82-7.78 (2H, m), 7.61 (1H, d, J=1.8 Hz), 7.57-7.52 (4H, m), 7.40 (1H, dd, J=8.4 Hz, 1.8 Hz), 7.26 (1H, t, J=8.3 Hz), 6.64 (1H, dd, J=8.3 Hz, 1.8 Hz), 6.58 (1H, broad d, J=8.2 Hz), 6.50 (1H, s), 4.74 (2H, s), 3.82 (3H, s), 3.72 (2H, d, J=11.8 Hz), 3.41-3.35 (2H, m), 3.25 (2H, t, J=4.7 Hz), 3.04 (2H, broad d, J=11.0 Hz), 2.91 (2H, broad s), 2.71 (2H, t, J=10.7 Hz), 2.54 (2H, td, J=14.3 Hz, 4.8 Hz), 2.22 (2H, d, J=13.4 Hz), 2.00 (2H, td, J=12.7 Hz, 3.1 Hz), 1.73 (2H, d, J=14.3 Hz). HRMS: calcd. for C₃₃H₃₉Cl₂N₄O₄S (M+H)⁺ 673.2018, found 673.2002.

528


Example 760

¹HNMR (400 MHz, CD₃OD) δ[ppm]: 8.43 (1H, broad s), 7.70 (1H, s), 7.65 (1H, d, J=1.6 Hz), 7.55 (1H, d, J=14.7 Hz), 7.41 (1H, dd, J=8.4 Hz, 1.8 Hz), 7.36-7.29 (4H, m), 7.26-7.22 (1H, m), 7.05 (1H, d, J=3.3 Hz), 6.62-6.59 (1H, m), 4.45-4.41 (4H, m), 3.40 (2H, s), 3.33-3.27 (4H, m), 3.05 (2H, d, J=12.1 Hz), 2.80 (2H, t, J=4.8 Hz), 2.40 (2H, t, J=12.5 Hz), 2.22 (2H, d, J=13.5 Hz), 2.05-1.94 (4H, m), 1.60 (2H, d, J=13.1 Hz). HRMS: calcd. for C₃₂H₃₇Cl₂N₄O₄ (M+H)⁺ 611.2192, found 611.2205. Elemental Analysis: calcd. for C₃₃H₃₉Cl₂N₄O₆ (formic acid salt) C 60.27%, H 5.82%, N 8.52%; found C 61.08%, H 5.91%, N 8.44%.

Example 761


¹HNMR (400 MHz, CD₃OD) δ[ppm]: 7.59 (1H, d, J=2.0 Hz), 7.46 (1H, d, J=8.4 Hz), 7.37-7.27 (5H, m), 7.23-7.20 (1H, m), 4.44-4.37 (3H, m), 3.97 (1H, d, J=12.8 Hz), 3.54-3.45 (2H, m), 3.34 (2H, s), 3.23-3.18 (2H, m), 3.11-3.00 (1H, m), 2.86 (2H, broad d, J=11.4 Hz), 2.60 (2H, t, J=15.5 Hz), 2.17-2.11 (4H, m), 1.95-1.49 (14H, m). HRMS: calcd. for C₃₃H₄₃Cl₂N₄O₃ (M+H)⁺ 613.2712, found 613.2723.

529

Example 762


¹HNMR (400 MHz, CD₃OD) δ[ppm]: 8.38 (1H, broad), 7.63 (1H, d, J=1.7 Hz), 7.51 (1H, d, J=8.4 Hz), 7.41-7.25 (6H, m), 4.52-4.41 (3H, m), 3.80 (2H, t, J=11.8 Hz), 3.53 (1H, t, J=13.2 Hz), 3.38 (2H, d, J=10.1 Hz), 3.26 (2H, broad s), 3.09-2.95 (4H, m), 2.83-2.67 (2H, m), 2.45-2.30 (2H, m), 2.17-1.81 (8H, m), 1.58-1.51 (2H, m). HRMS calcd for C₂₉H₃₇Cl₂N₄O₃ (M+H)⁺ 559.2243, found 559.2240.

10 Examples 763-774 were synthesized analogously to example 16 and 703.



Example	R ¹	R ²	ESI-MS m/z (M+H)
763			549
764			569
765			563
766			627
767			613

530




The following compounds were synthesized using chemistry described elsewhere in this application.

5

Example 775

tert-butyl 4-{3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]propyl}-4-phenylpiperidine-1-carboxylate




10

^1H NMR (400MHz, CDCl_3) δ 10.43 (m, 1H), 7.32-6.98 (m, 10H), 4.28 (m, 1H), 3.65 (m, 2H), 3.09 (m, 2H), 2.87-2.84 (m, 2H), 2.37 (m, 2H), 2.18 (m, 4H), 1.95 (m, 1H), 1.70 (m, 4H), 1.54 (m, 2H), 1.41 (s, 9H), 1.14-1.00 (m, 2H). MS (electrospray +) 519.27 (M+1).

531

Example 776

tert-butyl 4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxylate




5

^1H NMR (300MHz, methanol- d_4) δ 7.76 (m, 1H), 7.59-7.38 (m, 5H), 7.39-7.13 (m, 3H), 4.80-4.63 (m, 1H), 3.95 (m, 2H), 3.81-3.63 (m, 2H), 3.20-3.09 (m, 2H), 2.80-2.55 (m, 7H), 2.28-2.20 (m, 2H), 2.13-1.92 (m, 8H), 1.90-1.75 (m, 2H), 1.47 (s, 9H). MS (electrospray +) 529.60 (M+1).

10

Example 777

1-((1R,5S)-8-{2-[1-(cyclopentylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




15

^1H NMR (300 MHz, methanol- d_4) δ 7.65 (m, 1H), 7.48-7.32 (m, 5H), 7.26-7.06 (m, 3H), 4.65 (m, 1H), 4.04-3.71 (m, 4H), 3.20 (m, 1H), 3.09-2.94 (m, 2H), 2.71-2.46 (m, 7H), 2.32-2.16 (m, 2H), 2.10-1.86 (m, 8H), 1.83-1.47 (m, 10H). HR MS (M+H) calc: 525.3593, found 525.3595, delta 0.2mmu.

532

Example 778

1-((1R,5S)-8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (300 MHz, methanol- d_4) δ 7.80 (m, 1H), 7.62-7.17 (m, 13H), 4.74 (m, 1H), 4.30-4.13 (m, 1H), 4.02 (m, 2H), 3.71-3.55 (m, 1H), 3.32 (s, 2H), 2.84-2.71 (m, 4H), 2.65 (s, 3H), 2.45 (m, 1H), 2.29-1.81 (m, 11H). HRMS (M+H) calc: 533.3280, found 533.3267, delta 1.3 mmu.

10

Example 779

1-benzoyl-4-phenyl-4-{2-[4-(3-phenylpropyl)piperidin-1-yl]ethyl}piperidine




15

^1H NMR (300 MHz, methanol- d_4) δ 7.45-7.33 (m, 9H), 7.29-7.17 (m, 3H), 7.14-7.05 (m, 3H), 4.15 (m, 1H), 3.55 (m, 1H), 3.30-3.15 (m, 4H), 2.58-2.33 (m, 7H), 2.26-2.18 (m, 1H), 2.00-1.73 (m, 6H), 1.59 (m, 2H), 1.41 (m, 1H), 1.29-1.15 (m, 4H). HRMS (M+H) calc: 495.3375, found 495.3376, delta 0.1 mmu.

533

Example 780

1-benzoyl-4-{2-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]ethyl}-4-phenylpiperidine




5 ^1H NMR (300 MHz, methanol- d_4) δ 7.45-7.39 (m, 9H), 7.29-7.18 (m, 6H), 4.14 (m, 1H), 4.01 (s, 2H), 3.58 (m, 1H), 3.30-3.16 (m, 3H), 3.02-2.86 (m, 3H), 2.38 (m, 1H), 2.20 (m, 4H), 2.06-1.98 (m, 2H), 1.91-1.74 (m, 6H). HRMS (M+H) calc: 535.3073, found 535.3098, delta 2.5 mmu.

10

Example 781

1-(1-{2-[1-(cyclopentylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}piperidin-4-yl)-2-methyl-1H-benzimidazole




15 ^1H NMR (400 MHz, methanol- d_4) δ 7.65 (m, 1H), 7.52-7.44 (m, 2H), 7.39-7.30 (m, 5H), 7.24-7.14 (m, 1H), 4.89 (m, 1H), 4.02-3.91 (m, 1H), 3.81-3.75 (m, 1H), 3.62-3.53 (m, 2H), 3.13-3.02 (m, 3H), 3.00-2.73 (m, 8H), 2.26-2.09 (m, 6H), 1.84-1.49 (m, 10H), 1.24-1.13 (m, 1H). HRMS (M+H) calc: 499.3435, found 499.3434, delta 0.1mmu.

534

Example 782


1-(1-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]piperidin-4-yl)-2-methyl-1H-benzimidazole



5 ^1H NMR (400 MHz, methanol- d_4) δ 7.63 (m, 1H), 7.51-7.45 (m, 3H),
 7.40-7.32 (m, 6H), 7.24-7.16 (m, 2H), 6.91 (s, 1H), 6.70 (s, 1H), 4.89 (m, 1H),
 4.89 (m, 1H), 4.10 (m, 1H), 3.80 (m, 1H), 3.60 (m, 2H), 3.37-3.24 (m, 3H),
 3.10 (m, 3H), 2.95-2.86 (m, 2H), 2.77 (m, 2H), 2.31 (m, 2H), 2.22-2.13 (m,
 4H), 1.92-1.87 (m, 2H), 1.23-1.18 (m, 1H). HRMS (M+H) calc: 507.3126,
 10 found 507.3115, delta 1.1mmu.

Example 783

1-(1-[2-[1-(2-furoyl)-4-phenylpiperidin-4-yl]ethyl]piperidin-4-yl)-2-methyl-1H-benzimidazole




15 ^1H NMR (400 MHz, methanol- d_4) δ 8.22 (m, 1H), 7.67 (m, 1H), 7.58 (s,
 1H), 7.60-7.48 (m, 2H), 7.42-7.31 (m, 4H), 7.22 (m, 1H), 6.91 (m, 1H), 6.49 (s,
 1H), 4.89 (m, 1H), 4.06 (m, 2H), 3.68-3.56 (m, 2H), 3.08 (m, 2H), 3.00-2.75
 (m, 7H), 2.56 (s, 3H), 2.32-2.18 (m, 5H), 1.88 (m, 2H). MS (electrospray +)
 20 523.42 (M+1).

535

Example 784

1-(1-{2-[1-(isoxazol-5-ylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}piperidin-4-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ 7.64 (m, 1H), 7.46 (m, 2H), 7.41-7.27 (m, 7H), 7.24-7.10 (m, 1H), 4.88 (m, 1H), 4.07 (m, 2H), 3.61-3.49 (m, 1H), 3.20 (s, 2H), 3.11-3.00 (m, 2H), 2.93-2.84 (m, 2H), 2.79-2.71 (m, 4H), 2.30 (m, 1H), 2.21-2.09 (m, 4H), 1.92-1.75 (m, 2H), 1.21 (m, 1H). HRMS (M+H) calc: 498.2869, found 498.2845, delta 2.4 mmu.

10

Example 785

tert-butyl 4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxylate




15 ^1H NMR (400 MHz, CDCl_3) δ 7.22 (m, 1H), 6.91-6.68 (m, 8H), 4.15 (m, 1H), 3.23-3.18 (m, 2H), 2.82-2.67 (m, 4H), 2.12 (s, 3H), 1.97-1.87 (m, 2H), 1.76-1.64 (m, 2H), 1.51-1.29 (m, 10H), 1.17-1.13 (m, 2H), 1.00 (s, 9H). MS (electrospray +) 529.61 (M+1).

536

Example 786

1-[(1R,5S)-8-(2-{1-[(3-chlorothiophen-2-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ 7.66 (m, 1H), 7.56-7.43 (m, 5H), 7.34-7.23 (m, 3H), 7.01 (m, 2H), 4.72 (m, 1H), 4.10 (m, 2H), 3.41-3.28 (m, 4H), 2.90 (m, 2H), 2.79 (m, 2H), 2.68 (s, 3H), 2.41-1.94 (m, 12H). HRMS (M+H) calc: 573.2455, found 573.2452, delta 0.3 mmu.

10

Example 787

(1R,5S)-8-{2-[1-(2-furoyl)-4-phenylpiperidin-4-yl]ethyl}-3-phenyl-8-azabicyclo[3.2.1]octane




15 ^1H NMR (400 MHz, CDCl_3) δ 7.38 (s, 1H), 7.31-7.00 (m, 10H), 6.86 (m, 1H), 6.38 (m, 1H), 3.98 (m, 1H), 3.48-3.27 (m, 2H), 3.12 (m, 2H), 2.96-2.86 (m, 1H), 2.38-2.15 (m, 4H), 1.98 (m, 3H), 1.86-1.76 (m, 4H), 1.60-1.50 (m, 4H), 1.29 (m, 2H). HRMS (M+H) calc: 469.2855, found 469.2858, delta 0.3 mmu.

537

Example 788

(1R,5S)-8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-3-phenyl-8-azabicyclo[3.2.1]octane




5 ^1H NMR (400 MHz, CDCl_3) δ 7.44-7.26 (m, 13H), 7.15 (m, 2H), 4.16-4.12 (m, 1H), 3.58 (m, 1H), 3.45 (m, 1H), 3.32-3.16 (m, 3H), 3.01 (m, 1H), 2.41-2.26 (m, 3H), 2.16-1.86 (m, 5H), 1.78-1.63 (m, 5H), 1.38-1.24 (m, 3H). HRMS ($\text{M}+\text{H}$) calc: 479.3062, found 479.3057, delta 0.6 mmu.

10

Example 789

1-[(1R,5S)-8-(2-{1-[(2,4-dimethyl-1-oxidopyridin-3-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




15 ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.18 (m, 1H), 7.49 (m, 1H), 7.37 (m, 5H), 7.26-7.08 (m, 4H), 4.51 (m, 1H), 4.02-3.89 (m, 2H), 3.60-3.44 (m, 2H), 3.35-3.21 (m, 4H), 3.02 (m, 1H), 2.54-2.38 (m, 4H), 2.38-2.28 (m, 3H), 2.25-2.09 (m, 3H), 2.03 (m, 2H), 1.87-1.70 (m, 8H), 1.58 (m, 2H). HRMS ($\text{M}+\text{H}$) calc: 578.3495, found 578.3519, delta 2.4 mmu.

20

538

Example 790

(1R,5S)-3-(1,3-benzodioxol-5-yl)-8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]octane




5 ^1H NMR (400 MHz, CDCl_3) δ 7.3-7.12 (m, 9H), 6.67-6.63 (m, 2H), 5.83 (s, 2H), 4.04 (m, 1H), 3.61-3.10 (m, 5H), 2.89 (m, 1H), 2.41-2.17 (m, 3H), 2.10-1.82 (m, 6H), 1.71 (m, 1H), 1.64-1.46 (m, 4H), 1.36-1.28 (m, 2H), 1.19 (m, 2H). HRMS ($\text{M}+\text{H}$) calc: 523.2961, found 523.2957, delta 0.4 mmu.

10

Example 791

6-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide




15 ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 11.17 (s, 1H), 7.84-7.69 (m, 3H), 7.65-7.56 (m, 1H), 7.51-7.36 (m, 6H), 7.3-7.17 (m, 2H), 5.15 (m, 1H), 4.34-3.84 (m, 5H), 3.27 (m, 2H), 2.81-2.71 (m, 5H), 2.62 (m, 2H), 2.54-2.50 (m, 2H), 2.25-2.11 (m, 8H), 1.86 (m, 2H). MS (electrospray +) 653.18 ($\text{M}+1$).

539

Example 792

2-[(1R,5S)-8-[2-(1-benzoyl-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-isoindole-1,3(2H)-dione




- 5 ^1H NMR (500 MHz, DMSO- d_6) δ 7.80 (s, 4H), 7.43-7.33 (m, 9H), 7.21 (m, 1H), 4.31 (m, 1H), 4.07 (m, 1H), 3.88 (m, 1H), 3.13 (m, 3H), 2.50 (s, 2H), 2.18-1.98 (m, 4H), 1.80-1.66 (m, 9H), 1.42-1.36 (m, 2H).
HRMS (M+H) calc: 548.2913, found 548.2900, delta 1.3 mmu.

10

Example 793

methyl 3,3-dimethyl-4-(4-[2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-4-phenylpiperidin-1-yl)-4-oxobutanoate




- 15 ^1H NMR (400 MHz, CDCl_3) δ 7.61 (m, 1H), 7.32-7.05 (m, 8H), 4.62-4.52 (m, 1H), 4.10-3.99 (m, 1H), 3.89-3.82 (m, 2H), 3.59 (m, 4H), 2.51 (m, 5H), 2.31 (m, 2H), 2.17 (m, 1H), 1.91-1.70 (m, 9H), 1.54 (m, 2H), 1.18 (m, 6H). HRMS (M+H) calc: 571.3646, found 571.3666, delta 1.8 mmu.

540

Example 794

tert-butyl 4-{2-[(1R,5S)-3-(1H-1,2,3-benzotriazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidine-1-carboxylate




5 ^1H NMR (300 MHz, CDCl_3) δ 7.95 (m, 1H), 7.43-7.08 (m, 8H), 4.78 (m, 1H), 3.62-3.57 (m, 2H), 3.17-3.08 (m, 4H), 2.46-2.34 (m, 2H), 2.27-2.18 (m, 2H), 2.12-1.92 (m, 4H), 1.81-1.54 (m, 8H), 1.38 (s, 9H).
HRMS (M+H) calc: 516.3339, found 516.3336, delta 0.2 mmu.

10

Example 795

1-((1R,5S)-8-{2-[1-(cyclopropylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




15 ^1H NMR (400 MHz, methanol- d_4) δ 7.92 (m, 1H), 7.55-7.39 (m, 5H), 7.31-7.16 (m, 3H), 4.71 (m, 1H), 4.09-3.95 (m, 4H), 3.52-3.39 (m, 1H), 3.29-3.07 (m, 2H), 2.88-2.74 (m, 4H), 2.65 (s, 3H), 2.39-1.73 (m, 12H), 0.83-0.74 (m, 4H). HRMS (M+H) calc: 497.3280, found 497.3286, delta 0.6 mmu.

541

Example 796

1-((1R,5S)-8-{2-[1-(cyclobutylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ 8.28 (s, 1H), 7.50-7.38 (m, 5H), 7.29-7.13 (m, 3H), 4.69 (m, 1H), 4.10-3.93 (m, 3H), 3.62-3.57 (m, 1H), 3.37-3.04 (m, 4H), 2.86-2.66 (m, 4H), 2.60 (s, 3H), 2.26-1.89 (m, 14H), 1.77-1.70 (m, 3H). HRMS (M+H) calc: 511.3437, found 511.3434, delta 0.6 mmu.

10

Example 797

2-methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(thien-2-ylcarbonyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole




15 ^1H NMR (300 MHz, methanol- d_4) δ 7.96 (m, 1H), 7.62-7.59 (m, 1H), 7.52-7.17 (m, 9H), 7.10 (m, 1H), 4.73 (m, 1H), 4.06 (m, 4H), 3.49-3.36 (m, 2H), 2.90-2.73 (m, 4H), 2.64 (s, 3H), 2.38-1.91 (m, 12H). HRMS (M+H) calc: 539.2845, found 539.2854, delta 0.9 mmu.

542

Example 798

1-((1R,5S)-8-{2-[1-(2,2-dimethylpropanoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole




5 ^1H NMR (400 MHz, methanol- d_4) δ 7.84 (m, 1H), 7.56-7.40 (m, 5H), 7.32-7.26 (m, 1H), 7.20 (m, 2H), 4.73 (m, 1H), 4.03 (m, 3H), 3.30-3.20 (m, 3H), 2.85-2.74 (m, 4H), 2.64 (s, 3H), 2.32-2.29 (m, 2H), 2.20-2.11 (m, 4H), 2.03 (m, 4H), 1.87-1.82 (m, 3H), 1.27 (s, 9H). HRMS ($M+H$) calc: 513.3593, found 513.3607, delta 1.3 mmu.

10

Example 799

2-methyl-1-[(1R,5S)-8-(2-{1-[(3-methylthien-2-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




15

MS (electrospray +) 553 ($M+1$).

543


Example 800

2-methyl-1-[(1R,5S)-8-(2-{1-[(4-methyl-1,2,3-thiadiazol-5-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




5 MS (electrospray +) 555 (M+1).

Example 802

Preparation of 2-chloro-4-fluoro-5-[(methylamino)sulfonyl]benzoic acid

20.02g (73.4 mmol) of 2-chloro-3-chlorosulfonyl-4-fluorobenzoic acid was added as a solid to a cooled solution of 10.5 mL of methylamine (40% aqueous solution, 293.6mmol) in 400 mL of water. Reaction was monitored by LC/MS and complete after one hour. The reaction was acidified to pH=1 with concentrated HCl, and solid precipitated out. Product was obtained by filtration. 17.54 g obtained as a pale tan solid (89% yield). ^1H NMR (300 MHz, DMSO- d_6) δ 13.83-14.01 (br, 1 H), 8.21-8.26 (d, 1 H, $J=9.11$ Hz), 7.98-8.03 (q, 1 H, $J=4.82$), 7.88-7.92 (d, 1 H, $J=9.11$ Hz), 2.55-2.56 (d, 3 H, $J=4.82$ Hz).


Preparation of 4-chloro-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-methylbenzenesulfonamide



5.36g (12.0 mmol) 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole, 3.20 g (12.0 mmol) 2-chloro-4-fluoro-5-[(methylamino)sulfonyl]benzoic acid were combined following the general procedure in Example 5. 3.97 g recovered (47.6% yield). ^1H NMR (300 MHz, DMSO- d_6) δ 7.96-8.05 (br, 1 H), 7.75-7.94 (m, 2

H), 7.38-7.56 (m, 3 H), 7.24-7.30 (m, 2 H), 7.07-7.18 (m, 3 H), 4.48-4.60 (m, 1 H), 3.91-4.03 (m, 1 H), 3.23-3.49 (m, 6 H), 3.04-3.13 (m, 1 H), 2.52-2.60 (m, 4 H), 2.33-2.44 (m, 2 H), 2.12-2.32 (br, 2 H), 2.01-2.09 (m, 2H), 1.76-1.95 (m, 8 H), 1.60-1.66 (m, 2 H). LC/MS m/z (M+H): 696

Preparation of (1*R*,5*S*)-8-{2-[1-{2-chloro-4-fluoro-5-[(methylamino)sulfonyl]benzoyl}-4-(3-fluorophenyl)piperidin-4-yl]ethyl}-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azoniabicyclo[3.2.1]octane, toluenesulfonic acid salt




The reaction vessel was charged with (1*R*,5*S*)-8-{2-[1-{2-chloro-4-fluoro-5-[(methylamino)sulfonyl]benzoyl}-4-(3-fluorophenyl)piperidin-4-yl]ethyl}-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azoniabicyclo[3.2.1]octane (5.0 g) and tetrahydrofuran (65 ml, 13 volumes). The mixture was stirred and heated to 50°C. A solution of toluenesulfonic acid monohydrate (1.4 g, 1 M in tetrahydrofuran, 1 equivalent) was added to the hot mixture. After cooling, the solid was collected by filtration, washed with tetrahydrofuran (2 x 2.5 volumes) and dried *in vacuo*. Yield 93%.

Example 803

Preparation of 2-chloro-5-[(ethylamino)sulfonyl]-4-fluorobenzoic acid


546



1.023 g (3.6 mmol) 3-chlorosulfonyl-4-fluorobenzoic acid was added to 5.49 mL (10.98 mmol) ethylamine in THF. THF was evaporated off at the completion of the reaction. Diluted with dichloromethane and extracted with 6N NaOH. Combined aqueous layers were then acidified to pH=1 with 6N HCl. Product creashes out and is collected by filtration and rinsed with water. Crude product was used in subsequent step without further purification.

^1H NMR (300 MHz, DMSO- d_6) δ 8.13-8.16 (d, 1 H, $J=7.96$ Hz), 8.07-8.11 (t, 1 H, $J=9.79$ Hz), 7.79-7.82 (d, 1 H, $J=9.79$ Hz), 2.86-2.95 (m, 2H), 0.96-1.01 (t, 3 H, $J=7.34$ Hz).

Preparation of 4-chloro-*N*-ethyl-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide




0.103 g (.23 mmol) 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole and .129 g (.46 mmol) 2-chloro-5-[(ethylamino)sulfonyl]-4-fluorobenzoic acid were combined following the HATU general procedure in Example 5. This compound was purified by flash chromatography on a 0-100% gradient of 1N methanolic ammonia in ethyl acetate in ethyl acetate. 0.76 g obtained (44% yield). ^1H NMR (300 MHz, DMSO- d_6) δ 8.04-8.14 (m, 1 H), 7.86-7.89 (d, 1 H $J=9.83$ Hz), 7.72-7.79 (m, 3 H), 7.41-7.51 (m, 3 H), 7.21-7.26 (m, 2 H), 7.09-7.15 (m, 1 H), 5.00-5.11 (m, 1 H), 4.03-4.14 (m, 2 H), 3.87-3.99 (m, 1 H), 3.19-3.38 (m, 2 H), 2.96-3.05 (m, 1 H), 2.85-2.94 (m, 3 H), 2.69-2.80 (m, 4 H), 2.51-2.64 (m,

547

2 H), 1.93-2.26 (m, 11 H), 1.73-1.88 (m, 2H), 0.94-1.12 (m, 3H). LC/MS m/z (M+H): 710.


Example 804

Preparation of 2-chloro-4-fluoro-5-[(2,2,2-trifluoroethyl)amino]sulfonylbenzoic acid



4.997 g (18.3 mmol) 3-chlorosulfonyl-4-fluorobenzoic acid, 2.90 g (27.5 mmol) NaHCO_3 were dissolved in 50 mL water. 1.45 mL (18.3 mmol) trifluoroethylamine was added dropwise to solution. Solution was acidified to pH=1 with concentrated HCl and product was extracted into ethyl acetate. Dried over MgSO_4 and concentrated. 5.27 g recovered (83% yield). Crude product was used in subsequent step without further purification. ^1H NMR (300 MHz, DMSO-d_6) δ 9.22-9.37 (dt, 1 H, $J=6.44, 30.24$ Hz), 7.80-7.92 (dd, 1 H, $J=9.91, 25.78$ Hz), 4.04-4.16 (m, 1H), 3.77-3.90 (m, 1 H).

Preparation of 4-chloro-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]piperidin-1-yl)carbonyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide




8.792 g (19.7mmol) 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole and 6.59 g (19.7 mmol) 2-chloro-5-[(2,2,2-trifluoroethylamino)sulfonyl]-4-fluorobenzoic acid were combined following the HATU general procedure in Example 5. This

compound was purified by flash chromatography on a 0-100% gradient of 1N methanolic ammonia in ethyl acetate in ethyl acetate. 6.31 g obtained (42% yield). ^1H NMR (300 MHz, DMSO- d_6) δ 9.18-9.25 (br, 1 H), 7.75-7.94 (m, 2 H), 7.35-7.52 (m, 3 H), 7.22-7.28 (m, 2 H), 7.04-7.15 (m, 3 H), 4.45-4.56 (m, 1 H), 3.80-4.00 (m, 3 H), 3.20-3.43 (m, 6 H), 2.99-3.07 (m, 1 H), 2.48-2.52 (m, 3 H), 2.32-2.41 (m, 2 H), 1.97-2.29 (br, 2 H), 1.74-1.91 (m, 8 H), 1.59-1.64 (m, 2 H).


Example 805

Preparation of 2-chloro-4-fluoro-5-[(propylamino)sulfonyl]benzoic acid



2.512 g (9.2 mmol) 3-chlorosulfonyl-4-fluorobenzoic acid was added to 2.27 mL (27.6 mmol) propylamine following the general procedure in for 2-chloro-5-[(ethylamino)sulfonyl]-4-fluorobenzoic acid. Crude product was used in subsequent step without further purification. ^1H NMR (300 MHz, DMSO- d_6) δ 8.19-8.22 (d, 1 H, J = 7.84 Hz), 8.12-8.16 (t, 1 H, J =11.59 Hz), 7.85-7.88 (d, 1 H, J =9.90 Hz), 2.80-2.87 (q, 2 H, J =6.82), 1.33-1.45 (m, 2 H), 0.77-0.82 (t, 3 H, J =7.51 Hz).

Preparation of 4-chloro-2-fluoro-5-[(4-(3-fluorophenyl)-4-(2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)piperidin-1-yl)carbonyl]-*N*-propylbenzenesulfonamide




0.366 g (0.82 mmol) 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole and 0.363 g (1.23 mmol) 2-chloro-4-fluoro-5-[(propylamino)sulfonyl]benzoic acid were combined following the HATU general procedure in Example 5. This compound was purified by flash chromatography on a 0-100% gradient of 90:5:5 acetonitrile: ammonium hydroxide: water in acetonitrile. 0.24 g obtained (40% yield).

¹H NMR (300 MHz, DMSO-*d*₆) δ 8.04-8.15 (br, 1 H), 7.69-7.90 (m, 2 H), 7.32-7.52 (m, 3 H), 7.19-7.26 (m, 2 H), 7.01-7.15 (m, 3 H), 4.41-4.56 (m, 1 H), 3.86-3.98 (m, 1 H), 3.19-3.43 (m, 6 H), 2.97-3.08 (m, 1 H), 2.77-2.88 (m, 2 H), 2.44 (s, 3H), 2.28-2.41 (m, 2 H), 1.96-2.17 (m, 2H), 1.71-1.92 (m, 9 H), 1.56-1.64 (m, 2 H), 1.31-1.42 (m, 2 H), 0.73-0.81 (m, 3 H).

Example 806

Preparation of 2-chloro-4-fluoro-5-[(isopropylamino)sulfonyl]benzoic acid




1.002 g (3.6 mmol) 3-chlorosulfonyl-4-fluorobenzoic acid was added to 0.94 mL (10.9 mmol) isopropylamine following the general procedure in for 2-chloro-5-[(ethylamino)sulfonyl]-4-fluorobenzoic acid. Crude product was used in subsequent step without further purification

¹H NMR (300 MHz, DMSO-*d*₆) δ 8.20-8.23 (d, 1 H, J=8.28 Hz), 8.12-8.17 (t, 1 H, J=7.30 Hz), 7.83-7.87 (d, 1 H, J=10.23 Hz), 3.30-3.43 (m, 1H), 0.98-1.01 (d, 6 H, J=6.34 Hz).

Preparation of 4-chloro-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)piperidin-1-yl)carbonyl]-*N*-isopropylbenzenesulfonamide

550




0.290 g (0.65 mmol) 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole and 0.288 g (0.975 mmol) 2-chloro-4-fluoro-5-[(isopropylamino)sulfonyl]benzoic acid were combined following the HATU general procedure in Example 5. This compound was purified by reverse phase chromatography on a 0-100% gradient of 0.1% TFA in water in acetonitrile. 0.196 g obtained (42% yield).

¹H NMR (300 MHz, DMSO-*d*₆) δ 8.09-8.19 (m, 1 H), 7.76-7.99 (m, 2 H), 7.38-7.55 (m, 4 H), 7.25-7.31 (m, 1 H), 7.07-7.20 (m, 3 H), 4.52-4.62 (m, 1 H), 3.92-4.01 (m, 1 H), 3.29-3.43 (m, 6 H), 3.01-3.11 (m, 1 H), 2.76 (s, 1 H), 2.47-2.51 (m, 2 H), 2.36-2.45 (m, 1 H), 1.78-2.04 (m, 12 H), 1.25-1.32 (m, 3H), 0.99-1.07 (m, 6H).

Example 807


Preparation of 2-chloro-5-[(cyclopropylamino)sulfonyl]-4-fluorobenzoic acid



1.005 g (3.6 mmol) 3-chlorosulfonyl-4-fluorobenzoic acid was added to 0.76 mL (10.9 mmol) cyclopropylamine following the general procedure in for 2-chloro-5-[(ethylamino)sulfonyl]-4-fluorobenzoic acid. Crude product was used in subsequent step without further purification

¹H NMR (300 MHz, DMSO-*d*₆) δ 8.46-8.48 (d, 1 H, *J* = 2.83 Hz), 8.22-8.26 (d, 1 H, *J* = 7.69 Hz), 7.86-7.90 (d, 1 H, *J* = 9.70), 2.23-2.32 (m, 1 H), 0.46-0.56 (m, 2 H), 0.36-0.44 (m, 2 H).

Preparation of 4-chloro-N-cyclopropyl-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide




0.335 g (0.75 mmol) 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole and 0.242 g (0.83 mmol) 2-chloro-4-fluoro-5-[(cyclopropylamino)sulfonyl]benzoic acid were combined following the HATU general procedure in Example 5. This compound was purified by reverse phase chromatography on a 0-100% gradient of 0.1% TFA in water in acetonitrile. 0.231 g obtained (43% yield).

¹H NMR (300 MHz, DMSO-*d*₆) δ 8.38-8.47 (br, 1 H), 7.72-7.92 (m, 2 H), 7.33-7.51 (m, 3 H), 7.20-7.28 (m, 2 H), 7.01-7.16 (m, 3 H), 4.45-4.57 (m, 1 H), 4.06-4.12 (m, 1H), 3.87-3.98 (m, 1 H), 3.21-3.42 (m, 6 H), 2.97-3.10 (m, 1 H), 2.44 (s, 3 H), 2.23-2.42 (m, 2 H), 1.95-2.17 (m, 2 H), 1.72-1.92 (m, 8 H), 1.55-1.65 (m, 2 H), 0.34-0.53 (m, 4 H).

Example 808


Preparation of 2-chloro-5-[(cyclopentylamino)sulfonyl]-4-fluorobenzoic acid



1.01 g (3.7 mmol) 3-chlorosulfonyl-4-fluorobenzoic acid was added to 1.08 mL (10.9 mmol) cyclopentylamine following the general procedure in for 2-chloro-5-[(ethylamino)sulfonyl]-4-fluorobenzoic acid. Crude product was used in subsequent step without further purification

^1H NMR (300 MHz, DMSO- d_6) δ 8.21-8.24 (m, 2 H), 7.84-7.88 (d, 1 H, $J=10.14$ Hz), ..48-3.59 (m, 1 H), 1.48-1.70 (m, 4 H), 1.28-1.46 (m, 4 H).


Preparation of 4-chloro-N-cyclopentyl-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide



0.103 g (0.23 mmol) 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole and 0.148 g (0.46 mmol) 2-chloro-4-fluoro-5-[(cyclopentylamino)sulfonyl]benzoic acid were combined following the HATU general procedure in Example 5. This compound was purified by reverse phase chromatography on a 0-100% gradient of 0.1% TFA in water in acetonitrile. 0.068 g obtained (40% yield).

^1H NMR (300 MHz, DMSO- d_6) δ 9.32-9.49 (br, 1 H), 8.13-8.25 (m, 2 H), 7.73-7.91 (m, 3 H), 7.39-7.56 (m, 2 H), 7.08-7.30 (m, 3 H), 5.00-5.15 (m, 1 H), 4.03-4.16 (m, 2 H), 3.83-4.02 (m, 1 H), 3.35-3.58 (m, 2 H), 3.19-3.33 (m, 2 H), 3.16 (s, 1 H), 2.94-3.08 (m, 2 H), 2.67-2.80 (m, 6 H), 2.54-2.65 (m, 1 H), 2.02-2.26 (m, 8H), 1.72-2.01 (m, 2 H), 1.47-1.67 (m, 4H), 1.26-1.44 (m, 4 H)


(Alkyl- or alkoxy-amino)benzoic Acids listed below were prepared using the following scheme



R= methyl, ethyl, propyl, isopropyl, cyclopropyl
cyclopentyl, methoxy, ethoxy, etc.

X, Y = Cl, F,

Preparation of 2-Chloro-4-Fluoro-5-[(Methylamino)sulfonyl]benzoic Acid




At 0 °C, to a stirred ice-water suspension (~200 mL) of 2-chloro-5-(chlorosulfonyl)-4-fluorobenzoic acid was slowly added a precooled 40% methylamine (13 mL). The reaction mixture was then stirred for 2 hours before being acidified to pH~2. The desired product was precipitated and filtered out. After being dried overnight, the pure 2-chloro-4-fluoro-5-[(methylamino)sulfonyl]benzoic acid was obtained as white solid (9.8g, 100%).

The corresponding substituted aminosulfonyl benzoic acids used in this patent were prepared in the similar methods as described above.

Example 809

Preparation of 2,4-Difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-methoxybenzenesulfonamide


554



2,4-Difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-N-methoxybenzenesulfonamide (11mg, 17%) was obtained as solid from 3-(chlorosulfonyl)-2,6-difluorobenzoic acid (105 mg, 0.4 mmol), 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (52 mg, 0.1 mmol) and methoxyamine hydrochloride (33mg, 0.4 mmol) following the coupling procedure in example 473. ^1H NMR (400 MHz, CD_3OD), δ 8.04 (q, $J=3.3$ Hz, 1 H), 7.97 (s, 2 H), 7.53 (d, $J=9.6$ Hz, 1 H), 7.45-7.40 (m, 2 H), 7.36-7.16 (m, 4, H), 7.01 (t, $J=6.8$ Hz, 1 H), 4.80-4.71 (m, 1 H), 4.20-4.19 (br, 1 H), 3.74 (d, $J=10.1$ Hz, 3 H), 3.57-3.42 (m, 4 H), 3.30-3.27 (m, 1 H), 2.54 (s, 3 H), 2.51-2.25 (m, 4 H), 2.09-1.93 (m, 10 H), 1.75 (d, $J=7.6$ Hz, 2 H). HRMS m/z ($M+H$) $^+$ calcd: 696.2831, obsd: 696.2831.

Example 810


Preparation of 2-(4-fluorophenyl)-2-(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-N-methylacetamide



(4-Fluorophenyl)(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)acetic acid (prepared from 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole and 4-fluorophenylboronic acid following the procedure outlined in example 412. (19 mg, 0.032 mmol) was coupled with methylamine (16 μ L, 2M in THF) under promotion of HATU (12 mg, 0.032mmol) The title compound was obtained as solid (12mg, 60%) after purification by flash chromatography, eluting with a gradient of 0-10% methanol in ethyl acetate. ^1H NMR (400 MHz, CDCl_3) δ 7.66 (d, $J=7.1$ Hz, 1 H), 7.32-7.24 (m, 4 H), 7.19-7.12 (m, 2 H), 7.03-6.89 (m, 6H), 4.59 (br, 1 H), 3.75 (s, 1 H), 3.22 (br, 2 H), 2.84 (d, $J=4.9$ Hz, 3 H), 2.55 (s, 3 H), 2.52-2.47 (m, 1 H), 2.40-2.09 (m, 6 H), 1.93-1.87 (m, 7 H), 1.78-1.61 (m, 6 H). HRMS m/z ($M+H$) $^+$ calcd 612.3514, obsd 612.3530.

Example 811

Preparation of 2,4-difluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-methoxybenzenesulfonamide




2,4-Difluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-methoxybenzene sulfonamide (119 mg, 43%) was obtained as solid from 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-

benzimidazole dihydrochloride (244mg, 0.4 mmol) and 2,4-difluoro-5-[(methoxyamino)sulfonyl]benzoic acid (266mg, 1 mmol) and HATU (152 mg, 0.4 mmol), following the coupling procedure in example 5. ^1H NMR (400 MHz, CDCl_3) δ 7.66 (d, $J=7.3$ Hz, 1 H), 7.40-7.34 (m, 1 H), 7.0 (d, $J=7.3$ Hz, 1 H), 7.21-7.14 (m, 2 H), 7.04-6.96 (m, 5H), 4.65-4.60 (m, 1 H), 4.23-4.20 (m, 1 H), 3.80 (s, 3 H), 3.34-3.24 (m, 6 H), 2.58 (s, 3 H), 2.45-2.37 (m, 2 H), 2.34-2.14 (m, 2 H), 2.07-1.77 (m, 12 H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd 696.2831, obsd 696.2812.

Example 812


Preparation of 4-chloro-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-methoxybenzenesulfonamide



4-Chloro-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-methoxybenzenesulfonamide (170 mg, 60%) was obtained as solid from 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (244 mg, 0.4 mmol) and 2-chloro-4-fluoro-5-[(methoxyamino)sulfonyl]benzoic acid (283mg, 1 mmol) and HATU (152 mg, 0.4 mmol), following the procedures outlined in example 5. ^1H NMR (400 MHz, CDCl_3) δ 7.91 (d, $J=7.2$ Hz, $\frac{1}{2}$ H, rotamer), 7.76 (d, $J=7.1$ Hz, $\frac{1}{2}$ H, rotamer), 7.63 (d, $J=7.5$ Hz, 1 H), 7.38-7.28 (m, 3 H), 7.18-7.12 (m, 2 H), 7.08-7.04 (m, 1 H), 6.98-6.94 (m, 2 H), 4.62-4.57 (m, 1 H), 4.26-4.17 (m, 1 H), 3.78 (d, $J=9.9$ Hz, 3 H), 3.42-3.10 (m, 6 H), 2.55 (s, $\frac{3}{2}$ H, rotamer), 2.54 (s, $\frac{3}{2}$ H, rotamer), 2.42-2.32 (m, 3 H), 2.14-2.07 (m, 1 H), 1.94-1.70 (m, 10 H), 1.64-1.63 (m, 2 H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd 712.2536, obsd 712.2546.

Example 813

Preparation of 2,4-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-propylbenzenesulfonamide




2,4-Dichloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-propylbenzenesulfonamide (11 mg, 15%) was obtained as solid from 2,6-dichloro-3-(chlorosulfonyl)benzoic acid (58 mg, 0.2 mmol), propyl amine (20 μ L, 0.2mmol) and 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (61 mg, 0.1 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CD_2Cl_2), δ 8.06=8.01 (m, 1 H), 7.59-7.48 (m, 2 H), 7.42-7.34 (m, 2 H), 7.20-7.16 (m, 3 H), 7.14-6.96 (m, 2 H), 4.68 (br, 1 H), 4.23-4.20 (m, 1 H), 3.47-3.13 (m, 6 H), 2.96-2.82 (m, 4), 2.53 (s, 3/2 H), 2.41 (s, 3/2 H), 2.36-2.16 (m, 5 H), 1.98-1.84 (m, 7 h), 1.68-1.61 (m, 2 H), 1.52-1.44 (m, 2 H), 0.90-0.86 (m, 3 H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd: 740.2604, obsd: 740.2589.

Example 814

Preparation of 2,4-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-isopropylbenzenesulfonamide

558




2,4-Dichloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]piperidin-1-yl)carbonyl]-*N*-isopropylbenzene

sulfonamide (13.5 mg, 18%) was obtained as solid from 2,6-dichloro-3-(chlorosulfonyl)benzoic acid (58 mg, 0.2 mmol), isopropyl amine (20 μ L, 0.2 mmol) and 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (61 mg, 0.1 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CD_2Cl_2), δ 8.07 (d, $J=8.6$ Hz, 1 H), 7.58-7.50 (m, 2 H), 7.42-7.35 (m, 2 H), 7.21-7.12 (m, 2 H), 7.06-6.95 (m, 3 H), 4.70-4.65 (m, 1 H), 4.23-4.19 (m, 1 H), 3.47-3.27 (m, 5 H), 3.22-3.14 (m, 2 H), 2.53 (s, 3 H), 2.46-2.32 (m, 3 H), 2.16 (br, 1 H), 1.98-1.83 (m, 11 H), 1.68 (d, $J=7.7$ Hz, 2 H), 1.25-1.03 (m, 6 H). HRMS m/z ($M+H$) $^+$ calcd: 740.2604, obsd: 740.2590.

Example 815

Preparation of 2,4-dichloro-*N*-cyclopropyl-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]piperidin-1-yl)carbonyl]benzenesulfonamide




2,4-Dichloro-*N*-cyclopropyl-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzene

sulfonamide (12 mg, 15%) was obtained as solid from 2,6-dichloro-3-(chlorosulfonyl)benzoic acid (58 mg, 0.2 mmol), cyclopropyl amine (17 μ L, 0.2 mmol) and 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (61 mg, 0.1 mmol) following the procedure outlined in example 473. ^1H NMR (400 MHz, CD_2Cl_2), δ 8.10 (d, $J=7.6$ Hz, 1 H), 7.59-7.52 (m, 2 H), 7.42-7.36 (m, 2 H), 7.19-7.12 (m, 3 H), 7.07-6.97 (m, 2 H), 4.67-4.63 (m, 1 H), 4.24-4.20 (m, 1 H), 3.49-3.14 (m, 6 H), 2.53 (s, 3 H), 2.44-2.33 (m, 3 H), 2.12 (br, 1 H), 1.96-1.85 (m, 11 H), 1.67-1.65 (m, 2 H), 0.74-0.67 (m, 1 H), 0.61-0.51 (m, 3 H). HRMS m/z ($\text{M}+\text{H}$) $^+$ calcd: 738.2448, obsd: 738.2433.

Example 816

Preparation of 2,4-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-(2,2,2-trifluoroethyl)benzenesulfonamide




2,4-Dichloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-(2,2,2-trifluoroethyl)

benzenesulfonamide (220 mg, 56%) was obtained as solid from 2,6-dichloro-3-(chlorosulfonyl)benzoic acid (290 mg, 1 mmol), 2,2,2-trifluoroethylamine (160 μ L, 2 mmol) and 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (305 mg, 0.5 mmol) following the procedure outlined in example 473. ^1H NMR (400


MHz, CD₂Cl₂), δ 8.03 (d, J=8.4 Hz, 1 H), 7.59-7.54 (m, 1 H), 7.562-7.47 (m, 1 H), 7.42-7.34 (m, 2 H), 7.19-7.12 (m, 3 H), 7.06-6.96 (m, 2 H), 4.65-4.60 (m, 1 H), 4.22-4.18 (m, 1 H), 3.79-3.69 (m, 2 H), 3.48-3.45 (m, 1 H), 3.27-3.12 (m, 3 H), 3.11-3.05 (m, 1 H), 2.52 (s, 3 H), 2.43-2.30 (m, 3 H), 2.19-2.16 (m, 2 H), 1.97-1.81 (m, 10 H), 1.66-1.62 (m, 2 H). HRMS m/z (M+H)⁺ calcd: 780.2165, obsd: 780.2164.

Example 817

Preparation of 2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-(2,2,2-trifluoroethyl)benzenesulfonamide




2,4-Difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-(2,2,2-trifluoroethyl)benzenesulfonamide (260 mg, 70 %) was obtained as solid from 2,6-difluoro-3-(chlorosulfonyl)benzoic acid (260 mg, 1 mmol), 2,2,2-trifluoroethylamine (160 μ L, 2 mmol) and 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (305 mg, 0.5 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CD₂Cl₂), δ 7.98-7.92 (m, 1 H), 7.60-7.58 (m, 1 H), 7.41-7.32 (m, 2 H), 7.22-7.20 (m, 2 H), 7.16-6.98 (m, 4 H), 4.69-4.67 (m, 1 H), 4.18 (br, 1 H), 3.80-3.62 (m, 1 H), 3.45-3.39 (m, 3 H), 3.25-3.20 (m, 1 H), 2.55 (s, 3 H), 2.40-2.42 (m, 2 H), 2.42-2.40 (m, 1 H), 2.32-1.83 (m, 212 H), 1.73-1.38 (m, 2 H). HRMS m/z (M+H)⁺ calcd: 748.2756, obsd: 748.2759.

Example 818Preparation of 2-chloro-*N*-ethoxy-4-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide

2-Chloro-*N*-ethoxy-4-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide (60 mg, 16%) was obtained as solid from 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (305 mg, 0.5mmol) and 2-fluoro-4-chloro-5-[(ethoxyamino)sulfonyl]benzoic acid (297mg, 1 mmol) and HATU (190 mg, 0.5 mmol), following the procedures outlined in example 5. ¹H NMR (400 MHz, CD₂Cl₂) δ 8.15 (br, 1 H), 7.59-7.57 (m, 1 H), 7.42-7.35 (m, 3 H), 7.16-7.12 (m, 3 H), 7.07-6.97 (m, 2 H), 4.64-4.60 (m, 1 H), 4.15-4.01 (m, 4 H), 3.42-3.19 (m, 5 H), 2.53 (s, 3 H), 2.43-2.32 (m, 3 H), 2.18-2.11 (m, 1 H), 1.96-1.83 (m, 10 H), 1.66-1.64 (m, 2 H), 1.17 (t, J=6.9 Hz, 3 H). HRMS *m/z* (M+H)⁺ calcd 726.2692, obsd 726.2704.

Example 819Preparation of 2,4-dichloro-*N*-ethoxy-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide


562



2,4-Dichloro-*N*-ethoxy-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide (22.5 mg, 6%) was obtained as solid from 2,6-dichloro-3-(chlorosulfonyl)benzoic acid (290 mg, 1 mmol), ethoxyamine hydrochloride (195 mg, 2 mmol) and 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (305 mg, 0.5 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CD₂Cl₂), δ 8.10-8.08 (m, 1 H), 7.60-7.55 (m, 2 H), 7.40-7.35 (m, 2 H), 7.18-7.12 (m, 3 H), 7.07-6.96 (m, 2 H), 4.65-4.60 (m, 2 H), 4.23-4.20 (m, 1 H), 4.06-4.00 (m, 2 H), 3.34-3.12 (m, 6 H), 2.54-2.53 (m, 2 H), 2.44-2.44 (m, 4 H), 2.20-2.03 (m, 2 H), 1.97-1.84 (m, 12 H), 1.65 (d, *J*=7.9 Hz, 2 H), 1.18-1.14 (m, 3 H). HRMS *m/z* (*M*+*H*)⁺ calcd: 742.2397, obsd: 742.2424.

Example 820

Preparation of *N*-ethoxy-2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide




N-ethoxy-2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide

sulfonamide (27.9mg, 8%) was obtained as solid from 2,6-difluoro-3-(chlorosulfonyl)benzoic acid (260 mg, 1 mmol), ethoxyamine hydrochloride (195 mg, 2 mmol) and 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (305 mg, 0.5 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CD₂Cl₂), δ 8.00-7.95 (m, 1 H), 7.58-7.56 (m, 1 H), 7.42-7.35 (m, 2 H), 7.17-7.10 (m, 4 H), 7.06-6.97 (m, 2 H), 4.65-4.60 (m, 1 H), 4.21-4.00 (m, 3 H), 3.43-3.19 (m, 5 H), 2.53 (s, 3 H), 2.44-2.32 (m, 4 H), 2.17-2.15 (m, 1 H), 1.97-1.80 (m, 10 H), 1.65 (d, *J*=7.8 Hz, 2 H), 1.18-1.11 (m, 3 H). HRMS *m/z* (*M*+*H*)⁺ calcd: 710.2988, obsd: 710.2975.

Example 821

Preparation of *N*-ethoxy-2,4-difluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide



N-ethoxy-2,4-difluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzene


sulfonamide (25mg, 7%) was obtained as solid from 2,4-difluoro-3-(chlorosulfonyl)benzoic acid (260 mg, 1 mmol), ethoxyamine hydrochloride (195 mg, 2 mmol) and 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (305 mg, 0.5 mmol) following the procedure outlined in example 473. ¹H NMR (400 MHz, CD₂Cl₂), δ 7.96 (br, 1 H), 7.57-7.55 (m, 1 H), 7.42-7.35 (m, 2 H), 7.16-7.11 (m, 3 H), 7.08-6.96 (m, 3 H), 4.65-4.60 (m, 1 H), 4.14-4.03 (m, 3 H), 3.42-3.17 (m, 5 H), 2.52 (s, 3 H), 2.43-2.31 (m, 4 H), 2.13-2.09 (m, 1 H), 1.98-

564



1.80 (m, 10 H), 1.65 (d, J=7.8 Hz, 2 H), 1.18 (t, J=7.0 Hz, 3 H). HRMS m/z (M+H)⁺ calcd: 710.2988, obsd: 710.2975.



Example 822

Preparation of 1-((1*R*,5*S*)-8-{2-[1-{2,4-difluoro-5-[(4-methylpiperazin-1-yl)sulfonyl]benzoyl}-4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole



1-((1*R*,5*S*)-8-{2-[1-{2,4-difluoro-5-[(4-methylpiperazin-1-yl)sulfonyl]benzoyl}-4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (170mg, 44%) was obtained as solid from 2-chloro-4-fluoro-5-[(4-methylpiperazin-1-yl)sulfonyl]benzoic acid (170 mg, 0.5 mmol), HATU (190 mg, 0.5 mmol) and 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (305 mg, 0.5 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, DMSO-*d*₆), δ 7.93-7.88 (m, 1 H), 7.79-7.75 (m, 1 H), 7.47 (d, J=8.4 Hz, 1 H), 7.43-7.33 (m, 2 H), 7.23-7.21 (m, 3 H), 7.12-7.04 (m, 3 H), 4.50-4.46 (m, 1 H), 3.93-3.90 (m, 1 H), 3.30 (br, 4 H), 3.16-3.04 (m, 5 H), 2.43(s, 3 H), 2.32(br, 6 H), 2.13-2.12 (m, 4 H), 1.98-1.57 (m, 13 H). HRMS m/z (M+H)⁺ calcd: 765.3149, obsd: 765.3165.


# Example	Structure	¹ H NMR (400 MHz, CDCl ₃)	HRMS m/z (M+H) ⁺
823		δ 7.66 (d, J=7.1 Hz, 1 H), 7.33-7.24 (m, 4 H), 7.19-7.12 (m, 2 H), 7.04-6.89 (m, 6H), 4.59 (br, 1 H), 3.73 (s, 1 H), 3.29-3.22 (m, 4 H), 2.55 (s, 3 H), 2.52-2.48 (m, 1 H), 2.40-2.10 (m, 6 H), 1.93-1.87 (m, 8 H), 1.79-1.61 (m, 6 H), 1.53-1.46 (m, 2, H), 1.43-1.30 (m, 2 H), 0.92 (t, J=7.3 Hz, 3 H)	Calcd 654.3983, obsd 654.3998.
824		δ 8.06 (d, J=8.4 Hz, 1 H), 7.57-7.50 (m, 2 H), 7.42-7.35 (m, 2 H), 7.20-7.12 (m, 3 H), 7.06-6.96 (m, 2 H), 4.70-4.65 (m, 1 H), 4.22-4.18 (m, 1 H), 3.58-3.12 (m, 6 H), 2.52 (s, 3 H), 2.46-2.36 (m, 3 H), 2.18 (br, 2 H), 1.96-1.83 (m, 11 H), 1.79-1.61 (m, 6 H), 1.47-1.38 (m, 4 H).	calcd: 766.2761, obsd: 766.2776

825		δ 8.18 (br, 1 H), 7.59-7.57 (m, 1 H), 7.43-7.33 (m, 6 H), 7.29-7.25 (m, 1 H), 7.20-7.16 (m, 2 H), 4.67-4.62 (m, 1 H), 4.18-4.15 (m, 1 H), 3.78 (s, 3 H), 3.40-3.31 (m, 4 H), 3.18-3.15 (m, 1 H), 2.54 (s, 3 H), 2.46-2.34 (m, 3 H), 2.18-2.02 (m, 1 H), 1.99-1.84 (m, 11 H), 1.68-1.67 (2 H).	calcd 694.2630, obsd 694.2623.
826		δ 8.21 (d, J=10 Hz, 2 H), 7.66 (d, J=10 Hz, 1 H), 7.50 (s, 2 H), 7.35-7.29 (m, 2 H), 7.20-7.13 (m, 2 H), 7.10-6.90 (m, 3 H), 4.60 (br, 1 H), 4.20 (br, 1 H), 3.55 (br, 1 H), 3.40-3.25 (m, 4 H), 3.18 (s, 3 H), 3.04 (s, 3 H), 2.57 (s, 3 H), 2.45-2.35 (m, 2 H), 2.30-2.21 (m, 2 H), 1.95-1.89 (m, 12 H), 1.65-1.63 (m, 2 H).	calcd: 765.3149, obsd: 765.3165.

Example 827Preparation of

2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-5,6,7,8-tetrahydro-4(1H)-quinolinone


567



2-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-5,6,7,8-tetrahydro-4(1*H*)-quinolinone (5.2 mg; 17% yield) was obtained as a solid from 4-oxo-1,4,5,6,7,8-hexahydro-2-quinolinecarboxylic acid (9.66 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M-H): 602.36.

Example 828

3-hydroxy-5-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2-pyrrolidinone




3-hydroxy-5-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2-pyrrolidinone (12.05 mg; 43%

yield) was obtained as a solid from 4-hydroxy-5-oxoproline (7.25 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 556.22.

Example 829

N,N-dimethyl-4-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-1,3-thiazol-2-amine




N,N-dimethyl-4-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-1,3-thiazol-2-amine (14.49 mg; 50% yield) was obtained as a solid from 2-(dimethylamino)-1,3-thiazole-4-carboxylic acid hydrobromide (12.65 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 583.23.

Example 830

2-methyl-1-{8-[2-(1-[(1-methyl-4-(methyloxy)-1*H*-1,2,3-triazol-5-yl]carbonyl)-4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole


569



2-methyl-1-{8-[2-(1-[[1-methyl-4-(methoxy)-1H-1,2,3-triazol-5-yl]carbonyl]-4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole (2.99 mg; 11% yield) was obtained as a solid from 1-methyl-4-(methoxy)-1H-1,2,3-triazole-5-carboxylic acid (8.95 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 568.20.

Example 831

5-methyl-3-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]dihydro-2(3H)-furanone




5-methyl-3-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]dihydro-2(3H)-furanone (10.39 mg; 36% yield) was obtained as a solid from 5-methyl-2-oxotetrahydro-3-furancarboxylic acid (7.90 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole hydrochloride

570

(25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 569.25

Example 832

N-[2-methyl-3-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-3-oxopropyl]-1*H*-pyrrole-2-carboxamide




N-[2-methyl-3-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-3-oxopropyl]-1*H*-pyrrole-2-carboxamide (13.35 mg; 44% yield) was obtained as a solid from 2-methyl-3-[(1*H*-pyrrol-2-ylcarbonyl)amino]propanoic acid (7.90 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 607.26

Example 833

2-methyl-1-(8-[2-[4-phenyl-1-(1*H*-pyrrolo[2,3-*b*]pyridin-3-ylcarbonyl)-4-piperidinyl]ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole


571



2-methyl-1-(8-{2-[4-phenyl-1-(1*H*-pyrrolo[2,3-*b*]pyridin-3-ylcarbonyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole (9.29 mg; 32% yield) was obtained as a solid from 1*H*-pyrrolo[2,3-*b*]pyridine-3-carboxylic acid (8.10 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 573.21

Example 834

1-{8-[2-(1-{2-(1*H*-imidazol-4-yl)cyclopropyl]carbonyl}-4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-2-methyl-1*H*-benzimidazole




2-methyl-1-(8-{2-[4-phenyl-1-(1*H*-pyrrolo[2,3-*b*]pyridin-3-ylcarbonyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole (12.60 mg; 45% yield) was obtained as a solid from 2-(1*H*-imidazol-4-yl)cyclopropanecarboxylic acid hydrochloride (9.43 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-

benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 563.24

Example 835

4,5-diethyl-2-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]phenol




4,5-diethyl-2-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]phenol (6.39 mg; 21% yield) was obtained as a solid from 4,5-diethyl-2-hydroxybenzoic acid (9.71 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 605.27.

Example 836

1-[8-(2-{1-[(3,4-dichloro-2-furanyl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole


573



1-[8-(2-{1-[(3,4-dichloro-2-furanyl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole (12.19 mg; 41% yield) was obtained as a solid from 3,4-dichloro-2-furancarboxylic acid (9.04 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 591.12.

Example 837

(2*S*,3*S*)-*N,N*,3-trimethyl-1-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-1-oxo-2-pentanamine




(2*S*,3*S*)-*N,N*,3-trimethyl-1-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-1-oxo-2-pentanamine (10.05 mg; 35% yield) was obtained as a solid from *N,N*-dimethyl-L-isoleucine (7.96 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride # (25 mg, 0.05

mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 570.15.

Example 838

1-[8-(2-{1-[(2,6-difluoro-3-pyridinyl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




1-[8-(2-{1-[(2,6-difluoro-3-pyridinyl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole (8.35 mg; 29% yield) was obtained as a solid from 2,6-difluoro-3-pyridinecarboxylic acid (7.95 mg, 0.05 mmol), 2-methyl-1-[8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 570.19.

Example 839

1-(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-1-oxo-2-(2-thienyl)-2-propanol


575



1-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)-1-oxo-2-(2-thienyl)-2-propanol (4.95 mg; 17% yield) was obtained as a solid from 2-hydroxy-2-(2-thienyl)propanoic acid (8.60mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 583.17.

Example 840

2-methyl-1-{8-[2-(1-{[3-(1-methylethyl)-5-isoxazolyl]carbonyl}-4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole




2-methyl-1-{8-[2-(1-{[3-(1-methylethyl)-5-isoxazolyl]carbonyl}-4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (11.29 mg; 40% yield) was obtained as a solid from 3-(1-methylethyl)-5-isoxazolecarboxylic acid hydrochloride (8.86mg, 0.05 mmol), 2-methyl-1-{8-[2-

(4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 566.27.

Example 841

2-methyl-1-[8-(2-{4-phenyl-1-[(4-phenyl-1*H*-1,2,3-triazol-5-yl)carbonyl]-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole




2-methyl-1-[8-(2-{4-phenyl-1-[(4-phenyl-1*H*-1,2,3-triazol-5-yl)carbonyl]-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole (10.29 mg; 34% yield) was obtained as a solid from 4-phenyl-1*H*-1,2,3-triazole-5-carboxylic acid hydrochloride (9.45 mg, 0.05 mmol), 2-methyl-1-[8-[2-(4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 600.20.

Example 842

2-methyl-1-[8-(2-{1-[(4-methyl-1*H*-imidazol-5-yl)carbonyl]-4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole


577



2-methyl-1-[8-(2-{1-[(4-methyl-1*H*-imidazol-5-yl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole (9.10 mg; 34% yield) was obtained as a solid from 4-methyl-1*H*-imidazole-5-carboxylic acid (6.30 mg, 0.05 mmol), 2-methyl-1-[8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (*M*-*H*): 535.52.

Example 843


1-[2-[(4-[2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-4-phenyl-1-piperidinyl]carbonyl]-3-pyridinyl]ethanone



1-[2-[(4-[2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-4-phenyl-1-piperidinyl]carbonyl]-3-pyridinyl]ethanone (12.60 mg; 44% yield) was obtained as a solid from 3-acetyl-2-pyridinecarboxylic acid (9.35 mg, 0.05 mmol), 2-methyl-1-[8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (*M*+*H*): 576.24.

Example 844


5-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-4-pyridazinol



5-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-4-pyridazinol (9.75mg; 35% yield) was obtained as a solid from 5-hydroxy-4-pyridazinecarboxylic acid (7.00 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 551.24.

Example 845


2-methyl-1-{8-[2-(4-phenyl-1-{[3-(4-pyridinyl)-5-isoxazolyl]carbonyl}-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole



2-methyl-1-{8-[2-(4-phenyl-1-{[3-(4-pyridinyl)-5-isoxazolyl]carbonyl}-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (15.39mg; 51% yield) was obtained as a solid from 3-(4-pyridinyl)-5-isoxazolecarboxylic acid (9.51 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 601.16.

Example 846

1-(8-{2-[1-(2,3-dihydro-1-benzofuran-3-ylcarbonyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole




1-(8-{2-[1-(2,3-dihydro-1-benzofuran-3-ylcarbonyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (17.9 mg; 62% yield) was obtained as a solid from 2,3-dihydro-1-benzofuran-3-carboxylic acid (8.20 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 575.2.

Example 847

3-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2,3-dihydro-1*H*-pyrrolo[1,2-*a*]pyrrol-1-one


580



3-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2,3-dihydro-1*H*-pyrrolo[1,2-*a*]pyrrol-1-one (11.5 mg; 40% yield) was obtained as a solid from 1-oxo-2,3-dihydro-1*H*-pyrrolo[1,2-*a*]pyrrole-3-carboxylic acid (9.35 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (*M*+*H*): 576.22.

Example 848

3-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-3-oxo-1-(4-pyridinyl)-1-propanol




3-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-3-oxo-1-(4-pyridinyl)-1-propanol (18.59mg; 64% yield) was obtained as a solid from 3-hydroxy-3-(4-pyridinyl)propanoic acid (8.35 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-

azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 578.22.

Example 849

2-methyl-1-{8-[2-(1-[(2*S*)-1-methyl-2-phenylcyclopropyl]carbonyl]-4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole




2-methyl-1-{8-[2-(1-[(2*S*)-1-methyl-2-phenylcyclopropyl]carbonyl]-4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole (18.91 mg; 64% yield) was obtained as a solid from (2*S*)-1-methyl-2-phenylcyclopropanecarboxylic acid (8.81 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 587.26.

Example 850

4,6-dimethyl-3-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2(1*H*)-pyridinone


582



4,6-dimethyl-3-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2(1*H*)-pyridinone (17.84 mg; 62% yield) was obtained as a solid from 4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinecarboxylic acid (8.35 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 578.23.

Example 851


N-(hydroxymethyl)-5-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-3-pyridinecarboxamide



N-(hydroxymethyl)-5-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-3-pyridinecarboxamide (5.55 mg; 18% yield) was obtained as a solid from 5-[[[(hydroxymethyl)amino]carbonyl]-3-pyridinecarboxylic acid (10.90 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 601.2.

Example 852


1-(8-{2-[1-(1*H*-benzimidazol-5-ylacetyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole



1-(8-{2-[1-(1*H*-benzimidazol-5-ylacetyl)-4-phenyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (15.20 mg; 52% yield) was obtained as a solid from 1*H*-benzimidazol-5-ylacetic acid (10.63 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 587.18.

Example 853


6-chloro-4-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-2(1*H*)-pyridinone



6-chloro-4-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-2(1*H*)-pyridinone (7.69 mg; 26% yield) was obtained as a solid from 6-chloro-2-oxo-1,2-dihydro-4-pyridinecarboxylic acid (8.67 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 584.16.

Example 854


5-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-5,6,7,8-tetrahydro-2-naphthalenol



5-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-5,6,7,8-tetrahydro-2-naphthalenol (18.15 mg; 60% yield) was obtained as a solid from 6-hydroxy-1,2,3,4-tetrahydro-1-naphthalenecarboxylic acid (9.61 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 603.24.

Example 855


2-[2-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-2-oxoethyl][1,2,4]triazolo[1,5-*a*]pyrimidine



2-[2-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-2-oxoethyl][1,2,4]triazolo[1,5-*a*]pyrimidine (10.54 mg; 36% yield) was obtained as a solid from [1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylacetic acid (8.90 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 589.22.

Example 856


3-{1-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny]carbonyl]propyl}dihydro-2(3*H*)-furanone



3-{1-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny]carbonyl]propyl}dihydro-2(3*H*)-furanone (15.24 mg; 52% yield) was obtained as a solid from 2-(2-oxotetrahydro-3-furanyl)butanoic acid (8.60 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidiny]ethyl)-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 583.26.

Example 857


1-[8-(2-{1-[(3-ethenyl-2-pyridinyl)carbonyl]-4-phenyl-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole



1-[8-(2-{1-[(3-ethenyl-2-pyridinyl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole (5.05 mg; 18% yield) was obtained as a solid from 3-ethenyl-2-pyridinecarboxylic acid (7.54 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 560.22.

Example 858


5-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-1,3-benzothiazole



5-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-1,3-benzothiazole (7.95 mg; 27% yield) was obtained as a solid from 1,3-benzothiazole-5-carboxylic acid (8.95 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 590.17.

Example 859


1-[8-(2-{1-[(1,1-dioxidotetrahydro-2-thienyl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole



1-[8-(2-{1-[(1,1-dioxidotetrahydro-2-thienyl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole (8.89 mg; 31% yield) was obtained as a solid from tetrahydro-2-thiophenecarboxylic acid 1,1-dioxide (8.20 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 575.16.

Example 860


2-methyl-7-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]furo[2,3-*c*]pyridine



2-methyl-7-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]furo[2,3-*c*]pyridine (10.35 mg; 35% yield) was obtained as a solid from 2-methylfuro[2,3-*c*]pyridine-7-carboxylic acid (8.85 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 588.22.

Example 861


2-methyl-1-[8-(2-{1-[(1-oxidotetrahydro-2*H*-thiopyran-4-yl)carbonyl]-4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole



2-methyl-1-[8-(2-{1-[(1-oxidotetrahydro-2*H*-thiopyran-4-yl)carbonyl]-4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole (15.85 mg; 55% yield) was obtained as a solid from tetrahydro-2*H*-thiopyran-4-carboxylic acid 1-oxide (8.11 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 573.24.

Example 862

2-methyl-1-{8-[2-(1-{[2-(methyloxy)-1,3-thiazol-5-yl]carbonyl}-4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole




2-methyl-1-{8-[2-(1-{[2-(methyloxy)-1,3-thiazol-5-yl]carbonyl}-4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (10.75 mg; 38% yield) was obtained as a solid from 2-(methyloxy)-1,3-thiazole-5-carboxylic acid (7.95 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 570.21.

Example 863

4-methyl-1-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]cyclohexanol


591



4-methyl-1-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]cyclohexanol (11.20 mg; 40% yield) was obtained as a solid from 1-hydroxy-4-methylcyclohexanecarboxylic acid (7.90 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 569.27.

Example 864

4-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-2,1,3-benzoxadiazole




4-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-2,1,3-benzoxadiazole (19.39 mg; 67% yield) was obtained as a solid from 2,1,3-benzoxadiazole-4-carboxylic acid (8.20 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05

mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 575.22.

Example 865

2-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-2-oxo-1-(3-pyridinyl)ethanol




2-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-2-oxo-1-(3-pyridinyl)ethanol (15.04 mg; 54% yield) was obtained as a solid from hydroxy(3-pyridinyl)acetic acid (7.65 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 564.16.

Example 866

N-[2,2-dimethyl-3-[2-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-2-oxoethyl]cyclobutyl]acetamide


593



N-{2,2-dimethyl-3-[2-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-2-oxoethyl]cyclobutyl}acetamide (15.85 mg; 52% yield) was obtained as a solid from [3-(acetlamino)-2,2-dimethylcyclobutyl]acetic acid (9.96 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (*M*+*H*): 610.30.

Example 867

2-methyl-1-[8-(2-{4-phenyl-1-[(4-phenyl-2-pyridinyl)carbonyl]-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole




2-methyl-1-[8-(2-{4-phenyl-1-[(4-phenyl-2-pyridinyl)carbonyl]-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole (14.94 mg; 49% yield) was obtained as a solid from 4-phenyl-2-pyridinecarboxylic acid

(9.96 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 610.20.

Example 868

1-{8-[2-(1-{[6-chloro-4-(methyloxy)-3-pyridinyl]carbonyl}-4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-2-methyl-1*H*-benzimidazole




1-{8-[2-(1-{[6-chloro-4-(methyloxy)-3-pyridinyl]carbonyl}-4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-2-methyl-1*H*-benzimidazole (17.05 mg; 57% yield) was obtained as a solid from 6-chloro-4-(methyloxy)-3-pyridinecarboxylic acid (9.37 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidiny)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 598.19.

Example 869

8-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-2*H*-chromen-2-one


595



8-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-2*H*-chromen-2-one (20.64 mg; 68% yield) was obtained as a solid from 2-oxo-2*H*-chromene-8-carboxylic acid (9.50 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (*M*+*H*): 601.19.

Example 870

2-methyl-1-{8-[2-(4-phenyl-1-{[3-(2-pyridinyl)-5-isoxazolyl]carbonyl}-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole




2-methyl-1-{8-[2-(4-phenyl-1-{[3-(2-pyridinyl)-5-isoxazolyl]carbonyl}-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole (13.15 mg; 44% yield) was obtained as a solid from 3-(2-pyridinyl)-5-isoxazolecarboxylic acid (9.50 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-

azabicyclo[3.2.1]oct-3-yl)-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 601.22.

Example 871

methyl 2-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-3-pyridinecarboxylate




Methyl 2-[(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)carbonyl]-3-pyridinecarboxylate (8.45 mg; 28% yield) was obtained as a solid from 3-[(methyloxy)carbonyl]-2-pyridinecarboxylic acid (9.05 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (M+H): 592.21.

Example 872

(1*R*)-2-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-1-(3-methylphenyl)-2-oxoethanol


597



(1*R*)-2-(4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidinyl)-1-(3-methylphenyl)-2-oxoethanol (11.85 mg; 41% yield) was obtained as a solid from (2*R*)-hydroxy(3-methylphenyl)ethanoic acid (8.30 mg, 0.05 mmol), 2-methyl-1-[8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* (*M*+*H*): 577.24.

Example 873

2-methyl-1-[8-(2-{1-[(2-methyl-1-benzofuran-7-yl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole




2-methyl-1-[8-(2-{1-[(2-methyl-1-benzofuran-7-yl)carbonyl]-4-phenyl-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole (12.30 mg; 42% yield) was obtained as a solid from 2-methyl-1-benzofuran-7-carboxylic acid (8.80 mg, 0.05 mmol), 2-methyl-1-[8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole hydrochloride (25 mg, 0.05

mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H):587.22.

Example 874

2-methyl-1-{8-[2-(1-{[6-(methyloxy)-3-pyridinyl]carbonyl}-4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole




2-methyl-1-{8-[2-(1-{[6-(methyloxy)-3-pyridinyl]carbonyl}-4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole (13.0 mg; 43% yield) was obtained as a solid from 6-(methyloxy)-3-pyridinecarboxylic acid (9.37 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H):598.18.

Example 875

2-methyl-1-{8-[2-(4-phenyl-1-{[3-(trifluoromethyl)-2-pyridinyl]carbonyl}-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole


599



2-methyl-1-{8-[2-(4-phenyl-1-[[3-(trifluoromethyl)-2-pyridinyl]carbonyl]-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole (11.89 mg; 39% yield) was obtained as a solid from 3-(trifluoromethyl)-2-pyridinecarboxylic acid (9.56 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole hydrochloride (25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H):602.19.

Example 876

2-methyl-1-{8-[2-(4-phenyl-1-[[4-(trifluoromethyl)-1H-pyrazol-3-yl]carbonyl]-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole




2-methyl-1-{8-[2-(4-phenyl-1-[[4-(trifluoromethyl)-1H-pyrazol-3-yl]carbonyl]-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole (3.94 mg; 13% yield) was obtained as a solid from 4-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid (9.00 mg, 0.05 mmol), 2-methyl-1-{8-[2-(4-phenyl-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole hydrochloride

(25 mg, 0.05 mmol) and HATU (19 mg, 0.05 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 591.19.

Example 877

5-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-3*H*-1,2,3-benzoxathiazole 2,2-dioxide




5-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-3*H*-1,2,3-benzoxathiazole 2,2-dioxide

(18 mg; 27% yield) was obtained as a solid from 3*H*-1,2,3-benzoxathiazole-5-carboxylic acid 2,2-dioxide (22 mg, 0.1 mmol), 1-(8-{2-[4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole hydrochloride (50 mg, 0.1 mmol) and HATU (38 mg, 0.1 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 644.29.

Example 878

1-(8-{2-[4-(3-fluorophenyl)-1-(1*H*-pyrazol-4-ylcarbonyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole


601



1-(8-{2-[4-(3-fluorophenyl)-1-(1H-pyrazol-4-ylcarbonyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (38 mg; 37% yield) was obtained as a solid from 1H-pyrazole-4-carboxylic acid (21 mg, 0.2 mmol), 1-(8-{2-[4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole hydrochloride (100 mg, 0.2 mmol) and HATU (73 mg, 0.2 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 541.20.

Example 879

1-{8-[2-(4-(3-fluorophenyl)-1-{3-(methoxy)-1H-pyrazol-4-yl]carbonyl}-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-2-methyl-1H-benzimidazole




1-{8-[2-(4-(3-fluorophenyl)-1-{3-(methoxy)-1-(phenylmethyl)-1H-pyrazol-4-yl]carbonyl}-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-2-methyl-1H-benzimidazole was obtained as a crude mixture from 3-(methoxy)-1-(phenylmethyl)-1H-pyrazole-4-carboxylic acid (23 mg, 0.1 mmol), 1-(8-{2-[4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole hydrochloride (50 mg, 0.1 mmol) and HATU (38 mg, 0.1 mmol) following the procedure outlined in example 5. ES-LCMS m/z (M+H): 661.46.

The crude mixture was then treated with PdCl_2 (25 mg) under 50 psi H_2 to provide 1-{8-[2-(4-(3-fluorophenyl)-1-[[3-(methoxy)-1H-pyrazol-4-yl]carbonyl]-4-piperidinyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-2-methyl-1H-benzimidazole as solid (30, 52%). ES-LCMS m/z (M+H): 571.24


Example 880

2,4-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-N-methylbenzenesulfonamide



603

Example 880 was prepared according to figure below.



Synthesis of 880-1a
2,6-dichloro-3-(chlorosulfonyl)benzoic acid

Chlorosulfonic acid was slowly added to 2,6-dichlorobenzoic acid at RT under N₂. The reaction was heated to 150 °C for 3 h, then slowly poured over ice and the product extracted into Et₂O. The organic layer was dried over MgSO₄, filtered and concentrated to give 2,6-dichloro-3-(chlorosulfonyl)benzoic acid 880-1a as a brown solid (12.9 g, 85% yield).


¹H NMR (400 MHz, DMSO) δ 13.42 (broad s, 1H), 7.88 (d, *J* = 8. Hz, 1H), 7.46 (d, *J* = 8.4 Hz, 1H).

Synthesis of 880-1b
2,6-dichloro-3-[(methylamino)sulfonyl]benzoic acid

A mixture of 2,6-dichloro-3-(chlorosulfonyl)benzoic acid 880-1a (200 mg, 0.69 mmol, 1 equiv) and 4 mL CH₂Cl₂ was treated with diisopropylamine (248 μ L, 1.38 mmol, 2 equiv) and 2M methyl amine (415 μ L, 0.83 mmol, 1.2 equiv). The reaction was stirred at RT overnight, wherein the crude mixture contained 2,6-dichloro-3-[(methylamino)sulfonyl]benzoic acid 880-1b. The mixture was carried directly into the following reaction. ES-LCMS m/z 284.0 (M-H)

Synthesis of 880

2,4-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-N-methylbenzenesulfonamide




To a solution of 1-(8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (100 mg, 0.16 mmol, 1 equiv) and *N,N*-diisopropylethyl amine (117 μ L, 0.66 mmol, 4 equiv) in dimethylformamide (2 mL) was added the mixture of 2,6-dichloro-3-[(methylamino)sulfonyl]benzoic acid 880-1b. After stirring at RT for several min, *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluroniumhexafluorophosphate (62 mg, 0.16 mmol, 1 equiv) was added and the reaction was stirred for 18 h. The mixture was partitioned between dichloromethane and satd. aq. NaHCO₃. The organic layer was dried and concentrated and the residue was purified by SiO₂ flash column chromatography (100% EtOAc \rightarrow 10% 2M NH₃ in MeOH in EtOAc) to provide 2,4-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-N-

methylbenzenesulfonamide (example 880) as a white solid (25 mg, 22% yield).

^1H NMR (300 MHz, CDCl_3) δ 8.05 (m, 1H), 7.65 (m, 1H), 7.49 (m, 1H), 7.39-7.29 (m, 3H), 7.19-6.95 (m, 5H), 5.34 (m, 1H), 4.60 (m, 1H), 4.27 (m, 1H), 3.48-3.12 (m, 6H), 2.66 (m, 3H), 2.56 (m, 3H), 2.42-2.27 (m, 3H), 2.22-1.76 (m, 7H), 1.64 (m, 2H), 1.42 (m, 2H). ES-LCMS m/z 712.2 (M+H).


Example 881

4-chloro-N-(1,1-dimethylethyl)-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny)carbonyl]benzenesulfonamide




606

Example 881 was prepared according to figure below.



Synthesis of 881-2a

2-chloro-5-[[[(1,1-dimethylethyl)amino]sulfonyl]benzoic acid




Prepared from a mixture of 2-chloro-5-(chlorosulfonyl)benzoic acid (200 mg, 0.78 mmol, 1 equiv) *tert*-butyl amine (98 μ L, 0.94 mmol, 1.2 equiv) and DIEA (248 μ L, 1.38 mmol, 2 equiv) following the general procedure for 2,6-dichloro-3-[(methylamino)sulfonyl]benzoic acid 881-1b. The crude reaction mixture was carried on without further purification.

ES-LCMS m/z 315.2 ($M+Na$)

Synthesis of 881

4-chloro-N-(1,1-dimethylethyl)-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]benzenesulfonamide

607



Prepared from a mixture of 2-chloro-5-[(1,1-dimethylethyl)amino]sulfonyl]benzoic acid


2b, 1-(8-{2-[4-(3-fluorophenyl)-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (100 mg, 0.16 mmol, 1 equiv), DIEA (117 μ L, 0.66 mmol, 4 equiv) and HATU (62 mg, 0.16 mmol, 1 equiv) following the general procedure for 2,4-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]-N-methylbenzenesulfonamide example 880. The crude product was purified by column chromatography on silica gel eluting with 10% 2M NH_3 in methanol in ethyl acetate to afford 4-chloro-N-(1,1-dimethylethyl)-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]benzenesulfonamide as a white solid (40.3 mg, 35% yield).

^1H NMR (300 MHz, CDCl_3) δ 7.89-7.80 (m, 1H), 7.71-7.64 (m, 1H), 7.55-7.48 (m, 1H), 7.38-7.26 (m, 3H), 7.19-6.94 (m, 6H), 4.92-4.54 (m, 2H), 4.23 (m, 1H), 3.47-3.04 (m, 6H), 2.56 (m, 3H), 2.54-1.34 (m, 14H), 1.24 (m, 9H). ES-LCMS m/z 720.2 ($\text{M}+\text{H}$).


Example 882

N-(1,1-dimethylethyl)-2,4-difluoro-5-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]benzenesulfonamide

608




Prepared according to figure below.



Synthesis of 882-3a

5-[[[(1,1-dimethylethyl)amino]sulfonyl]-2,4-difluorobenzoic acid




Prepared from a mixture of 5-(chlorosulfonyl)-2,4-difluorobenzoic acid (200 mg, 0.78 mmol, 1 equiv), *tert*-butyl amine (98 μ L, 0.94 mmol, 1.2 equiv) and DIEA (280 μ L, 1.56 mmol, 2 equiv) following the general procedure for 2,6-

dichloro-3-[(methylamino)sulfonyl]benzoic acid 880-1b. The crude reaction mixture was carried on without further purification.

ES-LCMS m/z 292.3 (M-H)

Synthesis of 882

N-(1,1-dimethylethyl)-2,4-difluoro-5-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]benzenesulfonamide



Prepared from a mixture of 5-[[[(1,1-dimethylethyl)amino]sulfonyl]-2,4-difluorobenzoic acid 882-3b 1-(8-{2-[4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (100mg, 0.16 mmol, 1 equiv), DIEA (117 μ L, 0.66 mmol, 4 equiv) and HATU (62 mg, 0.16 mmol, 1 equiv) following the general procedure for 2,4-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-N-methylbenzenesulfonamide 1. The crude product was purified by column chromatography on silica gel eluting with 10% 2M NH_3 in methanol in ethyl acetate to afford N-(1,1-dimethylethyl)-2,4-difluoro-5-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]benzenesulfonamide (example 882) as a white solid (46 mg, 40% yield).


^1H NMR (400 MHz, CDCl_3) δ 8.00 (m, 1H), 7.66 (m, 1H), 7.93-6.95 (m, 9H), 4.86 (m, 1H), 4.62 (m, 1H), 4.15 (m, 2H), 3.44-3.14 (m, 5H), 2.92 (m, 3H),

610


2.58-1.60 (m, 14H), 1.25 (m, 9H). HRMS m/z (M+H): Calcd for $C_{39}H_{46}F_3N_5O_3S$, 722.34; found 722.3352.

Example 883

4-chloro-N-(1,1-dimethylethyl)-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]benzenesulfonamide




Prepared according to figure below



Synthesis of 883-4a

2-chloro-5-[(1,1-dimethylethyl)amino]sulfonyl-4-fluorobenzoic acid

611




tert-Butyl amine (77 mL, 0.7 mol, 10 equiv) was added to 300 mL dioxane at 0 °C. Ice chips were added to the flask for several minutes before the addition of 2-chloro-5-(chlorosulfonyl)-4-fluorobenzoic acid (20 g, 73.24 mmol, 1 equiv). Both the internal and external temperature of the reaction was maintained at or below 0 °C for 2 h. The reaction was then concentrated half-way and acidified to pH 2 with 1N HCl. The product was extracted into EtOAc. The organics were dried over Na₂SO₄, filtered and concentrated down to give 2-chloro-5-[[1,1-dimethylethyl]amino]sulfonyl-4-fluorobenzoic acid 883-4a as a brown solid (21 g; 92% yield).

¹H NMR (400 MHz, DMSO) δ 8.23 (d, *J* = 7.8 Hz, 1H), 8.06 (broad s, 1H), 7.82 (d, *J* = 9.8 Hz, 1H). ES-LCMS *m/z* 308.2 (M-H)

Synthesis of 883

4-chloro-N-(1,1-dimethylethyl)-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]benzenesulfonamide




To a solution of 1-(8-{2-[4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (32.0 g, 61.6 mmol, 1 equiv) in dimethylformamide (300 mL) was added 2-chloro-5-[[1,1-dimethylethyl]amino]sulfonyl-4-fluorobenzoic acid 883-4b (21 g, 67.8 mmol, 1.1 equiv) and *N,N*-diisopropylethyl amine (44 mL, 0.25 mol, 4 equiv). After

stirring at RT for several min, O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluroniumhexafluorophosphate (23.4 g, 61.6 mmol, 1 equiv) was added and the reaction was stirred for 2 h. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with satd. aq. NaHCO₃, H₂O and satd. aq. NaCl, then dried over Na₂SO₄, filtered and concentrated. The residue was taken up in 200 mL MeOH and stirred with Amberjet 4400 OH Basic Ion Exchanger (60 g) for 1 h. The mixture was filtered and concentrated and the residue was purified by silica gel flash column chromatography in 20% 2M NH₃ in MeOH in EtOAc to afford 4-chloro-N-(1,1-dimethylethyl)-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]benzenesulfonamide (example 883) as a white solid (21g; 46% yield).


¹H NMR (400 MHz, CDCl₃) δ 8.00 (m, 1H), 7.86–7.76 (m, 2H), 7.49 (m, 1H), 7.44–7.35 (m, 2H), 7.23 (m, 2H), 7.15–7.04 (m, 3H), 4.55–4.45 (m, 1H), 3.98–3.86 (m, 1H), 3.42–3.35 (m, 1H), 3.25 (m, 2H), 3.05–2.96 (m, 1H), 2.45 (m, 3H), 2.39–2.32 (m, 2H), 2.23–1.99 (m, 2H), 1.92–1.72 (m, 11H), 1.60 (m, 2H), 1.12 (m, 9H). HRMS *m/z* (M+H) Calcd for C₃₉H₄₆ClF₂N₅O₃S, 738.30; Found, 738.30.

Example 884

2,4-dichloro-N-(1,1-dimethylethyl)-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]benzenesulfonamide




Example 884 was prepared according to figure below.



Synthesis of 884-5a

2,6-dichloro-3-[[[(1,1-dimethylethyl)amino]sulfonyl]benzoic acid




Prepared from a mixture of 2,6-dichloro-3-[[[(1,1-dimethylethyl)amino]sulfonyl]benzoic acid 884-5a (200mg, 0.69 mmol, 1 equiv), *tert*-butyl amine and DIEA (248 μL , 1.38 mmol, equiv) following the general procedure for 2,6-dichloro-3-[(methylamino)sulfonyl]benzoic acid 880-1b. The crude reaction mixture was carried on without further purification.

ES-LCMS m/z 327.4 (M+H)

Synthesis of 884

2,4-dichloro-N-(1,1-dimethylethyl)-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]benzenesulfonamide




Prepared from a mixture of 2,6-dichloro-3-[[[(1,1-dimethylethyl)amino]sulfonyl]benzoic acid 884-5a, 1-(8-{2-[4-(3-fluorophenyl)-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (100 mg, 0.16 mmol, 1equiv), DIEA (117 μ L, 0.66 mmol, 4 equiv) and HATU (62 mg, 0.16 mmol, 1 equiv) following the general procedure for 2,4-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]-N-methylbenzenesulfonamide (example 880). The crude product was purified by column chromatography on silica gel eluting with 10% 2M NH_3 in methanol in ethyl acetate to afford 2,4-dichloro-N-(1,1-dimethylethyl)-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]benzenesulfonamide 5 as a white solid (21 mg, 17% yield).

^1H NMR (400 MHz, CDCl_3) δ 8.08 (m, 1H), 7.66 (m, 1H), 7.47 (m, 1H), 7.39-7.26 (m, 3H), 7.20-6.95 (m, 5H), 4.98 (m, 1H), 4.61 (m, 1H), 4.27 (m, 1H), 3.71 (m, 1H), 3.51 – 3.07 (m, 7H), 2.57 (m, 3H), 2.47-1.37 (m, 11H), 1.23 (m, 9H). HRMS m/z ($\text{M}+\text{H}$) Calcd for $\text{C}_{39}\text{H}_{46}\text{Cl}_2\text{FN}_5\text{O}_3\text{S}$, 754.2761: Found, 754.2761.



615

Example 885

2,4-difluoro-5-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny)carbonyl]benzenesulfonic acid




Example was prepared according the figure below.



Synthesis of 885-6a


5-(chlorosulfonyl)-2,4-difluorobenzoic acid



A mixture of chlorosulfonic acid (200 mL) and 2,4-difluorobenzoic acid (40 g, 253 mmol, 1 equiv) was heated to 155 °C for 3 h. The reaction was cooled to RT and poured slowly over ice. The product was extracted into ether and the organics dried over MgSO₄, filtered and concentrated to give 5-(chlorosulfonyl)-2,4-difluorobenzoic acid **6a** as brown solid (61 g, 94% yield).

¹H NMR (400 MHz, CDCl₃) δ 8.98 (broad s, 1H), 8.72 (t, *J* = 7.6 Hz, 1H), 7.21 (t, *J* = 9.5 Hz, 1H). ES-LCMS *m/z* 255.3 (M-H)

Synthesis of 885-6b
2,4-difluoro-5-sulfobenzoic acid




Sodium borohydride (0.59 g, 15.6 mmol, 8 equiv) was added portionwise to a solution of 5-(chlorosulfonyl)-2,4-difluorobenzoic acid **885-6a** (0.5 g, 1.9 mmol, 1 equiv) in 10 mL THF at 0 °C. The reaction was stirred at this temperature for 1 h and then concentrated down and the residue acidified to pH 2 with 5N HCl. The precipitate was removed by filtration and the liquid concentrated down to provide 2,4-difluoro-5-sulfobenzoic acid **885-6b** as a white solid (433 mg, 100% yield)

¹H NMR (400 MHz, DMSO) δ 8.18 (t, *J* = 8.0 Hz, 1H), 7.52 (t, *J* = 10.2 Hz, 1H).

Synthesis of example 885
2,4-difluoro-5-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]benzenesulfonic acid

617



Prepared from a mixture of 2,4-difluoro-5-sulfobenzoic acid 885-6b(580 mg, 0.58 mmol, 2 equiv), 1-(8-{2-[4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (150 mg, 0.29 mmol, 1 equiv), DIEA (260 μ L, 1.45 mmol, 5 equiv) and HATU (110 mg, 0.29 mmol, 1 equiv) following the general procedure for 2,4-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-N-methylbenzenesulfonamid, example 880. The crude product was purified by prep HPLC (HPLC Method C) to afford 2,4-difluoro-5-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]benzenesulfonic acid (example 885) as a white solid (40 mg, 22% yield).


^1H NMR (400 MHz, CDCl_3) δ 7.64 (m, 1H), 7.53 (m, 1H), 7.47-7.40 (m, 2H), 7.27-7.03 (m, 6H), 4.88 (m, 1H), 3.88-3.05 (m, 4H), 2.64-2.34 (m, 14H), 2.22-1.80 (m, 8H). ES-LCMS m/z 651.3 (M+H).

HPLC Method C

Preparative High Pressure Liquid Chromatography data was acquired using a Waters LC-UV system. The system operates using a Waters Symmetry Shield RP18 3.9x150mm, 5 μ m column at 35mL/minute. The mobile phase consists of Water (0.1%NH₄OH) and MeOH. The gradient used starts a 0% MeOH: 90% Water (0.1%NH₄OH) and moves to 90% MeOH : 10% Water (0.1%NH₄OH) over 7 minutes. There is a one minute wash of the column using 100% MeOH for one minute, until eight minutes and then original conditions return at 8.1 minutes to 8.5

Example 886

4-fluoro-7-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-1,3-benzoxazol-2(3H)-one




Prepared from a mixture of 4-fluoro-2-oxo-2,3-dihydro-1,3-benzoxazole-7-carboxylic acid (9.8 mg, 0.05 mmol, 1 equiv), endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride (25 mg, 0.05 mmol, 1 equiv), DIEA (36 μ L, 0.2 mmol, 4 equiv) and HATU (19 mg, 0.05 mmol, 1 equiv) following the general procedure for 2,4-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny)carbonyl]-N-methylbenzenesulfonamide (example 880). The crude product was purified by prep HPLC (HPLC Method C) to provide 4-fluoro-7-[(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenyl-1-piperidiny)carbonyl]-1,3-benzoxazol-2(3H)-one as a white solid (5 mg, 17% yield).


NMR (400 MHz, CDCl_3) δ 7.51-7.34 (m, 1H), 7.26-7.22 (m, 1H), 7.16-7.07 (m, 4H), 4.53 (m, 1H), 3.94 (m, 1H), 3.5-3.1 (m, 6H), 2.54-2.05 (m, 12H), 1.96-1.59 (m, 6H). ES-LCMS m/z 608.17 (M+H).

Example 887

1-[1-(2,2-dimethylpropanoyl)-4-phenylpiperdin-4-yl]-2-[3-(2-methyl-1 H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethanol




Synthesis of 2-bromo-1-[1-(2,2-dimethylpropanoyl)-4-phenylpiperdin-4-yl]ethanone



To a suspension of 4-acetyl-4-phenyl piperidine hydrochloride (20.8mmol) in DCM (200ml) was added TEA (541.1mmol) and the mixture was stirred under an inert atmosphere for 10 minutes. Pivaloyl chloride (22.8mmol) was added and the mixture was stirred until HPLC analysis indicated that the reaction was complete. Water and EtOAc were added. The ethyl acetate layer was separated and washed with satd. NaHCO_3 , water, brine and dried (Na_2SO_4). Removal of solvent under vacuum gave the intermediate ketone, which was used directly in the next step. ^1H NMR (400 MHz, DMSO d_6) 7.21-7.40 (m, 5 H), 3.77-3.82 (dt, 2 H), 3.14-3.21 (t, 2 H), 2.45-2.51 (m, 2H), 2.31-2.41 (d, 2H), 1.20 (s, 2H), 1.14 (s, 9H). LCMS m/z (M+H) calcd: 287.48 obsd: 288.44. To a solution of 1-[1-(2,2-dimethylpropanoyl)-4-phenylpiperdin-4-yl]ethanone in MeOH (125ml) at 0° C. Br_2 was added (24.5mmol) dropwise over 10 minutes. The mixture was stirred 12 hrs. at room temperature under an inert atmosphere. H_2O (20ml) was added and the resulting mixture was stirred for


an additional 0.5 hr. Et₂O and water (250ml 1:1) were added, the organic layer was washed with water, satd. K₂CO₃ solution, dried (Na₂SO₄) and the solvent was removed *in-vacuo* to give **2** as a lightly colored powder (7g, 92%). HPLC: *rt*=5.26 min. This compound was used directly in the following step.

The synthesis of 1-{1-(2,2-dimethylpropanoyl)-4-phenylpiperdin-4-yl}-2-[3-(2-methyl-1 *H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone



To the amine IV in scheme III (3mmol) in Et₂O was added TEA (17.9mmol) and the reaction mixture was stirred under inert atmosphere for 1hr. Next, 2-bromo-1-[1-(2,2-dimethylpropanoyl)-4-phenylpiperdin-4-yl]ethanone (2.7mmol) in Et₂O (20ml) was added and the resulting mixture was stirred overnight. Benzene (50ml) and TEA (14.3mmol) were added to the reaction and the whole was heated to 90° C overnight. The reaction was cooled to room temperature and concentrated *in-vacuo*. The crude material in DCM was washed with brine, and water and then dried (Na₂SO₄). Concentration under vacuum gave 1-{1-(2,2-dimethylpropanoyl)-4-phenylpiperdin-4-yl}-2-[3-(2-methyl-1 *H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone, which was purified by silica gel chromatography (DCM: MeOH; 9.5: 0.5) to give (400mg, 30%) as a white powder. ¹H NMR (400 MHz, CDCl₃), 7.67 (d, 1H), 7.29-7.42 (m, 6H), 7.08-7.22 (m, 2H), 4.63-4.78 (m, 1H), 4.08-4.18 (m, 3H), 3.28-3.39 (m, 2H), 3.12-3.23 (m, 2H), 3.08-3.10 (s, 2H), 2.61 (s, 3H), 2.50 (m, 2H), 2.39-2.40 (m, 2H), 2.10 (s, 2H), 1.84-1.90 (m, 2H), 1.61 (s, 3H), 1.28 (s, 9H). LCMS *m/z* (M+H) calcd: 526.72, obsd: 527.45

The synthesis of 1-{1-(2,2-dimethylpropanoyl)-4-phenylpiperidin-4-yl}-2-[3-(2-methyl-1 *H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethanol




To a solution of 1-{1-(2,2-dimethylpropanoyl)-4-phenylpiperidin-4-yl}-2-[3-(2-methyl-1 *H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone (30mg) in MeOH (5ml) was added NaBH₄ (0.9mmol) and the reaction mixture was stirred overnight. Satd. NaHCO₃ was added and the product was extracted with DCM (3x). The organics were dried (Na₂SO₄). Removal of solvent under of vacuum gave the desired product 4 as a white solid. ¹H NMR (CDCl₃) 7.64-7.70 (m, 1H), 7.35-7.41 (m, 4H), 7.29-7.30 (m, 1H), 7.11 (m, 2H), 4.49-4.62 (m, 1H), 4.22-4.30 (s, 2H), 3.50-3.60 (dd, 1H), 3.34 (t, 1H), 3.15 (t, 1H), 2.90-2.77 (q, 2H), 2.51 (s, 3H), 2.34-2.44 (m, 3H), 2.22 (d, 1H), 2.1 (dd, 1H), 1.94 (m, 4H), 1.90 (m, 1H), 1.71-1.80 (m, 3H), 1.25 (s, 9H). HPLC (3.483 min, 100%)

HPLC : ZORBAX (2.1x50mm; 3.5micron), T=40°C; ACN/water+0.05%TFA; 0-to-95% over 8min.

Example 888

3-(4-(3-isopropylphenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazole-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)2,2-dimethyl-3-oxopropan-1-ol

622




This compound was prepared from 3-isopropyl phenylmagnesium bromide and 16a according to the procedure described in example 16. To a solution of 3-hydroxy-2,2-dimethylpropanoic acid (0.14mmol), DIEA (1.7mmol) and HATU (0.14mmol) in DMF was added 1-(8-{2-[4-(3-isopropylphenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole hydrochloride (0.13mmol) in the same solvent and stirring was continued overnight. The reaction mixture was diluted with EtOAc, and washed with NaHCO₃, water, and satd. brine and dried (Na₂SO₄). The solvent was removed *in-vacuo* and the crude material was purified by HPLC to 1 as a clear film. H NMR (400MHz, CDCl₃) 9.72 (s, 2H), 8.48 (s, 1H), 7.64 (d, 1H), 7.04-7.36 (m, 8H), 4.74 (t, 1H), 3.19-3.32 (m, 4H), 2.88-2.97 (m, 3H), 2.60 (s, 3H), 2.43-2.47 (d, 4H), 2.37 (s, 2H), 1.86-2.33 (m, 10H), 1.77 (d, 2H), 1.26-1.28 (d, 6H). LCMS *m/z* (M+H) calc: 556.79, obsd: 557.79.

Example 889

Preparation of


1-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-cyclobutanecarboxylic acid




1-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-cyclobutanecarboxylic acid was obtained from a solution of 1-(ethoxycarbonyl)cyclobutane carboxylic acid (0.031 g, 0.18 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzoimidazole dihydrochloride (0.075 g, 0.18 mmol), and HATU (0.067 g, 0.18 mmol) following the procedure outlined in example 5 to produce 1-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-cyclobutanecarboxylic acid.ethyl ester. The ester (0.100 g, 0.167 mmol), 5 N NaOH (10 ml) and ethanol (4 ml) was stirred at 90°C for 3 hrs. The reaction was evaporated to dryness and residue was suspend in water (10 ml) and neutralized with 1N HCl. The aqueous layer was extracted with ethyl acetate (3 x 10 ml). The organic layer was dried using magnesium sulfate and concentrated down to form the title compound as a white solid (0.078 g, 81%). ¹H NMR (400 MHz, CDCl₃), 7.70 (m, 1H), 7.32-7.16 (m, 4H), 7.04 (m, 1H), 6.97-6.92 (m, 2H), 4.74 (m, 1H), 4.24-3.99 (m, 4H), 3.44-3.40 (m, 1H), 3.30 (br, 2H), 3.19 (m, 1H), 3.10 (m, 1H), 2.77 (m, 1H), 2.59 (s, 3H), 2.44-2.28 (br, 4H) 2.10-2.00 (m, 4H), 1.91-1.78 (m, 8H), 1.66 (m, 2H). ES-LCMS *m/z* 573 (M+1).

Example 890Preparation of

N-[1-Ethyl-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl]-piperidine-1-carbonyl)-propyl]-2,2-dimethyl-propionamide




Prepared as outlined below.



Example 890: R = t-butyl


Example 891: R = methyl

Preparation of [1-Ethyl-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-carbamic acid tert-butyl ester



A mixture of 2-tert-Butoxycarbonylamino-2-ethyl-butylric acid (0.291 g, 1.35 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1H-enzoimidazole dihydrochloride (0.700 g, 1.35 mmol), and HATU (0.514 g, 1.35 mmol) following the procedure outlined in example 5. Obtained 0.712 g (80%) of an oil. ES-LCMS m/z 660(M+1).

Preparation of 2-Amino-2-ethyl-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1] oct-8-yl]-ethyl}-piperidin-1-yl)-butan-1-one



[1-Ethyl-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-carbamic acid tert-butyl ester was treated with 4N HCl (20ml) in dioxane and then solvent was removed in vacuo. Residue was dissolved in water neutralized and extracted with EtOAcX3 to yield 0.600 g (99%) of the deprotected amine product as an oil. ES-LCMS m/z 560(M+1).


Preparation of title example 890:

A solution of 2-Amino-2-ethyl-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1] oct-8-yl]-ethyl}-piperidin-1-yl)-butan-


1-one (0.100 g, 0.178 mmol), 2,2-Dimethyl-propionyl chloride (0.021 g, 0.178 mmol) and DIEA (0.069 g, 0.534 mmol) were stirred at room temperature in DCE (3 ml) for 2 hours. Solvent was removed and compound was purified by RP-HPLC to yield 0.065 g (57%). ¹H NMR (400 MHz, CDCl₃) 7.82 (s, 1H), 7.67 (m, 1H), 7.36 (m, 1H), 7.29 (m, 1H), 7.16 (m, 2H), 7.09 (m, 1H), 6.99 (m, 1H), 4.60 (m, 1H), 4.07 (br, 2H), 3.32-3.23 (m, 4H), 2.79 (m, 2H), 2.57 (s, 3H), 2.36 (m, 2H), 2.21 (m, 2H), 1.92 (m, 6H), 1.80 (m, 4H), 1.65 (m, 6H), 1.23 (s, 9H) 0.76 (br, 5H). ES-LCMS *m/z* 644(M+1).

Example 891

Preparation of N-[1-Ethyl-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-acetamide




A solution of 2-Amino-2-ethyl-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1] oct-8-yl]-ethyl}-piperidin-1-yl)-butan-1-one (0.100 g, 0.178 mmol), acetyl chloride (0.014 g, 0.178 mmol) and DIEA (0.069 g, 0.534 mmol) were stirred at room temperature in DCM (3 ml) for 2 hours. Solvent was removed and compound was purified by RP-HPLC to yield 0.072 g (67%). ¹H NMR (400 MHz, CDCl₃) 7.67 (m, 1H), 7.40-7.29 (m, 2H), 7.18 (m, 2H), 7.09 (m, 1H), 6.99 (m, 2H), 4.60 (m, 1H) 4.04 (br, 2H), 3.32-3.23 (m, 4H), 2.74 (m, 2H), 2.57(s, 3H), 2.36 (m, 2H), 2.20 (m, 2H), 2.01 (s, 3H), 1.92 (m, 6H), 1.82-1.63 9 (m, 10H), 0.78 (br, 5H). ES-LCMS *m/z* 602(M+1).

Example 892Preparation of 2,4-Difluoro-5-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-N-propyl-benzenesulfonamide

2,4-Difluoro-5-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-N-propyl-benzenesulfonamide (0.068 g, 53%) was obtained from a solution of 2,4-Difluoro-5-propylsulfamoyl-benzoic acid (ACID 34) (0.050 g, 0.18 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (0.075 g, 0.18 mmol), and HATU (0.067 g, 0.18 mmol) following the procedure outlined in example 5. ¹H NMR (400MHz, CDCl₃) 7.63 (m, 1H), 7.36-7.28 (m, 3H), 7.15 (m, 2H), 7.08 (m, 1H), 6.96 (m, 3H), 4.60 (m, 1H), 4.22 (m, 1H), 3.37 (m, 2H), 3.23 (m, 3H), 2.98 (m, 2H) 2.56 (s, 3H), 2.38 (m, 3H), 2.12 (m, 1H), 1.93- 1.82 (m, 11H), 1.62 (m, 2H), 1.51 (m, 2H), 0.89 (m, 3H). ES-LCMS *m/z* 708(M+1).


Example 893Preparation of 2,4-Difluoro-5-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-N-isopropyl-benzenesulfonamide



2,4-Difluoro-5-(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-N-isopropyl-benzenesulfonamide (0.071 g, 55%) was obtained from a solution of 2,4-Difluoro-5-isopropylsulfonyl-benzoic acid (ACID 35) (0.050 g, 0.18 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzoimidazole dihydrochloride (0.075 g, 0.18 mmol), and HATU (0.067 g, 0.18 mmol) following the procedure outlined in example 5. ¹H NMR (400MHz, CDCl₃) 7.96 (m, 1H), 7.66 (m, 1H), 7.36-7.29 (m, 2H), 7.17 (m, 2H), 7.08 (m, 1H), 6.98 (m, 3H), 4.91 (m, 1H), 4.61 (m, 1H), 4.23 (m, 1H), 3.54 (m, 1H), 3.37 (m, 1H), 3.25 (m, 3H), 2.56 (s, 3H), 2.41-2.28 (m, 3H), 2.14 (m, 1H), 1.96-1.74 (m, 10H), 1.63 (m, 2H), 1.12 (m, 6H). ES-LCMS *m/z* 708(M+1).

Example 894


Preparation of N-Cyclopropyl-2,4-difluoro-5-(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-benzenesulfonamide



N-Cyclopropyl-2,4-difluoro-5-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-benzenesulfonamide (0.081 g, 64%) was obtained from a solution of 5-Cyclopropylsulfamoyl-2,4-difluoro-benzoic acid (ACID 36) (0.050 g, 0.18 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1H-enzoimidazole dihydrochloride (0.075 g, 0.18 mmol), and HATU (0.067 g, 0.18 mmol) following the procedure outlined in example 5. ¹H NMR (400MHz, CDCl₃) 8.01 (m, 1H), 7.66 (m, 1H), 7.37-7.29 (m, 2H), 7.16 (m, 2H), 7.08-6.90 (m, 4H), 5.47 (m, 1H), 4.64 (m, 1H), 4.24 (m, 1H), 3.37 (m, 2H), 3.27-3.17 (m, 3H), 2.57 (s, 3H), 2.42-2.29 (m, 4H), 2.13 (m, 1H), 1.94-1.78 (m, 10 H), 1.65 (m, 2H), 0.65 (m, 4H). ES-LCMS *m/z* 706(M+1).

Example 895


Preparation of 2,4-Difluoro-5-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-benzenesulfonamide



2,4-Difluoro-5-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-benzenesulfonamide (0.059 g, 49%) was obtained from a solution of 2,4-Difluoro-5-sulfamoyl-benzoic acid (ACID 31) (0.043 g, 0.18 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo [3.2.1]oct-3-yl)-2-methyl-1H-enzoimidazole dihydrochloride (0.075 g, 0.18 mmol), and HATU (0.067 g, 0.18 mmol) following the procedure outlined in example 5. ¹H NMR (400MHz, CDCl₃) 7.98 (m, 1H), 7.66 (m, 1H), 7.37-7.29 (m, 2H), 7.18-6.97 (m, 6H), 5.35 (m, 1H), 4.61 (m, 1H), 4.20 (m, 1H), 3.38 (m, 2H), 3.25 (m, 3H), 2.56 (s, 3H), 2.44-2.27 (m, 3H), 2.14 (m, 1H), 1.96-1.79 (m, 10 H), 1.66 (m, 2H). ES-LCMS *m/z* 666(M+1).

Example 896


Preparation of 2,4-Difluoro-5-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-N-methyl-benzenesulfonamide



2,4-Difluoro-5-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-N-methyl-benzenesulfonamide (0.063 g, 51%) was obtained from a solution of 2,4-Difluoro-5-methylsulfonyl-benzoic acid (ACID 32) (0.045 g, 0.18 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo [3.2.1]oct-3-yl)-2-methyl-1H-benzoimidazole dihydrochloride (0.075 g, 0.18 mmol), and HATU (0.067 g, 0.18 mmol) following the procedure outlined in example 5. ¹H NMR (400MHz, CDCl₃) 7.98 (m, 1H), 7.68 (m, 1H), 7.36 (m, 1H), 7.29 (m, 1H), 7.19 (m, 2H), 7.09 (m, 1H), 6.99 (m, 3H), 4.82 (m, 1H), 4.63 (m, 1H), 4.23 (m, 1H), 3.39 (m, 2 H), 3.30 (m, 2H), 3.22 (m, 1H), 2.74 (s, 3H), 2.59 (s, 3H), 2.42 (m, 2H), 2.29 (m, 2H), 2.17 (m, 2H), 1.98-1.71 (m, 10H), 1.67 (m, 2H). ES-LCMS *m/z* 680(M+1).

Example 897


Preparation of N-Ethyl-2,4-difluoro-5-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-benzenesulfonamide



Preparation of N-Ethyl-2,4-difluoro-5-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-benzenesulfonamide (0.067 g, 54%) was obtained from a solution of 5-Ethylsulfamoyl-2,4-difluoro-benzoic acid (ACID 33) (0.047 g, 0.18 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo [3.2.1]oct-3-yl)-2-methyl-1H-benzoimidazole dihydrochloride (0.075 g, 0.18 mmol), and HATU (0.067 g, 0.18 mmol) following the procedure outlined in example 5. ¹H NMR (400MHz, CDCl₃) 7.98 (m, 1H), 7.68 (m, 1H), 7.39 (m, 1H), 7.31 (m, 1H), 7.18 (m, 2H), 7.09 (m, 1H), 6.98 (m, 3H), 4.81 (br, 2H), 4.20 (m, 1H), 3.38 (m, 4H), 3.21 (m, 1H), 3.16 (m, 2H), 2.61 (s, 3H), 2.44 (m, 2H), 2.31 (m, 1H), 2.19 (m, 1H), 2.02-1.61 (m, 12H), 1.16 (m, 3H). ES-LCMS *m/z* 694(M+1).

Example 898


Preparation of [1-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-carbamic acid tert-butyl ester



[1-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-carbamic acid tert-butyl ester(0.580 g, 66%) was obtained as an oil from 2-tert-Butoxycarbonylamino-butyric acid (0.298 g, 1.40 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzoimidazole dihydrochloride (0.725 g, 1.40 mmol) and HATU(0.590 g, 1.50 mmol) following the procedure outlined in example 5. ES-LCMS m/z 632(M+1).

Example 899

Preparation of 2,2,2-Trifluoro-N-[1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1] oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-acetamide




2,2,2-Trifluoro-N-[1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1] oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-acetamide was obtained from treating [1-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-carbamic acid tert-butyl ester(0.580 g, 0.92 mmol) with HCl as outlined in the procedure for example 890 to form 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-butan-1-one(0.488 g, 99%). 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo [3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-butan-1-one(0.049 g, 0.09 mmol, trifluoroaceticanhydride (0.019 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure


outlined in example 890 to give the title compound, 2,2,2-Trifluoro-N-[1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1] oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-acetamide(0.034 g, 60%) as an oil. ES-LCMS m/z 628(M+1).

Example 900

Preparation of 2-Chloro-N-[1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-acetamide




2-Chloro-N-[1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-acetamide was obtained from treating [1-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-carbamic acid tert-butyl ester(0.580 g, 0.92 mmol) with HCl as outlined in the procedure for example 890 to form 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-butan-1-one(0.488 g, 99%). 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo [3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-butan-1-one(0.049 g, 0.09 mmol, Chloro-acetyl chloride (0.010 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in example 890 to give the title compound, 2-Chloro-N-[1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-acetamide (0.024 g, 44%) as an oil. ES-LCMS m/z 608(M+1).

Example 901Preparation of N-[1-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-2,2-dimethyl-propionamide

N-[1-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-2,2-dimethyl-propionamide was obtained from treating [1-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-carbamic acid tert-butyl ester (0.580 g, 0.92 mmol) with HCl as outlined in the procedure for example 890 to form 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-butan-1-one (0.488 g, 99%). 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-butan-1-one (0.049 g, 0.09 mmol), 2,2-Dimethyl-propionyl chloride (0.011 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in example 890 to give the title compound, N-[1-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-2,2-dimethyl-propionamide (0.030 g, 54%) as an oil. ES-LCMS m/z 616(M+1).

Example 892Preparation of 2,2-Dichloro-N-[1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-acetamide




2,2-Dichloro-N-[1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-acetamide was obtained from treating [1-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-carbamic acid tert-butyl ester (0.580 g, 0.92 mmol) with HCl as outlined in the procedure for example 890 to form 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-butan-1-one (0.488 g, 99%). 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-butan-1-one (0.049 g, 0.09 mmol), Dichloro-acetyl chloride (0.013 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in example 890 to give the title compound, 2,2-Dichloro-N-[1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidine-1-carbonyl)-propyl]-acetamide (0.039 g, 67%) as an oil. ES-LCMS m/z 642(M+1).

Example 893

Preparation of [2-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-1,1-dimethyl-2-oxo-ethyl]-carbamic acid tert-butyl ester

637




2-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-1,1-dimethyl-2-oxo-ethyl]-carbamic acid tert-butyl ester

(0.610 g, 69%) was obtained as a oil from 2-tert-Butoxycarbonylamino-2-methyl-propionic acid (0.284 g, 1.40 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzoimidazole dihydrochloride(0.725 g, 1.40 mmol) and HATU(0.590 g, 1.50 mmol) following the procedure outlined in example 5. ES-LCMS m/z 632(M+1).

Example 904

Preparation of 2,2,2-Trifluoro-N-[2-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1] oct-8-yl]-ethyl}-piperidin-1-yl)-1,1-dimethyl-2-oxo-ethyl]-acetamide




2,2,2-Trifluoro-N-[2-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1] oct-8-yl]-ethyl}-piperidin-1-yl)-1,1-dimethyl-2-oxo-ethyl]-acetamide

was obtained from treating 2-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-1,1-

dimethyl-2-oxo-ethyl]-carbamic acid tert-butyl ester (0.610 g, 0.97 mmol) with HCl as outlined in the procedure in example 890 to form 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-2-methyl-propan-1-one (0.510 g, 99%). 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-2-methyl-propan-1-one (0.050 g, 0.09 mmol, trifluoroacetic anhydride (0.019 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in example 890 to give the title compound, 2,2,2-Trifluoro-N-[2-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-1,1-dimethyl-2-oxo-ethyl]-acetamide (0.024 g, 42%) as an oil. ES-LCMS m/z 628(M+1).

Example 905

Preparation of 2,2-Dichloro-N-[2-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-1,1-dimethyl-2-oxo-ethyl]-acetamide




2,2-Dichloro-N-[2-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-1,1-dimethyl-2-oxo-ethyl]-acetamide

was obtained from treating 2-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-1,1-dimethyl-2-oxo-ethyl]-carbamic acid tert-butyl ester (0.610 g, 0.97 mmol) with HCl as outlined in the procedure for example 890 to form 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2[3-(2-methyl-benzoimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-

yl]-ethyl)-piperidin-1-yl)-2-methyl-propan-1-one (0.510 g, 99%). 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2[3-(2-methyl-benzimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl)-piperidin-1-yl)-2-methyl-propan-1-one (0.050 g, 0.09 mmol), Dichloro-acetyl chloride (0.013 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in example 890 to give the title compound, 2,2-Dichloro-N-[2-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl)-piperidin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-acetamide (0.028 g, 48%) as an oil. ES-LCMS m/z 642(M+1).

Example 906

Preparation of 2-Chloro-N-[2-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl)-piperidin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-acetamide




2-Chloro-N-[2-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl)-piperidin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-acetamide was obtained from treating 2-(4-(3-Fluoro-phenyl)-4-{2-[3-(2-methyl-benzimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl)-piperidin-1-yl)-1,1-dimethyl-2-oxo-ethyl]-carbamic acid tert-butyl ester (0.610 g, 0.97 mmol) with HCl as outlined in the procedure for Example 890 to form 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2[3-(2-methyl-benzimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl)-piperidin-1-yl)-2-methyl-propan-1-one (0.510 g, 99%). 2-Amino-1-(4-(3-fluoro-phenyl)-4-{2[3-(2-methyl-benzimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl)-piperidin-1-yl)-2-methyl-propan-1-one (0.050 g, 0.09 mmol, Chloro-acetyl chloride (0.010 g, 0.09 mmol) and DIEA (0.034 g,

0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, 2-Chloro-N-[2-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzimidazol-1-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethyl}-piperidin-1-yl)-1,1-dimethyl-2-oxo-ethyl]-acetamide (0.027 g, 49%) as an oil. ES-LCMS m/z 608 (M+1).

Example 907


Preparation of 1,1-dimethylethyl {(1S)-1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl})-1-piperidinyl] carbonyl]-2-methylpropyl}carbamate



1,1-dimethylethyl {(1S)-1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl})-1-piperidinyl] carbonyl]-2-methylpropyl}carbamate (0.614 g, 68%) was obtained as a oil from *N*-{[(1,1-dimethylethyl)oxy]carbonyl}-L-valine (0.303 g, 1.40 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (0.725 g, 1.40 mmol) and HATU (0.590 g, 1.50 mmol) following the procedure outlined in example 5. ES-LCMS m/z 648(M+1).

Example 908A


Preparation of 2,2-dichloro-N-{(1S)-1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl})-1-piperidinyl] carbonyl]-2-methylpropyl}acetamide



2,2-dichloro-*N*-{[(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2-methylpropyl]acetamide was obtained from treating 1,1-dimethylethyl {[(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl) carbonyl]-2-methylpropyl]carbamate(0.614 g, 0.95 mmol) with HCl as outlined in the procedure for Example 890 to form {[(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl) carbonyl]-2-methylpropyl]amine (0.512 g, 99%). {[(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl) carbonyl]-2-methylpropyl]amine(0.050 g, 0.09 mmol), Dichloro-acetyl chloride(0.013 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, 2,2-dichloro-*N*-{[(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2-methylpropyl]acetamide(0.031 g, 53%) as an oil. ES-LCMS *m/z* 656 (*M*+1).

Example 908B

Preparation of 2-chloro-*N*-{[(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2-methylpropyl]acetamide




2-chloro-N-((1S)-1-((4-(3-fluorophenyl)-4-{2-((1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)ethyl)-1-piperidinyl)carbonyl]-2-methylpropyl)acetamide was obtained from treating 1,1-dimethylethyl ((1S)-1-((4-(3-fluorophenyl)-4-{2-((1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)ethyl)-1-piperidinyl) carbonyl]-2-methylpropyl)carbamate(0.614 g, 0.95 mmol) with HCl as outlined in the procedure for Example 890 to form ((1S)-1-((4-(3-fluorophenyl)-4-{2-((1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)ethyl)-1-piperidinyl) carbonyl]-2-methylpropyl)amine (0.512 g, 99%). ((1S)-1-((4-(3-fluorophenyl)-4-{2-((1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)ethyl)-1-piperidinyl) carbonyl]-2-methylpropyl)amine(0.050 g, 0.09 mmol), Chloro-acetyl chloride(0.011 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, 2-chloro-N-((1S)-1-((4-(3-fluorophenyl)-4-{2-((1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)ethyl)-1-piperidinyl)carbonyl]-2-methylpropyl)acetamide(0.037 g, 66%) as an oil. ES-LCMS m/z 622 (M+1).

Example 909

Preparation of 1,1-dimethylethyl (2S)-2-((4-(3-fluorophenyl)-4-{2-((1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)ethyl)-1-piperidinyl)carbonyl]-1-pyrrolidinecarboxylate


643



1,1-dimethylethyl (2S)-2-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]-1-pyrrolidinecarboxylate (0.645 g, 72%) was obtained as a oil from 1-[[[(1,1-dimethylethyl)oxy]carbonyl]-L-proline (0.301 g, 1.4 mmol), 1-(8-{2-[4-(3-Fluorophenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1H-enzoimidazole dihydrochloride (0.725 g, 1.40 mmol) and HATU (0.590 g, 1.50 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* 644(M+1).

Example 910

Preparation of 1-[(1R,5S)-8-(2-{4-(3-fluorophenyl)-1-[1-(trifluoroacetyl)-L-prolyl]-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole




1-[(1R,5S)-8-(2-{4-(3-fluorophenyl)-1-[1-(trifluoroacetyl)-L-prolyl]-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole was obtained from treating 1,1-dimethylethyl (2S)-2-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]-1-pyrrolidinecarboxylate (0.645 g, 1.01 mmol) with HCl

as outlined in the procedure for Example 890 to form 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)-1-*L*-prolyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (0.545 g, 99%). 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)-1-*L*-prolyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (0.050 g, 0.09 mmol), trifluoroacetic anhydride (0.019 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, 1-[(1*R*,5*S*)-8-(2-{4-(3-fluorophenyl)-1-[1-(trifluoroacetyl)-*L*-prolyl]-4-piperidinyl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole (0.021 g, 36%) as an oil. ES-LCMS *m/z* 640 (*M*+1).

Example 911

Preparation of 1-((1*R*,5*S*)-8-{2-[1-[1-(dichloroacetyl)-*L*-prolyl]-4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole




1-((1*R*,5*S*)-8-{2-[1-[1-(dichloroacetyl)-*L*-prolyl]-4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole was obtained from treating 1,1-dimethylethyl (2*S*)-2-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-1-pyrrolidinecarboxylate (0.645 g, 1.01 mmol) with HCl as outlined in the procedure for Example 890 to form 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)-1-*L*-prolyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (0.545 g, 99%). 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)-1-*L*-prolyl-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-

645


benzimidazole(0.050 g, 0.09 mmol), Dichloro-acetyl chloride(0.013 g, 0.09 mmol)and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, 1-((1*R*,5*S*)-8-{2-[1-[1-(dichloroacetyl)-L-prolyl]-4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (0.029 g, 49%) as an oil. ES-LCMS m/z 654 ($M+1$).

Example 912

Preparation of 1,1-dimethylethyl {1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidinyl)carbonyl]cyclopentyl}carbamate




1,1-dimethylethyl {1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidinyl)carbonyl]cyclopentyl}carbamate (0.627 g, 68%) was obtained as a oil from 1-([[(1,1 dimethylethyl)oxy]carbonyl]amino)cyclopentanecarboxylic acid (0.320 g, 1.4 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride(0.725 g, 1.40 mmol) and HATU(0.590 g, 1.50 mmol) following the procedure outlined in example 5. ES-LCMS m/z 658($M+1$).

Example 913Preparation of 2,2,2-trifluoro-N-{1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny]carbonyl]cyclopentyl}acetamide

2,2,2-trifluoro-N-{1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny]carbonyl]cyclopentyl}acetamide was obtained from treating 1,1-dimethylethyl {1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny]carbonyl]cyclopentyl}carbamate (0.627 g, 0.95 mmol) with HCl as outlined in the procedure for Example 890 to form 1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny]carbonyl]cyclopentanamine (0.528 g, 99%). 1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny]carbonyl]cyclopentanamine (0.050 g, 0.09 mmol), trifluoroacetic anhydride (0.019 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, 2,2,2-trifluoro-N-{1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny]carbonyl]cyclopentyl}acetamide (0.027 g, 46%) as an oil. ES-LCMS m/z 654 (M+1).

Example 914


Preparation of *N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]cyclopentyl}-2,2-dimethylpropanamide



N-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]cyclopentyl}-2,2-dimethylpropanamide was obtained from treating 1,1-dimethylethyl {1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]cyclopentyl}carbamate (0.627 g, 0.95 mmol) with HCl as outlined in the procedure for Example 890 to form 1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]cyclopentanamine (0.528 g, 99%). 1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]cyclopentanamine (0.050 g, 0.09 mmol), 2,2-Dimethylpropionyl chloride (0.011 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, *N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]cyclopentyl}-2,2-dimethylpropanamide (0.031 g, 54%) as an oil. ES-LCMS *m/z* 642 (*M*+1).

Example 915


Preparation of 1,1-dimethylethyl {(1S)-1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl}carbamate



1,1-dimethylethyl {(1S)-1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl}carbamate (0.591 g, 64%) was obtained as a oil from *N*-{[(1,1-dimethylethyl)oxy]carbonyl}-3-methyl-L-valine (0.320 g, 1.4 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1H-enzoimidazole dihydrochloride (0.725 g, 1.40 mmol) and HATU (0.590 g, 1.50 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* 660(M+1).

Example 916


Preparation of 2,2,2-trifluoro-*N*-{(1S)-1-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl}acetamide



2,2,2-trifluoro-*N*-{[(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl)-1-piperidinyl)carbonyl]-2,2-dimethylpropyl}acetamide was obtained from treating 1,1-dimethylethyl {[(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidinyl)carbonyl]-2,2-dimethylpropyl} carbamate (0.591 g, 0.90 mmol) with HCl as outlined in the procedure for Example 890 to form (2*S*)-1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidinyl)-3,3-dimethyl-1-oxo-2-butanamine (0.500 g, 99%). (2*S*)-1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidinyl)-3,3-dimethyl-1-oxo-2-butanamine (0.050 g, 0.09 mmol), trifluoroacetic anhydride (0.019 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, 2,2,2-trifluoro-*N*-{[(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl)-1-piperidinyl)carbonyl]-2,2-dimethylpropyl} acetamide (0.033 g, 56%) as an oil. ES-LCMS *m/z* 656 (*M*+1).

Example 917


Preparation of 2-chloro-*N*-{[(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidinyl)carbonyl]-2,2-dimethylpropyl}acetamide



2-chloro-*N*-{(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl} acetamide was obtained from treating 1,1-dimethylethyl {(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl} carbamate (0.591 g, 0.90 mmol) with HCl as outlined in the procedure for Example 890 to form (2*S*)-1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-3,3-dimethyl-1-oxo-2-butanamine (0.500 g, 99%). (2*S*)-1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-3,3-dimethyl-1-oxo-2-butanamine (0.050 g, 0.09 mmol), Chloroacetyl chloride (0.011 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, 2-chloro-*N*-{(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl} acetamide (0.038 g, 66%) as an oil. ES-LCMS *m/z* 636 (*M*+1).

Example 918


Preparation of 2,2-dichloro-*N*-{(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl}acetamide



2,2-dichloro-*N*-{(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl} acetamide was obtained from treating 1,1-dimethylethyl {(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl} carbamate, example 915, (0.591 g, 0.90 mmol) with HCl as outlined in the procedure for Example 890 to form (2*S*)-1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-3,3-dimethyl-1-oxo-2-butanamine (0.500 g, 99%). (2*S*)-1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-3,3-dimethyl-1-oxo-2-butanamine (0.050 g, 0.09 mmol), Dichloro-acetyl chloride (0.013 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, 2,2-dichloro-*N*-{(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl) carbonyl]-2,2-dimethylpropyl}acetamide (0.036 g, 60%) as an oil. ES-LCMS *m/z* 670 (M+1).

Example 919


Preparation of *N*-{(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl}-2,2-dimethylpropanamide



N-{(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl}-2,2-dimethylpropanamide was obtained from treating 1,1-dimethylethyl {(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl} carbamate, example 915, (0.591 g, 0.90 mmol) with HCl as outlined in the procedure for Example 890 to form (2*S*)-1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-3,3-dimethyl-1-oxo-2-butanamine (0.500 g, 99%). (2*S*)-1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-3,3-dimethyl-1-oxo-2-butanamine (0.050 g, 0.09 mmol), 2,2-Dimethylpropionyl chloride (0.011 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, *N*-{(1*S*)-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2,2-dimethylpropyl}-2,2-dimethylpropanamide (0.032 g, 55%) as an oil. ES-LCMS *m/z* 644 (*M*+1).

Example 920


Preparation of 1,1-dimethylethyl {1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]cyclohexyl}carbamate



1,1-dimethylethyl {1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]cyclohexyl}carbamate (0.598 g, 64%) was obtained as a oil from 1-(((1,1-dimethylethyl)oxy)carbonyl)amino)cyclohexanecarboxylic acid (0.320 g, 1.4 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-enzoimidazole dihydrochloride(0.725 g, 1.40 mmol) and HATU(0.590 g, 1.50 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* 672(*M*+1).

Example 921


Preparation of 1,1-dimethylethyl {1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-1,2-dimethylpropyl}carbamate



1,1-dimethylethyl {1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-1,2-dimethylpropyl} carbamate (0.623 g, 67%) was obtained as a oil from *N*-(((1,1-dimethylethyl)oxy)carbonyl)-3-methylisovaline (0.320 g, 1.4 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-enzoimidazole dihydrochloride(0.725 g, 1.40 mmol) and HATU(0.590 g, 1.50 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* 660(*M*+1).

Example 922


Preparation of 2,2,2-trifluoro-*N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]-1,2-dimethylpropyl}acetamide



2,2,2-trifluoro-*N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]-1,2-dimethylpropyl} acetamide was obtained from treating 1,1-dimethylethyl {1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]-1,2-dimethylpropyl} carbamate, example 915, (0.623 g, 0.94 mmol) with HCl as outlined in the procedure for Example 890 to form 1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny)-2,3-dimethyl-1-oxo-2-butanamine (0.524 g, 99%). 1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny)-2,3-dimethyl-1-oxo-2-butanamine (0.050 g, 0.09 mmol), trifluoroacetic anhydride (0.019 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, 2,2,2-trifluoro-*N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]-1,2-dimethylpropyl} acetamide (0.036 g, 61%) as an oil. ES-LCMS *m/z* 656 (*M*+1).

Example 923A


Preparation of 2-chloro-*N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny]carbonyl}-1,2-dimethylpropyl}acetamide



2-chloro-*N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny]carbonyl}-1,2-dimethylpropyl}acetamide was obtained from treating 1,1-dimethylethyl {1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny]carbonyl}-1,2-dimethylpropyl}carbamate, example 915, (0.623 g, 0.94 mmol) with HCl as outlined in the procedure for Example 890 to form 1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny)-2,3-dimethyl-1-oxo-2-butanamine (0.524 g, 99%). 1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny)-2,3-dimethyl-1-oxo-2-butanamine (0.050 g, 0.09 mmol), Chloro-acetyl chloride (0.011 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, 2-chloro-*N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny]carbonyl}-1,2-dimethylpropyl}acetamide (0.030 g, 52%) as an oil. ES-LCMS *m/z* 636 (*M*+1).

Example 923B


Preparation of *N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidiny]carbonyl}-1,2-dimethylpropyl)-2,2-dimethylpropanamide



N-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-1,2-dimethylpropyl}-2,2-dimethylpropanamide was obtained from treating 1,1-dimethylethyl {1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-1,2-dimethylpropyl}carbamate, example 915, (0.623 g, 0.94 mmol) with HCl as outlined in the procedure for Example 890 to form 1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-2,3-dimethyl-1-oxo-2-butanamine (0.524 g, 99%). 1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-2,3-dimethyl-1-oxo-2-butanamine (0.050 g, 0.09 mmol), 2,2-Dimethyl-propionyl chloride (0.011 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, *N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl) carbonyl]-1,2-dimethylpropyl}-2,2-dimethylpropanamide (0.039 g, 67%) as an oil. ES-LCMS *m/z* 643 (*M*+1).

Example 924

Preparation of 2,2-dichloro-*N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-1,2-dimethylpropyl}acetamide




2,2-dichloro-*N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-1,2-dimethylpropyl} acetamide was obtained from treating 1,1-dimethylethyl {1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-1,2-dimethylpropyl} carbamate, example 915, (0.623 g, 0.94 mmol) with HCl as outlined in the procedure for Example 890 to form 1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-2,3-dimethyl-1-oxo-2-butanamine (0.524 g, 99%). 1-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-2,3-dimethyl-1-oxo-2-butanamine (0.050 g, 0.09 mmol), Dichloro-acetyl chloride (0.013 g, 0.09 mmol) and DIEA (0.034 g, 0.534 mmol) were reacted following the procedure outlined in Example 890 to give the title compound, 2,2-dichloro-*N*-{1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl) carbonyl]-1,2-dimethylpropyl} acetamide (0.042 g, 69%) as an oil. ES-LCMS *m/z* 643 (*M*+1).

Example 925

Preparation of 3-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-2,2-dimethyl-3-oxopropanoic acid


658



3-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-2,2-dimethyl-3-oxopropanoic acid was obtained from 3-Ethoxy-2,2-dimethyl-3-oxopropanoic acid, Example 628, (0.029 g, 0.18 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (0.075 g, 0.18 mmol), and HATU (0.067 g, 0.18 mmol) following the procedure outlined in example 5 to produce ethyl 3-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-2,2-dimethyl-3-oxopropanoate. Ethyl 3-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-2,2-dimethyl-3-oxopropanoate (0.100 g, 0.170 mmol), 5 N NaOH (10 ml) and ethanol (4 ml) was stirred at 90°C for 3 hrs. The reaction was evaporated to dryness and residue was suspended in water (10 ml) and neutralized with 1N HCl. The aqueous layer was extracted with ethyl acetate (3 x 10 ml). The organic layer was dried using magnesium sulfate and concentrated down to form the title compound as a white solid (0.081 g, 85%). ES-LCMS *m/z* 561 (*M*+1).

Example 926


Preparation of 2,2,2-trichloro-*N*-{1-ethyl-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]propyl}acetamide



2-Amino-2-ethyl-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzimidazol-1-yl)-8-aza-bicyclo[3.2.1] oct-8-yl]-ethyl}-piperidin-1-yl)-butan-1-one (0.100 g, 0.178 mmol), trichloroacetyl chloride (0.032 g, 0.178 mmol) and DIEA (0.069 g, 0.534 mmol) as outlined in procedure for procedure for **Example 890** to give title compound, 2,2,2-trichloro-*N*-{1-ethyl-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidinyl]carbonyl]propyl}acetamide (0.068 g, 54%). ES-LCMS *m/z* 706 (*M*+1).

Example 927

Preparation of *N*-{1-ethyl-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidinyl]carbonyl]propyl}-2,2,2-trifluoroacetamide




660

2-Amino-2-ethyl-1-(4-(3-fluoro-phenyl)-4-{2-[3-(2-methyl-benzimidazol-1-yl)-8-aza-bicyclo[3.2.1] oct-8-yl]-ethyl}-piperidin-1-yl)-butan-1-one example 890 (0.100 g, 0.178 mmol), trifluoroacetic anhydride (0.038 g, 0.178 mmol) and DIEA (0.069 g, 0.534 mmol) as outlined in procedure for procedure for Example 890 to give title compound, *N*-{1-ethyl-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl) carbonyl]propyl}-2,2,2-trifluoroacetamide (0.061 g, 52%). ES-LCMS *m/z* 656 (*M*+1).

Example 928


Preparation of [3-(1-(2,2-dimethylpropanoyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-piperidinyl)phenyl]methanol





[3-(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-piperidinyl) phenyl]methanol dihydrochloride (0.100 g, 0.188 mmol), Dimethyl-propionyl chloride (0.024 g, 0.188 mmol) and DIEA (0.069 g, 0.534 mmol) were stirred at room temperature in DCM (3 ml) for 2 hours. Solvent was removed and compound was purified by RP-HPLC to give the title compound, [3-(1-(2,2-dimethylpropanoyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-piperidinyl)phenyl]methanol (0.069 g, 71%). ES-LCMS *m/z* 543 (*M*+1).

Example 929

Preparation of *N*-{2,5-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl] phenyl}-1,1,1-trifluoromethanesulfonamide




N-{2,5-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl] phenyl}-1,1,1-trifluoromethanesulfonamide was obtained through procedure outlined in scheme.

**Preparation of methyl 3-amino-2,5-dichlorobenzoate**


3-amino-2,5-dichlorobenzoic acid(5.00 g, 24.27 mmol) was stirred in methanol(30 ml) at room temperature. Sulfuric Acid(5 ml) was added dropwise. Reaction stirred for 3 hours and was then diluted with water(30 ml) and basified using sodium hydroxide. Mixture was extracted with ethyl acetate x 3. Solvent was removed to afford methyl 3-amino-2,5-dichlorobenzoate(4.20 g, 79%) as a solid.

Preparation of methyl 2,5-dichloro-3-[[trifluoromethyl]sulfonyl]amino}benzoate



methyl 3-amino-2,5-dichlorobenzoate(2.10 g, 9.55 mmol), DIEA(3.0 ml) were stirred in DCM(40 ml) at 0°C. Triflic anhydride(3.90 g, 14.31 mmol) was added dropwise while stirring at 0°C. After 2hrs at 0°C, reaction was allowed to warm to room temperature while stirring overnight. Quenched rxn with saturated NH₄Cl and washed with brine. Organic layer with dried to yield crude methyl 2,5-dichloro-3-[[trifluoromethyl] sulfonyl]amino}benzoate(4.0 g) which will be carried on.

Preparation of 2,5-dichloro-3-[[trifluoromethyl] sulfonyl]amino}benzoic acid hydrochloride



Crude methyl 2,5-dichloro-3-[[trifluoromethyl] sulfonyl]amino}benzoate(4.0 g) was dissolved in methanol(30 ml) and 4N NaOH(30 ml) was added while stirring at room temperature for 18 hrs. Removed solvent and added 4N HCl(10 ml). Stirred at room temperature for 4hours. Filtered off solid to give 2,5-dichloro-3-[[trifluoromethyl] sulfonyl] amino}benzoic acid hydrochloride in quantitative yield.


Preparation of example 929

N-[2,5-dichloro-3-[[4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl]-1,1,1-trifluoromethanesulfonamide (0.140 g, 47%) was obtained as a


oil from (0.320 g, 1.4 mmol), 2,5-dichloro-3-[[trifluoromethyl] sulfonyl] amino]benzoic acid hydrochloride(0.157 g, 0.46 mmol), 1-(8-{2-[4-(3-Fluorophenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1H-enzoimidazole dihydrochloride(0.200 g, 0.39 mmol) and HATU(0.150 g, 0.46 mmol) following the procedure outlined in example 5. ES-LCMS m/z 766(M+1).

Example 930

Preparation of *N*-{2,5-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl)-1-piperidinyl]carbonyl]phenyl} methanesulfonamide



Preparation of methyl 2,5-dichloro-3-[(methylsulfonyl)amino]benzoate



From common intermediate methyl 3-amino-2,5-dichlorobenzoate following the procedure outlined in scheme. Methyl 3-amino-2,5-dichlorobenzoate(2.10 g, 9.55 mmol), DIEA(3.0 ml) were stirred in DCM(40 ml) at 0°C methanesulfonyl chloride (2.18 g, 19.08 mmol) was added dropwise while stirring at 0°C. After 2hrs at 0°C, reaction was allowed to warm to room temperature while stirring overnight. Quenched rxn with saturated NH₄Cl and


washed with brine. Organic layer with dried to yeild crude methyl 2,5-dichloro-3-[(methylsulfonyl)amino]benzoate(3.10 g) which will be carried on. methyl 2,5-dichloro-3-[(methylsulfonyl)amino]benzoate(3.10 g) was treated with NaOH, methanol following procedure outlined in scheme to form 2,5-dichloro-3-[(methylsulfonyl)amino]benzoic acid hydrochloride (3.53 g).

Preparation of example 930

N-{2,5-dichloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo [3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl} methanesulfonamide (0.127 g, 45%) was obtained as a oil from 2,5-dichloro-3-[(methylsulfonyl)amino]benzoic acid hydrochloride (0.132 g, 0.46 mmol), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride(0.200 g, 0.39 mmol) and HATU(0.150 g, 0.46 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* 712(*M*+1).

Example 931

Preparation of 1,1,1-trifluoro-*N*-({4-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl)methyl)methanesulfonamide




By the procedure outlined in example 929, starting from 4-(aminomethyl)benzoic acid(2.00 g, 13.24 mmol) was treated with sulfuric acid to form methyl 4-(aminomethyl)benzoate(1.20 g, 55%). Methyl 4-

(aminomethyl)benzoate(0.600 g, 3.63 mmol) was treated with triflic anhydride(1.512 g, 4.92 mmol) in DCM(20 ml) to give crude methyl 4-(((trifluoromethyl)sulfonyl)amino)methyl benzoate(0.402 g, 37%). Methyl 4-(((trifluoromethyl) sulfonyl)amino)methyl benzoate(0.402 g, 1.35 mmol) was treated with NaOH and methanol to give 4-(((trifluoromethyl)sulfonyl)amino)methylbenzoic acid hydrochloride(0.380 g, 95%). The title compound, 1,1,1-trifluoro-*N*-({4-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny] carbonyl]phenyl)methyl) methanesulfonamide(0.145 g, 52%) was obtained as a oil from 4-(((trifluoromethyl)sulfonyl)amino)methylbenzoic acid hydrochloride (0.157 g, 0.46l), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzoimidazole dihydrochloride(0.200 g, 0.39 mmol) and HATU(0.150 g, 0.46 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* 712(*M*+1).

Example 932

Preparation of *N*-({4-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl)methyl) methanesulfonamide




By the procedure outlined in scheme example 929, starting from 4-(aminomethyl)benzoic acid (2.00 g, 13.24 mmol) was treated with sulfuric acid to form methyl 4-(aminomethyl)benzoate(1.20 g, 55%). Methyl 4-(aminomethyl)benzoate (0.600 g, 3.63 mmol) was treated with

methanesulfonyl chloride (0.832 g, 7.26 mmol) in DCM(20 ml) to give crude methyl 4-[[[(methanesulfonyl)amino] methyl]benzoate(0.398 g, 45%). Methyl 4-[[[(methanesulfonyl)amino]methyl]benzoate(0.398 g, 1.63 mmol) was treated with NaOH and methanol to give 4-[[[(methanesulfonyl)amino]methyl]benzoic acid hydrochloride(0.370 g, 98%). The title compound, *N*-({4-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidinyl)carbonyl]phenyl)methyl) methanesulfonamide (0.128 g, 50%) was obtained as a oil from 4-[[[(methanesulfonyl)amino]methyl]benzoic acid hydrochloride (0.132 g, 0.46l), 1-(8-{2-[4-(3-Fluoro-phenyl)-piperidin-4-yl]-ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride(0.200 g, 0.39 mmol) and HATU(0.150 g, 0.46 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* 658(*M*+1).

Example 933

Preparation of 2-chloro-*N*-ethyl-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide



Preparation of 2-chloro-3-[(ethylamino)sulfonyl]benzoic acid. To a solution of methyl 2-chloro-3-(chlorosulfonyl)benzoate (608 mg, 2.26 mmol) and K₂CO₃ (770 mg, 5.6 mmol) in 10 mL benzene was added ethylamine (5.6 mL, 11.2 mmol). Purification of the product provided methyl 2-chloro-3-


[(ethylamino)sulfonyl]benzoate (335 mg, 53%) as a solid. ^1H NMR (400 MHz, CDCl_3), δ 8.24 (dd, 1H, $J = 8.0, 1.7$ Hz), 7.90 (dd, 1H, $J = 7.8, 1.7$ Hz), 7.47 (t, 1H, $J = 7.8$ Hz), 5.14 (t, 1H, $J = 5.9$ Hz), 3.94 (s, 3H), 2.98 (qd, 2H, $J = 7.3, 6.0$ Hz), 1.09 (t, 3H, $J = 7.2$ Hz); ESI-MS 278 (M+H), 300 (M+Na). Methyl 2-chloro-3-[(ethylamino)sulfonyl]benzoate was hydrolyzed using aqueous NaOH to provide 2-chloro-3-[(ethylamino)sulfonyl]benzoic acid as a solid, which was used without further purification. ESI-MS 264 (M+H), 286 (M+Na).

2-chloro-*N*-ethyl-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide (282 mg, 83%) was obtained as a solid from 2-chloro-3-[(ethylamino)sulfonyl]benzoic acid (51 mg, 0.19 mmol), 1-[(1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole dihydrochloride (117 mg, 0.19 mmol) and HATU (80 mg, 0.21 mmol) following the procedure outlined in example 5. ^1H NMR (400 MHz, CDCl_3), δ 8.12 (m, 1 H), 7.64 (m, 1 H), 7.53-7.40 (m, 2 H), 7.38-7.25 (m, 2 H), 7.14 (m, 2 H), 7.05 (m, 1 H), 7.00-6.92 (m, 2 H), 5.80-5.35 (m, 2 H), 4.52 (m, 1 H), 4.20 (m, 1 H), 3.45-2.87 (m, 7 H), 2.52 (m, 3 H, rotamers), 2.40-1.60 (m, 15 H), 1.1 (m, 3H); ESI-MS 692 (M+H).

Example 934

Preparation of 2-chloro-*N*-cyclopropyl-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide

668




Preparation of 2-chloro-3-[(cyclopropylamino)sulfonyl]benzoic acid. To a solution of methyl 2-chloro-3-(chlorosulfonyl)benzoate (608 mg, 2.26 mmol) and K_2CO_3 (770 mg, 5.6 mmol) in 10 mL benzene was added cyclopropylamine (0.78 mL, 11.2 mmol). Purification of the product provided methyl 2-chloro-3-[(cyclopropylamino)sulfonyl]benzoate (355 mg, 54%) as a solid. 1H NMR (400 MHz, $CDCl_3$), δ 8.28 (dd, 1H, $J = 7.9, 1.7$ Hz), 7.90 (dd, 1H, $J = 7.8, 1.7$ Hz), 7.48 (t, 1H, $J = 7.8$ Hz), 5.63 (s, 1H), 3.93 (s, 3H), 2.17 (m, 1H), 0.65-0.58 (m, 2H), 0.57-0.50 (m, 2H); ESI-MS 290 ($M+H$), 312 ($M+Na$). Methyl 2-chloro-3-[(cyclopropylamino)sulfonyl]benzoate was hydrolyzed using aqueous NaOH to provide 2-chloro-3-[(cyclopropylamino)sulfonyl]benzoic acid as a solid, which was used without further purification. ESI-MS 276 ($M+H$), 298 ($M+Na$).

2-chloro-*N*-cyclopropyl-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]benzenesulfonamide (288 mg, 91%) was obtained as a solid from 2-chloro-3-[(cyclopropylamino)sulfonyl]benzoic acid (41 mg, 0.15 mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (90 mg, 0.15 mmol) and HATU (62 mg, 0.16 mmol) following the procedure outlined in example 5. 1H NMR (400 MHz, $CDCl_3$), δ 8.18 (m, 1H), 7.65 (m, 1H), 7.56-7.25 (m, 4H), 7.15 (m, 2H), 7.05 (m, 1H), 7.01-6.91 (m, 2H), 5.95-5.44 (m, 2H), 4.61 (m, 1H), 4.23 (m, 1H), 3.45-3.05 (m, 5H), 2.56 (s, 1.5H, rotamer), 2.54 (s, 1.5H, rotamer), 2.43-1.74 (m, 15H), 1.70-1.58 (m, 2H), 0.78 (m, 1H), 0.63-0.50 (m, 2H); ESI-MS 704 ($M+H$).

Example 935

Preparation of 1,1,1-trifluoro-*N*-[3-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxopropyl]methanesulfonamide



Preparation of 2,2-dimethyl-3-[[[(trifluoromethyl)sulfonyl]amino]propanoic acid.


To a -78°C solution of methyl 3-amino-2,2-dimethylpropanoate (318 mg, 2.4 mmol) and Et_3N (0.34 mL, 2.44 mmol) in 4 mL CH_2Cl_2 was added trifluoromethanesulfonic anhydride (0.81 mL, 4.84 mmol). The reaction was stirred for 4h below -40°C and quenched with saturated aqueous NaHCO_3 . The crude methyl 2,2-dimethyl-3-[[[(trifluoromethyl)sulfonyl]amino]propanoate was isolated and hydrolyzed using aqueous NaOH to provide 2,2-dimethyl-3-[[[(trifluoromethyl)sulfonyl]amino]propanoic acid which was used without further purification.

1,1,1-trifluoro-*N*-[3-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxopropyl]methanesulfonamide (41 mg, 44%) was obtained as a solid from 2,2-dimethyl-3-[[[(trifluoromethyl)sulfonyl]amino]propanoic acid (100 mg, 0.40 mmol), 1-[(1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (83 mg, 0.14 mmol) and HATU (75 mg, 0.20 mmol) following the procedure outlined in example 5. ^1H NMR (400 MHz, CDCl_3), δ 7.1-7.67 (m, 1H), 7.41-7.21 (m, 4H), 7.07 (m, 1H), 7.02-6.94 (m, 2H), 4.84 (q, 1H, $J = 9.5$ Hz), 3.94 (m, 2H),

3.45 (m, 2H), 3.21 (m, 5H), 2.62 (s, 3H), 2.54 (m, 2H), 2.20 (m, 2H), 2.14-1.95 (m, 6H), 1.87 (m, 2H), 1.81-1.71 (m, 4H), 1.33 (s, 6H); ESI-MS 678 (M+H).

Example 936

Preparation of *N*-{2-chloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}methanesulfonamide




Preparation of 2-chloro-3-[(methanesulfonyl)amino]benzoic acid. To a solution of methyl 3-amino-2-chlorobenzoate (517 mg, 2.79 mmol) and pyridine (0.25 mL, 3.06 mmol) in 8 mL CH₂Cl₂ was added methanesulfonylchloride (0.24 mL, 3.06 mmol). After washing with 1M HCl, methyl 2-chloro-3-[(methanesulfonyl)amino]benzoate was isolated as a solid in quantitative yield. ¹H NMR (400 MHz, CDCl₃), δ 7.77 (dd, 1H, J = 8.2, 1.6 Hz), 7.61 (dd, 1H, J = 7.9, 1.6 Hz), 7.33 (t, 1H, J = 7.9 Hz), 7.16 (s, 1H), 3.91 (s, 3H), 2.99 (s, 3H); ESI-MS 262 (M-H). Methyl 2-chloro-3-[(methanesulfonyl)amino]benzoate was hydrolyzed using aqueous NaOH to provide 2-chloro-3-[(methanesulfonyl)amino]benzoic acid as a solid, which was used without further purification. ESI-MS 248 (M-H).

N-{2-chloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}methanesulfonamide (18 mg, 20%) was obtained as a solid from 2-chloro-3-[(methanesulfonyl)amino]benzoic acid (49 mg, 0.20 mmol),

1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (83 mg, 0.14 mmol) and HATU (75 mg, 0.20 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃), δ 7.72-7.63 (m, 2H), 7.41-7.25 (m, 4H), 7.16 (m, 2H), 7.07 (m, 1H), 7.02-6.93 (m, 2H), 4.62 (m, 1H), 4.22 (m, 1H), 3.48-3.09 (m, 5H), 3.07 (2, 1.5H, rotamer), 3.04 (s, 1.5H, rotamer), 2.58-2.53 (m, 3H, rotamers), 2.45-2.24 (m, 3H), 2.18-1.61 (m, 15H); ESI-MS 678 (M+H).

Example 937

Preparation of *N*-{4-chloro-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)piperidin-1-yl)carbonyl]phenyl}-1,1,1-trifluoromethanesulfonamide




Preparation of 2-chloro-4-fluoro-5-[[[(trifluoromethyl)sulfonyl]amino]benzoic acid. To a -78°C solution of methyl 5-amino-2-chloro-4-fluorobenzoate (195 mg, 1.0 mmol) and Et₃N (0.13 mL, 1.0 mmol) in 2 mL CH₂Cl₂ was added trifluoromethanesulfonic anhydride (0.32 mL, 1.9 mmol). The reaction was stirred for 4h below -40°C and quenched with saturated aqueous NaHCO₃. The crude methyl 2-chloro-4-fluoro-5-[[[(trifluoromethyl)sulfonyl]amino]benzoate (ESI-MS 336 (M+H)) was isolated and hydrolyzed using aqueous NaOH to provide 2-chloro-4-fluoro-5-[[[(trifluoromethyl)sulfonyl]amino]benzoic acid (ESI-MS 320 (M-H)) which was used without further purification.

N-{4-chloro-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}-1,1,1-trifluoromethanesulfonamide (27 mg, 26%) was obtained as a solid from 2-chloro-4-fluoro-5-[(trifluoromethyl)sulfonyl]amino]benzoic acid (90 mg, 0.28 mmol), 1-[(1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole dihydrochloride (83 mg, 0.14 mmol) and HATU (75 mg, 0.20 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃),
 □ 7.68 (m, 1H), 7.58-7.46 (m, 1H), 7.38 (m, 1H), 7.31-7.19 (m, 3H), 7.14 (m, 1H), 7.08-6.93 (m, 3H), 5.06 (m, 1H), 4.12 (m, 1H), 3.89-3.63 (m, 2H), 3.48-3.08 (m, 4H), 2.77-2.33 (m, 7H), 2.30-1.76 (m, 12H); ESI-MS 750 (M+H).

Example 938

Preparation of *N*-{1-ethyl-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]propyl}methanesulfonamide




Preparation of 2-ethyl-2-[(methylsulfonyl)amino]butanoic acid. To a solution of 0 °C solution of diethylglycine (205 mg, 1.56 mmol) in 2mL 1M NaOH was added methanesulfonyl chloride (0.14 mL, 1.81 mmol) with periodic stirring and addition of another 2mL 1M NaOH. The reaction mixture was stirred for 1h at 0 °C, 4h at room temperature, and then acidified with 1M HCl and extracted into EtOAc to provide the crude 2-ethyl-2-

[(methylsulfonyl)amino]butanoic acid (37 mg, 11%) as a solid, which was used without further purification. ^1H NMR (400 MHz, CDCl_3), δ 5.19 (s, 1H), 3.06 (s, 3H), 2.14 (m, 2H), 1.92 (m, 2H), 0.96 (t, 6H, $J = 7.4$ Hz).

N-{1-ethyl-1-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]propyl}methanesulfonamide (69 mg, 79%) was obtained as a solid from 2-ethyl-2-[(methylsulfonyl)amino]butanoic acid (37 mg, 0.18 mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (83 mg, 0.14 mmol) and HATU (75 mg, 0.20 mmol) following the procedure outlined in example 5. ^1H NMR (400 MHz, CDCl_3), δ 7.65-7.62 (m, 1H), 7.39-7.30 (m, 1H), 7.28 (m, 1H), 7.19-7.11 (m, 2H), 7.06 (m, 1H), 7.01-6.91 (m, 2H), 6.35 (s, 0.3H, rotamer), 6.28 (s, 0.7H, rotamer), 4.75 (br. s, 1H), 4.07-3.96 (m, 2H), 3.39-3.25 (m, 4H), 2.98 (s, 2H, rotamer), 2.97 (s, 1H, rotamer), 2.57 (s, 3H), 2.48-2.38 (m, 2H), 2.31 (m, 2H), 2.24-2.15 (m, 2H), 2.01-1.91 (m, 4H), 1.90-1.74 (m, 8H), 1.74-1.63 (m, 2H), 0.96-0.85 (m, 6H); ESI-MS 638 ($M+H$).

Example 939

Preparation of *N*-{4-chloro-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}methanesulfonamide




Preparation of 2-chloro-4-fluoro-5-[(methylsulfonyl)amino]benzoic acid. To a solution of methyl 5-amino-2-chloro-4-fluorobenzoate (152 mg, 0.75 mmol) and pyridine (0.07 mL, 0.82 mmol) in 3 mL CH₂Cl₂ was added methanesulfonyl chloride (0.06 mL, 0.82 mmol). After 3 days at room temperature, the reaction mixture was washed with saturated aqueous NaHCO₃ and filtered through a silica plug to provide methyl 2-chloro-4-fluoro-5-[(methylsulfonyl)amino]benzoate (96 mg, 44%) as a solid (ESI-MS 280 (M-H)), which was hydrolyzed using aqueous NaOH to provide 2-chloro-4-fluoro-5-[(methylsulfonyl)amino]benzoic acid (ESI-MS 266 (M-H)), which was used without further purification.

N-{4-chloro-2-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}methanesulfonamide (15.9 mg, 7%) was obtained as a solid from 2-chloro-4-fluoro-5-[(methylsulfonyl)amino]benzoic acid (91 mg, 0.34 mmol), 1-[(1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole dihydrochloride (210 mg, 0.34 mmol) and HATU (194 mg, 0.51 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃), δ 7.66 (m, 1H), 7.55 (m, 0.5H, rotamer), 7.42-7.32 (m, 1.5H, rotamer), 7.31-7.27 (m, 1H), 7.25-7.11 (m, 3H), 7.07 (m, 1H), 7.02-6.93 (m, 2H), 4.65 (br. s, 1H), 4.29-4.11 (m, 1H), 3.47-3.11 (m, 5H), 3.08 (s, 1.5H, rotamer), 3.05 (s, 1.5H, rotamer), 2.56 (s, 3H), 2.46-2.35 (m, 2H), 2.33-2.24 (m, 1H), 2.18-2.10 (m, 1H), 2.00-1.73 (m, 10H), 1.67 (m, 2H); ESI-MS 696 (M+H).

Example 940

Preparation of *N*-[3-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxopropyl]propane-2-sulfonamide

675




Preparation of 3-[(isopropylsulfonyl)amino]-2,2-dimethylpropanoic acid. To a solution of methyl 3-amino-2,2-dimethylpropanoate (200 mg, 1.53 mmol) and Et₃N (0.64 mL, 4.59 mmol) in 2 mL CH₂Cl₂ was added isopropylsulfonyl chloride (0.34 mL, 3.05 mmol). The reaction was stirred for 24h, quenched by the addition of saturated aqueous NaHCO₃, extracted with CHCl₃, and chromatographed (1:1 hex:EtOAc) to provide methyl 3-[(isopropylsulfonyl)amino]-2,2-dimethylpropanoate (77 mg, 21%) as a solid. ¹H NMR (400 MHz, CDCl₃), 4.78 (t, 1H, J = 6.6 Hz), 3.68 (s, 3H), 3.20-3.11 (m, 3H), 1.36 (d, 6H, J = 6.9 Hz), 1.23 (s, 6H). Methyl 3-[(isopropylsulfonyl)amino]-2,2-dimethylpropanoate was hydrolyzed using aqueous NaOH to provide 3-[(isopropylsulfonyl)amino]-2,2-dimethylpropanoic acid, which was used without further purification.

N-[3-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxopropyl]propane-2-sulfonamide (130mg, 74%) was obtained as a solid from 3-[(isopropylsulfonyl)amino]-2,2-dimethylpropanoic acid (60 mg, 0.27 mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (164 mg, 0.27 mmol) and HATU (154 mg, 0.41 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃), δ 7.68-7.64 (m, 1H), 7.36 (m, 1H), 7.29 (m, 1H), 7.16 (m, 2H), 7.08 (m, 1H), 7.00 (m, 1H), 6.96 (m, 1H), 5.36 (t, 1H, J = 6.6 Hz), 4.65 (br. s, 1H), 3.93 (m, 2H), 3.33-3.20 (m, 4H), 3.15 (m, 1H), 3.10 (m, 2H), 2.58 (s, 3H), 2.40 (m, 2H), 2.19 (m, 2H), 2.00-1.73 (m, 10H), 1.67 (m, 2H), 1.39 (s, 3H), 1.37 (s, 3H), 1.33 (s, 6H); ESI-MS 652 (M+H).

Example 941

Preparation of *N*-{2,4-difluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}methanesulfonamide




Preparation of 2,4-difluoro-5-[(methanesulfonyl)amino]benzoic acid. To a solution of methyl 5-amino-2,4-difluorobenzoate (252 mg, 1.35 mmol) and pyridine (0.13 mL, 1.61 mmol) in 5 mL CH₂Cl₂ was added methanesulfonyl chloride (0.12 mL, 1.48 mmol). After 24h at room temperature, the reaction mixture was washed with saturated aqueous NaHCO₃ and extracted with CHCl₃ to provide crude methyl 2, 4-difluoro-5-[(methanesulfonyl)amino]benzoate as a solid (ESI-MS 264 (M-H)), which was hydrolyzed using aqueous NaOH to provide 2,4-difluoro-5-[(methanesulfonyl)amino]benzoic acid (ESI-MS 250 (M-H)), which was used without further purification.

N-{2,4-difluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}methanesulfonamide (7.0 mg, 13%) was obtained as a solid from 2,4-difluoro-5-[(methanesulfonyl)amino]benzoic acid (20 mg, 0.08 mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (48 mg, 0.08 mmol) and HATU (45 mg, 0.12 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃), δ 7.73-7.68 (m, 1H), 7.60 (s, 1H), 7.41 (m, 1H), 7.25-7.15 (m, 3H), 7.12-7.07 (m, 1H), 7.04-6.93 (m, 3H), 4.26-4.11 (m, 1H), 3.89-3.63 (m, 2H), 3.58-3.43 (m, 2H), 3.29-3.16 (m, 2H), 3.07

(s, 2H, rotamer), 3.02 (s, 1H, rotamer), 2.70 (s, 3H), 2.41-1.61 (m, 16H); ESI-MS 681 (M+H).

Example 942

Preparation of *N*-{2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}methanesulfonamide



Preparation of 2,6-difluoro-3-[(methylsulfonyl)amino]benzoic acid. To a solution of methyl 3-amino-2,6-difluorobenzoate (530 mg, 2.83 mmol) and pyridine (0.28 mL, 3.40 mmol) in 10 mL CH₂Cl₂ was added methanesulfonyl chloride (0.24 mL, 3.11 mmol). After 24h at room temperature, the reaction mixture was washed with saturated aqueous NaHCO₃ and extracted with CHCl₃ to provide crude methyl 2,6-difluoro-3-[(methylsulfonyl)amino]benzoate as a solid (ESI-MS 264 (M-H)), which was hydrolyzed using aqueous NaOH to provide 2,6-difluoro-3-[(methylsulfonyl)amino]benzoic acid (ESI-MS 250 (M-H)), which was used without further purification.

N-{2,4-difluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}methanesulfonamide (30.5 mg, 49%) was obtained as a solid from


2,6-difluoro-3-[(methylsulfonyl)amino]benzoic acid (26 mg, 0.10 mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-

yl)-2-methyl-1*H*-benzimidazole dihydrochloride (56 mg, 0.09 mmol) and HATU (53 mg, 0.14 mmol) following the procedure outlined in example 5.

¹H NMR (400 MHz, CDCl₃), δ 7.79 (m, 1H), 7.55 (m, 1H), 7.42 (m, 1H), 7.34-7.23 (m, 3H), 7.13 (m, 1H), 7.05-6.94 (m, 3H), 6.02 (br. s, 1H), 4.13 (m, 1H), 3.98-3.80 (m, 2H), 3.59-3.43 (m, 2H), 3.23 (m, 1H), 3.08 (s, 3H), 2.97-3.85 (m, 2H), 2.82 (s, 3H), 2.61-2.46 (m, 2H), 2.39-1.86 (m, 12H); ESI-MS 681 (M+H).

Example 943

Preparation of *N*-(2-chloro-4-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]piperidin-1-yl)carbonyl]phenyl)methanesulfonamide




Preparation of 4-chloro-2-fluoro-5-[(methanesulfonyl)amino]benzoic acid. To a solution of methyl 5-amino-4-chloro-2-fluorobenzoate (248 mg, 1.22 mmol) and pyridine (0.12 mL, 1.46 mmol) in 5 mL CH₂Cl₂ was added methanesulfonyl chloride (0.10 mL, 1.34 mmol). After 5 days at room temperature, the reaction mixture was washed with saturated aqueous NaHCO₃ and extracted with CHCl₃ to provide crude methyl 4-chloro-2-fluoro-5-[(methanesulfonyl)amino]benzoate as a solid (ESI-MS 280 (M-H)), which was hydrolyzed using aqueous NaOH to provide 4-chloro-2-fluoro-5-[(methanesulfonyl)amino]benzoic acid (ESI-MS 266 (M-H)), which was used without further purification.

N-{2-chloro-4-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]piperidin-1-yl)carbonyl]phenyl}methanesulfonamide (56 mg, 59%) was obtained as a solid from 4-chloro-2-fluoro-5-[(methylsulfonyl)amino]benzoic acid (43 mg, 0.16 mmol), 1-[(1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole dihydrochloride (83 mg, 0.13 mmol) and HATU (78 mg, 0.20 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃), δ 7.68-7.61 (m, 1H), 7.61 (br. s, 1H), 7.36 (m, 1H), 7.31-7.26 (m, 1H), 7.25-7.21 (m, 1H), 7.21-7.12 (m, 2H), 7.07 (m, 1H), 7.02-6.93 (m, 2H), 4.68 (br. s, 1H), 4.19 (m, 1H), 3.50-3.15 (m, 5H), 3.04 (s, 3H), 2.58 (s, 3H), 2.51-2.34 (m, 2H), 2.28 (m, 2H), 2.15 (m, 2H), 2.07-1.76 (m, 10H), 1.69 (m, 2H); ESI-MS 696 (M+H).

Example 944

Preparation of 1-[(1*R*,5*S*)-8-(2-{4-(3-fluorophenyl)-1-[3-(1*H*-1,2,4-triazol-1-yl)benzoyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole




1-[(1*R*,5*S*)-8-(2-{4-(3-fluorophenyl)-1-[3-(1*H*-1,2,4-triazol-1-yl)benzoyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole (89 mg, 47%) was obtained as a solid from 3-(1*H*-1,2,4-triazol-1-yl)benzoic acid (107 mg, 0.56 mmol), 1-[(1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole dihydrochloride (160 mg, 0.31 mmol) and HATU (176 mg, 0.46 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz,

CDCl₃), δ 8.58 (s, 1H), 8.11 (s, 1H), 7.77-7.72 (m, 2H), 7.67 (d, 1H, J = 7.9 Hz), 7.56 (t, 1H, J = 7.8 Hz), 7.43-7.24 (m, 3H), 7.17 (m, 2H), 7.09 (d, 1H, J = 7.7 Hz), 7.04-6.94 (m, 2H), 4.61 (m, 1H), 4.19 (m, 1H), 3.60 (m, 1H), 3.47-3.17 (m, 3H), 2.56 (s, 3H), 2.43-2.26 (m, 3H), 2.13 (m, 1H), 2.02-1.55 (m, 12H); ESI-MS 618 (M+H).

Example 945

Preparation of 2-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)propanoic acid




To a -78°C solution of benzyl 2-hydroxypropanoate (250 mg, 1.39 mmol) and 4A molecular sieves in 2 mL CH₂Cl₂ was added trifluoromethanesulfonic anhydride (0.33 mL, 1.97 mmol). After stirring for 10 min at this temperature, 2,6-lutidine (0.31 mL, 2.62 mmol) was added. After 15 min, diisopropylethylamine (0.46 mL, 2.62 mmol) was added and after another 15 min, a solution of 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (400 mg, 0.66 mmol) in 3 mL CH₂Cl₂ was added. The reaction mixture was stirred at -78°C , then allowed to warm to room temperature overnight, washed with saturated aqueous NaHCO₃, and purified by chromatography (3% (2M NH₃ / MeOH) in CHCl₃) to provide benzyl 2-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)propanoate (146 mg, 37%) as a solid. ¹H NMR (400 MHz, CDCl₃), δ 7.68

(m, 1H), 7.37-7.26 (m, 7H), 7.22-7.13 (m, 2H), 7.08 (m, 1H), 6.98 (m, 1H), 6.92 (m, 1H), 5.09 (s, 2H), 4.62 (m, 1H), 3.39-3.17 (m, 2H), 2.89-1.26 (m, 27H); ESI-MS 609 (M+H).

A solution of benzyl 2-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)propanoate (136 mg, 0.223 mmol) in 8mL MeOH was stirred for 3h under an atmospheric pressure of hydrogen and in the presence of catalytic 5% Pd/C. Filtration and evaporation afforded 2-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)propanoic acid (90.0 mg, 78%) as a solid. ¹H NMR (400 MHz, CDCl₃), δ 7.69 (m, 1H), 7.40 (m, 1H), 7.26-7.12 (m, 4H), 7.09-6.95 (m, 2H), 5.37 (m, 1H), 3.85-3.55 (m, 5H), 2.81-1.77 (18H), 2.62 (s, 3H), 1.61-1.41 (3H); ESI-MS 517 (M-H).

Example 946

Preparation of 2-cyclohexyl-2-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-*N*-methylacetamide



Preparation of cyclohexyl(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)acetic acid.

To a -78 °C solution of benzyl cyclohexyl(hydroxy)acetate (61 mg, 0.25 mmol) and 4A molecular sieves in 1.2 mL CH₂Cl₂ was added

trifluoromethanesulfonic anhydride (0.05 mL, 0.30 mmol). After stirring for 10 min at this temperature, 2,6-lutidine (0.06 mL, 0.49 mmol) was added. After 15 min, diisopropylethylamine (0.09 mL, 0.49 mmol) was added and after another 15 min, a solution of 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (153 mg, 0.30 mmol) in 1 mL CH₂Cl₂ was added. The reaction mixture was stirred at -78 °C, then allowed to warm to room temperature overnight, washed with saturated aqueous NaHCO₃, and purified by preparatory TLC using 5% MeOH in CHCl₃ to afford benzyl cyclohexyl(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)acetate (33 mg, 20%) as an oil. ¹H NMR (400 MHz, CDCl₃), δ 7.68 – 7.64 (m, 1H), 7.33-7.23 (m, 7H), 7.20-7.12 (m, 2H), 7.05 (m, 1H), 6.97 (m, 1H), 6.89 (m, 1H), 5.05 (AB_q, 2H, *J* = 12.3 Hz), 4.61 (m, 1H), 3.26-3.18 (m, 2H), 2.92 (d, 1H, *J* = 10.4 Hz), 2.70 (m, 1H), 2.64-2.50 (m, 2H), 2.57 (s, 3H), 2.46-2.30 (m, 3H), 2.12-0.81 (m, 25H); ESI-MS 677 (M+H).


A solution of benzyl cyclohexyl(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)acetate (23.8 mg, 0.035 mmol) in 3 mL MeOH was stirred for 3h under an atmospheric pressure of hydrogen and in the presence of catalytic 5% Pd/C. Filtration and evaporation afforded cyclohexyl(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)acetic acid (17.5 mg, 85%). ESI-MS 585 (M-H).

To a solution of cyclohexyl(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)acetic acid (22.0 mg, 0.037 mmol), methylamine (0.056 mL of a 2M solution in THF, 0.11 mmol), N-hydroxybenzotriazole (10.1 mg, 0.075 mmol) and N-methylmorpholine (0.10 mL, 0.094 mmol) in 1 mL DMF was added EDC (14 mg, 0.075 mmol). The reaction mixture was stirred for 24h, then diluted with 4:1 EtOAc:hex and washed with saturated aqueous NaHCO₃, dried (Na₂SO₄)

and chromatographed (5% (2M NH₃ / MeOH) in CHCl₃) to provide 2-cyclohexyl-2-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-*N*-methylacetamide (8.1 mg, 36%) as a solid. ¹H NMR (400 MHz, CDCl₃), δ 7.66 (m, 1H), 7.33-7.27 (m, 2H), 7.20-7.11 (m, 2H), 7.05 (m, 1H), 6.98 (m, 1H), 6.90 (m, 1H), 4.64 (m, 1H), 3.33-3.20 (m, 2H), 2.80 (d, 3H, *J* = 4.9 Hz), 2.59 (s, 3H), 2.47-0.79 (m, 27H); ESI-MS 600 (M+H).

Example 947

Preparation of 2-cyclohexyl-2-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)acetamide




To a solution of cyclohexyl(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)acetic acid (22.0 mg, 0.037 mmol), hydroxylamine (0.2 mL of a 28% solution in water, 3.3 mmol), *N*-hydroxybenzotriazole (10.1 mg, 0.075 mmol) and *N*-methylmorpholine (0.10 mL, 0.094 mmol) in 1 mL DMF was added EDC (14 mg, 0.075 mmol). The reaction mixture was stirred for 24h, then diluted with 4:1 EtOAc:hex and washed with saturated aqueous NaHCO₃, dried (Na₂SO₄) and chromatographed (5% (2M NH₃ / MeOH) in CHCl₃) to provide 2-cyclohexyl-2-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)acetamide

(7.7 mg, 35%) as a solid. ^1H NMR (400 MHz, CDCl_3), δ 7.66 (m, 1H), 7.34-7.27 (m, 2H), 7.20-7.12 (m, 2H), 7.06 (m, 1H), 6.99 (m, 1H), 6.90 (m, 1H), 4.61 (m, 1H), 3.27-3.19 (m, 2H), 2.73-2.62 (m, 2H), 2.58 (s, 3H), 2.47-0.78 (m, 27H); ESI-MS 589 (M+H)

Example 948

Preparation of 2-chloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-methylbenzenesulfonamide



Preparation of 2-chloro-3-[(methylamino)sulfonyl]benzoic acid. To a solution of

To a solution of methyl 2-chloro-3-(chlorosulfonyl)benzoate (608 mg, 2.26 mmol) and K_2CO_3 (770 mg, 5.6 mmol) in 10 mL benzene was added a 2M solution of methylamine in THF (5.6 mL, 11.2 mmol). Purification of the product (2:1 hex:EtOAc) provided methyl 2-chloro-3-


[(methylamino)sulfonyl]benzoate (430 mg, 72%) as a solid. ^1H NMR (400 MHz, CDCl_3), δ 8.23 (dd, 1H, $J = 7.9, 1.7$ Hz), 7.90 (dd, 1H, $J = 7.8, 1.7$ Hz), 7.48 (t, 1H, $J = 7.9$ Hz), 5.16 (q, 1H, $J = 5.2$ Hz), 3.94 (s, 3H), 2.62 (d, 3H, $J = 5.3$ Hz); ESI-MS 264 (M+H). Methyl 2-chloro-3-

[(methylamino)sulfonyl]benzoate was hydrolyzed using aqueous NaOH to provide 2-chloro-3-[(methylamino)sulfonyl]benzoic acid as a solid, which was used without further purification. ESI-MS 250 (M+H), 272 (M+Na).

2-chloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-*N*-methylbenzenesulfonamide (87 mg, 62%) was obtained as a solid from 2-chloro-3-[(methylamino)sulfonyl]benzoic acid (52 mg, 0.21 mmol), 1-[(1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (127 mg, 0.21 mmol) and HATU (87 mg, 0.23 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃), δ 8.40 (m, 1H), 7.62 (m, 1H), 7.53-7.28 (m, 4H), 7.13 (m, 2H), 7.04 (m, 1H), 6.99-6.90 (m, 2H), 5.92-5.59 (m, 2H), 4.60 (m, 1H), 4.2 (m, 1H), 3.42-3.03 (m, 6H), 2.63-2.58 (m, 3H, rotamers), 2.54 (s, 1.5H, rotamer), 2.52 (s, 1.5H, rotamer), 2.41-2.23 (m, 3H), 2.17-1.58 (m, 11H); ESI-MS 678 (M+H).

Example 949

Preparation of 3-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxopropan-1-ol




3-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxopropan-1-ol (63 mg, 88%) was obtained as a solid from 3-hydroxy-2,2-dimethylpropanoic acid (23 mg, 0.20 mmol), 1-[(1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (80 mg, 0.13 mmol) and HATU (75 mg, 0.20 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃), δ 7.67-7.63

(m, 1H), 7.38-7.28 (m, 2H), 7.15 (m, 2H), 7.08 (m, 1H), 7.02-6.92 (m, 2H), 4.60 (m, 1H), 3.90 (m, 2H), 3.72 (m, 1H), 3.45 (m, 2H), 3.25 (m, 4H), 2.57 (s, 3H), 2.37 (m, 2H), 2.19 (m, 2H), 1.99-1.85 (m, 6H), 1.85-1.74 (m, 4H), 1.63 (m, 2H), 1.26 (s, 6H); ESI-MS 547 (M+H).

Example 950

Preparation of *N*-[3-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxopropyl]methanesulfonamide




Preparation of 2,2-dimethyl-3-[(methylsulfonyl)amino]propanoic acid. To a solution of methyl 3-amino-2,2-dimethylpropanoate (249 mg, 1.90 mmol) and Et₃N (0.80 mL, 5.70 mmol) in 2 mL CH₂Cl₂ was added methanesulfonyl chloride (0.29 mL, 3.80 mmol). The reaction was stirred for 2 days, quenched by the addition of saturated aqueous NaHCO₃, extracted with CHCl₃, and chromatographed (1:1 hex:EtOAc) to provide methyl 2,2-dimethyl-3-[(methylsulfonyl)amino]propanoate (124 mg, 31%) as a clear oil. ¹H NMR (400 MHz, CDCl₃), 4.95 (t, 1H, J = 6.8 Hz), 3.69 (s, 3H), 3.16 (d, 2H, J = 6.8 Hz), 2.95 (s, 3H), 1.24 (s, 6H). Methyl 2,2-dimethyl-3-[(methylsulfonyl)amino]propanoate was hydrolyzed using aqueous NaOH to provide 2,2-dimethyl-3-[(methylsulfonyl)amino]propanoic acid, which was used without further purification. ¹H NMR (400 MHz, CDCl₃), □ 10.28 (br. s, 1H), 5.56 (br. s, 1H), 3.14 (s, 2H), 2.94 (s, 3H), 1.25 (s, 6H).

N-[3-(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxopropyl]methanesulfonamide (41 mg, 48%) was obtained as a solid from 2,2-dimethyl-3-[(methylsulfonyl)amino]propanoic acid (38 mg, 0.20 mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (83 mg, 0.14 mmol) and HATU (75 mg, 0.20 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃), δ 7.63 (m, 1H), 7.34 (m, 1H), 7.28 (m, 1H), 7.14 (m, 2H), 7.06 (m, 1H), 6.99 (m, 1H), 6.94 (m, 1H), 5.52 (t, 1H, *J* = 6.8 Hz), 4.63 (m, 1H), 3.89 (m, 2H), 3.24 (m, 4H), 3.08 (d, 2H, *J* = 6.8 Hz), 2.93 (s, 3H), 2.56 (s, 3H), 2.37 (m, 2H), 2.18 (m, 2H), 1.92 (m, 6H), 1.78 (m, 4H), 1.64 (m, 2H), 1.32 (s, 6H); ESI-MS 624 (M+H).

Example 951

Preparation of *N*-[2,6-dichloro-4-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl]-1,1,1-trifluoromethanesulfonamide




N-[2,6-dichloro-4-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl]-1,1,1-trifluoromethanesulfonamide (63 mg, 60%) was obtained as an oil from 3,5-dichloro-4-[[[(trifluoromethyl)sulfonyl]amino]benzoic acid (70 mg, 0.21 mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole


dihydrochloride (83 mg, 0.14 mmol) and HATU (75 mg, 0.20 mmol) following the procedure outlined in example 5. ^1H NMR (400 MHz, CDCl_3), δ 7.68-7.64 (m, 1H), 7.37-7.25 (m, 4H), 7.18 (m, 2H), 7.08 (m, 1H), 7.01-6.90 (m, 2H), 5.17 (m, 1H), 4.02 (m, 1H), 3.52 (m, 1H), 3.30 (m, 2H), 2.64 (s, 3H), 2.56 (m, 2H), 2.23-1.69 (m, 13H); ESI-MS 766 (M+H).

Example 952

Preparation of *N*-{2-chloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}-1,1,1-trifluoromethanesulfonamide




N-{2-chloro-3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}-1,1,1-trifluoromethanesulfonamide (12 mg, 12%) was obtained as a solid from 2-chloro-3-[(trifluoromethyl)sulfonyl]amino}benzoic acid (66 mg, 0.22 mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (83 mg, 0.14 mmol) and HATU (75 mg, 0.20 mmol) following the procedure outlined in example 5. ^1H NMR (400 MHz, CDCl_3), δ 7.70-7.64 (m, 1H), 7.58 (m, 1H), 7.42-7.28 (m, 2H), 7.25-6.92 (m, 5H), 6.88-6.74 (m, 2H), 5.00-4.70 (m, 1H), 4.32-4.00 (m, 1H), 3.75-3.00 (m, 5H), 2.58 (s, 3H), 2.32-1.20 (m, 17H); ESI-MS 732 (M+H).

Example 953Preparation of 1-((1*R*,5*S*)-8-{2-[1-(2-chloro-4-fluoro-5-nitrobenzoyl)-4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole

1-((1*R*,5*S*)-8-{2-[1-(2-chloro-4-fluoro-5-nitrobenzoyl)-4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (14 mg, 16%) was obtained as an oil from 2-chloro-4-fluoro-5-nitrobenzoic acid (39 mg, 0.18 mmol), 1-((1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (83 mg, 0.14 mmol) and HATU (75 mg, 0.20 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃), δ 7.66 (m, 1H), 7.43-7.27 (m, 3H), 7.16 (m, 2H), 7.07 (m, 1H), 7.03-6.93 (m, 3H), 4.62 (m, 1H), 4.24 (m, 1H), 3.46-3.07 (m, 6H), 2.57 (s, 3H), 2.44-1.59 (m, 15H); ESI-MS 648 (M+H).

Example 954Preparation of *N*-{2,6-dichloro-4-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}methanesulfonamide

690










N-[2,6-dichloro-4-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl]methanesulfonamide (28 mg, 28%) was obtained as a solid from 3,5-dichloro-4-[(methanesulfonyl)amino]benzoic acid (59 mg, 0.21 mmol), 1-[(1*R*,5*S*)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole dihydrochloride (83 mg, 0.14 mmol) and HATU (75 mg, 0.20 mmol) following the procedure outlined in example 5. ¹H NMR (400 MHz, CDCl₃), δ 7.62 (m, 1H), 7.37-7.22 (m, 3H), 7.13 (m, 2H), 7.05 (m, 1H), 7.01-6.88 (m, 3H), 4.58 (m, 1H), 4.12 (m, 1H), 3.55-3.22 (m, 5H), 3.21 (m, 3H, rotamers), 2.53 (m, 3H, rotamers), 2.41-1.56 (m, 15H); ESI-MS 712 (M+H).








Additional examples of a the formula below were generated by coupling acids listed in the table using method A in example 5.

Example	% Yield	Acid	Method used	Observed mass (M+1)
958			A	556








691

959	47	 <chem>Cc1cc(Cl)nn1C(=O)O</chem>	A	572
960	53	 <chem>OCC1=NC2=CC=C(C(=O)O)C=C2N1</chem>	A	603
961	45	 <chem>CC1(C)C(=O)N(C1)CC(=O)O</chem>	A	596
962	28	 <chem>Cc1cc(=O)nn1C(=O)O</chem>	A	554
963	57	 <chem>CC(=O)Nc1ccccn1</chem>	A	578
964	59	 <chem>Fc1ccc2nc(C(=O)O)ccc2c1</chem>	A	602
965	30	 <chem>C1SC(=O)NC1CC(=O)O</chem>	A	606








692

966	46		A	587
967	57		A	582
968	40		A	589
969	43		A	564
970	40		A	607
971	44		A	593
972	54		A	581








693

973	54		A	552
974	42		A	607
975	48		A	583
976	28		A	524
977	54		A	608
978	45		A	582
979	51		A	607








694

980	47		A	574
981	31		A	600
982	31		A	606
983	16		A	559
984	38		A	565
985	42		A	568
986	21		A	538








695

987	34	 <chem>OC(=O)c1cc(C(F)(F)F)cn1</chem>	A	602
988	40	 <chem>CCOC1=CN(C1OC)CC(=O)O</chem>	A	596
989	20	 <chem>OC(=O)c1nc2cc(Cl)nc2n1</chem>	A	608
990	55	 <chem>NC#CCCC1CCCCN1C(=O)O</chem>	A	593
991	46	 <chem>OC(=O)CC1CCCCC1=O</chem>	A	567
992	49	 <chem>CCOC(=O)C(C)C(=O)O</chem>	A	599
993	32	 <chem>OC(=O)c1ccc2ncnc2cc1C</chem>	A	599








696

994	45		A	593
995	16		A	607
996	44		A	605
997	40		A	603
998	20		A	516
999	34		A	577
1000	33		A	569

697


1001	29		A	569
1002	45		A	607
1003	43		A	568
1004	45		A	597
1005	42		A	603
1006	16		A	608
1007	18		A	581

698


1008	21		A	570
1009	34		A	576
1010	43		A	608
1011			A	768
1012			A	700
1013			A	768
1014			A	575

Example 958

4-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-1H-pyrazol-3-amine


**Example 959**

1-[(1R,5S)-8-(2-{1-[(3-chloro-5-methylisoxazol-4-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole


**Example 960**

{6-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1H-benzimidazol-2-yl}methanol

700


**Example 961**

3-methyl-1-[1-methyl-2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-2-oxoethyl]pyrrolidine-2,5-dione


**Example 962**

5-methyl-4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]isoxazol-3(2H)-one

701


**Example 963**

1-[1-methyl-2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-2-oxoethyl]pyridin-2(1H)-one


**Example 964**

6-fluoro-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]quinoline

702


**Example 965**

4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1,3-benzothiazol-2(3H)-one


**Example 966**

1-((1R,5S)-8-{2-[1-((3S,4S)-3,4-dimethoxy-(2S)-tetrahydrofuran-2-carbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole

703


Example 967

1-[(1R,5S)-8-(2-{1-[(3-methoxy-4-methylisoxazol-5-yl)acetyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole


Example 968

4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1,3-dihydro-2H-benzimidazol-2-one

704


**Example 969**

2-methyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyridin-4-ol


**Example 970**

1-[(1R,5S)-8-(2-{1-[4-(2-methoxyethoxy)benzoyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole

705


**Example 971**

3-{4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-2-oxopyrrolidin-1-yl}propanenitrile


**Example 972**

1-((1R,5S)-8-{2-[1-(2-cyclohexyl-2-methylpropanoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole

706


**Example 973**

1-[(1R,5S)-8-(2-{1-[(2,4-dimethyl-1,3-oxazol-5-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole


**Example 974**

6-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one

707


**Example 975**

1-[(1R,5S)-8-(2-{1-[(5-chloro-2-methylpyrimidin-4-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole


**Example 976**

2-methyl-1-[(1R,5S)-8-{2-[1-(1,3-oxazol-4-ylcarbonyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole

708


**Example 977**

3-methoxy-1-[1-methyl-2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-2-oxoethyl]pyridin-2(1H)-one


**Example 978**

2-methyl-1-[(1R,5S)-8-(2-{4-phenyl-1-[(2-propyl-1,3-thiazol-5-yl)carbonyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole

709


**Example 979**

N-[1-methyl-3-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-3-oxopropyl]-1H-pyrrole-2-carboxamide


**Example 980**

4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-2,1-benzisoxazole

710


**Example 981**

8-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]quinolin-2(1H)-one


**Example 982**

N-{3-hydroxy-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}acetamide

711


Example 983

2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]nicotinonitrile


Example 984

1-[(1R,5S)-8-(2-{1-[(1-ethyl-5-methyl-1H-pyrazol-3-yl)carbonyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole

712


**Example 985**

2-methyl-1-[(1R,5S)-8-(2-{1-[oxo(piperidin-1-yl)acetyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole


**Example 986**

2-methyl-1-[(1R,5S)-8-(2-[4-phenyl-1-(2H-1,2,3-triazol-2-yl)acetyl]piperidin-4-yl)ethyl)-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole

713


**Example 987**

2-methyl-1-((1R,5S)-8-[2-(4-phenyl-1-[[5-(trifluoromethyl)pyridin-2-yl]carbonyl]piperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole


**Example 988**

1-[(1R,5S)-8-(2-{1-[(4-ethyl-3-methoxyisoxazol-5-yl)acetyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole

714


**Example 989**

6-chloro-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]imidazo[1,2-b]pyridazine


**Example 990**

3-{2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]piperidin-1-yl}propanenitrile

715


**Example 991**

2-[2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-2-oxoethyl]cyclohexanone


**Example 992**

ethyl 3,3-dimethyl-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]butanoate

716


**Example 993**

4-methyl-7-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]cinnoline


**Example 994**

1-((1R,5S)-8-{2-[1-(2-isopropyl-4,5-dimethyl-3-furoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole

717


**Example 995**

N-{4-hydroxy-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]phenyl}urea

**Example 996**


1-[(1R,5S)-8-(2-{1-[2-(3-methoxyphenyl)-2-methylpropanoyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole

718



Example 997


1-methyl-4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1,3-dihydro-2H-benzimidazol-2-one




Example 998 ,

2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-2-oxoethanethioamide

719


**Example 999**

5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]nicotinamide


**Example 1000**

2-methyl-1-[(1R,5S)-8-(2-{4-phenyl-1-[(2,2,2-trifluoroethoxy)acetyl]piperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-1H-benzimidazole

720


**Example 1001**

ethyl (1S,2S)-2-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]cyclopropanecarboxylate


**Example 1002**

1-[(1R,5S)-8-[2-(1-[(1S,2R)-2-(4-chlorophenyl)cyclopropyl]carbonyl]-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole

721


**Example 1003**

N-[1-cyclopropyl-2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-2-oxoethyl]acetamide


**Example 1004**

1-{1-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]propyl}cyclohexanol

722


**Example 1005**

1-((1R,5S)-8-[2-(1-((1R,2R)-2-(4-methoxyphenyl)cyclopropyl)carbonyl)-4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole


**Example 1006**

2-(dimethylamino)-5-methyl-6-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyrimidin-4-ol

723


**Example 1007**

3-methyl-5-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyrimidine-2,4(1H,3H)-dione


**Example 1008**

N-{1-methyl-1-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]propyl}acetamide

724


**Example 1009**

1-{3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]pyridin-2-yl}ethanone


**Example 1010**

7-[2-(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)-2-oxoethyl]octahydro-2H-indol-2-one


725

**Example 1011**

3-(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxo-N-[[3-(trifluoromethyl)phenyl]sulfonyl]propanamide



Synthesis of 2,2-dimethyl-3-oxo-3-((3-(trifluoromethyl)phenyl)sulfonyl)amino)propanoic acid




2,2-dimethyl-3-oxo-3-([3-(trifluoromethyl)phenyl]sulfonyl)amino)propanoic acid was prepared in the same manner as 2,2-dimethyl-3-oxo-3-[(phenylsulfonyl)amino]propanoic acid starting from 3-(trifluoromethyl)benzenesulfonyl chloride.


¹HNMR (300MHz, Chloroform-D1) δ ppm 1.4 (m, 6H) 5.1 (m, 1H) 7.9 (M, 1H) 8.1 (m, 1H) 8.2 (m, 1H) 8.3 (m, 1H) 10.0 (s, 1H), Electrospray LC-MS 362 (M+23)

Example 1012

3-(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxo-N-(phenylsulfonyl)propanamide



The synthesis of 2,2-dimethyl-3-oxo-3-[(phenylsulfonyl)amino]propanoic acid



Benzenesulfonamide was made by adding benzenesulfonyl chloride to a solution of ammonia in tetrahydrofuran and evaporating to a solid.


Benzenesulfonamide (87 mg, .50 mmole) was added to a shaken suspension

of 3-ethoxy-2,2-dimethyl-3-oxopropanoic acid (100 mg, .62 mmole) reactivated on PS-DCC resin (1.62 g, 1.25 mmole) and 1.50 mmole of *N,N*-dimethylpyridin-4-amine in DCE. When reaction is complete the resin is filtered off and the organic layer washed with 1N HCl dried and evaporated. The resulting residue was dissolved in 6 ml of ethanol and 6 ml of 1N LiOH was added and heated to 40 C°. The reaction was neutralized with 1N HCl and evaporated to afford 2,2-dimethyl-3-oxo-3-[(phenylsulfonyl)amino]propanoic acid as a crude product which was used with no further purification.


¹HNMR (300MHz, Chloroform-D1) δ ppm 1.4 (m, 6H) 4.9 (s, 1H) 7.6 (m, 3H) 7.9 (m, 1H) 8.1 (m, 1H) 9.8 (s, 1H), Electrospray LC-MS 180 (M+23).

Example 1013

3-(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxo-N-{[4-(trifluoromethyl)phenyl]sulfonyl}propanamide



The synthesis of 2,2-dimethyl-3-oxo-3-([4-(trifluoromethyl)phenyl]sulfonyl)amino)propanoic acid




2,2-dimethyl-3-oxo-3-([4-(trifluoromethyl)phenyl]sulfonyl)amino)propanoic acid was prepared in the same manner as 2,2-dimethyl-3-oxo-3-[(phenylsulfonyl)amino]propanoic acid starting from 4-(trifluoromethyl)benzenesulfonyl chloride.

^1H NMR (300MHz, Chloroform- D_1) δ ppm 1.4 (m, 6H) 5.1 (s, 1H) 7.8 (M, 2H) 8.1 (d, $J=8.78$ Hz, 1H) 8.2 (d, $J=9.0$ Hz, 1H) 9.9 (s, 1H)

Example 1014


4-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-1,2,5-thiadiazol-3-ol



Example 1015

1-[(1R,5S)-8-(2-{1-[2-(1H-imidazol-4-yl)-2-methylpropanoyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole

729




Using Method A (HATU) 2-(1*H*-imidazol-4-yl)-2-methylpropanoic acid and endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1*H*-benzimidazole dihydrochloride were coupled to afford 1-[(1*R*,5*S*)-8-(2-{1-[2-(1*H*-imidazol-4-yl)-2-methylpropanoyl]-4-phenylpiperidin-4-yl}ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1*H*-benzimidazole 11.8 mg 42% yield.

¹H NMR (400 MHz, DMSO-*D*₆) δ ppm 1.2 (m, 1 H) 1.5 (m, 8 H) 1.7 (m, 8 H) 2.3 (m, 2 H) 2.5 (m, 3 H) 2.5 (m, 8 H) 3.2 (m, 2 H) 4.5 (m, 1 H) 7.1 (m, 10 H) 11.9 (m, 1 H)

Electrospray LC-MS 565 (M+H)

Example 1016

4-methyl-8-[(4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]quinoline




Using Method A (HATU) 4-methylquinoline-8-carboxylic acid and endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride were coupled to afford 4-methyl-8-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]quinoline 14.8 mg 49% yeild.

¹H NMR (400 MHz, DMSO-D₆) δ ppm 1.7 (m, 10 H) 2.1 (m, 2 H) 2.3 (m, 6 H) 2.7 (m, 3 H) 2.9 (m, 1 H) 3.2 (m, 4 H) 3.6 (m, 1 H) 4.0 (m, 1 H) 4.5 (m, 1 H) 7.1 (m, 2 H) 7.2 (m, J=2.9 Hz, 1 H) 7.4 (m, 6 H) 7.5 (m, J=5.4 Hz, 1 H) 7.6 (m, 2 H) 8.2 (m, J=5.7, 2.1 Hz, 1 H) 8.7 (m, 1 H)

Electrospray LC-MS 598 (M+H)

Example 1017

4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1,3-benzoxazol-2(3H)-one



Using Method A (HATU) 2-oxo-2,3-dihydro-1,3-benzoxazole-4-carboxylic acid and endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride were coupled to afford 4-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1,3-benzoxazol-2(3H)-one 8.7 mg 30% yeild.


731

¹H NMR (400 MHz, DMSO-D₆) δ ppm 1.6 (m, 2 H) 1.8 (m, 9 H) 2.4 (m, 2 H)
2.4 (m, 3 H) 2.5 (m, 7 H) 3.2 (m, 3 H) 4.5 (m, 1 H) 7.2 (m, 5 H) 7.4 (m, 6 H)
7.5 (m, 1 H)

Electrospray LC-MS 590 (M+H)

Example 1018

7-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1H-1,2,3-benzotriazole




Using Method A (HATU) 1H-1,2,3-benzotriazole-7-carboxylic acid and endo 2-methyl-1-{8-[2-(4-phenylpiperidin-4-yl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl}-1H-benzimidazole dihydrochloride were coupled to afford 7-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]-1H-1,2,3-benzotriazole 9.9 mg 34% yield.

¹H NMR (400 MHz, DMSO-D₆) δ ppm 1.6 (m, 1 H) 1.8 (m, 8 H) 2.4 (m, 4 H)
2.5 (m, 8 H) 3.2 (m, 3 H) 4.0 (m, 1 H) 4.5 (m, 1 H) 7.1 (m, 2 H) 7.2 (m, 1 H)
7.4 (m, 8 H) 8.0 (m, 1 H)

Electrospray LC-MS 574 (M+H)

Example 1019

6-fluoro-7-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-1H-1,2,3-benzotriazole




Using Method A (HATU) 6-fluoro-1H-1,2,3-benzotriazole-7-carboxylic acid and endo-1-(8-{2-[4-(3-fluorophenyl) piperidin-4-yl]ethyl}-2-methyl-1H-benzimidazole dihydrochloride were coupled to afford 6-fluoro-7-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-1H-1,2,3-benzotriazole 83.9 mg 62% yield.

¹H NMR (400 MHz, METHANOL-D₄) δ ppm 1.7 (m, 1 H) 2.0 (m, 4 H) 2.4 (m, 4 H) 2.8 (m, 3 H) 3.4 (m, 13 H) 4.7 (m, 1 H) 7.2 (m, 10 H) 7.9 (m, 1 H)

Electrospray LC-MS 610 (M+H)


Preparation of the ethyl 6-fluoro-1H-1,2,3-benzotriazole-7-carboxylate



ethyl 2,3-diamino-6-fluorobenzoate (1.00 g, 5.04 mmole) in 50 ml of water and 10 ml acetic acid was cooled to $-10\text{ }^{\circ}\text{C}$. To this solution was added dropwise sodium nitrite (348 mg, 5.04 mmole) in 30 ml of water. After the addition the reaction was warmed to $0\text{ }^{\circ}\text{C}$ for 30 min, then to room temperature for 1 hr, and finally $50\text{ }^{\circ}\text{C}$ for 1 hr. The reaction was filtered after stirring over night and washed with water. The dark brownish purple solid was dissolved in ethylacetate dried over magnesium sulfate and evaporated to afford ethyl 6-fluoro-1*H*-1,2,3-benzotriazole-7-carboxylate (920 mg, 87% yield)

^1H NMR (400 MHz, METHANOL- D_4) δ ppm 1.3 (t, $J=7.1$ Hz, 3 H) 4.4 (q, $J=7.0$ Hz, 2 H) 7.2 (dd, $J=11.2, 9.0$ Hz, 1 H) 8.1 (dd, $J=9.1, 4.1$ Hz, 1 H)

Preparation of the 6-fluoro-1*H*-1,2,3-benzotriazole-7-carboxylic acid




ethyl 6-fluoro-1*H*-1,2,3-benzotriazole-7-carboxylate (920 mg) was heated in 6N HCl until all of the starting material disappeared. Evaporation of the HCl afforded 718 mg of a brownish solid.

^1H NMR (300 MHz, DMSO- D_6) δ ppm 7.4 (dd, $J=11.2, 9.0$ Hz, 1 H) 8.3 (dd, $J=9.1, 4.1$ Hz, 1 H)

Example 1020


5-fluoro-4-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-1,3-benzoxazol-2(3*H*)-one

734



Using Method A (HATU) 5-fluoro-2-oxo-2,3-dihydro-1,3-benzoxazole-4-carboxylic acid and endo-1-(8-{2-[4-(3-fluorophenyl) piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride were coupled to afford 5-fluoro-4-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]-1,3-benzoxazol-2(3H)-one. ¹H NMR (300 MHz, METHANOL-D₄) δ ppm 1.4 (d, J=6.5 Hz, 1 H) 1.8 (m, 3 H) 2.0 (m, 8 H) 2.2 (m, 3 H) 2.5 (m, 3 H) 3.0 (m, 3 H) 3.5 (m, 4 H) 4.2 (m, 1 H) 7.0 (m, 2 H) 7.3 (m, 7 H) 7.6 (m, 1 H) 8.0 (m, 1 H) Electrospray LC-MS 626(M+H)

Preparation of 2-amino-6-fluoro-3-hydroxybenzoic acid




2-amino-6-fluorobenzoic acid (5.00 g, 32.2 mmole) was dissolved in 30 ml of 2N sodium hydroxide. To this was added dropwise a solution of sodium persulfate (7.67 g, 32.2 mmole) in 80 ml of water. After stirring over night the resulting black solution was extracted with 2 L of ether and 1 L of ethylacetate. Evaporation of the water gave a black solid that was used with no purification.

^1H NMR (400 MHz, DMSO- D_6) δ ppm 6.2 (dd, $J=11.5, 8.6$ Hz, 1 H) 6.7 (dd, $J=8.6, 4.9$ Hz, 1 H)

LC-MS

5-fluoro-2-oxo-2,3-dihydro-1,3-benzoxazole-4-carboxylic acid



To a THF solution of 2-amino-6-fluoro-3-hydroxybenzoic acid (520 mg, 3.04 mmole) and *n,n*-diisopropylethylamine (942 mg, 7.29 mmole) was added bis(trichloromethyl) carbonate (1.08 g, 3.64 mmole) and stirred. Removal of solvent under vacuum afforded a residue, which was run on reversephase flash chromatography 10 to 90% acetonitrile water (0.01% TFA). The resulting fractions were evaporated.


APCI LC-MS 196 (M-H) 198 (M+H)

Examples below were synthesized as follows.

Method AA. Synthesis of functionalized carboxamide carboxylic acids via amination of cyclic anhydrides (Acids 69-79 and 97-153).

1mmol of anhydride was treated with 10mmol of either a 0.5M solution of NH_3 in Dioxane or a 2M solution of either methylamine, ethylamine, isopropylamine or cyclopropylamine in THF at 40°C in a sealed tube for 72h. The reaction mixtures were concentrated to remove solvent and excess amine to give the crude carboxamide carboxylic acid as the salt of the corresponding amine. Crude materials were used without further purification or characterization in the subsequent coupling reaction to generate final compounds.

736




Method BB. Synthesis of benzimidazole carboxylic acids (Acids 65-68, 88, and 89)

Step 1: 50mmol of an appropriately substituted 2-amino-3-nitrobenzoic acid ester in 250mL of EtOH/EtOAc (1:1) was treated with 980mg of 10%Pd/C and $\text{H}_2(\text{g})$ (1atm) at ambient temperature for 16h. The catalyst was filtered off and the filtrate concentrated to give the corresponding dianiline as a crystalline solid in quantitative yield. The crude material was carried on to either step 2A or 2B without further purification.

Step 2A: 5.6mmol of the dianiline was treated with 15mL of either triethyl orthoacetate or triethyl orthoformate at 120°C for 16h. The reaction mixture was concentrated to dryness to give the corresponding benzimidazole as a crystalline solid that was carried on to step 3 without further purification.

Step2B: Alternatively, 6.0mmol of dianiline was treated with 6.3mmol BrCN in 15mL CH_3OH at reflux for 3h. The reaction mixture was cooled to ambient temperature and precipitate was filtered off to give the corresponding 2-aminobenzimidazole.

Step 3: Benzimidazoles obtained from steps 2A and 2B were treated with 6N HCl at 80°C for 8h. The reaction mixtures were concentrated to dryness to give the benzimidazole carboxylic acids which were used without purification in coupling reactions to yield final compounds.




Method CC. Synthesis of carboxamide carboxylic acids by amination of dimethyl malonate (Acids 90-96).

Step 1: Diethyl dimethylpropanedioate (10g, 53mmol) in 170mL EtOH was treated with 3.00g (53mmol) KOH at ambient temperature for 4 days. The reaction mixture was concentrated to dryness and partitioned between EtOAc and water. The aqueous phase was isolated, combined with fresh EtOAc and the pH adj to 2 with 6N HCl. The organic phase was isolated and the aqueous portion extracted twice with EtOAc. The organic phases were combined, dried over MgSO₄, filtered and concentrated to give 6.56g (41mmol) 3-(ethyloxy)-2,2-dimethyl-3-oxopropanoic acid as a clear oil. ¹H NMR (300 MHz, CDCl₃) δ 4.20 (q, J=7.1Hz, 2H), 1.46(s, 6H), 1.26(t, J=7.1Hz, 3H).

Step 2: 400mg (2.50mmol) 3-(ethyloxy)-2,2-dimethyl-3-oxopropanoic acid dissolved in 4mL THF was treated with 1,1'-carbonyldiimidazole (405mg, 2.50mmol) at ambient temperature until CO₂ evolution ceased (~20min). To this solution was added 7.50mmol (3eq) of either ammonia, methylamine, ethylamine, 2-amino-2-methyl-1-propanol, cyclopropylamine, isopropylamine, 2-propen-1-ylamine, or N,N-dimethylamine. The reaction mixtures were shaken gently at ambient temperature for 16h, concentrated to dryness, partitioned between DCE (8mL) and 0.5N HCl (10mL), shaken vigorously, organic phases isolated, dried over MgSO₄ filtered and concentrated to dryness. Identity of these carboxamide ester intermediates was confirmed by ¹H NMR.

Step 3: The carboxamide esters so obtained were treated with 2.5mL (2.5mmol) of 1N LiOH in 2.5mL EtOH at ambient temperature for 16h. The reaction mixtures were concentrated to dryness and used in coupling reactions without further purification or characterization.



Method DD: Synthesis of carboxamide carboxylic acids from iodobenzoic acids or ester carboxylic acids (Acids 80-86) as exemplified by synthesis of 3-


[[[2,4-bis(methyloxy)phenyl]methyl]amino)carbonyl]-4-chlorobenzoic acid (Acid 84).

Step 1: 2-Chloro-5-iodobenzoic acid (2g, 7.08mmol) in 25mL THF was treated with 1,1'-carbonyldiimidazole (1.15g, 7.08mmol) at ambient temperature until CO₂ evolution ceased (~20min). 2,4-Dimethoxybenzylamine (1.18g, 7.08mmol) was added and stirred at ambient temperature for 16h. The reaction mixture was concentrated to dryness, partitioned between EtOAc and saturated NaHCO₃, the organic phase isolated, dried over MgSO₄, filtered and concentrated to give *N*-[[2,4-bis(methyloxy)phenyl]methyl]-2-chloro-5-iodobenzamide (3.00g, 6.95mmol) as a pale yellow oil that crystallized on standing. ¹H NMR (300 MHz, CDCl₃) δ 7.95(d, *J*=2.2Hz, 1H), 7.62(dd, *J*=8.5, 2.2Hz, 1H), 7.25(m, 1H), 7.10 (m, 1H), 6.63(m, 1H), 6.45 (m, 2H), 4.55(d, *J*=5.7 Hz, 2H), 3.83(s, 3H), 3.80(s, 3H). LCMS ES+ 431.82, 433.77 (M+H).

Step 2: *N*-[[2,4-bis(methyloxy)phenyl]methyl]-2-chloro-5-iodobenzamide (2.78g, 6.44mmol) dissolved in 100mL CH₃OH with dicyclohexylamine (3.85mL, 19mmol) was treated with POPd₂ catalyst (AC2000) under an atmosphere of CO(g) at 1atm pressure and ambient temperature for 3 days. The catalyst was filtered off and the filtrate concentrated to a small volume, cooled in ice bath, and the resultant precipitate filtered off. A second crop was obtained from the mother liquor and the two batches were combined to give methyl 3-[[[2,4-bis(methyloxy)phenyl]methyl]amino)carbonyl]-4-chlorobenzoate (2.26g, 6.21mmol) as a white crystalline solid. ¹H NMR (300 MHz, DMSO-*D*₆) δ 8.82(m, 1H), 7.96(dd, *J*=8.3, 2.2Hz, 1H), 7.91(m, 1H), 7.65(d, *J*=8.3Hz, 1H), 7.19(d, *J*=8.2Hz, 1H), 6.56 (d, *J*=2.5Hz, 1H), 6.51(dd, *J*=8.3, 2.5Hz, 1H), 4.34(d, *J*=5.9Hz, 2H), 3.86(s, 3H), 3.79(s, 3H), 3.74(s, 3H). LCMS ES+ 363.99, 365.97(M+H).

Step 3: Methyl 3-[[[2,4-bis(methyloxy)phenyl]methyl]amino)carbonyl]-4-chlorobenzoate (600mg, 1.65mmol) dissolved in 17mL CH₃OH was treated with 16.5mL 1N LiOH at ambient temperature for 16h. The reaction mixture was concentrated to dryness, partitioned between EtOAc and water, the aqueous phase isolated and the pH adjusted to 2 with 6N HCl. The resultant

precipitate was cooled in an ice bath with stirring, filtered, and washed with water to give 3-[[{[2,4-bis(methoxy)phenyl]methyl}amino]carbonyl]-4-chlorobenzoic acid (533mg, 1.52mmol) as a white crystalline solid. ¹H NMR (300 MHz, DMSO-D₆) δ ppm 8.96(m, 1H), 8.29(d, *J*=2.2 Hz, 1 H), 8.00(dd, *J*=8.4, 2.3 Hz, 1 H), 7.65(d, *J*=8.3 Hz, 1 H), 7.09(d, *J*=8.3 Hz, 1 H), 6.55(d, *J*=2.3 Hz, 1 H), 6.50(dd, *J*=8.3, 2.3 Hz, 1 H), 4.35(d, *J*=5.6 Hz, 1 H), 3.79(s, 3H), 3.73(s, 3H). LCMS ES+ 349.88, 351.91 (M+H).











Acids 80-83 were synthesized in an analogous fashion from the appropriately substituted iodobenzoic acid and the appropriate amine.









Acids 85, 86, and 154 were synthesized from diethyl dimethylpropanedioate, diethyl diethylpropanedioate, or diethyl 1,1-cyclobutanedicarboxylate, respectively, and 2,4-Dimethoxybenzylamine using Method CC, step 1 and Method DD steps 1 and 3.









The table below lists acids 55-154, their properties, method of their synthesis as well as yields.

Acid #	Structure	Yield	ES-LCMS	Ion	Method
Acid 55			293.94	(M+H)	H









740

Acid 56		75	267.95	(M+H)	H
Acid 57		57	317.96	(M+Na)	H
Acid 58		85	357.92	(M+Na)	H
Acid 59		23	332	(M+Na)	H
Acid 60		77	343.97	(M+Na)	H
Acid 61		55	275.87	(M+Na)	H
Acid 62			282.08	(M+H)	H
Acid 63			310.01	(M+Na)	H









Acid 64			298.1	(M+Na)	H
Acid 65					BB
Acid 66					BB
Acid 67					BB
Acid 68					BB
Acid 69					AA
Acid 70					AA
Acid 71					AA








Acid 72					AA
Acid 73					AA
Acid 74					AA
Acid 75					AA
Acid 76					AA
Acid 77					AA
Acid 78					AA
Acid 79					AA









743









glax					
Acid 80		68	239.9	(M+H)	DD
Acid 81		73	241.91	(M+H)	DD
Acid 80		68	239.9	(M+H)	DD
Acid 81		73	241.91	(M+H)	DD
comm ercial					
Acid 80		68	239.9	(M+H)	DD
Acid 81		73	241.91	(M+H)	DD








744








Acid 82		54	329.95	(M+H)	DD
Acid 83		94	349.89, 351.91	(M+H)	DD
Acid 84		92	349.88, 351.91	(M+H)	DD
Acid 85		100	304	(M+Na)	DD
Acid 86		82	331.98	(M+Na)	DD
comm ercial					
glax					
Acid 87		75	318.03	(M+Na)	H

Acid 88					BB
Acid 89					BB
Acid 90					CC
Acid 91					CC
Acid 92					CC
Acid 93					CC
Acid 94					CC








Acid 95					CC
Acid 96					CC
Acid 97					AA
Acid 98					AA
Acid 99					AA
Acid 100					AA
Acid 101					AA
Acid 102					AA








Acid 103					AA
Acid 104					AA
Acid 105					AA
Acid 106					AA
Acid 107					AA
Acid 108					AA
Acid 109					AA
Acid 110					AA








Acid 111					AA
Acid 112					AA
Acid 113					AA
Acid 114					AA
Acid 115					AA
Acid 116					AA
Acid 117					AA









Acid 118					AA
Acid 119					AA
Acid 120					AA
Acid 121					AA
Acid 122					AA
Acid 123					AA
Acid 124					AA








750









Acid 125	 <chem>CC(C)NC(=O)CC(C)(C)C(=O)O</chem>				AA
Acid 126	 <chem>CC(C)NC(=O)CC(Cc1ccccc1)C(=O)O</chem>				AA
Acid 127	 <chem>CC(C)NC(=O)C1CCCCC1C(=O)O</chem>				AA
Acid 128	 <chem>CC(C)NC(=O)CC(Cc1ccccc1)C(=O)O</chem>				AA
Acid 129	 <chem>CC(C)NC(=O)C1CCCCC1C(=O)O</chem>				AA
Acid 130	 <chem>CC(C)NC(=O)C1=CCCC1C(=O)O</chem>				AA
Acid 131	 <chem>CC(C)NC(=O)C1(C)CCCC1C(=O)O</chem>				AA

Acid 132					AA
Acid 133					AA
Acid 134					AA
Acid 135					AA
Acid 136					AA
Acid 137					AA
Acid 138					AA








Acid 139					AA
Acid 140					AA
Acid 141					AA
Acid 142					AA
Acid 143					AA
Acid 144					AA
Acid 145					AA

Acid 146					AA
Acid 147					AA
Acid 148					AA
Acid 149					AA
Acid 150					AA
Acid 151					AA
Acid 152					AA
Acid 153					AA





glax	 <chem>OC(=O)c1cnc2ccc(cc2c1)C(F)(F)F</chem>				
glax	 <chem>OC(=O)c1cnc2ccc(cc2c1)C(F)(F)F</chem>				
glax	 <chem>OC(=O)C1=CN(C(=O)N1)C(=O)N</chem>				
glax	 <chem>OC(=O)c1ccc(cc1)CN2CCCC2</chem>				
glax	 <chem>OC(=O)CN1C=CN(C)C1</chem>				
glax	 <chem>OC(=O)C1CCC(N1)C(=O)NCC(=O)Nc2ccccc2</chem>				
glax	 <chem>OC(=O)C1CCC(N1)C(=O)NCC(=O)Nc2ccccc2</chem>				

glax	 <chem>O=C1CC(O)C(=O)N1C(=O)O</chem>				
glax	 <chem>OC1=NC=C(C(=O)O)N=C1S</chem>				
glax	 <chem>CC1=CN(C(=O)O)C(=O)NC1=O</chem>				
glax	 <chem>O=C1C(=O)C(=O)C2=CC=CC=C2N1C(=O)O</chem>				
glax	 <chem>O=C1C(=O)C(=O)C2=CC=CC=C2N1C(=O)O</chem>				
glax	 <chem>O=C1C(=O)C(=O)C2=CC=CC=C2N1C(=O)O</chem>				
glax	 <chem>O=C1C(=O)C(=O)C2=CC=CC=C2N1C(=O)O</chem>				
glax	 <chem>O=C1C(=O)C(=O)C2=CC=CC=C2N1C(=O)O</chem>				


756












glax	 <chem>O=C(O)c1cc(O)c2c(c1)nn2</chem>				
glax	 <chem>O=C(O)c1cc(O)c2cc(F)ccc2n1</chem>				
glax	 <chem>O=C(O)c1cc(O)c2ocn2c1</chem>				
glax	 <chem>O=C(O)c1c(O)c2cc(C)ccc2n1</chem>				
glax	 <chem>O=C(O)[C@H]1CCN(C)CC1O</chem>				
glax	 <chem>O=C(O)c1cc(O)c2c(c1)cc(=O)[nH]2</chem>				
glax	 <chem>O=C(O)c1c(O)c2c(s1)nn2CS(=O)(=O)CC</chem>				

757













glax					
glax					
glax					
Acid 154		83	315.94	(M+Na)	DD












The following examples were prepared using acids described elsewhere in this invention

























Example	Acid # or source	R	X	Y	% Yield	LCMS ES	Ion	Method
1021	Acid 83		H	C	36	610.18	(M+H)	F
1022	Acid 82		CH 3	C	52	604.24	(M+H)	F
1023	Acid 83		CH 3	C	52	624.22	(M+H)	F
1024	Acid 85		CH 3	C	38	556.27	(M+H)	F
1025	Acid 55		F	C	42	722.36	(M+H)	A
1026	Acid 56		F	C	36	696.18	(M+H)	A
1027	Acid 57		F	C	52	724.38	(M+H)	A
1028	Acid 58		F	C	56	764.33	(M+H)	A
1029	Acid 59		F	C	32	738.37	(M+H)	A
1030	Acid 60		F	C	50	750.23	(M+H)	A
1031	Acid 61		F	C	49	682.32	(M+H)	A












1032	Acid 62		F	C	54	710.34	(M+H)	A
1033	Acid 63		F	C	26	716.42	(M+H)	A
1034	Acid 64		F	C	29	704.42	(M+H)	A
1035	Acid 65		F	C	28	605.35	(M+H)	A
1036	Acid 66		F	C	48	623.32	(M+H)	A
1037	Acid 67		F	C	46	609.28	(M+H)	A
1038	Acid 68		F	C	13	624.34	(M+H)	A
1039	Acid 69		F	C	44	558.38	(M+H)	A
1040	Acid 70		F	C	57	584.39	(M+H)	A
1041	Acid 71		F	C	58	588.45	(M+H)	A
1042	Acid 72		F	C	52	596.35	(M+H)	A












1043	Acid 73		F	C	23	572.34	(M+H)	A
1044	Acid 74		F	C	41	572.35	(M+H)	A
1045	Acid 75		F	C	29	628.39	(M+H)	A
1046	Acid 76		F	C	43	614.42	(M+H)	A
1047	Acid 77		F	C	64	598.42	(M+H)	A
1048	Acid 78		F	C	27	616.5	(M+H)	A
1049	Acid 79		F	C	39	600.45	(M+H)	A
1050	glax		F	C	37	608.4	(M+H)	A
1051	Acid 86		F	C	37	588.4	(M+H)	A
1052	Acid 80		H	C	48	650.19	(M+H)	A
1053	Acid 81		H	C	39	652.22	(M+H)	A
1054	Acid 80		F	C	56	668.22	(M+H)	A











1055	Acid 81		F	C	43	670.21	(M+H)	A
1056	comm ercial		F	C	39	584.24	(M+H)	A
1057	Acid 80		CH 3	C	41	664.25	(M+H)	A
1058	Acid 81		CH 3	C	41	666.26	(M+H)	A
1059	Acid 82		F	C	45	758.33	(M+H)	A
1060	Acid 83		F	C	36	778.29	(M+H)	A
1061	Acid 84		F	C	66	778.29	(M+H)	A
1062	Acid 85		F	C	41	710.28	(M+H)	A
1063	Acid 86		F	C	56	738.33	(M+H)	A
1064	Acid 82		H	C	39	590.25	(M+H)	F
1065	Acid 84		H	C	13	610.18	(M+H)	F











1066	Acid 82		F	C	48	608.24	(M+H)	F
1067	Acid 83		F	C	53	628.18	(M+H)	F
1068	Acid 84		F	C	47	628.17	(M+H)	F
1069	Acid 154		F	C	46	572.27	(M+H)	F
1070	Acid 85		F	C	33	560.26	(M+H)	F
1071	Acid 84		CH 3	C	23	624.24	(M+H)	F
1072	Acid 154		CH 3	C	34	568.28	(M+H)	F
1073	Acid 85		H	C	18	542.29	(M+H)	F
1075	commercial		F	C	49	559.14	(M+H)	A
1076	glax		F	C	39	573.05	(M+H)	A
1077	Acid 87		F	C	52	724.38	(M+H)	A











1078	Acid 88		F	C	27	591.27	(M+H)	A
1079	Acid 89		F	C	22	606.35	(M+H)	A
1080	Acid 90		F	C	24	574.35	(M+H)	A
1081	Acid 91		F	C	34	588.36	(M+H)	A
1082	Acid 92		F	C	23	632.47	(M+H)	A
1083	Acid 93		F	C	33	598.79	(M-1)	A
1084	Acid 94		F	C	18	588.33	(M+H)	A
1085	Acid 95		F	C	41	600.37	(M+H)	A
1086	Acid 96		F	C	45	602.4	(M+H)	A
1087	Acid 97		F	C	33	574.36	(M+H)	A
1088	Acid 98		F	C	32	598.39	(M+H)	A











1089	Acid 99		F	C	49	622.42	(M+H)	A
1090	Acid 100		F	C	55	614.44	(M+H)	A
1091	Acid 101		F	C	50	546.36	(M+H)	A
1092	Acid 102		F	C	15	594.37	(M+H)	A
1093	Acid 103		F	C	54	560.41	(M+H)	A
1094	Acid 104		F	C	27	650.43	(M+H)	A
1095	Acid 105		F	C	40	610.32	(M+H)	A
1096	Acid 106		F	C	42	612.35	(M+H)	A
1097	Acid 107		F	C	27	636.39	(M+H)	A
1098	Acid 108		F	C	31	614.39	(M+H)	A
1099	Acid 109		F	C	31	628.44	(M+H)	A












1100	Acid 110		F	C	34	560.37	(M+H)	A
1101	Acid 111		F	C	40	602.38	(M+H)	A
1102	Acid 112		F	C	39	574.4	(M+H)	A
1103	Acid 113		F	C	34	610.35	(M+H)	A
1104	Acid 114		F	C	20	676.4	(M+H)	A
1105	Acid 115		F	C	31	638.38	(M+H)	A
1106	Acid 116		F	C	27	662.42	(M+H)	A
1107	Acid 117		F	C	25	640.49	(M+H)	A
1108	Acid 118		F	C	37	624.44	(M+H)	A
1109	Acid 119		F	C	19	654.44	(M+H)	A
1110	Acid 120		F	C	53	586.41	(M+H)	A







1111	Acid 121		F	C	29	628.44	(M+H)	A
1112	Acid 122		F	C	41	634.42	(M+H)	A
1113	Acid 123		F	C	47	600.45	(M+H)	A
1114	Acid 124		F	C	31	636.36	(M+H)	A
1115	Acid 125		F	C	21	630.43	(M+H)	A
1116	Acid 126		F	C	24	678.51	(M+H)	A
1117	Acid 127		F	C	38	640.51	(M+H)	A
1118	Acid 128		F	C	33	664.5	(M+H)	A
1119	Acid 129		F	C	35	642.51	(M+H)	A
1120	Acid 130		F	C	38	626.47	(M+H)	A


1121	Acid 131		F	C	15	656.49	(M+H)	A
1122	Acid 132		F	C	34	588.45	(M+H)	A
1123	Acid 133		F	C	36	630.51	(M+H)	A
1124	Acid 134		F	C	33	636.45	(M+H)	A
1125	Acid 135		F	C	34	602.48	(M+H)	A
1126	Acid 136		F	C	29	638.43	(M+H)	A
1127	Acid 137		F	C	20	664.52	(M+H)	A
1128	Acid 138		F	C	25	602.45	(M+H)	A
1129	Acid 139		F	C	26	626.45	(M+H)	A
1130	Acid 140		F	C	31	650.51	(M+H)	A

1131	Acid 141		F	C	25	628.52	(M+H)	A
1132	Acid 142		F	C	44	586.42	(M+H)	A
1133	Acid 143		F	C	34	612.49	(M+H)	A
1134	Acid 144		F	C	18	640.49	(M+H)	A
1135	Acid 145		F	C	41	574.43	(M+H)	A
1136	Acid 146		F	C	23	616.48	(M+H)	A
1137	Acid 147		F	C	25	622.44	(M+H)	A
1138	Acid 148		F	C	37	588.45	(M+H)	A
1139	Acid 149		F	C	35	624.44	(M+H)	A
1140	Acid 150		F	C	35	600.46	(M+H)	A

1141	Acid 151		F	C	33	544.35	(M+H)	A
1142	Acid 152		F	C	15	694.34	(M+H)	A
1143	Acid 153		F	C	14	654.43	(M+H)	A
1144	glax		F	C	52	686.4	(M+H)	A
1145	glax		F	C	18	585.34	(M+H)	A
1146	glax		F	C	29	631.37	(M+H)	A
1147	glax		F	C	30	569.35	(M+H)	A
1148	glax		F	C	30	684.4	(M+H)	A
1149	glax		F	C	12	704.44	(M+H)	A
1150	glax		F	C	11	574.41	(M+H)	A


1151	glax		F	C	45	601.36	(M+H)	A
1152	glax		F	C	65	583.38	(M+H)	A
1153	glax		F	C	47	618.41	(M+H)	A
1154	glax		F	C	17	619.39	(M+H)	A
1155	glax		F	C	54	568.38	(M+H)	A
1156	glax		F	C	63	619.4	(M+H)	A
1157	glax		F	C	44	568.37	(M+H)	A
1158	glax		F	C	15	608.43	(M+H)	A
1159	glax		F	C	38	636.4	(M+H)	A
1160	glax		F	C	13	558.36	(M+H)	A
1161	glax		F	C	76	633.43	(M+H)	A

1162	glax		F	C	47	588.45	(M+H)	A
1163	glax		F	C	12	635.45	(M+H)	A
1164	glax		F	C	23	666.36	(M+H)	A
1165	glax		F	C	70	588.45	(M+H)	A
1166	glax		F	C	41	612.41	(M+H)	A
1167	glax		F	C	20	652.26	(M+H)	A

Example 1021


4-chloro-3-[(4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylpiperidin-1-yl)carbonyl]benzamide. ^1H NMR (300 MHz, CD_3OD) δ 7.96-7.07(m, 12H), 4.75(m, 1H), 4.21 (m, 1H), 3.90-3.10(m, 6H), 2.53 (s, 3H), 2.50-1.68 (m, 15H).

Example 1022




4-methyl-3-[[4-[2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-4-(3-methylphenyl)-1-piperidinyl]carbonyl}benzamide. . ¹H NMR (300 MHz, CD₃OD) δ 7.96-7.07(m, 11H), 4.75(m, 1H), 4.31-4.15(m, 1H), 3.91-3.10(m, 6H), 2.53 (s, 3H), 2.50-1.68 (m, 15H), 2.43(s, 1.5H), 2.38 (s, 3H), 2.25(s, 1.5H).

Example 1023



4-chloro-3-[[4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(3-methylphenyl)-1-piperidinyl]carbonyl}benzamide. ¹H NMR (300 MHz, CD₃OD) δ 7.96-7.07(m, 11H), 4.75(m, 1H), 4.22 (m, 1H), 3.80-3.16(m, 6H), 2.53 (s, 3H), 2.50-1.68 (m, 15H), 2.38 (s, 3H).


Example 1024



2,2-dimethyl-3-[4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-(3-methylphenyl)-1-piperidinyl]-3-


oxopropanamide. ^1H NMR (300 MHz, CD_3OD) δ 7.55-7.06(m, 8H), 4.77(m, 1H), 4.02 (m, 1H), 3.89-3.17(m, 6H), 2.67-1.68 (m, 21H), 2.56 (s, 3H), 2.37 (s, 3H).

Example 1025




2-chloro-N-cyclopropyl-4-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]benzenesulfonamide. ^1H NMR (300 MHz, CD_3OD) δ ppm 8.18(m, 1H), 7.67(d, $J=8.8\text{Hz}$, 1H), 7.58(m, 1H), 7.47(m, 2H), 7.30(s, 1H), 7.29-7.20(m, 3H), 7.05(m, 1H), 4.79(m, 1H), 4.21(m, 1H), 3.60-3.25(m, 8H), 2.59(s, 3H), 2.52-1.70(m, 15H), 0.56(m, 4H).


Example 1026




2-chloro-4-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-N-methylbenzenesulfonamide. ^1H NMR (300 MHz, CD_3OD) δ ppm 8.09(m, 1H), 7.60(d, $J=8.8\text{Hz}$, 1H), 7.53(m, 1H), 7.40(m, 2H), 7.25-7.16(m, 4H), 7.00(m, 1H), 4.75(m, 1H), 4.16(m, 1H), 3.53-3.18(m, 8H), 2.55(d, $J=9.3\text{Hz}$, 3H), 2.52-1.70(m, 16H).

Example 1027

2-chloro-4-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny)carbonyl]-N-(1-methylethyl)benzenesulfonamide. ^1H NMR (300 MHz, CD_3OD) δ ppm 8.11(m, 1H), 7.60(d, $J=8.8\text{Hz}$, 1H), 7.53(m, 1H), 7.40(m, 2H), 7.25-7.16(m, 4H), 7.00(m, 1H), 4.74(m, 1H), 4.17(m, 1H), 3.53-3.18(m, 8H), 2.53(s, 3H), 2.52-1.70(m, 14H), 1.07 (d, $J=6.5\text{Hz}$, 6H).

Example 1028

2-chloro-4-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny)carbonyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide. ^1H NMR (300 MHz, CD_3OD) δ ppm 8.10(m, 1H), 7.60(d, $J=8.8\text{Hz}$, 1H), 7.51(m, 1H), 7.40(m, 2H), 7.25-7.16(m, 4H), 7.00(m, 1H), 4.73(m, 1H), 4.16(m, 1H), 3.77 (q, $J=9.4\text{ Hz}$, 2 H), 3.53-3.18(m, 8H), 2.53(s, 3H), 2.52-1.68(m, 13H).


Example 1029

2-chloro-N-(1,1-dimethylethyl)-4-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny)carbonyl]-N-(1,1-dimethylethyl)benzenesulfonamide.

775


piperidiny]carbonyl]benzenesulfonamide. ^1H NMR (300 MHz, CD_3OD) δ ppm
 8.10(m, 1H), 7.58(d, $J=8.8\text{Hz}$, 1H), 7.51(m, 1H), 7.40(m, 2H), 7.25-7.16(m,
 4H), 7.00(m, 1H), 4.74(m, 1H), 4.17(m, 1H), 3.53-3.18(m, 8H), 2.53(s, 3H),
 2.52-1.69(m, 13H), 1.20(s, 9H).

Example 1030




2-chloro-N-cyclopentyl-4-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-
 methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-
 piperidiny]carbonyl]benzenesulfonamide. ^1H NMR (300 MHz, CD_3OD) δ ppm
 8.11(m, 1H), 7.60(d, $J=8.8\text{Hz}$, 1H), 7.51(m, 1H), 7.40(m, 2H), 7.25-7.16(m,
 4H), 7.00(m, 1H), 4.72(m, 1H), 4.16(m, 1H), 3.57-3.18(m, 8H), 2.53(s, 3H),
 2.52-1.39(m, 22H).


Example 1031




2-chloro-4-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-
 benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-
 piperidiny]carbonyl]benzenesulfonamide. ^1H NMR (300 MHz, CD_3OD) δ ppm
 8.10(m, 1H), 7.58(d, $J=9.0\text{Hz}$, 1H), 7.51(m, 1H), 7.40(m, 2H), 7.25-7.16(m,
 4H), 7.00(m, 1H), 4.73(m, 1H), 4.16(m, 1H), 3.52-3.19(m, 8H), 2.53(s, 3H),
 2.52-1.69(m, 13H).

Example 1032

2-chloro-N-ethyl-4-fluoro-5-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]benzenesulfonamide. ^1H NMR (300 MHz, CD_3OD) \square ppm 8.09(m, 1H), 7.59(d, $J=9.1\text{Hz}$, 1H), 7.51(m, 1H), 7.40(m, 2H), 7.25-7.16(m, 4H), 7.00(m, 1H), 4.74(m, 1H), 4.16(m, 1H), 3.52-3.19(m, 8H), 2.97(q, $J=7.2\text{Hz}$, 2H), 2.53(s, 3H), 2.52-1.69(m, 13H), 1.06(t, $J=7.2\text{Hz}$, 3H).

Example 1033

N-cyclopentyl-4-fluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]benzenesulfonamide. ^1H NMR (300 MHz, CD_3OD) \square ppm 7.98(m, 1H), 7.88(m, 1H), 7.53(m, 1H), 7.41(m, 3H), 7.25-7.16(m, 4H), 7.00(m, 1H), 4.73(m, 1H), 4.17(m, 1H), 3.60-3.18(m, 8H), 2.52(s, 3H), 2.52-1.34(m, 22H).


Example 1034

N-(1,1-dimethylethyl)-4-fluoro-3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]benzenesulfonamide.

777


piperidiny]carbonyl]benzenesulfonamide. ^1H NMR (300 MHz, CD_3OD) \square ppm 8.01(m, 1H), 7.89(m, 1H), 7.52(m, 1H), 7.40(m, 3H), 7.25-7.16(m, 4H), 7.00(m, 1H), 4.74(m, 1H), 4.17(m, 1H), 3.52-3.17(m, 8H), 2.53(s, 3H), 2.52-1.68(m, 13H), 1.19(s, 9H).

Example 1035




1-[(1R,5S)-8-(2-{4-(3-fluorophenyl)-1-[(2-methyl-1H-benzimidazol-4-yl)carbonyl]-4-piperidiny]ethyl)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole. ^1H NMR (300 MHz, CD_3OD) \square ppm 8.01-6.94(m, 11H), 4.90-4.72(m, 1H), 3.97(m, 1H), 3.70-3.16(m, 8H), 2.65(s, 3H), 2.55(s, 3H), 2.46-1.38(m, 14H).


Example 1039




2-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]cyclopropanecarboxamide. ^1H NMR (300 MHz, CD_3OD) \square ppm 7.53(m, 1H), 7.40(m, 2H), 7.25-7.14(m, 4H), 6.98(m, 1H), 4.74(m, 1H), 4.11-3.79(m, 2H), 3.52-3.29(m, 7H), 3.08(m, 1H), 2.55(s, 3H), 2.52-1.17(m, 16H).

Example 1040


2-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-1-cyclopentene-1-carboxamide. ^1H NMR (300 MHz, CD_3OD) δ ppm 7.53(m, 1H), 7.41(m, 2H), 7.25-7.14(m, 4H), 6.97(m, 1H), 4.74(m, 1H), 4.0(m, 1H), 3.55(m, 1H), 3.35-3.20(m, 5H), 3.00(m, 1H), 2.54(s, 3H), 2.80-1.17(m, 20H).

Example 1041


5-(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-3,3-dimethyl-5-oxopentanamide. ^1H NMR (300 MHz, CD_3OD) δ ppm 7.50(m, 1H), 7.40(m, 2H), 7.25-7.16(m, 4H), 6.98(m, 1H), 4.74(m, 1H), 4.00(m, 1H), 3.83(m, 1H), 3.42-1.68(m, 24H), 2.55(s, 3H), 1.10(d, $J=3.8\text{Hz}$, 6H).

Example 1042

3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-2-pyrazinecarboxamide. ^1H NMR (300 MHz, CD_3OD) \square ppm 8.78(d, $J=2.5\text{Hz}$, 1H), 8.73(d, $J=2.5\text{Hz}$, 1H), 7.52(m, 1H), 7.40(m, 2H), 7.25-7.16(m, 4H), 6.98(m, 1H), 4.74(m, 1H), 4.15(m, 1H), 3.46-1.68(m, 21H), 2.52(s, 3H).


Example 1043

2-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]cyclobutanecarboxamide. ^1H NMR (300 MHz, CD_3OD) \square ppm 7.52(m, 1H), 7.40(m, 2H), 7.25-7.16(m, 4H), 6.97(m, 1H), 4.73(m, 1H), 4.15-1.68(m, 28H), 2.55(s, 3H).

Example 1045


N-cyclopropyl-5-(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)-4,4-dimethyl-5-oxopentanamide. ^1H NMR (300 MHz, CD_3OD) δ ppm 7.52(m, 1H), 7.40(m, 2H), 7.25-7.12(m, 4H), 6.96(m, 1H), 4.75(m, 1H), 3.98(m, 1H), 3.36-1.68(m, 28H), 2.55(s, 3H).

Example 1050



3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]-N-methylbenzamide. ^1H NMR (300 MHz, CD_3OD) δ ppm 7.85(m, 1H), 7.84(m, 1H), 7.55(m, 3H), 7.40(m, 2H), 7.26-7.16(m, 4H), 7.00(m, 1H), 4.73(m, 1H), 4.13(m, 1H), 3.58(m, 1H), 3.46-1.68(m, 20H), 2.91(s, 3H), 2.51(s, 3H).


Example 1051



2-ethyl-2-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]butanamide. ^1H NMR (300 MHz, CD_3OD) δ 7.52(m, 1H), 7.41(m, 2H), 7.26-7.16(m, 4H), 6.98(m, 1H), 4.74(m, 1H), 3.97(m, 1H), 3.67(m, 1H), 3.34-3.21(m, 5H), 2.55(s, 3H), 2.41(m, 2H), 2.22(m, 2H), 2.03-1.69(m, 15H), 0.80(m, 6H).

Example 1168


Preparation of
1-(4-(1,3-benzodioxol-5-yl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2-methyl-1-oxopropan-2-ol



A mixture of 1-(8-{2-[4-(1,3-benzodioxol-5-yl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole dihydrochloride (0.20 g, 0.39 mmol), triethylamine (0.17 mL, 1.25 mmol) and 2-hydroxyisobutyric acid (41 mg, 0.39 mmol) in dimethylformamide (1.25 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (163 mg, 0.43 mmol) and the resulting mixture was stirred for 1 h at rt. The mixture was diluted with water and the resulting precipitate was collected, washed with saturated sodium bicarbonate solution, with water, dried and purified by chromatography on silica gel eluting with a dichloromethane to methanol-dichloromethane 1:19 gradient to give 1-(4-(1,3-benzodioxol-5-yl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2-methyl-1-oxopropan-2-ol as a solid (0.10g, 44%). HRMS C₃₃H₄₂N₄O₄ *m/z* 559.3284 (*M*+*H*)_{Cal.} 559.3276 (*M*+*H*)_{Obs.}.

Example 1169

Preparation of
1-((1*R*,5*S*)-8-{2-[4-(1,3-benzodioxol-5-yl)-1-isobutyrylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole




A mixture of 1-(8-{2-[4-(1,3-benzodioxol-5-yl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (0.20 g, 0.39 mmol), triethylamine (0.17 mL, 1.25 mmol) and isobutyric acid (34 mg, 0.39 mmol) in dimethylformamide (1.25 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (163 mg, 0.43 mmol) and the resulting mixture was stirred for 1 h at rt. The mixture was diluted with water and the resulting precipitate was collected, washed with saturated sodium bicarbonate solution, with water and dried to give 1-((1*R*,5*S*)-8-{2-[4-(1,3-benzodioxol-5-yl)-1-isobutyrylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole as a solid (0.15g, 72%). HRMS $C_{33}H_{42}N_4O_3$ m/z 543.3335 ($M+H$)_{Cal.} 543.3322 ($M+H$)_{Obs.}

Example 1170

Preparation of

3-(4-(1,3-benzodioxol-5-yl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxopropan-1-ol




A mixture of 1-(8-{2-[4-(1,3-benzodioxol-5-yl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride (0.20 g, 0.39 mmol), triethylamine (0.17 mL, 1.25 mmol) and 2,2-dimethyl-3-hydroxypropionic acid (46 mg, 0.39 mmol) in dimethylformamide (1.25 mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (163 mg, 0.43 mmol) and the resulting mixture was stirred for 1 h at rt. The mixture was diluted with water and the resulting gummy precipitate was dissolved in dichloromethane, washed with saturated sodium bicarbonate solution, with water, dried and purified by chromatography on silica gel eluting with a dichloromethane to methanol-dichloromethane 1:9 gradient to give 3-(4-(1,3-benzodioxol-5-yl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)-2,2-dimethyl-3-oxopropan-1-ol as a solid (0.13g, 59%). ^1H NMR (400 MHz, CDCl_3) δ 7.66 (m, 1H), 7.29 (m, 1H), 7.15 (m, 2H), 6.80 (m, 2H), 6.73 (m, 1H), 5.97 (s, 2H), 4.62 (m, 1H), 3.92 (m, 2H), 3.75 (m, 1H), 3.46 (s, 2H), 3.26 (m, 4H), 2.57 (s, 3H), 2.38 (m, 2H), 2.14 (m, 2H), 1.91 – 2.00 (m, 6H), 1.70 – 1.78 (m, 4H), 1.64 (m, 2H), 1.25 (s, 6H). HRMS $\text{C}_{34}\text{H}_{44}\text{N}_4\text{O}_4$ m/z 573.3441 ($\text{M}+\text{H}$) $_{\text{Cal}}$. 573.3428 ($\text{M}+\text{H}$) $_{\text{Obs.}}$.


Example 1171

N-{4-chloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}-1,1,1-trifluoromethanesulfonamide.

784




a) *Preparation of methyl 5-amino-2-chlorobenzoate.*



To a solution of 5-amino-2-chlorobenzoic acid (6.0 g, 35 mmol) in anhydrous methanol (100 ml) was added dropwise thionyl chloride (15 ml) with stirring under a nitrogen atmosphere. After stirring for 3 hours the volatiles were removed by spin evaporation in vacuo and the residue was dissolved in ethyl acetate and washed with saturated aqueous sodium bicarbonate and then water. The organic layer was concentrated by spin evaporation in vacuo with the addition of dichloromethane (3 times) to give methyl 5-amino-2-chlorobenzoate as a white solid (6.2 g, 95%). $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 7.20-7.14 (m, 1H), 7.13-7.02 (m, 1H), 6.73-6.67 (m, 1H), 3.89 (s, 3H). ES-LCMS m/z 186 ($\text{M}+\text{H}$).


b) *Preparation of methyl 2-chloro-5-
{[(trifluoromethyl)sulfonyl]amino}benzoate.*

785




Triflic anhydride (1.53 g, 5.39 mmol) was added dropwise to a solution of methyl 5-amino-2-chlorobenzoate (2.0 g, 10.8 mmol) in dichloromethane (35 ml) at 0 °C while stirring under a nitrogen atmosphere. After warming to room temperature over 1 hour, the thick slurry was diluted with additional dichloromethane (200 ml) and washed with aqueous 1 N hydrochloric acid and then water. The dichloromethane layer was dried with MgSO_4 and the volatiles were removed by spin evaporation in vacuo to give methyl 2-chloro-5-((trifluoromethyl)sulfonyl)amino)benzoate as a tan oil (1.7 g, 100%). ^1H -NMR (400 MHz, $\text{DMSO}-d_6$): δ 9.43 (s, 1H), 7.55-7.18 (m, 5H), 3.92-3.82 (m, 2H), 3.31-3.18 (m, 2H), 2.40-1.92 (m, 4H), and 1.38 (s, 9H). ES-LCMS m/z 317 (M+H).

c) *Preparation of 2-chloro-5-((trifluoromethyl)sulfonyl)amino)benzoic acid.*



A solution of methyl 2-chloro-5-((trifluoromethyl)sulfonyl)amino)benzoate (1.0 g, 3.15 mmol), sodium hydroxide (378 mg, 9.44 mmol), methanol (6 ml) and water (6 ml) was stirred for 1 hour. Removal of the volatiles by spin evaporation in vacuo gave a residue that was dissolved in 1 N aqueous hydrochloric acid. The aqueous solution was extracted with ethyl acetate (3 times) and the organic layers were combined, washed with water, and concentrated by spin evaporation in vacuo to give 2-chloro-5-((trifluoromethyl)sulfonyl)amino)benzoic acid as a crystalline solid (0.78 g, 82%). ^1H -NMR (400 MHz, $\text{DMSO}-d_6$): δ 7.63-7.60 (m, 1H), 7.59-7.54 (m, 1H), 7.40-7.35 (m, 1H). ES-LCMS m/z 304 (M+H).


d) Preparation of *N*-{4-chloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}-1,1,1-trifluoromethanesulfonamide.




N-{4-Chloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}piperidin-1-yl)carbonyl]phenyl}-1,1,1-trifluoromethanesulfonamide (43m g, 23 %) was obtained as a solid from 1-(8-{2-[4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (150 mg, 246 mmol), 2-chloro-5-[[[(trifluoromethyl)sulfonyl]amino]benzoic acid (82 mg, 270 mmol), HATU (140 mg, 389 mmol), and DIEA (95 mg, 738 mmol) following the procedure outlined in example 5. ¹H-NMR (400 MHz, DMSO-*d*₆): 8.6 (bs, 1H), 7.56-7.38 (m, 3H), 7.32-7.06 (m, 6H), 6.96-6.77 (m, 2H), 4.90-4.76 (bs, 1H), 4.04-3.82 (m, 3H), 3.40-3.15 (m, 5H+H₂O), 3.07-2.94 (m, 1H), 2.64-2.36 (m, 2H+DMSO), 2.23-1.68 (m, 14H). ES-LCMS *m/z* 732 (M+H).

Example 1172


1,1,1-Trifluoro-*N*-{3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl}methanesulfonamide



787




a) *Preparation of methyl 3-amino-benzoate.*



To a solution of 3-amino-benzoic acid (10.0 g, 72 mmol) in anhydrous methanol (100 ml) was added dropwise acetyl chloride (15 ml) with stirring under a nitrogen atmosphere. After stirring for 3 hours the volatiles were removed by spin evaporation in vacuo and the residue was dissolved in ethyl acetate and washed with saturated aqueous sodium bicarbonate and then water. The organic layer was concentrated by spin evaporation in vacuo with the addition of dichloromethane (3 times) give methyl 5-amino-2-chlorobenzoate as a white solid. (9.8 g, 89%). ¹H-NMR (400 MHz, DMSO-*d*₆, δ 7.92-7.78 (m, 2H), 7.50-7.44 (m, 1H), 7.4-7.36 (m, 1H), 3.94 (s, 3H) ES-LCMS *m/z* 152 (M+H).


b) *Preparation of methyl 3-{bis[(trifluoromethyl)sulfonyl]amino}benzoate.*



Triflic anhydride (3.73 g, 13.2 mmol) was added dropwise to a solution of methyl 3-amino-benzoate (2.0 g, 13.2 mmol) and DIEA (2.3 ml) in dichloromethane (50 ml) at 0 °C while stirring under a nitrogen atmosphere. After warming to room temperature over 1 hour, the thick slurry was diluted with additional dichloromethane (200 ml) and washed with aqueous 1 N hydrochloric acid and the water. The dichloromethane layer was dried with

MgSO₄ and the volatiles were removed by spin evaporation in vacuo to give methyl 3-bis[(trifluoromethyl)sulfonyl]amino}benzoate as a tan oil (5.4 g, 100%). ¹H-NMR (400 MHz, DMSO-*d*₆): δ 7.73-7.65 (m, 2H), 7.55-7.50 (m, 1H), 7.44-7.36 (m, 1H), 3.95 (s, 3H). ES-LCMS *m/z* 416 (M+H).


c) Preparation of 3-[[[(trifluoromethyl)sulfonyl]amino]benzoic acid.



A solution of methyl 3-bis[(trifluoromethyl)sulfonyl]amino}benzoate (5.4 g, 13.0 mmol), sodium hydroxide (3.12 g, 78.0 mmol), methanol (125 ml) and water (125 ml) was stirred for 2 hours. The solution from concentration to 75 ml by spin evaporation in vacuo and dilution with 100 ml water was extracted with ethyl acetate. The aqueous layer was acidified with 12 N hydrochloric acid and again extracted with ethyl acetate. The organic layer was washed with water and concentrated by spin evaporation in vacuo, with the addition of dichloromethane (3 times) to give a residue that was dissolved in 1 N aqueous hydrochloric acid. The aqueous solution was extracted with ethyl acetate (3 times) and the organic layers were combined, washed with water, and concentrated by spin evaporation in vacuo to 3-[[[(trifluoromethyl)sulfonyl]amino]benzoic acid as a solid (2.3 g, 66%). ¹H-NMR (400 MHz, DMSO-*d*₆): δ 7.83-7.78 (m, 2H), 7.55-7.50 (m, 1H), 7.50-7.46 (m, 1H). ES-LCMS *m/z* 269 (M+H).

d) Preparation of 1,1,1-trifluoro-N-{3-[[4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-1-piperidiny]carbonyl]phenyl}methanesulfonamide.


789




1,1,1-Trifluoro-*N*-{3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide (72 mg, 100%) was obtained as a solid from 1-(8-{2-[4-(3-fluorophenyl)-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (150 mg, 246 mmol), 3-[[trifluoromethyl)sulfonyl]amino]benzoic acid (73 mg, 270 mmol), HATU (140 mg, 369 mmol), and DIEA (95 mg, 738 mmol) following the procedure outlined in example 5. ¹H-NMR (400 MHz, DMSO-*d*₆): δ 8.83-8.68 (bs, 1H), 7.58-7.49 (m, 1H), 7.59-7.49 (m, 2H), 7.49-7.38 (m, 2H), 7.21-7.05 (m, 4H), 7.02-6.91 (m, 2H), 6.79-6.67 (m, 1H), 5.03-4.76 (m, 1H), 4.13-3.96 (m, 3H), 3.57-3.01 (m, 6H), 2.54-2.39 (M, 5H), 2.24-1.97 (m, 8H), 1.97-1.68 (m, 3H), 1.31-1.14 (m, 2H). ES-LCMS *m/z* 698 (M+H).

Example 1173

N-{3-[(4-(3-Fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide




a) Preparation of 3-[(methanesulfonyl)amino]benzoic acid.



To a solution of methyl 3-amino-benzoate (2.0 g, 13.2 mmol) and pyridine (2.30 g, 29.1 mmol) in dichloromethane (50 ml) at -10°C under a nitrogen atmosphere was slowly added methanesulfonyl chloride (2.25 ml, 29.1 mmol) by syringe. After 2 hours, water was added and the volatiles were removed by spin evaporation in vacuo. A solution of the residue and sodium hydroxide (3.175 g, 79.4 mmol) in methanol (50 ml) and water (50 ml) was stirred for 18 hours. The residue after removal of the volatiles by spin evaporation in vacuo was dissolved in 1 N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and the volatiles were removed by spin evaporation in vacuo to give 3-[(methanesulfonyl)amino]benzoic acid as an oil. (1.32 g, 46 %). $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 7.83-7.78 (m, 2H), 7.55-7.50 (m, 1H), 7.50-7.46 (m, 1H), 3.80 (s, 3H). ES-LCMS m/z 216 (M+H).

b) Preparation of N-{3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide.




N-{3-[(4-(3-Fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide (72 mg, 100%) was obtained as a solid from 1-(8-{2-[4-(3-fluorophenyl)-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (150 mg, 246 mmol 3-


[(methylsulfonyl)amino]benzoic acid (73 mg, 270 μ mol), HATU (140 mg, 369 μ mol), and DIEA (95 mg, 738 μ mol) following the procedure outlined in example 5. $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 9.90 (bs 1H), 7.49-7.49 (m, 1H), 7.44-7.31 (m, 3H), 7.27-7.20 (m, 3H), 7.19-7.15 (m, 1H), 7.14-7.00 (m, 4H), 4.55-4.39 (m, 1H), 3.91-3.79 (m, 1H), 3.53-3.40 (m, 1H), 3.40-3.09 (m, 2H), 3.03-2.96 (m, 3H), 2.51-2.45 (m, 5H), 2.44-2.40 (m, 3H), 2.40-2.30 (m, 2H), 2.17-1.96 (m, 2H), 1.91-1.70 (m, 4H), 1.64-1.52 (m, 2H), 1.25-1.10 (m, 1H). ES-LCMS m/z 644 ($M+H$).

Example 1174

N-(3-Chloro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl)methanesulfonamide.




a) *Preparation of methyl 4-amino-2-chlorobenzoate.*



Methyl 4-amino-2-chlorobenzoate (5.1 g, 94 %) was obtained as solid from 4-amino-2-chlorobenzoic acid (5.0 g, 29.1 μ mol) following the procedure outlined for *methyl 5-amino-2-chlorobenzoate*. $^1\text{H-NMR}$ (400 MHz, DMSO-


d_6): δ 7.64-7.57 (m, 1H), 6.65-6.57 (m, 1H), 6.51-6.39 (m, 1H), 6.16 (bs, 2H), 3.71 (s, 3H). ES-LCMS m/z 186 (M+H).

b) Preparation of 2-chloro-4-[(methylsulfonyl)amino]benzoic acid.



2-Chloro-4-[(methylsulfonyl)amino]benzoic acid (5.1 g, 94 %) was obtained as an oil from methyl 4-amino-2-chlorobenzoate (5.0 g, 29.1 mmol) following the procedure outlined for **3-[(methylsulfonyl)amino]benzoic acid**. $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 13.11 (bs, 1H), 10.29 (bs, 1H), 7.83-7.80 (m, 1H), 7.24-7.22 (m, 1H), 7.21-7.18 (m, 1H), 3.11 (s, 3H). ES-LCMS m/z 250 (M+H).

c) Preparation of N-{3-chloro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide.




N-{3-Chloro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide (29 mg, 17.4%) was obtained as a solid from 1-(8-{2-[4-(3-fluorophenyl)-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (150 mg, 246 mmol), 2-chloro-4-[(methylsulfonyl)amino]benzoic acid (68 mg, 0.270 mmol), HATU (140 mg, 369 mmol), and DIEA (95 mg, 738 mmol) following the procedure


outlined in example 5. $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 7.55-7.44 (m, 1H), 7.44-7.27 (m, 3H), 7.27-6.98 (m, 8H), 4.56-4.42 (m, 1H), 3.97-3.82 (m, 1H), 3.39-3.17 (m, 3H), 3.10-2.93 (m, 5H), 2.44-2.40 (m, 3H), 2.39-2.29 (m, 2H), 2.19-2.02 (m, 3H), 1.93-1.69 (m, 6H), 1.62-1.54 (m, 2H), 1.24-1.07 (m, 2H), 0.98-0.91 (m, 1H). ES-LCMS m/z 678 ($\text{M}+\text{H}$).

Example 1175

N-(4-chloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl)methanesulfonamide



a) *Preparation of 2-chloro-5-[(methylsulfonyl)amino]benzoic acid.*




2-Chloro-5-[(methylsulfonyl)amino]benzoic acid (1.83 g, 68 %) was obtained as an oil from methyl 5-amino-2-chlorobenzoate (2.0 g, 10.8 mmol)

following the procedure outlined for **2-chloro-4-**

[(methylsulfonyl)amino]benzoic acid. $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ

13.46 (bs, 1H), 10.05 (s, 1H), 7.62-7.55 (m, 1H), 7.50-7.45 (m, 1H), 7.37-7.30 (m, 1H), 3.02 (s, 3H). ES-LCMS m/z 249 (M+H).


b) Preparation of N-{4-chloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl}methanesulfonamide.




N-{4-Chloro-3-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl}methanesulfonamide (103 mg, 61.6 %) was obtained as a solid from 1-(8-{2-[4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (150 mg, 246 μmol), 2-chloro-5-[(methylsulfonyl)amino]benzoic acid (68 mg, 0.270 μmol), HATU (140 mg, 369 μmol), and DIEA (95 mg, 738 μmol) following the procedure outlined in example 5. $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 10.00 (bs, 1H), 7.57-7.47 (m, 2H), 7.45-7.34 (m, 2H), 7.28-7.21 (m, 3H), 7.18-7.02 (m, 4H), 4.57-4.43 (m, 1H), 3.98-3.83 (m, 1H), 3.45-3.21 (m, 8H), 3.11-2.99 (m, 4H), 2.46-2.41 (m, 3H), 2.41-2.30 (m, 2H), 2.21-2.02 (m, 2H), 1.99-1.72 (m, 6H), 1.65-1.56 (m, 2H). ES-LCMS m/z 678 (M+H).

Example 1176

N-{3-Fluoro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide.




a) *Preparation of methyl 4-amino-2-fluorobenzoate.*



Methyl 4-amino-2-fluorobenzoate (1.98 g, 98 %) was obtained as solid from 4-amino-2-fluorobenzoic acid (2.0 g, 12.90 mmol) following the procedure outlined for **methyl 5-amino-2-chlorobenzoate**. ¹H-NMR (400 MHz, DMSO-*d*₆): δ 7.61-7.58 (m, 1H), 6.42-6.37 (m, 1H), 6.32-6.25 (m, 3H), 3.72 (s, 3H). ES-LCMS *m/z* 170 (M+H).

b) *Preparation of 2-fluoro-4-[(methanesulfonyl)amino]benzoic acid.*




2-Fluoro-4-[(methanesulfonyl)amino]benzoic acid (5.1 g, 94 %) was obtained as an oil from methyl 4-amino-2-fluorobenzoate (5.0 g, 29.1 mmol) following the procedure outlined in example 3-

[(methanesulfonyl)amino]benzoic acid. ¹H-NMR (400 MHz, DMSO-*d*₆): δ

7.69-7.59 (m, 1H), 6.45-6.40 (m, 1H), 6.40-6.32 (m, 3H), 3.72 (s, 3H). ES-LCMS m/z 234 (M+H).


c) Preparation of *N*-{3-fluoro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny)carbonyl]phenyl}methanesulfonamide.




N-{3-Fluoro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny)carbonyl]phenyl}methanesulfonamide (26 mg, 15%) was obtained as a solid from 1-(8-{2-[4-(3-fluorophenyl)-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (150 mg, 246 mmol), 2-chloro-4-[(methylsulfonyl)amino]benzoic acid (U20375/163/1) (68 mg, 0.270 mmol), HATU (140 mg, 369 mmol), and DIEA (95 mg, 738 mmol) following the procedure outlined in example 5. $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 7.49-7.45 (m, 1H), 7.43-7.28 (m, 3H), 7.25-7.01 (m, 8H), 4.54-4.42 (m, 1H), 3.95-3.83 (m, 1H), 3.38-3.196 (m, 5H+H₂O), 3.08-2.97 (m, 4H), 2.51-2.40 (m, 2H), 2.39-2.29 (m, 2H), 2.18-2.01 (m, 3H), 1.91-1.70 (m, 6H), 1.62-1.55 (m, 2H), 1.23-1.10 (m, 2H), 0.98-0.92 (m, 1H). ES-LCMS m/z 662 (M+H).

Example 1177

N-{3-Chloro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl}-1,1,1-trifluoromethanesulfonamide




b) Preparation of methyl 4-{bis[(trifluoromethyl)sulfonyl]amino}-2-chlorobenzoate.



Triflic anhydride (3.73 g, 13.2 mmol) was added dropwise to a solution of methyl 4-amino-2-chlorobenzoate (2.45 g, 13.2 mmol) and ethyl[bis(1-methylethyl)]amine (2.3 ml) in dichloromethane (50 ml) at 0 °C while stirring under a nitrogen atmosphere. After warming to room temperature over 1 hour, the thick slurry was diluted with additional dichloromethane (200 ml) and washed with aqueous 1 N hydrochloric acid and the water. The dichloromethane layer was dried with MgSO₄ and the volatiles were removed by spin evaporation in vacuo to give methyl 4-


{bis[(trifluoromethyl)sulfonyl]amino}-2-chlorobenzoate as a tan oil (5.9 g, 100 %). ES-LCMS m/z 450 (M+H).

c) Preparation of 2-chloro-4-[[[(trifluoromethyl)sulfonyl]amino]benzoic acid.



A solution of methyl 4-{bis[(trifluoromethyl)sulfonyl]amino}-2-chlorobenzoate (5.9 g, 13.1 mmol), sodium hydroxide (3.12 g, 78.0 mmol), methanol (125 ml) and water (125 ml) was stirred for 2 hours. The solution from concentration to 75 ml by spin evaporation in vacuo and dilution with 100 ml water was extracted with ethyl acetate. The aqueous layer was acidified with 12 N hydrochloric acid and again extracted with ethyl acetate. The organic layer was washed with water and concentrated by spin evaporation in vacuo, with the addition of dichloromethane (3 times) to give a residue that was dissolved in 1 N aqueous hydrochloric acid. The aqueous solution was extracted with ethyl acetate (3 times) and the organic layers were combined, washed with water, and concentrated by spin evaporation in vacuo 2-chloro-4-[[[(trifluoromethyl)sulfonyl]amino]benzoic acid as a solid (3.6 g, 61%). ES-LCMS m/z 304 (M+H).


d) Preparation of N-{3-chloro-4-[[4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}-1,1,1-trifluoromethanesulfonamide.




N-{3-chloro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl}-1,1,1-trifluoromethanesulfonamide (35 mg, 19%) was obtained as a solid from 1-(8-{2-[4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1*H*-benzimidazole (150 mg, 246 mmol), 2-chloro-4-[[[(trifluoromethyl)sulfonyl]amino]benzoic (82 mg, 270 mmol), HATU (140 mg, 369 mmol), and DIEA (95 mg, 738 mmol) following the procedure outlined in example 5. ES-LCMS *m/z* 732 (M+H).

Example 1178

1,1,1-Trifluoro-*N*-{2-fluoro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl}methanesulfonamide.




a) *Preparation of Methyl 4-amino-3-fluorobenzoate.*




Methyl 4-amino-3-fluorobenzoate (1.01 g, 92 %) was obtained as solid from 4-amino-3-fluorobenzoic acid (1.0 g, 6.4 mmol) following the procedure outlined in example 1171. ES-LCMS *m/z* 170 (M+H).

b) Preparation of 3-fluoro-4-[[trifluoromethyl)sulfonyl]amino]benzoic acid.



3-Fluoro-4-[[trifluoromethyl)sulfonyl]amino]benzoic acid (0.892 g, 97 %) was obtained as an oil from methyl 4-amino-3-fluorobenzoate (1.80 g, 6.39 mmol) following the procedure outlined in example 1174. ES-LCMS m/z 288 (M+H).


c) Preparation of 1,1,1-trifluoro-N-{2-fluoro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidinyl]carbonyl]phenyl}methanesulfonamide.




1,1,1-Trifluoro-N-{2-fluoro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl)-1-piperidinyl]carbonyl]phenyl}methanesulfonamide (85 mg, 48%) was obtained as a solid from 1-(8-{2-[4-(3-fluorophenyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (150 mg, 246 mmol), 3-fluoro-4-[[trifluoromethyl)sulfonyl]amino]benzoic acid (78 mg, 270 mmol), HATU (140 mg, 369 mmol), and DIEA (95 mg, 738 mmol) following the procedure outlined in example 5. ES-LCMS m/z 716 (M+H).

Example 1179

1,1,1-Trifluoro-N-{3-fluoro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl}methanesulfonamide.




a) *Preparation of methyl 4-amino-2-fluorobenzoate.*



Methyl 4-amino-2-fluorobenzoate (1.85 g, 84 %) was obtained as solid from 4-amino-2-fluorobenzoic acid (2.0 g, 12.90 mmol) following the procedure outlined in example 1171. ES-LCMS m/z 170 ($M+H$).


b) *Preparation of 2-fluoro-4-[(trifluoromethyl)sulfonyl]amino}benzoic acid.*



2-Fluoro-4-[(trifluoromethyl)sulfonyl]amino}benzoic acid (1.32 g, 74 %) was obtained as an oil from methyl 4-amino-2-fluorobenzoate (1.05 g, 6.2

mmol)) following the procedure outlined in example 1174. ES-LCMS m/z 288 (M+H).



c) Preparation of 1,1,1-trifluoro-N-{3-fluoro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide.




1,1,1-Trifluoro-N-{3-fluoro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide (85 mg, 48%) was obtained as a solid from 1-(8-{2-[4-(3-fluorophenyl)-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (150 mg, 246 mmol), 2-fluoro-4-[[[(trifluoromethyl)sulfonyl]amino]benzoic acid (78 mg, 270 mmol), HATU (140 mg, 369 mmol), and DIEA (95 mg, 738 mmol) following the procedure outlined in example 5. ES-LCMS m/z 716 (M+H).

Example 1180

N-{2-fluoro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidinyl)carbonyl]phenyl}methanesulfonamide.

**a) Preparation of methyl 4-amino-3-fluorobenzoate**


Methyl 4-amino-3-fluorobenzoate (0.98 g, 90.0 %) was obtained as solid from 4-amino-3-fluorobenzoic acid (1.0 g, 6.45 mmol) following the procedure outlined in example 1171. ES-LCMS *m/z* 170 (M+H).

b) Preparation of 3-fluoro-4-[(methylsulfonyl)amino]benzoic acid.

3-Fluoro-4-[(methylsulfonyl)amino]benzoic acid (490 mg, 66 %) was obtained as an oil from methyl 4-amino-3-fluorobenzoate (0.54 g, 3.19 mmol)

) following the procedure outlined in example 1174. ES-LCMS m/z 234 (M+H).


c) Preparation of N-{2-fluoro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide.




N-{2-Fluoro-4-[(4-(3-fluorophenyl)-4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide (92 mg, 52 %) was obtained as a solid from 1-(8-{2-[4-(3-fluorophenyl)-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (150 mg, 246 mmol), 3-fluoro-4-[(methylsulfonyl)amino]benzoic acid (U20375/147/1) (78 mg, 270 mmol), HATU (140 mg, 369 mmol), and DIEA (95 mg, 738 mmol) following the procedure outlined in example 5. ES-LCMS m/z 662 (M+H).

Example 1181

N-{4-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide



The synthesis of 4-[(methylsulfonyl)amino]benzoic acid



2.1 g (15.6 mmol) of 4-aminobenzoic acid was dissolved in anhydrous MeOH, added 14.47g (123.3 mmol) of thionyl chloride dropwise under N₂ while stirring at rt. After stirring for four hours, solvents were removed and redissolved in 100 mL EtOAc and 40 mL of saturated NaHCO₃ aq, stirred 30 min, separated and washed with 3 x 20 mL water. Organics were dried yielding 2.17g (yield 92.1%) of methyl 4-aminobenzoate. ¹H NMR (300 MHz, CDCl₃): 7.88 (2H, d, *J*=8.6 Hz), 6.66 (2H, d, *J*=8.6 Hz), 4.19 (2H, broad s), 3.88 (3H, s). ¹³C NMR (300 MHz, CDCl₃): 167.8 (C=O), 151.4 (Cq), 131.9 (2x CH), 120.0 (Cq), 113.8 (2x CH), 50.9 (CH₃).


1.13g (7.48 mmol) of methyl 4-aminobenzoate was dissolved in 20 mL of anhydrous DCM and 1.97g (17.19 mmol) of mesyl chloride was added at 4 deg C, followed by the 2.22 g (17.19 mmol) of the diethylisopropylamine. Reaction was carried out overnight at room temperature resulting methyl 4-[(methylsulfonyl)amino]benzoate, which was used in the next step without additional purification.

3.6 g (90 mmol) of NaOH was added to the solution of methyl 4-[(methylsulfonyl)amino]benzoate in 40 mL methanol and 20 mL water and stirred overnight at room temperature. Solvents were then removed and the product purified by ethyl acetate extraction from 1N aqueous hydrochloric acid, providing 1.2g (yield 74.6%) of the 4-[(methylsulfonyl)amino]benzoic acid. ¹H NMR in d-chloroform: 8.03 (2H, d, J=8.7 Hz), 7.34 (2H, d, J=8.7 Hz), 3.09 (3H, s). ¹³C NMR in d-chloroform: 131.2, 117.9, 38.6.

The synthesis of N-{4-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide


270 mg (0.61 mmol) of 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole dihydrochloride salt trihydrate was dissolved in the dichloromethane, and added 195 mg (0.91 mmol) of the 4-[(methylsulfonyl)amino]benzoic acid, 440 mg (0.91 mmol) of HATU and 391 mg (3.03 mmol) of the diethylisopropylamine an the reaction carried out as described in example 5, resulting in title N-{4-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]phenyl}methanesulfonamide, yield 32% after HPLC purification.

¹H NMR (d4-methanol, 400 MHz): 7.53 (1H, m), 7.40 (4H, m), 7.31 (2H, d, J=7.7 Hz), 7.22 (4H), 6.99 (1H, m), 4.74 (1H, m), 4.09 (1H, broad s), 3.68 (1H, broad s), 3.39 (4H, m), 3.03 (4H, m), 2.52 (s, 3H), 2.45 (2H, m), 2.32 (1H, broad s), 2.23 (1H, broad s), 1.95 (10H, m), 1.71 (1H, m)

Example 1074

3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]-N-hydroxybenzamide

Example 1074 was prepared according to scheme below.



1-((1R,5S)-8-{2-[4-(3-fluorophenyl)-4-piperidiny]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole (500mg, 0.962mmol) was combined with 3-[(methoxy)carbonyl]benzoic acid (173mg, 0.962mmol) and DIPEA (373mg, 2.88mmol) in 8mL DMF and treated with HATU (366mg, 0.962mmol) at ambient temperature for 16h. The reaction mixture was treated with satd. NaHCO₃ which yielded a solid precipitate that was filtered off, washed with water and dried to give methyl 3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]benzoate (395mg, 0.649mmol, 67%) as a white solid. ES-LCMS *m/z* 609.1 (M+H).

Hydroxylamine.HCl (26mg, 0.360mmol) dissolved in 5mL EtOH was cooled in an ice bath and treated with 0.5M NaOCH₃ (1.92mL, 0.96mmol) for 15min with stirring. Methyl 3-[(4-(3-fluorophenyl)-4-{2-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]benzoate (183mg, 0.300mmol) was added to the reaction

mixture and allowed to stir 16h at ambient temperature. The reaction mixture was concentrated to dryness and purified by RP-HPLC on a C-18 column eluted with 0→50%CH₃CN in H₂O with 0.1% formic acid buffer. The appropriate fractions were combined and concentrated to give 3-[(4-(3-fluorophenyl)-4-{2-[(1*R*,5*S*)-3-(2-methyl-1*H*-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-1-piperidiny]carbonyl]-*N*-hydroxybenzamide (20mg, 0.032mmol, 9%) as a clear glass. ES-LCMS *m/z* 610.14 (M+H), 608.21 (M-1).

CC-Chemokine Receptor-5 Binding by Scintillation Proximity Assay

The compounds of this invention were evaluated as antagonists of CCR5 by high-throughput screening using scintillation proximity assay (SPA) binding that measures inhibition of binding of ¹²⁵I-MIP1 to the human CCR5 chemokine receptor.

Human CCR5 receptors were expressed in Chinese Hamster Ovary (CHO) cells. Cells were grown in suspension and 50 to 80 ml CCR5 cell pellets were prepared.

Membranes were prepared according to the following procedure: 1) weighed pellet; 2) prepared an ice-cold 50 mM HEPES buffer, containing 0.0025 mg/ml Pefabloc, 0.0001 mg/ml Pepstatin A, 0.0001 mg/ml Leupeptin, 0.0001 mg/ml Aprotinin (protease inhibitor cocktail), pH 7.4; 3) homogenized pellet in 5 volumes of HEPES buffer; 4) homogenized again with a glass homogenizer for 10 to 20 strokes; 5) centrifuged homogenate at 18,000 rpm in a F28/36 rotor using a Sorvall RC26 PIUS refrigerated Centrifuge for 30 minutes; 6) discarded supernatant and resuspended pellet in 3 volumes of HEPES buffer; 7) homogenized and centrifuged again using steps 4-6 for two more times; 8) re-weighed pellet and homogenize in three times weight-to-volume of HEPES buffer; 9) placed aliquot 0.5 to 1.5 ml of the membrane preparation into small vials and stored at -80°C; 10) determined the protein concentration of the membrane preparation using the Bio-Rad or BCA

method; and 11) characterized the membrane homogenate for the assay conditions including protein concentration, optimal protein-to-bead ratio in SPA, and saturation curve to determine K_d and B_{max} (number of binding sites) in SPA.

The saturation curve binding experiment was performed by adding varying amounts of [125 I]MIP1 α (0-8.5 nM) to membranes and beads in concentrations chosen from the optimal protein/bead ratio. The data was analyzed using a non-linear curve-fitting program. The K_d and B_{max} were derived from the curve.

Bacitracin 50 mg/ml was dissolved in deionized water, brought to a boil for 5 minutes (to destroy protease activity) and cooled. One milliliter aliquots were prepared and stored at -80°C .

Protease inhibitor cocktail was prepared by dissolving 25 mg/ml of Pefabloc, 1 mg/ml of Leupeptin, 1 mg/ml of Aprotinin and 1 mg/ml of Pepstatin A in 100% DMSO. The cocktail could be aliquoted and stored frozen at -20°C until needed.

Any reagent bottles and reservoirs that come in contact with the radioligand were treated with Sigmacote to reduce sticking. Containers were rinsed with undiluted Sigmacote and with deionized water for several times and allowed to air dry before using.

Color quench assay was performed with a [125 I] SPA PVT color quench kit (Cat. No. RPAQ 4030, Amersham Ltd.). A color quench curve was generated for each Packard TopCount and was stored in each counting protocol specific for the assay. This was done to prevent colored compounds from quenching the scintillation counts.

Compounds of this invention were prepared for SPA according to the following protocol. Compounds for a single concentration determination (one shots) were delivered in 96 well Packard Optiplates containing 1 μl of compound in 100% DMSO in columns A1-H10 (80 compounds/plate). Column A11 to H11 was used for total binding (Bo: zero standard - bound radioactive counts in the absence of added inhibitor or test compound) (vehicle-5 μl of the appropriate DMSO concentration) and column A12 to D12

was used for determination of nonspecific binding (NSB). No further preparation was required. Compounds for concentration-response curves (10 points) were delivered in 96- Packard Optiplates containing 1 μ l of compound in 100% DMSO in columns A1-H10. A 10-point concentration-response curve was desired for each compound with a starting high concentration of 30 μ M (in the assay final). Column A11 to H11 was used for total binding (Bo) (vehicle-5 μ l of the appropriate DMSO concentration) and column A12 to D12 was used for determination of nonspecific binding. No further preparation was required.

Assay buffer was prepared by mixing 50 mM HEPES buffer (pH 7.4), 1 mM CaCl_2 , 5 mM MgCl_2 which could be made ahead as a 100X stock, 1% BSA (bovine serum albumin), 0.5 mg/ml Bacitracin, and protease inhibitor cocktail (100 μ L/100 ml). DMSO was added to equal a final concentration of 2% per well (includes compound %DMSO) if needed.

$[^{125}\text{I}]\text{MIP1}\alpha$ radioligand dilutions was prepared in containers treated with Sigmacote. Each 50 μ Ci vial was reconstituted with 0.5 ml of deionized water and stored at 4°C. The specific activity was 2,000 Ci/mmol. 50 μ L (~60,000 cpm; 0.17 nM) of $[^{125}\text{I}]\text{MIP1}\alpha$ was added to each assay well.

Zero standard (Bo) was prepared by making a 20% DMSO solution and adding 5 μ l of 20% DMSO solution to each well in columns A11-H11. This gave a final 2% DMSO concentration for the well when added to the 1% in the assay buffer.

A stock dilution of MIP1 α at 100 μ M was made using deionized water and aliquoted and frozen. The MIP-1 α stock solution was diluted to a concentration of 2 μ M in the same 20% DMSO solution used above. 5 μ l of the resultant solution was added to the wells in column A12 to D12 to give a final assay concentration of 100 nM. This procedure was conducted in a Sigmacote-treated container.

The final assay concentration for the membrane was 15 μ g per well. SPA beads were prepared by adding 5 ml of assay buffer to a 500 mg vial. The final concentration of SPA beads in the assay was 0.25 mg/well.

Membranes and beads were premixed as a 1:1 (membrane:bead) mixture and maintained at mixture at 4°C with constant stirring. 50 µl of the mixture was added to each assay well. After all reagents had been added to the plates (total assay volume 100 µl), plates were shaken for 4 hours at room temperature. After 4 hours, the plates were placed on the TopCount in a count the plates on the TopCount for 30 sec per well using an appropriate program (i.e., one with a quench curve established for the conditions of the assay).

Data reduction was performed using the Microsoft Excel Addins Robofit or Robosage. For single concentration assays (one shots), the result of each test well was expressed as % inhibition using the following formula: $100 * (1 - (U1 - C2) / (C1 - C2))$, where U1 was the unknown sample in cpm observed in a particular well, C1 was the average of column 12 cpm observed in the absence of any added inhibitor, and C2 was the average of column 11 cpm observed in the presence of 1 µM of MIP1α. For concentration-response assays, the result of each test well was expressed as %B/Bo (% total specific binding) using the following formula: $100 * (U1 - C2) / (C1 - C2)$. Curves were generated by plotting the %B/Bo versus the concentration and the IC₅₀ was derived using the equation $y = V_{max} * (1 - (x^n / (k^n + x^n)))$.

For controls and standards, each plate contained 12 wells of total binding (column A11-H11). The cpm/well were averaged and used in data reduction as value C1. Each plate also contained 4 wells of non-specific binding (wells A12-D12). The counts of these wells were averaged and used in data reduction as value C2. A standards plate was included in each experiment. This plate contained a 14-point concentration-response curve (in triplicate) for the standard compound MIP1α at a starting concentration of 1 µM. The average historical pK_i obtained with MIP1α was 7.6.

The relevant biological response field for a single concentration (one shots) was % inhibition. Inhibition values of >40 or >50% were considered positive responses. The relevant biological response field for a concentration-response experiment was pK_i.

HOS Assay (Also referred to as HOS-LTR-Luciferase Assay)

HOS-CD4.CCR5-LTR-Luciferase (Bioresource Registration # 21164): Human Osteosarcoma cell line was engineered to overexpress human CD4 and human CCR5 (AIDS Repository cat# 3318) stably transfected with HIV-1-LTR-Luciferase reporter.

Growth and Maintenance of the HOS-CD4.CCR5-LTR-Luciferase cell line: The cells were propagated in DMEM containing 2% FBS. Cells were split by standard trypsinization when confluency reached 80% (roughly every 2 to 3 days).

Titring of virus stocks: HIV-1 virus stocks were titred in the assay system in order to obtain an estimate of the number of infectious particles per unit volume (described as RLU/ml). Virus stocks were diluted into DMEM containing 2% FBS and assayed as described in the "procedure" section below.

Procedure: Black-walled 96-well tissue culture plates were seeded with HOS-CD4.CCR5-LTR-Luciferase @ 0.6 to 1.2×10^3 cells per well in $50\mu\text{l}$ DMEM containing 2% FBS and placed in a humidified incubator @ 37°C , 5% CO_2 overnight. The following day, test compounds were titrated 4-fold at 2X the final concentration in DMEM + 2% FBS + 0.2% DMSO. $50\mu\text{l}$ of titrated compound was transferred to the HOS cells and the plates were placed in a humidified incubator at 37°C , 5% CO_2 for 1 hr. An additional $60\mu\text{l}$ of 2X titrated compound was transferred to a clear-walled 96-well tissue culture plate and $60\mu\text{l}$ of HIV (diluted to appropriate m.o.i.) was added to each well and thoroughly mixed. $100\mu\text{l}$ of the HIV/compound mixture was transferred to the black-walled plates containing $100\mu\text{l}$ of cells/compound. The plates were placed in a humidified incubator at 37°C , 5% CO_2 for 72hr. Following the 72 hour incubation, $150\mu\text{l}$ of supernatant was removed and $50\mu\text{l}$ of reconstituted LUCITE (kit reagent) was added to each well. Each plate was sealed and read in a Topcount (Packard) luminometer at 1s/well.

Data Reduction: Relative Light Units (RLU) were expressed as % control ($\text{RLU at drug concentration} / \text{RLU no drug} \times 100 = \% \text{ Control}$). IC_{50}

values were determined by any one of the following four nonlinear regression models:

$$y = V_{\max} * (1 - (x^n / (K^n + x^n))) + Y_2;$$

$$y = V_{\max} * (1 - (x^n / (K^n + x^n)));$$

$$y = V_{\max} * (1 - (x / (K + x))) + Y_2;$$

$$y = V_{\max} * (1 - (x / (K + x)));$$

where K is IC_{50} , Y_2 is baseline, and N is Hill Coefficient.


Each of the compounds of the present invention provides a pIC_{50} value of at least 5 when tested in each of the above-described assays.

Test compounds are employed in free or salt form.

While we have hereinbefore presented a number of embodiments of this invention, it is apparent that our basic construction can be altered to provide other embodiments which utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of the invention is to be defined by the appended claims rather than by the specific embodiments which have been represented by way of example.

What is Claimed is:

1. A compound of formula (I):



or a pharmaceutically acceptable derivative thereof, wherein:

R^1 is alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl, wherein said alkyl is optionally substituted by one or more R^7 , said carbocyclyl or heterocyclyl is optionally substituted by one or more R^8 and said aryl or heteroaryl is optionally substituted by one or more R^6 ; or R^1 and X taken together form a saturated, partially saturated or aromatic 5-7 membered ring, having 0-3 heteroatoms chosen from oxygen, sulfur, nitrogen and phosphorus, that is fused to Ring A;

X is a C_{1-5} alkylene chain, wherein said C_{1-5} alkylene chain is optionally substituted by one or more groups chosen from $=O$, $=S$ and halo, and wherein said C_{1-5} alkylene chain optionally contains 1-3 heteroatoms chosen from oxygen, sulfur, nitrogen and phosphorus;

Ring A is a saturated, partially saturated or aromatic 5-6 membered monocyclic or 8-10 membered bicyclic ring having 0-5 ring heteroatoms chosen from oxygen, sulfur and nitrogen;

each R^2 is independently chosen from $-OR^0$, $-C(O)R^0$, $-C(O)N(R^0)_2$, $-N(R^0)(-V_m-R^+)$, $-S(O)_2R^0$, $-S(O)_2N(R^0)_2$, $-(CH_2)_a-N(R^0)(-V_b-R^+)$, $-(CH_2)_a(-V_b-R^+)$, halo, alkyl, aryl, carbocyclyl, heteroaryl and heterocyclyl, wherein said alkyl is optionally substituted by one or more R^7 , said aryl or heteroaryl is optionally substituted by one or more R^6 , and said carbocyclyl or heterocyclyl is optionally substituted by one or more R^8 ; or two adjacent R^2 s on Ring A are optionally taken together to form a fused, saturated, partially saturated or aromatic 4-7 membered ring having 0-3 heteroatoms chosen from oxygen, sulfur, nitrogen and phosphorus; or two geminal R^2 s are optionally taken together to form a spiro, saturated, partially saturated or

aromatic 5-6 membered ring having 0-3 heteroatoms chosen from oxygen, sulfur and nitrogen, said fused or spiro ring being optionally substituted by one or more groups chosen from oxo, alkyl optionally substituted by one or more R^7 , and aryl optionally substituted by one or more R^6 ;

each a is independently 0-3;

each b is independently 0 or 1;

V is alkyl, $-C(O)-$, $-S(O)_2-$, $-C(O)O-$, or $-C(O)-N(R^0)-$ (when V is attached to R^+ through the right hand side of the radical;

R^+ is alkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, wherein said alkyl is optionally substituted by one or more R^7 and said aralkyl or aryl is optionally substituted by one or more R^6 ;

m is 0 or 1;

n is 0-5;

R^3 is H, halo, $-N(R^0)_2$, $-N(R^0)C(O)R^0$, $-CN$, $-CF_3$, alkyl optionally substituted by one or more groups chosen from R^7 and $-S$ -aryl optionally substituted by $-(CH_2)_{1-6}-N(R^0)SO_2(R^0)$, carbocyclyl, aryl, heteroaryl or heterocyclyl, wherein said carbocyclyl or heterocyclyl is optionally substituted by one or more R^8 , and said aryl or heteroaryl is optionally substituted by one or more R^6 ;

Y is $-(CR^4R^5)_p-$, $-C(O)-$, $-C(O)C(O)-$, $-C(S)-$, $-O-(CH_2)_{0-4}-C(O)-$, $-N(R^0)-C(O)-$, $-C(O)-N(R^0)-$, $-N(R^0)-C(S)-$, $-S(O)_t-$, $-O-C(=N-CN)-$, $-O-C(=N-R^0)-$, $-S-C(=N-CN)-$, $-N(R^0)-C(=N-CN)-$, $-C(=N-CN)-$, $-N(R^0)-C[=N-C(O)-R^0]-$, $-N(R^0)-C[=N-S(O)_t-R^0]-$, $-N(R^0)-C(=N-OR^0)-$, $-N(R^0)-C(=N-R^0)-$, $-C(=N-R^0)-$, $-(CH_2)_{0-4}-C(O)-O-$, $-C(=N-CN)-O-$, $-C(=N-R^0)-O-$, or $-C(=N-CN)-S-$ when Y is attached to R^3 through the left hand side of the radical;

each R^4 is independently H or alkyl optionally substituted by R^7 ;

each R^5 is independently chosen from H, $-C(O)-OR^0$, aryl optionally substituted by R^6 , $-C(O)-OR^6$, $-C(O)-N(R^0)_2$, $-S(O)_2-N(R^0)_2$, $-S(O)_2-R^0$, and heteroaryl optionally substituted by R^6 ;

p is 1-5;

t is 1 or 2;

each R^6 is independently chosen from halo, $-CF_3$, $-OCF_3$, $-OR^0$, $-SR^0$, $-SCF_3$, $-R^0$, methylenedioxy, ethylenedioxy, $-NO_2$, $-CN$, $-N(R^0)_2$, $-NR^0C(O)R^0$, $-NR^0C(O)N(R^0)_2$, $-NR^0C(S)N(R^0)_2$, $-NR^0CO_2R^0$, $-NR^0NR^0C(O)R^0$, $-NR^0NR^0C(O)N(R^0)_2$, $-NR^0NR^0CO_2R^0$, $-C(O)C(O)R^0$, $-C(O)CH_2C(O)R^0$, $-CO_2R^0$, $-O-C(O)R^0$, $-C(O)R^0$, $-C(O)N(R^0)_2$, $-OC(O)N(R^0)_2$, $-S(O)_lR^0$, $-S(O)_l-OR^0$, $-SO_2N(R^0)C(O)R^0$, $-NR^0SO_2N(R^0)_2$, $-NR^0SO_2R^0$, $-C(=S)N(R^0)_2$, $-C(=NH)-N(R^0)_2$, $-C(=N-OR^0)-N(R^0)_2$, $-O-(CH_2)_{0-6}-SO_2N(R^0)_2$, $-(CH_2)_{1-6}NHC(O)R^0$, $-SO_2N(R^0)_2$, $-(CH_2)_{1-6}-OR^0$, $-(CH_2)_{1-6}-SR^0$, $-(CH_2)_{1-6}-CN$, $-(CH_2)_{1-6}-N(R^0)_2$, $-(CH_2)_{1-6}CO_2R^0$, $-C(O)N(R^0)N(R^0)_2$, $-C(O)N(R^0)OH$, $-C(O)N(R^0)SO_2R^0$, $-S(O)_lN(R^0)OR$, and $-(CH_2)_{1-6}-C(O)R^0$, wherein the two R^0 s on the same nitrogen optionally taken together forming a 5-8 membered saturated, partially saturated or aromatic ring having additional 0-4 ring heteroatoms chosen from oxygen, nitrogen, sulfur and phosphorus;

each R^7 is independently chosen from halogen, $-CF_3$, $-R^0$, $-OR^0$, $-SR^0$, aryl optionally substituted by R^6 , $-NO_2$, $-CN$, $-N(R^0)_2$, $-NR^0C(O)R^0$, $-NR^0C(O)N(R^0)_2$, $-N(R^0)C(S)N(R^0)_2$, $-NR^0CO_2R^0$, $-NR^0NR^0C(O)R^0$, $-NR^0NR^0C(O)N(R^0)_2$, $-NR^0NR^0CO_2R^0$, $-C(O)C(O)R^0$, $-C(O)CH_2C(O)R^0$, $-CO_2R^0$, $-C(O)R^0$, $-C(O)N(R^0)-N(R^0)_2$, $-C(O)N(R^0)_2$, $-C(O)NR^0SO_2R^0$, $-OC(O)N(R^0)_2$, $-S(O)_lR^0$, $-NR^0SO_2N(R^0)_2$, $-NR^0SO_2R^0$, $-C(=S)N(R^0)_2$, $-C(=NH)-N(R^0)_2$, $-(CH_2)_{1-6}-C(O)R^0$, $-SO_2N(R^0)_2$, $-OCF_3$, $-SCF_3$, $-(CH_2)_{1-6}-SR^0$, methylenedioxy, ethylenedioxy, $-(CH_2)_{1-6}-CN$, $-(CH_2)_{1-6}-N(R^0)_2$, $-S(O)_lN(R^0)OR^0$, $-(CH_2)_{1-6}-C(O)R^0$, $-C(=N-OR^0)-N(R^0)_2$, $-O-(CH_2)_{0-6}-SO_2N(R^0)_2$, and $-(CH_2)_{1-6}NHC(O)R^0$, wherein the two R^0 s on the same nitrogen optionally taken together form a 5-8 membered saturated, partially saturated or aromatic ring having additional 0-4 ring heteroatoms chosen from oxygen, nitrogen, sulfur and phosphorous;

each R^8 is independently chosen from R^7 , $=O$, $=S$, $=N(R^0)$, and $=N(CN)$;

each R^0 is independently chosen from R^* , $-C(O)$ -aralkyl, $-S(O)_l$ -heteroaryl, carbocyclylalkyl, aralkyl, heteroaralkyl, and heterocyclylalkyl, wherein each member of R^0 except H is optionally substituted by one or more groups chosen from R^* , $-OR^*$, $N(R^*)_2$, $=O$, $=S$, halo, $-CF_3$, $-NO_2$, $-CN$,

-C(O)R*, -CO₂R*, -C(O)-aryl, -C(O)-heteroaryl, -O-aryl, aralkyl, -S(O)_t-aryl, -NR*SO₂R*, -NR*C(O)R*, -NR*C(O)N(R*)₂, -N(R*)C(S)N(R*)₂, -NR*CO₂R*, -NR*NR*C(O)R*, -NR*NR*C(O)N(R*)₂, -NR*NR*CO₂R*, -C(O)C(O)R*, -C(O)CH₂C(O)R*, -C(O)N(R*)N(R*)₂, -C(O)N(R*)₂, -C(O)NR*SO₂R*, -OC(O)N(R*)₂, -S(O)_tR*, -NR*SO₂N(R*)₂, and -SO₂N(R*)₂ wherein the two R*s on the same nitrogen optionally taken together form a 5-8 membered saturated, partially saturated or aromatic ring having additional 0-4 ring heteroatoms chosen from oxygen, nitrogen, sulfur and phosphorus; and each R* is independently H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl.

2. The compound according to claim 1 having one or more of the features selected from the group consisting of:

(a) R¹ is alkyl, aryl, heteroaryl or heterocyclyl, wherein said alkyl is optionally substituted by one or more R⁷, said aryl or heteroaryl is optionally substituted by one or more R⁶, and said heterocyclyl is optionally substituted by one or more R⁶;

(b) X is a C₁₋₅ alkylene chain optionally substituted by one or more groups chosen from =O and halo;

(c) Ring A is an 8-10 membered bicyclic ring having 0-5 ring heteroatoms chosen from oxygen, sulfur and nitrogen;

(d) R² is aryl, heteroaryl or heterocyclyl, wherein said aryl or heteroaryl is optionally substituted by one or more R⁶ and said heterocyclyl is optionally substituted by one or more R⁶;

(e) Y is -C(R⁰)[C(O)OR⁰]-, -C(O)-, -O-C(O)-, -N(R⁰)-C(O)-, -S(O)₂-, -O-C(=N-CN)-, -S-C(=N-CN)-, -N(R⁰)-C(=N-CN)-, -C(=N-CN)-, -N(R⁰)-C(S)-, -N(R⁰)-C(=N-OR⁰)-, -N(R⁰)-C[=N-S(O)_t-R⁰]-, -O-C(=N-R⁰)-, -N(R⁰)-C[=N-C(O)-R⁰]-, -N(R⁰)-C(=N-R⁰)-, or -C(=N-R⁰)-; wherein each R⁰ is independently R* and m is 1; and

(f) R³ is alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, wherein said alkyl is optionally substituted by one or more R⁷, said aryl or

heteroaryl is optionally substituted by one or more R^6 , and said heterocyclyl or carbocyclyl is optionally substituted by one or more R^8 .

3. The compound according to claim 2, wherein:

(a) R^1 is aryl optionally substituted by one or more R^6 ;

(b) X is a C_2 alkylene chain optionally substituted by one or more groups chosen from =O and halo;

(c) Ring A is an 8-9 membered bicyclic ring having one ring nitrogen and 0-4 additional ring heteroatoms chosen from oxygen, sulfur and nitrogen;

(d) R^2 is heteroaryl optionally substituted by one or more R_6 , or heterocyclyl optionally substituted by one or more R_8 ;

(e) Y is $-C(R^0)[C(O)OR^0]-$, $-CH(COOH)-$, $-C(O)-$, $-O-C(O)-$, $S(O)_t-$, $-N(R^0)-C(O)-$, $-O-C(=N-CN)-$, or $-N(R^0)-C(S)-$; wherein each R^0 is independently R^* and m is 1; and


(f) R^3 is alkyl optionally substituted by one or more R^7 , aryl or heteroaryl wherein said aryl or heteroaryl is optionally substituted by one or more R^6 .

4. The compound of claim 1 wherein R^1 is optionally substituted aryl.


5. The compound of claim 4 wherein R^1 is phenyl mono- or di- substituted with halogen.


6. The compound of claim 5 wherein R^1 is phenyl substituted with F.

7. The compound of claim 1 wherein m is 1, Y is selected from the group consisting of




8. The compound of claim 1 wherein m is 1, and Y-R³ selected from the group consisting of








821




822






9. The compound of claim 1 wherein m is 1, Y-R³ is selected from the group consisting of



10. The compound of claim 1 wherein m is 0, R³ is directly attached to N, and R³ is optionally substituted aryl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl.


11. The compound of claim 1 wherein m is 1, Y-R³ is selected from the group consisting of




12. The compound of claim 1 wherein m is 1, Y is -C(O)O-, and R³ is optionally substituted alkyl or optionally substituted aryl.


13. The compound of claim 1 where X is $-(CH_2)-$, $-(CH_2-CH_2)-$, or $-(CH_2-CH_2-CH_2)-$.
14. The compound of claim 13 wherein X is optionally substituted by one or more halogen or oxo.
15. The compound of claim 14 wherein X is disubstituted with halogen.
16. The compound of claim 15 wherein X is disubstituted with fluoro.
17. The compound of claim 16 wherein X is $-(CF_2-CH_2)-$.
18. The compound of claim 13 wherein X optionally has 1-3 heteroatoms selected from oxygen, phosphorus, sulfur, and nitrogen.


19. The compound of claim 1 wherein the A ring is selected from, where the asterisk (*) indicates the preferred, but not limiting point(s) of substitution,



20. The compound of claim 1 wherein each R^2 , with an asterisk indicating a point of substitution from ring A, independently is selected from the group consisting of









21. The compound of claim 1 wherein the A ring, with two geminal R²s, is selected from the group consisting of

830




22. The compound of claim 1 wherein the A ring is tropane or piperidine, either optionally substituted with one or more R^2 .


23. The compound of claim 22 wherein the A ring in combination with R^2 is




831




832





833





24. The compound according to claim 1 selected from among the group consisting of:
















































851



25. A composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
26. The composition according to claim 25 further comprising a second therapeutic agent.
27. The composition according to claim 25 in the form of a tablet or capsule.
28. The composition according to claim 25 in the form of a liquid.
29. The composition according to claim 26, wherein said second therapeutic agent is chosen from (1-alpha, 2-beta, 3-alpha)-9-[2,3-bis(hydroxy methyl)cyclobutyl]guanine [(-)BHCG, SQ-34514, lobucavir], 9-[(2R,3R,4S)-3,4-bis(hydroxy methyl)-2-oxetanosyl]adenine (oxetanocin-G), acyclic nucleosides, ribonucleotide reductase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitors, interferons, renal excretion inhibitors, nucleoside transport inhibitors, immunomodulators, non-nucleoside reverse transcriptase inhibitors, glycoprotein 120 antagonists, cytokine antagonists, integrase inhibitors, and fusion inhibitors.
30. The composition according to claim 29, wherein said acyclic nucleoside is chosen from acyclovir, valaciclovir, famciclovir, ganciclovir, penciclovir, acyclic nucleoside phosphonates, (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC), [[[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]phosphinyld-ene]bis(oxymethylene)-2,2-dimethylpropanoic acid (bis-POM PMEA, adefovir dipivoxil), [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid (tenofovir) and (R)-[[2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid bis-(isopropoxycarbonyloxymethyl)ester (bis-POC-PMPA).
31. The composition according to claim 29, wherein said ribonucleotide reductase inhibitor is chosen from 2-acetylpyridine 5-[(2-chloroanilino) thiocarbonyl]thiocarbonohydrazone and hydroxyurea.

32. The composition according to claim 29, wherein said nucleoside reverse transcriptase inhibitor is chosen from 3'-azido-3'-deoxythymidine (AZT, zidovudine), 2',3'-dideoxycytidine (ddC, zalcitabine), 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine (ddI, didanosine), 2',3'-didehydrothymidine (d4T, stavudine), (-)-beta-D-2,6-diamino purine dioxolane (DAPD), 3'-azido-2',3'-dideoxy thymidine-5'-H-phosphophonate (phosphonovir), 2'-deoxy-5-iodo-uridine (idoxuridine), (-)-cis-1-(2-hydroxy methyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine), cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC), 3'-deoxy-3'-fluorothymidine, 5-chloro-2',3'-dideoxy-3'-fluorouridine, (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (abacavir), 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G), and ABT-606 (2HM-H2G) ribavirin.

33. The composition according to claim 29, wherein said protease inhibitor is chosen from indinavir, ritonavir, nelfinavir, amprenavir, saquinavir, fosamprenavir, (R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-N-[(R)-2-N-(isoquinolin-5-yloxyacetyl) amino-3-methylthiopropionyl]amino-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide (KNI-272), 4R-(4alpha,5alpha,6beta)]-1,3-bis[(3-aminophenyl) methyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one dimethanesulfonate (mozenavir), 3-[1-[3-[2-(5-trifluoromethylpyridinyl)-sulfonylamino] phenyl]propyl]-4-hydroxy-6alpha-phenethyl-6beta-propyl-5,6-dihydro-2-pyranone (tipranavir), N'-[2(S)-Hydroxy-3(S)-[N-(methoxycarbonyl)-l-tert-leucylamino]-4- phenylbutyl-N^{alpha}-(methoxycarbonyl)-N'-[4-(2-pyridyl)benzyl]-L-tert-leucylhydrazide (BMS-232632), 3-(2(S)-Hydroxy-3(S)-(3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethyl-N-(2-methylbenzyl) thiazolidine-4(R)-carboxamide (AG-1776), and N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(1-(4-benzo[b]furanylmethyl)-2(S)-N'-(tert-butylcarboxamido)piperazinyl)pentanamide (MK-944A).

34. The composition according to claim 29, wherein said interferon is α -interferon.
35. The composition according to claim 29, wherein said renal excretion inhibitor is probenecid.
36. The composition according to claim 29, wherein said nucleoside transport inhibitor is chosen from dipyridamole, pentoxifylline, N-acetylcysteine (NAC), Procysteine, α -trichosanthin and phosphono-formic acid.
37. The composition according to claim 29, wherein said immunomodulator is chosen from interleukin II, thymosin, granulocyte macrophage colony stimulating factors, erythropoetin, soluble CD₄ and genetically engineered derivatives thereto.
38. The composition according to claim 29, wherein said non-nucleoside reverse transcriptase inhibitor (NNRTI) is chosen from nevirapine (BI-RG-587), α -((2-acetyl-5-methyl phenyl)amino)-2,6-dichlorobenzeneacetamide (loviride), 1-[3-(isopropyl amino)-2-pyridyl]-4-[5-(methane-sulfonamido)-1H-indol-2-ylcarbonyl]piperazine monomethanesulfonate (delavirdine), (10R, 11S, 12S)-12-hydroxy-6, 6, 10, 11-tetramethyl-4-propyl-11,12-dihydro-2H, 6H, 10H-benzo(1, 2-b:3, 4-b':5, 6-b'')tripyrans-2-one ((+) calanolide A), (4S)-6-chloro-4-[1E]-cyclopropylethenyl)-3,4-dihydro-4-(trifluoro-methyl)-2(1H)-quinazolinone (DPC-083), (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one (efavirenz, DMP 266), 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)-2,4(1H,3H)-pyrimidinedione (MKC-442), and 5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(4-pyridyl)methyl-1H-imidazol-2-ylmethyl carbamate (capravirine).
39. The composition according to claim 29, wherein said glycoprotein 120 antagonist is chosen from PRO-2000, PRO-542, and 1,4-bis[3-[(2,4-

dichlorophenyl) carbonylamino]-2-oxo-5,8-disodiumsulfanyl]naphthalyl-2, 5-dimethoxyphenyl-1,4-dihydrazone (FP-21399).

40. The composition according to claim 29, wherein said cytokine antagonists is chosen from reticulose (Product-R), 1,1'-azobis-formamide (ADA), and 1,11-(1,4-phenylene bis(methylene))bis-1,4,8,11-tetraaza cyclotetradecane octahydrochloride (AMD-3100).

41. The composition according to claim 33, wherein said protease inhibitor is ritonavir.

42. A method of antagonizing a chemokine CCR-5 receptor activity in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a composition according to claim 25.

43. A method of antagonizing a chemokine CCR-5 receptor activity in a biological sample, comprising contacting the biological sample with an effective amount of a compound according to Claim 1 or a composition according to claim 25.

44. A method of treating a viral infection in a patient comprising administering to said patient a therapeutically effective amount of a composition according to claim 25.

45. The method according to claim 44 wherein the viral infection is an HIV infection.

46. A method of treating of a viral infection in a patient comprising administering to said patient a therapeutically effective amount of a composition according to Claim 26.

47. The method according to claim 33 wherein the viral infection is an HIV infection.

48. A method of treating a disease or disorder selected from AIDS related complex, progressive generalized lymphadenopathy, Kaposi's sarcoma,

thromobocytopenic purpura, AIDS-related neurological conditions, multiple sclerosis, tropical paraperesis, anti-HIV antibody-positive, or HIV-positive conditions in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a composition according to claim 25.

49. The method according to claim 48, wherein said disease or disorder is AIDS related complex, Kaposi's sarcoma or AIDS dementia. /

50. A method of treating a disease or disorder selected from AIDS related complex, progressive generalized lymphadenopathy, Kaposi's sarcoma, thromobocytopenic purpura, AIDS-related neurological conditions, multiple sclerosis, tropical paraperesis, anti-HIV antibody-positive, or HIV-positive conditions in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a composition according Claim 26.

51. The method according to claim 50, wherein said disease or disorder is AIDS related complex, Kaposi's sarcoma or AID dementia.

52. A method of treating or preventing multiple sclerosis, rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma, rheumatoid arthritis, Crohns Disease, inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease, autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis, Sjogren's syndrome, systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or organs, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis, immune-mediated disorders, or bacterial infections in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a composition according to claim 25.

53. A method of treating or preventing multiple sclerosis, rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma, rheumatoid arthritis, Crohns Disease, inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease, autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis, Sjogren's syndrome (dermatomyositis), systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or organs, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis or immune-mediated disorders in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a composition according to Claim 26.

54. A compound according to any one of claims 1-24 for use in medical therapy.

55. Use of a compound according to any one of claims 1-24 in the manufacture of a medicament for the treatment of a viral infection.

56. The use according to claim 55 wherein the viral infection is an HIV infection.

57. Use of a compound according to any one of claims 1-24 in the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder selected from AIDS related complex, progressive generalized lymphadenopathy, Kaposi's sarcoma, thrombocytopenic purpura, AIDS-related neurological conditions, multiple sclerosis, tropical paraperesis, anti-HIV antibody-positive, and HIV-positive conditions.

58. The use according to claim 57 wherein said disease or disorder is AIDS related complex, Kaposi's sarcoma or AID dementia.

59. A use of a compound according to any one of claims 1-24 in the manufacture of a medicament for the treatment of multiple sclerosis,

rheumatoid arthritis, autoimmune diabetes, chronic implant rejection, asthma, rheumatoid arthritis, Crohns Disease, inflammatory bowel disease, chronic inflammatory disease, glomerular disease, nephrotoxic serum nephritis, kidney disease, Alzheimer's Disease, autoimmune encephalomyelitis, arterial thrombosis, allergic rhinitis, arteriosclerosis, Sjogren's syndrome, systemic lupus erythematosus, graft rejection, cancers with leukocyte infiltration of the skin or organs, human papilloma virus infection, prostate cancer, wound healing, amyotrophic lateral sclerosis or immune-mediated disorders.

60. The use according to any one of claims 55-59, said medicament further comprises a second therapeutic agent.

61. The use according to claim 60 wherein said second therapeutic agent is chosen from (1-alpha, 2-beta, 3-alpha)-9-[2,3-bis(hydroxy methyl)cyclobutyl] guanine [(-)BHCG, SQ-34514, lobucavir], 9-[(2R,3R,4S)-3,4-bis(hydroxy methyl)-2-oxetanosyl]adenine (oxetanocin-G), acyclic nucleosides, ribonucleotide reductase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitors, interferons, renal excretion inhibitors, nucleoside transport inhibitors, immunomodulators, non-nucleoside reverse transcriptase inhibitors, glycoprotein 120 antagonists, cytokine antagonists, integrase inhibitors, and fusion inhibitors.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/054974 A3

(51) International Patent Classification⁷: **A61K 31/46**,
31/445, C07D 451/04, A61P 31/18

(21) International Application Number:
PCT/US2003/039644

(22) International Filing Date:
12 December 2003 (12.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/433,634 13 December 2002 (13.12.2002) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA PA
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KAZMIERSKI**,
Wieslaw, Mieczyslaw [US/US]; GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park, NC
27709 (US). **AQUINO, Christopher, Joseph** [US/US];
GlaxoSmithKline, Five Moore Drive, PO Box 13398,
Research Triangle Park, NC 27709 (US). **BIFULCO, Neil**
[US/US]; GlaxoSmithKline, Five Moore Drive, PO Box
13398, Research Triangle Park, NC 27709 (US). **BOROS**,
Eric, Eugene [US/US]; GlaxoSmithKline, Five Moore
Drive, PO Box 13398, Research Triangle Park, NC 27709
(US). **CHAUDER, Brian, Andrew** [CA/US]; Glaxo-
SmithKline, Five Moore Drive, PO Box 13398, Research
Triangle Park, NC 27709 (US). **CHONG, Pek, Yoke**
[MY/US]; GlaxoSmithKline, Five Moore Drive, PO Box
13398, Research Triangle Park, NC 27709 (US). **DUAN**,
Maosheng [CN/US]; GlaxoSmithKline, Five Moore
Drive, PO Box 13398, Research Triangle Park, NC 27709
(US). **DEANDA, JR., Felix** [US/US]; GlaxoSmithKline,
Five Moore Drive, PO Box 13398, Research Triangle
Park, NC 27709 (US). **KOBLE, Cecilia, Suarez** [VE/US];
GlaxoSmithKline, Five Moore Drive, PO Box 13398,
Research Triangle Park, NC 27709 (US). **MCLEAN, Ed**,
Williams [US/US]; GlaxoSmithKline, Five Moore Drive,

PO Box 13398, Research Triangle Park, NC 27709 (US).
PECKHAM, Jennifer, Poole [US/US]; GlaxoSmithKline,
Five Moore Drive, PO Box 13398, Research Triangle Park,
NC 27709 (US). **PERKINS, Angilique, C** [US/US]; Glaxo-
SmithKline, Five Moore Drive, PO Box 13398, Research
Triangle Park, NC 27709 (US). **THOMPSON, James**,
Benjamin [US/US]; GlaxoSmithKline, Five Moore Drive,
PO Box 13398, Research Triangle Park, NC 27709 (US).
VANDERWALL, Dana [US/US]; GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park, NC
27709 (US).

(74) Agents: **LEVY, David, J** et al.; GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park, NC
27709 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
2 September 2004

For two-letter codes and other abbreviations, refer to the "Guidance
Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS



(57) Abstract: The present invention relates to compounds
of formula (I) or pharmaceutically acceptable derivatives
thereof, useful in the treatment or prophylaxis of CCR5-related
diseases and disorders, for example, in the inhibition of HIV
replication, the prevention or treatment of an HIV infection, and
in the treatment of the resulting acquired immune deficiency
syndrome (AIDS).

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/39644

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/46 A61K31/445 C07D451/04 A61P31/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99/04794 A (OATES BRYAN ; FINKE PAUL E (US); MACCOSS MALCOLM (US); MERCK & CO INC) 4 February 1999 (1999-02-04) page 103, line 12 - line 17; claims 1,15,18,20	1-61
Y	WO 00/38680 A (EDWARDS MARTIN PAUL ; PRICE DAVID ANTHONY (GB); PFIZER LTD (GB); WOOD) 6 July 2000 (2000-07-06) page 27, line 10; claims 1,2,5-20	1-61
A	WO 02/079190 A (COOPER DAVID GWYN ; FORBES IAN THOMSON (GB); GRIBBLE ANDREW DERRICK (G) 10 October 2002 (2002-10-10) page 12, line 1 - line 3; claim 1; table 1 ----- -/-	1-61



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the International search

4 June 2004

Date of mailing of the International search report

25.06.04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seymour, L

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/39644

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/25605 A (SPRINGER MARTIN S ; MACCOSS MALCOLM (US); MERCK & CO INC (US); MILLS S) 18 June 1998 (1998-06-18) page 61, line 5 - line 11; claims 1,11 page 16 - page 34 -----	1-61
X	US 5 340 822 A (EMONDS-ALT XAVIER ET AL) 23 August 1994 (1994-08-23) column 1, line 11 - line 24; claim 1; examples 22-24 -----	1-23, 25-28, 52-54, 59,60
X	BE 601 228 A (JANSSEN PHARMACEUTICA) 1961 page 2, line 23 - line 27; claim 1 page 9, line 10 - page 28, line 10 -----	1-23, 25-28,54
X	US 2 773 870 A (BILL ELPERN) 11 December 1956 (1956-12-11) column 1, line 20 - line 61 examples -----	1-23, 25-28,54
X	US 3 539 580 A (HERMANS HUBERT KAREL FRANS ET AL) 10 November 1970 (1970-11-10) column 1, line 13 - line 15; claims 1,5-7 table -----	1-23, 25-28,54
X	US 3 334 106 A (BIEL JOHN H) 1 August 1967 (1967-08-01) the whole document -----	1-23, 25-28,54
X	REHSE K ET AL: "Platelet aggregation inhibiting and anticoagulant effects of oligoamines, 1: N-(4-piperidiny1)methanamines" ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, vol. 319, no. 319, 1986, pages 505-515, XP001085385 ISSN: 0365-6233 the whole document -----	1,25-28, 52-54, 59,60
X	STEVENTON ET AL: "4,4-disubstituted Piperidine High-Affinity NK1 Antagonists: Structure-Activity Relationships and in Vivo Activity" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 41, no. 23, 1998, pages 4623-4622, XP002173109 ISSN: 0022-2623 the whole document -----	1,25-28, 54

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/39644

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2 248 018 A (OTTO EISLEB) 1 July 1941 (1941-07-01) column 1, line 52 - line 55; claim 6; examples 3,4 -----	1,25-28, 54
X	WO 98/25604 A (SPRINGER MARTIN S ; MACCOSS MALCOLM (US); MERCK & CO INC (US); MILLS S) 18 June 1998 (1998-06-18) page 30, line 26 - line 30 page 34, line 1 - line 22 page 55 - page 85; claim 1 -----	1,7-12, 20,25-61
X	DATABASE WPI Section Ch, Week 200335 Derwent Publications Ltd., London, GB; Class B02, AN 2003-367209 XP002283279 -& JP 2002 348288 A (ONO PHARM CO LTD) 4 December 2002 (2002-12-04) abstract -----	1,7-12, 20,25-61

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/39644

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 42-53 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 42-53 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: -

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claims is impossible. Consequently, the search has been restricted to compounds according to claim 3 for invention 1. For invention 2, a selection of novelty-destroying documents disclosing spiro fused CCR5 modulators have been cited.

In addition, the present claims do not meet the requirements of Article 6 PCT in that the matter for which protection is sought is not clearly defined. The term "pharmaceutically acceptable derivative" does not enable the skilled person to determine which technical features are necessary to perform the stated function. It is thus unclear which specific compounds fall within the scope of said claim. A lack of clarity within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search does not include "pharmaceutically acceptable derivatives" of the compounds of formula I.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT
information on patent family members

International Application No

PCT/US 03/39644

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9904794	A	04-02-1999	AU 8576098 A	16-02-1999
			CA 2296314 A1	04-02-1999
			EP 1003514 A1	31-05-2000
			JP 2002510327 T	02-04-2002
			WO 9904794 A1	04-02-1999
			US 6136827 A	24-10-2000
WO 0038680	A	06-07-2000	AU 769449 B2	29-01-2004
			AU 1290400 A	31-07-2000
			AU 763644 B2	31-07-2003
			AU 1675100 A	31-07-2000
			BG 105709 A	28-02-2002
			BG 105721 A	28-02-2002
			BR 9905977 A	14-01-2003
			BR 9916585 A	16-10-2001
			BR 9917007 A	30-10-2001
			CA 2292984 A1	23-06-2000
			CA 2350073 A1	06-07-2000
			CA 2350573 A1	06-07-2000
			CN 1331691 T	16-01-2002
			CN 1331591 T	16-01-2002
			CZ 20012297 A3	11-09-2002
			CZ 20012298 A3	11-09-2002
			EE 200100344 A	15-10-2002
			EE 200100345 A	16-12-2002
			EP 1013276 A1	28-06-2000
			EP 1140920 A1	10-10-2001
			EP 1140085 A1	10-10-2001
			HR 20010468 A1	28-02-2003
			HR 20010478 A1	30-06-2002
			HU 0104795 A2	29-04-2002
			HU 0104910 A2	28-10-2002
			WO 0039125 A1	06-07-2000
			WO 0038680 A1	06-07-2000
			ID 29031 A	26-07-2001
			ID 28965 A	19-07-2001
			JP 2000212159 A	02-08-2000
			JP 2002533393 T	08-10-2002
			JP 3522691 B2	26-04-2004
			JP 2002533461 T	08-10-2002
			JP 2004099618 A	02-04-2004
			NO 20013149 A	23-08-2001
			NO 20013183 A	08-08-2001
			NZ 511794 A	31-10-2003
			NZ 511796 A	28-11-2003
			PL 349091 A1	01-07-2002
			PL 349495 A1	29-07-2002
			SK 8752001 A3	04-02-2003
			SK 8762001 A3	04-02-2003
			TR 200101793 T2	21-12-2001
			TR 200101867 T2	21-11-2001
			TR 200200938 T2	21-05-2002
			US 6586430 B1	01-07-2003
			ZA 200104211 A	14-01-2002
WO 02079190	A	10-10-2002	WO 02079190 A1	10-10-2002
WO 9825605	A	18-06-1998	AU 5803398 A	03-07-1998

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/US 03/39644

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9825605	A		WO 9825605 A1	18-06-1998
			US 5962462 A	05-10-1999
US 5340822	A	23-08-1994	FR 2676055 A1	06-11-1992
			AT 181550 T	15-07-1999
			AU 652046 B2	11-08-1994
			AU 1591692 A	05-11-1992
			BR 9201656 A	15-12-1992
			CA 2067877 A1	04-11-1992
			CS 9201329 A3	18-11-1992
			DE 69229460 D1	29-07-1999
			DE 69229460 T2	20-01-2000
			DK 512901 T3	06-12-1999
			EP 0512901 A1	11-11-1992
			ES 2137176 T3	16-12-1999
			FI 921951 A	04-11-1992
			FI 951242 A	16-03-1995
			FI 951243 A	16-03-1995
			GR 3030755 T3	30-11-1999
			HK 1005138 A1	12-05-2000
			HU 61539 A2	28-01-1993
			IE 921364 A1	04-11-1992
			IL 101760 A	18-02-1997
			IL 117921 A	18-02-1997
			JP 3242980 B2	25-12-2001
			JP 5186425 A	27-07-1993
			KR 258373 B1	01-07-2000
			MX 9202027 A1	01-01-1993
			NO 921734 A ,B,	04-11-1992
			NZ 242586 A	26-10-1995
			RU 2083574 C1	10-07-1997
			US 5770735 A	23-06-1998
			US 5625060 A	29-04-1997
			ZA 9203178 A	27-01-1993
BE 601228	A		NONE	
US 2773870	A	11-12-1956	NONE	
US 3539580	A	10-11-1970	BE 717143 A	27-12-1968
			CH 485720 A	15-02-1970
			DE 1770604 A1	04-11-1971
			ES 354905 A1	16-11-1969
			FR 7453 M	24-11-1969
			FR 1569475 A	30-05-1969
			GB 1199365 A	22-07-1970
			NL 6808415 A	27-12-1968
US 3334106	A	01-08-1967	NONE	
US 2248018	A	01-07-1941	NONE	
WO 9825604	A	18-06-1998	AU 5604998 A	03-07-1998
			WO 9825604 A1	18-06-1998
			US 6013664 A	11-01-2000
JP 2002348288	A	04-12-2002	NONE	